<SEC-DOCUMENT>0001628280-23-027430.txt : 20230804
<SEC-HEADER>0001628280-23-027430.hdr.sgml : 20230804
<ACCEPTANCE-DATETIME>20230804092326
ACCESSION NUMBER:		0001628280-23-027430
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		66
CONFORMED PERIOD OF REPORT:	20230630
FILED AS OF DATE:		20230804
DATE AS OF CHANGE:		20230804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ovid Therapeutics Inc.
		CENTRAL INDEX KEY:			0001636651
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				465270895
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38085
		FILM NUMBER:		231142397

	BUSINESS ADDRESS:	
		STREET 1:		441 NINTH AVENUE, 14TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10001
		BUSINESS PHONE:		212-776-4381

	MAIL ADDRESS:	
		STREET 1:		441 NINTH AVENUE, 14TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10001
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ovid-20230630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:bac70ec3-5ee7-4b97-a85c-498b4f8489b1,g:499e488f-fe63-4d10-9e0b-b93d763975f8,d:447d75b6bca148d0bd5c21482392c4f0--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ovid="http://www.ovidrx.com/20230630" xmlns:srt="http://fasb.org/srt/2023" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ovid-20230630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-26">0001636651</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-27">12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-28">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-29">Q2</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-30">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ovid-20230630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2014-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ovid:GensaicIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ovid:GensaicIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ovid:GravitonBioscienceCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ovid:MarinusTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ovid:MarinusTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ovid:MoneyMarketFundsAndShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ovid:MoneyMarketFundsAndShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-10</xbrli:startDate><xbrli:endDate>2022-03-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>ovid:vote</xbrli:measure></xbrli:unit><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:CowenAndCompanyLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ovid:ATMAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:CowenAndCompanyLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ovid:ATMAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:NonemployeePerformanceBasedOptionAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:NonemployeePerformanceBasedOptionAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:EmployeePerformanceBasedOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:EmployeePerformanceBasedOptionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:NorthwesternUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:NorthwesternUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:NorthwesternUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>ovid:product</xbrli:measure></xbrli:unit><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:AstrazenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-30</xbrli:startDate><xbrli:endDate>2021-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:AstrazenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:AstrazenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:HLundbeckASMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-30</xbrli:startDate><xbrli:endDate>2021-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ovid:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-29</xbrli:startDate><xbrli:endDate>2021-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:HealxLicenseAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:HealxLicenseAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:HealxLicenseAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:HealxLicenseAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:MarinusPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:MarinusLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ovid:MarinusPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:PatentLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-18</xbrli:startDate><xbrli:endDate>2022-03-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ovid:MarinusPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:MarinusLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ovid:MarinusPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:MarinusLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ovid:GravitonBioscienceCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-30</xbrli:startDate><xbrli:endDate>2023-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i447d75b6bca148d0bd5c21482392c4f0_1"></div><div style="min-height:22.5pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________________________________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">x</ix:nonNumeric> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">June&#160;30, 2023</ix:nonNumeric></span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">o</ix:nonNumeric> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from ______________________ to ______________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-38085</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________________________________________________</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">Ovid Therapeutics Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________________________________________________ </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:94%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:94%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">46-5270895</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or Other Jurisdiction of<br/>Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">441 Ninth Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-10">14th Floor</ix:nonNumeric></span></div><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">New York</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-12">New York</ix:nonNumeric> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">10001</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%">(Zip Code)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">646</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">661-7661</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(Former name, former address and former fiscal year, if changed since last report)</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.143%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:94%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:95%">Trading</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:95%">Symbol(s)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:94%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:94%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:94%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">OVID</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:94%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(g) of the Act: None</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________________________________________________</span></div><div style="margin-top:3pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to the filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-19">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:3pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-20">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:3pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:94%">Large Accelerated Filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:94%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:94%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" id="f-21">Accelerated Filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:94%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:94%">Non-accelerated Filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:94%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:94%">Smaller Reporting Company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:94%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-22">x</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:94%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:94%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-23">o</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:94%">&#160;</span></td></tr></table></div><div style="margin-top:3pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:3pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.) Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-24">x</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of August&#160;1, 2023, the registrant had <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-25">70,602,793</ix:nonFraction> shares of common stock, $0.001 par value per share, outstanding.</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:22.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div></div></div><div id="i447d75b6bca148d0bd5c21482392c4f0_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Page</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_10">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:none" href="#i447d75b6bca148d0bd5c21482392c4f0_10">i</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%;text-decoration:none" href="#i447d75b6bca148d0bd5c21482392c4f0_13">PART I.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_13">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:none" href="#i447d75b6bca148d0bd5c21482392c4f0_16">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_16">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:none" href="#i447d75b6bca148d0bd5c21482392c4f0_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_19">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:none" href="#i447d75b6bca148d0bd5c21482392c4f0_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_22">Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:none" href="#i447d75b6bca148d0bd5c21482392c4f0_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_25">Condensed Consolidated Statements of Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:none" href="#i447d75b6bca148d0bd5c21482392c4f0_25">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_28">Condensed Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:none" href="#i447d75b6bca148d0bd5c21482392c4f0_28">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_31">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:none" href="#i447d75b6bca148d0bd5c21482392c4f0_31">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_34">Notes to Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:none" href="#i447d75b6bca148d0bd5c21482392c4f0_34">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:none" href="#i447d75b6bca148d0bd5c21482392c4f0_79">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_79">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:none" href="#i447d75b6bca148d0bd5c21482392c4f0_79">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:none" href="#i447d75b6bca148d0bd5c21482392c4f0_103">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_103">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:none" href="#i447d75b6bca148d0bd5c21482392c4f0_103">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:none" href="#i447d75b6bca148d0bd5c21482392c4f0_106">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_106">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:none" href="#i447d75b6bca148d0bd5c21482392c4f0_106">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%;text-decoration:none" href="#i447d75b6bca148d0bd5c21482392c4f0_109">PART II.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_109">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:none" href="#i447d75b6bca148d0bd5c21482392c4f0_112">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_112">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:none" href="#i447d75b6bca148d0bd5c21482392c4f0_112">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:none" href="#i447d75b6bca148d0bd5c21482392c4f0_115">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_115">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:none" href="#i447d75b6bca148d0bd5c21482392c4f0_115">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:none" href="#i447d75b6bca148d0bd5c21482392c4f0_118">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_118">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:none" href="#i447d75b6bca148d0bd5c21482392c4f0_118">66</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_121">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i447d75b6bca148d0bd5c21482392c4f0_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical fact are &#8220;forward-looking statements&#8221; for purposes of this Quarterly Report on Form 10-Q. In some cases, you can identify forward-looking statements by terminology such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; continue,&#8221; &#8220;could,&#8221; &#8220;design,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;positioned,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative or plural of those terms, and similar expressions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements include, but are not limited to, statements about:</span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to identify additional novel compounds with significant commercial potential to acquire or in-license; </span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to successfully acquire or in-license additional drug candidates on reasonable terms; </span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our estimates regarding expenses, future revenue including any royalty or milestone payments, capital requirements and needs for additional financing; </span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to obtain regulatory approval of our current and future drug candidates; </span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our expectations regarding the timing of clinical trials and potential regulatory filings;</span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our expectations regarding the potential market size and the rate and degree of market acceptance of such drug candidates;</span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to fund our working capital requirements; </span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the implementation of our business model and strategic plans for our business and drug candidates; </span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">developments or disputes concerning our intellectual property or other proprietary rights; </span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to maintain and establish collaborations or obtain additional funding; </span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our expectations regarding government and third-party payor coverage and reimbursement; </span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to compete in the markets we serve; </span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the impact of government laws and regulations; </span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">developments relating to our competitors and our industry; and </span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the factors that may impact our financial results. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may cause actual results to differ materially from current expectations include, among other things, those set forth in Part II, Item 1A, &#8220;Risk Factors,&#8221; herein and for the reasons described elsewhere in this Quarterly Report on Form 10-Q. Any forward-looking statement in this Quarterly Report on Form 10-Q reflects our current view with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, industry and future growth. Given these uncertainties, you should not rely on these forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q also contains estimates, projections and other information concerning our industry, our business and the markets for certain drugs and consumer products, including data regarding the estimated size of those markets, their projected growth rates and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained these industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources and we have not independently verified the data from third party sources. In some cases, we do not expressly refer to the sources from which these data are derived.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this Quarterly Report on Form 10-Q, unless otherwise stated or as the context otherwise requires, references to &#8220;Ovid,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar references refer to Ovid Therapeutics Inc. and its wholly owned </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">i</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsidiary. This Quarterly Report on Form 10-Q also contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to, including logos, artwork and other visual displays, may appear without the &#174; or TM symbols, but such references are not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ii</span></div></div></div><div id="i447d75b6bca148d0bd5c21482392c4f0_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I&#8212;FINANCIAL INFORMATION</span></div><div id="i447d75b6bca148d0bd5c21482392c4f0_16"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements.</span></div><div id="i447d75b6bca148d0bd5c21482392c4f0_19"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVID THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="f-31">71,623,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="f-32">44,867,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-33">24,894,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-34">84,133,565</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-35">5,653,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-36">2,379,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-37">102,170,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="f-38">131,380,691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term equity investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="0" id="f-39">16,470,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="0" id="f-40">5,622,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="0" id="f-41">1,930,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="0" id="f-42">1,930,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="f-43">14,412,068</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="f-44">14,922,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-45">955,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-46">1,147,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-47">289,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-48">261,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="f-49">136,229,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="f-50">155,265,814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders' Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="f-51">3,763,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="f-52">1,952,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-53">5,433,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-54">4,504,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion, lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="f-55">944,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="f-56">533,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-57">10,141,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-58">6,991,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-59">15,389,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-60">16,001,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="f-61">25,531,089</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="f-62">22,993,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-63"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-64">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-65"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-66">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized; Series A convertible preferred stock, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="ovid:PreferredStockShareDesignated" format="ixt:num-dot-decimal" scale="0" id="f-67"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="ovid:PreferredStockShareDesignated" format="ixt:num-dot-decimal" scale="0" id="f-68">10,000</ix:nonFraction></ix:nonFraction> shares designated, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-69"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-70"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-71"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-72">1,250</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at June&#160;30, 2023 and December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:PreferredStockValue" scale="0" id="f-73">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:PreferredStockValue" scale="0" id="f-74">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-75"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-76">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-77"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-78">125,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-79"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-80">70,602,793</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-81"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-82">70,466,885</ix:nonFraction></ix:nonFraction> shares issued and outstanding at June&#160;30, 2023 and December&#160;31, 2022, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="f-83">70,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="f-84">70,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in-capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="0" id="f-85">361,913,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="0" id="f-86">357,770,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-87">5,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-88">42,187</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="f-89">251,291,081</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="f-90">225,526,542</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-91">110,698,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-92">132,272,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-93">136,229,764</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-94">155,265,814</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3</span></div></div></div><div id="i447d75b6bca148d0bd5c21482392c4f0_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVID THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.014%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.014%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.014%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.018%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For The Three Months Ended<br/>June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For The Three Months Ended<br/>June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For The Six Months Ended<br/>June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For The Six Months Ended<br/>June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and other revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-95">75,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-97">141,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-98">1,445,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-99">75,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-100">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-101">141,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="f-102">1,445,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-103">5,998,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-104">6,046,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-105">12,613,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="f-106">13,878,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="f-107">8,248,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="f-108">8,257,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="f-109">16,591,964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="f-110">18,137,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="f-111">14,246,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="f-112">14,304,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="f-113">29,205,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="f-114">32,016,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-115">14,171,982</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-116">14,304,287</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-117">29,064,286</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-118">30,571,393</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="f-119">1,763,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="f-120">284,127</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="f-121">3,299,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="f-122">125,076</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-123">12,408,330</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-124">14,588,414</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-125">25,764,539</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="f-126">30,696,470</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-127">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-128">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-129">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-130">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-131">12,408,330</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-132">14,588,414</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-133">25,764,539</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-134">30,696,470</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-135">0.18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-136">0.21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-137">0.37</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-138">0.44</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-139">0.18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-140">0.21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-141">0.37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-142">0.44</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-143">70,534,181</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-144">70,391,458</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-145">70,512,479</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-146">70,391,236</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-147">70,534,181</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-148">70,391,458</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-149">70,512,479</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-150">70,391,236</ix:nonFraction></span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4</span></div></div></div><div id="i447d75b6bca148d0bd5c21482392c4f0_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVID THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Loss </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.727%"><tr><td style="width:1.0%"></td><td style="width:43.086%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.390%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For The Three Months Ended<br/>June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For The Three Months Ended<br/>June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For The Six Months Ended<br/>June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For The Six Months Ended<br/>June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-151">12,408,330</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-152">14,588,414</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-153">25,764,539</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-154">30,696,470</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (loss) gain on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="f-155">422</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-156">90,127</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-157">47,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-158">90,127</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-159">12,408,752</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-160">14,678,541</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-161">25,717,144</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="0" id="f-162">30,786,597</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5</span></div></div></div><div id="i447d75b6bca148d0bd5c21482392c4f0_28"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVID THERAPEUTICS INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity (unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.261%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.669%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.669%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.998%"></td><td style="width:0.1%"></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Series A<br/>Convertible<br/>Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-163">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="f-164">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-165">70,466,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-166">70,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-167">357,770,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-168">42,187</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-169">225,526,542</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-170">132,272,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock from exercise of stock options and purchases from employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-171">24,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="0" id="f-172">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="0" id="f-173">66,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="0" id="f-174">66,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-175">1,916,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-176">1,916,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="0" id="f-177">47,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="0" id="f-178">47,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-179">13,356,209</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-180">13,356,209</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance, March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-181">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="f-182">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-183">70,491,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-184">70,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-185">359,754,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-186">5,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-187">238,882,751</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-188">120,947,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock from exercise of stock options and purchases from employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-189">112,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="0" id="f-190">111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="0" id="f-191">210,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="0" id="f-192">211,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-193">1,948,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-194">1,948,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="0" id="f-195">422</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="0" id="f-196">422</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-197">12,408,330</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-198">12,408,330</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance, June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-199">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="f-200">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-201">70,603,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-202">70,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-203">361,913,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-204">5,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-205">251,291,081</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-206">110,698,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Series A<br/>Convertible<br/>Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-207">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="f-208">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-209">70,364,912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-210">70,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-211">351,033,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="0" id="f-212">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-213">171,357,513</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-214">179,746,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock from exercise of stock options and purchases from employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-38" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-215">52,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="0" id="f-216">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="0" id="f-217">33,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="0" id="f-218">33,079</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-219">1,324,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-220">1,324,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-221">16,108,056</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-222">16,108,056</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance, March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-223">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="f-224">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-43" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-225">70,417,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-226">70,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-227">352,391,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="0" id="f-228">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-229">187,465,569</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-230">164,996,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock from exercise of stock options and purchases from employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-48" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-231">2,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="0" id="f-232">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="0" id="f-233">109,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="0" id="f-234">109,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-235">1,720,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="f-236">1,720,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="0" id="f-237">90,127</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="0" id="f-238">90,127</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-239">14,588,414</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-240">14,588,414</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance, June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-52" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-241">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="f-242">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-53" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-243">70,419,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-244">70,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-245">354,221,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-246">90,127</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-247">202,053,983</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="f-248">152,147,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6</span></div></div></div><div id="i447d75b6bca148d0bd5c21482392c4f0_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVID THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For The Six Months Ended<br/>June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For The Six Months Ended<br/>June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-249">25,764,539</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-250">30,696,470</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash consideration received in licensing agreement transaction</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="ovid:NoncashConsiderationReceivedInLicensingAgreementTransaction" format="ixt:fixed-zero" scale="0" id="f-251">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="ovid:NoncashConsiderationReceivedInLicensingAgreementTransaction" format="ixt:num-dot-decimal" scale="0" id="f-252">945,366</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (gain) loss on equity investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="f-253">847,995</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="f-254">348,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in accrued interest and accretion of discount on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="ovid:ChangeInAccruedInterestAndAccretionOfDiscountsShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="f-255">1,139,113</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" sign="-" name="ovid:ChangeInAccruedInterestAndAccretionOfDiscountsShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="f-256">223,649</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-257">3,865,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-258">3,045,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="0" id="f-259">282,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="0" id="f-260">172,105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="0" id="f-261">510,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="0" id="f-262">354,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="ovid:AccretionOfLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="f-263">573,015</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="ovid:AccretionOfLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="f-264">368,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="f-265">4,048,361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="f-266">230,877</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Security deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="0" id="f-267">12,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="0" id="f-268">15,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" format="ixt:num-dot-decimal" scale="0" id="f-269">1,810,379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" format="ixt:num-dot-decimal" scale="0" id="f-270">2,510,503</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-271">928,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-272">3,072,434</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="f-273">23,817,614</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="f-274">33,375,022</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="0" id="f-275">24,574,071</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="0" id="f-276">79,416,203</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales/maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-277">85,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:fixed-zero" scale="0" id="f-278">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of long-term equity investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:PaymentsToAcquireLongtermInvestments" format="ixt:num-dot-decimal" scale="0" id="f-279">10,000,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:PaymentsToAcquireLongtermInvestments" format="ixt:fixed-zero" scale="0" id="f-280">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of convertible short-term note receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="ovid:PaymentsForProceedsFromIssuanceOfShortTermNoteReceivable" format="ixt:fixed-zero" scale="0" id="f-281">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="ovid:PaymentsForProceedsFromIssuanceOfShortTermNoteReceivable" format="ixt:num-dot-decimal" scale="0" id="f-282">1,000,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-283">21,357</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-284">1,085,840</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software development and other costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:PaymentsToDevelopSoftware" format="ixt:num-dot-decimal" scale="0" id="f-285">109,637</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:PaymentsToDevelopSoftware" format="ixt:num-dot-decimal" scale="0" id="f-286">251,340</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="f-287">50,294,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="f-288">81,753,383</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of options and purchases from employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-289">278,089</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-290">142,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="f-291">278,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="f-292">142,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="f-293">26,755,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="f-294">114,985,777</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-295">46,798,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-296">189,728,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-297">73,554,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-298">74,742,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset in exchange for lease liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="0" id="f-299">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="f-300">15,791,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7</span></div></div></div><div id="i447d75b6bca148d0bd5c21482392c4f0_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVID THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="i447d75b6bca148d0bd5c21482392c4f0_37"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NOTE 1 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-301" continuedAt="i9e9fbc4df8f24a05a1599770294acfcd" escape="true">NATURE OF OPERATIONS</ix:nonNumeric></span></div><ix:continuation id="i9e9fbc4df8f24a05a1599770294acfcd"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ovid Therapeutics Inc. (the &#8220;Company&#8221;) was incorporated under the laws of the state of Delaware and commenced operations on April 1, 2014 and maintains its principal executive office in New York, New York. The Company is a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its inception, the Company has devoted substantially all of its efforts to business development, research and development, recruiting management and technical staff, and raising capital, and has financed its operations through the issuance of convertible preferred stock, common stock and other equity instruments. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development and regulatory success, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, and the ability to secure additional capital to fund operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s major sources of cash have been licensing revenue, proceeds from various public and private offerings of its capital stock, option exercises and interest income. As of June&#160;30, 2023, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-302">96.5</ix:nonFraction> million in cash, cash equivalents and marketable securities. Since inception, the Company has generated $<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-303">222.6</ix:nonFraction> million in revenue, primarily from the Company&#8217;s royalty, license and termination agreement (&#8220;RLT Agreement&#8221;) with Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;). Historically, the Company has incurred recurring losses, has experienced negative operating cash flows and has required significant cash resources to execute its business plans, which the Company expects will continue for the foreseeable future. The Company has an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-304">251.3</ix:nonFraction> million as of June&#160;30, 2023, working capital of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ovid:WorkingCapital" format="ixt:num-dot-decimal" scale="6" id="f-305">92.0</ix:nonFraction> million and had cash used in operating activities of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-306">23.8</ix:nonFraction> million for the six months ended June&#160;30, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded net losses of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-307">12.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-308">25.8</ix:nonFraction> million during the three and six months ended June&#160;30, 2023, respectively, and expects to incur losses in subsequent periods for at least the next several years. The Company is highly dependent on its ability to find additional sources of funding through either equity offerings, debt financings, collaborations, strategic alliances, licensing agreements or a combination of any such transactions. Management believes that the Company&#8217;s existing cash, cash equivalents and marketable securities as of June&#160;30, 2023 will be sufficient to fund its current operating plans through at least the next 12 months from the date of filing of the Company&#8217;s Quarterly Report on Form 10-Q. Adequate additional funding may not be available to the Company on acceptable terms or at all. The failure to raise capital as and when needed could have a negative impact on the Company&#8217;s financial condition and ability to pursue its business strategy. The Company may be required to delay, reduce the scope of or eliminate research and development programs, or obtain funds through arrangements with collaborators or others that may require the Company to relinquish rights to certain drug candidates that the Company might otherwise seek to develop or commercialize independently.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to other challenges and risks specific to its business and its ability to execute on its strategy, as well as risks and uncertainties common to companies in the pharmaceutical industry with development and commercial operations, including, without limitation, risks and uncertainties associated with: delays or problems in the supply of the Company's product candidates, loss of single source suppliers or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing additional products or product candidates; pharmaceutical product development and the inherent uncertainty of clinical success; the challenges of protecting and enhancing intellectual property rights; complying with applicable regulatory requirements; and obtaining regulatory approval of any of the Company's product candidates.</span></div></ix:continuation><div id="i447d75b6bca148d0bd5c21482392c4f0_40"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-309" continuedAt="i471021bcc6ec45208178a54bfe3f1778" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i471021bcc6ec45208178a54bfe3f1778" continuedAt="i20c85db840c64cd4b3ec65b620c9489d"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant accounting policies are described in Note 2, &#8220;Summary of Significant Accounting Policies,&#8221; in the Company&#8217;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March 13, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(A) <ix:nonNumeric contextRef="c-1" name="ovid:UnauditedInterimFinancialStatementsPolicyPolicyTextBlock" id="f-310" continuedAt="id155f16f75ed40018e1e60da62d77c74" escape="true">Unaudited Interim Condensed Consolidated Financial Statements</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id155f16f75ed40018e1e60da62d77c74" continuedAt="i433089121c0d481d97d3e28d8564fdc5">The interim condensed consolidated balance sheet at June&#160;30, 2023 and the condensed consolidated statements of operations, comprehensive loss, cash flows, and stockholders&#8217; equity for the three and six months ended June&#160;30, 2023 and 2022 are unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in </ix:continuation></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><ix:continuation id="i20c85db840c64cd4b3ec65b620c9489d" continuedAt="i361c0147efbb48aa91010879ac162dc1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i433089121c0d481d97d3e28d8564fdc5">accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) and following the requirements of the SEC for interim reporting. As permitted under those rules, certain notes or other financial information that are normally required by GAAP are condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of its financial information. The results of operations for the three and six month periods ended June&#160;30, 2023 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2023 or for any other future annual or interim period. The balance sheet as of December&#160;31, 2022 included herein was derived from the audited financial statements as of that date. These interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited financial statements as of and for the year ended December&#160;31, 2022 included in the Company&#8217;s Annual Report on Form 10-K.</ix:continuation></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(B) <ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-311" continuedAt="iefe6cdb44bc04fd79b4581beb6527a9c" escape="true">Basis of Presentation and Consolidation</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iefe6cdb44bc04fd79b4581beb6527a9c">The accompanying condensed consolidated financial statements have been prepared in conformity with GAAP and include the accounts of Ovid Therapeutics Inc. and its wholly owned subsidiary, Ovid Therapeutics Hong Kong Limited. All intercompany transactions and balances have been eliminated in consolidation.</ix:continuation></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(C) <ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-312" continuedAt="i24e1d9168a404701b347955ce9baf921" escape="true">Use of Estimates</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i24e1d9168a404701b347955ce9baf921">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ materially from those estimates.</ix:continuation></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(D) <ix:nonNumeric contextRef="c-1" name="us-gaap:MarketableSecuritiesPolicy" id="f-313" continuedAt="i45041c0983a84c3b82eeffae271c00d7" escape="true">Marketable Securities</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i45041c0983a84c3b82eeffae271c00d7">Marketable securities consist of investments in U.S. treasury instruments which are considered available-for-sale securities. The Company classifies its marketable securities with maturities of less than one year from the balance sheet date as current assets on its condensed consolidated balance sheets. The Company classifies its marketable securities with original maturities of less than three months as cash equivalents on its consolidated balance sheets. Unrealized gains and losses on these securities that are determined to be temporary are reported as a separate component of accumulated other comprehensive income (loss) in stockholder's equity.</ix:continuation></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(E) <ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="f-314" continuedAt="i96e7320581ae495292306741c58a27e6" escape="true">Restricted Cash</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i96e7320581ae495292306741c58a27e6">The Company classifies as restricted cash all cash pledged as collateral to secure long-term obligations and all cash whose use is otherwise limited by contractual provisions. Amounts are reported as non-current unless restrictions are expected to be released in the next 12 months.</ix:continuation></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(F) <ix:nonNumeric contextRef="c-1" name="us-gaap:EquityMethodInvestmentsPolicy" id="f-315" continuedAt="i6317e86042be4b94ae170221bb52965c" escape="true">Long-Term Equity Investments</ix:nonNumeric></span></div><ix:continuation id="i6317e86042be4b94ae170221bb52965c"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Long-term equity investments consist of equity investments in the preferred shares of Gensaic, Inc., formerly M13 Therapeutics, Inc. (&#8220;Gensaic&#8221;), and Graviton Bioscience Corporation (&#8220;Graviton&#8221;), both privately held corporations. The preferred shares are not considered in-substance common stock, and the investments are accounted for at cost, with adjustments for observable changes in prices or impairments, and are classified within long-term equity investments on the consolidated balance sheets with adjustments recognized in other income (expense), net on the condensed consolidated statements of operations. The Company has determined that these equity investments do not have a readily determinable fair value and elected the measurement alternative. Therefore, the carrying amount of the equity investments will be adjusted to fair value at the time of the next observable price change for the identical or similar investment of the same issuer or when an impairment is recognized. Each reporting period, the Company performs a qualitative assessment to evaluate whether the investments are impaired. The assessment includes a review of recent operating results and trends, recent sales/acquisitions of the investees' securities, and other publicly available data. If an investment is determined to be impaired, the Company will then write it down to its estimated fair value. As of June&#160;30, 2023 and December&#160;31, 2022, the equity investment in Gensaic had a carrying value of $<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-5" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-316"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-5" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-317">5.1</ix:nonFraction></ix:nonFraction>&#160;million. As of June&#160;30, 2023, the equity investment in Graviton had a carrying value of $<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-5" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-318">10.0</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term equity investments also consist of an equity investment in the common shares of Marinus Pharmaceuticals, Inc. (&#8220;Marinus&#8221;) that were received as non-cash consideration via the terms of a licensing agreement executed between the two companies effective March 2022. The equity shares are marked-to-market at each reporting date with changes in the fair value being reflected in the carrying value of the investment on the Company's consolidated balance sheets and other income (expense) on the Company's consolidated statements of operations. As of June&#160;30, 2023 and December&#160;31, 2022, the equity investment in Marinus had a carrying value of approximately $<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-5" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-319">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-320">0.5</ix:nonFraction> million, respectively.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><ix:continuation id="i361c0147efbb48aa91010879ac162dc1" continuedAt="ib2898118e8ce4d36b1cf232e975f59c9"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(G) <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-321" continuedAt="i88425486e0564c52a9006e7786acbd8b" escape="true">Fair Value of Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="i88425486e0564c52a9006e7786acbd8b"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Accounting Standards Board (&#8220;FASB&#8221;) guidance specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three levels of the fair value hierarchy are as follows:</span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 1&#8212;Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities. The Company&#8217;s Level 1 assets consisted of investments in a U.S. treasury money market fund and equity securities totaling $<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-322">42.2</ix:nonFraction> million as of June&#160;30, 2023. The Company's Level 1 assets totaled $<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-323">42.5</ix:nonFraction> million as of December&#160;31, 2022.</span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 2&#8212;Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly (e.g., quoted prices of similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active). Level 2 includes financial instruments that are valued using models or other valuation methodologies. The Company's Level 2 assets consisted of U.S. treasury bills, totaling $<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-324">54.8</ix:nonFraction> million as of June&#160;30, 2023 and $<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-325">84.1</ix:nonFraction> million as of December&#160;31, 2022.</span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 3&#8212;Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable. There were no Level 3 assets or liabilities as of June&#160;30, 2023 or December&#160;31, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reported in the balance sheets for cash and cash equivalents, other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(H) <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-326" continuedAt="i6526e970d4974a17ae0d1f94fa16caeb" escape="true">Leases</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6526e970d4974a17ae0d1f94fa16caeb">The Company determines if an arrangement is a lease at inception and recognizes the lease in accordance with ASC 842. Operating leases are included in right-of-use (&#8220;ROU&#8221;) assets, current liabilities, and long-term lease liability in the Company's consolidated balance sheets. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. The Company determines the portion of the lease liability that is current as the difference between the calculated lease liability at the end of the current period and the lease liability that is projected 12 months from the current period.</ix:continuation></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(I) <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-327" continuedAt="id5d8c49cbbd34caeb3e053a003aa451a" escape="true">Property and Equipment</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id5d8c49cbbd34caeb3e053a003aa451a">Property and equipment are stated at cost and depreciated over their estimated useful lives of three years using the straight-line method. Repair and maintenance costs are expensed. The Company reviews the recoverability of all long-lived assets, including the related useful life, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable.</ix:continuation></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(J) <ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-328" continuedAt="ib485704762ef4a448071152fa541a784" escape="true">Research and Development Expenses</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib485704762ef4a448071152fa541a784">The Company expenses the cost of research and development as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and preclinical materials as well as contracted services, license fees, and other external costs. Research and development expenses also include the cost of licensing agreements acquired from third-parties. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received in accordance with ASC 730, Research and Development</ix:continuation>.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(K) <ix:nonNumeric contextRef="c-1" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="f-329" continuedAt="i5f875b69283945bca0b63508c34802f9" escape="true">Stock-based Compensation</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5f875b69283945bca0b63508c34802f9" continuedAt="ieb70812ed55e4a6281f10ad1731ed2de">The Company accounts for its stock-based compensation in accordance with ASC 718, Compensation&#8212;Stock Compensation, which establishes accounting for stock-based awards granted to employees for services and requires companies to expense the estimated fair value of these awards over the requisite service period. The Company estimates </ix:continuation></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><ix:continuation id="ib2898118e8ce4d36b1cf232e975f59c9" continuedAt="i0d5733c2effb493e89e3241d495200a5"><ix:continuation id="ieb70812ed55e4a6281f10ad1731ed2de"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the fair value of all awards granted using the Black-Scholes valuation model. Key inputs and assumptions include the expected term of the option, stock price volatility, risk-free interest rate, dividend yield, stock price and exercise price. Many of the assumptions require significant judgment and any changes could have an impact in the determination of stock-based compensation expense. The Company elected an accounting policy to record forfeitures as they occur. The Company recognizes employee stock-based compensation expense based on the fair value of the award on the date of the grant. The compensation expense is recognized over the vesting period under the straight-line method.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for option awards granted to nonemployee consultants and directors in accordance with ASC 718. The fair value of the option issued or committed to be issued is used to measure the transaction, as this is more reliable than the fair value of the services received. The fair value is measured at the value of the Company&#8217;s common stock award at the earlier of the date that the commitment for performance by the counterparty has been reached or the counterparty&#8217;s performance is complete.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(L) <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-330" continuedAt="if8a64e0ab67f4959a7845c823bbebefa" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if8a64e0ab67f4959a7845c823bbebefa">The Company accounts for income taxes under the asset and liability method, which requires deferred tax assets and liabilities to be recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts and respective tax bases of existing assets and liabilities, as well as for net operating loss carryforwards and research and development credits. Valuation allowances are provided if it is more likely than not that some portion or all of the deferred tax assets will not be realized. The impact of a change in the tax laws is recorded in the period in which the law is enacted.</ix:continuation></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(M) <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-331" continuedAt="ida544972a5ba4cc3b49cb1e54ea07425" escape="true">Net Loss per Share</ix:nonNumeric></span></div><ix:continuation id="ida544972a5ba4cc3b49cb1e54ea07425"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per common share is determined by dividing net loss attributable to common stockholders by the basic and diluted weighted-average common shares outstanding during the period. The Company applies the two-class method to allocate earnings between common stock and participating securities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When applicable, net income per diluted share attributable to common stockholders adjusts the basic earnings per share attributable to common stockholders and the weighted-average number of shares of common stock outstanding for the potential dilutive impact of stock options using the treasury-stock method and the potential impact of preferred stock using the if-converted method.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(N) <ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="f-332" continuedAt="i0e0b7c498d28477ea1654ef22cfddeb5" escape="true">Revenue Recognition</ix:nonNumeric></span></div><ix:continuation id="i0e0b7c498d28477ea1654ef22cfddeb5"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, Revenue from Contracts with Customers, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. In applying ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the promises and performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) it satisfies the performance obligations. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services the Company transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to recognizing revenue, the Company makes estimates of the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If there are multiple distinct performance obligations, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The standalone selling price is generally determined using expected cost and comparable transactions. Revenue for performance obligations recognized over time is recognized by measuring the progress toward complete satisfaction of the performance obligations using an input measure.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-refundable upfront fees allocated to licenses that are not contingent on any future performance and require no consequential continuing involvement by the Company, are recognized as revenue when the license term commences and the licensed data, technology or product is delivered. The Company defers recognition of upfront license fees if the performance obligations are not satisfied.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><ix:continuation id="i0d5733c2effb493e89e3241d495200a5"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(O) <ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-333" continuedAt="i6a83b863bbb940fa9af8e20475d39777" escape="true">Recent Accounting Pronouncements</ix:nonNumeric></span></div><ix:continuation id="i6a83b863bbb940fa9af8e20475d39777"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has reviewed recently issued accounting standards and plans to adopt those that are applicable. The Company does not expect the adoption of those standards to have a material impact on its financial position, results of operations, or cash flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopts new pronouncements relating to generally accepted accounting principles applicable to the Company as they are issued, which may be in advance of their effective date. Management does not believe that any recently issued, but not yet effective accounting standards, if currently adopted, would have a material effect on the accompanying financial statements.</span></div></ix:continuation></ix:continuation><div id="i447d75b6bca148d0bd5c21482392c4f0_43"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" id="f-334" continuedAt="id29a9710e9694e14bf0d23f7a4af33fb" escape="true">CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES</ix:nonNumeric></span></div><ix:continuation id="id29a9710e9694e14bf0d23f7a4af33fb"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="f-335" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="f-336" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the fair value of cash, cash equivalents and marketable securities as well as gross unrealized holding gains and losses as of June&#160;30, 2023 and December&#160;31, 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrealized holding gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrealized holding losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="0" id="f-337">868,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="0" id="f-338">868,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="ovid:CashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="0" id="f-339">70,754,658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="ovid:CashEquivalentsUnrealizedHoldingGains" format="ixt:num-dot-decimal" scale="0" id="f-340">5,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="ovid:CashEquivalentsUnrealizedHoldingLosses" format="ixt:fixed-zero" scale="0" id="f-341">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="f-342">70,759,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-343">24,888,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="f-344">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="0" id="f-345">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-346">24,888,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="ovid:CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost" format="ixt:num-dot-decimal" scale="0" id="f-347">96,512,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="ovid:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingGain" format="ixt:num-dot-decimal" scale="0" id="f-348">5,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="ovid:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingLoss" format="ixt:fixed-zero" scale="0" id="f-349">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="f-350">96,517,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="24" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents as of June 30, 2023 include money market funds of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:MoneyMarketFundsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-351">40.9</ix:nonFraction> million.</span></div></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrealized holding gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrealized holding losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="0" id="f-352">2,853,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="0" id="f-353">2,853,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="ovid:CashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="0" id="f-354">42,014,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="ovid:CashEquivalentsUnrealizedHoldingGains" format="ixt:fixed-zero" scale="0" id="f-355">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="ovid:CashEquivalentsUnrealizedHoldingLosses" format="ixt:fixed-zero" scale="0" id="f-356">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="f-357">42,014,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="f-358">84,175,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="f-359">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="f-360">42,187</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="f-361">84,133,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="ovid:CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost" format="ixt:num-dot-decimal" scale="0" id="f-362">129,043,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="ovid:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingGain" format="ixt:fixed-zero" scale="0" id="f-363">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="ovid:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingLoss" format="ixt:num-dot-decimal" scale="0" id="f-364">42,187</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="f-365">129,001,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not hold any securities that were in an unrealized loss position for more than 12 months as of June&#160;30, 2023 and December&#160;31, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" format="ixt:fixed-zero" scale="0" id="f-366"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" format="ixt:fixed-zero" scale="0" id="f-367"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" format="ixt:fixed-zero" scale="0" id="f-368"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" format="ixt:fixed-zero" scale="0" id="f-369">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> material realized gains or losses on available-for-sale securities during the three and six months ended June&#160;30, 2023 and 2022.</span></div></ix:continuation><div id="i447d75b6bca148d0bd5c21482392c4f0_46"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" id="f-370" continuedAt="i034a137a7c4d4243baf1cf4c0cd15a5b" escape="true">PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS</ix:nonNumeric></span></div><ix:continuation id="i034a137a7c4d4243baf1cf4c0cd15a5b" continuedAt="i24bc7dcc675248cba292264a82522706"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-371" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is summarized as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Furniture and equipment</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-372">1,444,389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-373">1,423,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-374">306,312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="f-375">306,312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-376">795,132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="f-377">581,381</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-378">955,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="f-379">1,147,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="f-380">105,292</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="f-381">54,631</ix:nonFraction> for the three months ended June&#160;30, 2023 and 2022, respectively. Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="f-382">213,751</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="f-383">85,470</ix:nonFraction> for the six months ended June&#160;30, 2023 and 2022, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net of accumulated amortization, were $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="f-384">263,367</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="f-385">222,100</ix:nonFraction> as of June&#160;30, 2023 and December&#160;31, 2022, respectively, and are included in other assets. Amortization expense was $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="f-386">32,180</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="f-387">32,153</ix:nonFraction> for the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i24bc7dcc675248cba292264a82522706">three months ended June&#160;30, 2023 and 2022, respectively. Amortization expense was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="f-388">68,370</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="f-389">86,636</ix:nonFraction> for the six months ended June&#160;30, 2023 and 2022, respectively.</ix:continuation></span></div><div id="i447d75b6bca148d0bd5c21482392c4f0_49"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-390" continuedAt="ibfc06fd8c72a40b3ab30111a564d9cb3" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="ibfc06fd8c72a40b3ab30111a564d9cb3"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During September 2021, the Company entered into a <ix:nonNumeric contextRef="c-72" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="f-391">10-year</ix:nonNumeric> lease agreement for its corporate headquarters with a term commencing March 10, 2022, for approximately <ix:nonFraction unitRef="sqft" contextRef="c-3" decimals="-3" name="us-gaap:LandSubjectToGroundLeases" format="ixt:num-dot-decimal" scale="0" id="f-392">19,000</ix:nonFraction> square feet of office space at Hudson Commons in New York, New York. The lease provides for monthly rental payments over the lease term. The base rent under the lease is currently $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ovid:LesseeOperatingLeaseBaseRent" format="ixt:num-dot-decimal" scale="6" id="f-393">2.3</ix:nonFraction>&#160;million per year. Rent payments commenced <ix:nonNumeric contextRef="c-73" name="ovid:LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod" format="ixt-sec:durmonth" id="f-394">10</ix:nonNumeric> months following the commencement date of the lease, or January 10, 2023, and continue for <ix:nonNumeric contextRef="c-72" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-395">10</ix:nonNumeric> years following the rent commencement date. The Company issued a letter of credit in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="f-396">1.9</ix:nonFraction>&#160;million in association with the execution of the lease agreement; the letter of credit is characterized as restricted cash on the Company's condensed consolidated balance sheets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Hudson Commons lease has a remaining lease term of approximately <ix:nonNumeric contextRef="c-3" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="f-397">10</ix:nonNumeric> years and includes a single renewal option for an additional <ix:nonNumeric contextRef="c-3" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-398">five years</ix:nonNumeric>. The Company did not include the renewal option in the lease term when calculating the lease liability as the Company is not reasonably certain that it will exercise the renewal option. The present value of the lease payments is calculated using an incremental borrowing rate of <ix:nonFraction unitRef="number" contextRef="c-3" decimals="4" name="ovid:LeaseIncrementalBorrowingRate" scale="-2" id="f-399">7.02</ix:nonFraction>%. Lease expense is included in general and administrative and research and development expenses in the condensed consolidated statements of operations.</span></div><ix:nonNumeric contextRef="c-1" name="ovid:RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock" id="f-400" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU asset and lease liabilities related to the Company's operating lease are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Right-of-use asset, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="f-401">14,412,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Current lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="f-402">944,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Long-term lease liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="f-403">15,389,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-404" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease cost for the six months ended June&#160;30, 2023 were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="0" id="f-405">1,083,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:VariableLeaseCost" format="ixt:fixed-zero" scale="0" id="f-406">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:ShortTermLeaseCost" format="ixt:fixed-zero" scale="0" id="f-407">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-408" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum commitments under the non-cancelable operating lease are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="0" id="f-409">898,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="0" id="f-410">2,316,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="0" id="f-411">2,316,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="0" id="f-412">2,316,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="0" id="f-413">2,316,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="ovid:LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" format="ixt:num-dot-decimal" scale="0" id="f-414">12,347,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="0" id="f-415">22,511,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i447d75b6bca148d0bd5c21482392c4f0_52"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="f-416" continuedAt="i45dc5544c134446f931db326496e0310" escape="true">ACCRUED EXPENSES</ix:nonNumeric></span></div><ix:continuation id="i45dc5544c134446f931db326496e0310"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-417" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payroll and bonus accrual</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-418">2,996,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-419">3,233,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development accrual</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="ovid:AccruedResearchAndDevelopment" format="ixt:num-dot-decimal" scale="0" id="f-420">1,972,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="ovid:AccruedResearchAndDevelopment" format="ixt:num-dot-decimal" scale="0" id="f-421">395,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Professional fees accrual</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-422">401,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-423">682,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-424">63,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-425">192,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-426">5,433,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="f-427">4,504,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13</span></div></div></div><div id="i447d75b6bca148d0bd5c21482392c4f0_55"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-428" continuedAt="ieb29570a0e55451e87e051848359a881" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="ieb29570a0e55451e87e051848359a881"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s capital structure consists of common stock and convertible preferred stock. Pursuant to the Company&#8217;s amended and restated certificate of incorporation, as amended, the Company is authorized to issue up to <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-429">125,000,000</ix:nonFraction> shares of common stock and <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-430">10,000,000</ix:nonFraction> shares of preferred stock. The Company has designated <ix:nonFraction unitRef="shares" contextRef="c-75" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-431">1,250</ix:nonFraction> of the <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-432">10,000,000</ix:nonFraction> authorized shares of preferred stock as non-voting Series A Convertible Preferred Stock (&#8220;Series A Preferred Stock&#8221;).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of common stock are entitled to <ix:nonFraction unitRef="vote" contextRef="c-1" decimals="0" name="ovid:CommonStockNumberOfVotesForEachShare" format="ixt-sec:numwordsen" scale="0" id="f-433">one</ix:nonFraction> vote for each share held. The holders of common stock have no preemptive or other subscription rights, and there are no redemption or sinking fund provisions with respect to such shares. Subject to preferences that may apply to any outstanding series of preferred stock, holders of the common stock are entitled to receive ratably any dividends declared on a non-cumulative basis. The common stock is subordinate to all series of preferred stock with respect to rights upon liquidation, winding up and dissolution of the Company. The holders of common stock are entitled to liquidation proceeds after all liquidation preferences for the preferred stock are satisfied.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="shares" contextRef="c-75" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-434"><ix:nonFraction unitRef="shares" contextRef="c-76" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-435">1,250</ix:nonFraction></ix:nonFraction> shares of Series A Preferred Stock outstanding as of June&#160;30, 2023 and December&#160;31, 2022. Each share of Series A Preferred Stock is convertible into <ix:nonFraction unitRef="shares" contextRef="c-75" decimals="INF" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" format="ixt:num-dot-decimal" scale="0" id="f-436">1,000</ix:nonFraction> shares of common stock at any time at the holder&#8217;s option. However, the holder will be prohibited, subject to certain exceptions, from converting shares of Series A Preferred Stock into shares of common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than, at the written election of the holder, either <ix:nonFraction unitRef="number" contextRef="c-77" decimals="4" name="ovid:MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" scale="-2" id="f-437">9.99</ix:nonFraction>% or <ix:nonFraction unitRef="number" contextRef="c-77" decimals="4" name="ovid:MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders" scale="-2" id="f-438">14.99</ix:nonFraction>% of the total number of shares of common stock then issued and outstanding, which percentage may be changed at the holder&#8217;s election to any other number less than or equal to <ix:nonFraction unitRef="number" contextRef="c-77" decimals="4" name="ovid:AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" scale="-2" id="f-439">19.99</ix:nonFraction>% upon <ix:nonNumeric contextRef="c-77" name="ovid:AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod" format="ixt-sec:durday" id="f-440">61</ix:nonNumeric> days&#8217; notice to the Company; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that effective <ix:nonNumeric contextRef="c-77" name="ovid:AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod" format="ixt-sec:durday" id="f-441">61</ix:nonNumeric> days after delivery of such notice, such beneficial ownership limitations shall not be applicable to any holder that beneficially owns either <ix:nonFraction unitRef="number" contextRef="c-78" decimals="3" name="ovid:BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock" scale="-2" id="f-442">10.0</ix:nonFraction>% or <ix:nonFraction unitRef="number" contextRef="c-79" decimals="3" name="ovid:BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock" scale="-2" id="f-443">15.0</ix:nonFraction>%, as applicable based on the holder&#8217;s initial written election noted above, of the total number of shares of common stock issued and outstanding immediately prior to delivery of such notice. In the event of a liquidation, dissolution, or winding up of the Company, holders of Series A Preferred Stock will receive a payment equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-75" decimals="3" name="us-gaap:PreferredStockLiquidationPreference" scale="0" id="f-444">0.001</ix:nonFraction> per share of Series A Preferred Stock before any proceeds are distributed to the holders of common stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the Company entered into a sales agreement (the &#8220;2020 ATM agreement&#8221;) with Cowen and Company, LLC (&#8220;Cowen&#8221;), under which the Company may offer and sell in &#8220;at the market offerings,&#8221; from time to time at its sole discretion, shares of its common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-5" name="ovid:AggregateOfferingPriceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-445">75.0</ix:nonFraction>&#160;million through Cowen acting as sales agent. As of June&#160;30, 2023, the Company has <ix:nonFraction unitRef="shares" contextRef="c-81" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:fixed-zero" scale="0" id="f-446">not</ix:nonFraction> sold any shares of its common stock under the 2020 ATM agreement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through June&#160;30, 2023, the Company has <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:Dividends" format="ixt:fixed-zero" scale="0" id="f-447">not</ix:nonFraction> declared any dividends. <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:Dividends" format="ixt:fixed-zero" scale="0" id="f-448">No</ix:nonFraction> dividends on the common stock shall be declared and paid unless dividends on the preferred stock have been declared and paid.</span></div></ix:continuation><div id="i447d75b6bca148d0bd5c21482392c4f0_58"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-449" continuedAt="i2324445fb9af4b01ab36497966a5d1cb" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="i2324445fb9af4b01ab36497966a5d1cb" continuedAt="icca51ac613314c88a36da4928a2e619b"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Board of Directors adopted, and the Company's stockholders approved, the 2017 Equity Incentive Plan (&#8220;2017 Plan&#8221;), which became effective on May 4, 2017. The initial reserve of shares of common stock issuable under the 2017 Plan was <ix:nonFraction unitRef="shares" contextRef="c-82" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-450">3,052,059</ix:nonFraction> shares. The 2017 Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance-based stock awards, and other forms of stock-based awards. Additionally, the 2017 Plan provides for the grant of performance cash awards. The Company's employees, officers, directors, consultants and advisors are eligible to receive awards under the 2017 Plan. Following the adoption of the 2017 Plan, no further awards will be granted under the Company&#8217;s prior plan. Pursuant to the terms of the 2017 Plan, on each January 1st, the plan limit shall be increased by the lesser of (x) <ix:nonFraction unitRef="number" contextRef="c-83" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="f-451">5</ix:nonFraction>% of the number of shares of common stock outstanding as of the immediately preceding December 31 and (y) such lesser number as the Board of Directors may determine at its discretion. On January&#160;1, 2023 and January&#160;1, 2022 an additional <ix:nonFraction unitRef="shares" contextRef="c-84" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-452">3,523,344</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-85" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-453">1,000,000</ix:nonFraction> shares, respectively, were reserved for issuance under the 2017 Plan. As of June&#160;30, 2023, there were <ix:nonFraction unitRef="shares" contextRef="c-86" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-454">4,131,738</ix:nonFraction> shares of the Company&#8217;s common stock reserved and available for issuance under the 2017 Plan.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Board of Directors adopted, and the Company's stockholders approved, the 2017 Employee Stock Purchase Plan (&#8220;2017 ESPP&#8221;), which became effective on May 4, 2017. The initial reserve of shares of common stock  issuable under the 2017 ESPP was <ix:nonFraction unitRef="shares" contextRef="c-87" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-455">279,069</ix:nonFraction> shares. The 2017 ESPP allows employees to purchase common stock of the Company at a <ix:nonFraction unitRef="number" contextRef="c-88" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" scale="-2" id="f-456">15</ix:nonFraction>% discount to the market price on designated semi-annual purchase dates. During the three months ended June&#160;30, 2023 and 2022, there were <ix:nonFraction unitRef="shares" contextRef="c-89" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" format="ixt:fixed-zero" scale="0" id="f-457"><ix:nonFraction unitRef="shares" contextRef="c-90" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" format="ixt:fixed-zero" scale="0" id="f-458">no</ix:nonFraction></ix:nonFraction> shares purchased under the 2017 ESPP, and the Company recorded expense of $<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-459">13,446</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-460">20,176</ix:nonFraction>, respectively. During the six months ended June&#160;30, 2023 and 2022, <ix:nonFraction unitRef="shares" contextRef="c-88" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" format="ixt:num-dot-decimal" scale="0" id="f-461">29,830</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-91" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" format="ixt:num-dot-decimal" scale="0" id="f-462">38,583</ix:nonFraction> shares, respectively, were purchased under the 2017 ESPP, and the Company recorded expenses of $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-463">28,600</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-464">41,195</ix:nonFraction>, respectively. The number of shares of common stock reserved for issuance under the 2017 ESPP automatically increases </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><ix:continuation id="icca51ac613314c88a36da4928a2e619b" continuedAt="i7bdb5e6193934a669bdaca28f18f6ec3"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on January 1 of each year, beginning on January 1, 2018 and continuing through and including January 1, 2027, by the lesser of (i) <ix:nonFraction unitRef="number" contextRef="c-88" decimals="2" name="ovid:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease" scale="-2" id="f-465">1</ix:nonFraction>% of the total number of shares of the Company&#8217;s common stock outstanding on December 31 of the preceding calendar year, (ii) <ix:nonFraction unitRef="shares" contextRef="c-88" decimals="INF" name="ovid:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum" format="ixt:num-dot-decimal" scale="0" id="f-466">550,000</ix:nonFraction> shares or (iii) such lesser number of shares determined by the Board. The Board acted prior to each of January&#160;1, 2023 and January&#160;1, 2022 to provide that there be <ix:nonFraction unitRef="shares" contextRef="c-92" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:fixed-zero" scale="0" id="f-467"><ix:nonFraction unitRef="shares" contextRef="c-93" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:fixed-zero" scale="0" id="f-468">no</ix:nonFraction></ix:nonFraction> increase in the number of shares reserved for issuance under the 2017 ESPP on either such date. As of June&#160;30, 2023, there were <ix:nonFraction unitRef="shares" contextRef="c-94" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-469">386,777</ix:nonFraction> shares of the Company&#8217;s common stock reserved and available for issuance under the 2017 ESPP.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s Board of Directors adopted and the Company&#8217;s stockholder&#8217;s approved the 2014 Equity Incentive Plan (&#8220;2014 Plan&#8221;), which authorized the Company to grant shares of common stock in the form of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock and restricted stock units. The 2014 Plan was terminated as to future awards in May 2017, although it continues to govern the terms of options that remain outstanding under the 2014 Plan. No additional stock awards will be granted under the 2014 Plan, and all outstanding stock awards granted under the 2014 Plan that are repurchased, forfeited, expire or are cancelled will become available for grant under the 2017 Plan in accordance with its terms. As of June&#160;30, 2023, options to purchase <ix:nonFraction unitRef="shares" contextRef="c-95" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-470">1,663,597</ix:nonFraction> shares of common stock were outstanding under the 2014 Plan.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless specified otherwise in an individual option agreement, stock options granted under the prior plan and the 2017 Plan generally have a <ix:nonNumeric contextRef="c-83" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-471">ten-year</ix:nonNumeric> term and a <ix:nonNumeric contextRef="c-83" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-472">four-year</ix:nonNumeric> graded vesting period. The vesting requirement is generally conditioned upon the grantee&#8217;s continued service with the Company during the vesting period. Once vested, all options granted are exercisable from the date of grant until they expire. The option grants are non-transferable. Vested options generally remain exercisable for <ix:nonNumeric contextRef="c-83" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:durday" id="f-473">90</ix:nonNumeric> days subsequent to the termination of the option holder&#8217;s service with the Company. In the event of the option holder&#8217;s death or disability while employed by or providing service to the Company, the exercisable period extends to <ix:nonNumeric contextRef="c-96" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:durmonth" id="f-474">12</ix:nonNumeric> months.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance-based option awards generally have similar terms, with vesting commencing on the date the performance condition is achieved and expire in accordance with the specific terms of the agreement. At June&#160;30, 2023, there were <ix:nonFraction unitRef="shares" contextRef="c-97" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" format="ixt:fixed-zero" scale="0" id="f-475">no</ix:nonFraction> performance-based options outstanding.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of options granted during the three and six months ended June&#160;30, 2023 and 2022 was estimated using the Black-Scholes option valuation model. The inputs for the Black-Scholes option valuation model require significant assumptions that are detailed in the table below. The risk-free interest rates were based on the rate for U.S. Treasury securities at the date of grant with maturity dates approximately equal to the expected life at the grant date. The expected life was based on the simplified method in accordance with the SEC Staff Accounting Bulletin No. Topic 14D. Beginning in January 1, 2023, the expected volatility was estimated based on historical volatility information of the Company since the Company's initial public offering.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All assumptions used to calculate the grant date fair value of nonemployee options are generally consistent with the assumptions used for options granted to employees. In the event the Company terminates any of its consulting agreements, the unvested options underlying the agreements would also be canceled.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted <ix:nonFraction unitRef="shares" contextRef="c-98" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-476"><ix:nonFraction unitRef="shares" contextRef="c-99" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-477">50,000</ix:nonFraction></ix:nonFraction> stock options to nonemployee consultants for services rendered during the three and six months ended June&#160;30, 2023 and <ix:nonFraction unitRef="shares" contextRef="c-100" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt-sec:numwordsen" scale="0" id="f-478"><ix:nonFraction unitRef="shares" contextRef="c-101" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt-sec:numwordsen" scale="0" id="f-479">no</ix:nonFraction></ix:nonFraction> stock options during the three and six months ended June 30, 2022. There were <ix:nonFraction unitRef="shares" contextRef="c-102" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="f-480">130,834</ix:nonFraction> unvested nonemployee options outstanding as of June&#160;30, 2023 and 2022. Total expense recognized related to nonemployee stock options for the three months ended June&#160;30, 2023 and 2022 was $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-481">163,199</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-482">160,337</ix:nonFraction>, respectively. Total expense recognized related to nonemployee stock options for the six months ended June&#160;30, 2023 and 2022, was $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-483">271,784</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-484">355,107</ix:nonFraction>, respectively. Total unrecognized compensation expenses related to the nonemployee stock options was $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="0" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="0" id="f-485">994,411</ix:nonFraction> as of June&#160;30, 2023. The Company did <ix:nonFraction unitRef="usd" contextRef="c-103" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="f-486"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="f-487">not</ix:nonFraction></ix:nonFraction> recognize any expense for nonemployee performance-based option awards during the six months ended June&#160;30, 2023 or 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted <ix:nonFraction unitRef="shares" contextRef="c-105" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-488">270,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-106" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-489">2,426,750</ix:nonFraction> stock options to employees during the three months ended June&#160;30, 2023 and 2022, respectively. The Company granted <ix:nonFraction unitRef="shares" contextRef="c-107" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-490">2,950,500</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-108" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-491">4,296,355</ix:nonFraction> stock options to employees during the six months ended June&#160;30, 2023 and 2022, respectively. There were <ix:nonFraction unitRef="shares" contextRef="c-109" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="f-492">6,710,485</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-110" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="f-493">7,354,964</ix:nonFraction> unvested employee options outstanding as of June&#160;30, 2023, and 2022, respectively. Total expense recognized related to the employee stock options for the three months ended June&#160;30, 2023 and 2022 was $<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-494">1.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-495">1.5</ix:nonFraction>&#160;million, respectively. Total expense recognized related to the employee stock options for the six months ended June&#160;30, 2023 and 2022 was $<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-496">3.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-497">2.6</ix:nonFraction> million, respectively. Total unrecognized compensation expense related to employee stock options was $<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="f-498">12.8</ix:nonFraction> million as of June&#160;30, 2023. <ix:nonFraction unitRef="usd" contextRef="c-111" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="f-499"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="f-500">No</ix:nonFraction></ix:nonFraction> expense for employee performance-based options was recognized during the six months ended in June&#160;30, 2023 and 2022.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><ix:continuation id="i7bdb5e6193934a669bdaca28f18f6ec3" continuedAt="i407be9feab6f42a488f379537af999cc"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-501" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s stock-based compensation expense was recognized in operating expenses as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.606%"><tr><td style="width:1.0%"></td><td style="width:41.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Research and development</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-502">579,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-503">387,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-504">1,090,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-505">782,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-506">1,368,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-507">1,332,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-508">2,774,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-509">2,262,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-510">1,948,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-511">1,720,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-512">3,865,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-513">3,045,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="f-514" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.606%"><tr><td style="width:1.0%"></td><td style="width:41.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-515">1,935,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-516">1,700,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-517">3,836,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-518">3,003,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-519">13,446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-520">20,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-521">28,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-522">41,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-523">1,948,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-524">1,720,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-525">3,865,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-526">3,045,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-527" continuedAt="i86c09f028821450391f42153a9669e05" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of employee options granted during the three and six months ended June&#160;30, 2023 and 2022 was estimated utilizing the following assumptions:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.757%"><tr><td style="width:1.0%"></td><td style="width:41.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.665%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.591%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.665%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.665%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.671%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="c-105" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-528">84.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="c-106" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-529">87.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="c-107" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-530">84.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="c-108" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-531">87.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonNumeric contextRef="c-105" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-532">6.08</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonNumeric contextRef="c-106" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-533">6.08</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonNumeric contextRef="c-107" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-534">6.07</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonNumeric contextRef="c-108" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-535">6.08</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="c-105" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-536">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="c-106" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-537">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="c-107" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-538">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="c-108" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-539">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="c-105" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-540">3.63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="c-106" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-541">2.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="c-107" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-542">3.97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="c-108" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-543">2.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Fair value of option on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-105" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-544">2.66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-106" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-545">2.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-107" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-546">1.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-108" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-547">2.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span><br/></span></div><ix:continuation id="i407be9feab6f42a488f379537af999cc"><ix:continuation id="i86c09f028821450391f42153a9669e05"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of non-employee options granted during the three and six months ended June&#160;30, 2023 and 2022 was estimated utilizing the following assumptions:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:33.050%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.932%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.936%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="c-98" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-548">83.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="c-100" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" format="ixt:fixed-zero" scale="-2" id="f-549">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="c-99" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-550">83.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="c-101" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" format="ixt:fixed-zero" scale="-2" id="f-551">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Expected term in years</span></td><td colspan="3" style="padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonNumeric contextRef="c-98" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-552">5.25</ix:nonNumeric></span></td><td colspan="3" style="padding:0 7pt 0 1pt"></td><td colspan="3" style="padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonNumeric contextRef="c-100" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-553">0.00</ix:nonNumeric></span></td><td colspan="3" style="padding:0 8.02pt 0 1pt"></td><td colspan="3" style="padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonNumeric contextRef="c-99" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-554">5.25</ix:nonNumeric></span></td><td colspan="3" style="padding:0 7pt 0 1pt"></td><td colspan="3" style="padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonNumeric contextRef="c-101" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-555">0.00</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="c-98" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-556">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="c-100" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-557">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="c-99" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-558">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="c-101" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-559">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Risk-free interest rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="c-98" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-560">3.89</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="c-100" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" format="ixt:fixed-zero" scale="-2" id="f-561">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="c-99" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-562">3.89</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="number" contextRef="c-101" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" format="ixt:fixed-zero" scale="-2" id="f-563">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Fair value of option on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-98" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-564">2.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-100" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-565">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-99" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-566">2.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-567">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-568" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the number of options outstanding and the weighted average exercise price:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life in Years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-569">12,961,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-570">4.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-129" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-571">7.42</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="f-572">62,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-573">3,000,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-574">2.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="ovid:ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife" format="ixt-sec:duryear" id="f-575">9.69</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-576">91,078</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-577">2.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-578">421,825</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-579">3.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-580">15,448,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-581">3.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-582">7.37</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="f-583">5,854,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable at June 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-584">8,607,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="f-585">4.64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-586">6.17</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="f-587">2,406,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2023 there was approximately $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="f-588">13.8</ix:nonFraction> million of unrecognized stock&#8211;based compensation expense related to employee and nonemployee grants, which is expected to be recognized over a remaining average vesting period of <ix:nonNumeric contextRef="c-1" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-589">2.43</ix:nonNumeric> years.</span></div></ix:continuation><div id="i447d75b6bca148d0bd5c21482392c4f0_61"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-590" continuedAt="i9399287e2a4c4df7899f7dce66a2ccec" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="i9399287e2a4c4df7899f7dce66a2ccec"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s interim income tax provision consists of U.S. federal and state income taxes based on the estimated annual effective tax rate that the Company expects for the full year together with the tax effect of discrete items. Each quarter the Company updates its estimate of the annual effective tax rate and records cumulative adjustments as necessary. As of June&#160;30, 2023, the Company was in a pre-tax loss position, and is anticipated to remain so throughout the year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June&#160;30, 2023, the Company did <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-591">no</ix:nonFraction>t record any tax benefit or expense.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, management evaluates whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in those periods in which temporary differences become deductible and/or net operating losses can be utilized. Management assesses all positive and negative evidence when determining the amount of the net deferred tax assets that are more likely than not to be realized. This evidence includes, but is not limited to, prior earnings history, scheduled reversal of taxable temporary differences, tax planning strategies and projected future taxable income. Significant weight is given to positive and negative evidence that is objectively verifiable. Based on these factors, including cumulative losses in recent years, the Company continues to maintain a full valuation allowance against its net deferred tax assets as of June&#160;30, 2023.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17</span></div></div></div><div id="i447d75b6bca148d0bd5c21482392c4f0_64"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-592" continuedAt="i3215a82e78c34b45a5dee654bf346321" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i3215a82e78c34b45a5dee654bf346321" continuedAt="i822b3a63f9f74217a37a14c12d3e35ac"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License Agreements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Northwestern University License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, the Company entered into a license agreement with Northwestern University, (&#8220;Northwestern&#8221;), pursuant to which Northwestern granted the Company an exclusive, worldwide license to patent rights of certain inventions (&#8220;Northwestern Patent Rights&#8221;) which relate to a specific compound and related methods of use for such compound, along with certain Know-How related to the practice of the inventions claimed in the Northwestern Patents. The Company is developing OV329 under this agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Northwestern agreement, the Company was granted exclusive rights to research, develop, manufacture and commercialize products utilizing the Northwestern Patent Rights for all uses. The Company has agreed that it will not use the Northwestern Patent Rights to develop any products for the treatment of cancer, but Northwestern may not grant rights in the technology to others for use in cancer. The Company also has an option, exercisable during the term of the agreement to an exclusive license under certain intellectual property rights covering novel compounds with the same or similar mechanism of action as the primary compound that is the subject of the license agreement. Northwestern has retained the right, on behalf of itself and other non-profit institutions, to use the Northwestern Patent Rights and practice the inventions claimed therein for educational and research purposes and to publish information about the inventions covered by the Northwestern Patent Rights. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon entry into the Northwestern agreement, the Company paid an upfront non-creditable one-time license issuance fee of $<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="ovid:UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment" format="ixt:num-dot-decimal" scale="0" id="f-593">75,000</ix:nonFraction>, and is required to pay an annual license maintenance fee of $<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="ovid:AnnualLicenseMaintenanceFeePayable" format="ixt:num-dot-decimal" scale="0" id="f-594">20,000</ix:nonFraction>, which will be creditable against any royalties payable to Northwestern following first commercial sale of licensed products under the agreement. The Company is responsible for all ongoing costs of filing, prosecuting and maintaining the Northwestern Patents, but also has the right to control such activities using its own patent counsel. In consideration for the rights granted to the Company under the Northwestern agreement, the Company is required to pay to Northwestern up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="ovid:ConsiderationPayableForRightsGrant" format="ixt:num-dot-decimal" scale="6" id="f-595">5.3</ix:nonFraction>&#160;million upon the achievement of certain development and regulatory milestones for the first product covered by the Northwestern Patents, and upon commercialization of any such products, will be required to pay to Northwestern a tiered royalty on net sales of such products by the Company, its affiliates or sublicensees, at percentages in the low to mid-single-digits, subject to standard reductions and offsets. The Company&#8217;s royalty obligations continue on a product-by-product and country-by-country basis until the later of the expiration of the last-to-expire valid claim in a licensed patent covering the applicable product in such country and <ix:nonNumeric contextRef="c-132" name="ovid:RoyaltyObligationTerm" format="ixt-sec:duryear" id="f-596">10</ix:nonNumeric> years following the first commercial sale of such product in such country. If the Company sublicenses a Northwestern Patent Right, it will be obligated to pay to Northwestern a specified percentage of sublicense revenue received by the Company, ranging from the high single digits to the low-teens. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Northwestern agreement requires that the Company use commercially reasonable efforts to develop and commercialize at least <ix:nonFraction unitRef="product" contextRef="c-130" decimals="INF" name="ovid:MinimumNumberOfProductCoveredUnderLicenseAgreement" format="ixt-sec:numwordsen" scale="0" id="f-597">one</ix:nonFraction> product that is covered by the Northwestern Patent Rights.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the Northwestern agreement will remain in force until the expiration of the Company&#8217;s payment obligations thereunder. The Company has the right to terminate the agreement for any reason upon prior written notice or for an uncured material breach by Northwestern. Northwestern may terminate the agreement for the Company&#8217;s uncured material breach or insolvency.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AstraZeneca AB License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2021, the Company entered into an exclusive license agreement with AstraZeneca AB (&#8220;AstraZeneca&#8221;), for a library of early-stage small molecules targeting the KCC2 transporter, including lead candidate OV350. Upon execution of the agreement, the Company was obligated to pay an upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="ovid:UpfrontCashPayment" format="ixt:num-dot-decimal" scale="6" id="f-598">5.0</ix:nonFraction>&#160;million and issued shares of the Company's common stock in an amount that equaled $<ix:nonFraction unitRef="shares" contextRef="c-134" decimals="-5" name="ovid:LicenseAgreementConsiderationSharesIssued" format="ixt:num-dot-decimal" scale="6" id="f-599">7.3</ix:nonFraction>&#160;million based on the volume-weighted average price of shares of the Company's common stock for the <ix:nonNumeric contextRef="c-133" name="ovid:CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate" format="ixt-sec:durday" id="f-600">30</ix:nonNumeric> business days immediately preceding the execution date of the transaction. Since the intangibles acquired in the AstraZeneca license agreement do not have an alternative future use, all costs incurred were treated as research and development expense. The Company recorded a total of $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-601">12.3</ix:nonFraction>&#160;million as research and development expense related to this agreement during December 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the AstraZeneca license agreement, the Company agreed to potential milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-5" name="ovid:LicenseAgreementMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-602">203.0</ix:nonFraction>&#160;million upon the achievement of certain developmental, regulatory and sales milestones. The first payment of $<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-5" name="ovid:FirstPaymentDueUponCompletionOfFirstPhase" format="ixt:num-dot-decimal" scale="6" id="f-603">3.0</ix:nonFraction>&#160;million is due upon the successful completion of the first Phase 2 clinical study of a licensed product following a positive biomarker readout in a Phase 1 clinical study.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gensaic Collaboration and Option Agreement</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><ix:continuation id="i822b3a63f9f74217a37a14c12d3e35ac"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Company entered into a collaboration and option agreement (&#8220;Collaboration Agreement&#8221;) with Gensaic. The Collaboration Agreement involves the research and development of phage-derived particle (&#8220;PDP&#8221;) products on Gensaic's proprietary platform for certain central nervous system rare disorder targets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Collaboration Agreement, Gensaic grants the Company an exclusive option to obtain an exclusive license with respect to certain identified lead PDP products, which are exercisable at any time prior to the expiration of the option period. Once a product is identified by the Company that demonstrates sufficient efficacy, the Company may exercise its option with respect to the specific research program for that PDP product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company shall reimburse Gensaic for Gensaic's research costs related to the specific research plan for PDP products identified, the research plan and budget shall be mutually agreed upon by the parties and shall not exceed $<ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-5" name="ovid:CollaborationAndOptionAgreementResearchPlanAndBudgetExpectedCosts" format="ixt:num-dot-decimal" scale="6" id="f-604">3.0</ix:nonFraction>&#160;million in any research year. The Company will record these reimbursement payments as research and development costs in the period the research costs are incurred. In May 2023, the Company identified a lead PDP candidate for further research and provided $<ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-5" name="ovid:CollaborationAndOptionAgreementResearchPlanAndBudgetExpectedCosts" format="ixt:num-dot-decimal" scale="6" id="f-605">3.5</ix:nonFraction>&#160;million to Gensaic to support the approved research plan and budget. The amount is included in prepaid expenses and other current assets in the condensed consolidated balance sheets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product is ultimately commercialized under this agreement, the Company shall make tiered royalty payments to Gensaic in the mid-single to low double-digit range based on the net sales of all licensed PDP products during the royalty term. The Company is also responsible for potential tiered milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-5" name="ovid:LicenseAgreementMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-606">452.0</ix:nonFraction>&#160;million based upon the achievement of certain sales milestone events and developmental milestone approvals for <ix:nonFraction unitRef="product" contextRef="c-139" decimals="0" name="ovid:LicenseAgreementDevelopmentMilestoneApprovalsProductThreshold" format="ixt-sec:numwordsen" scale="0" id="f-607">three</ix:nonFraction> or more products. Gensaic also has the option to become a collaborative partner in the development and commercialization of PDP products in exchange for a fee based on a percentage of the costs incurred by the Company through the date Gensaic exercises its option. The Company would no longer be required to pay Gensaic royalty or milestone payments if Gensaic elects to exercise its option.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may terminate this agreement by providing written notice to Gensaic <ix:nonNumeric contextRef="c-140" name="ovid:LicenseAgreementTerminationAdvanceNoticePeriod" format="ixt-sec:durday" id="f-608">90</ix:nonNumeric> days in advance of the termination date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2023, none of these contingent payments were considered probable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. The Company is not currently involved in any legal matters arising in the normal course of business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of their respective employment agreements, certain of our executive officers are eligible to receive severance payments and benefits upon a termination without &#8220;cause&#8221; or due to &#8220;permanent disability,&#8221; or upon &#8220;resignation for good reason,&#8221; contingent upon the executive officer&#8217;s delivery to the Company of a satisfactory release of claims, and subject to the executive officer&#8217;s compliance with non-competition and non-solicitation restrictive covenants.</span></div></ix:continuation><div id="i447d75b6bca148d0bd5c21482392c4f0_67"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-609" continuedAt="i759ae77b68324a7e9c611cee23f688c2" escape="true">COLLABORATION AND LICENSE AGREEMENTS</ix:nonNumeric></span></div><ix:continuation id="i759ae77b68324a7e9c611cee23f688c2" continuedAt="i937f1f7a584c49ae8b0678d336227bba"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Takeda Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 6, 2017, the Company entered into a license and collaboration agreement with Takeda under which the Company licensed from Takeda certain exclusive rights to develop and commercialize soticlestat in certain territories.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Company entered into the RLT Agreement, pursuant to which Takeda secured rights to the Company&#8217;s <ix:nonFraction unitRef="number" contextRef="c-141" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-610">50</ix:nonFraction>% global share in soticlestat, and the Company granted to Takeda an exclusive worldwide license under the Company&#8217;s relevant intellectual property rights to develop and commercialize the investigational medicine soticlestat for the treatment of developmental and epileptic encephalopathies, including Dravet syndrome and Lennox-Gastaut syndrome.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the RLT Agreement, all rights in soticlestat were owned by Takeda or exclusively licensed to Takeda by the Company. Takeda assumed all responsibility for, and costs of, both development and commercialization of soticlestat, and the Company will no longer have any financial obligation to Takeda under the original collaboration agreement, including milestone payments or any future development and commercialization costs. On March 29, 2021 upon the closing of the RLT Agreement, the Company received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-5" name="ovid:UpfrontPaymentReceivable" format="ixt:num-dot-decimal" scale="6" id="f-611">196.0</ix:nonFraction>&#160;million and, if soticlestat is successfully developed, will be eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-5" name="ovid:AgreementMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-612">660.0</ix:nonFraction>&#160;million upon Takeda achieving developmental, regulatory and sales milestones. In addition, the Company will be entitled to receive tiered royalties beginning in the low double-digits, and up to <ix:nonFraction unitRef="number" contextRef="c-143" decimals="2" name="ovid:AdditionalPaymentReceivableOnSalesPercentage" scale="-2" id="f-613">20</ix:nonFraction>% on sales of soticlestat if regulatory approval is achieved. Royalties will be payable on a country-by-country and product-by-product basis for any indications that soticlestat is approved for and sold during the period beginning on the date of the first commercial sale of such product in such country and ending on the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><ix:continuation id="i937f1f7a584c49ae8b0678d336227bba" continuedAt="i47f82de7c6f847b5845f066fdb55b6e0"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">later to occur of the expiration of patent rights covering the product in such country and a specified anniversary of such first commercial sale.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified the following material promises under the RLT Agreement: (1) no later than the second business day prior to the closing of the RLT Agreement (the &#8220;Closing Date&#8221;), the Company and Takeda were required to agree on an estimate of the development expenses that accrued, or would accrue, under the original collaboration agreement as of March 31, 2021; (2) on the Closing Date, the Company was required to (i) provide and transfer to Takeda the materials, information and data relating to the soticlestat program, including clinical trial data and results, as further set forth in the RLT Agreement, (ii) assign to Takeda certain agreements applicable to the soticlestat program, and (iii) assign to Takeda all of its right, title and interest in, to and under all intellectual property rights developed or created pursuant to the original collaboration agreement and owned jointly by the Company and Takeda as of the Closing Date; (3) within 45 days after March 31, 2021, the Company and Takeda were required to provide a written report to the finance officer designated by the other party setting forth a final total of the development expenses that accrued as of March 31, 2021 and, within 10 business days after receipt of such report, the finance officers shall agree on whether a net settlement payment is due from Takeda to the Company or from the Company to Takeda; and (4) within 75 days after the Closing Date, to the extent not provided on the Closing Date, Ovid shall provide to Takeda (i) any materials, information and data relating to the soticlestat program, including clinical trial data and results, as further set forth in the RLT Agreement, (ii) other documents (including all expired agreements and related data developed thereunder) to the extent relating to the soticlestat program that are necessary for the exploitation, development, commercialization and manufacture of soticlestat, as further set forth in the RLT Agreement and (iii) any tangible embodiment of the intellectual property rights controlled by Ovid that are reasonably necessary for, used in or held for use in Takeda&#8217;s exploitation of the soticlestat program.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the transaction price is equal to the upfront fee of $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="ovid:UpFrontFeeAmount" format="ixt:num-dot-decimal" scale="6" id="f-614">196.0</ix:nonFraction>&#160;million and is associated with all four performance obligations identified above. It is noted that the incremental effort associated with performance obligations three and four is negligible and not material in the context of the RLT Agreement since all of the information is related to the collaboration period for which the Company already has the information readily available. Therefore, since they are not material in the context of the RLT Agreement, the full upfront fee was allocated to the two performance obligations satisfied at closing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2023, <ix:nonFraction unitRef="usd" contextRef="c-145" decimals="INF" name="ovid:LicenseAndCollaborationAgreementExpense" format="ixt:fixed-zero" scale="0" id="f-615">no</ix:nonFraction> expense was recognized pursuant to the RLT Agreement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Healx License and Option Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2022, the Company entered an exclusive license option agreement (&#8220;Healx License and Option Agreement&#8221;) with Healx, Ltd. (&#8220;Healx&#8221;). Under the terms of the Healx License and Option Agreement, Healx has secured a one-year option to investigate gaboxadol (&#8220;OV101&#8221;) as part of a potential combination therapy for Fragile X syndrome in a Phase 1B/2A clinical trial, as well as a treatment for other indications, for an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-5" name="ovid:UpFrontPayment" format="ixt:num-dot-decimal" scale="6" id="f-616">0.5</ix:nonFraction>&#160;million, and fees to support prosecution and maintenance of our relevant intellectual property rights. At the end of the one-year option period, Healx has the option to secure rights to an exclusive license under the Company's relevant intellectual property rights, in exchange for an additional payment of $<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-5" name="ovid:LicenseOptionAgreementDevelopmentAndCommercialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-617">2.0</ix:nonFraction>&#160;million, development and commercial milestone payments, and low to mid-tier double digit royalties. On February 1, 2023, the Company granted an extension of the option period for up to <ix:nonNumeric contextRef="c-147" name="ovid:LicenseOptionAgreementExtensionPeriod" format="ixt-sec:durwordsen" id="f-618">four months</ix:nonNumeric> for Healx to continue to investigate gaboxadol. Royalties are payable on a country-by-country and product-by-product basis during the period beginning on the date of the first commercial sale of such product in such country and ending on the later to occur of the expiration of patent rights covering the product in such country and a specified anniversary of such first commercial sale. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healx will assume all responsibility for, and costs of, both development and commercialization of gaboxadol following the exercise of the option. The Company will retain the option to co-develop and co-commercialize the program with Healx (&#8220;Ovid Opt-In Right&#8221;) at the end of a positive readout of clinical Phase 2B and would share net profits and losses in lieu of the milestones and royalty payments. If the Ovid Opt-In Right were exercised, the Company would be required to pay Healx <ix:nonFraction unitRef="number" contextRef="c-148" decimals="2" name="ovid:PercentageOfDevelopmentCosts" scale="-2" id="f-619">50</ix:nonFraction>% of development costs. The Company does not plan to conduct further trials of gaboxadol. The term of the Healx License and Option Agreement will continue until the later of (a) the expiration of all relevant royalty terms, or in the event that Healx does not exercise its option during the option period defined in the Healx License and Option Agreement, or the Option Period, the expiration of such period, or (b) in the event that Healx does exercise its option during the Option Period, and the Company does not exercise the Ovid Opt-In Right during the period of time it has to opt-in, or the Opt-In Period, or the opt-in terms are otherwise terminated, upon the expiration of all payment obligations, or (c) in the event that Healx does exercise the Option during the Option Period, and the Company does exercise the Ovid Opt-In Right during the Opt-In Period, such time as neither Healx nor the Company is continuing to exploit gaboxadol. Further, if the Company exercises the Ovid Opt-In Right to co-develop and co-commercialize the program, it will owe a share of the net profit share to a third party with which it previously established a licensing agreement. If the Company does not exercise the Ovid Opt-In Right, it will owe the third party a share of all milestone and royalty payments.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><ix:continuation id="i47f82de7c6f847b5845f066fdb55b6e0"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 9, 2023, the Company entered into an amendment to the Healx License and Option Agreement whereby revisions were made to terms regarding the timing of the option exercise fee payable by Healx to the Company, the clinical and regulatory milestone payment structure, and the royalty payment structure. Additionally, the parties agreed that following the exercise of the option, Healx would assume direct responsibility for patent maintenance and prosecution and that the Company would transfer to Healx all supply obligations with respect to the active pharmaceutical ingredient and finished gaboxadol products and any related licensed technology and know-how in the Company's possession that is relevant to the manufacture of such licensed products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-620">No</ix:nonFraction> revenue was recognized relating to this agreement during the six months ended June&#160;30, 2023. During the six months ended June&#160;30, 2022, the Company recorded revenue of $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-621">0.5</ix:nonFraction>&#160;million associated with the Healx License and Option Agreement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marinus Pharmaceuticals Out-License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 1, 2022, the Company entered into an exclusive patent license agreement with Marinus (&#8220;Marinus License Agreement&#8221;). Under the Marinus License Agreement, the Company granted Marinus an exclusive, non-transferable (except as expressly provided therein), royalty-bearing right and license under certain Ovid patents relating to ganaxolone to develop, make, have made, commercialize, promote, distribute, sell, offer for sale and import licensed products in the territory (which consist of the United States, the European Economic Area, United Kingdom and Switzerland) for the treatment of CDKL5 deficiency disorders. Following the date of regulatory approval by the FDA of the first licensed product in the territory which was received on March 18, 2022, Marinus issued, at the Company's option, <ix:nonFraction unitRef="shares" contextRef="c-150" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-622">123,255</ix:nonFraction> shares of Marinus common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-150" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-623">0.001</ix:nonFraction> per share, as payment. The Marinus License Agreement also provides for payment of royalties from Marinus to the Company in single digits on net sales of each such licensed product sold.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded revenue and an associated investment in equity securities of approximately $<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-624">0.9</ix:nonFraction>&#160;million related to the patent license agreement on March 18, 2022, based on the price of Marinus common stock on March 1, 2022. The Company had unrealized gains on the Marinus common stock of $<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="f-625">0.8</ix:nonFraction>&#160;million and unrealized losses of $<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="f-626">0.3</ix:nonFraction>&#160;million for the six months ended June&#160;30, 2023 and 2022, respectively, which were recorded as unrealized gains (losses) on equity securities and are reflected in other income (expense), net in the condensed consolidated statements of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Graviton License Agreement and Equity Purchase</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 30, 2023, the Company entered into a collaboration and license agreement with Graviton (&#8220;Graviton Agreement&#8221;), whereby it secured from Graviton an exclusive license to develop and commercialize Graviton's library of ROCK2 inhibitors including their lead program GV101 in rare central nervous system (&#8220;CNS&#8221;) disorders (excluding amyotrophic lateral sclerosis) worldwide (excluding China, Hong Kong, Macau and Taiwan). Under the Graviton Agreement, the Company and Graviton plan to investigate GV101 in cerebral cavernous malformations as well as Graviton's library of ROCK2 inhibitors in other rare CNS disorders. The Company will be responsible for all development and commercialization costs of the products. Should the Company receive regulatory approval and commercialize any of Graviton&#8217;s ROCK2 inhibitors, it will pay Graviton tiered royalties on net sales ranging from the mid to high teens. As part of the Graviton Agreement, the Company also purchased shares of Graviton's preferred stock for $<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" format="ixt:num-dot-decimal" scale="6" id="f-627">10.0</ix:nonFraction>&#160;million. The Company recorded the purchase of the preferred stock as a long-term equity investment on its condensed consolidated balance sheets.</span></div></ix:continuation><div id="i447d75b6bca148d0bd5c21482392c4f0_70"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 12 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-628" continuedAt="i7dd30c80c2a647579d0f2e2442af6c07" escape="true">RELATED PARTY TRANSACTIONS</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7dd30c80c2a647579d0f2e2442af6c07">In March 2021, the Company entered into the RLT Agreement with Takeda. For a description of the RLT Agreement, see Note 11.</ix:continuation></span></div><div id="i447d75b6bca148d0bd5c21482392c4f0_73"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 13 &#8211; <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-629" continuedAt="i4d8cea5d77f74710bef722786fc2884f" escape="true">NET LOSS PER SHARE</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4d8cea5d77f74710bef722786fc2884f" continuedAt="i2870655277a64bcf843185ab27859b87">Basic net loss per share is calculated based upon the weighted-average number of common shares outstanding during the period, excluding outstanding stock options that have not yet vested. For any period in which the Company records net income, diluted net income per share is calculated based upon the weighted-average number of common shares outstanding during the period plus the dilutive impact of weighted-average common equivalent shares outstanding during the period resulting from the assumed exercise of outstanding stock options determined under the treasury stock method and the assumed conversion of preferred stock into common shares determined using the if-converted method. Diluted net loss per share is equivalent to the basic net loss per share due to the exclusion of outstanding stock options and convertible preferred stock because the inclusion of these securities would result in an anti-dilutive effect on per share amounts.</ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><ix:continuation id="i2870655277a64bcf843185ab27859b87"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The basic and diluted net loss per common share is presented in conformity with the two-class method required for participating securities and multiple classes of shares. The Company considers its preferred stock to be participating securities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For any period in which the Company records net income, undistributed earnings allocated to the participating securities are subtracted from net income in determining net income attributable to common stockholders. The undistributed earnings have been allocated based on the participation rights of preferred stock and common shares as if the earnings for the year have been distributed. For periods in which the Company recognizes a net loss, undistributed losses are allocated only to common shares as the participating securities do not contractually participate in the Company&#8217;s losses. Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Participating securities are excluded from basic weighted-average common shares outstanding.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-630" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the calculation of basic and diluted net loss per share:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"><tr><td style="width:1.0%"></td><td style="width:44.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.989%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.989%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.989%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-631">12,408,330</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-632">14,588,414</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-633">25,764,539</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="f-634">30,696,470</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to participating securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" format="ixt:fixed-zero" scale="0" id="f-635">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" format="ixt:fixed-zero" scale="0" id="f-636">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" format="ixt:fixed-zero" scale="0" id="f-637">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" format="ixt:fixed-zero" scale="0" id="f-638">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="0" id="f-639">12,408,330</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="0" id="f-640">14,588,414</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="0" id="f-641">25,764,539</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="0" id="f-642">30,696,470</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="0" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="0" id="f-643">12,408,330</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="0" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="0" id="f-644">14,588,414</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="0" id="f-645">25,764,539</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="0" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="0" id="f-646">30,696,470</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding used in</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;computing net loss per share - basic</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-647">70,534,181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-648">70,391,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-649">70,512,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-650">70,391,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding used in</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;computing loss per share - diluted</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-651">70,534,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-652">70,391,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-653">70,512,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-654">70,391,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-655">0.18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-656">0.21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-657">0.37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-658">0.44</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-659">0.18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-660">0.21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-661">0.37</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-662">0.44</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-663" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding as they would be anti-dilutive:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.839%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.839%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-155" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-664">15,448,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-156" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-665">13,451,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-157" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-666">15,448,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-158" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-667">13,103,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issuable upon conversion of Series A convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-159" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-668">1,250,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-160" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-669">1,250,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-161" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-670">1,250,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-162" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-671">1,250,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22</span></div></div></div><div id="i447d75b6bca148d0bd5c21482392c4f0_79"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The following information should be read in conjunction with our unaudited condensed consolidated financial statements and notes thereto included in this Quarterly Report on Form 10-Q and the audited financial information and the notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2022, which was filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on March 13, 2023. In addition to historical financial information, the following discussion contains forward-looking statements based upon our current plans, expectations and beliefs that involve risks, uncertainties and assumptions. Our actual results and the timing of selected events may differ materially from those described in or implied by these forward-looking statements as a result of many factors, including those set forth under the section titled &#8220;Risk Factors&#8221; in Part II, Item 1A. You should carefully read the &#8220;Risk Factors&#8221; section of this Quarterly Report on Form 10-Q to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. Please also see the section entitled &#8220;Special Note Regarding Forward-Looking Statements.&#8221;</span></div><div id="i447d75b6bca148d0bd5c21482392c4f0_82"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders in a manner that is scientifically driven, patient focused and is coupled with an integrated and disciplined approach to research, clinical development and business development. Our team has significant experience and understanding of rare epilepsies and seizure-related neurological conditions, and we continue to build insight into the way the different molecular mechanisms and pathways underlying these disorders impact the symptoms patients suffer. We have set out to be a leader in the field, and have developed a differentiated pipeline containing three novel mechanisms of action to target different causes of epilepsies and seizures. Our knowledge of epilepsy disease biology and pathology, which was acquired through our small molecule development programs, now contributes to our pursuit of additional relevant genetic targets and molecular pathways. Over time, we have built a scalable scientific platform and efficient development capabilities in epilepsies that focus on clear, clinical endpoints. We are initially pursuing therapeutic assets for rare disorders as they can leverage accelerated development programs. If successfully developed and marketed in rare conditions, we intend to explore these assets for broader neurologic indications, as applicable. Our cohesive focus in rare epilepsies and seizures reinforces our belief that we can develop and produce multiple novel medicines, scale our infrastructure, and thereby succeed in our mission.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in April 2014, we have devoted substantially all of our efforts to organizing and planning our business, building our management and technical team, acquiring operating assets and raising capital. We have historically funded our business primarily through the sale of our capital stock. Through June&#160;30, 2023, we have raised net proceeds of $275.4 million from the sale of our convertible preferred stock and our common stock. We have also, in previous periods, generated revenue through license and collaboration agreements. As of June&#160;30, 2023, we had $96.5&#160;million in cash, cash equivalents and marketable securities. As of June&#160;30, 2023, we had an accumulated deficit of $251.3&#160;million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant expenses and operating losses for at least the next several years. Our net losses may fluctuate significantly from period to period, depending on the timing of our planned clinical trials and expenditures on our other research and development and commercial development activities. We expect our expenses will increase substantially over time as we:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">continue the ongoing and planned preclinical and clinical development of our drug candidates;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">build a portfolio of drug candidates through the development, acquisition or in-license of drugs, drug candidates or technologies;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">initiate preclinical studies and clinical trials for any additional drug candidates that we may pursue in the future;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">seek marketing approvals for our current and future drug candidates that successfully complete clinical trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">establish a sales, marketing and distribution infrastructure to commercialize any drug candidate for which we may obtain marketing approval;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">develop, maintain, expand and protect our intellectual property portfolio;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">implement operational, financial and management systems; and </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">attract, hire and retain additional administrative, clinical, regulatory, manufacturing, commercial and scientific personnel.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following chart sets forth the status and mechanism of action of our drug candidates:</span></div><div style="margin-top:6pt;text-align:center;text-indent:-9pt"><img src="ovid-20230630_g1.jpg" alt="pipeline.jpg" style="height:337px;margin-bottom:5pt;vertical-align:text-bottom;width:768px"/></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2023, Takeda provided a corporate update in which it reiterated that the anticipated timeline for regulatory filing of the two pivotal Phase 3 trials evaluating soticlestat for Lennox-Gastaut and Dravet syndromes are expected in Takeda&#8217;s 2024 fiscal year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2022, the FDA cleared our investigational new drug application for OV329, a GABA-aminotransferase inhibitor, and we subsequently initiated a Phase 1 trial in healthy volunteers.</span></div><div id="i447d75b6bca148d0bd5c21482392c4f0_85"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Risks and Uncertainties</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global economic slowdown, the overall disruption of global healthcare systems and other risks and uncertainties associated with bank failures, public health crises and the ongoing war between Russia and Ukraine may have a material adverse effect on our business, financial condition, results of operations and growth prospects. The resulting high inflation rates may materially affect our business and corresponding financial position and cash flows. Inflationary factors, such as increases in the cost of our clinical trial materials and supplies, interest rates and overhead costs may adversely affect our operating results. Rising interest rates also present a recent challenge impacting the U.S. economy and could make it more difficult for us to obtain traditional financing on acceptable terms, if at all, in the future. Furthermore, economic conditions have produced downward pressure on share prices. Although we do not believe that inflation has had a material impact on our financial position or results of operations to date, we may experience increases in the near future (especially if inflation rates remain high or begin to rise again) on our operating costs, including our labor costs and research and development costs, due to supply chain constraints, the global geopolitical tension as a result of the ongoing war between Russia and Ukraine, worsening global macroeconomic conditions and employee availability and wage increases, which may result in additional stress on our working capital resources.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, we are subject to other challenges and risks specific to our business and our ability to execute on our strategy, as well as risks and uncertainties common to companies in the pharmaceutical industry with development and commercial operations, including, without limitation, risks and uncertainties associated with: identifying, acquiring or in-licensing products or product candidates; obtaining regulatory approval of product candidates; pharmaceutical product development and the inherent uncertainty of clinical success; and the challenges of protecting and enhancing our intellectual property rights; complying with applicable regulatory requirements.</span></div><div id="i447d75b6bca148d0bd5c21482392c4f0_88"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have generated revenue under various licensing and collaboration agreements. We have not generated any revenue from commercial drug sales and we do not expect to generate any further revenue unless or until we obtain regulatory approval and commercialize one or more of our current or future drug candidates. In the future, we may also </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">seek to generate revenue from a combination of research and development payments, license fees and other upfront or milestone payments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred for our research activities, including our product discovery efforts and the development of our product candidates, which include, among other things:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">employee-related expenses, including salaries, benefits and stock-based compensation expense;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">fees paid to consultants for services directly related to our drug development and regulatory effort;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">expenses incurred under agreements with contract research organizations, as well as contract manufacturing organizations and consultants that conduct preclinical studies and clinical trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">costs associated with preclinical activities and development activities;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">costs associated with technology and intellectual property licenses;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">milestone payments and other costs and payments under licensing agreements, research agreements and collaboration agreements; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">depreciation expense for assets used in research and development activities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs incurred in connection with research and development activities are expensed as incurred. Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or other information provided to us by our vendors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are and will continue to be central to our business model. We expect our research and development expenses to increase for the foreseeable future as we advance our current and future drug candidates through preclinical studies and clinical trials. The process of conducting preclinical studies and clinical trials necessary to obtain regulatory approval is costly and time-consuming. It is difficult to determine with certainty the duration and costs of any preclinical study or clinical trial that we may conduct. The duration, costs and timing of clinical trial programs and development of our current and future drug candidates will depend on a variety of factors that include, but are not limited to, the following:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">number of clinical trials required for approval and any requirement for extension trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">per patient trial costs; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">number of patients who participate in the clinical trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">number of sites included in the clinical trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">countries in which the clinical trial is conducted;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">length of time required to enroll eligible patients;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">number of doses that patients receive;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">drop-out or discontinuation rates of patients;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">potential additional safety monitoring or other studies requested by regulatory agencies;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">duration of patient follow-up; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">efficacy and safety profile of the drug candidate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the probability of success for any of our current or future drug candidates will depend on numerous factors, including competition, manufacturing capability and commercial viability. We will determine which programs to pursue and how much to fund each program in response to the scientific and clinical success of each drug candidate, as well as an assessment of each drug candidate&#8217;s commercial potential.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of employee-related expenses, including salaries, benefits and stock-based compensation expense, related to our executive, finance, legal, business development and support functions. Other general and administrative expenses include costs associated with operating as a public company, travel expenses, conferences, and professional fees for auditing, tax and legal services.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net primarily consists of unrealized gains (losses) on long-term equity investments and interest income and accretion of discount on investments in marketable securities.</span></div><div id="i447d75b6bca148d0bd5c21482392c4f0_91"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended June&#160;30, 2023 and 2022</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of our operations for the periods indicated:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change $</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;License and other revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Research and development </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,047&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total operating expenses </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,304&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,172)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,304)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(284)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,048&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,408)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,588)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,180&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,408)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,588)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,180&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of $75,000 was generated in the three months ended June&#160;30, 2023. No revenue was recognized in the three months ended June&#160;30, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change $</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,623&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,643&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and payroll-related expenses </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,547</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,330</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,074</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,999&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,047&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June&#160;30, 2023 and 2022, total research and development expenses were $6.0 million. Payroll and related expenses increased with the additions of new management hires. Other expense decreased due to cost reduction measures.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change $</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and payroll-related expenses </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,030&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,860&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and professional fees</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,616</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,560</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(944)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General office expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,602</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,837</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(235)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total general and administrative</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,248&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,258&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $8.2 million and $8.3 million for the three months ended June&#160;30, 2023 and 2022, respectively. The increase in payroll and payroll-related expenses between the periods was primarily due to $1.1 million in severance costs recognized during the three months ended June&#160;30, 2023, partially offset by a decrease in legal and professional fees relating to projects during the same period in 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net for the three months ended June&#160;30, 2023 and 2022 includes unrealized gain (loss) on long-term equity investments and interest earned and accretion of discount on marketable securities. Other income, net for the three months ended June&#160;30, 2023 was $1.8 million compared to other expense of $0.3 million for the same period in 2022. The increase of $2.0 million is primarily due to interest and accretion on investments in marketable securities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Six Months Ended June&#160;30, 2023 and 2022</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of our operations for the periods indicated:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change $</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;License and other revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,304)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,445&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,304)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Research and development </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,266)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,546)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total operating expenses </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,205&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,017&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,812)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,064)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,571)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,764)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,697)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,933&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,764)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,697)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,933&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of $141,160 was generated in the six months ended June&#160;30, 2023, compared to revenue of $1.4 million recognized in the same period in 2022 relating to licensing agreements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change $</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical and development expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and payroll-related expenses </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,401</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,266</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,865)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,607</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,889</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(282)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,613&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,879&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,266)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2023, total research and development expenses were $12.6 million compared to $13.9 million for the same period in 2022. The decrease of $1.3 million was primarily due to a $1.9 million reduction in payroll and payroll-related expenses following an organizational restructuring in 2022, and a reduction in severance costs of $0.1 million compared to $1.3 million for the same period in 2022. The decrease in payroll and payroll-related expenses was offset by a $0.8 million increase in preclinical and development expenses relating to the Phase 1 clinical trial for OV329.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change $</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and payroll-related expenses </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and professional fees</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,496</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,532)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General office expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,319</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,572</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,253)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total general and administrative</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,592&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,138&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,546)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $16.6 million for the six months ended June&#160;30, 2023 compared to $18.1 million for the same period in 2022. The decrease of $1.5 million was primarily due to a reduction in legal and professional fees of $1.5 million and a decrease in general office expenses of $1.3 million, partially offset by an increase in payroll and payroll-related expenses of $1.2 million. Severance costs of $1.6 million were recognized during the six months ended June&#160;30, 2023 compared to $0.7 million for the same period in 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net for the six months ended June&#160;30, 2023 results from unrealized gain (loss) on long-term equity investments and interest earned and accretion of discount on marketable securities. Other income, net for the six months ended June&#160;30, 2023 was $3.3 million compared to other expense of $0.1 million for the same period in 2022. The increase of $3.4 million is primarily due to interest and accretion on investments in marketable securities.</span></div><div id="i447d75b6bca148d0bd5c21482392c4f0_94"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of June&#160;30, 2023, we had total cash, cash equivalents and marketable securities of $96.5&#160;million as compared to $129.0&#160;million as of December&#160;31, 2022. We believe that our cash, cash equivalents and marketable securities as of June&#160;30, 2023 will fund our projected operating expenses and capital expenditure requirements for at least 12 months from the issuance of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to other development-stage biotechnology companies, we have generated limited revenue, which has been through various license and collaboration agreements. With the exception of the three months ended March 31, 2021, when we received a one-time upfront payment of $196.0 million as part of the RLT Agreement, we have incurred losses and experienced negative operating cash flows since our inception and anticipate that we will continue to incur losses and experience negative operating cash flows for at least the next several years. We recorded net losses of approximately $12.4&#160;million and $14.6&#160;million for the three months ended June&#160;30, 2023 and 2022, respectively. As of June&#160;30, 2023, we had an accumulated deficit of $251.3&#160;million and working capital of $92.0&#160;million.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Funding Requirements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our available cash, and cash equivalents and marketable securities are sufficient to fund existing and planned cash requirements for at least the next 12 months. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research and development services, clinical costs, legal and other regulatory expenses and general overhead costs. We have based our estimates on assumptions that may prove to be incorrect, and we could use our capital resources sooner than we currently expect. Additionally, the process of testing drug candidates in clinical trials is costly, and the timing of progress in these trials is uncertain. We cannot estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates or whether, or when, we may achieve profitability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2023, we had no long-term debt and no material non-cancelable purchase commitments with service providers, as we have generally contracted on a cancellable, purchase order basis. We cannot estimate whether we will receive or the timing of any potential contingent payments upon the achievement by us of clinical, regulatory and commercial events, as applicable. In addition, we cannot estimate the timing of any potential royalty payments that we may be required to make under license agreements we have entered into with various entities pursuant to which we have in-licensed certain intellectual property as contractual obligations or commitments, including agreements with AstraZeneca and Northwestern. Pursuant to these license agreements, we have agreed to make milestone payments up to an aggregate of $279.3 million upon the achievement of certain development, regulatory and sales milestones. We excluded these contingent payments from the condensed consolidated financial statements, given that the timing, probability, and amount, if any, of such payments cannot be reasonably estimated at this time.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we entered into a 10-year lease agreement for our corporate headquarters with a term commencing March 10, 2022, for approximately 19,000 square feet of office space at Hudson Commons in New York, New York. The lease provides for monthly rental payments over the lease term. The base rent under the lease is currently $2.3 million per year. Rent payments commenced January 10, 2023, and will continue for 10 years following the rent commencement date. We issued a letter of credit in the amount of $1.9 million in association with the execution of the lease agreement, which is reflected as restricted cash on our condensed consolidated balance sheets. Payment obligations under the lease agreement include approximately $1.9 million in the 12 months subsequent to June&#160;30, 2023 and approximately $22.5 million over the remaining term of the agreement. For additional information see Note 5 to our condensed consolidated financial statements under the heading 'Leases.'</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have no products approved for commercial sale and have not generated any revenue from product sales to date. Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings and additional funding from license and collaboration arrangements. Except for any obligations of our collaborators to reimburse us for research and development expenses or to make milestone or royalty payments under our agreements with them, we will not have any committed external source of liquidity. To the extent that we raise additional capital through future equity offerings or debt financings, ownership interests may be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt and equity financings, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. There can be no assurance that such financings will be obtained on terms acceptable to us, if at all. Additionally, inflation rates have increased recently to levels not seen in decades, contributing to the ongoing economic slowdown. Increased inflation may result in increased operating costs (including labor costs) and may affect our operating budgets. In response to concerns about inflation, the U.S. Federal Reserve has raised, and is expected to further raise, interest rates. Increases in interest rates, especially if coupled with reduced government spending and volatility in financial markets, may further increase economic uncertainty and heighten these risks. If the disruptions and slowdown deepen or persist, we may not be able to access additional capital on favorable terms, or at all, which could in the future negatively affect our ability to pursue our business strategy. If we raise additional funds through collaborations, strategic alliances or licensing agreements with third parties for one or more of our current or future drug candidates, we may be required to relinquish valuable rights to our technologies, future revenue streams, research programs or drug candidates or to grant licenses on terms that may not be favorable to us. Our failure to raise capital as and when needed would have a material adverse effect on our financial condition and our ability to pursue our business strategy. See &#8220;Risk Factors&#8221; for additional risks associated with our capital requirements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-the-Market Offering Program</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, we filed a shelf registration statement on Form S-3 (Registration No. 333-250054) that allows us to sell up to an aggregate of $250.0 million of our common stock, preferred stock, debt securities and/or warrants (&#8220;S-3 Registration Statement&#8221;), which includes a prospectus covering the issuance and sale of up to $75.0 million of common stock pursuant to an at-the-market (&#8220;ATM&#8221;) offering program. As of June&#160;30, 2023, we had up to $250.0 million available under our S-3 Registration Statement, including up to $75.0 million available pursuant to our ATM offering program.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,818)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,375)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81,753)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net  increase (decrease)  in cash, cash equivalents, and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,755&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114,986)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Used In Operating Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net cash used in operating activities was $23.8 million for the six months ended June&#160;30, 2023, which consisted of a net loss of $25.8&#160;million offset by a net of $2.0 million of non-cash charges and indirect cash charges, primarily related to $3.9 million of stock-based compensation expense. Net cash used in operating activities was $33.4 million for the six months ended June&#160;30, 2022, which consisted of net loss of $30.7 million offset by a net of $3.1 million in stock-based compensation expense, $0.1 million, net, of other noncash transactions and charges and decreases in accounts payable and accrued expenses of $5.5 million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Provided By (Used In) Investing Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was $50.3 million for the six months ended June&#160;30, 2023, which was due to sales/maturities of marketable securities during the period. Net cash used in investing activities was $81.8 million for the six months ended June&#160;30, 2022, which was due to purchases of marketable securities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Provided By Financing Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities during the six months ended June&#160;30, 2023 and 2022 resulted from proceeds from the exercise of stock options under the 2017 equity incentive plan and purchases of shares under the 2017 employee stock purchase plan.</span></div><div id="i447d75b6bca148d0bd5c21482392c4f0_97"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Smaller Reporting Company Status</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a smaller reporting company as defined in the Exchange Act. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as (i) our voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As a smaller reporting company, we are permitted to comply with scaled-back disclosure obligations in our SEC filings compared to other issuers, including with respect to disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We have elected to adopt the accommodations available to smaller reporting companies, including but not limited to:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">reduced disclosure obligations regarding our executive compensation arrangements; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">.</span></div><div id="i447d75b6bca148d0bd5c21482392c4f0_100"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the revenue and expenses incurred during the reported periods. On an ongoing basis, we evaluate our estimates and judgments, including those related to accrued expenses and stock-based compensation. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not apparent from </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other sources. Changes in estimates are reflected in reported results for the period in which they become known. Actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2023, there were no material changes to our critical accounting policies as reported for the year ended December&#160;31, 2022 as part of our Annual Report on Form 10-K, which was filed with the SEC on March 13, 2023. In addition, see Note 2 of our Condensed Consolidated Financial Statements under the heading &#8220;Recent Accounting Pronouncements&#8221; for new accounting pronouncements or changes to the accounting pronouncements during the three and six months ended June&#160;30, 2023.</span></div><div id="i447d75b6bca148d0bd5c21482392c4f0_103"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objectives of our investment activities are to ensure liquidity and to preserve capital. As of June&#160;30, 2023, we had cash, cash equivalents and marketable securities totaling $96.5&#160;million. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Due to the short-term maturities of our cash equivalents and marketable securities and the low risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents and marketable securities. To minimize the risk in the future, we intend to maintain our portfolio of cash equivalents and marketable securities in institutional market funds that are comprised of U.S. Treasury and U.S. Treasury-backed repurchase agreements as well as treasury notes and high quality short-term corporate bonds. We maintain our cash, cash equivalents and marketable securities with domestic financial institutions of high credit quality.</span></div><div id="i447d75b6bca148d0bd5c21482392c4f0_106"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Evaluation of our Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) is (1) recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms and (2) accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2023, our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our principal executive officer and principal financial officer have concluded based upon the evaluation described above that, as of June&#160;30, 2023, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting during our most recent quarter ended June&#160;30, 2023 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31</span></div></div></div><div id="i447d75b6bca148d0bd5c21482392c4f0_109"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="i447d75b6bca148d0bd5c21482392c4f0_112"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently subject to any material legal proceedings.</span></div><div id="i447d75b6bca148d0bd5c21482392c4f0_115"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">An investment in our securities involves a high degree of risk. You should carefully consider the following information about these risks, together with the other information appearing elsewhere in this Quarterly Report on Form 10-Q, including our unaudited condensed financial statements and related notes hereto, before deciding to invest in our common stock. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. In these circumstances, the market price of our common stock could decline and you may lose all or part of your investment. We cannot assure you that any of the events discussed below will not occur.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Selected Risks Associated with Our Business</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to numerous risks and uncertainties. If any of the following risks are realized, our business, financial condition and results of operations could be materially and adversely affected. Some of the more significant risks we face include the following:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">Historically, we have incurred significant operating losses and expect to continue to incur substantial operating losses for the foreseeable future and may never achieve or maintain profitability.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our operating history may make it difficult to evaluate the success of our business to date and to assess our future viability.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We will require additional capital to finance our operations, which may not be available on acceptable terms, if at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate certain of our drug development efforts or other operations.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We are early in our development efforts of our current drug candidates and all our drug candidates are in preclinical development. If we are unable to successfully develop, receive regulatory approval for and commercialize our drug candidates, or successfully develop any other drug candidates, or experience significant delays in doing so, our business will be harmed. </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our future success is dependent on the successful clinical development, regulatory approval and commercialization of our current and future drug candidates. If we, or our licensees, are not able to obtain the required regulatory approvals, we, or our licensees, will not be able to commercialize our drug candidates, and our ability to generate revenue will be adversely affected.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Because the results of preclinical studies or earlier clinical trials are not necessarily predictive of future results, our drug candidates may not have favorable results in planned or future preclinical studies or clinical trials, or may not receive regulatory approval.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Interim topline and preliminary results from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures, which could result in material changes in the final data.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Preclinical studies and clinical trials are very expensive, time-consuming and difficult to design and implement and involve uncertain outcomes. Further, we may encounter substantial delays in our clinical trials or we may fail to demonstrate safety and efficacy in our preclinical studies and clinical trials to the satisfaction of applicable regulatory authorities.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">If we are not successful in discovering, developing and commercializing additional drug candidates, our ability to expand our business and achieve our strategic objectives would be impaired.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our drug candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial potential or result in significant negative consequences following any potential marketing approval.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Even if our current or future drug candidates receive marketing approval, they may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Under the RLT Agreement, we are entitled to receive royalty and milestone payments in connection with the development and commercialization of soticlestat. If Takeda fails to progress, delays, or discontinues the development of soticlestat, or if soticlestat fails to achieve market acceptance or commercial success, we may not receive some or all of such payments, which would materially harm our business.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Our relationships with customers, physicians, and third-party payors may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Coverage and adequate reimbursement may not be available for our current or any future drug candidates, which could make it difficult for us to sell profitably, if approved.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">If we are unable to obtain and maintain patent protection for our current or any future drug candidates, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We may be involved in lawsuits to protect or enforce our patents, the patents of our licensors or our other intellectual property rights, which could be expensive, time consuming and unsuccessful.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We do not have our own manufacturing capabilities and will rely on third parties to produce clinical and commercial supplies of our current and any future drug candidates.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We intend to rely on third parties to conduct, supervise and monitor our preclinical studies and clinical trials, and if those third parties perform in an unsatisfactory manner, it may harm our business.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We may need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We may be subject to numerous and varying privacy and security laws, and our failure to comply could result in penalties and reputational damage.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to continue to incur substantial operating losses for the foreseeable future and may never achieve or maintain profitability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically incurred significant operating losses with the exception of net income we reported in 2021 primarily due to a one-time, upfront payment of $196.0 million received pursuant to the RLT Agreement with Takeda. As of June&#160;30, 2023, we had an accumulated deficit of $251.3&#160;million. We expect to incur substantial operating losses for the foreseeable future. Since inception, we have devoted substantially all of our efforts to research and preclinical and clinical development of our drug candidates, as well as hiring employees and building our infrastructure.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no drugs approved for commercialization and have never generated any revenue from drug sales. All of our drug candidates are still in the preclinical or clinical testing stage. It could be several years, if ever, before we have a commercialized drug. We expect to continue to incur significant expenses and operating losses over the next several years, and the net losses we incur may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if, and as, we:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">continue to advance the ongoing and planned preclinical and clinical development of our drug candidates;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">continue to build a portfolio of drug candidates through the acquisition or in-license of drugs, drug candidates or technologies;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">initiate preclinical studies and clinical trials for any additional drug candidates that we may pursue in the future;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">seek marketing approvals for our current and future drug candidates that successfully complete clinical trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">establish a sales, marketing and distribution infrastructure to commercialize any drug candidate for which we may obtain marketing approval;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">develop, maintain, expand and protect our intellectual property portfolio;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">implement operational, financial and management systems; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">attract, hire and retain additional administrative, clinical, regulatory and scientific personnel.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we complete the development and regulatory processes described above, we anticipate incurring significant costs associated with launching and commercializing our current and future drug candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating history may make it difficult to evaluate the success of our business to date and to assess our future viability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations have consumed substantial amounts of cash since our inception, primarily due to expenses associated with the research and development of our drug candidates, organizing and staffing our company, business planning, raising capital, and acquiring assets. We have not yet demonstrated the ability to obtain marketing approvals, manufacture a commercial-scale drug or conduct sales and marketing activities necessary for successful commercialization. Consequently, any predictions about our future success or viability may not be as accurate as they could be if we had more experience developing drug candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our financial condition and operating results to continue to fluctuate from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. We will need to eventually transition from a company with a research and development focus to a company capable of undertaking commercial activities. We may encounter unforeseen expenses, difficulties, complications and delays and may not be successful in such a transition. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will require additional capital to finance our operations, which may not be available on acceptable terms, if at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate certain of our drug development efforts or other operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations have consumed substantial amounts of cash since our inception. We expect our expenses to increase as we advance our current and future drug candidates through preclinical studies and clinical trials, commercialize our drug candidates, and pursue the acquisition or in-licensing of any additional drug candidates. Our expenses could increase beyond expectations if the FDA or other regulatory authorities require us to perform preclinical studies or clinical trials in addition to those that we currently anticipate. In addition, even if we obtain marketing approval for our drug candidates, they may not achieve commercial success. Our revenue, if any, will be derived from sales of drugs that we do not expect to be commercially available for a number of years, if at all. If we obtain marketing approval for any drug candidates that we develop or otherwise acquire, we expect to incur significant expenses related to manufacturing, marketing, sales and distribution. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2023, our cash, cash equivalents and marketable securities were $96.5&#160;million, and we had an accumulated deficit of $251.3&#160;million. We believe that our cash, cash equivalents and marketable securities will fund our current operating plans through at least 12 months from the filing of this Quarterly Report on Form 10-Q. However, our operating plans may change because of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings, third-party funding, marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or any combination of these approaches. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will require more capital in order to advance the preclinical and clinical development, obtain regulatory approval, and, following regulatory approval, commercialize our current or future drug candidates. Any additional capital raising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our current and future drug candidates. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the long-term economic impacts associated with public health crises and global geopolitical tensions, like the ongoing war between Russia and Ukraine are difficult to assess or predict, each of these events has caused significant disruptions to the global financial markets and contributed to a general global economic slowdown. Furthermore, inflation rates have increased recently to levels not seen in decades. Increased inflation may result in increased operating costs (including labor costs) and may affect our operating budgets. In response to concerns about inflation, the U.S. Federal Reserve has raised, and is expected to further raise, interest rates. Increases in interest rates, especially if coupled with reduced government spending and volatility in financial markets, may further increase economic uncertainty and heighten these risks. If the disruptions and slowdown deepen or persist, we may not be able to access additional capital on favorable </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">terms, or at all, which could in the future negatively affect our financial condition and our ability to pursue our business strategy.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to raise additional capital when needed, we may be required to delay, limit, reduce or terminate our drug development or future commercialization efforts, or grant rights to develop and market drug candidates that we would otherwise develop and market ourselves.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss (&#8220;NOL&#8221;) carryforwards and certain other tax attributes to offset future taxable income may be subject to limitation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our NOL carryforwards could expire unused and be unavailable to offset future income tax liabilities because of their limited duration or because of restrictions under U.S. tax law. Our federal NOLs generated in tax years beginning on or before December 31, 2017, are permitted to be carried forward for only 20 years under applicable U.S. tax law. Under the Tax Cuts and Jobs Act, or the Tax Act, as modified by the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, federal NOLs incurred in taxable years beginning after December 31, 2017, may be carried forward indefinitely, but the utilization of such federal NOLs incurred in taxable years beginning after December 31, 2020, is limited.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under Section 382 and Section 383 of the Internal Revenue Code of 1986, as amended ("Code"), and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; its ability to use its pre-change NOL carryforwards and other pre-change tax attributes (such as research tax credits) to offset its post-change income may be limited. A Section 382 &#8220;ownership change&#8221; generally occurs if one or more stockholders or groups of stockholders that own at least 5% of our stock increase their ownership by more than 50 percentage points (by value) over their lowest ownership percentage over a rolling three-year period. We may have experienced ownership changes in the past and may experience ownership changes in the future as a result of shifts in our stock ownership (some of which are outside our control). As a result, if we earn net taxable income, our ability to use our pre-change NOLs to offset such taxable income may be subject to limitations. Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June&#160;30, 2023, we recorded no U.S. federal or state income tax provision, based on a pre-tax loss of approximately $12.4 million. As of June&#160;30, 2023, we had available approximately $141.6 million of unused NOL carryforwards for federal income tax purposes, $13.0 million of unused NOL carryforwards for Massachusetts income tax purposes, $164.1 million of unused NOL carryforwards for New York income tax purposes, and $163.9 million of unused NOL carryforwards for New York City income tax purposes, that may be applied against future taxable income. All of our NOL carryforwards are significantly limited such that even if we achieve profitability in future periods, we may not be able to utilize a material portion of our NOL carryforwards and certain other tax attributes, which could have a material adverse effect on our cash flow and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition, or results of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New tax laws, statutes, rules, regulations, or ordinances could be enacted at any time. For instance, the recently enacted Inflation Reduction Act of 2022 (the &#8220;IRA&#8221;) imposes, among other rules, a 15% minimum tax on the book income of certain large corporations and a 1% excise tax on certain corporate stock repurchases. Further, existing tax laws, statutes, rules, regulations, or ordinances could be interpreted differently, changed, repealed, or modified at any time. Any such enactment, interpretation, change, repeal, or modification could adversely affect us, possibly with retroactive effect. In particular, changes in corporate tax rates, the realization of our net deferred tax assets, the taxation of foreign earnings, and the deductibility of expenses under the Tax Act, as amended by the CARES Act or any future tax reform legislation, could have a material impact on the value of our deferred tax assets, result in significant one-time charges, and increase our future tax expenses.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Development and Commercialization of Our Drug Candidates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are very early in our development efforts and all of our drug candidates are in Phase 1 clinical trials or preclinical development. If we are unable to successfully develop, receive regulatory approval for and commercialize our drug candidates for these or any other indications, or successfully develop any other drug candidates, or experience significant delays in doing so, our business will be harmed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are very early in our development efforts and the drug candidates for which we control developmental and commercial responsibility are still in Phase 1 clinical trials or preclinical development. We cannot guarantee success of preclinical development to achieve filing investigational new drug (&#8220;IND&#8221;) applications or whether the FDA will impose clinical holds on any of our planned INDs. Following IND acceptance, each of our drug candidates will need to be </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">progressed through clinical development in order to achieve regulatory approval, and we will also need to address issues relating to manufacture and supply, which may involve building our own capacity and expertise. In order to commercialize any product that achieves regulatory approval, we will need to build a commercial organization or successfully outsource commercialization, all of which will require substantial investment and significant marketing efforts before we have the ability to generate any revenue from drug sales. We do not have any drugs that are approved for commercial sale, and we may never be able to develop or commercialize marketable drugs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to generate revenue from drug sales and achieve profitability depends on our ability, alone or with any current or future collaborative partners, to successfully complete the development of, and obtain the regulatory approvals necessary to commercialize, our current and future drug candidates. We do not anticipate generating revenue from drug sales for the next several years, if ever. Our ability to generate revenue from drug sales depends heavily on our, or any current or future collaborators&#8217;, success in the following areas, including but not limited to:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">timely and successfully completing preclinical and clinical development of our current and future drug candidates;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtaining regulatory approvals for our current and future drug candidates for which we successfully complete clinical trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">launching and commercializing any drug candidates for which we obtain regulatory approval by establishing a sales force, marketing and distribution infrastructure or, alternatively, collaborating with a commercialization partner;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">qualifying for coverage and adequate reimbursement by government and third-party payors for any drug candidates for which we obtain regulatory approval, both in the United States and internationally;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">developing, validating and maintaining a commercially viable, sustainable, scalable, reproducible and transferable manufacturing process for our current and future drug candidates that is compliant with current good manufacturing practices (&#8220;cGMP&#8221;);</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">establishing and maintaining supply and manufacturing relationships with third parties that can provide an adequate amount and quality of drugs and services to support clinical development, as well as the market demand for our current and future drug candidates, if approved;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtaining market acceptance, if and when approved, of our current or any future drug candidates as a viable treatment option by physicians, patients, third-party payors and others in the medical community;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">effectively addressing any competing technological and market developments;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">implementing additional internal systems and infrastructure, as needed;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter and performing our obligations pursuant to such arrangements;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtaining and maintaining orphan drug exclusivity for any of our current and future drug candidates for which we obtain regulatory approval;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">avoiding and defending against third-party interference or infringement claims; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">securing appropriate pricing in the United States, the European Union and other countries.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are not successful with respect to one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize the drug candidates we develop, which would materially harm our business. If we do not receive marketing approvals for any drug candidate we develop, we may not be able to continue our operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success is dependent on the successful clinical development, regulatory approval and commercialization of our current and future drug candidates. If we, or our licensees, are not able to obtain the required regulatory approvals, we, or our licensees, will not be able to commercialize our drug candidates, and our ability to generate revenue will be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any drugs that have received regulatory approval. Our business is dependent on our ability to successfully complete preclinical and clinical development of, obtain regulatory approval for, and, if approved, successfully commercialize our current and future drug candidates in a timely manner. Activities associated with the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development and commercialization of our current and future drug candidates are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and similar regulatory authorities outside the United States. Failure to obtain regulatory approval in the United States or other jurisdictions would prevent us from commercializing and marketing our current and future drug candidates. An inability to effectively develop and commercialize our current and future drug candidates could have an adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soticlestat, the most advanced compound we aided in developing, is continuing to be developed by Takeda and is currently in a pivotal trial program. If the pivotal trials are unsuccessful, or the compound is not approved, we will not receive the milestone payments and royalties from the RLT Agreement. Without those funds, we may need to raise significant additional capital to pursue the development and commercialization of our current and future pipeline.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, activities associated with the development and commercialization of our current and future drug candidates are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and similar regulatory authorities outside the United States. Failure to obtain regulatory approval in the United States or other jurisdictions would prevent us from commercializing and marketing our current and future drug candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain approval from the FDA and comparable foreign regulatory authorities for our current and future drug candidates, any approval might contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, or may be subject to burdensome post-approval study or risk management requirements. If we are unable to obtain regulatory approval, or any approval contains significant limitations, we may not be able to obtain sufficient funding or generate sufficient revenue to continue the development of that drug candidate or any other drug candidate that we may in-license, develop or acquire in the future. In certain circumstances, our third-party licensees are responsible for obtaining regulatory approvals in the countries covered by the license, and we are dependent on their efforts in order to achieve the necessary approvals in order to commercialize our products. If any future licensees fail to perform their obligations to develop and obtain regulatory approvals for the licensed products, we may not be able to commercialize our products in the affected countries, or our ability to do so may be substantially delayed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, even if we obtain regulatory approval for our current and future drug candidates, we will still need to develop a commercial organization, establish a commercially viable pricing structure and obtain approval for adequate reimbursement from third-party and government payors. If we are unable to successfully commercialize our current and future drug candidates, we may not be able to generate sufficient revenue to continue our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because the results of preclinical studies or earlier clinical trials are not necessarily predictive of future results, our drug candidates may not have favorable results in planned or future preclinical studies or clinical trials, or may not receive regulatory approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Success in preclinical testing and early clinical trials does not ensure that subsequent clinical trials will generate similar results or otherwise provide adequate data to demonstrate the efficacy and safety of a drug candidate. Frequently, drug candidates that have shown promising results in early clinical trials have subsequently suffered significant setbacks in later clinical trials. The results from preclinical studies of our current and future drug candidates may not be predictive of the effects of these compounds in later stage clinical trials. If we do not observe favorable results in clinical trials of one of our drug candidates, we may decide to delay or abandon clinical development of that drug candidate. Any such delay or abandonment could harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">It is difficult to predict the time and cost of product candidate development and subsequently obtaining regulatory approval for our gene therapy candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success depends in part on the successful development of our early-stage gene therapy product candidates. We may experience delays in developing a sustainable, reproducible, and scalable manufacturing process or transferring that process to internal and external commercial manufacturing sites, which may prevent us from initiating or completing our clinical trials or commercializing our product candidates on a timely or profitable basis, if at all.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory approval process for novel gene therapy products such as ours can be more expensive and take longer than for other product types, which are better known or more extensively studied to date. Regulatory approaches and requirements for gene therapy products continue to evolve, and any changes could create significant delay and unpredictability for product development and approval as compared to technologies with which regulatory authorities have more substantial experience.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, before a clinical trial can begin to enroll at a site, each clinical site's Institutional Review Board (&#8220;IRB&#8221;) and its Institutional Biosafety Committee will have to review the proposed clinical trial to assess appropriateness to conduct the clinical trial at that site. In addition, adverse events in clinical trials of gene therapy products conducted by others may </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cause the FDA or other regulatory authorities outside the U.S. to change the requirements for human research on or for approval of any of our product candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Negative public opinion and increased regulatory scrutiny of gene therapy and genetic research may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain marketing approvals for our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public perception may be influenced by claims that gene therapy is unsafe, and gene therapy may not gain the acceptance of the public or the medical community. More restrictive government regulations or negative public opinion would have a negative effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop. Trials using early versions of retroviral vectors, which integrate into, and thereby alter, the host cell&#8217;s DNA, have led to several well-publicized adverse events. The risk of serious adverse events remains a concern for gene therapy and we cannot assure that it will not occur in any of our future clinical trials. In addition, there is the potential risk of delayed adverse events following exposure to gene therapy products due to persistent biological activity of the genetic material or other components of products used to carry the genetic material.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse events in trials or studies conducted by us or other parties, even if not ultimately attributable to our product candidates, and resulting publicity, could result in increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our product candidates, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim topline and preliminary results from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures, which could result in material changes in the final data.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we have and may in the future publish or report preliminary or interim data from our clinical trials. Preliminary or interim data from our clinical trials and those of our partners may not be indicative of the final results of the trial and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and/or more patient data become available. Preliminary or topline results also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published or reported. As a result, preliminary or interim data should be considered carefully and with caution until final data are available. Differences between preliminary or interim data and final data could significantly harm our business prospects and may cause the trading price of our common stock to fluctuate significantly.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical studies and clinical trials are very expensive, time-consuming and difficult to design and implement and involve uncertain outcomes. Further, we may encounter substantial delays in our clinical trials or we may fail to demonstrate safety and efficacy in our preclinical studies and clinical trials to the satisfaction of applicable regulatory authorities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our current drug candidates are in Phase 1 clinical trials or preclinical development and their risk of failure is high. We must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that each of our drug candidates are safe and effective for its intended indications before we are prepared to submit a new drug application (&#8220;NDA&#8221;) or Biologics License Application (&#8220;BLA&#8221;) for regulatory approval. We cannot predict with any certainty if or when we might submit an NDA or BLA for any of our product candidates or whether any such application will be approved by the FDA. Human clinical trials are very expensive and difficult to design and implement, in part because they are subject to rigorous review and regulatory requirements by numerous government authorities in the United States and in other countries where we intend to test and market our product candidates. For instance, the FDA may not agree with our proposed endpoints for any future clinical trial of our product candidates, which may delay the commencement of such clinical trial.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that the successful completion of clinical trials of our product candidates will take at least several years to complete, if not longer. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. Furthermore, failure can occur at any stage and we could encounter problems that cause us to abandon or repeat clinical trials. Events that may prevent successful or timely completion of clinical development include:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our inability to generate sufficient preclinical, toxicology or other data to support the initiation of clinical trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our inability to develop and validate disease-relevant clinical endpoints;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in reaching a consensus with regulatory authorities on trial design;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in reaching agreement on acceptable terms with prospective clinical research organizations (&#8220;CROs&#8221;) and clinical trial sites;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in opening investigational sites;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays or difficulty in recruiting and enrollment of suitable patients to participate in our clinical trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">imposition of a clinical hold by regulatory authorities because of a serious adverse event, concerns with a class of drug candidates or after an inspection of our clinical trial operations or trial sites;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delays in having patients complete participation in a trial or return for post-treatment follow-up;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">occurrence of serious adverse events associated with the drug candidate that are viewed to outweigh its potential benefits; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; or</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">business interruptions resulting from geopolitical actions, including the ongoing war between Russia and Ukraine, any other war or the perception that hostilities may be imminent, including, terrorism, natural disasters or public health crises.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, clinical endpoints for certain diseases we are targeting have not been established, and accordingly we may have to develop new modalities or modify existing endpoints to measure efficacy, which may increase the time it takes for us to commence or complete clinical trials. In addition, we believe investigators in this area may be inexperienced in conducting trials in this area due to the current lack of drugs to treat these disorders, which may result in increased time and expense to train investigators and open clinical sites.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenue from future drug sales and regulatory and commercialization milestones. In addition, if we make manufacturing or formulation changes to our drug candidates, we may need to conduct additional testing to bridge our modified drug candidate to earlier versions. Clinical trial delays could also shorten any periods during which we may have the exclusive right to commercialize our drug candidates, if approved, or allow our competitors to bring comparable drugs to market before we do, which could impair our ability to successfully commercialize our drug candidates and may harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if the results of our clinical trials are inconclusive or if there are safety concerns or serious adverse events associated with our drug candidates, we may:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">be delayed in obtaining marketing approval, if at all;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtain approval for indications or patient populations that are not as broad as intended or desired;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">be subject to additional post-marketing testing requirements;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">have regulatory authorities withdraw, or suspend, their approval of the drug or impose restrictions on its distribution in the form of a modified risk evaluation and mitigation strategy (&#8220;REMS&#8221;);</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">be subject to the addition of labeling statements, such as warnings or contraindications;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">be sued; or</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">experience damage to our reputation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our drug development costs will also increase if we experience delays in testing or obtaining marketing approvals. We do not know whether any of our preclinical studies or clinical trials will begin as planned, need to be restructured or be completed on schedule, if at all.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, we, the FDA or an IRB may suspend our clinical trials at any time if it appears that we or our collaborators are failing to conduct a trial in accordance with regulatory requirements, including the FDA&#8217;s current Good Clinical Practice (&#8220;GCP&#8221;) regulations, that we are exposing participants to unacceptable health risks, or if the FDA finds deficiencies in our IND applications or the conduct of these trials. Therefore, we cannot predict with any certainty the schedule for commencement and completion of future clinical trials. If we experience delays in the commencement or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">completion of our clinical trials, or if we terminate a clinical trial prior to completion, the commercial prospects of our drug candidates could be negatively impacted, and our ability to generate revenues from our drug candidates may be delayed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are not successful in discovering, developing and commercializing additional drug candidates, our ability to expand our business and achieve our strategic objectives would be impaired.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A key element of our current strategy is to identify, discover, develop and potentially commercialize a portfolio of drug candidates to treat rare epilepsies, seizure-related disorders, and rare neurological disorders. However, our business development activities and research activities may present attractive opportunities outside of rare epilepsies and seizure-related disorders and we may choose to pursue drug candidates in other areas of interest including other disorders that we believe would be in the best interest of the Company and our stockholders. We plan to continuously review our strategies and modify as necessary based on attractive areas of interest and assets that we choose to pursue. We intend to develop our portfolio of drug candidates by in-licensing and entering into collaborations with leading biopharmaceutical companies or academic institutions for new drug candidates. Identifying new drug candidates requires substantial technical, financial and human resources, whether or not any drug candidates are ultimately identified. Even if we identify drug candidates that initially show promise, we may fail to in-license or acquire these assets and may also fail to successfully develop and commercialize such drug candidates for many reasons, including the following:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the research methodology used may not be successful in identifying potential drug candidates;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">competitors may develop alternatives that render any drug candidate we develop obsolete;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any drug candidate we develop may nevertheless be covered by third parties&#8217; patents or other exclusive rights;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a drug candidate may, on further study, be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a drug candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a drug candidate may not be accepted as safe and effective by physicians, patients, the medical community or third-party payors, even if approved.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited financial and management resources and, as a result, we may forego or delay the pursuit of opportunities with other drug candidates or for other indications that later prove to have greater market potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial drugs or profitable market opportunities. If we do not accurately evaluate the commercial potential or target market for a particular drug candidate, we may relinquish valuable rights to that drug candidate through collaboration, licensing or other royalty arrangements in circumstances under which it would have been more advantageous for us to retain sole development and commercialization rights to such drug candidate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unsuccessful in identifying and developing additional drug candidates or are unable to do so, our key growth strategy and business will be harmed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifying and qualifying patients to participate in our clinical trials is critical to our success. The number of patients suffering from some of the seizure related disorders and rare neurological disorders we are pursuing is small and has not been established with precision. If the actual number of patients with these disorders is smaller than we anticipate, we may encounter difficulties in enrolling patients in our clinical trials, thereby delaying or preventing development and approval of our drug candidates. Even once enrolled we may be unable to retain a sufficient number of patients to complete any of our trials. Patient enrollment and retention in clinical trials depends on many factors, including the size of the patient population, the nature of the trial protocol, the existing body of safety and efficacy data, the number and nature of competing treatments and ongoing clinical trials of competing therapies for the same indication, the proximity of patients to clinical sites and the eligibility criteria for the trial, any such enrollment issues could cause delays or prevent development and approval of our drug candidates. Since we are focused on addressing seizure-related disorders and rare neurological disorders, there are limited patient pools from which to draw in order to complete our clinical trials in a timely and cost-effective manner. Furthermore, our efforts to build relationships with patient communities may not succeed, which could result in delays in patient enrollment in our clinical trials. In addition, any negative results we may report in clinical trials of our drug candidate may make it difficult or impossible to recruit and retain patients in other clinical trials of that same drug candidate. Delays or failures in planned patient enrollment or retention may result in increased costs, program delays or both, which could have a harmful effect on our ability to develop our drug candidates, or could render further development impossible.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our drug candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial potential or result in significant negative consequences following any potential marketing approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the conduct of clinical trials, patients report changes in their health, including illnesses, injuries and discomforts, to their doctor. Often, it is not possible to determine whether or not the drug candidate being studied caused these conditions. Regulatory authorities may draw different conclusions or require additional testing to confirm these determinations, if they occur. In addition, it is possible that as we test our drug candidates in larger, longer and more extensive clinical programs, or as use of these drug candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by subjects. Many times, side effects are only detectable after investigational drugs are tested in large-scale, Phase 3 trials or, in some cases, after they are made available to patients on a commercial scale after approval. For example, adverse events were reported in certain clinical trials for OV101, our former drug candidate, and soticlestat. Clinical trials may not demonstrate any ocular safety benefits for OV329 relative to vigabatrin. If clinical experience indicates that any of our drug candidates causes adverse events or serious or life-threatening adverse events, the development of that drug candidate may fail or be delayed, or, if the drug candidate has received regulatory approval, such approval may be revoked, which would harm our business, prospects, operating results and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, if we elect, or are required, to delay, suspend or terminate any clinical trial of our drug candidates, the commercial prospects of our drug candidates may be harmed and our ability to generate revenue through their sale may be delayed or eliminated. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if any of our drug candidates receive marketing approval, the FDA could require us to include a black box warning in our label or adopt REMS to ensure that the benefits outweigh its risks, which may include, among other things, a medication guide outlining the risks of the drug for distribution to patients and a communication plan to health care practitioners. Furthermore, if we or others later identify undesirable side effects caused by our drug candidates, several potentially significant negative consequences could result, including:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory authorities may suspend or withdraw approvals of such drug candidate;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory authorities may require additional warnings on the label;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may be required to change the way a drug candidate is administered or conduct additional clinical trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we could be sued and held liable for harm caused to patients;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may need to conduct a recall; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our reputation may suffer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us from achieving or maintaining market acceptance of our drug candidates and could significantly harm our business, prospects, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the market opportunities for our drug candidates are smaller than we believe they are, even assuming approval of a drug candidate, our business may suffer. Because the patient populations in the market for our drug candidates may be small or difficult to assess, we must be able to successfully identify patients and acquire a significant market share to achieve profitability and growth.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We focus our research and drug development on treatments for rare epilepsies, seizure-related disorders and rare neurological disorders. Given the small number of patients who have the disorders that we are targeting, our eligible patient population and pricing estimates may differ significantly from the actual market addressable by our drug candidates. Our projections of both the number of people who have these disorders, as well as the subset of people with these disorders who have the potential to benefit from treatment with our drug candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including the scientific literature, patient foundations, or market research, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these disorders. The number of patients may turn out to be lower than expected. Likewise, the potentially addressable patient population for each of our drug candidates may be limited or may not be amenable to treatment with our drug candidates, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our results of operations and our business. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, which may result in others developing or commercializing drugs before or more successfully than us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercialization of new drugs is highly competitive. We face competition with respect to our current drug candidates and will face competition with respect to any other drug candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. There are a number of large pharmaceutical and biotechnology companies that currently market and sell drugs or are pursuing the development of drug candidates for the treatment of the indications that we are pursuing. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More established companies may have a competitive advantage over us due to their greater size, resources and institutional experience. In particular, these companies have greater experience and expertise in securing reimbursement, government contracts, relationships with key opinion leaders, conducting testing and clinical trials, obtaining and maintaining regulatory approvals and distribution relationships to market products, and marketing approved drugs. These companies also have significantly greater research and marketing capabilities than we do. If we are not able to compete effectively against existing and potential competitors, our business and financial condition may be harmed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these factors, our competitors may obtain regulatory approval of their drugs before we are able to, which may limit our ability to develop or commercialize our drug candidates. Our competitors may also develop therapies that are safer, more effective, more widely accepted and cheaper than ours, and may also be more successful than us in manufacturing and marketing their drugs. These appreciable advantages could render our drug candidates obsolete or non-competitive before we can recover the expenses of such drug candidates&#8217; development and commercialization.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific, management and commercial personnel, establishing clinical trial sites and subject registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if our current or future drug candidates receive marketing approval, they may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if our current or future drug candidates receive marketing approval, they may fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. If they do not achieve an adequate level of acceptance, we may not generate significant drug revenue and may not become profitable. The degree of market acceptance of our current or future drug candidates, if approved for commercial sale, will depend on a number of factors, including but not limited to:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the efficacy and potential advantages compared to alternative treatments and therapies;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the safety profile of our drug candidate compared to alternative treatments and therapies;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">effectiveness of sales and marketing efforts;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the strength of our relationships with patient communities;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost of treatment in relation to alternative treatments and therapies, including any similar generic treatments;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to offer such drug for sale at competitive prices;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the convenience and ease of administration compared to alternative treatments and therapies;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the strength of marketing and distribution support;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the availability of third-party coverage and adequate reimbursement;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the prevalence and severity of any side effects; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any restrictions on the use of the drug together with other medications.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our efforts to educate physicians, patients, third-party payors and others in the medical community on the benefits of our drug candidates may require significant resources and may never be successful. Such efforts may require more resources than are typically required due to the complexity and uniqueness of our drug candidates. Since we expect sales of our drug candidates, if approved, to generate substantially all of our drug revenues for the foreseeable future, the failure of our drugs to find market acceptance would harm our business and could require us to seek additional financing.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain and maintain approval for our current or future drug candidates from the FDA, we may never obtain approval for our current or future drug candidates outside of the United States, which would limit our market opportunities and could harm our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approval of a drug candidate in the United States by the FDA does not ensure approval of such drug candidate by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. Sales of our current and future drug candidates outside of the United States will be subject to foreign regulatory requirements governing clinical trials and marketing approval. Even if the FDA grants marketing approval for a drug candidate, comparable regulatory authorities of foreign countries also must approve the manufacturing and marketing of the drug candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and more onerous than, those in the United States, which may require additional preclinical studies or clinical trials. In many countries outside the United States, a drug candidate must be approved for reimbursement before it can be approved for sale in that country. In some cases, the price that we intend to charge for any drug candidates, if approved, is also subject to approval. Obtaining approval for our current and future drug candidates in the European Union from the European Commission following the opinion of the European Medicines Agency, if we choose to submit a marketing authorization application there, would be a lengthy and expensive process. The FDA and comparable foreign regulatory authorities have the ability to limit the indications for which the drug may be marketed, require extensive warnings on the drug labeling or require expensive and time-consuming additional clinical trials or reporting as conditions of approval. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our current and future drug candidates in certain countries. In certain cases, we are dependent on third parties to obtain such foreign regulatory approvals, and any delay or failure of performance of such third parties could delay or prevent our ability to commercialize our products in the affected countries.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Also, regulatory approval for our drug candidates may be withdrawn. If we fail to comply with the regulatory requirements, our target market will be reduced and our ability to realize the full market potential of our current and future drug candidates will be harmed and our business, financial condition, results of operations and prospects could be harmed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we seek approval to commercialize our current or future drug candidates outside of the United States, a variety of risks associated with international operations could harm our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we seek approval of our current or future drug candidates outside of the United States, we expect that we will be subject to additional risks in commercialization including:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">different regulatory requirements for approval of therapies in foreign countries;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">reduced protection for intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the potential requirement of additional clinical studies in international jurisdictions;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">unexpected changes in tariffs, trade barriers and regulatory requirements;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">foreign reimbursement, pricing and insurance regimes;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">business interruptions resulting from geopolitical actions, including the ongoing war between Russia and Ukraine, any other war or the perception that hostilities may be imminent, terrorism, natural disasters or public health crises.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no prior experience in these areas. In addition, there are complex regulatory, tax, labor and other legal requirements imposed by many of the individual countries in and outside of Europe with which we will need to comply. Many biopharmaceutical companies have found the process of marketing their own products in foreign countries to be very challenging.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any drug candidate that we may develop.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability exposure related to the testing of our current and any future drug candidates in clinical trials and may face an even greater risk if we commercialize any drug candidate that we may develop. If we cannot successfully defend ourselves against claims that any such drug candidates caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">decreased demand for any drug candidate that we may develop;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">loss of revenue;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">substantial monetary awards to trial participants or patients;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">significant time and costs to defend the related litigation;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">withdrawal of clinical trial participants;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the inability to commercialize any drug candidate that we may develop; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">injury to our reputation and significant negative media attention.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain product liability insurance coverage, such insurance may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage each time we commence a clinical trial and if we successfully commercialize any drug candidate. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Licensing and Collaboration Arrangements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Under the RLT Agreement, we are entitled to receive royalty and milestone payments in connection with the development and commercialization of soticlestat. If Takeda fails to progress or discontinues the development of soticlestat, we may not receive some or all of such payments, which would materially harm our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we entered into the RLT Agreement, pursuant to which Takeda secured rights to our 50% global share in soticlestat, which we had originally licensed from Takeda, and we granted to Takeda an exclusive worldwide license under our relevant intellectual property rights to develop and commercialize the investigational medicine soticlestat for the treatment of developmental and epileptic encephalopathies, including Dravet syndrome and Lennox-Gastaut syndrome. All rights in soticlestat are now owned by Takeda or exclusively licensed to Takeda by us. Following the closing date of the RLT Agreement, Takeda assumed all responsibility for, and costs of, both development and commercialization of soticlestat, and we will no longer have any financial obligation to Takeda under the original collaboration agreement, including for milestone payments or any future development and commercialization costs. Upon closing of the RLT Agreement, we received a one-time, upfront payment of $196.0 million and, if soticlestat is successfully developed, we will be eligible to receive up to an additional $660.0 million upon Takeda achieving specified regulatory and sales milestones. In addition, if soticlestat achieves regulatory approval, we will be entitled to receive tiered royalties at percentages ranging from the low double-digits, up to 20% on sales of soticlestat. Royalties will be payable on a country-by-country and product-by-product basis during the period beginning on the date of the first commercial sale of such product in such country and ending on the later to occur of the expiration of patent rights covering the product in such country and a specified anniversary of such first commercial sale.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the RLT Agreement, Takeda now has sole discretion over the conduct of the development and commercialization of soticlestat. If for any reason, Takeda fails to progress, or elects to terminate the development of soticlestat as contemplated by the RLT Agreement, or if the development or commercialization of soticlestat is delayed or deprioritized by Takeda, we may not receive some or all of the royalty and milestone payments under such agreement. We are dependent upon Takeda&#8217;s progression of such development and the resulting payments to fund the regulatory development of our current and future drug candidates. If we are unable to find alternative sources of revenue, our inability </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to receive royalty or milestone payments under the RLT Agreement would negatively impact our business and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks associated with the in-licensing or acquisition of drug candidates could cause substantial delays in the preclinical and clinical development of our drug candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have previously acquired and we may acquire or in-license drug candidates for preclinical or clinical development in the future as we continue to build our pipeline. Such arrangements with third parties, such as our collaboration and license agreement with Graviton, may impose, diligence, development and commercialization obligations, milestone payments, royalty payments, indemnification and other obligations on us. Our obligations to pay milestone, royalty and other payments to our licensors may be substantial, and the amount and timing of such payments may impact our ability to progress the development and commercialization of our drug candidates. Our rights to use any licensed intellectual property may be subject to the continuation of and our compliance with the terms of any such agreements. Additionally, disputes may arise regarding our rights to intellectual property licensed to us or acquired by us from a third party, including but not limited to:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the scope of intellectual property rights included in, and rights granted under, any license or other agreement;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the sublicensing of patent and other rights under such agreements;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our compliance with our diligence obligations under any license agreement;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the ownership of inventions and know-how resulting from the creation or use of intellectual property by us, alone or with our licensors and collaborators;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the scope and duration of our payment obligations, and our ability to make such payments when they are owed;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our need to acquire additional intellectual property rights from third parties that may impact payments due under such agreements;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the rights of our licensors to terminate any such agreement;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our rights and obligations upon termination of such agreement; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the scope and duration of exclusivity obligations of each party to the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes over intellectual property and other rights that we have licensed or acquired, or may license or acquire in the future, from third parties could prevent or impair our ability to maintain any such arrangements on acceptable terms, result in delays in the commencement or completion of our preclinical studies and clinical trials and impact our ability to successfully develop and commercialize the affected drug candidates. If we fail to comply with our obligations under any future licensing agreements, these agreements may be terminated or the scope of our rights under them may be reduced and we might be unable to develop, manufacture or market any product that is licensed under these agreements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be required to relinquish important rights to and control over the development and commercialization of our drug candidates to any future collaborators.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and future collaborations could subject us to a number of risks, including:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may be required to undertake the expenditure of substantial operational, financial and management resources;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may be required to issue equity securities that would dilute our stockholders&#8217; percentage of ownership;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may be required to assume substantial actual or contingent liabilities;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may not be able to control the amount and timing of resources that our strategic collaborators devote to the development or commercialization of our drug candidates;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">strategic collaborators may delay clinical trials, provide insufficient funding, terminate a clinical trial or abandon a drug candidate, repeat or conduct new clinical trials or require a new version of a drug candidate for clinical testing;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">strategic collaborators may not pursue further development and commercialization of products resulting from the strategic collaboration arrangement or may elect to discontinue research and development programs;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">strategic collaborators may not commit adequate resources to the marketing and distribution, or even commercial launch of our drug candidates, limiting our potential revenues from these products;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we rely on our current collaborators to manufacture drug substance and drug product and may do so with respect to future collaborators, which could result in disputes or delays;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">disputes may arise between us and our strategic collaborators that result in the delay or termination of the research, development or commercialization of our drug candidates or that result in costly litigation or arbitration that diverts management&#8217;s attention and consumes resources;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">disputes may arise between us and our current or future collaborators regarding any termination of any collaboration, license, or other business development arrangement in which we may enter;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">strategic collaborators may experience financial difficulties;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">strategic collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in a manner that could jeopardize or invalidate our proprietary information or expose us to potential litigation;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">business combinations or significant changes in a strategic collaborator&#8217;s business strategy may also adversely affect a strategic collaborator&#8217;s willingness or ability to complete its obligations under any arrangement;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">strategic collaborators could decide to move forward with a competing drug candidate developed either independently or in collaboration with others, including our competitors; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">strategic collaborators could terminate the arrangement or allow it to expire, which would delay the development and may increase the cost of developing our drug candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities and subject us to other risks.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business plan is to continue to evaluate various acquisitions and strategic partnerships, including licensing or acquiring complementary drugs, intellectual property rights, technologies, or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased operating expenses and cash requirements;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the assumption of additional indebtedness or contingent liabilities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">assimilation of operations, intellectual property and drugs of an acquired company, including difficulties associated with integrating new personnel;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the diversion of our management&#8217;s attention from our existing drug programs and initiatives in pursuing such a strategic partnership, merger or acquisition;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing drugs or drug candidates and regulatory approvals;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to generate revenue from acquired technology and/or drugs sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">challenges related to integrating acquired businesses or entering into or realizing the benefits of strategic transactions generally; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks associated with potential international acquisition transactions, including in countries where we do not currently have a material presence.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if we engage in future acquisitions or strategic partnerships, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities and this inability could impair our ability to grow or obtain access to technology or drugs that may be important to the development of our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may explore additional strategic collaborations that may never materialize or may fail.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business strategy is based on acquiring or in-licensing compounds directed at rare epilepsies, seizure-related disorders, and rare neurological disorders. As a result, we intend to periodically explore a variety of possible additional strategic collaborations in an effort to gain access to additional drug candidates or resources. At the current time, we cannot predict what form such a strategic collaboration might take. We are likely to face significant competition in seeking </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">appropriate strategic collaborators, and strategic collaborations can be complicated and time consuming to negotiate and document. We may not be able to negotiate strategic collaborations on acceptable terms, or at all. We are unable to predict when, if ever, we will enter into any additional strategic collaborations because of the numerous risks and uncertainties associated with establishing them. Further, our business development activities and research activities may present attractive opportunities outside of rare epilepsies and seizure related disorders and we may choose to pursue drug candidates in other areas of interest including other disorders and diseases that we believe would be in the best interest of the Company and our stockholders. We plan to continuously review our strategies and modify as necessary based on attractive areas of interest and assets that we choose to pursue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Regulatory Compliance</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with customers, physicians, and third-party payors may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any drug candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third-party payors may subject us to various federal and state fraud and abuse laws and other healthcare laws, including, without limitation, the federal Anti-Kickback Statute, the federal civil and criminal false claims laws and the law commonly referred to as the Physician Payments Sunshine Act and regulations. These laws will impact, among other things, our clinical research, proposed sales, marketing and educational programs. In addition, we may be subject to patient privacy laws by both the federal government and the states in which we conduct or may conduct our business. The laws that will affect our operations include, but are not limited to:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, in return for the purchase, recommendation, leasing or furnishing of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand, and prescribers, purchasers and formulary managers on the other. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the &#8220;PPACA&#8221;), amended the intent requirement of the federal Anti-Kickback Statute. A person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">federal civil and criminal false claims laws, including, without limitation, the False Claims Act, and civil monetary penalty laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid or other government payors that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. The PPACA provides, and recent government cases against pharmaceutical and medical device manufacturers support, the view that federal Anti-Kickback Statute violations and certain marketing practices, including off-label promotion, may implicate the False Claims Act;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which created additional federal criminal statutes that prohibit a person from knowingly and willfully executing a scheme or making false or fraudulent statements to defraud any healthcare benefit program, regardless of the payor (e.g., public or private);</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), and their implementing regulations, and as amended again by the final HIPAA omnibus rule, Modifications to the HIPAA Privacy, Security, Enforcement, and Breach Notification Rules Under HITECH and the Genetic Information Nondiscrimination Act; Other Modifications to HIPAA, published in January 2013, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization by entities subject to the rule, such as health plans, healthcare clearinghouses and certain healthcare providers, known as covered entities, and their respective business associates, individuals or entities that perform certain services on behalf of a covered entity that involves the use or disclosure of individually identifiable health information and their subcontractors that use, disclose or otherwise process individually identifiable health information;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Physician Payments Sunshine Act, which is part of the PPACA, requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), information related to: (i) payments or other &#8220;transfers of value&#8221; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals; and (ii) ownership and investment interests held by physicians and their immediate family members;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">state and foreign law equivalents of each of the above federal laws, state laws that require manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and/or information regarding drug pricing, state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or to adopt compliance programs as prescribed by state laws and regulations, or that otherwise restrict payments that may be made to healthcare providers, state laws and regulations that require drug manufacturers to file reports relating to drug pricing and marketing information, and state and local laws that require the registration of pharmaceutical sales representatives; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">state and foreign laws that govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage and adequate reimbursement may not be available for our current or any future drug candidates, which could make it difficult for us to sell profitably, if approved.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market acceptance and sales of any drug candidates that we commercialize, if approved, will depend in part on the extent to which coverage and adequate reimbursement for these drugs and related treatments will be available from third-party payors, including government health administration authorities, managed care organizations and other private health insurers. Third-party payors decide which therapies they will pay for and establish reimbursement levels. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies. However, decisions regarding the extent of coverage and amount of reimbursement to be provided for any drug candidates that we develop will be made on a payor-by-payor basis. One third-party payor&#8217;s determination to provide coverage for a drug does not assure that other payors will also provide coverage, and adequate reimbursement, for the drug. Additionally, a third-party payor&#8217;s decision to provide coverage for a therapy does not imply that an adequate reimbursement rate will be approved. Each third-party payor determines whether or not it will provide coverage for a therapy, what amount it will pay the manufacturer for the therapy, and on what tier of its formulary it will be placed. The position on a third-party payor&#8217;s list of covered drugs, or formulary, generally determines the co-payment that a patient will need to make to obtain the therapy and can strongly influence the adoption of such therapy by patients and physicians. Patients who are prescribed treatments for their conditions and providers prescribing such services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our drugs unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our drugs.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. We cannot be sure that coverage and reimbursement will be available for any drug that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Inadequate coverage and reimbursement may impact the demand for, or the price of, any drug for which we obtain marketing approval. If coverage and adequate reimbursement are not available, or are available only to limited levels, we may not be able to successfully commercialize our current and any future drug candidates that we develop. Further, coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare legislative reform measures may have a negative impact on our business and results of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of drug candidates, restrict or regulate post-approval activities, and affect our ability to profitably sell any drug candidates for which we obtain marketing approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. In March 2010, the PPACA was passed, which substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There have been executive, judicial, Congressional and executive branch challenges to certain aspects of the PPACA. For example, President Trump signed Executive Orders and other directives designed to delay the implementation of certain provisions of the PPACA or otherwise circumvent some of the requirements for health insurance mandated by the PPACA. Concurrently, Congress considered legislation to repeal or repeal and replace all or part of the PPACA. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the PPACA such as removing penalties, effective January 1, 2019, for not complying with the PPACA&#8217;s individual mandate to carry health insurance, delaying the implementation of certain PPACA-mandated fees, and increasing the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D. On June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the PPACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Further, there have been a number of health reform measures by the Biden administration that have impacted the PPACA. For example, on August 16, 2022, President Biden signed the IRA into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in PPACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and by creating a new manufacturer discount program. It is possible that the PPACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact the PPACA and our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted since the PPACA was enacted. These changes include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013, and due to subsequent legislative amendments to the statute will remain in effect until 2031 unless additional Congressional action is taken. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 4% in the final fiscal year of this sequester. The American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional changes that may affect our business include the expansion of new programs such as Medicare payment for performance initiatives for physicians under the Medicare Access and CHIP Reauthorization Act of 2015 (&#8220;MACRA&#8221;), which ended the use of the statutory formula and established a quality payment program, also referred to as the Quality Payment Program. In November 2019, CMS issued a final rule finalizing the changes to the Quality Payment Program. At this time, the full impact to overall physician reimbursement as a result of the introduction of the Quality Payment Program remains unclear.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Also, there has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products, which have resulted in several Presidential executive orders, Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. At the federal level, in July 2021, the Biden administration released an </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, the U.S. Department of Health and Human Services (&#8220;HHS&#8221;), released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. In addition, the IRA, among other things, (i) directs the Secretary of HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare Part B and Medicare Part D, and subjects drug manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law, and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions will take effect progressively starting in fiscal year 2023, although they may be subject to legal challenges. Further, the Biden administration released an additional executive order on October 14, 2022, directing HHS to report on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries. At the state level, legislatures have increasingly passed and implemented regulations designed to control pharmaceutical and biological product pricing, including pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We expect that these and other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved drug. For example, based on a recent executive order, the Biden administration expressed its intent to pursue certain policy initiatives to reduce drug prices. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our drugs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to obtain or maintain orphan drug designations or exclusivity for our drug candidates, which could limit the potential profitability of our drug candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities in some jurisdictions, including the United States, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act of 1983, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States. Generally, if a drug with an orphan drug designation subsequently receives the first marketing approval for an indication for which it receives the designation, then the drug is entitled to a period of marketing exclusivity that precludes the applicable regulatory authority from approving another marketing application for the same drug for the same indication for the exclusivity period except in limited situations. For purposes of small molecule drugs, the FDA defines &#8220;same drug&#8221; as a drug that contains the same active moiety and is intended for the same use as the drug in question. A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining orphan drug designations is important to our business strategy; however, obtaining an orphan drug designation can be difficult and we may not be successful in doing so. Even if we were to obtain orphan drug designation for a drug candidate, we may not obtain orphan exclusivity and that exclusivity may not effectively protect the drug from the competition of different drugs for the same condition, which could be approved during the exclusivity period. Additionally, after an orphan drug is approved, the FDA could subsequently approve another application for the same drug for the same indication if the FDA concludes that the later drug is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusive marketing rights in the United States also may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. The failure to obtain an orphan drug designation for any drug candidates we may develop, the inability to maintain that designation for the duration of the applicable period, or the inability to obtain or maintain orphan drug exclusivity could reduce our ability to make sufficient sales of the applicable drug candidate to balance our expenses incurred to develop it, which would have a negative impact on our operational results and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain regulatory approval for our current or future drug candidates, they will remain subject to ongoing regulatory oversight.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain any regulatory approval for our current or future drug candidates, such approvals will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping and submission of safety and other post-market information. Any regulatory approvals that we receive for our current or future drug candidates may also be subject to a REMS, limitations on the approved indicated uses for which the drug may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 trials, and surveillance to monitor the quality, safety and efficacy of the drug.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, drug manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP requirements and adherence to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commitments made in the NDA, BLA or foreign marketing application. If we, or a regulatory authority, discover previously unknown problems with a drug, such as adverse events of unanticipated severity or frequency, or problems with the facility where the drug is manufactured or if a regulatory authority disagrees with the promotion, marketing or labeling of that drug, a regulatory authority may impose restrictions relative to that drug, the manufacturing facility or us, including requesting a recall or requiring withdrawal of the drug from the market or suspension of manufacturing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to comply with applicable regulatory requirements following approval of our current or future drug candidates, a regulatory authority may:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">issue an untitled letter or warning letter asserting that we are in violation of the law;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">seek an injunction or impose administrative, civil or criminal penalties or monetary fines;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">suspend or withdraw regulatory approval;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">suspend any ongoing clinical trials;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">refuse to approve a pending NDA or comparable foreign marketing application (or any supplements thereto) submitted by us or our strategic partners;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">restrict the marketing or manufacturing of the drug;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">seize or detain the drug or otherwise require the withdrawal of the drug from the market;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">refuse to permit the import or export of drug candidates; or</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">refuse to allow us to enter into supply contracts, including government contracts.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the FDA strictly regulates the promotional claims that may be made about drug products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant civil, criminal and administrative penalties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our current or future drug candidates and harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FDA&#8217;s policies, and those of equivalent foreign regulatory agencies, may change and additional government regulations may be enacted that could cause changes to or delays in the drug review process, or suspend or restrict regulatory approval of our drug candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would harm our business, financial condition, results of operations and prospects. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain patent protection for our current or any future drug candidates, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our development programs and drug candidates. Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our current and any future drug candidates. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our current and future development programs and drug candidates. The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our current or any future drug candidates in the United States or in other foreign countries. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue and even if such patents cover our current or any future drug candidates, third parties may challenge their </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">validity, enforceability or scope, which may result in such patents being narrowed, invalidated, or held unenforceable. Any successful opposition to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any drug candidates or companion diagnostic that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a drug candidate and companion diagnostic under patent protection could be reduced. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the patent applications we hold or have in-licensed with respect to our development programs and drug candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for our current or any future drug candidates, it could dissuade companies from collaborating with us to develop drug candidates, and threaten our ability to commercialize future drugs. Any such outcome could have a negative effect on our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. For example, European patent law restricts the patentability of methods of treatment of the human body more than United States law does. Publications of discoveries in scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or drugs, in whole or in part, or which effectively prevent others from commercializing competitive technologies and drugs. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. On December 16, 2011, the Leahy-Smith America Invents Act (the &#8220;Leahy-Smith Act&#8221;) was signed into law. The Leahy-Smith Act includes a number of significant changes to United States patent law. These include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. The United States Patent Office recently developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, only became effective on March 16, 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could harm our business and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we may be subject to a third-party pre-issuance submission of prior art to the U.S. Patent and Trademark Office (the &#8220;USPTO&#8221;) or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or drugs and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize drugs without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future drug candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. An adverse determination in any such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and drugs, or limit the duration of the patent protection of our technology and drugs. Moreover, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years from the earliest filing date of a non-provisional patent application. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Without patent protection for our current or future drug candidates, we may be open to competition from generic versions of such drugs. Given the amount of time required for the development, testing and regulatory review of new drug candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing drugs similar or identical to ours.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or applications will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our owned and licensed patents and/or applications and any patent rights we may own or license in the future. We rely on our outside counsel or our licensing partners to pay these fees due to non-U.S. patent agencies. The USPTO and various non-U.S. government patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply and we are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market and this circumstance could harm our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent terms may be inadequate to protect our competitive position on our drug candidates for an adequate amount of time.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the amount of time required for the development, testing and regulatory review of new drug candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. We expect to seek extensions of patent terms in the United States and, if available, in other countries where we are prosecuting patents. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the normal expiration of the patent, which is limited to the approved indication (or any additional indications approved during the period of extension). However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their drug earlier than might otherwise be the case.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats to our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business. The following examples are illustrative:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">others may be able to make compounds or formulations that are similar to our drug candidates but that are not covered by the claims of any patents, should they issue, that we own or control;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we or any strategic partners might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own or control;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we might not have been the first to file patent applications covering certain of our inventions;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">it is possible that our pending patent applications will not lead to issued patents;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">issued patents that we own or control may not provide us with any competitive advantages, or may be held invalid or unenforceable because of legal challenges;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights and then use the information learned from such activities to develop competitive drugs for sale in our major commercial markets;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may not develop additional proprietary technologies that are patentable; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the patents of others may have an adverse effect on our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proprietary map of disease-relevant biological pathways underlying orphan disorders of the brain that we developed would not be appropriate for patent protection and, as a result, we rely on trade secrets to protect this aspect of our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a negative impact on the success of our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends, in part, upon our ability and the ability of our current or future collaborators to develop, manufacture, market and sell our current and any future drug candidates and use our proprietary technologies without infringing the proprietary rights and intellectual property of third parties. The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual property rights. We may in the future become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our current and any future drug candidates and technology, including interference proceedings, post grant review and inter partes review before the USPTO. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit. There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise assert their patent rights against us. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, which could have a negative impact on our ability to commercialize our current and any future drug candidates. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. If we are found to infringe a third party&#8217;s valid and enforceable intellectual property rights, we could be required to obtain a license from such third party to continue developing, manufacturing and marketing our drug candidate(s) and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or drug candidate. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent or other intellectual property right. A finding of infringement could prevent us from manufacturing and commercializing our current or any future drug candidates or force us to cease some or all of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations and prospects. See the section herein titled &#8220;Legal Proceedings&#8221; for additional information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be involved in lawsuits to protect or enforce our patents, the patents of our licensors or our other intellectual property rights, which could be expensive, time consuming and unsuccessful.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe or otherwise violate our patents, the patents of our licensors or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file legal claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing. The initiation of a claim against a third party may also cause the third party to bring </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">counter claims against us such as claims asserting that our patents are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement or lack of statutory subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant material information from the USPTO, or made a materially misleading statement, during prosecution. Third parties may also raise similar validity claims before the USPTO in post-grant proceedings such as ex parte reexaminations, inter partes review, or post-grant review, or oppositions or similar proceedings outside the United States, in parallel with litigation or even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. For the patents and patent applications that we have licensed, we may have limited or no right to participate in the defense of any licensed patents against challenge by a third party. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of any future patent protection on our current or future drug candidates. Such a loss of patent protection could harm our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. Our business could be harmed if in litigation the prevailing party does not offer us a license on commercially reasonable terms. Any litigation or other proceedings to enforce our intellectual property rights may fail, and even if successful, may result in substantial costs and distract our management and other employees.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our current and any future drug candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States has recently enacted and implemented wide-ranging patent reform legislation. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we have licensed or that we might obtain in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we have licensed or that we may obtain in the future. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world, which could negatively impact our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents covering our current and any future drug candidates throughout the world would be prohibitively expensive. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own drugs and, further, may export otherwise infringing drugs to territories where we may obtain patent protection, but where patent enforcement is not as strong as that in the United States. These drugs may compete with our drugs in jurisdictions where we do not have any issued or licensed patents and any future patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we rely on third parties to manufacture or commercialize our current or any future drug candidates, or if we collaborate with additional third parties for the development of our current or any future drug candidates, we must, at times, share trade secrets with them. We may also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development partnerships or similar agreements. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure could have an adverse effect on our business and results of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any third-party collaborators. A competitor&#8217;s discovery of our trade secrets would harm our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not have our own manufacturing capabilities and will rely on third parties to produce clinical and commercial supplies of our current and any future drug candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate, and we do not expect to own or operate, facilities for drug manufacturing, drug formulation, storage and distribution or testing. We have been in the past, and will continue to be, dependent on third parties to manufacture the clinical supplies of our drug candidates. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, we also will rely on third-party manufacturers to supply us with sufficient quantities of our drug candidates to be used, if approved, for commercialization. Any significant delay in the supply of a drug candidate, or the raw material components thereof, for an ongoing clinical trial due to the need to replace a third-party manufacturer could considerably delay completion of our clinical trials, product testing and potential regulatory approval of our drug candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, our reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured drug candidates ourselves including:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">inability to meet our drug specifications and quality requirements consistently;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">delay or inability to procure or expand sufficient manufacturing capacity;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">issues related to scale-up of manufacturing;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">costs and validation of new equipment and facilities required for scale-up;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">failure to comply with cGMP and similar foreign standards;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">inability to negotiate manufacturing agreements with third parties under commercially reasonable terms, if at all;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">reliance on single sources for drug components;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">lack of qualified backup suppliers for those components that are currently purchased from a sole or single source supplier;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">operations of our third-party manufacturers or suppliers could be disrupted by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">carrier disruptions or increased costs that are beyond our control.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could lead to clinical trial delays, failure to obtain regulatory approval or impact our ability to successfully commercialize our current or any future drug candidates once approved. Some of these events could be the basis for FDA action, including injunction, request for recall, seizure, or total or partial suspension of production.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We intend to rely on third parties to conduct, supervise and monitor our preclinical studies and clinical trials, and if those third parties perform in an unsatisfactory manner, it may harm our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have the ability to independently conduct any preclinical studies or clinical trials. We intend to rely on CROs and clinical trial sites to ensure the proper and timely conduct of our preclinical studies and clinical trials, and we expect to have limited influence over their actual performance. We intend to rely upon CROs to monitor and manage data for our clinical programs, as well as the execution of future preclinical studies. We expect to control only certain aspects of our CROs&#8217; activities. Nevertheless, we will be responsible for ensuring that each of our preclinical </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">studies or clinical trials are conducted in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on the CROs does not relieve us of our regulatory responsibilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our CROs will be required to comply with good laboratory practices (&#8220;GLPs&#8221;) and GCPs, which are regulations and guidelines enforced by the FDA and are also required by the Competent Authorities of the Member States of the European Economic Area and comparable foreign regulatory authorities in the form of International Council for Harmonization guidelines for any of our drug candidates that are in preclinical and clinical development. The regulatory authorities enforce GCPs through periodic inspections of trial sponsors, principal investigators and clinical trial sites. Although we will rely on CROs to conduct GCP-compliant clinical trials, we remain responsible for ensuring that each of our GLP preclinical studies and clinical trials is conducted in accordance with its investigational plan and protocol and applicable laws and regulations, and our reliance on the CROs does not relieve us of our regulatory responsibilities. If we or our CROs fail to comply with GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. Accordingly, if our CROs fail to comply with these regulations or fail to recruit a sufficient number of subjects, we may be required to repeat clinical trials, which would delay the regulatory approval process.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we will have agreements governing their activities, our CROs will not be our employees, and we will not control whether or not they devote sufficient time and resources to our future clinical and preclinical programs. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials, or other drug development activities which could harm our business. We face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CROs, which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology. If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize any drug candidate that we develop. As a result, our financial results and the commercial prospects for any drug candidate that we develop would be harmed, our costs could increase, and our ability to generate revenue could be delayed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA. The FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the trial. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and may ultimately lead to the denial of marketing approval of our current and future drug candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our relationship with these CROs terminates, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or adding additional CROs involves substantial cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can negatively impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a negative impact on our business, financial condition and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business Operations, Employee Matters and Managing Growth</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are highly dependent on the services of our senior management team, including our Chairman and Chief Executive Officer, Dr. Jeremy Levin, and if we are not able to retain these members of our management team or recruit and retain additional management, clinical and scientific personnel, our business will be harmed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on our senior management team, including our Chairman and Chief Executive Officer, Dr. Levin. The employment agreements we have with these officers do not prevent such persons from terminating their employment with us at any time. The loss of the services of any of these persons could impede the achievement of our research, development, operational, financial and commercialization objectives.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are dependent on our continued ability to attract, retain and motivate highly qualified additional management, clinical and scientific personnel. If we are not able to retain our management and to attract, on acceptable terms, additional qualified personnel necessary for the continued development of our business, we may not be able to sustain our operations or grow. This risk may be further amplified given the particularly competitive hiring market in New York City, the location of our corporate headquarters.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to attract or retain qualified personnel in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses. Many of the other pharmaceutical companies that we compete against for qualified personnel and consultants have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates and consultants than what we have to offer. If we are unable to continue to attract, retain and motivate high-quality personnel and consultants to accomplish our business objectives, the rate and success at which we can discover and develop drug candidates and our business will be limited and we may experience constraints on our development objectives.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future performance will also depend, in part, on our ability to successfully integrate newly hired executive officers into our management team and our ability to develop an effective working relationship among senior management. Our failure to integrate these individuals and create effective working relationships among them and other members of management could result in inefficiencies in the development and commercialization of our drug candidates, harming future regulatory approvals, sales of our drug candidates and our results of operations. Additionally, we do not currently maintain &#8220;key person&#8221; life insurance on the lives of our executives or any of our employees.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2023, we had 40 full-time employees. As our development and commercialization plans and strategies for our current pipeline of product candidates develop, we expect to need additional managerial, operational, sales, marketing, financial, legal and other resources. Our management may need to divert a disproportionate amount of its attention away from our day-to-day operations and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, operational inefficiencies, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of our current and potential future drug candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and grow revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance, our ability to commercialize drug candidates, develop a scalable infrastructure and compete effectively will depend, in part, on our ability to effectively manage any future growth.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, consultants, distributors, and collaborators may engage in fraudulent or illegal activity. Misconduct by these parties could include intentional, reckless or negligent conduct or disclosure of unauthorized activities to us that violates the regulations of the FDA and non-U.S. regulators, including those laws requiring the reporting of true, complete and accurate information to such regulators, manufacturing standards, healthcare fraud and abuse laws and regulations in the United States and abroad or laws that require the true, complete and accurate reporting of financial information or data. In particular, sales, marketing and business arrangements in the healthcare industry, including the sale of pharmaceuticals, are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. It is not always possible to identify and deter misconduct by our employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. Further, because of our hybrid work policies, information that is normally protected, including company confidential information, may be less secure. If actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could result in the imposition of significant fines or other sanctions, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings and curtailment of operations, any of which could adversely affect our ability to operate our business and our results of operations. Whether or not we are successful in defending against such actions or investigations, we could incur substantial costs, including legal fees, and divert the attention of management in defending ourselves against any of these claims or investigations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant disruptions of our information technology systems or data security incidents could result in significant financial, legal, regulatory, business and reputational harm to us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasingly dependent on information technology systems and infrastructure, including mobile technologies, to operate our business. In the ordinary course of our business, we collect, store, process and transmit large amounts of sensitive information, including intellectual property, proprietary business information, personal information and other confidential information. It is critical that we do so in a secure manner to maintain the confidentiality, integrity and availability of such sensitive information. We have also outsourced elements of our operations (including elements of our information technology infrastructure) to third parties, and as a result, we manage a number of third-party vendors who may or could have access to our computer networks or our confidential information. In addition, many of those third parties in turn subcontract or outsource some of their responsibilities to third parties. While all information technology operations are inherently vulnerable to inadvertent or intentional security breaches, incidents, attacks and exposures, the accessibility and distributed nature of our information technology systems, and the sensitive information stored on those systems, make such systems potentially vulnerable to unintentional or malicious, internal and external attacks on our technology environment. In addition, due to our hybrid work environment, we may be more vulnerable to cyberattacks. Potential vulnerabilities can be exploited from inadvertent or intentional actions of our employees, third-party vendors, business partners, or by malicious third parties. Attacks of this nature are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives (including, but not limited to, industrial espionage) and expertise, including organized criminal groups, &#8220;hacktivists,&#8221; nation states and others. In addition to the extraction of sensitive information, such attacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information. In addition, the prevalent use of mobile devices increases the risk of data security incidents.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant disruptions of our, our third-party vendors&#8217; and/or business partners&#8217; information technology systems or other similar data security incidents could adversely affect our business operations and/or result in the loss, misappropriation, and/or unauthorized access, use or disclosure of, or the prevention of access to, sensitive information, which could result in financial, legal, regulatory, business and reputational harm to us. In addition, information technology system disruptions, whether from attacks on our technology environment or from computer viruses, natural disasters, terrorism, war and telecommunication and electrical failures, could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no way of knowing with certainty whether we have experienced any data security incidents that have not been discovered. While we have no reason to believe this to be the case, attackers have become very sophisticated in the way they conceal access to systems, and many companies that have been attacked are not aware that they have been attacked. Any event that leads to unauthorized access, use or disclosure of personal information, including but not limited to personal information regarding our patients or employees, could disrupt our business, harm our reputation, compel us to comply with applicable federal and/or state breach notification laws and foreign law equivalents, subject us to time consuming, distracting and expensive litigation, regulatory investigation and oversight, mandatory corrective action, require us to verify the correctness of database contents, or otherwise subject us to liability under laws, regulations and contractual obligations, including those that protect the privacy and security of personal information. This could result in increased costs to us, and result in significant legal and financial exposure and/or reputational harm. In addition, any failure or perceived failure by us or our vendors or business partners to comply with our privacy, confidentiality or data security-related legal or other obligations to third parties, or any further security incidents or other inappropriate access events that result in the unauthorized access, release or transfer of sensitive information, which could include personally identifiable information, may result in governmental investigations, enforcement actions, regulatory fines, litigation, or public statements against us by advocacy groups or others, and could cause third parties, including clinical sites, regulators or current and potential partners, to lose trust in us or we could be subject to claims by third parties that we have breached our privacy- or confidentiality-related obligations, which could materially and adversely affect our business and prospects. Moreover, data security incidents and other inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above. While we have implemented security measures intended to protect our information technology systems and infrastructure, there can be no assurance that such measures will successfully prevent service interruptions or security incidents.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to numerous and varying privacy and security laws, and our failure to comply could result in penalties and reputational damage.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to laws and regulations covering data privacy and the protection of personal information including health information. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has been an increasing focus on privacy and data protection issues which may affect our business. In the U.S., we may be subject to state security breach notification laws, state health information privacy laws and federal and state consumer protections laws which impose requirements for the collection, use, disclosure and transmission of personal information. Each of these laws is subject to varying interpretations by courts and government agencies, creating complex compliance issues for us. If we fail to comply with applicable laws and regulations we could be subject to penalties or sanctions, including criminal penalties if we knowingly obtain individually identifiable health information from a covered entity in a manner that is not authorized or permitted by HIPAA or for aiding and abetting the violation of HIPAA.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous other countries have, or are developing, laws governing the collection, use and transmission of personal information as well. EU member states and other jurisdictions have adopted data protection laws and regulations, which impose significant compliance obligations. For example, in May 2016, the EU formally adopted the General Data Protection Regulation, or GDPR, which applies to all EU member states as of May 25, 2018 and replaces the former EU Data Protection Directive. The regulation introduces new data protection requirements in the EU and imposes substantial fines for breaches of the data protection rules. The GDPR must be implemented into national laws by the EU member states imposes strict obligations and restrictions on the ability to collect, analyze, and transfer personal data, including health data from clinical trials and adverse event reporting. Data protection authorities from different EU member states have interpreted the privacy laws differently, which adds to the complexity of processing personal data in the EU, and guidance on implementation and compliance practices are often updated or otherwise revised. Any failure to comply with the rules arising from the GDPR and related national laws of EU member states could lead to government enforcement actions and significant penalties against us, and adversely impact our operating results. The GDPR will increase our responsibility and liability in relation to personal data that we process and we may be required to put in place additional mechanisms ensuring compliance with EU data protection rules.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, California enacted the California Consumer Privacy Act (the &#8220;CCPA&#8221;) legislation that has been dubbed the first &#8220;GDPR-like&#8221; law in the United States. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used by requiring covered companies to provide new disclosures to California consumers (as that term is broadly defined) and provide such consumers new ways to opt-out of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Being a Public Company</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a &#8220;smaller reporting company&#8221; and the reduced disclosure requirements applicable to such companies may make our common stock less attractive to investors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently a &#8220;smaller reporting company&#8221; as defined in the Exchange Act. We will be a smaller reporting company and may take advantage of the scaled-back disclosures available to smaller reporting companies for so long as (i) the market value of our voting and non-voting ordinary shares held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter or (ii) (a) our annual revenue is less than $100.0 million during the most recently completed fiscal year and (b) the market value of our voting and non-voting ordinary shares held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As a smaller reporting company, we are permitted to comply with scaled-back disclosure obligations in our SEC filings compared to other issuers, including with respect to disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We have elected to adopt the accommodations available to smaller reporting companies. Until we cease to be a smaller reporting company, the scaled-back disclosure in our SEC filings will result in less information about our company being available than for other public companies. If investors consider our common shares less attractive as a result of our election to use the scaled-back disclosure permitted for smaller reporting companies, there may be a less active trading market for our common shares and our share price may be more volatile.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may take advantage of certain of the scaled-back disclosures available to smaller reporting companies, including but not limited to:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">reduced disclosure obligations regarding executive compensation arrangements; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain an effective system of internal control over financial reporting in the future, we may not be able to accurately report our financial condition, results of operations or cash flows, which may adversely affect investor confidence in us and, as a result, the value of our common stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Sarbanes-Oxley Act requires, among other things, that we maintain effective internal controls for financial reporting and disclosure controls and procedures. We are required, under Section 404, to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting. This assessment will need to include disclosure of any material weaknesses identified by our management in our internal control over financial reporting. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting that results in more than a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented or detected on a timely basis. Section 404 also generally requires an attestation from our independent registered public accounting firm on the effectiveness of our internal control over financial reporting.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to include and have included an attestation from our independent registered public accounting firm on the effectiveness of our internal control over financial reporting. However, as of the last business day of our second fiscal quarter of 2023, we determined that we continue to qualify as a smaller reporting company and requalify as a non-accelerated filer for the year ended December 31, 2023. We therefore will no longer be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023. Our compliance with Section 404 requires that we incur substantial expense and expend significant management efforts. We currently do not have an internal audit group, and rely on experienced consultants to support this function. We may need to hire additional consultants or accounting and financial staff with appropriate public company experience and technical accounting knowledge and compile the system and process documentation necessary to perform the evaluation needed to comply with Section 404. We may not be able to complete our evaluation, testing and any required remediation in a timely fashion. During the evaluation and testing process, if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal control over financial reporting is effective. We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting, we could lose investor confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by The Nasdaq Stock Market LLC, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Ownership of Our Common Stock and Other General Matters</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for our common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">market price of our common stock has been and likely will remain volatile. The stock market in general and the market for biopharmaceutical or pharmaceutical companies in particular, has experienced extreme volatility that has often been unrelated to the operating performance of particular companies, which has resulted in decreased stock prices for many companies notwithstanding the lack of a fundamental change in their underlying business models or prospects. Broad market and industry factors, including potentially worsening economic conditions and other adverse effects or developments relating to new or ongoing public health crises or other inflationary factors, may negatively affect the market price of our common stock, regardless of our actual operating performance. As a result of this volatility, you may lose all or part of your investment in our common stock since you might be unable to sell your shares at or above the price you paid for the shares. The market price for our common stock may be influenced by many factors, including</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">results of clinical trials of our current and any future drug candidates or those of our competitors;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the success of competitive drugs or therapies;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory or legal developments in the United States and other countries;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the recruitment or departure of key personnel;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the level of expenses related to our current and any future drug candidates or clinical development programs;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the results of our efforts to discover, develop, acquire or in-license additional drug candidates;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our inability to obtain or delays in obtaining adequate drug supply for any approved drug or inability to do so at acceptable prices;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">significant lawsuits, including patent or stockholder litigation;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">variations in our financial results or those of companies that are perceived to be similar to us;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">market conditions in the pharmaceutical and biotechnology sectors;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">general economic, industry and market conditions; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the other factors described in this &#8220;Risk Factors&#8221; section.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the past, stockholders have initiated class action lawsuits against companies following periods of volatility in the market prices of these companies&#8217; stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management&#8217;s attention and resources.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and share price.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, increases in inflation rates and uncertainty about economic stability. The Russia-Ukraine war has created extreme volatility in the global capital markets and is expected to have further global economic consequences, including disruptions of the global supply chain and energy markets. Any such volatility and disruptions may have adverse consequences on us or the third parties on whom we rely. If the equity and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity financing more difficult to obtain in a timely manner or on favorable terms, more costly or more dilutive.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There is no public market for our Series A convertible preferred stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no established public trading market for our Series A convertible preferred stock, and we do not expect a market to develop. In addition, we do not intend to apply for listing of the Series A convertible preferred stock on any national securities exchange or other nationally recognized trading system. Without an active market, the liquidity of the Series A convertible preferred stock will be limited.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may sell additional equity or debt securities or enter into other arrangements to fund our operations, which may result in dilution to our stockholders and impose restrictions or limitations on our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time as we can generate substantial revenue from drug sales, if ever, we expect to finance our cash needs through a combination of equity and debt financings, strategic alliances, and license and development agreements in connection with any collaborations. We do not have any committed external source of funds. To the extent that we issue additional equity securities, our stockholders may experience substantial dilution, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a stockholder. In addition, we may issue equity or debt securities as consideration for obtaining rights to additional compounds.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2020, we filed a shelf registration statement on Form S-3 (Registration No. 333-250054) that allows us to sell up to an aggregate of $250.0 million of our common stock, preferred stock, debt securities and/or warrants (the &#8220;S-3 Registration Statement&#8221;), which includes a prospectus covering the issuance and sale of up to $75.0 million of common stock pursuant to an at-the-market (&#8220;ATM&#8221;) offering program. As of June&#160;30, 2023, we had $250.0 million available under our S-3 Registration Statement, including $75.0 million available pursuant to our ATM program. Debt and equity financings, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as redeeming our shares, making investments, issuing additional equity, incurring additional debt, making capital expenditures, declaring dividends or placing limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could negatively impact our ability to conduct our business. If we raise additional capital through future collaborations, strategic alliances or third-party licensing arrangements, we may have to relinquish valuable rights to our intellectual property, future revenue streams, research programs or drug candidates, or grant licenses on terms that may not be favorable to us. Any of these events could significantly harm our business, financial condition and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">You will be diluted by any conversions of outstanding Series A convertible preferred stock and exercises of outstanding options.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2023, we had outstanding options to purchase an aggregate of 15,448,835 shares of our common stock at a weighted average exercise price of $3.87 per share and 1,250,000 shares of common stock issuable upon conversion of outstanding Series A convertible preferred stock for no additional consideration. Such Series A convertible preferred stock is convertible any time at the option of the holder thereof subject to the beneficial ownership limitations described in Note 7 to the financial statements contained in this Quarterly Report on Form 10-Q. The exercise of such options and conversion of the Series A convertible preferred stock for shares of our common stock will result in further dilution of your investment and could negatively affect the market price of our common stock. In addition, you may experience further dilution if we issue common stock, or securities convertible into common stock, in the future. As a result of this dilution, you may receive significantly less than the full purchase price you paid for the shares in the event of liquidation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of ownership of our common stock among our executive officers, directors and principal stockholders may prevent new investors from influencing significant corporate decisions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon our shares of our common stock outstanding as of June&#160;30, 2023, our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock, in the aggregate, beneficially own shares representing approximately 50% of our outstanding common stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Takeda, a greater than 5% holder, has agreed to, among other things, (i) a standstill provision, (ii) restrictions on its ability to sell or otherwise transfer its shares of our stock, (iii) vote its shares on certain matters in accordance with the holders of a majority of shares of our common stock and (iv) restrictions on the percentage of our outstanding common stock it may own, in accordance with the terms of the RLT Agreement with Takeda.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock acted together, they may be able to significantly influence all matters requiring stockholder approval, including the election and removal of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. The concentration of voting power, Takeda standstill provisions, voting obligations and transfer restrictions could delay or prevent an acquisition of our company on terms that other stockholders may desire or result in the management of our company in ways with which other stockholders disagree.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock relies, in part, on the research and reports that industry or financial analysts publish about us or our business. We do currently have research coverage offered by four industry or financial analysts, although two analysts have withdrawn research coverage in the last twelve months. We do not have any control over these analysts. If additional analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If additional analysts cease to cover our stock or fail to regularly publish reports, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our corporate charter and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">establish a classified board of directors such that not all members of the board are elected at one time;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">allow the authorized number of our directors to be changed only by resolution of our board of directors;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">limit the manner in which stockholders can remove directors from the board;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">limit who may call stockholder meetings;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a stockholder rights plan, or so-called &#8220;poison pill,&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">require the approval of the holders of at least 66 2/3% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Takeda standstill provisions and transfer restrictions in the RLT Agreement may delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to securities litigation, which is expensive and could divert management attention.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock may be volatile. In the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would benefit our stockholders and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders, or remove our current management. These provisions include:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">authorizing the issuance of &#8220;blank check&#8221; preferred stock, the terms of which we may establish and shares of which we may issue without stockholder approval;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">prohibiting cumulative voting in the election of directors, which would otherwise allow for less than a majority of stockholders to elect director candidates;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">prohibiting stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of our stockholders;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">eliminating the ability of stockholders to call a special meeting of stockholders; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, who are responsible for appointing the members of our management. Because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law (the &#8220;DGCL&#8221;), which may discourage, delay or prevent someone from acquiring us or merging with us whether or not it is desired by or beneficial to our stockholders. Under the DGCL, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other things, the board of directors has approved the transaction. Any provision of our amended and restated certificate of incorporation or amended and restated bylaws or Delaware law that has the effect of delaying or deterring a change of control could limit the opportunity for our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stockholders to receive a premium for their shares of our common stock and could also affect the price that some investors are willing to pay for our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of a substantial number of shares of our common stock in the public market could cause the market price of our common stock to drop significantly.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. Some of the holders of our securities have rights, subject to certain conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. Registration of these shares would result in the shares becoming freely tradable without restriction under the Securities Act except for shares held by our affiliates. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">65</span></div></div></div><div id="i447d75b6bca148d0bd5c21482392c4f0_118"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.143%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1636651/000119312517166080/d382437dex31.htm">Amended and Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001-38085), filed with the Commission on May 10, 2017).</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1636651/000156459019035235/ovid-ex31_6.htm">Corrected Amended and Restated Certificate of Designation of Series A Convertible Preferred Stock (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001-38085), filed with the Commission on September 24, 2019).</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1636651/000119312517166080/d382437dex32.htm">Amended and Restated Bylaws (incorporated herein by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K (File No. 001-38085), filed with the Commission on May 10, 2017).</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1636651/000119312517135563/d286200dex41.htm">Form of Common Stock Certificate of the Company (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Registration Statement on Form S-1/A (File No. 333-217245), filed with the Commission on April 25, 2017).</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1636651/000119312519047109/d714860dex41.htm">Form of Series A Preferred Stock Certificate (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001-38085), filed with the Commission on February 21, 2019).</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1636651/000119312517118846/d286200dex42.htm">Second Amended and Restated Investors&#8217; Rights Agreement, by and among the Company and certain of its stockholders, dated January 6, 2017 (incorporated herein by reference to Exhibit 4.2 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-217245), filed with the Commission on April 10, 2017).</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ovid2023q2exhibit311.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ovid2023q2exhibit312.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ovid2023q2exhibit321.htm">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained within Exhibit 101)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________</span></div><div style="margin-top:2pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Furnished herewith and not deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">66</span></div></div></div><div id="i447d75b6bca148d0bd5c21482392c4f0_121"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i447d75b6bca148d0bd5c21482392c4f0_7">Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.477%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OVID THERAPEUTICS INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: August&#160;4, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jeremy M. Levin</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeremy M. Levin</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer<br/>(Principal Executive Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: August&#160;4, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jeffrey Rona</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey Rona</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Business and Financial Officer<br/>(Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ovid2023q2exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i4195fa9097434944a20f0790beea3007_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Jeremy M. Levin, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Quarterly Report on Form 10-Q of Ovid Therapeutics Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August&#160;4, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jeremy M. Levin</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeremy M. Levin</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ovid2023q2exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i581860cf234d4d578548c56bd4329780_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Jeffrey Rona, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Quarterly Report on Form 10-Q of Ovid Therapeutics Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August&#160;4, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jeffrey Rona</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey Rona</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Business and Financial Officer<br>(Principal Financial Officer and Principal Accounting Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ovid2023q2exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i53887ce695ba49f5bd3ca3ca877de7a6_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jeremy M. Levin, Chief Executive Officer of Ovid Therapeutics Inc. (the &#8220;Company&#8221;), and Jeffrey Rona, Chief Business and Financial Officer of the Company, each hereby certifies that, to the best of his knowledge&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The Company&#8217;s Quarterly Report on Form 10-Q for the period ended June&#160;30, 2023, to which this Certification is attached as Exhibit 32.1 (the &#8220;Periodic Report&#8221;), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act&#59; and</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; August&#160;4, 2023</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jeremy M. Levin</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jeffrey Rona</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeremy M. Levin</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey Rona</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer<br>(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Business and Financial Officer<br>(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>ovid-20230630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:bac70ec3-5ee7-4b97-a85c-498b4f8489b1,g:499e488f-fe63-4d10-9e0b-b93d763975f8-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ovid="http://www.ovidrx.com/20230630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.ovidrx.com/20230630">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ovid-20230630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ovid-20230630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ovid-20230630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ovid-20230630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.ovidrx.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofComprehensiveLoss">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>0000007 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFOPERATIONS" roleURI="http://www.ovidrx.com/role/NATUREOFOPERATIONS">
        <link:definition>0000008 - Disclosure - NATURE OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>0000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHCASHEQUIVALENTSANDMARKETABLESECURITIES" roleURI="http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIES">
        <link:definition>0000010 - Disclosure - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTANDINTANGIBLEASSETS" roleURI="http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETS">
        <link:definition>0000011 - Disclosure - PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASES" roleURI="http://www.ovidrx.com/role/LEASES">
        <link:definition>0000012 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSES" roleURI="http://www.ovidrx.com/role/ACCRUEDEXPENSES">
        <link:definition>0000013 - Disclosure - ACCRUED EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://www.ovidrx.com/role/STOCKHOLDERSEQUITY">
        <link:definition>0000014 - Disclosure - STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATION" roleURI="http://www.ovidrx.com/role/STOCKBASEDCOMPENSATION">
        <link:definition>0000015 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://www.ovidrx.com/role/INCOMETAXES">
        <link:definition>0000016 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.ovidrx.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>0000017 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COLLABORATIONANDLICENSEAGREEMENTS" roleURI="http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTS">
        <link:definition>0000018 - Disclosure - COLLABORATION AND LICENSE AGREEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONS" roleURI="http://www.ovidrx.com/role/RELATEDPARTYTRANSACTIONS">
        <link:definition>0000019 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHARE" roleURI="http://www.ovidrx.com/role/NETLOSSPERSHARE">
        <link:definition>0000020 - Disclosure - NET LOSS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>9954701 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHCASHEQUIVALENTSANDMARKETABLESECURITIESTables" roleURI="http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESTables">
        <link:definition>9954702 - Disclosure - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSTables" roleURI="http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSTables">
        <link:definition>9954703 - Disclosure - PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESTables" roleURI="http://www.ovidrx.com/role/LEASESTables">
        <link:definition>9954704 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESTables" roleURI="http://www.ovidrx.com/role/ACCRUEDEXPENSESTables">
        <link:definition>9954705 - Disclosure - ACCRUED EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONTables" roleURI="http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONTables">
        <link:definition>9954706 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHARETables" roleURI="http://www.ovidrx.com/role/NETLOSSPERSHARETables">
        <link:definition>9954707 - Disclosure - NET LOSS PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFOPERATIONSAdditionalInformationDetail" roleURI="http://www.ovidrx.com/role/NATUREOFOPERATIONSAdditionalInformationDetail">
        <link:definition>9954708 - Disclosure - NATURE OF OPERATIONS - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail" roleURI="http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail">
        <link:definition>9954709 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail" roleURI="http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail">
        <link:definition>9954710 - Disclosure - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Fair Value of Cash and Cash Equivalents and Gross Unrealized Holding Gains and Losses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail_1" roleURI="http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail_1">
        <link:definition>9954710 - Disclosure - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Fair Value of Cash and Cash Equivalents and Gross Unrealized Holding Gains and Losses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHCASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail" roleURI="http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail">
        <link:definition>9954711 - Disclosure - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSSummaryofPropertyandEquipmentDetail" roleURI="http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSSummaryofPropertyandEquipmentDetail">
        <link:definition>9954712 - Disclosure - PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS - Summary of Property and Equipment (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSAdditionalInformationDetail" roleURI="http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSAdditionalInformationDetail">
        <link:definition>9954713 - Disclosure - PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESAdditionalInformationDetail" roleURI="http://www.ovidrx.com/role/LEASESAdditionalInformationDetail">
        <link:definition>9954714 - Disclosure - LEASES - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESScheduleofROUAssetandLeaseLiabilitiesRelatedtotheCompanyOperatingLeaseDetail" roleURI="http://www.ovidrx.com/role/LEASESScheduleofROUAssetandLeaseLiabilitiesRelatedtotheCompanyOperatingLeaseDetail">
        <link:definition>9954715 - Disclosure - LEASES - Schedule of ROU Asset and Lease Liabilities Related to the Company Operating Lease (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESScheduleofComponentsofOperatingLeaseCostDetail" roleURI="http://www.ovidrx.com/role/LEASESScheduleofComponentsofOperatingLeaseCostDetail">
        <link:definition>9954716 - Disclosure - LEASES - Schedule of Components of Operating Lease Cost (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESScheduleofFutureMinimumCommitmentsUnderUndertheNonCancelableOperatingLeaseDetail" roleURI="http://www.ovidrx.com/role/LEASESScheduleofFutureMinimumCommitmentsUnderUndertheNonCancelableOperatingLeaseDetail">
        <link:definition>9954717 - Disclosure - LEASES - Schedule of Future Minimum Commitments Under Under the Non-Cancelable Operating Lease (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESScheduleofAccruedExpensesDetail" roleURI="http://www.ovidrx.com/role/ACCRUEDEXPENSESScheduleofAccruedExpensesDetail">
        <link:definition>9954718 - Disclosure - ACCRUED EXPENSES - Schedule of Accrued Expenses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYAdditionalInformationDetail" roleURI="http://www.ovidrx.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetail">
        <link:definition>9954719 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONAdditionalInformationDetail" roleURI="http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail">
        <link:definition>9954720 - Disclosure - STOCK-BASED COMPENSATION - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONScheduleofRecognizedStockBasedCompensationExpenseDetail" roleURI="http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONScheduleofRecognizedStockBasedCompensationExpenseDetail">
        <link:definition>9954721 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Recognized Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONScheduleofAllocationofStockBasedCompensationExpensebyPlanDetail" roleURI="http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONScheduleofAllocationofStockBasedCompensationExpensebyPlanDetail">
        <link:definition>9954722 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Allocation of Stock-Based Compensation Expense by Plan (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail" roleURI="http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail">
        <link:definition>9954723 - Disclosure - STOCK-BASED COMPENSATION - Summary of Assumptions Used to Compute Fair Value of Options Granted (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail" roleURI="http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail">
        <link:definition>9954724 - Disclosure - STOCK-BASED COMPENSATION - Summary of Options Outstanding and Weighted Average Exercise Price (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESAdditionalInformationDetail" roleURI="http://www.ovidrx.com/role/INCOMETAXESAdditionalInformationDetail">
        <link:definition>9954725 - Disclosure - INCOME TAXES - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail" roleURI="http://www.ovidrx.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail">
        <link:definition>9954726 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail" roleURI="http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail">
        <link:definition>9954727 - Disclosure - COLLABORATION AND LICENSE AGREEMENTS - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHARESummaryofCalculationofBasicandDilutedEarningsLossperShareDetails" roleURI="http://www.ovidrx.com/role/NETLOSSPERSHARESummaryofCalculationofBasicandDilutedEarningsLossperShareDetails">
        <link:definition>9954728 - Disclosure - NET LOSS PER SHARE - Summary of Calculation of Basic and Diluted Earnings (Loss) per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHAREScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageSharesOutstandingDetail" roleURI="http://www.ovidrx.com/role/NETLOSSPERSHAREScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageSharesOutstandingDetail">
        <link:definition>9954729 - Disclosure - NET LOSS PER SHARE - Schedule of Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Shares Outstanding (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ovid_AccretionOfLeaseLiability" abstract="false" name="AccretionOfLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_CowenAndCompanyLLCMember" abstract="true" name="CowenAndCompanyLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ovid_AstrazenecaMember" abstract="true" name="AstrazenecaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ovid_AnnualLicenseMaintenanceFeePayable" abstract="false" name="AnnualLicenseMaintenanceFeePayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod" abstract="false" name="AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ovid_NorthwesternUniversityMember" abstract="true" name="NorthwesternUniversityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ovid_PatentLicenseAgreementMember" abstract="true" name="PatentLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ovid_AdditionalPaymentReceivableOnSalesPercentage" abstract="false" name="AdditionalPaymentReceivableOnSalesPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock" abstract="false" name="BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders" abstract="false" name="MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ovid_LeaseIncrementalBorrowingRate" abstract="false" name="LeaseIncrementalBorrowingRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ovid_ConsiderationPayableForRightsGrant" abstract="false" name="ConsiderationPayableForRightsGrant" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_AggregateOfferingPriceOfCommonStock" abstract="false" name="AggregateOfferingPriceOfCommonStock" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_SummaryOfSignificantAccountingPolicyTable" abstract="true" name="SummaryOfSignificantAccountingPolicyTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ovid_PaymentsForProceedsFromIssuanceOfShortTermNoteReceivable" abstract="false" name="PaymentsForProceedsFromIssuanceOfShortTermNoteReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_GravitonBioscienceCorporationMember" abstract="true" name="GravitonBioscienceCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ovid_UpFrontPayment" abstract="false" name="UpFrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_LicenseAgreementMember" abstract="true" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ovid_UpfrontPaymentReceivable" abstract="false" name="UpfrontPaymentReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_GensaicIncMember" abstract="true" name="GensaicIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ovid_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_CollaborationAndOptionAgreementResearchPlanAndBudgetExpectedCosts" abstract="false" name="CollaborationAndOptionAgreementResearchPlanAndBudgetExpectedCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ovid_SummaryOfSignificantAccountingPolicyLineItems" abstract="true" name="SummaryOfSignificantAccountingPolicyLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ovid_MarinusLicenseAgreementMember" abstract="true" name="MarinusLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ovid_UnauditedInterimFinancialStatementsPolicyPolicyTextBlock" abstract="false" name="UnauditedInterimFinancialStatementsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ovid_LesseeOperatingLeaseBaseRent" abstract="false" name="LesseeOperatingLeaseBaseRent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost" abstract="false" name="CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandSeventeenEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife" abstract="false" name="ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ovid_LicenseAgreementDevelopmentMilestoneApprovalsProductThreshold" abstract="false" name="LicenseAgreementDevelopmentMilestoneApprovalsProductThreshold" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ovid_PreferredStockShareDesignated" abstract="false" name="PreferredStockShareDesignated" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ovid_TakedaPharmaceuticalCompanyLimitedMember" abstract="true" name="TakedaPharmaceuticalCompanyLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ovid_CashEquivalentsUnrealizedHoldingLosses" abstract="false" name="CashEquivalentsUnrealizedHoldingLosses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_ChangeInAccruedInterestAndAccretionOfDiscountsShortTermInvestments" abstract="false" name="ChangeInAccruedInterestAndAccretionOfDiscountsShortTermInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_HealxLicenseAndOptionAgreementMember" abstract="true" name="HealxLicenseAndOptionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ovid_MarinusPharmaceuticalsIncMember" abstract="true" name="MarinusPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ovid_HLundbeckASMember" abstract="true" name="HLundbeckASMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ovid_LicenseOptionAgreementExtensionPeriod" abstract="false" name="LicenseOptionAgreementExtensionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" abstract="false" name="AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ovid_LicenseAgreementMilestonePayments" abstract="false" name="LicenseAgreementMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction" abstract="false" name="NoncashConsiderationReceivedInLicensingAgreementTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_FirstPaymentDueUponCompletionOfFirstPhase" abstract="false" name="FirstPaymentDueUponCompletionOfFirstPhase" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_NonemployeePerformanceBasedOptionAwardsMember" abstract="true" name="NonemployeePerformanceBasedOptionAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ovid_EmployeePerformanceBasedOptionAwardsMember" abstract="true" name="EmployeePerformanceBasedOptionAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ovid_UpfrontCashPayment" abstract="false" name="UpfrontCashPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement" abstract="false" name="MinimumNumberOfProductCoveredUnderLicenseAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ovid_SeriesAConvertiblePreferredStockMember" abstract="true" name="SeriesAConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ovid_A2014EmployeeStockPurchasePlanMember" abstract="true" name="A2014EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ovid_CashEquivalentsUnrealizedHoldingGains" abstract="false" name="CashEquivalentsUnrealizedHoldingGains" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_LicenseAndCollaborationAgreementExpense" abstract="false" name="LicenseAndCollaborationAgreementExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_MarinusTherapeuticsIncMember" abstract="true" name="MarinusTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ovid_RoyaltyObligationTerm" abstract="false" name="RoyaltyObligationTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" abstract="false" name="MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment" abstract="false" name="UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock" abstract="false" name="RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ovid_PercentageOfDevelopmentCosts" abstract="false" name="PercentageOfDevelopmentCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ovid_CashEquivalentsAmortizedCost" abstract="false" name="CashEquivalentsAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_AccruedResearchAndDevelopment" abstract="false" name="AccruedResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_LicenseAgreementConsiderationSharesIssued" abstract="false" name="LicenseAgreementConsiderationSharesIssued" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ovid_UpFrontFeeAmount" abstract="false" name="UpFrontFeeAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod" abstract="false" name="LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ovid_WorkingCapital" abstract="false" name="WorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_CommonStockNumberOfVotesForEachShare" abstract="false" name="CommonStockNumberOfVotesForEachShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ovid_LicenseOptionAgreementDevelopmentAndCommercialMilestonePayments" abstract="false" name="LicenseOptionAgreementDevelopmentAndCommercialMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_TwoThousandSeventeenEquityIncentivePlanMember" abstract="true" name="TwoThousandSeventeenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingLoss" abstract="false" name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_MoneyMarketFundsAndShortTermInvestmentsMember" abstract="true" name="MoneyMarketFundsAndShortTermInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ovid_LicenseAgreementTerminationAdvanceNoticePeriod" abstract="false" name="LicenseAgreementTerminationAdvanceNoticePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ovid_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ovid_AgreementMilestonePayments" abstract="false" name="AgreementMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingGain" abstract="false" name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingGain" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate" abstract="false" name="CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ovid_ATMAgreementMember" abstract="true" name="ATMAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>ovid-20230630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:bac70ec3-5ee7-4b97-a85c-498b4f8489b1,g:499e488f-fe63-4d10-9e0b-b93d763975f8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ovid-20230630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_30e6c837-5f8d-4f9b-b0d1-bf4a4ebc4181" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_99c7c06b-1ed0-4d21-93f8-4d02d73d62c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_30e6c837-5f8d-4f9b-b0d1-bf4a4ebc4181" xlink:to="loc_us-gaap_AssetsCurrent_99c7c06b-1ed0-4d21-93f8-4d02d73d62c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_ac61e734-e0a7-484c-907d-de4d0d23e93d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_30e6c837-5f8d-4f9b-b0d1-bf4a4ebc4181" xlink:to="loc_us-gaap_LongTermInvestments_ac61e734-e0a7-484c-907d-de4d0d23e93d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_14a9a1c8-a100-4ad9-a243-2ea914e6fe3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_30e6c837-5f8d-4f9b-b0d1-bf4a4ebc4181" xlink:to="loc_us-gaap_RestrictedCash_14a9a1c8-a100-4ad9-a243-2ea914e6fe3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b5f8448f-6bd0-480c-80b1-2722bb18c2b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_30e6c837-5f8d-4f9b-b0d1-bf4a4ebc4181" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b5f8448f-6bd0-480c-80b1-2722bb18c2b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1f90f363-5976-4662-8e38-408471c44c29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_30e6c837-5f8d-4f9b-b0d1-bf4a4ebc4181" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1f90f363-5976-4662-8e38-408471c44c29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_d60bd632-9a7e-4219-9ac9-3d714da77891" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_30e6c837-5f8d-4f9b-b0d1-bf4a4ebc4181" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_d60bd632-9a7e-4219-9ac9-3d714da77891" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c12a6326-e264-4aed-af0a-e7e3b392e420" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4576085e-e372-4d83-ac51-6a687f1c953f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c12a6326-e264-4aed-af0a-e7e3b392e420" xlink:to="loc_us-gaap_LiabilitiesCurrent_4576085e-e372-4d83-ac51-6a687f1c953f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d6f9ad2d-f28e-4096-b8d3-c091f234adc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c12a6326-e264-4aed-af0a-e7e3b392e420" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d6f9ad2d-f28e-4096-b8d3-c091f234adc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_49fc4857-0ca8-4cb1-88e1-d535452f5fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_554f111e-b220-4662-83e4-e96eaa8ef327" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_49fc4857-0ca8-4cb1-88e1-d535452f5fcf" xlink:to="loc_us-gaap_PreferredStockValue_554f111e-b220-4662-83e4-e96eaa8ef327" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_572b0828-a3bd-4a9d-98c1-e3ea865fbbb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_49fc4857-0ca8-4cb1-88e1-d535452f5fcf" xlink:to="loc_us-gaap_CommonStockValue_572b0828-a3bd-4a9d-98c1-e3ea865fbbb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_6f9c18a1-e786-47d4-a4e9-b8dbe6d36184" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_49fc4857-0ca8-4cb1-88e1-d535452f5fcf" xlink:to="loc_us-gaap_AdditionalPaidInCapital_6f9c18a1-e786-47d4-a4e9-b8dbe6d36184" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4a4b6123-a4ce-401b-b327-ad0fd91f1b82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_49fc4857-0ca8-4cb1-88e1-d535452f5fcf" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4a4b6123-a4ce-401b-b327-ad0fd91f1b82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b0f3fa9f-fe90-4ccc-9443-d603b875cf32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_49fc4857-0ca8-4cb1-88e1-d535452f5fcf" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b0f3fa9f-fe90-4ccc-9443-d603b875cf32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_8560e178-bdfd-45d9-ac19-55db32c22ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5d5ad02a-46c4-465d-82f0-ff968215347d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8560e178-bdfd-45d9-ac19-55db32c22ee1" xlink:to="loc_us-gaap_Liabilities_5d5ad02a-46c4-465d-82f0-ff968215347d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e176ee60-f1f6-42a2-91e6-313768db3c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8560e178-bdfd-45d9-ac19-55db32c22ee1" xlink:to="loc_us-gaap_StockholdersEquity_e176ee60-f1f6-42a2-91e6-313768db3c7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2a266188-1f34-4b77-8c37-a4750a1cd4b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_44791196-6d50-47c4-a696-d032dca6a5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2a266188-1f34-4b77-8c37-a4750a1cd4b9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_44791196-6d50-47c4-a696-d032dca6a5a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b48939fb-2869-40c2-9a05-0f636ec6dbaa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2a266188-1f34-4b77-8c37-a4750a1cd4b9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b48939fb-2869-40c2-9a05-0f636ec6dbaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bcdcf4f6-7afe-4b16-9ef6-770af95ed2a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2a266188-1f34-4b77-8c37-a4750a1cd4b9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bcdcf4f6-7afe-4b16-9ef6-770af95ed2a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_dfaea97e-ceb2-4da5-8913-9b39d0313b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_35526709-3c9f-45a6-bdb0-fdbe35af40ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_dfaea97e-ceb2-4da5-8913-9b39d0313b1d" xlink:to="loc_us-gaap_AccountsPayableCurrent_35526709-3c9f-45a6-bdb0-fdbe35af40ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_115cf5d1-02e2-4dc1-83fc-c4b926fcf47c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_dfaea97e-ceb2-4da5-8913-9b39d0313b1d" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_115cf5d1-02e2-4dc1-83fc-c4b926fcf47c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_06f6359a-a490-4ff7-b905-1f106566a0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_dfaea97e-ceb2-4da5-8913-9b39d0313b1d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_06f6359a-a490-4ff7-b905-1f106566a0f5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ovid-20230630.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_e74f441c-6499-4297-a957-9137a4ab0d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d18bb8d8-114c-432f-a8fa-f7149c4e6d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_e74f441c-6499-4297-a957-9137a4ab0d7b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d18bb8d8-114c-432f-a8fa-f7149c4e6d7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_afbf885f-b441-4090-846b-fa18e1b6876c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_e74f441c-6499-4297-a957-9137a4ab0d7b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_afbf885f-b441-4090-846b-fa18e1b6876c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a2dd4b94-b017-4ac4-b906-5f55a7d03b38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d5d623fe-f158-4cfd-aada-72bd481c997a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a2dd4b94-b017-4ac4-b906-5f55a7d03b38" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d5d623fe-f158-4cfd-aada-72bd481c997a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_cca9029c-5350-43cb-968a-e436402e6ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a2dd4b94-b017-4ac4-b906-5f55a7d03b38" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_cca9029c-5350-43cb-968a-e436402e6ed8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3aa6aae9-4bd9-400f-8040-5610b710d31d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2dcbd72e-973d-4e35-bd20-04b08a3797a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3aa6aae9-4bd9-400f-8040-5610b710d31d" xlink:to="loc_us-gaap_OperatingIncomeLoss_2dcbd72e-973d-4e35-bd20-04b08a3797a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_75fdde5a-d188-4cd6-b2d4-f757ded42f93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3aa6aae9-4bd9-400f-8040-5610b710d31d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_75fdde5a-d188-4cd6-b2d4-f757ded42f93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_da93cafd-a72a-4e26-b3ad-e8e6a9b7e78f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_788170fd-d74e-490d-b3d8-3dbd4c2ce756" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_da93cafd-a72a-4e26-b3ad-e8e6a9b7e78f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_788170fd-d74e-490d-b3d8-3dbd4c2ce756" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_cb28985b-6502-460b-b370-092d3a0aca28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_da93cafd-a72a-4e26-b3ad-e8e6a9b7e78f" xlink:to="loc_us-gaap_OperatingExpenses_cb28985b-6502-460b-b370-092d3a0aca28" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="ovid-20230630.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0dc723d8-0112-4838-aede-3cf11565b226" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8f160832-93e4-41fb-802f-96af51f46fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_0dc723d8-0112-4838-aede-3cf11565b226" xlink:to="loc_us-gaap_NetIncomeLoss_8f160832-93e4-41fb-802f-96af51f46fb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8e38914e-e17b-4e2c-821e-c0c365bf4558" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_0dc723d8-0112-4838-aede-3cf11565b226" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8e38914e-e17b-4e2c-821e-c0c365bf4558" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ovid-20230630.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a04fe713-1c42-4553-a4b9-4446ae682fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3380a957-1cc6-4661-bd85-ac02a5575d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a04fe713-1c42-4553-a4b9-4446ae682fd3" xlink:to="loc_us-gaap_NetIncomeLoss_3380a957-1cc6-4661-bd85-ac02a5575d7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction_2fb48933-0725-41c3-a876-16ce195f5a2a" xlink:href="ovid-20230630.xsd#ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a04fe713-1c42-4553-a4b9-4446ae682fd3" xlink:to="loc_ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction_2fb48933-0725-41c3-a876-16ce195f5a2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_a33ade32-1976-430a-983c-3838ed450442" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a04fe713-1c42-4553-a4b9-4446ae682fd3" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_a33ade32-1976-430a-983c-3838ed450442" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_ChangeInAccruedInterestAndAccretionOfDiscountsShortTermInvestments_ae266a73-2c0a-46ca-8ffe-33af3d9e9371" xlink:href="ovid-20230630.xsd#ovid_ChangeInAccruedInterestAndAccretionOfDiscountsShortTermInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a04fe713-1c42-4553-a4b9-4446ae682fd3" xlink:to="loc_ovid_ChangeInAccruedInterestAndAccretionOfDiscountsShortTermInvestments_ae266a73-2c0a-46ca-8ffe-33af3d9e9371" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_15dc74b5-e441-4e5b-b56c-7c91b8eb2a74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a04fe713-1c42-4553-a4b9-4446ae682fd3" xlink:to="loc_us-gaap_ShareBasedCompensation_15dc74b5-e441-4e5b-b56c-7c91b8eb2a74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_195c53b2-d7c7-4cda-b99b-7127e8fe0b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a04fe713-1c42-4553-a4b9-4446ae682fd3" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_195c53b2-d7c7-4cda-b99b-7127e8fe0b8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_b84751bd-0fa0-482c-a57f-2c72f23f1bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a04fe713-1c42-4553-a4b9-4446ae682fd3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_b84751bd-0fa0-482c-a57f-2c72f23f1bf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AccretionOfLeaseLiability_552c340d-3d36-491b-8e8b-4b356b4852e7" xlink:href="ovid-20230630.xsd#ovid_AccretionOfLeaseLiability"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a04fe713-1c42-4553-a4b9-4446ae682fd3" xlink:to="loc_ovid_AccretionOfLeaseLiability_552c340d-3d36-491b-8e8b-4b356b4852e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_bf234682-d379-4040-8d51-b5082ab5d9c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a04fe713-1c42-4553-a4b9-4446ae682fd3" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_bf234682-d379-4040-8d51-b5082ab5d9c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_62d0bacc-a762-4a2c-91de-af73fc611ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a04fe713-1c42-4553-a4b9-4446ae682fd3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_62d0bacc-a762-4a2c-91de-af73fc611ce5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_87dcb1b8-0480-4b11-bf6b-d353071a47c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a04fe713-1c42-4553-a4b9-4446ae682fd3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_87dcb1b8-0480-4b11-bf6b-d353071a47c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_f8781cab-1863-4b6f-a890-197682781513" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a04fe713-1c42-4553-a4b9-4446ae682fd3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_f8781cab-1863-4b6f-a890-197682781513" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ad99689d-c50e-4d3a-9744-4eae8bcf4d34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_6e9d0910-520c-4150-aa3a-8289c9197ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ad99689d-c50e-4d3a-9744-4eae8bcf4d34" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_6e9d0910-520c-4150-aa3a-8289c9197ec8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5b0f9b17-9f63-4353-8694-d0e4056ee414" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f1e49932-3f14-4de1-8df6-e489cc3e45c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5b0f9b17-9f63-4353-8694-d0e4056ee414" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f1e49932-3f14-4de1-8df6-e489cc3e45c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_7ceba3d0-205a-4bb1-bb21-4c182b41bb6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5b0f9b17-9f63-4353-8694-d0e4056ee414" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_7ceba3d0-205a-4bb1-bb21-4c182b41bb6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_PaymentsForProceedsFromIssuanceOfShortTermNoteReceivable_b03b080f-2c90-4db0-b5c5-4513ead87b81" xlink:href="ovid-20230630.xsd#ovid_PaymentsForProceedsFromIssuanceOfShortTermNoteReceivable"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5b0f9b17-9f63-4353-8694-d0e4056ee414" xlink:to="loc_ovid_PaymentsForProceedsFromIssuanceOfShortTermNoteReceivable_b03b080f-2c90-4db0-b5c5-4513ead87b81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_64b09cc0-94c2-4950-83fa-4f508ddeb976" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5b0f9b17-9f63-4353-8694-d0e4056ee414" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_64b09cc0-94c2-4950-83fa-4f508ddeb976" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToDevelopSoftware_45929e05-e9e4-4bdc-92a7-cd7cc7283f04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToDevelopSoftware"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5b0f9b17-9f63-4353-8694-d0e4056ee414" xlink:to="loc_us-gaap_PaymentsToDevelopSoftware_45929e05-e9e4-4bdc-92a7-cd7cc7283f04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments_714a97e5-a347-47c4-82da-1daaf78e268b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5b0f9b17-9f63-4353-8694-d0e4056ee414" xlink:to="loc_us-gaap_PaymentsToAcquireLongtermInvestments_714a97e5-a347-47c4-82da-1daaf78e268b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_73f917aa-0b4e-4a98-8ebf-1a3d2c8403ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c7806f40-c0b9-4b0f-90e5-58e51dc9f6b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_73f917aa-0b4e-4a98-8ebf-1a3d2c8403ff" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c7806f40-c0b9-4b0f-90e5-58e51dc9f6b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ea492637-0574-42a1-93a5-f2255ea1d03a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_73f917aa-0b4e-4a98-8ebf-1a3d2c8403ff" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ea492637-0574-42a1-93a5-f2255ea1d03a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_12784867-0e57-4e68-b9d2-383792ae769d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_73f917aa-0b4e-4a98-8ebf-1a3d2c8403ff" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_12784867-0e57-4e68-b9d2-383792ae769d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail" xlink:type="simple" xlink:href="ovid-20230630.xsd#CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail"/>
  <link:calculationLink xlink:role="http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost_a30eb0a4-02b7-4f49-9f30-de6e40d8ccef" xlink:href="ovid-20230630.xsd#ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingLoss_44f7a0b7-d156-422d-b818-a9d3d5a8726a" xlink:href="ovid-20230630.xsd#ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost_a30eb0a4-02b7-4f49-9f30-de6e40d8ccef" xlink:to="loc_ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingLoss_44f7a0b7-d156-422d-b818-a9d3d5a8726a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingGain_69a050de-0e86-4641-8c23-8e0f74e209b0" xlink:href="ovid-20230630.xsd#ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingGain"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost_a30eb0a4-02b7-4f49-9f30-de6e40d8ccef" xlink:to="loc_ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingGain_69a050de-0e86-4641-8c23-8e0f74e209b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_ab4ced67-6737-4777-9186-d2f1a68fd987" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost_a30eb0a4-02b7-4f49-9f30-de6e40d8ccef" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_ab4ced67-6737-4777-9186-d2f1a68fd987" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_40beeded-df22-4fe3-9861-600fb93d9863" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ff5c0495-e344-4dae-8e68-d4642fe974a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_40beeded-df22-4fe3-9861-600fb93d9863" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ff5c0495-e344-4dae-8e68-d4642fe974a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_96515305-68c4-4d70-8f8f-880d42d655e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_40beeded-df22-4fe3-9861-600fb93d9863" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_96515305-68c4-4d70-8f8f-880d42d655e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_43c85fa3-b37a-4973-aef6-c0b88a0042d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_40beeded-df22-4fe3-9861-600fb93d9863" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_43c85fa3-b37a-4973-aef6-c0b88a0042d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CashEquivalentsAmortizedCost_063c7a2f-055b-467d-beb3-e655619790cc" xlink:href="ovid-20230630.xsd#ovid_CashEquivalentsAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CashEquivalentsUnrealizedHoldingGains_04f72600-f459-4e6a-b524-71b957a97f3e" xlink:href="ovid-20230630.xsd#ovid_CashEquivalentsUnrealizedHoldingGains"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ovid_CashEquivalentsAmortizedCost_063c7a2f-055b-467d-beb3-e655619790cc" xlink:to="loc_ovid_CashEquivalentsUnrealizedHoldingGains_04f72600-f459-4e6a-b524-71b957a97f3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CashEquivalentsUnrealizedHoldingLosses_a9f5307a-3a0b-4982-8e91-9cc7b13e9fb3" xlink:href="ovid-20230630.xsd#ovid_CashEquivalentsUnrealizedHoldingLosses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ovid_CashEquivalentsAmortizedCost_063c7a2f-055b-467d-beb3-e655619790cc" xlink:to="loc_ovid_CashEquivalentsUnrealizedHoldingLosses_a9f5307a-3a0b-4982-8e91-9cc7b13e9fb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_8bcd8e83-6b11-45b7-a78c-583fbcdd3f13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ovid_CashEquivalentsAmortizedCost_063c7a2f-055b-467d-beb3-e655619790cc" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_8bcd8e83-6b11-45b7-a78c-583fbcdd3f13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingGain_90756fe5-f911-4e3a-8852-e3776b9521e5" xlink:href="ovid-20230630.xsd#ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingGain"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CashEquivalentsUnrealizedHoldingGains_fe6d1e6d-4034-4e91-9d5f-4da5644df570" xlink:href="ovid-20230630.xsd#ovid_CashEquivalentsUnrealizedHoldingGains"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingGain_90756fe5-f911-4e3a-8852-e3776b9521e5" xlink:to="loc_ovid_CashEquivalentsUnrealizedHoldingGains_fe6d1e6d-4034-4e91-9d5f-4da5644df570" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f09c4991-c7d5-4e71-9a81-0168ca752228" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingGain_90756fe5-f911-4e3a-8852-e3776b9521e5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f09c4991-c7d5-4e71-9a81-0168ca752228" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingLoss_71528d79-ecd6-4c72-8c7e-1b0fa8456739" xlink:href="ovid-20230630.xsd#ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CashEquivalentsUnrealizedHoldingLosses_0d05d0d7-582e-4a53-89ea-ee36dc80e896" xlink:href="ovid-20230630.xsd#ovid_CashEquivalentsUnrealizedHoldingLosses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingLoss_71528d79-ecd6-4c72-8c7e-1b0fa8456739" xlink:to="loc_ovid_CashEquivalentsUnrealizedHoldingLosses_0d05d0d7-582e-4a53-89ea-ee36dc80e896" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d2f9690d-a116-4e98-9c92-15293d46814e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingLoss_71528d79-ecd6-4c72-8c7e-1b0fa8456739" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d2f9690d-a116-4e98-9c92-15293d46814e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_75493089-3f9a-4474-8a11-f78085f5ea6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_09eb96fe-18bd-45cc-9f19-384e14d0129c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_75493089-3f9a-4474-8a11-f78085f5ea6d" xlink:to="loc_us-gaap_Cash_09eb96fe-18bd-45cc-9f19-384e14d0129c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_b8149258-c1d3-43d2-9e75-169f0a33b8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_75493089-3f9a-4474-8a11-f78085f5ea6d" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_b8149258-c1d3-43d2-9e75-169f0a33b8ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_54d047c4-3e24-46fe-b419-b1552d86c899" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_75493089-3f9a-4474-8a11-f78085f5ea6d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_54d047c4-3e24-46fe-b419-b1552d86c899" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail_1" xlink:type="simple" xlink:href="ovid-20230630.xsd#CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail_1"/>
  <link:calculationLink xlink:role="http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost_f88567eb-dbad-4c39-825e-de92350cda8a" xlink:href="ovid-20230630.xsd#ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CashEquivalentsAmortizedCost_6b65dffb-a88d-418e-aa0c-4e961d5f8532" xlink:href="ovid-20230630.xsd#ovid_CashEquivalentsAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost_f88567eb-dbad-4c39-825e-de92350cda8a" xlink:to="loc_ovid_CashEquivalentsAmortizedCost_6b65dffb-a88d-418e-aa0c-4e961d5f8532" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ebfe6415-c74e-4a0d-a76e-a4b807b55df7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost_f88567eb-dbad-4c39-825e-de92350cda8a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ebfe6415-c74e-4a0d-a76e-a4b807b55df7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_b6822d91-7621-4211-908d-c5b92e53c509" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost_f88567eb-dbad-4c39-825e-de92350cda8a" xlink:to="loc_us-gaap_Cash_b6822d91-7621-4211-908d-c5b92e53c509" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSSummaryofPropertyandEquipmentDetail" xlink:type="simple" xlink:href="ovid-20230630.xsd#PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSSummaryofPropertyandEquipmentDetail"/>
  <link:calculationLink xlink:role="http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSSummaryofPropertyandEquipmentDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e56a8560-f298-48bf-86d5-8535bffc2a71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_b0b0877a-13d8-4c48-bdbb-4dc97847272a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_e56a8560-f298-48bf-86d5-8535bffc2a71" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_b0b0877a-13d8-4c48-bdbb-4dc97847272a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_498da813-fe43-4897-9c9e-4b4ea2705d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_e56a8560-f298-48bf-86d5-8535bffc2a71" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_498da813-fe43-4897-9c9e-4b4ea2705d4c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/LEASESScheduleofFutureMinimumCommitmentsUnderUndertheNonCancelableOperatingLeaseDetail" xlink:type="simple" xlink:href="ovid-20230630.xsd#LEASESScheduleofFutureMinimumCommitmentsUnderUndertheNonCancelableOperatingLeaseDetail"/>
  <link:calculationLink xlink:role="http://www.ovidrx.com/role/LEASESScheduleofFutureMinimumCommitmentsUnderUndertheNonCancelableOperatingLeaseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1ba25736-3e1e-459b-9b18-80282568c679" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c82a9809-fc16-4c9c-b169-13fda9f403c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1ba25736-3e1e-459b-9b18-80282568c679" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c82a9809-fc16-4c9c-b169-13fda9f403c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d0a0c342-dfc3-4ab1-b5a6-804ab82083ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1ba25736-3e1e-459b-9b18-80282568c679" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d0a0c342-dfc3-4ab1-b5a6-804ab82083ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_63994ff6-57d2-47a9-8ed1-e8f15731cd8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1ba25736-3e1e-459b-9b18-80282568c679" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_63994ff6-57d2-47a9-8ed1-e8f15731cd8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7ea77a67-eba4-475b-bcb9-1c409d33887e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1ba25736-3e1e-459b-9b18-80282568c679" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7ea77a67-eba4-475b-bcb9-1c409d33887e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5392a974-4180-4079-81de-da217d28efa1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1ba25736-3e1e-459b-9b18-80282568c679" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5392a974-4180-4079-81de-da217d28efa1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_9b88ba83-8646-458f-b275-9a0905982e5e" xlink:href="ovid-20230630.xsd#ovid_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1ba25736-3e1e-459b-9b18-80282568c679" xlink:to="loc_ovid_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_9b88ba83-8646-458f-b275-9a0905982e5e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/ACCRUEDEXPENSESScheduleofAccruedExpensesDetail" xlink:type="simple" xlink:href="ovid-20230630.xsd#ACCRUEDEXPENSESScheduleofAccruedExpensesDetail"/>
  <link:calculationLink xlink:role="http://www.ovidrx.com/role/ACCRUEDEXPENSESScheduleofAccruedExpensesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3c091717-12f1-491d-87f5-9fab0699d1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b0ced057-34f8-4f82-993b-86c0673f58d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3c091717-12f1-491d-87f5-9fab0699d1e7" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b0ced057-34f8-4f82-993b-86c0673f58d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AccruedResearchAndDevelopment_72d364c2-8317-4470-8fe8-e8b11bca96a2" xlink:href="ovid-20230630.xsd#ovid_AccruedResearchAndDevelopment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3c091717-12f1-491d-87f5-9fab0699d1e7" xlink:to="loc_ovid_AccruedResearchAndDevelopment_72d364c2-8317-4470-8fe8-e8b11bca96a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_608319c1-19f1-4995-9ef1-7656d644637e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3c091717-12f1-491d-87f5-9fab0699d1e7" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_608319c1-19f1-4995-9ef1-7656d644637e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a333e451-ec65-4f96-ad6c-96cf3bd18e71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3c091717-12f1-491d-87f5-9fab0699d1e7" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a333e451-ec65-4f96-ad6c-96cf3bd18e71" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/NETLOSSPERSHARESummaryofCalculationofBasicandDilutedEarningsLossperShareDetails" xlink:type="simple" xlink:href="ovid-20230630.xsd#NETLOSSPERSHARESummaryofCalculationofBasicandDilutedEarningsLossperShareDetails"/>
  <link:calculationLink xlink:role="http://www.ovidrx.com/role/NETLOSSPERSHARESummaryofCalculationofBasicandDilutedEarningsLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_36b63217-b23e-47e5-8b60-7b12ec220b89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a99224ff-5156-49bc-bced-46bc0bc035f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_36b63217-b23e-47e5-8b60-7b12ec220b89" xlink:to="loc_us-gaap_NetIncomeLoss_a99224ff-5156-49bc-bced-46bc0bc035f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_6000836c-a571-446f-a0a7-386834cc3239" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_36b63217-b23e-47e5-8b60-7b12ec220b89" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_6000836c-a571-446f-a0a7-386834cc3239" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>ovid-20230630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:bac70ec3-5ee7-4b97-a85c-498b4f8489b1,g:499e488f-fe63-4d10-9e0b-b93d763975f8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="ovid-20230630.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i866468d88bff467b88a4eef0742fca12_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9bd619a0-85b6-4eb3-bae3-d39f93e3fc82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61c1ff40-20c4-45fc-a1fd-2e3c168212a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9bd619a0-85b6-4eb3-bae3-d39f93e3fc82" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61c1ff40-20c4-45fc-a1fd-2e3c168212a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_9de9dc49-6db3-441d-99d2-fb78302bfce7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61c1ff40-20c4-45fc-a1fd-2e3c168212a5" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_9de9dc49-6db3-441d-99d2-fb78302bfce7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_aab25577-bf41-4add-ba71-0cc307ea1b95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61c1ff40-20c4-45fc-a1fd-2e3c168212a5" xlink:to="loc_us-gaap_StockholdersEquity_aab25577-bf41-4add-ba71-0cc307ea1b95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3d864a21-35b2-422e-b0b4-eba9ca7d4c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61c1ff40-20c4-45fc-a1fd-2e3c168212a5" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3d864a21-35b2-422e-b0b4-eba9ca7d4c7c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7923c50f-57d2-426c-bda2-8c54eab20e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61c1ff40-20c4-45fc-a1fd-2e3c168212a5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7923c50f-57d2-426c-bda2-8c54eab20e2c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3ccc3ef3-9acf-410d-a211-5687d7f979f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61c1ff40-20c4-45fc-a1fd-2e3c168212a5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3ccc3ef3-9acf-410d-a211-5687d7f979f7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1292bec0-ce62-4e08-8ac2-5828de1a90e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61c1ff40-20c4-45fc-a1fd-2e3c168212a5" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1292bec0-ce62-4e08-8ac2-5828de1a90e9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_728297ee-4a8e-4c11-bd39-7bd38747489b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61c1ff40-20c4-45fc-a1fd-2e3c168212a5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_728297ee-4a8e-4c11-bd39-7bd38747489b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_05ecef5b-ee00-4f5a-9c79-90476489179a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61c1ff40-20c4-45fc-a1fd-2e3c168212a5" xlink:to="loc_us-gaap_NetIncomeLoss_05ecef5b-ee00-4f5a-9c79-90476489179a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4944e06a-3996-48f6-bba9-6c7bdfba3741" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_279bed59-2ae6-435f-b6b0-ce705c1bf9f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9e430411-5677-4b0c-a265-b708787f2713" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_32cee9e7-0e4d-45b7-b75c-1128b969dfcb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_9bd619a0-85b6-4eb3-bae3-d39f93e3fc82" xlink:to="loc_us-gaap_StatementTable_32cee9e7-0e4d-45b7-b75c-1128b969dfcb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d416ffa9-1a04-4576-b333-b8cf89a5de00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_32cee9e7-0e4d-45b7-b75c-1128b969dfcb" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d416ffa9-1a04-4576-b333-b8cf89a5de00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d416ffa9-1a04-4576-b333-b8cf89a5de00_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d416ffa9-1a04-4576-b333-b8cf89a5de00" xlink:to="loc_us-gaap_EquityComponentDomain_d416ffa9-1a04-4576-b333-b8cf89a5de00_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0d4c7275-3dec-4627-91e2-9bd82c20a456" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d416ffa9-1a04-4576-b333-b8cf89a5de00" xlink:to="loc_us-gaap_EquityComponentDomain_0d4c7275-3dec-4627-91e2-9bd82c20a456" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_73d1394d-d74b-4145-a325-4fce1b731770" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0d4c7275-3dec-4627-91e2-9bd82c20a456" xlink:to="loc_us-gaap_PreferredStockMember_73d1394d-d74b-4145-a325-4fce1b731770" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9078672d-ff58-4498-8c4c-84f33157d799" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0d4c7275-3dec-4627-91e2-9bd82c20a456" xlink:to="loc_us-gaap_CommonStockMember_9078672d-ff58-4498-8c4c-84f33157d799" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_13c825ee-1448-40c4-a67b-3f66c0452584" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0d4c7275-3dec-4627-91e2-9bd82c20a456" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_13c825ee-1448-40c4-a67b-3f66c0452584" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e3d676ff-5446-417f-a5e5-98d26226b7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0d4c7275-3dec-4627-91e2-9bd82c20a456" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e3d676ff-5446-417f-a5e5-98d26226b7c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_0db63f06-0d30-44e0-8f7a-6e98c38e0bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0d4c7275-3dec-4627-91e2-9bd82c20a456" xlink:to="loc_us-gaap_RetainedEarningsMember_0db63f06-0d30-44e0-8f7a-6e98c38e0bf3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a560871e-e428-4ebe-a248-4b669b2bd494" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_32cee9e7-0e4d-45b7-b75c-1128b969dfcb" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a560871e-e428-4ebe-a248-4b669b2bd494" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a560871e-e428-4ebe-a248-4b669b2bd494_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a560871e-e428-4ebe-a248-4b669b2bd494" xlink:to="loc_us-gaap_ClassOfStockDomain_a560871e-e428-4ebe-a248-4b669b2bd494_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3a5eb6ec-0931-4fb1-844a-337aeec48b24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a560871e-e428-4ebe-a248-4b669b2bd494" xlink:to="loc_us-gaap_ClassOfStockDomain_3a5eb6ec-0931-4fb1-844a-337aeec48b24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_2e0c6a16-2375-4db8-a276-091068e4f6c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3a5eb6ec-0931-4fb1-844a-337aeec48b24" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_2e0c6a16-2375-4db8-a276-091068e4f6c0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail" xlink:type="simple" xlink:href="ovid-20230630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail" xlink:type="extended" id="ie1f8800d7c934c968feea54e43deb2fd_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_ovid_SummaryOfSignificantAccountingPolicyLineItems_583153a4-d947-4df0-9894-315b0de2b9a4" xlink:href="ovid-20230630.xsd#ovid_SummaryOfSignificantAccountingPolicyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_7efa82ab-5374-4440-930c-4b68ba35c7f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyLineItems_583153a4-d947-4df0-9894-315b0de2b9a4" xlink:to="loc_us-gaap_LongTermInvestments_7efa82ab-5374-4440-930c-4b68ba35c7f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2e247dde-fd79-4c98-94c9-128bfffac787" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyLineItems_583153a4-d947-4df0-9894-315b0de2b9a4" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_2e247dde-fd79-4c98-94c9-128bfffac787" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7c190afb-aa73-4933-a226-3177f809c7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyLineItems_583153a4-d947-4df0-9894-315b0de2b9a4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7c190afb-aa73-4933-a226-3177f809c7c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_SummaryOfSignificantAccountingPolicyTable_f7a1a32e-c764-4a5f-884b-b522f0cc0736" xlink:href="ovid-20230630.xsd#ovid_SummaryOfSignificantAccountingPolicyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyLineItems_583153a4-d947-4df0-9894-315b0de2b9a4" xlink:to="loc_ovid_SummaryOfSignificantAccountingPolicyTable_f7a1a32e-c764-4a5f-884b-b522f0cc0736" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_e8e5adc4-8617-4ed9-bd56-16272b308a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyTable_f7a1a32e-c764-4a5f-884b-b522f0cc0736" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_e8e5adc4-8617-4ed9-bd56-16272b308a9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_e8e5adc4-8617-4ed9-bd56-16272b308a9c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_e8e5adc4-8617-4ed9-bd56-16272b308a9c" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_e8e5adc4-8617-4ed9-bd56-16272b308a9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_48d6b9f7-b694-4ee9-8239-5bde1ebf945f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_e8e5adc4-8617-4ed9-bd56-16272b308a9c" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_48d6b9f7-b694-4ee9-8239-5bde1ebf945f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MoneyMarketFundsAndShortTermInvestmentsMember_0260e7e4-c29d-49c3-862c-1e8a5a9ff12c" xlink:href="ovid-20230630.xsd#ovid_MoneyMarketFundsAndShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_48d6b9f7-b694-4ee9-8239-5bde1ebf945f" xlink:to="loc_ovid_MoneyMarketFundsAndShortTermInvestmentsMember_0260e7e4-c29d-49c3-862c-1e8a5a9ff12c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_37e0d5ec-e1c7-4ae0-8258-d84c2ddb30fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyTable_f7a1a32e-c764-4a5f-884b-b522f0cc0736" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_37e0d5ec-e1c7-4ae0-8258-d84c2ddb30fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_37e0d5ec-e1c7-4ae0-8258-d84c2ddb30fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_37e0d5ec-e1c7-4ae0-8258-d84c2ddb30fc" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_37e0d5ec-e1c7-4ae0-8258-d84c2ddb30fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_779d865d-933d-441e-a894-675a18dc6172" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_37e0d5ec-e1c7-4ae0-8258-d84c2ddb30fc" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_779d865d-933d-441e-a894-675a18dc6172" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_fd65d26d-c137-4361-81c9-489bdf310358" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_779d865d-933d-441e-a894-675a18dc6172" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_fd65d26d-c137-4361-81c9-489bdf310358" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1618721c-89c3-463f-b32d-c44466386a48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_779d865d-933d-441e-a894-675a18dc6172" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1618721c-89c3-463f-b32d-c44466386a48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d1dda017-2af3-481a-a1e8-dde534ab8564" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyTable_f7a1a32e-c764-4a5f-884b-b522f0cc0736" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d1dda017-2af3-481a-a1e8-dde534ab8564" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_d1dda017-2af3-481a-a1e8-dde534ab8564_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d1dda017-2af3-481a-a1e8-dde534ab8564" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_d1dda017-2af3-481a-a1e8-dde534ab8564_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_e78bafd0-68d7-4667-9e33-1024ab8d587f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d1dda017-2af3-481a-a1e8-dde534ab8564" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_e78bafd0-68d7-4667-9e33-1024ab8d587f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_GravitonBioscienceCorporationMember_7d249ac6-9f95-470c-b09c-8c4e9c07cf2b" xlink:href="ovid-20230630.xsd#ovid_GravitonBioscienceCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e78bafd0-68d7-4667-9e33-1024ab8d587f" xlink:to="loc_ovid_GravitonBioscienceCorporationMember_7d249ac6-9f95-470c-b09c-8c4e9c07cf2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MarinusTherapeuticsIncMember_78e1b361-6103-48dc-8a72-2b67c5185752" xlink:href="ovid-20230630.xsd#ovid_MarinusTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e78bafd0-68d7-4667-9e33-1024ab8d587f" xlink:to="loc_ovid_MarinusTherapeuticsIncMember_78e1b361-6103-48dc-8a72-2b67c5185752" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_GensaicIncMember_c485e850-7bf0-4416-80e8-70b64b6a6f65" xlink:href="ovid-20230630.xsd#ovid_GensaicIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e78bafd0-68d7-4667-9e33-1024ab8d587f" xlink:to="loc_ovid_GensaicIncMember_c485e850-7bf0-4416-80e8-70b64b6a6f65" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSSummaryofPropertyandEquipmentDetail" xlink:type="simple" xlink:href="ovid-20230630.xsd#PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSSummaryofPropertyandEquipmentDetail"/>
  <link:definitionLink xlink:role="http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSSummaryofPropertyandEquipmentDetail" xlink:type="extended" id="ia6e9b39589824c00af806f97fa812773_PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSSummaryofPropertyandEquipmentDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c9abad77-a2de-47a3-8a9c-8d6b73436582" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_3cc6a649-978b-43aa-9e45-1ec9462c2bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c9abad77-a2de-47a3-8a9c-8d6b73436582" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_3cc6a649-978b-43aa-9e45-1ec9462c2bcc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c608ba24-239f-46de-a75e-b696327681bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c9abad77-a2de-47a3-8a9c-8d6b73436582" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c608ba24-239f-46de-a75e-b696327681bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1618780a-e898-4610-8ec0-535638d54f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c9abad77-a2de-47a3-8a9c-8d6b73436582" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1618780a-e898-4610-8ec0-535638d54f9b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2abc5f9b-ee66-439b-9356-65a9982d53cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c9abad77-a2de-47a3-8a9c-8d6b73436582" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2abc5f9b-ee66-439b-9356-65a9982d53cb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a43a0eb5-1918-43bb-8439-2dd5abded7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2abc5f9b-ee66-439b-9356-65a9982d53cb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a43a0eb5-1918-43bb-8439-2dd5abded7a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a43a0eb5-1918-43bb-8439-2dd5abded7a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a43a0eb5-1918-43bb-8439-2dd5abded7a9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a43a0eb5-1918-43bb-8439-2dd5abded7a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_be465f0f-ccdf-404b-9c02-ded5be91d7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a43a0eb5-1918-43bb-8439-2dd5abded7a9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_be465f0f-ccdf-404b-9c02-ded5be91d7bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_61d921b7-c435-4913-a516-d7a589644faa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_be465f0f-ccdf-404b-9c02-ded5be91d7bb" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_61d921b7-c435-4913-a516-d7a589644faa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_3f05ebad-5a5e-4c8f-97ce-e51cd412ecb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_be465f0f-ccdf-404b-9c02-ded5be91d7bb" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_3f05ebad-5a5e-4c8f-97ce-e51cd412ecb3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/LEASESAdditionalInformationDetail" xlink:type="simple" xlink:href="ovid-20230630.xsd#LEASESAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.ovidrx.com/role/LEASESAdditionalInformationDetail" xlink:type="extended" id="i8418da801c1d41069218e20377b88662_LEASESAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_8a90234a-c35d-4465-9425-c80ae02e4171" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_b73bf226-08ce-4a4e-a16d-bfe027bc2efa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8a90234a-c35d-4465-9425-c80ae02e4171" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_b73bf226-08ce-4a4e-a16d-bfe027bc2efa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_5838059e-1a47-41a4-8281-a31db3e6ed9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8a90234a-c35d-4465-9425-c80ae02e4171" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_5838059e-1a47-41a4-8281-a31db3e6ed9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LesseeOperatingLeaseBaseRent_5ea3c333-1ffa-4f73-9b0b-eccd9813e469" xlink:href="ovid-20230630.xsd#ovid_LesseeOperatingLeaseBaseRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8a90234a-c35d-4465-9425-c80ae02e4171" xlink:to="loc_ovid_LesseeOperatingLeaseBaseRent_5ea3c333-1ffa-4f73-9b0b-eccd9813e469" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod_c8b45c8a-2dc4-4d9e-8e1e-1a558fa8b36e" xlink:href="ovid-20230630.xsd#ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8a90234a-c35d-4465-9425-c80ae02e4171" xlink:to="loc_ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod_c8b45c8a-2dc4-4d9e-8e1e-1a558fa8b36e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_8a375785-6d25-4c3e-bb98-e25416f7ca10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8a90234a-c35d-4465-9425-c80ae02e4171" xlink:to="loc_us-gaap_RestrictedCash_8a375785-6d25-4c3e-bb98-e25416f7ca10" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_bc25e0c4-2997-444e-a90b-1651804f6cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8a90234a-c35d-4465-9425-c80ae02e4171" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_bc25e0c4-2997-444e-a90b-1651804f6cd7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_a9ed583e-737c-4528-b9c9-2505fdda02bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8a90234a-c35d-4465-9425-c80ae02e4171" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_a9ed583e-737c-4528-b9c9-2505fdda02bb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LeaseIncrementalBorrowingRate_187afe0f-8448-44ac-b523-fee6dedd6ce1" xlink:href="ovid-20230630.xsd#ovid_LeaseIncrementalBorrowingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8a90234a-c35d-4465-9425-c80ae02e4171" xlink:to="loc_ovid_LeaseIncrementalBorrowingRate_187afe0f-8448-44ac-b523-fee6dedd6ce1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_8f9012ea-d3c4-4783-a51b-9e7fe1ad03d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8a90234a-c35d-4465-9425-c80ae02e4171" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_8f9012ea-d3c4-4783-a51b-9e7fe1ad03d5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_b72fc0e2-0599-4808-98d0-5554489365f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_8f9012ea-d3c4-4783-a51b-9e7fe1ad03d5" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_b72fc0e2-0599-4808-98d0-5554489365f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_b72fc0e2-0599-4808-98d0-5554489365f3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_b72fc0e2-0599-4808-98d0-5554489365f3" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_b72fc0e2-0599-4808-98d0-5554489365f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_b94f07a8-ff89-4727-8a8d-f4998173efdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_b72fc0e2-0599-4808-98d0-5554489365f3" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_b94f07a8-ff89-4727-8a8d-f4998173efdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_0f26bdec-945f-48de-89e0-d9a9508f6e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_b94f07a8-ff89-4727-8a8d-f4998173efdb" xlink:to="loc_us-gaap_LetterOfCreditMember_0f26bdec-945f-48de-89e0-d9a9508f6e5d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetail" xlink:type="simple" xlink:href="ovid-20230630.xsd#STOCKHOLDERSEQUITYAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.ovidrx.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetail" xlink:type="extended" id="i8ce1a5ce91b749499cf849fdd4c5bf47_STOCKHOLDERSEQUITYAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_780cf5ec-0770-4ca8-8d76-bafa766742d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_8d583848-6c82-46e8-93c8-b0604db1ba75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_780cf5ec-0770-4ca8-8d76-bafa766742d1" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_8d583848-6c82-46e8-93c8-b0604db1ba75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2743b22c-7f51-4462-b343-1862b8e7c332" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_780cf5ec-0770-4ca8-8d76-bafa766742d1" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2743b22c-7f51-4462-b343-1862b8e7c332" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CommonStockNumberOfVotesForEachShare_d53002e4-625d-4837-aa1a-3aadd05e2ca9" xlink:href="ovid-20230630.xsd#ovid_CommonStockNumberOfVotesForEachShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_780cf5ec-0770-4ca8-8d76-bafa766742d1" xlink:to="loc_ovid_CommonStockNumberOfVotesForEachShare_d53002e4-625d-4837-aa1a-3aadd05e2ca9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_3cda2bd7-a2f3-4748-af6d-d67b4c173c25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_780cf5ec-0770-4ca8-8d76-bafa766742d1" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_3cda2bd7-a2f3-4748-af6d-d67b4c173c25" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_902c8ea3-aea8-4894-ab21-abc5a12d007b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_780cf5ec-0770-4ca8-8d76-bafa766742d1" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_902c8ea3-aea8-4894-ab21-abc5a12d007b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates_dde2b7ed-eb9b-4aee-8dca-ae6e1c48aeef" xlink:href="ovid-20230630.xsd#ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_780cf5ec-0770-4ca8-8d76-bafa766742d1" xlink:to="loc_ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates_dde2b7ed-eb9b-4aee-8dca-ae6e1c48aeef" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders_83478555-3a0d-42bc-b2c6-3586905f633c" xlink:href="ovid-20230630.xsd#ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_780cf5ec-0770-4ca8-8d76-bafa766742d1" xlink:to="loc_ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders_83478555-3a0d-42bc-b2c6-3586905f633c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates_e041034f-8095-42bf-98c2-c94e6953bab4" xlink:href="ovid-20230630.xsd#ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_780cf5ec-0770-4ca8-8d76-bafa766742d1" xlink:to="loc_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates_e041034f-8095-42bf-98c2-c94e6953bab4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod_45d31ab5-9e79-4f88-8b44-4dc969a3ace2" xlink:href="ovid-20230630.xsd#ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_780cf5ec-0770-4ca8-8d76-bafa766742d1" xlink:to="loc_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod_45d31ab5-9e79-4f88-8b44-4dc969a3ace2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock_de7081f4-6083-4ef1-9222-db0aa1cd3931" xlink:href="ovid-20230630.xsd#ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_780cf5ec-0770-4ca8-8d76-bafa766742d1" xlink:to="loc_ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock_de7081f4-6083-4ef1-9222-db0aa1cd3931" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockLiquidationPreference_af3d5b03-973d-45c8-a712-0948ccb8acdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreference"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_780cf5ec-0770-4ca8-8d76-bafa766742d1" xlink:to="loc_us-gaap_PreferredStockLiquidationPreference_af3d5b03-973d-45c8-a712-0948ccb8acdb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AggregateOfferingPriceOfCommonStock_67376fe6-7b55-4c93-a474-63a7898d15e2" xlink:href="ovid-20230630.xsd#ovid_AggregateOfferingPriceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_780cf5ec-0770-4ca8-8d76-bafa766742d1" xlink:to="loc_ovid_AggregateOfferingPriceOfCommonStock_67376fe6-7b55-4c93-a474-63a7898d15e2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7ec34851-e8ed-491f-a6e6-02044606c31d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_780cf5ec-0770-4ca8-8d76-bafa766742d1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7ec34851-e8ed-491f-a6e6-02044606c31d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_2b775415-56fb-4fc1-b114-fc4267b8408a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Dividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_780cf5ec-0770-4ca8-8d76-bafa766742d1" xlink:to="loc_us-gaap_Dividends_2b775415-56fb-4fc1-b114-fc4267b8408a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1813e5f0-7047-4147-8ef4-aae54c3814c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_780cf5ec-0770-4ca8-8d76-bafa766742d1" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1813e5f0-7047-4147-8ef4-aae54c3814c0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0a7ed296-11d0-41a5-960a-3b19dd7bf221" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1813e5f0-7047-4147-8ef4-aae54c3814c0" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0a7ed296-11d0-41a5-960a-3b19dd7bf221" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0a7ed296-11d0-41a5-960a-3b19dd7bf221_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0a7ed296-11d0-41a5-960a-3b19dd7bf221" xlink:to="loc_us-gaap_ClassOfStockDomain_0a7ed296-11d0-41a5-960a-3b19dd7bf221_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_168f1f3d-ee2c-4338-8b14-c3f6ed55b051" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0a7ed296-11d0-41a5-960a-3b19dd7bf221" xlink:to="loc_us-gaap_ClassOfStockDomain_168f1f3d-ee2c-4338-8b14-c3f6ed55b051" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_SeriesAConvertiblePreferredStockMember_36b34ab0-2813-456f-ba57-943b8eca718a" xlink:href="ovid-20230630.xsd#ovid_SeriesAConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_168f1f3d-ee2c-4338-8b14-c3f6ed55b051" xlink:to="loc_ovid_SeriesAConvertiblePreferredStockMember_36b34ab0-2813-456f-ba57-943b8eca718a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5d229b3a-79ed-4a64-a56b-e40c2625e9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1813e5f0-7047-4147-8ef4-aae54c3814c0" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5d229b3a-79ed-4a64-a56b-e40c2625e9a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5d229b3a-79ed-4a64-a56b-e40c2625e9a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5d229b3a-79ed-4a64-a56b-e40c2625e9a1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5d229b3a-79ed-4a64-a56b-e40c2625e9a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a880afdc-53bd-4a06-afeb-acc17ae220db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5d229b3a-79ed-4a64-a56b-e40c2625e9a1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a880afdc-53bd-4a06-afeb-acc17ae220db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_ATMAgreementMember_7294afa4-8135-4a0b-ba9c-5b48a868cc3f" xlink:href="ovid-20230630.xsd#ovid_ATMAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a880afdc-53bd-4a06-afeb-acc17ae220db" xlink:to="loc_ovid_ATMAgreementMember_7294afa4-8135-4a0b-ba9c-5b48a868cc3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fc6e899d-924f-4b9d-a0dd-f15414c162ba" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1813e5f0-7047-4147-8ef4-aae54c3814c0" xlink:to="loc_srt_RangeAxis_fc6e899d-924f-4b9d-a0dd-f15414c162ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fc6e899d-924f-4b9d-a0dd-f15414c162ba_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fc6e899d-924f-4b9d-a0dd-f15414c162ba" xlink:to="loc_srt_RangeMember_fc6e899d-924f-4b9d-a0dd-f15414c162ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a65f29fc-9907-4dd2-9e9f-5af3baa05d70" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fc6e899d-924f-4b9d-a0dd-f15414c162ba" xlink:to="loc_srt_RangeMember_a65f29fc-9907-4dd2-9e9f-5af3baa05d70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3450f4b3-16cf-4aac-a0c6-7e2951b90d49" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a65f29fc-9907-4dd2-9e9f-5af3baa05d70" xlink:to="loc_srt_MinimumMember_3450f4b3-16cf-4aac-a0c6-7e2951b90d49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_574e9b46-4f52-4a1b-ac71-016d7f6040f9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a65f29fc-9907-4dd2-9e9f-5af3baa05d70" xlink:to="loc_srt_MaximumMember_574e9b46-4f52-4a1b-ac71-016d7f6040f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_67ab73b4-07db-43cd-8e4b-73a7cdcee81b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1813e5f0-7047-4147-8ef4-aae54c3814c0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_67ab73b4-07db-43cd-8e4b-73a7cdcee81b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_67ab73b4-07db-43cd-8e4b-73a7cdcee81b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_67ab73b4-07db-43cd-8e4b-73a7cdcee81b" xlink:to="loc_us-gaap_EquityComponentDomain_67ab73b4-07db-43cd-8e4b-73a7cdcee81b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_926e029c-de92-43a6-9f7e-0a34cde1c017" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_67ab73b4-07db-43cd-8e4b-73a7cdcee81b" xlink:to="loc_us-gaap_EquityComponentDomain_926e029c-de92-43a6-9f7e-0a34cde1c017" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6f66d500-eda6-499c-b798-e68f26bcac84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_926e029c-de92-43a6-9f7e-0a34cde1c017" xlink:to="loc_us-gaap_CommonStockMember_6f66d500-eda6-499c-b798-e68f26bcac84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_bd5060c1-4a68-4993-bd54-ec47ab949f0b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1813e5f0-7047-4147-8ef4-aae54c3814c0" xlink:to="loc_srt_CounterpartyNameAxis_bd5060c1-4a68-4993-bd54-ec47ab949f0b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bd5060c1-4a68-4993-bd54-ec47ab949f0b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_bd5060c1-4a68-4993-bd54-ec47ab949f0b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bd5060c1-4a68-4993-bd54-ec47ab949f0b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_892c776a-3c04-445e-a254-bed167fe94c5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_bd5060c1-4a68-4993-bd54-ec47ab949f0b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_892c776a-3c04-445e-a254-bed167fe94c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CowenAndCompanyLLCMember_2c07a4a3-eb68-48b6-8192-eed66e9dc33c" xlink:href="ovid-20230630.xsd#ovid_CowenAndCompanyLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_892c776a-3c04-445e-a254-bed167fe94c5" xlink:to="loc_ovid_CowenAndCompanyLLCMember_2c07a4a3-eb68-48b6-8192-eed66e9dc33c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail" xlink:type="simple" xlink:href="ovid-20230630.xsd#STOCKBASEDCOMPENSATIONAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail" xlink:type="extended" id="i5c0837c309974c4f9fd3ed8a0320b983_STOCKBASEDCOMPENSATIONAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56b7c12f-f379-47aa-a75f-49010f98c000" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_cf1c40d5-613b-488a-80fa-9b804d0c4d69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56b7c12f-f379-47aa-a75f-49010f98c000" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_cf1c40d5-613b-488a-80fa-9b804d0c4d69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_d89df948-86d7-4702-b3c0-110ecd8aa403" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56b7c12f-f379-47aa-a75f-49010f98c000" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_d89df948-86d7-4702-b3c0-110ecd8aa403" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_7b93ffde-16ca-4d3e-b7ff-3503c5032a56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56b7c12f-f379-47aa-a75f-49010f98c000" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_7b93ffde-16ca-4d3e-b7ff-3503c5032a56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_4936ae33-6666-4d5f-b07c-bf0ef37b626c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56b7c12f-f379-47aa-a75f-49010f98c000" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_4936ae33-6666-4d5f-b07c-bf0ef37b626c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_56a99248-3a97-4121-b255-20782bc3495a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56b7c12f-f379-47aa-a75f-49010f98c000" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_56a99248-3a97-4121-b255-20782bc3495a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_f1d2cb08-0e5f-49d0-b587-8674dd14926e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56b7c12f-f379-47aa-a75f-49010f98c000" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_f1d2cb08-0e5f-49d0-b587-8674dd14926e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ae113fd4-31f9-4baf-ac46-2424327c6b46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56b7c12f-f379-47aa-a75f-49010f98c000" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ae113fd4-31f9-4baf-ac46-2424327c6b46" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease_d6d45436-5bc0-4726-ad2a-ac003cda04ce" xlink:href="ovid-20230630.xsd#ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56b7c12f-f379-47aa-a75f-49010f98c000" xlink:to="loc_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease_d6d45436-5bc0-4726-ad2a-ac003cda04ce" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum_153fb89e-8cc4-42cb-a491-f8cea8a6e6d6" xlink:href="ovid-20230630.xsd#ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56b7c12f-f379-47aa-a75f-49010f98c000" xlink:to="loc_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum_153fb89e-8cc4-42cb-a491-f8cea8a6e6d6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3e2c1e3a-5664-4603-863d-1ce3ce5e84a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56b7c12f-f379-47aa-a75f-49010f98c000" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3e2c1e3a-5664-4603-863d-1ce3ce5e84a5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_90c1d6ca-0f40-483b-b597-c90ec9846019" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56b7c12f-f379-47aa-a75f-49010f98c000" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_90c1d6ca-0f40-483b-b597-c90ec9846019" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5deb5a4e-a6a6-4788-a156-a4e984cfe124" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56b7c12f-f379-47aa-a75f-49010f98c000" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5deb5a4e-a6a6-4788-a156-a4e984cfe124" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a43a64ef-3d44-4297-bca2-a69436617b67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56b7c12f-f379-47aa-a75f-49010f98c000" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a43a64ef-3d44-4297-bca2-a69436617b67" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_856e8b35-48c8-47fc-87d2-f8a48ce18f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56b7c12f-f379-47aa-a75f-49010f98c000" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_856e8b35-48c8-47fc-87d2-f8a48ce18f2b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f6c74401-dd12-435c-8b8d-7898b3dc738d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56b7c12f-f379-47aa-a75f-49010f98c000" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f6c74401-dd12-435c-8b8d-7898b3dc738d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_9c0d0c1c-9d7c-4171-8698-c788c94e5cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_b55c4a7b-687b-4249-aab0-58ca08c20cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56b7c12f-f379-47aa-a75f-49010f98c000" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_b55c4a7b-687b-4249-aab0-58ca08c20cf6" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3248e339-ac47-468f-bb8e-3fb9d896573e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56b7c12f-f379-47aa-a75f-49010f98c000" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3248e339-ac47-468f-bb8e-3fb9d896573e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e33db-af4b-45c2-a2bd-ea81e214310a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56b7c12f-f379-47aa-a75f-49010f98c000" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e33db-af4b-45c2-a2bd-ea81e214310a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9e20ce50-c86c-4b7f-ae34-daae8d9ee5c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e33db-af4b-45c2-a2bd-ea81e214310a" xlink:to="loc_us-gaap_PlanNameAxis_9e20ce50-c86c-4b7f-ae34-daae8d9ee5c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9e20ce50-c86c-4b7f-ae34-daae8d9ee5c4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_9e20ce50-c86c-4b7f-ae34-daae8d9ee5c4" xlink:to="loc_us-gaap_PlanNameDomain_9e20ce50-c86c-4b7f-ae34-daae8d9ee5c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2c1bf2bc-bba3-4fa6-95ec-7964cddbad27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_9e20ce50-c86c-4b7f-ae34-daae8d9ee5c4" xlink:to="loc_us-gaap_PlanNameDomain_2c1bf2bc-bba3-4fa6-95ec-7964cddbad27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_TwoThousandSeventeenEquityIncentivePlanMember_b89484bb-0c48-45a0-872a-e517c340b7e4" xlink:href="ovid-20230630.xsd#ovid_TwoThousandSeventeenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_2c1bf2bc-bba3-4fa6-95ec-7964cddbad27" xlink:to="loc_ovid_TwoThousandSeventeenEquityIncentivePlanMember_b89484bb-0c48-45a0-872a-e517c340b7e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember_8e6ebc90-607a-43dd-85d0-e87b7e76a618" xlink:href="ovid-20230630.xsd#ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_2c1bf2bc-bba3-4fa6-95ec-7964cddbad27" xlink:to="loc_ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember_8e6ebc90-607a-43dd-85d0-e87b7e76a618" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_A2014EmployeeStockPurchasePlanMember_e59797c5-0805-4ae4-8fc9-c2e6163c3ed8" xlink:href="ovid-20230630.xsd#ovid_A2014EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_2c1bf2bc-bba3-4fa6-95ec-7964cddbad27" xlink:to="loc_ovid_A2014EmployeeStockPurchasePlanMember_e59797c5-0805-4ae4-8fc9-c2e6163c3ed8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_73e84e71-854c-44d2-ad88-8f70cfcfcf5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e33db-af4b-45c2-a2bd-ea81e214310a" xlink:to="loc_us-gaap_AwardTypeAxis_73e84e71-854c-44d2-ad88-8f70cfcfcf5b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_73e84e71-854c-44d2-ad88-8f70cfcfcf5b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_73e84e71-854c-44d2-ad88-8f70cfcfcf5b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_73e84e71-854c-44d2-ad88-8f70cfcfcf5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc951b13-7b4a-49f9-9078-f62f3ae1e7f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_73e84e71-854c-44d2-ad88-8f70cfcfcf5b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc951b13-7b4a-49f9-9078-f62f3ae1e7f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_f8814181-bb36-4f8b-b7c1-52bdc0832c31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc951b13-7b4a-49f9-9078-f62f3ae1e7f3" xlink:to="loc_us-gaap_PerformanceSharesMember_f8814181-bb36-4f8b-b7c1-52bdc0832c31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0167d7af-195e-4946-b0aa-138255d4a19b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc951b13-7b4a-49f9-9078-f62f3ae1e7f3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0167d7af-195e-4946-b0aa-138255d4a19b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_NonemployeePerformanceBasedOptionAwardsMember_5ac5fecc-6cf9-4086-87ff-255ef4ad21f9" xlink:href="ovid-20230630.xsd#ovid_NonemployeePerformanceBasedOptionAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc951b13-7b4a-49f9-9078-f62f3ae1e7f3" xlink:to="loc_ovid_NonemployeePerformanceBasedOptionAwardsMember_5ac5fecc-6cf9-4086-87ff-255ef4ad21f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_EmployeePerformanceBasedOptionAwardsMember_2ed7b35d-a01b-4af1-aca6-919bbb972048" xlink:href="ovid-20230630.xsd#ovid_EmployeePerformanceBasedOptionAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc951b13-7b4a-49f9-9078-f62f3ae1e7f3" xlink:to="loc_ovid_EmployeePerformanceBasedOptionAwardsMember_2ed7b35d-a01b-4af1-aca6-919bbb972048" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_1ae41743-aa57-40b6-8b6a-918799a99301" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e33db-af4b-45c2-a2bd-ea81e214310a" xlink:to="loc_us-gaap_GranteeStatusAxis_1ae41743-aa57-40b6-8b6a-918799a99301" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_1ae41743-aa57-40b6-8b6a-918799a99301_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GranteeStatusAxis_1ae41743-aa57-40b6-8b6a-918799a99301" xlink:to="loc_us-gaap_GranteeStatusDomain_1ae41743-aa57-40b6-8b6a-918799a99301_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_dcfb23ea-ca34-4d81-ae2a-57602ec62117" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GranteeStatusAxis_1ae41743-aa57-40b6-8b6a-918799a99301" xlink:to="loc_us-gaap_GranteeStatusDomain_dcfb23ea-ca34-4d81-ae2a-57602ec62117" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_6622253f-e6e2-4d87-abf7-339b84dc75eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_dcfb23ea-ca34-4d81-ae2a-57602ec62117" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_6622253f-e6e2-4d87-abf7-339b84dc75eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_93bdfd13-ae91-4545-9b33-f85ec29303f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_dcfb23ea-ca34-4d81-ae2a-57602ec62117" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_93bdfd13-ae91-4545-9b33-f85ec29303f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_de984da4-dc44-4ee2-82e2-2fbcddae1057" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e33db-af4b-45c2-a2bd-ea81e214310a" xlink:to="loc_srt_RangeAxis_de984da4-dc44-4ee2-82e2-2fbcddae1057" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_de984da4-dc44-4ee2-82e2-2fbcddae1057_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_de984da4-dc44-4ee2-82e2-2fbcddae1057" xlink:to="loc_srt_RangeMember_de984da4-dc44-4ee2-82e2-2fbcddae1057_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_36727336-2dd6-4139-9edc-b0b9898df373" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_de984da4-dc44-4ee2-82e2-2fbcddae1057" xlink:to="loc_srt_RangeMember_36727336-2dd6-4139-9edc-b0b9898df373" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3cb084bc-a19d-4a32-a509-03a37a2a2d3b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_36727336-2dd6-4139-9edc-b0b9898df373" xlink:to="loc_srt_MaximumMember_3cb084bc-a19d-4a32-a509-03a37a2a2d3b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONScheduleofRecognizedStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="ovid-20230630.xsd#STOCKBASEDCOMPENSATIONScheduleofRecognizedStockBasedCompensationExpenseDetail"/>
  <link:definitionLink xlink:role="http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONScheduleofRecognizedStockBasedCompensationExpenseDetail" xlink:type="extended" id="i35bb3fdec52747978318e48f24ff283e_STOCKBASEDCOMPENSATIONScheduleofRecognizedStockBasedCompensationExpenseDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc644d8e-bd28-4973-9d1b-7cc5ec89ac80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_02f3c014-926a-4968-8a33-ec5f86cc8104" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc644d8e-bd28-4973-9d1b-7cc5ec89ac80" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_02f3c014-926a-4968-8a33-ec5f86cc8104" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_54390a50-4465-4a98-97d6-975ac14c32f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc644d8e-bd28-4973-9d1b-7cc5ec89ac80" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_54390a50-4465-4a98-97d6-975ac14c32f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2d2df5ff-17c1-4f7e-af2f-155e76f79d86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_54390a50-4465-4a98-97d6-975ac14c32f3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2d2df5ff-17c1-4f7e-af2f-155e76f79d86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2d2df5ff-17c1-4f7e-af2f-155e76f79d86_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2d2df5ff-17c1-4f7e-af2f-155e76f79d86" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2d2df5ff-17c1-4f7e-af2f-155e76f79d86_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8fa52429-3817-4c7e-af0a-ee1e05437fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2d2df5ff-17c1-4f7e-af2f-155e76f79d86" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8fa52429-3817-4c7e-af0a-ee1e05437fdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d7d5df5e-eba0-4489-b09b-5f5533efce43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8fa52429-3817-4c7e-af0a-ee1e05437fdf" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d7d5df5e-eba0-4489-b09b-5f5533efce43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b96475ba-b549-4b9a-ae9a-5ca1796a169f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8fa52429-3817-4c7e-af0a-ee1e05437fdf" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b96475ba-b549-4b9a-ae9a-5ca1796a169f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONScheduleofAllocationofStockBasedCompensationExpensebyPlanDetail" xlink:type="simple" xlink:href="ovid-20230630.xsd#STOCKBASEDCOMPENSATIONScheduleofAllocationofStockBasedCompensationExpensebyPlanDetail"/>
  <link:definitionLink xlink:role="http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONScheduleofAllocationofStockBasedCompensationExpensebyPlanDetail" xlink:type="extended" id="i84b7d60665d34d8e8fe13922718f1670_STOCKBASEDCOMPENSATIONScheduleofAllocationofStockBasedCompensationExpensebyPlanDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_978dd9dd-7e21-443d-bb82-482c125ca515" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5dfe7df4-bb28-4e20-b62e-7426a88ef1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_978dd9dd-7e21-443d-bb82-482c125ca515" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5dfe7df4-bb28-4e20-b62e-7426a88ef1a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_11417bbc-4db2-4060-b468-6c4161983dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_978dd9dd-7e21-443d-bb82-482c125ca515" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_11417bbc-4db2-4060-b468-6c4161983dfb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0177de1f-573a-4c89-a474-82fc821d0c79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_11417bbc-4db2-4060-b468-6c4161983dfb" xlink:to="loc_us-gaap_AwardTypeAxis_0177de1f-573a-4c89-a474-82fc821d0c79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0177de1f-573a-4c89-a474-82fc821d0c79_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0177de1f-573a-4c89-a474-82fc821d0c79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0177de1f-573a-4c89-a474-82fc821d0c79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2d4e2890-e6f5-4585-a533-03d039fb3330" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0177de1f-573a-4c89-a474-82fc821d0c79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2d4e2890-e6f5-4585-a533-03d039fb3330" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ff6ee1b7-44f8-4b0c-8abc-69bdeb471c35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2d4e2890-e6f5-4585-a533-03d039fb3330" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ff6ee1b7-44f8-4b0c-8abc-69bdeb471c35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_EmployeeStockPurchasePlanMember_f662d5f5-410d-4c9c-b7ed-09adfb1a431b" xlink:href="ovid-20230630.xsd#ovid_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2d4e2890-e6f5-4585-a533-03d039fb3330" xlink:to="loc_ovid_EmployeeStockPurchasePlanMember_f662d5f5-410d-4c9c-b7ed-09adfb1a431b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail" xlink:type="simple" xlink:href="ovid-20230630.xsd#STOCKBASEDCOMPENSATIONSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail"/>
  <link:definitionLink xlink:role="http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail" xlink:type="extended" id="i7e2628e527c341a0b5fe37e36d52d1cb_STOCKBASEDCOMPENSATIONSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7238dc71-e33e-4df2-b501-c6b6ddb6a466" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_e48ef4c1-4b98-4a67-b527-55bed7faba4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7238dc71-e33e-4df2-b501-c6b6ddb6a466" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_e48ef4c1-4b98-4a67-b527-55bed7faba4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0bbe11e9-a366-421d-b656-3c9c9190cca7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7238dc71-e33e-4df2-b501-c6b6ddb6a466" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0bbe11e9-a366-421d-b656-3c9c9190cca7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b067385c-3239-40c2-b7b4-a8c5a7cf1727" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7238dc71-e33e-4df2-b501-c6b6ddb6a466" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b067385c-3239-40c2-b7b4-a8c5a7cf1727" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_08c15ba4-e853-462a-85b6-344405d25f81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7238dc71-e33e-4df2-b501-c6b6ddb6a466" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_08c15ba4-e853-462a-85b6-344405d25f81" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0a2a858e-8a69-4f9a-9723-53e2604140ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7238dc71-e33e-4df2-b501-c6b6ddb6a466" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0a2a858e-8a69-4f9a-9723-53e2604140ce" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ef531cfa-b116-4d55-bc4c-e4207355a1e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7238dc71-e33e-4df2-b501-c6b6ddb6a466" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ef531cfa-b116-4d55-bc4c-e4207355a1e8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_17965999-6907-4511-b1d7-29fe415939f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ef531cfa-b116-4d55-bc4c-e4207355a1e8" xlink:to="loc_us-gaap_AwardTypeAxis_17965999-6907-4511-b1d7-29fe415939f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_17965999-6907-4511-b1d7-29fe415939f7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_17965999-6907-4511-b1d7-29fe415939f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_17965999-6907-4511-b1d7-29fe415939f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45f1177d-8ec0-4ecf-b61f-cfa55c3b0a49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_17965999-6907-4511-b1d7-29fe415939f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45f1177d-8ec0-4ecf-b61f-cfa55c3b0a49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9b5c16f5-9165-4e89-af0b-f7ab589a9cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45f1177d-8ec0-4ecf-b61f-cfa55c3b0a49" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9b5c16f5-9165-4e89-af0b-f7ab589a9cd7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_226cde09-ee10-4b2d-86f7-00665063c26b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ef531cfa-b116-4d55-bc4c-e4207355a1e8" xlink:to="loc_us-gaap_GranteeStatusAxis_226cde09-ee10-4b2d-86f7-00665063c26b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_226cde09-ee10-4b2d-86f7-00665063c26b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GranteeStatusAxis_226cde09-ee10-4b2d-86f7-00665063c26b" xlink:to="loc_us-gaap_GranteeStatusDomain_226cde09-ee10-4b2d-86f7-00665063c26b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_7b0bd26c-9c64-4570-92e5-3537bde8787a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GranteeStatusAxis_226cde09-ee10-4b2d-86f7-00665063c26b" xlink:to="loc_us-gaap_GranteeStatusDomain_7b0bd26c-9c64-4570-92e5-3537bde8787a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_b6ff1958-ad6f-498c-a7d6-951beeb23e47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_7b0bd26c-9c64-4570-92e5-3537bde8787a" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_b6ff1958-ad6f-498c-a7d6-951beeb23e47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_d7a0ba38-4d6c-4618-a54b-a4f9d28e0b73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_7b0bd26c-9c64-4570-92e5-3537bde8787a" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_d7a0ba38-4d6c-4618-a54b-a4f9d28e0b73" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail" xlink:type="simple" xlink:href="ovid-20230630.xsd#COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.ovidrx.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail" xlink:type="extended" id="ic15bec3ce1eb4361a968439a3cb91dc7_COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_ff8556f4-fc3e-4a8f-ba9c-1e82f5dd6cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment_9f974638-2c49-4a9c-b614-341e958d4034" xlink:href="ovid-20230630.xsd#ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_ff8556f4-fc3e-4a8f-ba9c-1e82f5dd6cd5" xlink:to="loc_ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment_9f974638-2c49-4a9c-b614-341e958d4034" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AnnualLicenseMaintenanceFeePayable_d6cc4a2c-fc08-4e44-8dff-93078b7e72ec" xlink:href="ovid-20230630.xsd#ovid_AnnualLicenseMaintenanceFeePayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_ff8556f4-fc3e-4a8f-ba9c-1e82f5dd6cd5" xlink:to="loc_ovid_AnnualLicenseMaintenanceFeePayable_d6cc4a2c-fc08-4e44-8dff-93078b7e72ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_ConsiderationPayableForRightsGrant_64cbda7f-7a4b-4935-b0b6-9223059a7f38" xlink:href="ovid-20230630.xsd#ovid_ConsiderationPayableForRightsGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_ff8556f4-fc3e-4a8f-ba9c-1e82f5dd6cd5" xlink:to="loc_ovid_ConsiderationPayableForRightsGrant_64cbda7f-7a4b-4935-b0b6-9223059a7f38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_RoyaltyObligationTerm_674375af-6507-4d8b-8036-effdf49004c9" xlink:href="ovid-20230630.xsd#ovid_RoyaltyObligationTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_ff8556f4-fc3e-4a8f-ba9c-1e82f5dd6cd5" xlink:to="loc_ovid_RoyaltyObligationTerm_674375af-6507-4d8b-8036-effdf49004c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement_ee457584-4a6f-4e4c-9a91-78f4ad52d54f" xlink:href="ovid-20230630.xsd#ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_ff8556f4-fc3e-4a8f-ba9c-1e82f5dd6cd5" xlink:to="loc_ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement_ee457584-4a6f-4e4c-9a91-78f4ad52d54f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_UpfrontCashPayment_d2f42cbc-5a57-4952-86e5-696e155f8d5c" xlink:href="ovid-20230630.xsd#ovid_UpfrontCashPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_ff8556f4-fc3e-4a8f-ba9c-1e82f5dd6cd5" xlink:to="loc_ovid_UpfrontCashPayment_d2f42cbc-5a57-4952-86e5-696e155f8d5c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LicenseAgreementConsiderationSharesIssued_902f8440-2e3d-4ed9-9c92-bcec8062a154" xlink:href="ovid-20230630.xsd#ovid_LicenseAgreementConsiderationSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_ff8556f4-fc3e-4a8f-ba9c-1e82f5dd6cd5" xlink:to="loc_ovid_LicenseAgreementConsiderationSharesIssued_902f8440-2e3d-4ed9-9c92-bcec8062a154" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate_64f4b2a2-3633-4ae2-88ac-76a48c539e9f" xlink:href="ovid-20230630.xsd#ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_ff8556f4-fc3e-4a8f-ba9c-1e82f5dd6cd5" xlink:to="loc_ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate_64f4b2a2-3633-4ae2-88ac-76a48c539e9f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9e540dd2-f5f9-4576-b41f-f43524503613" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_ff8556f4-fc3e-4a8f-ba9c-1e82f5dd6cd5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9e540dd2-f5f9-4576-b41f-f43524503613" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LicenseAgreementMilestonePayments_5b2d0b0c-18da-4641-8ccb-a3b40e30236b" xlink:href="ovid-20230630.xsd#ovid_LicenseAgreementMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_ff8556f4-fc3e-4a8f-ba9c-1e82f5dd6cd5" xlink:to="loc_ovid_LicenseAgreementMilestonePayments_5b2d0b0c-18da-4641-8ccb-a3b40e30236b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_FirstPaymentDueUponCompletionOfFirstPhase_c2c16910-7ce9-4a57-a184-a6f17781e0d9" xlink:href="ovid-20230630.xsd#ovid_FirstPaymentDueUponCompletionOfFirstPhase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_ff8556f4-fc3e-4a8f-ba9c-1e82f5dd6cd5" xlink:to="loc_ovid_FirstPaymentDueUponCompletionOfFirstPhase_c2c16910-7ce9-4a57-a184-a6f17781e0d9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CollaborationAndOptionAgreementResearchPlanAndBudgetExpectedCosts_b72f35c4-8bce-486e-8c18-4a834f8713e2" xlink:href="ovid-20230630.xsd#ovid_CollaborationAndOptionAgreementResearchPlanAndBudgetExpectedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_ff8556f4-fc3e-4a8f-ba9c-1e82f5dd6cd5" xlink:to="loc_ovid_CollaborationAndOptionAgreementResearchPlanAndBudgetExpectedCosts_b72f35c4-8bce-486e-8c18-4a834f8713e2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LicenseAgreementDevelopmentMilestoneApprovalsProductThreshold_30e75d00-c1b6-4e73-8620-d8da303684d8" xlink:href="ovid-20230630.xsd#ovid_LicenseAgreementDevelopmentMilestoneApprovalsProductThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_ff8556f4-fc3e-4a8f-ba9c-1e82f5dd6cd5" xlink:to="loc_ovid_LicenseAgreementDevelopmentMilestoneApprovalsProductThreshold_30e75d00-c1b6-4e73-8620-d8da303684d8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LicenseAgreementTerminationAdvanceNoticePeriod_9598e842-389e-463f-adf7-ac1b73d2ee22" xlink:href="ovid-20230630.xsd#ovid_LicenseAgreementTerminationAdvanceNoticePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_ff8556f4-fc3e-4a8f-ba9c-1e82f5dd6cd5" xlink:to="loc_ovid_LicenseAgreementTerminationAdvanceNoticePeriod_9598e842-389e-463f-adf7-ac1b73d2ee22" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_10113294-4df5-422b-88d2-bd157027e2f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_ff8556f4-fc3e-4a8f-ba9c-1e82f5dd6cd5" xlink:to="loc_us-gaap_LossContingenciesTable_10113294-4df5-422b-88d2-bd157027e2f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_29185a2a-c08b-4e68-8c65-7be3887590c1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_10113294-4df5-422b-88d2-bd157027e2f5" xlink:to="loc_srt_CounterpartyNameAxis_29185a2a-c08b-4e68-8c65-7be3887590c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_29185a2a-c08b-4e68-8c65-7be3887590c1_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_29185a2a-c08b-4e68-8c65-7be3887590c1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_29185a2a-c08b-4e68-8c65-7be3887590c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_979e3d0b-0343-4b2c-aa8a-467a0cc71729" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_29185a2a-c08b-4e68-8c65-7be3887590c1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_979e3d0b-0343-4b2c-aa8a-467a0cc71729" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_NorthwesternUniversityMember_2fb2f0c5-6552-4a74-b85e-daed789ef622" xlink:href="ovid-20230630.xsd#ovid_NorthwesternUniversityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_979e3d0b-0343-4b2c-aa8a-467a0cc71729" xlink:to="loc_ovid_NorthwesternUniversityMember_2fb2f0c5-6552-4a74-b85e-daed789ef622" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AstrazenecaMember_5229bee4-a7db-4a42-87ef-47c8bb2f6a8b" xlink:href="ovid-20230630.xsd#ovid_AstrazenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_979e3d0b-0343-4b2c-aa8a-467a0cc71729" xlink:to="loc_ovid_AstrazenecaMember_5229bee4-a7db-4a42-87ef-47c8bb2f6a8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_HLundbeckASMember_ed28f8b0-7499-4bd1-84d1-398bd6a65695" xlink:href="ovid-20230630.xsd#ovid_HLundbeckASMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_979e3d0b-0343-4b2c-aa8a-467a0cc71729" xlink:to="loc_ovid_HLundbeckASMember_ed28f8b0-7499-4bd1-84d1-398bd6a65695" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_cc0bca8f-1092-44ff-bd41-dfedc5b6414e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_10113294-4df5-422b-88d2-bd157027e2f5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_cc0bca8f-1092-44ff-bd41-dfedc5b6414e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc0bca8f-1092-44ff-bd41-dfedc5b6414e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cc0bca8f-1092-44ff-bd41-dfedc5b6414e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc0bca8f-1092-44ff-bd41-dfedc5b6414e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ceb2d60c-075e-47bd-b58b-bc39b5d1a17a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cc0bca8f-1092-44ff-bd41-dfedc5b6414e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ceb2d60c-075e-47bd-b58b-bc39b5d1a17a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LicenseAgreementMember_8de84737-14b8-4854-a232-096467057069" xlink:href="ovid-20230630.xsd#ovid_LicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ceb2d60c-075e-47bd-b58b-bc39b5d1a17a" xlink:to="loc_ovid_LicenseAgreementMember_8de84737-14b8-4854-a232-096467057069" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8c0a5046-8680-4e0f-ad37-4639fb9d3c04" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_10113294-4df5-422b-88d2-bd157027e2f5" xlink:to="loc_srt_RangeAxis_8c0a5046-8680-4e0f-ad37-4639fb9d3c04" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8c0a5046-8680-4e0f-ad37-4639fb9d3c04_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8c0a5046-8680-4e0f-ad37-4639fb9d3c04" xlink:to="loc_srt_RangeMember_8c0a5046-8680-4e0f-ad37-4639fb9d3c04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2b42fd29-2540-461f-8130-577aaecb9d37" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8c0a5046-8680-4e0f-ad37-4639fb9d3c04" xlink:to="loc_srt_RangeMember_2b42fd29-2540-461f-8130-577aaecb9d37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a829a84f-9189-4eb1-bdb0-2656b8f81867" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2b42fd29-2540-461f-8130-577aaecb9d37" xlink:to="loc_srt_MaximumMember_a829a84f-9189-4eb1-bdb0-2656b8f81867" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail" xlink:type="simple" xlink:href="ovid-20230630.xsd#COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail" xlink:type="extended" id="i1e3797b999424be78a2d251c4b713a7b_COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12cdbfd3-5761-4cae-8849-bc17502a1c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_17e823c1-947a-42d8-9260-81566e7967ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12cdbfd3-5761-4cae-8849-bc17502a1c7d" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_17e823c1-947a-42d8-9260-81566e7967ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_UpfrontPaymentReceivable_110a8a31-1835-49e1-962c-c3318d66b8be" xlink:href="ovid-20230630.xsd#ovid_UpfrontPaymentReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12cdbfd3-5761-4cae-8849-bc17502a1c7d" xlink:to="loc_ovid_UpfrontPaymentReceivable_110a8a31-1835-49e1-962c-c3318d66b8be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AgreementMilestonePayments_f3a8ace4-62cd-4704-b562-1219a91d544e" xlink:href="ovid-20230630.xsd#ovid_AgreementMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12cdbfd3-5761-4cae-8849-bc17502a1c7d" xlink:to="loc_ovid_AgreementMilestonePayments_f3a8ace4-62cd-4704-b562-1219a91d544e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AdditionalPaymentReceivableOnSalesPercentage_b5951430-41a4-4d31-9cb2-0d5d648a56d0" xlink:href="ovid-20230630.xsd#ovid_AdditionalPaymentReceivableOnSalesPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12cdbfd3-5761-4cae-8849-bc17502a1c7d" xlink:to="loc_ovid_AdditionalPaymentReceivableOnSalesPercentage_b5951430-41a4-4d31-9cb2-0d5d648a56d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_UpFrontFeeAmount_ee5c9f1c-67f9-4ae0-b518-eaae8f10dadf" xlink:href="ovid-20230630.xsd#ovid_UpFrontFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12cdbfd3-5761-4cae-8849-bc17502a1c7d" xlink:to="loc_ovid_UpFrontFeeAmount_ee5c9f1c-67f9-4ae0-b518-eaae8f10dadf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LicenseAndCollaborationAgreementExpense_70da4a0e-f50a-4816-b8bc-b2c77a89fc60" xlink:href="ovid-20230630.xsd#ovid_LicenseAndCollaborationAgreementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12cdbfd3-5761-4cae-8849-bc17502a1c7d" xlink:to="loc_ovid_LicenseAndCollaborationAgreementExpense_70da4a0e-f50a-4816-b8bc-b2c77a89fc60" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_UpFrontPayment_021189be-e22f-4d51-b9fd-7b218aead1a0" xlink:href="ovid-20230630.xsd#ovid_UpFrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12cdbfd3-5761-4cae-8849-bc17502a1c7d" xlink:to="loc_ovid_UpFrontPayment_021189be-e22f-4d51-b9fd-7b218aead1a0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LicenseOptionAgreementDevelopmentAndCommercialMilestonePayments_deff84ec-d4bb-48a6-a408-11e941e4ae00" xlink:href="ovid-20230630.xsd#ovid_LicenseOptionAgreementDevelopmentAndCommercialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12cdbfd3-5761-4cae-8849-bc17502a1c7d" xlink:to="loc_ovid_LicenseOptionAgreementDevelopmentAndCommercialMilestonePayments_deff84ec-d4bb-48a6-a408-11e941e4ae00" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LicenseOptionAgreementExtensionPeriod_17ff2b22-a583-4791-8834-af3b0d7ce44b" xlink:href="ovid-20230630.xsd#ovid_LicenseOptionAgreementExtensionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12cdbfd3-5761-4cae-8849-bc17502a1c7d" xlink:to="loc_ovid_LicenseOptionAgreementExtensionPeriod_17ff2b22-a583-4791-8834-af3b0d7ce44b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_PercentageOfDevelopmentCosts_9499d029-3570-4587-bdc0-ee1c5cf1ed9a" xlink:href="ovid-20230630.xsd#ovid_PercentageOfDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12cdbfd3-5761-4cae-8849-bc17502a1c7d" xlink:to="loc_ovid_PercentageOfDevelopmentCosts_9499d029-3570-4587-bdc0-ee1c5cf1ed9a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_567029e2-ca97-4dd5-b2de-e3be0c1ce776" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12cdbfd3-5761-4cae-8849-bc17502a1c7d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_567029e2-ca97-4dd5-b2de-e3be0c1ce776" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_15c67a5a-5698-4d9b-b8db-5d2c40683924" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12cdbfd3-5761-4cae-8849-bc17502a1c7d" xlink:to="loc_us-gaap_CommonStockSharesIssued_15c67a5a-5698-4d9b-b8db-5d2c40683924" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_6c0b7688-c44c-496d-be2f-ffa052362f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12cdbfd3-5761-4cae-8849-bc17502a1c7d" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_6c0b7688-c44c-496d-be2f-ffa052362f5f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_cf25ca16-4b59-48b8-bf38-b15c7ec34d41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12cdbfd3-5761-4cae-8849-bc17502a1c7d" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_cf25ca16-4b59-48b8-bf38-b15c7ec34d41" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock_ebe02bce-93d4-4d20-844d-eeb49f46620f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12cdbfd3-5761-4cae-8849-bc17502a1c7d" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock_ebe02bce-93d4-4d20-844d-eeb49f46620f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d80c429-1b84-43a4-8f81-6566f04e9209" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12cdbfd3-5761-4cae-8849-bc17502a1c7d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d80c429-1b84-43a4-8f81-6566f04e9209" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7d04e5e0-0be7-4536-a263-e5019fbae934" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d80c429-1b84-43a4-8f81-6566f04e9209" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7d04e5e0-0be7-4536-a263-e5019fbae934" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7d04e5e0-0be7-4536-a263-e5019fbae934_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7d04e5e0-0be7-4536-a263-e5019fbae934" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_7d04e5e0-0be7-4536-a263-e5019fbae934_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_2d58a240-8174-4e46-8198-3fe91140f7b3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7d04e5e0-0be7-4536-a263-e5019fbae934" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_2d58a240-8174-4e46-8198-3fe91140f7b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_TakedaPharmaceuticalCompanyLimitedMember_1005a210-4325-4b9e-8612-148da4ec2f45" xlink:href="ovid-20230630.xsd#ovid_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_2d58a240-8174-4e46-8198-3fe91140f7b3" xlink:to="loc_ovid_TakedaPharmaceuticalCompanyLimitedMember_1005a210-4325-4b9e-8612-148da4ec2f45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MarinusPharmaceuticalsIncMember_09625768-1795-421d-b4bc-e550e58dcfd3" xlink:href="ovid-20230630.xsd#ovid_MarinusPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_2d58a240-8174-4e46-8198-3fe91140f7b3" xlink:to="loc_ovid_MarinusPharmaceuticalsIncMember_09625768-1795-421d-b4bc-e550e58dcfd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_GravitonBioscienceCorporationMember_65dce5e0-c660-4abf-b2ca-31229f53b59a" xlink:href="ovid-20230630.xsd#ovid_GravitonBioscienceCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_2d58a240-8174-4e46-8198-3fe91140f7b3" xlink:to="loc_ovid_GravitonBioscienceCorporationMember_65dce5e0-c660-4abf-b2ca-31229f53b59a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_19eea97b-5832-4097-bc39-14652c95938e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d80c429-1b84-43a4-8f81-6566f04e9209" xlink:to="loc_us-gaap_TypeOfArrangementAxis_19eea97b-5832-4097-bc39-14652c95938e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19eea97b-5832-4097-bc39-14652c95938e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_19eea97b-5832-4097-bc39-14652c95938e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19eea97b-5832-4097-bc39-14652c95938e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_01eb28ef-ac63-42f6-a2c9-c843f8fb22cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_19eea97b-5832-4097-bc39-14652c95938e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_01eb28ef-ac63-42f6-a2c9-c843f8fb22cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_e40e8c8f-0e48-4965-8840-2daf12b6d415" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_01eb28ef-ac63-42f6-a2c9-c843f8fb22cd" xlink:to="loc_us-gaap_CollaborativeArrangementMember_e40e8c8f-0e48-4965-8840-2daf12b6d415" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_HealxLicenseAndOptionAgreementMember_5dd42088-a86b-461a-98e6-8f77e00e9280" xlink:href="ovid-20230630.xsd#ovid_HealxLicenseAndOptionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_01eb28ef-ac63-42f6-a2c9-c843f8fb22cd" xlink:to="loc_ovid_HealxLicenseAndOptionAgreementMember_5dd42088-a86b-461a-98e6-8f77e00e9280" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MarinusLicenseAgreementMember_9725ff5c-03f1-45e9-92f8-c21d4c624142" xlink:href="ovid-20230630.xsd#ovid_MarinusLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_01eb28ef-ac63-42f6-a2c9-c843f8fb22cd" xlink:to="loc_ovid_MarinusLicenseAgreementMember_9725ff5c-03f1-45e9-92f8-c21d4c624142" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_PatentLicenseAgreementMember_75e86e84-8005-4c7c-b9c4-5691b50269af" xlink:href="ovid-20230630.xsd#ovid_PatentLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_01eb28ef-ac63-42f6-a2c9-c843f8fb22cd" xlink:to="loc_ovid_PatentLicenseAgreementMember_75e86e84-8005-4c7c-b9c4-5691b50269af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_38c15dc9-a5de-4404-9cc7-0c868523112b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d80c429-1b84-43a4-8f81-6566f04e9209" xlink:to="loc_dei_LegalEntityAxis_38c15dc9-a5de-4404-9cc7-0c868523112b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_38c15dc9-a5de-4404-9cc7-0c868523112b_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_38c15dc9-a5de-4404-9cc7-0c868523112b" xlink:to="loc_dei_EntityDomain_38c15dc9-a5de-4404-9cc7-0c868523112b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b63b851f-b574-4752-b1f1-56af20c40847" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_38c15dc9-a5de-4404-9cc7-0c868523112b" xlink:to="loc_dei_EntityDomain_b63b851f-b574-4752-b1f1-56af20c40847" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_TakedaPharmaceuticalCompanyLimitedMember_bf95a4b9-c5c6-4dfb-a00f-8e96b1a9683e" xlink:href="ovid-20230630.xsd#ovid_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b63b851f-b574-4752-b1f1-56af20c40847" xlink:to="loc_ovid_TakedaPharmaceuticalCompanyLimitedMember_bf95a4b9-c5c6-4dfb-a00f-8e96b1a9683e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MarinusPharmaceuticalsIncMember_5cab7436-fae1-42a3-be22-88424c3c5921" xlink:href="ovid-20230630.xsd#ovid_MarinusPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b63b851f-b574-4752-b1f1-56af20c40847" xlink:to="loc_ovid_MarinusPharmaceuticalsIncMember_5cab7436-fae1-42a3-be22-88424c3c5921" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_312b85e9-85cf-419f-abe7-165ba6084601" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d80c429-1b84-43a4-8f81-6566f04e9209" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_312b85e9-85cf-419f-abe7-165ba6084601" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_312b85e9-85cf-419f-abe7-165ba6084601_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_312b85e9-85cf-419f-abe7-165ba6084601" xlink:to="loc_us-gaap_RelatedPartyDomain_312b85e9-85cf-419f-abe7-165ba6084601_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_cf3750b1-1ba0-42d9-9f89-5f342db48047" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_312b85e9-85cf-419f-abe7-165ba6084601" xlink:to="loc_us-gaap_RelatedPartyDomain_cf3750b1-1ba0-42d9-9f89-5f342db48047" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_7c5b6a20-ce28-4413-b466-ba5437d8a210" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_cf3750b1-1ba0-42d9-9f89-5f342db48047" xlink:to="loc_us-gaap_RelatedPartyMember_7c5b6a20-ce28-4413-b466-ba5437d8a210" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_71fa09e5-6279-417c-b4af-60016481a445" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d80c429-1b84-43a4-8f81-6566f04e9209" xlink:to="loc_us-gaap_StatementClassOfStockAxis_71fa09e5-6279-417c-b4af-60016481a445" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_71fa09e5-6279-417c-b4af-60016481a445_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_71fa09e5-6279-417c-b4af-60016481a445" xlink:to="loc_us-gaap_ClassOfStockDomain_71fa09e5-6279-417c-b4af-60016481a445_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_829240a0-7791-4277-ac7e-de898f37967e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_71fa09e5-6279-417c-b4af-60016481a445" xlink:to="loc_us-gaap_ClassOfStockDomain_829240a0-7791-4277-ac7e-de898f37967e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_39195e8d-1e07-4b29-9faf-1dd554321de4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_829240a0-7791-4277-ac7e-de898f37967e" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_39195e8d-1e07-4b29-9faf-1dd554321de4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/NETLOSSPERSHAREScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageSharesOutstandingDetail" xlink:type="simple" xlink:href="ovid-20230630.xsd#NETLOSSPERSHAREScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageSharesOutstandingDetail"/>
  <link:definitionLink xlink:role="http://www.ovidrx.com/role/NETLOSSPERSHAREScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageSharesOutstandingDetail" xlink:type="extended" id="i4f09bf2f8d1444a190bd3a229d7e0880_NETLOSSPERSHAREScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageSharesOutstandingDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cf23fd84-2c76-430b-9c19-4a53ccbb679f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e2ed304c-a8aa-4e41-9e63-d341ddb64dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cf23fd84-2c76-430b-9c19-4a53ccbb679f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e2ed304c-a8aa-4e41-9e63-d341ddb64dbb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e1248751-25be-459b-8afe-6b13ef24a1aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cf23fd84-2c76-430b-9c19-4a53ccbb679f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e1248751-25be-459b-8afe-6b13ef24a1aa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_78129ad4-9f5b-40c2-8672-08c9fb5458d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e1248751-25be-459b-8afe-6b13ef24a1aa" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_78129ad4-9f5b-40c2-8672-08c9fb5458d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_78129ad4-9f5b-40c2-8672-08c9fb5458d4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_78129ad4-9f5b-40c2-8672-08c9fb5458d4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_78129ad4-9f5b-40c2-8672-08c9fb5458d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dd01bc73-ac56-4fa4-be13-3426adb2fd9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_78129ad4-9f5b-40c2-8672-08c9fb5458d4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dd01bc73-ac56-4fa4-be13-3426adb2fd9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_20bd633d-35f6-4119-be30-a5fa06dccecd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dd01bc73-ac56-4fa4-be13-3426adb2fd9e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_20bd633d-35f6-4119-be30-a5fa06dccecd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_SeriesAConvertiblePreferredStockMember_4deba7fe-8625-457d-9ec6-bfd683985e80" xlink:href="ovid-20230630.xsd#ovid_SeriesAConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dd01bc73-ac56-4fa4-be13-3426adb2fd9e" xlink:to="loc_ovid_SeriesAConvertiblePreferredStockMember_4deba7fe-8625-457d-9ec6-bfd683985e80" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>ovid-20230630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:bac70ec3-5ee7-4b97-a85c-498b4f8489b1,g:499e488f-fe63-4d10-9e0b-b93d763975f8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_643802de-c3e4-419b-84c5-8f0a67fc3ece_terseLabel_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land subject to ground leases (sqft)</link:label>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_label_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land Subject to Ground Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandSubjectToGroundLeases" xlink:to="lab_us-gaap_LandSubjectToGroundLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_1692a546-362b-4c41-a3e9-46e04990fbfc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonemployee</link:label>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonemployee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_e27d022b-c581-45b2-b0a9-e9a542494e40_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_fe585d6d-6504-40b6-9da2-1f1a6bf09245_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_6f16f15a-9bc0-4a17-b559-d3eeb0b304cc_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_0ee647e4-15da-4c8c-9f89-f0af89f77afd_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_fd40b076-b77e-4afa-aa8c-8adf408e6e22_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_PercentageOfDevelopmentCosts_f5b7f3c6-f182-49c7-b444-3b4be5318d12_terseLabel_en-US" xlink:label="lab_ovid_PercentageOfDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of development costs</link:label>
    <link:label id="lab_ovid_PercentageOfDevelopmentCosts_label_en-US" xlink:label="lab_ovid_PercentageOfDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Development Costs</link:label>
    <link:label id="lab_ovid_PercentageOfDevelopmentCosts_documentation_en-US" xlink:label="lab_ovid_PercentageOfDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of development costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_PercentageOfDevelopmentCosts" xlink:href="ovid-20230630.xsd#ovid_PercentageOfDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_PercentageOfDevelopmentCosts" xlink:to="lab_ovid_PercentageOfDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d39be6c4-4b7a-4f23-be3e-0fa7f4af4672_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_646b9245-b843-4984-b3ef-5206e105c4b0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation, term of plan</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_37609ae6-8735-4825-aaa3-181a290f7b7d_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued for each share of convertible preferred stock that is converted (in shares)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockLiquidationPreference_82bc41d4-aa4f-42a6-9cc6-cc3ffc858b64_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, liquidation preference per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockLiquidationPreference_label_en-US" xlink:label="lab_us-gaap_PreferredStockLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Liquidation Preference Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockLiquidationPreference" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreference"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockLiquidationPreference" xlink:to="lab_us-gaap_PreferredStockLiquidationPreference" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02e296ed-28b9-45fe-b44a-664ca006c661_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_186aea55-2100-473b-95bb-6c4aa0c6c8c5_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_96fa2356-d0bd-46a0-a523-df6685bec1d1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease terms</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_541350f3-5b2f-4d9c-b0b7-9d7f820015f3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_81aa80dc-2c25-4d11-bf21-2a190b16c3df_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_fff29a22-7dbe-4065-85da-574e9c745432_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-based Option Awards</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_891e6840-57fa-4065-9de5-512d57dc1bf5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_bb360d36-2c56-4822-855a-86718cbfb178_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation, exercisable period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ac1df5b6-df3c-4dc2-8b00-c82851091d56_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_03ce393c-34f3-4d7d-bbd9-75559b9e47da_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock_f195c262-f8a0-4151-8c54-5ee152c3c530_terseLabel_en-US" xlink:label="lab_ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial ownership limitations, percentage of issued and outstanding common stock</link:label>
    <link:label id="lab_ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock_label_en-US" xlink:label="lab_ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial Ownership Limitations, Percentage of Issued and Outstanding Common Stock</link:label>
    <link:label id="lab_ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock_documentation_en-US" xlink:label="lab_ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial Ownership Limitations, Percentage of Issued and Outstanding Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock" xlink:href="ovid-20230630.xsd#ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock" xlink:to="lab_ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_59269475-e1cd-454b-8865-ab46b05c8175_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security deposit</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_89e94bf3-bf31-4a79-8152-ae254eacdeee_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_31299087-4c69-4f9f-87e9-f893b08880c5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a6e0d9c7-5de1-434c-ae5d-cd481ac5afae_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement_2a0ca720-2ba3-4ff9-93a9-8bc02c4e3b65_terseLabel_en-US" xlink:label="lab_ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum number of product covered under license agreement</link:label>
    <link:label id="lab_ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement_label_en-US" xlink:label="lab_ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Number Of Product Covered Under License Agreement</link:label>
    <link:label id="lab_ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement_documentation_en-US" xlink:label="lab_ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum number of product covered under license agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement" xlink:href="ovid-20230630.xsd#ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement" xlink:to="lab_ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_eef9942f-79d1-4ce3-98a0-83adc3949296_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_9b8486ac-b2d9-48fc-8c28-debcd7d6e8fc_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_02000466-8054-425d-b430-adf7af1d953f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock_3b8446ff-cd86-4034-8410-da133fbd1fbb_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of preferred stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Preferred Stock and Preference Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_TwoThousandSeventeenEquityIncentivePlanMember_1af8635b-60a7-45de-8559-bef188e51f34_terseLabel_en-US" xlink:label="lab_ovid_TwoThousandSeventeenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Equity Incentive Plan</link:label>
    <link:label id="lab_ovid_TwoThousandSeventeenEquityIncentivePlanMember_label_en-US" xlink:label="lab_ovid_TwoThousandSeventeenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Seventeen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_ovid_TwoThousandSeventeenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_ovid_TwoThousandSeventeenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 equity incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_TwoThousandSeventeenEquityIncentivePlanMember" xlink:href="ovid-20230630.xsd#ovid_TwoThousandSeventeenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_TwoThousandSeventeenEquityIncentivePlanMember" xlink:to="lab_ovid_TwoThousandSeventeenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6a89a435-b22f-4567-93c6-eeb33cda2817_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_77bafab8-dac0-48f7-8037-688e45b63345_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 10,000,000 shares authorized; Series A convertible preferred stock, 10,000 shares designated, 1,250 shares issued and outstanding at June&#160;30, 2023 and December&#160;31, 2022</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_7002600a-35ad-4320-a905-39f653465cf9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_25557102-50d1-44a7-8291-cbe750cd63f0_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5d555a2f-d6ea-4855-a103-759299fec6a8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment_a0ca702f-57b9-4b2f-ab91-4ccc2c02d62e_terseLabel_en-US" xlink:label="lab_ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront non-creditable one-time license issuance fee payment</link:label>
    <link:label id="lab_ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment_label_en-US" xlink:label="lab_ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Non Creditable One Time License Issuance Fee Payment</link:label>
    <link:label id="lab_ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment_documentation_en-US" xlink:label="lab_ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront non-creditable one-time license issuance fee payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment" xlink:href="ovid-20230630.xsd#ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment" xlink:to="lab_ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b4f68bfa-2659-4759-bb0f-60878eccce81_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b080b97d-e178-495c-b7e1-bc700282ccfd_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60e73529-fd28-409a-9b45-2bf91c0c19fb_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_d2895872-263b-4c67-bf8e-3a2a425e8685_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_86c20bdc-3327-43b2-a91a-983c88b26752_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6c32b3b3-3ed5-4c97-804e-5029e4924059_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_646ca359-3c41-48c5-9ef0-6eb0518f5719_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of option on grant date</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate_aad49a49-c522-4586-986b-9117a3a1d6ec_terseLabel_en-US" xlink:label="lab_ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Days immediately preceding the execution date</link:label>
    <link:label id="lab_ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate_label_en-US" xlink:label="lab_ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Issuance , Period Immediately Preceding Execution Date</link:label>
    <link:label id="lab_ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate_documentation_en-US" xlink:label="lab_ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Issuance , Period Immediately Preceding Execution Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate" xlink:href="ovid-20230630.xsd#ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate" xlink:to="lab_ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_4f668132-89fb-474f-af44-9fe458131c00_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_be6bb8dd-cd6c-4274-927e-e9576cf1ba7b_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_3f334661-9f63-4fc3-9d70-6631c8f0530d_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f93f21fb-5c3c-4d0a-9a58-9177dc5d9652_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_96b93038-066e-4152-a766-8b1c4161e5f0_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_4ba9bf3f-1e62-41ad-a563-2c9f4fc1899b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_3355ccde-69c5-419d-8c3e-bb49fde597dc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b46668d2-b58e-4247-abc3-862d0510cead_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_LicenseAgreementMilestonePayments_c90161cb-e638-4afd-8ae9-cb95fd7681f9_terseLabel_en-US" xlink:label="lab_ovid_LicenseAgreementMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement milestone payments (up to)</link:label>
    <link:label id="lab_ovid_LicenseAgreementMilestonePayments_label_en-US" xlink:label="lab_ovid_LicenseAgreementMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Milestone Payments</link:label>
    <link:label id="lab_ovid_LicenseAgreementMilestonePayments_documentation_en-US" xlink:label="lab_ovid_LicenseAgreementMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global commercial and regulatory milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LicenseAgreementMilestonePayments" xlink:href="ovid-20230630.xsd#ovid_LicenseAgreementMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_LicenseAgreementMilestonePayments" xlink:to="lab_ovid_LicenseAgreementMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_835cedde-6f67-4d9a-8427-a85bfdbb0ff3_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a9187d8c-0644-4e61-af1f-0de0feef5003_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, unrealized holding losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_244e348e-14af-4c5b-acce-96db217f2095_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod_6f8830d0-538a-48ac-992c-0bfc0a9dfc37_terseLabel_en-US" xlink:label="lab_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowable voting right percentage of outstanding common stock holders upon notice of days</link:label>
    <link:label id="lab_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod_label_en-US" xlink:label="lab_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowable Owning Percentage Of Outstanding Common Stock By Associates Or Affiliates, Notice Period</link:label>
    <link:label id="lab_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod_documentation_en-US" xlink:label="lab_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowable Owning Percentage Of Outstanding Common Stock By Associates Or Affiliates, Notice Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod" xlink:href="ovid-20230630.xsd#ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod" xlink:to="lab_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_6f2e40bc-a261-4866-b411-7bbc5d793663_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8b380ae2-f307-4b20-a0b4-fe57921b9672_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation, graded vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_da57b15d-0229-46ae-96b5-dc68570d223b_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_41002a2e-2378-4236-9b16-322d5c0dc581_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_f54748b2-21ce-4b20-808c-97f10fc77ff3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingLoss_3bac64ec-72fc-41a7-bc2c-8637be10a86a_negatedTotalLabel_en-US" xlink:label="lab_ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and marketable securities, unrealized holding losses</link:label>
    <link:label id="lab_ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingLoss_label_en-US" xlink:label="lab_ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax, Including Cash Equivalents, Accumulated Unrealized Holding Loss</link:label>
    <link:label id="lab_ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingLoss_documentation_en-US" xlink:label="lab_ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax, Including Cash Equivalents, Accumulated Unrealized Holding Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingLoss" xlink:href="ovid-20230630.xsd#ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingLoss" xlink:to="lab_ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_9f911666-c534-4b54-a872-45d79efe5664_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_ea9dbfa9-0e8b-4ea8-90a0-bb39e2be7452_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_5b1d71bd-e4ad-458e-9f1b-6a29982f5f4a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e68829af-5c63-4f93-a028-d90c1bc6b7cb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of company's common stock reserved for issuance under the plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6978918c-a0e9-434f-95b9-58b06091e252_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_9c467493-233a-41f8-982a-e5c188957806_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_18296f58-532b-4018-b8ef-f6ffed96e2a3_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_74d47327-a947-4e37-96e6-7240c1bf25cc_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_a9925617-5007-4f9c-8a1f-7d28ce07c593_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_9b264cfc-bb4a-4715-a95d-4f8a2f4f3288_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (loss) gain on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_2fcb5330-5d21-4b10-ae37-7f341659faed_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_8268482f-2d63-4810-8f16-5fc88d52cd3a_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_edaec067-fc71-499f-bece-f714ee613fc9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_2e0c836e-e19d-46ea-873e-5dba1938c69e_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_MarinusTherapeuticsIncMember_afb54d40-2107-4fa9-853b-10986ed79bf8_terseLabel_en-US" xlink:label="lab_ovid_MarinusTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marinus Therapeutics, Inc</link:label>
    <link:label id="lab_ovid_MarinusTherapeuticsIncMember_label_en-US" xlink:label="lab_ovid_MarinusTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marinus Therapeutics Inc [Member]</link:label>
    <link:label id="lab_ovid_MarinusTherapeuticsIncMember_documentation_en-US" xlink:label="lab_ovid_MarinusTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marinus therapeutics inc member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MarinusTherapeuticsIncMember" xlink:href="ovid-20230630.xsd#ovid_MarinusTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_MarinusTherapeuticsIncMember" xlink:to="lab_ovid_MarinusTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireLongtermInvestments_89d55cfe-4b51-4360-854f-969bb4aa3d15_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of long-term equity investment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireLongtermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_6e36aede-182c-4b8d-8c08-b8997119ada0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_daadf01e-32c7-4626-8f64-d0430839ee68_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f0377086-99df-44d4-95e9-7a03962e8e46_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Commitments Under the non-cancelable Operating Lease</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_748478d2-5290-46c7-9451-e4dac65f2b94_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_9d67ffd1-be48-449e-9d38-d5144015e420_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Shares Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusAxis_a1587ee1-d54f-4601-b147-0fec2780aa86_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusAxis_label_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusAxis" xlink:to="lab_us-gaap_GranteeStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_LesseeOperatingLeaseBaseRent_c286770f-b3a1-42e0-ad46-3101ba67c5ef_terseLabel_en-US" xlink:label="lab_ovid_LesseeOperatingLeaseBaseRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent lease</link:label>
    <link:label id="lab_ovid_LesseeOperatingLeaseBaseRent_label_en-US" xlink:label="lab_ovid_LesseeOperatingLeaseBaseRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease, Base Rent</link:label>
    <link:label id="lab_ovid_LesseeOperatingLeaseBaseRent_documentation_en-US" xlink:label="lab_ovid_LesseeOperatingLeaseBaseRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease, Base Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LesseeOperatingLeaseBaseRent" xlink:href="ovid-20230630.xsd#ovid_LesseeOperatingLeaseBaseRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_LesseeOperatingLeaseBaseRent" xlink:to="lab_ovid_LesseeOperatingLeaseBaseRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_37f5fe5f-c788-4844-a4ff-2901eaeac9f8_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Operating Lease Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_FirstPaymentDueUponCompletionOfFirstPhase_756555ab-eda4-46da-b13d-2a0228896782_terseLabel_en-US" xlink:label="lab_ovid_FirstPaymentDueUponCompletionOfFirstPhase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First payment due upon completion of first phase</link:label>
    <link:label id="lab_ovid_FirstPaymentDueUponCompletionOfFirstPhase_label_en-US" xlink:label="lab_ovid_FirstPaymentDueUponCompletionOfFirstPhase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Payment Due Upon Completion Of First Phase</link:label>
    <link:label id="lab_ovid_FirstPaymentDueUponCompletionOfFirstPhase_documentation_en-US" xlink:label="lab_ovid_FirstPaymentDueUponCompletionOfFirstPhase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First payment due upon completion of first phase.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_FirstPaymentDueUponCompletionOfFirstPhase" xlink:href="ovid-20230630.xsd#ovid_FirstPaymentDueUponCompletionOfFirstPhase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_FirstPaymentDueUponCompletionOfFirstPhase" xlink:to="lab_ovid_FirstPaymentDueUponCompletionOfFirstPhase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_c5f4011e-a576-4e74-aa1a-051d3c72d4eb_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_82d6e8f8-fad0-4779-acd5-c1f9d98bcfa1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_ChangeInAccruedInterestAndAccretionOfDiscountsShortTermInvestments_d3e8ef67-4f78-4822-8f52-8be1156d3f7d_terseLabel_en-US" xlink:label="lab_ovid_ChangeInAccruedInterestAndAccretionOfDiscountsShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in accrued interest and accretion of discount on marketable securities</link:label>
    <link:label id="lab_ovid_ChangeInAccruedInterestAndAccretionOfDiscountsShortTermInvestments_label_en-US" xlink:label="lab_ovid_ChangeInAccruedInterestAndAccretionOfDiscountsShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Accrued Interest And Accretion Of Discounts Short Term Investments</link:label>
    <link:label id="lab_ovid_ChangeInAccruedInterestAndAccretionOfDiscountsShortTermInvestments_documentation_en-US" xlink:label="lab_ovid_ChangeInAccruedInterestAndAccretionOfDiscountsShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest and accretion of discounts, short term investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_ChangeInAccruedInterestAndAccretionOfDiscountsShortTermInvestments" xlink:href="ovid-20230630.xsd#ovid_ChangeInAccruedInterestAndAccretionOfDiscountsShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_ChangeInAccruedInterestAndAccretionOfDiscountsShortTermInvestments" xlink:to="lab_ovid_ChangeInAccruedInterestAndAccretionOfDiscountsShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_CashEquivalentsAmortizedCost_ca686f99-b59c-4d41-906c-60ae09e046bd_totalLabel_en-US" xlink:label="lab_ovid_CashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents, amortized cost</link:label>
    <link:label id="lab_ovid_CashEquivalentsAmortizedCost_label_en-US" xlink:label="lab_ovid_CashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, Amortized Cost</link:label>
    <link:label id="lab_ovid_CashEquivalentsAmortizedCost_documentation_en-US" xlink:label="lab_ovid_CashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CashEquivalentsAmortizedCost" xlink:href="ovid-20230630.xsd#ovid_CashEquivalentsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_CashEquivalentsAmortizedCost" xlink:to="lab_ovid_CashEquivalentsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_CollaborationAndOptionAgreementResearchPlanAndBudgetExpectedCosts_854a40c6-cc00-4d13-9aef-8401d735603c_terseLabel_en-US" xlink:label="lab_ovid_CollaborationAndOptionAgreementResearchPlanAndBudgetExpectedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research plan and budget, expected costs</link:label>
    <link:label id="lab_ovid_CollaborationAndOptionAgreementResearchPlanAndBudgetExpectedCosts_label_en-US" xlink:label="lab_ovid_CollaborationAndOptionAgreementResearchPlanAndBudgetExpectedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Option Agreement, Research Plan And Budget, Expected Costs</link:label>
    <link:label id="lab_ovid_CollaborationAndOptionAgreementResearchPlanAndBudgetExpectedCosts_documentation_en-US" xlink:label="lab_ovid_CollaborationAndOptionAgreementResearchPlanAndBudgetExpectedCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Option Agreement, Research Plan And Budget, Expected Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CollaborationAndOptionAgreementResearchPlanAndBudgetExpectedCosts" xlink:href="ovid-20230630.xsd#ovid_CollaborationAndOptionAgreementResearchPlanAndBudgetExpectedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_CollaborationAndOptionAgreementResearchPlanAndBudgetExpectedCosts" xlink:to="lab_ovid_CollaborationAndOptionAgreementResearchPlanAndBudgetExpectedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost_af7622e3-a167-4372-8113-f56f4b0faae2_totalLabel_en-US" xlink:label="lab_ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and marketable securities, amortized cost</link:label>
    <link:label id="lab_ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost_label_en-US" xlink:label="lab_ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents And Available-for-sale Debt Securities, Amortized Cost</link:label>
    <link:label id="lab_ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost_documentation_en-US" xlink:label="lab_ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents And Available-for-sale Debt Securities, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost" xlink:href="ovid-20230630.xsd#ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost" xlink:to="lab_ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_915499e3-b083-426a-8662-d3f1a8a4e738_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive securities excluded from computations of diluted weighted average shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_MarinusLicenseAgreementMember_fd88d3e2-3707-4dbb-bee5-3d1b4c7be37f_terseLabel_en-US" xlink:label="lab_ovid_MarinusLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marinus License Agreement</link:label>
    <link:label id="lab_ovid_MarinusLicenseAgreementMember_label_en-US" xlink:label="lab_ovid_MarinusLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marinus License Agreement [Member]</link:label>
    <link:label id="lab_ovid_MarinusLicenseAgreementMember_documentation_en-US" xlink:label="lab_ovid_MarinusLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">marinus license agreement member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MarinusLicenseAgreementMember" xlink:href="ovid-20230630.xsd#ovid_MarinusLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_MarinusLicenseAgreementMember" xlink:to="lab_ovid_MarinusLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_0502d52c-4ac2-4beb-917f-493e982a6c8b_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingGain_2b0bd182-208f-41ea-8d74-eb8416fcaec8_totalLabel_en-US" xlink:label="lab_ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingGain" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and marketable securities, unrealized holding gains</link:label>
    <link:label id="lab_ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingGain_label_en-US" xlink:label="lab_ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax, Including Cash Equivalents, Accumulated Unrealized Holding Gain</link:label>
    <link:label id="lab_ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingGain_documentation_en-US" xlink:label="lab_ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax, Including Cash Equivalents, Accumulated Unrealized Holding Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingGain" xlink:href="ovid-20230630.xsd#ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingGain" xlink:to="lab_ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_6b1a220e-5fbc-4f78-9a2c-12dc44848f6b_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_CashEquivalentsUnrealizedHoldingLosses_48dc43e3-2894-4dbc-8ac3-17309cac3ff3_negatedTerseLabel_en-US" xlink:label="lab_ovid_CashEquivalentsUnrealizedHoldingLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents, unrealized holding losses</link:label>
    <link:label id="lab_ovid_CashEquivalentsUnrealizedHoldingLosses_label_en-US" xlink:label="lab_ovid_CashEquivalentsUnrealizedHoldingLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, Unrealized Holding Losses</link:label>
    <link:label id="lab_ovid_CashEquivalentsUnrealizedHoldingLosses_documentation_en-US" xlink:label="lab_ovid_CashEquivalentsUnrealizedHoldingLosses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, Unrealized Holding Losses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CashEquivalentsUnrealizedHoldingLosses" xlink:href="ovid-20230630.xsd#ovid_CashEquivalentsUnrealizedHoldingLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_CashEquivalentsUnrealizedHoldingLosses" xlink:to="lab_ovid_CashEquivalentsUnrealizedHoldingLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_5f0f0107-aee1-4db0-9c0a-26465a560548_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5c874c19-9a61-447d-a27e-c5c6988590b8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_82ca1c31-162d-4757-940a-c42b26ec123a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d204f0a5-bf38-46a8-bd22-222db179f2d4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life in Years, Options outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_dad1dfeb-cbc7-4f69-af2c-aa6949aad337_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset in exchange for lease liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_de7c32bd-2a89-4498-a616-4cd770169839_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_99052005-541d-43db-972b-0066b985aa0d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation, number of shares purchased (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_d25d2ab3-444e-4d15-ba4b-55cf39a73d5a_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_fd485254-23fd-496a-a06b-b1b7144d648c_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_UpfrontCashPayment_d9e2088d-2013-4f7a-8935-a6292dea2fe9_terseLabel_en-US" xlink:label="lab_ovid_UpfrontCashPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront cash payment</link:label>
    <link:label id="lab_ovid_UpfrontCashPayment_label_en-US" xlink:label="lab_ovid_UpfrontCashPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Cash Payment</link:label>
    <link:label id="lab_ovid_UpfrontCashPayment_documentation_en-US" xlink:label="lab_ovid_UpfrontCashPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Cash Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_UpfrontCashPayment" xlink:href="ovid-20230630.xsd#ovid_UpfrontCashPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_UpfrontCashPayment" xlink:to="lab_ovid_UpfrontCashPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_7791dd37-0a27-4ef5-a1dd-76151987680f_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_85a946ef-2234-43e5-a962-3a6deaa1a3ed_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_a0160352-a919-4e69-97d1-792bfc10d514_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion, lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_ad6548eb-aae9-453e-a878-6b9b521a88da_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_01db66be-8d2f-4508-9fe8-ae9f1af07944_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock from exercise of stock options and purchases from employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_afda1e92-7070-4f9c-a3da-7a611ba7cab2_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_72d484fc-1967-4c0f-b57a-cbfe301afdab_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales/maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_cc1fdb82-3044-4335-99da-ea73d0f52945_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e108301d-9625-48e3-85d5-5123dee35081_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_3e236c21-fdfb-450d-a90d-e00a6f5aaabc_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term equity investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_b459fd88-84a5-4509-9188-0cde6f070b81_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net of accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_bef15ab1-c938-4ec4-bfb4-b373ddce9c6e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_04be6d47-23d9-40fc-99f7-02fa44b75897_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_1d7530c2-beb7-4e6f-a31b-32de67855f07_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_73e0b77f-8b30-42e2-98be-3e86c0f294d6_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_84a7b18c-44d9-4a32-b8e9-e7cf8c14b130_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_0402e235-796c-43fe-942b-f056b4b47d01_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e05f6745-ec97-40c4-8bc4-acc29a8abc00_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_a19f71a6-db24-4b08-abb9-d5a5266aca5c_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_a05b320f-b158-460b-b737-7bd636eed2fe_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_842a95ef-b59b-49e4-bdfe-9df7d2c3b245_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_UpfrontPaymentReceivable_f00949e9-73c7-4a4a-bbb9-da69873b7e0d_terseLabel_en-US" xlink:label="lab_ovid_UpfrontPaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment under royalty and termination agreement</link:label>
    <link:label id="lab_ovid_UpfrontPaymentReceivable_label_en-US" xlink:label="lab_ovid_UpfrontPaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment Receivable</link:label>
    <link:label id="lab_ovid_UpfrontPaymentReceivable_documentation_en-US" xlink:label="lab_ovid_UpfrontPaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_UpfrontPaymentReceivable" xlink:href="ovid-20230630.xsd#ovid_UpfrontPaymentReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_UpfrontPaymentReceivable" xlink:to="lab_ovid_UpfrontPaymentReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_d66513fd-f0e6-4e23-9b7c-2ecb2c95d32d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assumptions Used to Compute Fair Value of Employee Option Granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2b8ed2ec-a200-45d1-acd9-4b01d17a5aaf_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested stock options, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_d2d5f2c7-fc9c-4097-9da7-5d635e62c594_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_UpFrontFeeAmount_19b46cf1-a3da-4e17-a92d-bf5bcd1e9d81_terseLabel_en-US" xlink:label="lab_ovid_UpFrontFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up-front fee</link:label>
    <link:label id="lab_ovid_UpFrontFeeAmount_label_en-US" xlink:label="lab_ovid_UpFrontFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up Front Fee Amount</link:label>
    <link:label id="lab_ovid_UpFrontFeeAmount_documentation_en-US" xlink:label="lab_ovid_UpFrontFeeAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up-front fee amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_UpFrontFeeAmount" xlink:href="ovid-20230630.xsd#ovid_UpFrontFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_UpFrontFeeAmount" xlink:to="lab_ovid_UpFrontFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_bfa8b2f6-5047-4513-8a2c-209871fc295b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ce31a29f-4cf3-46ae-8866-99fdfc2599a6_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_893aec81-b6d0-4202-96bf-787f334b84da_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COLLABORATION AND LICENSE AGREEMENTS</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_0572510a-26c3-473b-b98f-aef16802e723_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_727644e7-7e9e-487e-a990-8d0780d97c3d_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_cf63e40e-869b-4512-ba23-4982fcc00e22_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation not yet recognized, period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates_955e93b8-a839-48db-9fbd-70184ed95179_terseLabel_en-US" xlink:label="lab_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowable voting right percentage of outstanding common stock holders</link:label>
    <link:label id="lab_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates_label_en-US" xlink:label="lab_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowable Owning Percentage Of Outstanding Common Stock By Associates Or Affiliates</link:label>
    <link:label id="lab_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates_documentation_en-US" xlink:label="lab_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowable Owning Percentage Of Outstanding Common Stock By Associates Or Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" xlink:href="ovid-20230630.xsd#ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" xlink:to="lab_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_8f1d8ec0-5472-42fb-8871-bd21cd7b3cb1_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_4ab566c4-b586-4055-8e32-1a2f6ca0f1b4_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5d1817db-18a4-4985-b92e-a70b8b6f8be3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_19ab6146-6a8f-41a1-a300-fa358e8eb5df_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents, fair value</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_0488ad9d-c558-4eee-8d7e-b23ad0d2fc1e_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_LicenseAndCollaborationAgreementExpense_f565f3b5-fddd-409c-9263-5de6be33d717_terseLabel_en-US" xlink:label="lab_ovid_LicenseAndCollaborationAgreementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party transaction expenses recognized</link:label>
    <link:label id="lab_ovid_LicenseAndCollaborationAgreementExpense_label_en-US" xlink:label="lab_ovid_LicenseAndCollaborationAgreementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Collaboration Agreement, Expense</link:label>
    <link:label id="lab_ovid_LicenseAndCollaborationAgreementExpense_documentation_en-US" xlink:label="lab_ovid_LicenseAndCollaborationAgreementExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Collaboration Agreement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LicenseAndCollaborationAgreementExpense" xlink:href="ovid-20230630.xsd#ovid_LicenseAndCollaborationAgreementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_LicenseAndCollaborationAgreementExpense" xlink:to="lab_ovid_LicenseAndCollaborationAgreementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_MarinusPharmaceuticalsIncMember_16daa0ca-0767-4c0c-9ab1-fdea24f27093_terseLabel_en-US" xlink:label="lab_ovid_MarinusPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marinus Pharmaceuticals, Inc</link:label>
    <link:label id="lab_ovid_MarinusPharmaceuticalsIncMember_label_en-US" xlink:label="lab_ovid_MarinusPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marinus Pharmaceuticals, Inc [Member]</link:label>
    <link:label id="lab_ovid_MarinusPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_ovid_MarinusPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marinus pharmaceuticals, inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MarinusPharmaceuticalsIncMember" xlink:href="ovid-20230630.xsd#ovid_MarinusPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_MarinusPharmaceuticalsIncMember" xlink:to="lab_ovid_MarinusPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_767918ec-6a3c-45a4-8035-fc0e1b6652fc_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_56767f72-1a36-4e44-9646-94bcc7cd15b6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_42aa71d8-0d8e-4641-97c6-a0da9eff699f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_LicenseAgreementMember_cca8172b-71a0-4fef-9ee9-c56af19d27ea_terseLabel_en-US" xlink:label="lab_ovid_LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement</link:label>
    <link:label id="lab_ovid_LicenseAgreementMember_label_en-US" xlink:label="lab_ovid_LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement [Member]</link:label>
    <link:label id="lab_ovid_LicenseAgreementMember_documentation_en-US" xlink:label="lab_ovid_LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LicenseAgreementMember" xlink:href="ovid-20230630.xsd#ovid_LicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_LicenseAgreementMember" xlink:to="lab_ovid_LicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_AstrazenecaMember_56baa6ee-4e2a-45f1-98e9-8e60b7b29d4e_terseLabel_en-US" xlink:label="lab_ovid_AstrazenecaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca</link:label>
    <link:label id="lab_ovid_AstrazenecaMember_label_en-US" xlink:label="lab_ovid_AstrazenecaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:label id="lab_ovid_AstrazenecaMember_documentation_en-US" xlink:label="lab_ovid_AstrazenecaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AstrazenecaMember" xlink:href="ovid-20230630.xsd#ovid_AstrazenecaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_AstrazenecaMember" xlink:to="lab_ovid_AstrazenecaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_52fd377a-8122-4af6-8e3a-5124bf776648_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_bf30ad9e-009c-47d2-bee9-9884ac74847f_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_ba3ef05f-67c9-4152-b20a-7eac30b7ef12_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Equity Instruments, Cash and Cash Equivalents, Unrealized and Realized Gains (Losses) [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2554afec-77e2-4ee2-ba90-c15a2c4e3c3d_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_dbe228c7-307c-4070-8573-f04877f5881c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f1f4f0af-5b1a-496c-b234-b18063cf4024_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction_1e5bd2fd-4c78-4c90-9a9b-6dda6b1ea1da_negatedLabel_en-US" xlink:label="lab_ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash consideration received in licensing agreement transaction</link:label>
    <link:label id="lab_ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction_label_en-US" xlink:label="lab_ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Consideration Received in Licensing Agreement Transaction</link:label>
    <link:label id="lab_ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction_documentation_en-US" xlink:label="lab_ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash consideration received in licensing agreement transaction.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction" xlink:href="ovid-20230630.xsd#ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction" xlink:to="lab_ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_LicenseOptionAgreementDevelopmentAndCommercialMilestonePayments_b9272ef7-fa98-45bb-9bb4-47f835072aa2_terseLabel_en-US" xlink:label="lab_ovid_LicenseOptionAgreementDevelopmentAndCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and commercial milestone payments</link:label>
    <link:label id="lab_ovid_LicenseOptionAgreementDevelopmentAndCommercialMilestonePayments_label_en-US" xlink:label="lab_ovid_LicenseOptionAgreementDevelopmentAndCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Option Agreement, Development and Commercial Milestone Payments</link:label>
    <link:label id="lab_ovid_LicenseOptionAgreementDevelopmentAndCommercialMilestonePayments_documentation_en-US" xlink:label="lab_ovid_LicenseOptionAgreementDevelopmentAndCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Option Agreement, Development and Commercial Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LicenseOptionAgreementDevelopmentAndCommercialMilestonePayments" xlink:href="ovid-20230630.xsd#ovid_LicenseOptionAgreementDevelopmentAndCommercialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_LicenseOptionAgreementDevelopmentAndCommercialMilestonePayments" xlink:to="lab_ovid_LicenseOptionAgreementDevelopmentAndCommercialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_AnnualLicenseMaintenanceFeePayable_dc4c7d62-b5f3-49f8-a315-9e2e651d6437_terseLabel_en-US" xlink:label="lab_ovid_AnnualLicenseMaintenanceFeePayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual license maintenance fee payable</link:label>
    <link:label id="lab_ovid_AnnualLicenseMaintenanceFeePayable_label_en-US" xlink:label="lab_ovid_AnnualLicenseMaintenanceFeePayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual License Maintenance Fee Payable</link:label>
    <link:label id="lab_ovid_AnnualLicenseMaintenanceFeePayable_documentation_en-US" xlink:label="lab_ovid_AnnualLicenseMaintenanceFeePayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual license maintenance fee payable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AnnualLicenseMaintenanceFeePayable" xlink:href="ovid-20230630.xsd#ovid_AnnualLicenseMaintenanceFeePayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_AnnualLicenseMaintenanceFeePayable" xlink:to="lab_ovid_AnnualLicenseMaintenanceFeePayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_5770ebbf-6385-4162-b7f7-8f00ef61c5eb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a7a9c0cf-da99-4cfc-a8df-57a0482cfab0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_5215189f-7ab4-4ec7-977e-febe3fbac3b7_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_99101369-a24b-4a86-9edb-73ee935e6e66_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_c29eabfe-95d8-43b8-bea4-a1b487e9f4f6_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_57983ca0-8d36-4ef0-b351-f6afc88af8d0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_AggregateOfferingPriceOfCommonStock_e2142937-58af-4e44-a2c6-8d3d934004e2_terseLabel_en-US" xlink:label="lab_ovid_AggregateOfferingPriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from offering, value</link:label>
    <link:label id="lab_ovid_AggregateOfferingPriceOfCommonStock_label_en-US" xlink:label="lab_ovid_AggregateOfferingPriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Offering Price Of Common Stock</link:label>
    <link:label id="lab_ovid_AggregateOfferingPriceOfCommonStock_documentation_en-US" xlink:label="lab_ovid_AggregateOfferingPriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate offering price of common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AggregateOfferingPriceOfCommonStock" xlink:href="ovid-20230630.xsd#ovid_AggregateOfferingPriceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_AggregateOfferingPriceOfCommonStock" xlink:to="lab_ovid_AggregateOfferingPriceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_65893bf0-c022-4f8d-8ccf-82a12955a1e3_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_65bb2320-09f7-4039-b51a-8f31a170750d_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_LicenseAgreementConsiderationSharesIssued_bf313292-b6b1-439a-9191-ebc613171b9b_terseLabel_en-US" xlink:label="lab_ovid_LicenseAgreementConsiderationSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, consideration (in shares)</link:label>
    <link:label id="lab_ovid_LicenseAgreementConsiderationSharesIssued_label_en-US" xlink:label="lab_ovid_LicenseAgreementConsiderationSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Consideration, Shares Issued</link:label>
    <link:label id="lab_ovid_LicenseAgreementConsiderationSharesIssued_documentation_en-US" xlink:label="lab_ovid_LicenseAgreementConsiderationSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Consideration, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LicenseAgreementConsiderationSharesIssued" xlink:href="ovid-20230630.xsd#ovid_LicenseAgreementConsiderationSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_LicenseAgreementConsiderationSharesIssued" xlink:to="lab_ovid_LicenseAgreementConsiderationSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_9834a958-c0d4-4169-89ad-9ac6769feaa2_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_cfa22155-1963-48f3-a555-6576462911ec_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease_55c412c8-1116-4589-9b97-a48e625e8185_terseLabel_en-US" xlink:label="lab_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage increase, outstanding stock maximum</link:label>
    <link:label id="lab_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease_label_en-US" xlink:label="lab_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum, Increase</link:label>
    <link:label id="lab_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease_documentation_en-US" xlink:label="lab_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum, Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease" xlink:href="ovid-20230630.xsd#ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease" xlink:to="lab_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_fc53e2a0-9cea-4a4c-a98a-5af1ccaf2a6d_verboseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_2ca85368-ead9-44c1-b05b-e0f9f3de56d5_terseLabel_en-US" xlink:label="lab_ovid_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ovid_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_label_en-US" xlink:label="lab_ovid_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Due after Year Four</link:label>
    <link:label id="lab_ovid_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_documentation_en-US" xlink:label="lab_ovid_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Due after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:href="ovid-20230630.xsd#ovid_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:to="lab_ovid_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_UpFrontPayment_3ca70e28-7c7e-4b76-9d90-2f82216b8e04_terseLabel_en-US" xlink:label="lab_ovid_UpFrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_ovid_UpFrontPayment_label_en-US" xlink:label="lab_ovid_UpFrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up Front Payment</link:label>
    <link:label id="lab_ovid_UpFrontPayment_documentation_en-US" xlink:label="lab_ovid_UpFrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up front Payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_UpFrontPayment" xlink:href="ovid-20230630.xsd#ovid_UpFrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_UpFrontPayment" xlink:to="lab_ovid_UpFrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_ConsiderationPayableForRightsGrant_91f18601-c89a-4a4d-9fee-59495ae55cc0_terseLabel_en-US" xlink:label="lab_ovid_ConsiderationPayableForRightsGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration payable for rights grant</link:label>
    <link:label id="lab_ovid_ConsiderationPayableForRightsGrant_label_en-US" xlink:label="lab_ovid_ConsiderationPayableForRightsGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration Payable For Rights Grant</link:label>
    <link:label id="lab_ovid_ConsiderationPayableForRightsGrant_documentation_en-US" xlink:label="lab_ovid_ConsiderationPayableForRightsGrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration payable for rights grant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_ConsiderationPayableForRightsGrant" xlink:href="ovid-20230630.xsd#ovid_ConsiderationPayableForRightsGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_ConsiderationPayableForRightsGrant" xlink:to="lab_ovid_ConsiderationPayableForRightsGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_370150cf-2fd9-49c8-a975-4dadeea2cd4b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_3ad44468-ba37-4969-b70d-3d500de3565f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_28eb9452-7b2a-4fca-ab0e-dded65d11c23_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_f9e6d6c9-cca0-4d16-9892-343f30e60f96_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c50f754e-fdc1-495a-aea0-81d3ad646c35_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_LicenseOptionAgreementExtensionPeriod_f42b8c06-958b-40ae-8ca8-00455a0a5644_terseLabel_en-US" xlink:label="lab_ovid_LicenseOptionAgreementExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted option extension period</link:label>
    <link:label id="lab_ovid_LicenseOptionAgreementExtensionPeriod_label_en-US" xlink:label="lab_ovid_LicenseOptionAgreementExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Option Agreement, Extension Period</link:label>
    <link:label id="lab_ovid_LicenseOptionAgreementExtensionPeriod_documentation_en-US" xlink:label="lab_ovid_LicenseOptionAgreementExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Option Agreement, Extension Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LicenseOptionAgreementExtensionPeriod" xlink:href="ovid-20230630.xsd#ovid_LicenseOptionAgreementExtensionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_LicenseOptionAgreementExtensionPeriod" xlink:to="lab_ovid_LicenseOptionAgreementExtensionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum_ddc30d9b-7981-4b28-bfbe-aed196f8b8fc_terseLabel_en-US" xlink:label="lab_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, reserved for future issuance increase (in shares)</link:label>
    <link:label id="lab_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum_label_en-US" xlink:label="lab_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized, Maximum</link:label>
    <link:label id="lab_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum_documentation_en-US" xlink:label="lab_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum" xlink:href="ovid-20230630.xsd#ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum" xlink:to="lab_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_LicenseAgreementDevelopmentMilestoneApprovalsProductThreshold_adeebb5b-bcc2-4eeb-9dc4-5ec70204950f_terseLabel_en-US" xlink:label="lab_ovid_LicenseAgreementDevelopmentMilestoneApprovalsProductThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developmental milestone approvals, number of products (at least)</link:label>
    <link:label id="lab_ovid_LicenseAgreementDevelopmentMilestoneApprovalsProductThreshold_label_en-US" xlink:label="lab_ovid_LicenseAgreementDevelopmentMilestoneApprovalsProductThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Development Milestone Approvals, Product Threshold</link:label>
    <link:label id="lab_ovid_LicenseAgreementDevelopmentMilestoneApprovalsProductThreshold_documentation_en-US" xlink:label="lab_ovid_LicenseAgreementDevelopmentMilestoneApprovalsProductThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Development Milestone Approvals, Product Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LicenseAgreementDevelopmentMilestoneApprovalsProductThreshold" xlink:href="ovid-20230630.xsd#ovid_LicenseAgreementDevelopmentMilestoneApprovalsProductThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_LicenseAgreementDevelopmentMilestoneApprovalsProductThreshold" xlink:to="lab_ovid_LicenseAgreementDevelopmentMilestoneApprovalsProductThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_3fa4bb94-ca1c-437d-aa41-e534ae5bc64e_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_3dee68e6-08ab-42c3-b6e2-e6b388cf4bb6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_2796d8cf-56d5-47c5-a93d-cb7a16c8092d_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_9206afb5-65b1-4b10-ad2c-d00f1dd1e5fe_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_d914d9fb-e70c-42e9-b4f2-8f6d0ad41faa_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_90d77fe0-38d1-414d-a129-3618acc11136_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_845ebd3b-7d86-4271-91e1-fa90cedc32c7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Securities Included and Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember_bbfaff6c-4508-4e69-9173-6851eef7ecf9_terseLabel_en-US" xlink:label="lab_ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 ESPP</link:label>
    <link:label id="lab_ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Seventeen Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember" xlink:href="ovid-20230630.xsd#ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember" xlink:to="lab_ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_HLundbeckASMember_7da7c5ae-d605-48f7-850a-3b84eb13b4d6_terseLabel_en-US" xlink:label="lab_ovid_HLundbeckASMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lundbeck</link:label>
    <link:label id="lab_ovid_HLundbeckASMember_label_en-US" xlink:label="lab_ovid_HLundbeckASMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">H Lundbeck A S [Member]</link:label>
    <link:label id="lab_ovid_HLundbeckASMember_documentation_en-US" xlink:label="lab_ovid_HLundbeckASMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">H. Lundbeck A/S.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_HLundbeckASMember" xlink:href="ovid-20230630.xsd#ovid_HLundbeckASMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_HLundbeckASMember" xlink:to="lab_ovid_HLundbeckASMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_ba967397-d713-4436-aa13-e2f4757710d7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocation of Stock-based Compensation Expense by Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_8aef5d8a-01c9-46c1-b522-2d0eaecafceb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_bd28e892-ec2a-4aa7-9e93-4a4a4f6bca71_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_8141c924-596a-4f08-bc23-b2d3a32f667d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_LicenseAgreementTerminationAdvanceNoticePeriod_097715ba-5335-4416-8bd0-98778ba1c14c_terseLabel_en-US" xlink:label="lab_ovid_LicenseAgreementTerminationAdvanceNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance written notice required to terminate agreement</link:label>
    <link:label id="lab_ovid_LicenseAgreementTerminationAdvanceNoticePeriod_label_en-US" xlink:label="lab_ovid_LicenseAgreementTerminationAdvanceNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Termination, Advance Notice Period</link:label>
    <link:label id="lab_ovid_LicenseAgreementTerminationAdvanceNoticePeriod_documentation_en-US" xlink:label="lab_ovid_LicenseAgreementTerminationAdvanceNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Termination, Advance Notice Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LicenseAgreementTerminationAdvanceNoticePeriod" xlink:href="ovid-20230630.xsd#ovid_LicenseAgreementTerminationAdvanceNoticePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_LicenseAgreementTerminationAdvanceNoticePeriod" xlink:to="lab_ovid_LicenseAgreementTerminationAdvanceNoticePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Dividends_204b3de5-980c-477d-bc0f-ea0e8e2e2e77_terseLabel_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared</link:label>
    <link:label id="lab_us-gaap_Dividends_label_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Dividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends" xlink:to="lab_us-gaap_Dividends" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_ATMAgreementMember_55c511d0-84ea-4d7a-9327-03e865192350_terseLabel_en-US" xlink:label="lab_ovid_ATMAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Agreement</link:label>
    <link:label id="lab_ovid_ATMAgreementMember_label_en-US" xlink:label="lab_ovid_ATMAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A T M Agreement [Member]</link:label>
    <link:label id="lab_ovid_ATMAgreementMember_documentation_en-US" xlink:label="lab_ovid_ATMAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_ATMAgreementMember" xlink:href="ovid-20230630.xsd#ovid_ATMAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_ATMAgreementMember" xlink:to="lab_ovid_ATMAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0bf4108a-0aa0-4d7f-9d4e-222cd5a2eccd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_eb0cea54-8a1e-439c-9360-9b60d9a38966_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_52814659-eb40-4c26-9ef5-069479bd5123_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_297d11cb-c9c3-4f8c-a819-fbf71bdbfba5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_b3a1eed2-3349-4b3f-8714-b59cb2921a0b_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_02afaeca-e2f8-4157-ad63-bbfeafa7fe13_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a44e1866-ac1c-409b-a144-8f848296ca6e_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_601e32b3-e349-4818-bcc6-ffbc846affa0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_edcb4290-8579-44e6-b1e3-28e9fd88486b_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Co-promotion</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_a9bdd5cd-3fac-4a03-b3d5-2f3b38cdd16f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, vested and exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_41134b41-174b-49c2-8d6e-dd43ed5ac852_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_687f6e4b-ec69-4a40-9f49-b443c18ee79d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_9dbcd9bc-5726-45b3-a5b6-bb3a386c33f0_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NATURE OF OPERATIONS</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_cca8ccbf-23a3-41cc-b804-17a910b51f81_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c3a41f5d-7632-4ee4-80d8-2163ec4a7e57_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_90941c8c-19c2-4ffe-adc3-1767691a4d61_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_195b5f06-01eb-4e9d-b445-85b03f71c340_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and marketable securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_0d0c16b2-6bf6-4333-9db2-acfc94cce675_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and marketable securities, fair value</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_4e7d3823-19e1-46ef-ab80-cba276e8ec41_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_325280ec-5972-4b24-be41-ca4125e0808c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_242b7254-e0be-4878-b0c5-ed103db644c5_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_0105e4cc-56a8-462f-bb45-e45cbf48577e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCRUED EXPENSES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_0b4cce05-98fc-4175-8d40-1aaac7a75e2a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_4fae3f4b-d67c-438f-8caa-329c6cc173e3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_532150dd-df89-47a6-8260-deff89d9933c_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_7d626911-d437-47c4-9c4d-e8b6b4413801_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 125,000,000 shares authorized; 70,602,793 and 70,466,885 shares issued and outstanding at June&#160;30, 2023 and December&#160;31, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_22f0c492-2158-47d4-a43c-5ea61634d265_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3caf5e83-adad-435d-aa48-8d12056083d1_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_e3b4ec35-f7ab-4ed0-9cab-ee9426694eb4_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees accrual</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_2c9439f7-e1a8-4993-98d8-77a4f60fc718_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_MoneyMarketFundsAndShortTermInvestmentsMember_a8e9ff9f-be98-4a61-b18f-b32134b195b8_terseLabel_en-US" xlink:label="lab_ovid_MoneyMarketFundsAndShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds and Short-term Investments</link:label>
    <link:label id="lab_ovid_MoneyMarketFundsAndShortTermInvestmentsMember_label_en-US" xlink:label="lab_ovid_MoneyMarketFundsAndShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds And Short Term Investments [Member]</link:label>
    <link:label id="lab_ovid_MoneyMarketFundsAndShortTermInvestmentsMember_documentation_en-US" xlink:label="lab_ovid_MoneyMarketFundsAndShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds and short-term investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MoneyMarketFundsAndShortTermInvestmentsMember" xlink:href="ovid-20230630.xsd#ovid_MoneyMarketFundsAndShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_MoneyMarketFundsAndShortTermInvestmentsMember" xlink:to="lab_ovid_MoneyMarketFundsAndShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_0a596712-e0e9-4611-914f-e3556faaf84e_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_f85bd3f1-88ee-4a09-a791-2a8780571b62_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock_9294e88b-6ff0-4ad9-867f-5fd080727b14_terseLabel_en-US" xlink:label="lab_ovid_RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of ROU Asset and Lease Liabilities Related to the Company Operating Lease</link:label>
    <link:label id="lab_ovid_RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock_label_en-US" xlink:label="lab_ovid_RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Asset and Lease Liabilities Operating Lease [Table Text Block]</link:label>
    <link:label id="lab_ovid_RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock_documentation_en-US" xlink:label="lab_ovid_RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset and lease liabilities operating lease table text block.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock" xlink:href="ovid-20230630.xsd#ovid_RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock" xlink:to="lab_ovid_RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_12617977-acbe-4848-8718-447b203d9a8e_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_231f9b8f-b15f-4721-b07c-42479ca89e8d_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_RoyaltyObligationTerm_4941d141-5002-4f55-a605-4ae76f5d6c81_terseLabel_en-US" xlink:label="lab_ovid_RoyaltyObligationTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty obligation period</link:label>
    <link:label id="lab_ovid_RoyaltyObligationTerm_label_en-US" xlink:label="lab_ovid_RoyaltyObligationTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Obligation, Term</link:label>
    <link:label id="lab_ovid_RoyaltyObligationTerm_documentation_en-US" xlink:label="lab_ovid_RoyaltyObligationTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Obligation, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_RoyaltyObligationTerm" xlink:href="ovid-20230630.xsd#ovid_RoyaltyObligationTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_RoyaltyObligationTerm" xlink:to="lab_ovid_RoyaltyObligationTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_EmployeeStockPurchasePlanMember_99d8481b-1e34-4272-a638-e04a522ace74_terseLabel_en-US" xlink:label="lab_ovid_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_ovid_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_ovid_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_ovid_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_ovid_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_EmployeeStockPurchasePlanMember" xlink:href="ovid-20230630.xsd#ovid_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_EmployeeStockPurchasePlanMember" xlink:to="lab_ovid_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_d1c8161e-fb26-4c6b-9e68-0eb86954fcdb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_6b40fe79-638a-40e1-9631-f56f6700b39b_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_5568cb03-c740-4f89-90a8-06c1f43e799a_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_45977dbc-c75f-4e29-922b-02e7c9468f04_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_b458e9b9-61bb-4fab-943b-d7c45224360a_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_f915a738-c37d-47cc-b523-049727439ee0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_345860e7-7349-4c07-99e3-c7def959d082_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_949647f6-9859-4357-85aa-90cf29920f43_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_f926c12b-2963-4b03-866d-bf764d97a632_periodStartLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_4fec9204-ff06-4311-bec4-55f94a0afae3_periodEndLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock_4efb2c1b-227c-42f1-ba71-6db25903eba5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Intangible Assets [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_7cc7a422-565a-48c0-9d83-631c5d0889b4_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_e1d54153-5365-4cd9-a113-97d6bfd3cc98_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_NorthwesternUniversityMember_b679c6ec-5864-4bb1-a927-4e8839b4d029_terseLabel_en-US" xlink:label="lab_ovid_NorthwesternUniversityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Northwestern University</link:label>
    <link:label id="lab_ovid_NorthwesternUniversityMember_label_en-US" xlink:label="lab_ovid_NorthwesternUniversityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Northwestern University [Member]</link:label>
    <link:label id="lab_ovid_NorthwesternUniversityMember_documentation_en-US" xlink:label="lab_ovid_NorthwesternUniversityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Northwestern University.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_NorthwesternUniversityMember" xlink:href="ovid-20230630.xsd#ovid_NorthwesternUniversityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_NorthwesternUniversityMember" xlink:to="lab_ovid_NorthwesternUniversityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_a0f748f6-8c7d-40b6-9995-366c03f814e6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_GensaicIncMember_adef2893-86c4-4da9-8e04-02fe0cbe997b_terseLabel_en-US" xlink:label="lab_ovid_GensaicIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gensaic, Inc</link:label>
    <link:label id="lab_ovid_GensaicIncMember_label_en-US" xlink:label="lab_ovid_GensaicIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gensaic, Inc [Member]</link:label>
    <link:label id="lab_ovid_GensaicIncMember_documentation_en-US" xlink:label="lab_ovid_GensaicIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gensaic, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_GensaicIncMember" xlink:href="ovid-20230630.xsd#ovid_GensaicIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_GensaicIncMember" xlink:to="lab_ovid_GensaicIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_879cbe56-ac82-4f0a-aa86-6ea9767cfb8c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_85f7761b-69d6-40c3-9b8b-77341798ce3b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_GravitonBioscienceCorporationMember_9d7655c9-77e2-4c42-ba79-67755cd04f1b_terseLabel_en-US" xlink:label="lab_ovid_GravitonBioscienceCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Graviton Bioscience Corporation</link:label>
    <link:label id="lab_ovid_GravitonBioscienceCorporationMember_label_en-US" xlink:label="lab_ovid_GravitonBioscienceCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Graviton Bioscience Corporation [Member]</link:label>
    <link:label id="lab_ovid_GravitonBioscienceCorporationMember_documentation_en-US" xlink:label="lab_ovid_GravitonBioscienceCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Graviton Bioscience Corporation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_GravitonBioscienceCorporationMember" xlink:href="ovid-20230630.xsd#ovid_GravitonBioscienceCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_GravitonBioscienceCorporationMember" xlink:to="lab_ovid_GravitonBioscienceCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_bd321c59-8514-4278-9cb4-fb87aa34a435_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_bd91ca14-9180-4a5a-b60e-0b1dc459a2b7_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and equipment</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToDevelopSoftware_027db6b4-8f37-4e73-b61b-bea146224c52_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToDevelopSoftware" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software development and other costs</link:label>
    <link:label id="lab_us-gaap_PaymentsToDevelopSoftware_label_en-US" xlink:label="lab_us-gaap_PaymentsToDevelopSoftware" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Develop Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToDevelopSoftware" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToDevelopSoftware"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToDevelopSoftware" xlink:to="lab_us-gaap_PaymentsToDevelopSoftware" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_87e361de-f719-4195-9325-48e020af49ab_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_65973f75-d29e-4f18-83e4-fd20943bb2b3_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_22090294-d085-4793-9ecb-4e289db73883_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_071adf44-5162-4b10-bc25-ec09b6aa4886_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e1013c2-fb71-4e20-962d-eeee6f3ce106_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_UnauditedInterimFinancialStatementsPolicyPolicyTextBlock_d79b85cc-2e61-4eef-aea2-0b0112bbc07d_terseLabel_en-US" xlink:label="lab_ovid_UnauditedInterimFinancialStatementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unaudited Interim Condensed Consolidated Financial Statements</link:label>
    <link:label id="lab_ovid_UnauditedInterimFinancialStatementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_ovid_UnauditedInterimFinancialStatementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unaudited Interim Financial Statements Policy [Policy Text Block]</link:label>
    <link:label id="lab_ovid_UnauditedInterimFinancialStatementsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_ovid_UnauditedInterimFinancialStatementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unaudited interim financial statements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_UnauditedInterimFinancialStatementsPolicyPolicyTextBlock" xlink:href="ovid-20230630.xsd#ovid_UnauditedInterimFinancialStatementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_UnauditedInterimFinancialStatementsPolicyPolicyTextBlock" xlink:to="lab_ovid_UnauditedInterimFinancialStatementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_80f49b71-a16b-4f72-89fe-f852f6c57cb2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Stock By Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8ba77c26-41f9-42f5-a3f0-88f91837866f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a280128a-0e03-403a-8652-3232cc788557_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_8f96c91f-6035-4f61-be6e-17b2850b7bae_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_58f78360-1365-4428-aa9b-294008d49be2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_82fe4404-59b4-408f-ad29-c4fa4e7bef50_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_bdff22b2-6a79-46ff-860a-83ec1edc02e5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_WorkingCapital_ba9a5d2a-27c4-4dcf-b810-63cf4b722b72_terseLabel_en-US" xlink:label="lab_ovid_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working capital</link:label>
    <link:label id="lab_ovid_WorkingCapital_label_en-US" xlink:label="lab_ovid_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital</link:label>
    <link:label id="lab_ovid_WorkingCapital_documentation_en-US" xlink:label="lab_ovid_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working capital.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_WorkingCapital" xlink:href="ovid-20230630.xsd#ovid_WorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_WorkingCapital" xlink:to="lab_ovid_WorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_HealxLicenseAndOptionAgreementMember_7334b6b3-b44f-46b9-b6db-07d6a555c1b4_terseLabel_en-US" xlink:label="lab_ovid_HealxLicenseAndOptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healx License and Option Agreement</link:label>
    <link:label id="lab_ovid_HealxLicenseAndOptionAgreementMember_label_en-US" xlink:label="lab_ovid_HealxLicenseAndOptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healx License and Option Agreement [Member].</link:label>
    <link:label id="lab_ovid_HealxLicenseAndOptionAgreementMember_documentation_en-US" xlink:label="lab_ovid_HealxLicenseAndOptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healx License and Option Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_HealxLicenseAndOptionAgreementMember" xlink:href="ovid-20230630.xsd#ovid_HealxLicenseAndOptionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_HealxLicenseAndOptionAgreementMember" xlink:to="lab_ovid_HealxLicenseAndOptionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_008f51c7-f853-4124-9ac0-318a319bb3ed_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_73e2e843-abf8-4b4e-9a59-abc22d3e35f3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_8f969d95-8dbd-49e2-9b52-9ce9cc93452a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Employee</link:label>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Employee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_3e3047ab-9bdd-4915-960a-f03622ca81f4_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_01bbf4ef-c511-4569-b67b-1d8782e2cbed_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_de0e5682-1d44-4ce8-b263-dcf7844efffd_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_b3e3897f-9d5f-48ae-82ac-5334c42d648f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation, percentage of discount from market price on purchase date</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_fbad4b43-750b-408e-89f8-c23a3d28bc0c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c05849c9-0d4a-49d0-be2a-9875b64e79c8_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a75ca36c-bfda-4eb5-8827-6e04f4342074_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_d88374f8-f722-4ef5-9d34-b1dd8a25be8d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_AdditionalPaymentReceivableOnSalesPercentage_88ce53fe-77d2-4318-8de9-d4a940b3820b_terseLabel_en-US" xlink:label="lab_ovid_AdditionalPaymentReceivableOnSalesPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional payment on sales percentage (up to)</link:label>
    <link:label id="lab_ovid_AdditionalPaymentReceivableOnSalesPercentage_label_en-US" xlink:label="lab_ovid_AdditionalPaymentReceivableOnSalesPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Payment Receivable On Sales Percentage</link:label>
    <link:label id="lab_ovid_AdditionalPaymentReceivableOnSalesPercentage_documentation_en-US" xlink:label="lab_ovid_AdditionalPaymentReceivableOnSalesPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional payment receivable on sales percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AdditionalPaymentReceivableOnSalesPercentage" xlink:href="ovid-20230630.xsd#ovid_AdditionalPaymentReceivableOnSalesPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_AdditionalPaymentReceivableOnSalesPercentage" xlink:to="lab_ovid_AdditionalPaymentReceivableOnSalesPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_c197dc4d-13ea-4cd8-b88b-53f57dbf5443_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_f19f9196-962a-4b37-ba1e-afa445e42c02_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_035492e7-ca74-4c0e-a5d2-a1b6f48f608b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_cff3a050-fcfd-4e9f-94a3-f14ca1e6995f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET LOSS PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_879c8c25-a813-402d-a5e7-daf03beca76d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_5e1245e3-65e2-4e71-8f21-d4ee4ad6f588_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement ownership share</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_509a7824-1c33-4a34-bf3c-7b143c1aa69e_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_6792159f-6e41-494c-bd9e-88351b732c44_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_6c256e16-a368-420e-9418-ad662fa36a45_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_24f9fd14-c811-4d35-8d9e-b46206edc7c1_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_fd755aa8-c386-40a6-86d5-5cca75d4c2f3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_9e55579d-97f1-480f-9453-19463fd363d3_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_078e800e-1220-4b40-9cd8-ce9454c3843b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Options Outstanding and Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Cash_1aa3cabc-1c96-4f49-968b-6350b1a3f1df_terseLabel_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Amortized cost</link:label>
    <link:label id="lab_us-gaap_Cash_label_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_144a6b8d-670a-4090-981c-be5b9743bb6a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_CommonStockNumberOfVotesForEachShare_36a652ed-21a5-4f1c-b5d1-99c3b8b62419_terseLabel_en-US" xlink:label="lab_ovid_CommonStockNumberOfVotesForEachShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of votes per share</link:label>
    <link:label id="lab_ovid_CommonStockNumberOfVotesForEachShare_label_en-US" xlink:label="lab_ovid_CommonStockNumberOfVotesForEachShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number Of Votes For Each Share</link:label>
    <link:label id="lab_ovid_CommonStockNumberOfVotesForEachShare_documentation_en-US" xlink:label="lab_ovid_CommonStockNumberOfVotesForEachShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number Of Votes For Each Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CommonStockNumberOfVotesForEachShare" xlink:href="ovid-20230630.xsd#ovid_CommonStockNumberOfVotesForEachShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_CommonStockNumberOfVotesForEachShare" xlink:to="lab_ovid_CommonStockNumberOfVotesForEachShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_22a2aade-9dc8-4db2-9ee0-a71b72880b5f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_bc5c0d86-c342-4eb0-8003-db857a5733de_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_199cef87-413f-4e32-bf0b-0292d4f6a85e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_209ec1be-8e9f-4112-bc19-c3c852fc9314_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_fbd87c15-16ba-488e-9a83-d8ded6f6eedb_negatedLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to participating securities</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed Earnings (Loss) Allocated to Participating Securities, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:to="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_46222937-32d5-4f4a-b8e7-ebcea6ac5ccd_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_a1f17c41-edd8-471e-b620-8103e1675b6f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_eb361ba2-b903-476f-95cb-6650322a2b5c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7c622e07-645f-4ece-b584-87ab8c9fe566_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, Amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_b567e8fa-1172-4a89-94bd-abb69f0894f3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_aed9a714-e09c-409e-b0c6-68080ade0f6e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_b88b5761-5463-4a2f-bb55-2d69dfee9813_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_f061e447-7a68-4f50-b1db-3270e6f1eb36_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_79cf2307-3879-4208-b615-33f13b71eff1_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_d1ef9a4c-eaa3-43aa-97d0-6def632df4c2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock from exercise of stock options and purchases from employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_SummaryOfSignificantAccountingPolicyTable_9fc3587d-2eab-4236-99b8-bef49b8beeed_terseLabel_en-US" xlink:label="lab_ovid_SummaryOfSignificantAccountingPolicyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policy [Table]</link:label>
    <link:label id="lab_ovid_SummaryOfSignificantAccountingPolicyTable_label_en-US" xlink:label="lab_ovid_SummaryOfSignificantAccountingPolicyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policy [Table]</link:label>
    <link:label id="lab_ovid_SummaryOfSignificantAccountingPolicyTable_documentation_en-US" xlink:label="lab_ovid_SummaryOfSignificantAccountingPolicyTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of significant accounting policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_SummaryOfSignificantAccountingPolicyTable" xlink:href="ovid-20230630.xsd#ovid_SummaryOfSignificantAccountingPolicyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyTable" xlink:to="lab_ovid_SummaryOfSignificantAccountingPolicyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_c1054ada-7eb0-44b2-b586-26a4800a3019_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_f31a91de-6dfd-489e-ab1e-4b44b5e46dce_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_AccruedResearchAndDevelopment_ff09d4da-b53b-4d1b-8022-5f1ac09da746_terseLabel_en-US" xlink:label="lab_ovid_AccruedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development accrual</link:label>
    <link:label id="lab_ovid_AccruedResearchAndDevelopment_label_en-US" xlink:label="lab_ovid_AccruedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development</link:label>
    <link:label id="lab_ovid_AccruedResearchAndDevelopment_documentation_en-US" xlink:label="lab_ovid_AccruedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AccruedResearchAndDevelopment" xlink:href="ovid-20230630.xsd#ovid_AccruedResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_AccruedResearchAndDevelopment" xlink:to="lab_ovid_AccruedResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_362e3d5b-bfe0-4e55-8afa-487898fe4422_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders_2813118d-e8fe-49c6-920b-e12fb2ec7602_terseLabel_en-US" xlink:label="lab_ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum allowable voting right percentage of outstanding common stock holders</link:label>
    <link:label id="lab_ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders_label_en-US" xlink:label="lab_ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Allowable Voting Right Percentage Of Outstanding Common Stock Holders</link:label>
    <link:label id="lab_ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders_documentation_en-US" xlink:label="lab_ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum allowable voting right percentage of outstanding common stock holders.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders" xlink:href="ovid-20230630.xsd#ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders" xlink:to="lab_ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_2a75a1c9-18dc-42fb-8c5b-f2ca2c6d66a6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_0b420514-bb6b-4860-8c3b-92476f267779_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_TakedaPharmaceuticalCompanyLimitedMember_09b57bbe-f256-47c1-9ed0-c2a2efa7f14f_terseLabel_en-US" xlink:label="lab_ovid_TakedaPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Pharmaceutical Company Limited</link:label>
    <link:label id="lab_ovid_TakedaPharmaceuticalCompanyLimitedMember_label_en-US" xlink:label="lab_ovid_TakedaPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Pharmaceutical Company Limited [Member]</link:label>
    <link:label id="lab_ovid_TakedaPharmaceuticalCompanyLimitedMember_documentation_en-US" xlink:label="lab_ovid_TakedaPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Pharmaceutical Company Limited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_TakedaPharmaceuticalCompanyLimitedMember" xlink:href="ovid-20230630.xsd#ovid_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_TakedaPharmaceuticalCompanyLimitedMember" xlink:to="lab_ovid_TakedaPharmaceuticalCompanyLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_1d5d2a94-2bdc-45a3-afb0-e61f14a939b3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_2bf8cf05-dc7c-43e8-872b-74fc12908124_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_679d5b28-4183-46bb-ba6d-db1dff623f59_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_4070d9b1-8b7b-43c2-a182-3a39809aec11_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_PreferredStockShareDesignated_7f7d28a3-1a5d-4eb4-8d06-3d35cb7ed1d7_terseLabel_en-US" xlink:label="lab_ovid_PreferredStockShareDesignated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, share designated (in shares)</link:label>
    <link:label id="lab_ovid_PreferredStockShareDesignated_label_en-US" xlink:label="lab_ovid_PreferredStockShareDesignated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Share Designated</link:label>
    <link:label id="lab_ovid_PreferredStockShareDesignated_documentation_en-US" xlink:label="lab_ovid_PreferredStockShareDesignated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock shares designated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_PreferredStockShareDesignated" xlink:href="ovid-20230630.xsd#ovid_PreferredStockShareDesignated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_PreferredStockShareDesignated" xlink:to="lab_ovid_PreferredStockShareDesignated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_43c8ecb4-b5a7-47c5-98b0-07217b663d97_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b8c4b705-b7a0-4970-a6b2-b18fe5eda95c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, unrealized holding gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_ce46c69b-95eb-41bd-be8d-7e77ef975356_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_4cecac24-1640-44d2-94eb-7b5fc202d18c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_61565676-ff3b-42ce-93fe-bef41f7c16bf_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_719d582a-d9b4-49ce-98cf-448fa279d609_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_4e474bc9-ba2c-449d-a003-d679a5267696_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_21dc432b-8a2c-4c8e-b2fb-8a7a8ca51d2d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of number of shares of common stock outstanding (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_9be998ec-d006-45c1-bf71-b37cace6d546_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in-capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_7ea880a3-c17c-4600-be9e-0a665312f9bd_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of options and purchases from employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_573ff74b-9439-4667-99cf-0effb0ff9845_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_PatentLicenseAgreementMember_0f858be0-1667-403c-839a-b32063f60aab_terseLabel_en-US" xlink:label="lab_ovid_PatentLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent License Agreement</link:label>
    <link:label id="lab_ovid_PatentLicenseAgreementMember_label_en-US" xlink:label="lab_ovid_PatentLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent License Agreement [Member]</link:label>
    <link:label id="lab_ovid_PatentLicenseAgreementMember_documentation_en-US" xlink:label="lab_ovid_PatentLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent license agreement [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_PatentLicenseAgreementMember" xlink:href="ovid-20230630.xsd#ovid_PatentLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_PatentLicenseAgreementMember" xlink:to="lab_ovid_PatentLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_AccretionOfLeaseLiability_afa33d49-82aa-42e9-a368-0e847654140b_terseLabel_en-US" xlink:label="lab_ovid_AccretionOfLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of lease liability</link:label>
    <link:label id="lab_ovid_AccretionOfLeaseLiability_label_en-US" xlink:label="lab_ovid_AccretionOfLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of Lease Liability</link:label>
    <link:label id="lab_ovid_AccretionOfLeaseLiability_documentation_en-US" xlink:label="lab_ovid_AccretionOfLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of lease liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AccretionOfLeaseLiability" xlink:href="ovid-20230630.xsd#ovid_AccretionOfLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_AccretionOfLeaseLiability" xlink:to="lab_ovid_AccretionOfLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_2b808ac3-a9c9-414f-93e1-0edd1566e3dc_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_6f48dd16-e2e5-460c-91b6-53dfa131de00_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_77b875cf-1057-4ec8-a929-013139f040ea_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_1c314ff7-ae3e-4357-ba9c-b6e6982ba85c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Equity Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_01bfb2a8-e04c-4885-bfae-4766be5e5cc9_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7434c901-c5da-4f42-a133-39963e5e4979_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife_b40adebd-505d-4df4-8978-c869d560a217_terseLabel_en-US" xlink:label="lab_ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life in Years, Granted</link:label>
    <link:label id="lab_ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife_label_en-US" xlink:label="lab_ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation By Share Based Payment Award Options Granted Contractual Life</link:label>
    <link:label id="lab_ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife_documentation_en-US" xlink:label="lab_ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation by share based payment award options granted contractual life.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife" xlink:href="ovid-20230630.xsd#ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife" xlink:to="lab_ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_6e1e7c53-6bdc-4824-9f8e-851b17368882_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_49d1ce2b-8bcc-476b-acf7-dc044aaa7d95_negatedLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (gain) loss on equity investment</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d3062858-2841-483c-9c88-a160dd4fab84_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_6e47a964-6dd0-48b1-bd9b-62241b61ef8f_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_308234ae-721f-4a51-aa1a-8413453ed975_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_baf0e6f0-7aa1-44f0-8b8a-cfb42f002fe2_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_8d08e9c0-4274-43f8-a9d8-d071e095ce8e_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_2cf31cc2-a1fb-4703-94f8-80de690e2bc6_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense, Total</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_9e7f7bde-20ce-4e30-9058-90215f5f593b_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_5615edfd-172d-4d73-8d96-86606c5a5c78_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Benefit) provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_AgreementMilestonePayments_f2f1715a-d78f-4f2a-aa77-184ce07e10d4_terseLabel_en-US" xlink:label="lab_ovid_AgreementMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate milestone payments</link:label>
    <link:label id="lab_ovid_AgreementMilestonePayments_label_en-US" xlink:label="lab_ovid_AgreementMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement Milestone Payments</link:label>
    <link:label id="lab_ovid_AgreementMilestonePayments_documentation_en-US" xlink:label="lab_ovid_AgreementMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AgreementMilestonePayments" xlink:href="ovid-20230630.xsd#ovid_AgreementMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_AgreementMilestonePayments" xlink:to="lab_ovid_AgreementMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_dc9315fe-efcb-4aa7-a66b-7e5026d781d5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll and bonus accrual</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_90cdc90a-b019-4096-b9ec-f4f32243e61f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_aa5e6d80-f3b7-4e04-b80b-092d1d3c6ed4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_NonemployeePerformanceBasedOptionAwardsMember_0c2603e9-5ba2-4c40-8cbd-402e226f25eb_terseLabel_en-US" xlink:label="lab_ovid_NonemployeePerformanceBasedOptionAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-employee Performance Based Option Awards</link:label>
    <link:label id="lab_ovid_NonemployeePerformanceBasedOptionAwardsMember_label_en-US" xlink:label="lab_ovid_NonemployeePerformanceBasedOptionAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonemployee Performance Based Option Awards [Member]</link:label>
    <link:label id="lab_ovid_NonemployeePerformanceBasedOptionAwardsMember_documentation_en-US" xlink:label="lab_ovid_NonemployeePerformanceBasedOptionAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-employee performance based option awards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_NonemployeePerformanceBasedOptionAwardsMember" xlink:href="ovid-20230630.xsd#ovid_NonemployeePerformanceBasedOptionAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_NonemployeePerformanceBasedOptionAwardsMember" xlink:to="lab_ovid_NonemployeePerformanceBasedOptionAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_LeaseIncrementalBorrowingRate_f9acfd20-278b-4db4-a15b-c4382f280450_terseLabel_en-US" xlink:label="lab_ovid_LeaseIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease incremental borrowing rate</link:label>
    <link:label id="lab_ovid_LeaseIncrementalBorrowingRate_label_en-US" xlink:label="lab_ovid_LeaseIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Incremental Borrowing Rate</link:label>
    <link:label id="lab_ovid_LeaseIncrementalBorrowingRate_documentation_en-US" xlink:label="lab_ovid_LeaseIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease incremental borrowing rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LeaseIncrementalBorrowingRate" xlink:href="ovid-20230630.xsd#ovid_LeaseIncrementalBorrowingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_LeaseIncrementalBorrowingRate" xlink:to="lab_ovid_LeaseIncrementalBorrowingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_475dbd50-ba80-410c-bdf5-f8884d328510_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_bdb53d84-64d0-4bc1-a025-07d633390fbf_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_070284c9-6d4d-4090-8f29-cf5f663afe0c_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_CashEquivalentsUnrealizedHoldingGains_52f564aa-05f8-4f76-a4cc-0ca77dcd5411_terseLabel_en-US" xlink:label="lab_ovid_CashEquivalentsUnrealizedHoldingGains" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents, unrealized holding gains</link:label>
    <link:label id="lab_ovid_CashEquivalentsUnrealizedHoldingGains_label_en-US" xlink:label="lab_ovid_CashEquivalentsUnrealizedHoldingGains" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, Unrealized Holding Gains</link:label>
    <link:label id="lab_ovid_CashEquivalentsUnrealizedHoldingGains_documentation_en-US" xlink:label="lab_ovid_CashEquivalentsUnrealizedHoldingGains" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, Unrealized Holding Gains</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CashEquivalentsUnrealizedHoldingGains" xlink:href="ovid-20230630.xsd#ovid_CashEquivalentsUnrealizedHoldingGains"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_CashEquivalentsUnrealizedHoldingGains" xlink:to="lab_ovid_CashEquivalentsUnrealizedHoldingGains" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_d3e30738-a21c-4a07-8d4e-5f5145373d8f_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_EmployeePerformanceBasedOptionAwardsMember_372d72c2-2d95-4762-b94d-f411bce2f5da_terseLabel_en-US" xlink:label="lab_ovid_EmployeePerformanceBasedOptionAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Performance Based Option Awards</link:label>
    <link:label id="lab_ovid_EmployeePerformanceBasedOptionAwardsMember_label_en-US" xlink:label="lab_ovid_EmployeePerformanceBasedOptionAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Performance Based Option Awards [Member]</link:label>
    <link:label id="lab_ovid_EmployeePerformanceBasedOptionAwardsMember_documentation_en-US" xlink:label="lab_ovid_EmployeePerformanceBasedOptionAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee performance based option awards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_EmployeePerformanceBasedOptionAwardsMember" xlink:href="ovid-20230630.xsd#ovid_EmployeePerformanceBasedOptionAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_EmployeePerformanceBasedOptionAwardsMember" xlink:to="lab_ovid_EmployeePerformanceBasedOptionAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7afa923a-d72f-4463-aceb-7072319fbf7c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_A2014EmployeeStockPurchasePlanMember_31dbe8cd-f9cc-48cf-8452-f99d250e0085_terseLabel_en-US" xlink:label="lab_ovid_A2014EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_ovid_A2014EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_ovid_A2014EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_ovid_A2014EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_ovid_A2014EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_A2014EmployeeStockPurchasePlanMember" xlink:href="ovid-20230630.xsd#ovid_A2014EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_A2014EmployeeStockPurchasePlanMember" xlink:to="lab_ovid_A2014EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_SummaryOfSignificantAccountingPolicyLineItems_78f2ddd4-f28f-4d2c-8d85-853a95a6f78e_terseLabel_en-US" xlink:label="lab_ovid_SummaryOfSignificantAccountingPolicyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policy [Line Items]</link:label>
    <link:label id="lab_ovid_SummaryOfSignificantAccountingPolicyLineItems_label_en-US" xlink:label="lab_ovid_SummaryOfSignificantAccountingPolicyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policy [Line Items]</link:label>
    <link:label id="lab_ovid_SummaryOfSignificantAccountingPolicyLineItems_documentation_en-US" xlink:label="lab_ovid_SummaryOfSignificantAccountingPolicyLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of significant accounting policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_SummaryOfSignificantAccountingPolicyLineItems" xlink:href="ovid-20230630.xsd#ovid_SummaryOfSignificantAccountingPolicyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="lab_ovid_SummaryOfSignificantAccountingPolicyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_c74c6654-d2aa-49cf-8d13-c65d58400708_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_PaymentsForProceedsFromIssuanceOfShortTermNoteReceivable_f0a60f9c-a012-4760-a2b7-858da76cce68_negatedTerseLabel_en-US" xlink:label="lab_ovid_PaymentsForProceedsFromIssuanceOfShortTermNoteReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of convertible short-term note receivable</link:label>
    <link:label id="lab_ovid_PaymentsForProceedsFromIssuanceOfShortTermNoteReceivable_label_en-US" xlink:label="lab_ovid_PaymentsForProceedsFromIssuanceOfShortTermNoteReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Issuance of Short-Term Note Receivable</link:label>
    <link:label id="lab_ovid_PaymentsForProceedsFromIssuanceOfShortTermNoteReceivable_documentation_en-US" xlink:label="lab_ovid_PaymentsForProceedsFromIssuanceOfShortTermNoteReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Issuance of Short-Term Note Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_PaymentsForProceedsFromIssuanceOfShortTermNoteReceivable" xlink:href="ovid-20230630.xsd#ovid_PaymentsForProceedsFromIssuanceOfShortTermNoteReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_PaymentsForProceedsFromIssuanceOfShortTermNoteReceivable" xlink:to="lab_ovid_PaymentsForProceedsFromIssuanceOfShortTermNoteReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2a6babcc-50ca-49aa-94df-f696530a7819_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3666c719-e7d4-4b4f-9759-9a2f68b0d58b_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding used in computing net loss per share - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusDomain_8d24a629-e299-49a5-bbd5-d39d1cef4b71_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusDomain_label_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusDomain" xlink:to="lab_us-gaap_GranteeStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_SeriesAConvertiblePreferredStockMember_3db7c312-14c5-4f11-804c-281e47962197_terseLabel_en-US" xlink:label="lab_ovid_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_ovid_SeriesAConvertiblePreferredStockMember_9ee74dbf-2a4b-4276-8109-40923f3f2b5b_verboseLabel_en-US" xlink:label="lab_ovid_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issuable upon conversion of Series A convertible preferred stock</link:label>
    <link:label id="lab_ovid_SeriesAConvertiblePreferredStockMember_label_en-US" xlink:label="lab_ovid_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_ovid_SeriesAConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_ovid_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A convertible preferred stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_SeriesAConvertiblePreferredStockMember" xlink:href="ovid-20230630.xsd#ovid_SeriesAConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_SeriesAConvertiblePreferredStockMember" xlink:to="lab_ovid_SeriesAConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates_e7edb55a-dce7-4a9e-9a95-7a8628f3cda3_terseLabel_en-US" xlink:label="lab_ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum allowable owning percentage of outstanding common stock by associates or affiliates</link:label>
    <link:label id="lab_ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates_label_en-US" xlink:label="lab_ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Allowable Owning Percentage Of Outstanding Common Stock By Associates Or Affiliates</link:label>
    <link:label id="lab_ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates_documentation_en-US" xlink:label="lab_ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum allowable owning percentage of outstanding common stock by associates or affiliates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" xlink:href="ovid-20230630.xsd#ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" xlink:to="lab_ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_f8fa1b29-080f-4ae6-8d35-6e71e5949c0d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains or losses on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsAtCarryingValue_197064e6-9fcc-4cd4-b604-fb33257e5d3a_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_8b5861a6-be6e-4e29-a527-f859b21049cd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares reserved for issuance under the plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_0d346e33-8c73-4e08-9099-66d85729ce02_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_437e6a6e-25e2-418e-96e7-7137199c71d0_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_2c744733-90fe-4e60-a73d-46c1e480fd7f_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_CowenAndCompanyLLCMember_e5328cf3-bd74-43f2-a802-226b10d1811d_terseLabel_en-US" xlink:label="lab_ovid_CowenAndCompanyLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cowen And Company, LLC</link:label>
    <link:label id="lab_ovid_CowenAndCompanyLLCMember_label_en-US" xlink:label="lab_ovid_CowenAndCompanyLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cowen And Company L L C [Member]</link:label>
    <link:label id="lab_ovid_CowenAndCompanyLLCMember_documentation_en-US" xlink:label="lab_ovid_CowenAndCompanyLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cowen and Company, LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CowenAndCompanyLLCMember" xlink:href="ovid-20230630.xsd#ovid_CowenAndCompanyLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_CowenAndCompanyLLCMember" xlink:to="lab_ovid_CowenAndCompanyLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_ace32377-62c6-44bf-8291-c0b6ee30b73c_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_e0b98cb3-7eb7-4e18-a6c1-40d872864929_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_7244391f-ff19-493a-9182-294fe19f945a_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_1eadc561-5377-4efb-9950-c9791815f2a5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life in Years, Vested and exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_89fdc20e-b49b-4eb3-b764-b9cdde0a1587_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_364a6dda-5cfe-4c60-91ae-144254f50d18_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_045a4421-7d1a-4adc-a343-2574807042e4_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0e025651-e162-48c7-b724-368ada5516ef_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease, liability, to be paid</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_9065b428-8f0f-41a3-a620-1994e389f50b_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod_7b9e6858-4079-4254-93e2-763a51a7f26c_terseLabel_en-US" xlink:label="lab_ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent payments commencement following this period</link:label>
    <link:label id="lab_ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod_label_en-US" xlink:label="lab_ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Rent Payments Commencement Following This Period</link:label>
    <link:label id="lab_ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod_documentation_en-US" xlink:label="lab_ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Rent Payments Commencement Following This Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod" xlink:href="ovid-20230630.xsd#ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod" xlink:to="lab_ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_7bb0ab90-0c90-4274-84a7-b1df1a5d4a7e_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1cd22d3c-c843-4fde-9fa4-c9e770ce2f4e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_c0744c39-3992-48d7-8d6e-a365411a4fc2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal option term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_e14fc4d5-ddc2-4430-8b32-fb276d6d83de_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_30b8d3ea-da84-43b5-813c-b428025e4350_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0cb02e18-de6c-473a-bbed-094e25ae3288_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding used in computing net loss per share - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_f8e4e865-cfa9-46a7-b688-d70547605f8f_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_5c4477b3-f015-48f4-a4d8-44fce4303326_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_160b20ba-1104-4a50-ba28-fc43dc4f5b8a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-term Debt [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-Term Debt [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_e0cf6de8-1641-4cb8-b78e-de9bde408400_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b8e9dd4f-7836-483d-8a3e-28860256a33f_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_49312e1c-3ed5-4c12-bab0-97f8629daf0d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1da76885-013e-4fb6-b42a-4a96ea74654c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_facf9d99-a052-4a8e-a450-f436153b7216_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_52c3dcbf-b305-4380-9c98-fff1d1a6e87a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life in Years and Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_72d5e7c7-3e64-493f-99d2-c3c99094d6c7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt Securities, Available-for-Sale</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>ovid-20230630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:bac70ec3-5ee7-4b97-a85c-498b4f8489b1,g:499e488f-fe63-4d10-9e0b-b93d763975f8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ovidrx.com/role/CoverPage" xlink:type="simple" xlink:href="ovid-20230630.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_761b86e9-6472-410f-a98a-13eeb5c2db59" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_7ea19f40-df6b-41d1-adba-8341db62e27e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_761b86e9-6472-410f-a98a-13eeb5c2db59" xlink:to="loc_dei_DocumentType_7ea19f40-df6b-41d1-adba-8341db62e27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_f147ce40-9f26-4571-a0f7-0004deffce26" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_761b86e9-6472-410f-a98a-13eeb5c2db59" xlink:to="loc_dei_DocumentQuarterlyReport_f147ce40-9f26-4571-a0f7-0004deffce26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_eb155aee-21a9-4862-a46e-dc6a5163131e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_761b86e9-6472-410f-a98a-13eeb5c2db59" xlink:to="loc_dei_DocumentPeriodEndDate_eb155aee-21a9-4862-a46e-dc6a5163131e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_8fde23bf-7fc3-420f-965a-df0359b0af90" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_761b86e9-6472-410f-a98a-13eeb5c2db59" xlink:to="loc_dei_DocumentTransitionReport_8fde23bf-7fc3-420f-965a-df0359b0af90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_b6dab902-aad7-4524-8030-4cec35db53e3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_761b86e9-6472-410f-a98a-13eeb5c2db59" xlink:to="loc_dei_EntityFileNumber_b6dab902-aad7-4524-8030-4cec35db53e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_d5a58bcf-a53b-4b8f-a7a9-f1330c9b03e2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_761b86e9-6472-410f-a98a-13eeb5c2db59" xlink:to="loc_dei_EntityRegistrantName_d5a58bcf-a53b-4b8f-a7a9-f1330c9b03e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_19d716f1-4fbe-4363-8bbc-ffeb88e564cc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_761b86e9-6472-410f-a98a-13eeb5c2db59" xlink:to="loc_dei_EntityIncorporationStateCountryCode_19d716f1-4fbe-4363-8bbc-ffeb88e564cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_1664bd0d-a3ac-4c75-9d10-bb08c04cefb7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_761b86e9-6472-410f-a98a-13eeb5c2db59" xlink:to="loc_dei_EntityTaxIdentificationNumber_1664bd0d-a3ac-4c75-9d10-bb08c04cefb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_23fc9b9d-b82f-4c71-b7e4-a950172543b2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_761b86e9-6472-410f-a98a-13eeb5c2db59" xlink:to="loc_dei_EntityAddressAddressLine1_23fc9b9d-b82f-4c71-b7e4-a950172543b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_30ce6356-2e7f-4de3-8fc8-1925fefa954f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_761b86e9-6472-410f-a98a-13eeb5c2db59" xlink:to="loc_dei_EntityAddressAddressLine2_30ce6356-2e7f-4de3-8fc8-1925fefa954f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_5d8731ad-76af-4661-8db1-9a7064347340" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_761b86e9-6472-410f-a98a-13eeb5c2db59" xlink:to="loc_dei_EntityAddressCityOrTown_5d8731ad-76af-4661-8db1-9a7064347340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_388325fc-9f32-42fc-bf2b-18c9b5ea0256" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_761b86e9-6472-410f-a98a-13eeb5c2db59" xlink:to="loc_dei_EntityAddressStateOrProvince_388325fc-9f32-42fc-bf2b-18c9b5ea0256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_7312c381-9802-4ae2-ab61-e0a129be14f0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_761b86e9-6472-410f-a98a-13eeb5c2db59" xlink:to="loc_dei_EntityAddressPostalZipCode_7312c381-9802-4ae2-ab61-e0a129be14f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_29484b43-470a-49b6-a851-187528ee0753" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_761b86e9-6472-410f-a98a-13eeb5c2db59" xlink:to="loc_dei_CityAreaCode_29484b43-470a-49b6-a851-187528ee0753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_34800a63-a0d9-498f-8046-056b28bbc316" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_761b86e9-6472-410f-a98a-13eeb5c2db59" xlink:to="loc_dei_LocalPhoneNumber_34800a63-a0d9-498f-8046-056b28bbc316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_8f3f4445-dbec-4ad9-9e1c-2964cb72a95f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_761b86e9-6472-410f-a98a-13eeb5c2db59" xlink:to="loc_dei_Security12bTitle_8f3f4445-dbec-4ad9-9e1c-2964cb72a95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d25ccd1f-a21c-4bd5-9da1-7a8eb5da67f3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_761b86e9-6472-410f-a98a-13eeb5c2db59" xlink:to="loc_dei_TradingSymbol_d25ccd1f-a21c-4bd5-9da1-7a8eb5da67f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_267f777d-a9d2-40cf-959c-e6d630152d79" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_761b86e9-6472-410f-a98a-13eeb5c2db59" xlink:to="loc_dei_SecurityExchangeName_267f777d-a9d2-40cf-959c-e6d630152d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_2c634693-4885-4cf2-8de7-fdaba6d1983c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_761b86e9-6472-410f-a98a-13eeb5c2db59" xlink:to="loc_dei_EntityCurrentReportingStatus_2c634693-4885-4cf2-8de7-fdaba6d1983c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_db983b06-bc56-4afa-9151-521ebccd5970" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_761b86e9-6472-410f-a98a-13eeb5c2db59" xlink:to="loc_dei_EntityInteractiveDataCurrent_db983b06-bc56-4afa-9151-521ebccd5970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_f18d2d7d-93ee-444d-a732-23fb5d10819f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_761b86e9-6472-410f-a98a-13eeb5c2db59" xlink:to="loc_dei_EntityFilerCategory_f18d2d7d-93ee-444d-a732-23fb5d10819f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_32baaa8d-1f8a-45f2-a255-336c0eea3fcf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_761b86e9-6472-410f-a98a-13eeb5c2db59" xlink:to="loc_dei_EntitySmallBusiness_32baaa8d-1f8a-45f2-a255-336c0eea3fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_6c870e7a-b760-4522-8411-1af4d7ff41e9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_761b86e9-6472-410f-a98a-13eeb5c2db59" xlink:to="loc_dei_EntityEmergingGrowthCompany_6c870e7a-b760-4522-8411-1af4d7ff41e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_86863c01-9232-47d3-b246-23f6f5001cbb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_761b86e9-6472-410f-a98a-13eeb5c2db59" xlink:to="loc_dei_EntityShellCompany_86863c01-9232-47d3-b246-23f6f5001cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_03bf93ed-6917-47d6-aa00-e796f01c66ec" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_761b86e9-6472-410f-a98a-13eeb5c2db59" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_03bf93ed-6917-47d6-aa00-e796f01c66ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_d611cc9e-315c-48ac-bfae-1476ff346250" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_761b86e9-6472-410f-a98a-13eeb5c2db59" xlink:to="loc_dei_EntityCentralIndexKey_d611cc9e-315c-48ac-bfae-1476ff346250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_9236de1f-aafb-4487-a08b-a71eb7cd66f4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_761b86e9-6472-410f-a98a-13eeb5c2db59" xlink:to="loc_dei_CurrentFiscalYearEndDate_9236de1f-aafb-4487-a08b-a71eb7cd66f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_470bebbf-4831-40a3-8312-7d5bd6d2edc5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_761b86e9-6472-410f-a98a-13eeb5c2db59" xlink:to="loc_dei_DocumentFiscalYearFocus_470bebbf-4831-40a3-8312-7d5bd6d2edc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_95da6263-15e7-405d-aec7-96b2b0f5991b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_761b86e9-6472-410f-a98a-13eeb5c2db59" xlink:to="loc_dei_DocumentFiscalPeriodFocus_95da6263-15e7-405d-aec7-96b2b0f5991b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_411fea1f-da71-404f-bf73-84262a542805" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_761b86e9-6472-410f-a98a-13eeb5c2db59" xlink:to="loc_dei_AmendmentFlag_411fea1f-da71-404f-bf73-84262a542805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ovid-20230630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_aae4f46f-0837-419f-b74e-30b273a16652" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_515bbe1b-35b7-42e5-85b6-1596cdacb4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_aae4f46f-0837-419f-b74e-30b273a16652" xlink:to="loc_us-gaap_AssetsAbstract_515bbe1b-35b7-42e5-85b6-1596cdacb4f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_c43d9f32-9ee0-430b-8ec3-4bbad9800b60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_515bbe1b-35b7-42e5-85b6-1596cdacb4f1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_c43d9f32-9ee0-430b-8ec3-4bbad9800b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6a093d1e-6574-4b5c-b2fe-a530ba2aa12c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c43d9f32-9ee0-430b-8ec3-4bbad9800b60" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6a093d1e-6574-4b5c-b2fe-a530ba2aa12c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f88193b4-5f76-4e44-b110-ba7a090956b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c43d9f32-9ee0-430b-8ec3-4bbad9800b60" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f88193b4-5f76-4e44-b110-ba7a090956b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9adcc2af-7981-41ae-8eb3-de8716d62638" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c43d9f32-9ee0-430b-8ec3-4bbad9800b60" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9adcc2af-7981-41ae-8eb3-de8716d62638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e1e68af3-6ac1-420f-a277-8efce5c11ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c43d9f32-9ee0-430b-8ec3-4bbad9800b60" xlink:to="loc_us-gaap_AssetsCurrent_e1e68af3-6ac1-420f-a277-8efce5c11ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_0712605d-c0c9-4698-bcd8-64c47083217a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_515bbe1b-35b7-42e5-85b6-1596cdacb4f1" xlink:to="loc_us-gaap_LongTermInvestments_0712605d-c0c9-4698-bcd8-64c47083217a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_8b376c09-72e0-4ba2-80cc-1637f6674d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_515bbe1b-35b7-42e5-85b6-1596cdacb4f1" xlink:to="loc_us-gaap_RestrictedCash_8b376c09-72e0-4ba2-80cc-1637f6674d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_afa9f83e-0f23-4900-bf91-c4bbd05689f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_515bbe1b-35b7-42e5-85b6-1596cdacb4f1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_afa9f83e-0f23-4900-bf91-c4bbd05689f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_655e9eb2-558f-406f-a1ea-f3f59a51be21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_515bbe1b-35b7-42e5-85b6-1596cdacb4f1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_655e9eb2-558f-406f-a1ea-f3f59a51be21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_24d59a1e-8b14-4252-b571-7a19a6222412" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_515bbe1b-35b7-42e5-85b6-1596cdacb4f1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_24d59a1e-8b14-4252-b571-7a19a6222412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b4a1b862-0f5e-4e31-8ea2-59e1750bf35e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_515bbe1b-35b7-42e5-85b6-1596cdacb4f1" xlink:to="loc_us-gaap_Assets_b4a1b862-0f5e-4e31-8ea2-59e1750bf35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_58f6d8d9-d63a-408e-9a37-882dc1996875" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_aae4f46f-0837-419f-b74e-30b273a16652" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_58f6d8d9-d63a-408e-9a37-882dc1996875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_ad00bac9-09e6-4789-af1f-d6ce8d996c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_58f6d8d9-d63a-408e-9a37-882dc1996875" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_ad00bac9-09e6-4789-af1f-d6ce8d996c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3870d17a-112b-4d65-b8ea-f09eeec855cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ad00bac9-09e6-4789-af1f-d6ce8d996c7b" xlink:to="loc_us-gaap_AccountsPayableCurrent_3870d17a-112b-4d65-b8ea-f09eeec855cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_13d7555c-aa42-434f-970c-3884a0d17991" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ad00bac9-09e6-4789-af1f-d6ce8d996c7b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_13d7555c-aa42-434f-970c-3884a0d17991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_9c57ddcb-f5ce-44fb-8736-4cd2254b2a53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ad00bac9-09e6-4789-af1f-d6ce8d996c7b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_9c57ddcb-f5ce-44fb-8736-4cd2254b2a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c7064e6e-5c6e-4239-aed5-e62191b00bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ad00bac9-09e6-4789-af1f-d6ce8d996c7b" xlink:to="loc_us-gaap_LiabilitiesCurrent_c7064e6e-5c6e-4239-aed5-e62191b00bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_ec9530f1-08f5-44cb-ab23-8e38f36c3ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_58f6d8d9-d63a-408e-9a37-882dc1996875" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_ec9530f1-08f5-44cb-ab23-8e38f36c3ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3207aade-d567-436b-9d2d-91d1c8ce798e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_ec9530f1-08f5-44cb-ab23-8e38f36c3ae4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3207aade-d567-436b-9d2d-91d1c8ce798e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_2a29d219-cfeb-4772-901e-3ae8e04c7faa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_58f6d8d9-d63a-408e-9a37-882dc1996875" xlink:to="loc_us-gaap_Liabilities_2a29d219-cfeb-4772-901e-3ae8e04c7faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_9b348da2-21ca-4358-9aba-5ab8966ccdd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_58f6d8d9-d63a-408e-9a37-882dc1996875" xlink:to="loc_us-gaap_StockholdersEquityAbstract_9b348da2-21ca-4358-9aba-5ab8966ccdd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_f1890e7c-7610-4258-a561-3d6462f0cff7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9b348da2-21ca-4358-9aba-5ab8966ccdd4" xlink:to="loc_us-gaap_PreferredStockValue_f1890e7c-7610-4258-a561-3d6462f0cff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_c57a8e28-2f3a-496d-a43e-f0bce0f09b07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9b348da2-21ca-4358-9aba-5ab8966ccdd4" xlink:to="loc_us-gaap_CommonStockValue_c57a8e28-2f3a-496d-a43e-f0bce0f09b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_0fe11125-b236-4f6e-81cd-291394c00b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9b348da2-21ca-4358-9aba-5ab8966ccdd4" xlink:to="loc_us-gaap_AdditionalPaidInCapital_0fe11125-b236-4f6e-81cd-291394c00b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a24893e5-3539-4c5c-850e-5c69be059ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9b348da2-21ca-4358-9aba-5ab8966ccdd4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a24893e5-3539-4c5c-850e-5c69be059ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5c906962-8b76-4ef1-bd08-1081b5f2dffd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9b348da2-21ca-4358-9aba-5ab8966ccdd4" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5c906962-8b76-4ef1-bd08-1081b5f2dffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_703d6a5a-02ac-43f0-a9c5-3d2ad741b590" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9b348da2-21ca-4358-9aba-5ab8966ccdd4" xlink:to="loc_us-gaap_StockholdersEquity_703d6a5a-02ac-43f0-a9c5-3d2ad741b590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_75d695bf-811b-4884-a0b5-56f59724ae22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_58f6d8d9-d63a-408e-9a37-882dc1996875" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_75d695bf-811b-4884-a0b5-56f59724ae22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="ovid-20230630.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_25826fac-a159-45af-8035-d3d01551de49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_afb90e3a-9b41-479f-a1aa-0a50a4a86868" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_25826fac-a159-45af-8035-d3d01551de49" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_afb90e3a-9b41-479f-a1aa-0a50a4a86868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_0fffc4f0-8387-4a95-a845-10ef75308010" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_25826fac-a159-45af-8035-d3d01551de49" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_0fffc4f0-8387-4a95-a845-10ef75308010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_PreferredStockShareDesignated_422f13a4-2550-4414-85a5-d26a32404bc6" xlink:href="ovid-20230630.xsd#ovid_PreferredStockShareDesignated"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_25826fac-a159-45af-8035-d3d01551de49" xlink:to="loc_ovid_PreferredStockShareDesignated_422f13a4-2550-4414-85a5-d26a32404bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_30b8bd23-6cb9-4051-baaa-9a9759d7e3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_25826fac-a159-45af-8035-d3d01551de49" xlink:to="loc_us-gaap_PreferredStockSharesIssued_30b8bd23-6cb9-4051-baaa-9a9759d7e3ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_7a238355-05f4-4c04-8df4-9b92e0383dea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_25826fac-a159-45af-8035-d3d01551de49" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_7a238355-05f4-4c04-8df4-9b92e0383dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_21ca2c4f-8553-4c57-8b71-4045bb011257" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_25826fac-a159-45af-8035-d3d01551de49" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_21ca2c4f-8553-4c57-8b71-4045bb011257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_4cc64b92-26b3-4c93-9692-589335a2c456" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_25826fac-a159-45af-8035-d3d01551de49" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_4cc64b92-26b3-4c93-9692-589335a2c456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_5534df46-8897-4fe9-aa83-3b04486cb70f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_25826fac-a159-45af-8035-d3d01551de49" xlink:to="loc_us-gaap_CommonStockSharesIssued_5534df46-8897-4fe9-aa83-3b04486cb70f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2a236e35-9722-4e87-b9d9-18f1e1aeabf6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_25826fac-a159-45af-8035-d3d01551de49" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2a236e35-9722-4e87-b9d9-18f1e1aeabf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ovid-20230630.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_fcb53161-f857-43fa-824a-11b4c23f796c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_729b2bec-a39c-448f-a753-57fe2614df0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_fcb53161-f857-43fa-824a-11b4c23f796c" xlink:to="loc_us-gaap_RevenuesAbstract_729b2bec-a39c-448f-a753-57fe2614df0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0bde28a6-e4c8-4f06-a672-c3f3b680c31e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_729b2bec-a39c-448f-a753-57fe2614df0e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0bde28a6-e4c8-4f06-a672-c3f3b680c31e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_a148310d-7595-43c6-ab21-ba390bb490c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_fcb53161-f857-43fa-824a-11b4c23f796c" xlink:to="loc_us-gaap_OperatingExpensesAbstract_a148310d-7595-43c6-ab21-ba390bb490c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7ce550a6-5808-482b-a991-c6e974d90146" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a148310d-7595-43c6-ab21-ba390bb490c7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7ce550a6-5808-482b-a991-c6e974d90146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1d610a87-6ab6-4876-95bb-b29092bb42da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a148310d-7595-43c6-ab21-ba390bb490c7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1d610a87-6ab6-4876-95bb-b29092bb42da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_283917b4-8f4c-4b48-9a53-8d3a5f84e851" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a148310d-7595-43c6-ab21-ba390bb490c7" xlink:to="loc_us-gaap_OperatingExpenses_283917b4-8f4c-4b48-9a53-8d3a5f84e851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ca1e7714-9047-41fb-8003-df43a3f1f94b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_fcb53161-f857-43fa-824a-11b4c23f796c" xlink:to="loc_us-gaap_OperatingIncomeLoss_ca1e7714-9047-41fb-8003-df43a3f1f94b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_39d747d8-3365-41ab-85a9-a9ff9d0a0a16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_fcb53161-f857-43fa-824a-11b4c23f796c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_39d747d8-3365-41ab-85a9-a9ff9d0a0a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e27b287d-ccd2-4ae4-b39f-064fd119e984" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_fcb53161-f857-43fa-824a-11b4c23f796c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e27b287d-ccd2-4ae4-b39f-064fd119e984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_91f1636d-f1f4-4733-8789-8b36b872e49f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_fcb53161-f857-43fa-824a-11b4c23f796c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_91f1636d-f1f4-4733-8789-8b36b872e49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5c5f70e9-3f3b-4ba3-8abf-f4a3596b0b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_fcb53161-f857-43fa-824a-11b4c23f796c" xlink:to="loc_us-gaap_NetIncomeLoss_5c5f70e9-3f3b-4ba3-8abf-f4a3596b0b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a726588f-f529-41d7-bcf7-385ca89b3964" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_fcb53161-f857-43fa-824a-11b4c23f796c" xlink:to="loc_us-gaap_EarningsPerShareBasic_a726588f-f529-41d7-bcf7-385ca89b3964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f6a19279-d923-4994-8b87-dbcf1d2697cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_fcb53161-f857-43fa-824a-11b4c23f796c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f6a19279-d923-4994-8b87-dbcf1d2697cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_248262a3-badd-476d-92f8-c5491e89a27f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_fcb53161-f857-43fa-824a-11b4c23f796c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_248262a3-badd-476d-92f8-c5491e89a27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ebde5258-eb1f-44ed-b105-8bef72ed3c98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_fcb53161-f857-43fa-824a-11b4c23f796c" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ebde5258-eb1f-44ed-b105-8bef72ed3c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="ovid-20230630.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1b9cea47-726b-4c17-91ce-1516f98cd1f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_258b5e29-f5eb-4083-9211-7efd23f64a87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1b9cea47-726b-4c17-91ce-1516f98cd1f5" xlink:to="loc_us-gaap_NetIncomeLoss_258b5e29-f5eb-4083-9211-7efd23f64a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_d26851f3-4c7b-43ee-850f-14d81a444be7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1b9cea47-726b-4c17-91ce-1516f98cd1f5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_d26851f3-4c7b-43ee-850f-14d81a444be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5bd27523-e565-4d91-a0b4-ad6362d37d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_d26851f3-4c7b-43ee-850f-14d81a444be7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5bd27523-e565-4d91-a0b4-ad6362d37d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_109cc92b-073a-4fc2-befb-d13caa37cbf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1b9cea47-726b-4c17-91ce-1516f98cd1f5" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_109cc92b-073a-4fc2-befb-d13caa37cbf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="ovid-20230630.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_580c8ad2-e324-4274-9082-efce7b206c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_32cee9e7-0e4d-45b7-b75c-1128b969dfcb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_580c8ad2-e324-4274-9082-efce7b206c9b" xlink:to="loc_us-gaap_StatementTable_32cee9e7-0e4d-45b7-b75c-1128b969dfcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d416ffa9-1a04-4576-b333-b8cf89a5de00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_32cee9e7-0e4d-45b7-b75c-1128b969dfcb" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d416ffa9-1a04-4576-b333-b8cf89a5de00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0d4c7275-3dec-4627-91e2-9bd82c20a456" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d416ffa9-1a04-4576-b333-b8cf89a5de00" xlink:to="loc_us-gaap_EquityComponentDomain_0d4c7275-3dec-4627-91e2-9bd82c20a456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_73d1394d-d74b-4145-a325-4fce1b731770" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0d4c7275-3dec-4627-91e2-9bd82c20a456" xlink:to="loc_us-gaap_PreferredStockMember_73d1394d-d74b-4145-a325-4fce1b731770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9078672d-ff58-4498-8c4c-84f33157d799" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0d4c7275-3dec-4627-91e2-9bd82c20a456" xlink:to="loc_us-gaap_CommonStockMember_9078672d-ff58-4498-8c4c-84f33157d799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_13c825ee-1448-40c4-a67b-3f66c0452584" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0d4c7275-3dec-4627-91e2-9bd82c20a456" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_13c825ee-1448-40c4-a67b-3f66c0452584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e3d676ff-5446-417f-a5e5-98d26226b7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0d4c7275-3dec-4627-91e2-9bd82c20a456" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e3d676ff-5446-417f-a5e5-98d26226b7c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_0db63f06-0d30-44e0-8f7a-6e98c38e0bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0d4c7275-3dec-4627-91e2-9bd82c20a456" xlink:to="loc_us-gaap_RetainedEarningsMember_0db63f06-0d30-44e0-8f7a-6e98c38e0bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a560871e-e428-4ebe-a248-4b669b2bd494" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_32cee9e7-0e4d-45b7-b75c-1128b969dfcb" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a560871e-e428-4ebe-a248-4b669b2bd494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3a5eb6ec-0931-4fb1-844a-337aeec48b24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a560871e-e428-4ebe-a248-4b669b2bd494" xlink:to="loc_us-gaap_ClassOfStockDomain_3a5eb6ec-0931-4fb1-844a-337aeec48b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_2e0c6a16-2375-4db8-a276-091068e4f6c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3a5eb6ec-0931-4fb1-844a-337aeec48b24" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_2e0c6a16-2375-4db8-a276-091068e4f6c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9bd619a0-85b6-4eb3-bae3-d39f93e3fc82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_32cee9e7-0e4d-45b7-b75c-1128b969dfcb" xlink:to="loc_us-gaap_StatementLineItems_9bd619a0-85b6-4eb3-bae3-d39f93e3fc82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61c1ff40-20c4-45fc-a1fd-2e3c168212a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9bd619a0-85b6-4eb3-bae3-d39f93e3fc82" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61c1ff40-20c4-45fc-a1fd-2e3c168212a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_9de9dc49-6db3-441d-99d2-fb78302bfce7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61c1ff40-20c4-45fc-a1fd-2e3c168212a5" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_9de9dc49-6db3-441d-99d2-fb78302bfce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_aab25577-bf41-4add-ba71-0cc307ea1b95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61c1ff40-20c4-45fc-a1fd-2e3c168212a5" xlink:to="loc_us-gaap_StockholdersEquity_aab25577-bf41-4add-ba71-0cc307ea1b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3d864a21-35b2-422e-b0b4-eba9ca7d4c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61c1ff40-20c4-45fc-a1fd-2e3c168212a5" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3d864a21-35b2-422e-b0b4-eba9ca7d4c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7923c50f-57d2-426c-bda2-8c54eab20e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61c1ff40-20c4-45fc-a1fd-2e3c168212a5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7923c50f-57d2-426c-bda2-8c54eab20e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3ccc3ef3-9acf-410d-a211-5687d7f979f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61c1ff40-20c4-45fc-a1fd-2e3c168212a5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3ccc3ef3-9acf-410d-a211-5687d7f979f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1292bec0-ce62-4e08-8ac2-5828de1a90e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61c1ff40-20c4-45fc-a1fd-2e3c168212a5" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1292bec0-ce62-4e08-8ac2-5828de1a90e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_728297ee-4a8e-4c11-bd39-7bd38747489b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61c1ff40-20c4-45fc-a1fd-2e3c168212a5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_728297ee-4a8e-4c11-bd39-7bd38747489b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_05ecef5b-ee00-4f5a-9c79-90476489179a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61c1ff40-20c4-45fc-a1fd-2e3c168212a5" xlink:to="loc_us-gaap_NetIncomeLoss_05ecef5b-ee00-4f5a-9c79-90476489179a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4944e06a-3996-48f6-bba9-6c7bdfba3741" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61c1ff40-20c4-45fc-a1fd-2e3c168212a5" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_4944e06a-3996-48f6-bba9-6c7bdfba3741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_279bed59-2ae6-435f-b6b0-ce705c1bf9f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61c1ff40-20c4-45fc-a1fd-2e3c168212a5" xlink:to="loc_us-gaap_StockholdersEquity_279bed59-2ae6-435f-b6b0-ce705c1bf9f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9e430411-5677-4b0c-a265-b708787f2713" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_61c1ff40-20c4-45fc-a1fd-2e3c168212a5" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9e430411-5677-4b0c-a265-b708787f2713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ovid-20230630.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_ede92c47-baef-4102-8aa1-6a93ade4253b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2aaedeef-9145-4d9d-9a18-fde613e15969" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ede92c47-baef-4102-8aa1-6a93ade4253b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2aaedeef-9145-4d9d-9a18-fde613e15969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_12720739-9e10-46ca-b50b-bb84cad50abf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2aaedeef-9145-4d9d-9a18-fde613e15969" xlink:to="loc_us-gaap_NetIncomeLoss_12720739-9e10-46ca-b50b-bb84cad50abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a1cbf21a-fc4c-4c32-9aab-53ddccb2045a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2aaedeef-9145-4d9d-9a18-fde613e15969" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a1cbf21a-fc4c-4c32-9aab-53ddccb2045a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction_689ba29b-a10c-4c1e-8abb-12d05e1b7b1c" xlink:href="ovid-20230630.xsd#ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a1cbf21a-fc4c-4c32-9aab-53ddccb2045a" xlink:to="loc_ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction_689ba29b-a10c-4c1e-8abb-12d05e1b7b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_36a1eb8d-c437-4d80-a1dc-4cd61730fdf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a1cbf21a-fc4c-4c32-9aab-53ddccb2045a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_36a1eb8d-c437-4d80-a1dc-4cd61730fdf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_ChangeInAccruedInterestAndAccretionOfDiscountsShortTermInvestments_d2c147cc-5ed6-4e94-8eb9-0cdddabfe094" xlink:href="ovid-20230630.xsd#ovid_ChangeInAccruedInterestAndAccretionOfDiscountsShortTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a1cbf21a-fc4c-4c32-9aab-53ddccb2045a" xlink:to="loc_ovid_ChangeInAccruedInterestAndAccretionOfDiscountsShortTermInvestments_d2c147cc-5ed6-4e94-8eb9-0cdddabfe094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c9cf987b-6f2a-4dec-98e5-71cb170fad3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a1cbf21a-fc4c-4c32-9aab-53ddccb2045a" xlink:to="loc_us-gaap_ShareBasedCompensation_c9cf987b-6f2a-4dec-98e5-71cb170fad3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f94a69bd-8b2c-40ef-bdfd-a10bca3b52b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a1cbf21a-fc4c-4c32-9aab-53ddccb2045a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f94a69bd-8b2c-40ef-bdfd-a10bca3b52b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_5c7205c1-305b-4d6d-80d6-5f0614d4e43e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a1cbf21a-fc4c-4c32-9aab-53ddccb2045a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_5c7205c1-305b-4d6d-80d6-5f0614d4e43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AccretionOfLeaseLiability_f8a925ac-69d9-40d9-8a11-75357e6a0c46" xlink:href="ovid-20230630.xsd#ovid_AccretionOfLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a1cbf21a-fc4c-4c32-9aab-53ddccb2045a" xlink:to="loc_ovid_AccretionOfLeaseLiability_f8a925ac-69d9-40d9-8a11-75357e6a0c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ad6f6081-c42c-42fb-b095-e308d301a615" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2aaedeef-9145-4d9d-9a18-fde613e15969" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ad6f6081-c42c-42fb-b095-e308d301a615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0e8a893b-f7f9-4bc8-9228-e60341baf4b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ad6f6081-c42c-42fb-b095-e308d301a615" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0e8a893b-f7f9-4bc8-9228-e60341baf4b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_d479ed71-6bc0-4284-b30d-844645e04cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ad6f6081-c42c-42fb-b095-e308d301a615" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_d479ed71-6bc0-4284-b30d-844645e04cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_91208212-850b-471a-bedd-1ce57f6fb0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ad6f6081-c42c-42fb-b095-e308d301a615" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_91208212-850b-471a-bedd-1ce57f6fb0ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ac9172dc-71c3-458c-aeef-c63a173b2246" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ad6f6081-c42c-42fb-b095-e308d301a615" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ac9172dc-71c3-458c-aeef-c63a173b2246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5afb84a-22d9-4704-88a5-1e0f709acade" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2aaedeef-9145-4d9d-9a18-fde613e15969" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d5afb84a-22d9-4704-88a5-1e0f709acade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d1bdf3d2-3eeb-4656-b7ac-3a40be14f51d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ede92c47-baef-4102-8aa1-6a93ade4253b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d1bdf3d2-3eeb-4656-b7ac-3a40be14f51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f66b62d1-1375-49ea-a5f6-ea5bb6b91fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d1bdf3d2-3eeb-4656-b7ac-3a40be14f51d" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f66b62d1-1375-49ea-a5f6-ea5bb6b91fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_3b440f89-d11e-4c94-b23d-a08c58740e63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d1bdf3d2-3eeb-4656-b7ac-3a40be14f51d" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_3b440f89-d11e-4c94-b23d-a08c58740e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments_cc1be343-dc2d-45b4-b4ea-cc21ce942f6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d1bdf3d2-3eeb-4656-b7ac-3a40be14f51d" xlink:to="loc_us-gaap_PaymentsToAcquireLongtermInvestments_cc1be343-dc2d-45b4-b4ea-cc21ce942f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_PaymentsForProceedsFromIssuanceOfShortTermNoteReceivable_e2ac3d95-9b65-4380-a54d-5608fa923e60" xlink:href="ovid-20230630.xsd#ovid_PaymentsForProceedsFromIssuanceOfShortTermNoteReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d1bdf3d2-3eeb-4656-b7ac-3a40be14f51d" xlink:to="loc_ovid_PaymentsForProceedsFromIssuanceOfShortTermNoteReceivable_e2ac3d95-9b65-4380-a54d-5608fa923e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1560720b-4a3d-4e51-b63c-ba6501d4e3e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d1bdf3d2-3eeb-4656-b7ac-3a40be14f51d" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1560720b-4a3d-4e51-b63c-ba6501d4e3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToDevelopSoftware_b925dc90-6a40-4682-881d-5651eaf5e447" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToDevelopSoftware"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d1bdf3d2-3eeb-4656-b7ac-3a40be14f51d" xlink:to="loc_us-gaap_PaymentsToDevelopSoftware_b925dc90-6a40-4682-881d-5651eaf5e447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dd8fafcc-44f2-4ca1-ab5a-aa16785d6d08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d1bdf3d2-3eeb-4656-b7ac-3a40be14f51d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dd8fafcc-44f2-4ca1-ab5a-aa16785d6d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3ddb2d38-09c7-4d8e-a423-1b82e7db6e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ede92c47-baef-4102-8aa1-6a93ade4253b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3ddb2d38-09c7-4d8e-a423-1b82e7db6e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_27748d1a-457f-48cc-9293-cbd8e68cbcfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3ddb2d38-09c7-4d8e-a423-1b82e7db6e0e" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_27748d1a-457f-48cc-9293-cbd8e68cbcfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_546381f8-92b0-4e21-807d-df27d391eedb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3ddb2d38-09c7-4d8e-a423-1b82e7db6e0e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_546381f8-92b0-4e21-807d-df27d391eedb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_dea5a154-82df-4295-9276-a53e1cbfb60d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ede92c47-baef-4102-8aa1-6a93ade4253b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_dea5a154-82df-4295-9276-a53e1cbfb60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_27bc4fe6-f5c4-4faa-8fe0-05cbf86f934c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ede92c47-baef-4102-8aa1-6a93ade4253b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_27bc4fe6-f5c4-4faa-8fe0-05cbf86f934c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8af770d4-e292-453d-b6c0-3522acedf235" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ede92c47-baef-4102-8aa1-6a93ade4253b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8af770d4-e292-453d-b6c0-3522acedf235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_c6e61050-cf34-481c-8d9a-60903662d519" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ede92c47-baef-4102-8aa1-6a93ade4253b" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_c6e61050-cf34-481c-8d9a-60903662d519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_8933bdde-0f0d-47cf-ac89-f1dbcfcd1896" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_c6e61050-cf34-481c-8d9a-60903662d519" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_8933bdde-0f0d-47cf-ac89-f1dbcfcd1896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/NATUREOFOPERATIONS" xlink:type="simple" xlink:href="ovid-20230630.xsd#NATUREOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/NATUREOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4c8b6a90-1bbd-4b7d-a8d3-f6a0ee666b86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_7aad18bf-fdac-4caf-9746-970caf20057b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4c8b6a90-1bbd-4b7d-a8d3-f6a0ee666b86" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_7aad18bf-fdac-4caf-9746-970caf20057b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="ovid-20230630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_313b21f5-10e5-4b76-a4a7-d64a7f9d4efd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_98020837-3615-4463-9b86-22f6c631ba76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_313b21f5-10e5-4b76-a4a7-d64a7f9d4efd" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_98020837-3615-4463-9b86-22f6c631ba76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIES" xlink:type="simple" xlink:href="ovid-20230630.xsd#CASHCASHEQUIVALENTSANDMARKETABLESECURITIES"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_d8caaddb-32b5-46ef-acf6-6d0d2a47d495" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_3c51dd1c-a7da-45b3-bf00-68a99a60af75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_d8caaddb-32b5-46ef-acf6-6d0d2a47d495" xlink:to="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_3c51dd1c-a7da-45b3-bf00-68a99a60af75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETS" xlink:type="simple" xlink:href="ovid-20230630.xsd#PROPERTYANDEQUIPMENTANDINTANGIBLEASSETS"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_36105713-3043-486e-9052-6f6d835a93af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock_2b143942-8174-409e-a491-90deb248a31d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_36105713-3043-486e-9052-6f6d835a93af" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock_2b143942-8174-409e-a491-90deb248a31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/LEASES" xlink:type="simple" xlink:href="ovid-20230630.xsd#LEASES"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/LEASES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c0a03cd5-40c9-439d-9ac9-c7c653e3c7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_340a96d4-6405-488c-a622-91dd97799cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c0a03cd5-40c9-439d-9ac9-c7c653e3c7d3" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_340a96d4-6405-488c-a622-91dd97799cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/ACCRUEDEXPENSES" xlink:type="simple" xlink:href="ovid-20230630.xsd#ACCRUEDEXPENSES"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/ACCRUEDEXPENSES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_b4d86020-cc27-4597-94d2-f1e861bbe697" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_557dc668-b402-4bca-9902-7eda6916d8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b4d86020-cc27-4597-94d2-f1e861bbe697" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_557dc668-b402-4bca-9902-7eda6916d8ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="ovid-20230630.xsd#STOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f23d4ebb-b3c2-4c6c-9dc2-2c777b73a2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_c824bdb1-031a-43b4-8e9d-2f2b9bed671f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f23d4ebb-b3c2-4c6c-9dc2-2c777b73a2e0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_c824bdb1-031a-43b4-8e9d-2f2b9bed671f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="ovid-20230630.xsd#STOCKBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6f3f4e2d-970e-4cd4-9533-0e0afc9e1eee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a6647e29-4dc1-4c1c-bf88-7923b71f49b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6f3f4e2d-970e-4cd4-9533-0e0afc9e1eee" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a6647e29-4dc1-4c1c-bf88-7923b71f49b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/INCOMETAXES" xlink:type="simple" xlink:href="ovid-20230630.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_933edd10-4650-4000-b257-87cc7a06effa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_572b9e3f-5f8c-4b21-8bf5-123e44324db4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_933edd10-4650-4000-b257-87cc7a06effa" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_572b9e3f-5f8c-4b21-8bf5-123e44324db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="ovid-20230630.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_012de475-fe06-4c4e-85dd-3f76a78c3b03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5c0aacec-e5bf-44cb-9b09-bbec1d08556f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_012de475-fe06-4c4e-85dd-3f76a78c3b03" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5c0aacec-e5bf-44cb-9b09-bbec1d08556f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTS" xlink:type="simple" xlink:href="ovid-20230630.xsd#COLLABORATIONANDLICENSEAGREEMENTS"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_08661ce8-1e13-45ff-8d0a-860344e2491b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_00ea3168-5573-4809-b890-a7c1bfc14779" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_08661ce8-1e13-45ff-8d0a-860344e2491b" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_00ea3168-5573-4809-b890-a7c1bfc14779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="ovid-20230630.xsd#RELATEDPARTYTRANSACTIONS"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_53b86559-5764-478c-9ba8-3ca5c4ee3c39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_da445ecd-a4c7-43cf-ba12-f2695065fd14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_53b86559-5764-478c-9ba8-3ca5c4ee3c39" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_da445ecd-a4c7-43cf-ba12-f2695065fd14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/NETLOSSPERSHARE" xlink:type="simple" xlink:href="ovid-20230630.xsd#NETLOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/NETLOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f4ee1ffb-f1e7-46a9-89c8-cdd1c857e4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_553dfe7e-a925-4884-aef3-409e20c19f98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f4ee1ffb-f1e7-46a9-89c8-cdd1c857e4ec" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_553dfe7e-a925-4884-aef3-409e20c19f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="ovid-20230630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8faf370e-4304-422e-8fad-d65da0f94386" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_UnauditedInterimFinancialStatementsPolicyPolicyTextBlock_00c504f6-7882-4fdd-bd19-42c4097344ca" xlink:href="ovid-20230630.xsd#ovid_UnauditedInterimFinancialStatementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8faf370e-4304-422e-8fad-d65da0f94386" xlink:to="loc_ovid_UnauditedInterimFinancialStatementsPolicyPolicyTextBlock_00c504f6-7882-4fdd-bd19-42c4097344ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_8d3a3427-f432-4cc1-81f0-22ec704537e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8faf370e-4304-422e-8fad-d65da0f94386" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_8d3a3427-f432-4cc1-81f0-22ec704537e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_0eb89aad-958e-4a7c-bb15-a9e38e920d60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8faf370e-4304-422e-8fad-d65da0f94386" xlink:to="loc_us-gaap_UseOfEstimates_0eb89aad-958e-4a7c-bb15-a9e38e920d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_9d7aec71-400d-4e4a-870b-dccba2d92d25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8faf370e-4304-422e-8fad-d65da0f94386" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_9d7aec71-400d-4e4a-870b-dccba2d92d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_d2bb40d2-4e51-42fa-8266-aa38427f99a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8faf370e-4304-422e-8fad-d65da0f94386" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_d2bb40d2-4e51-42fa-8266-aa38427f99a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_fa6b3c1d-bf9a-4b5d-839e-9df66c0f4754" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8faf370e-4304-422e-8fad-d65da0f94386" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_fa6b3c1d-bf9a-4b5d-839e-9df66c0f4754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_3571fea2-7f93-44ea-b5d6-3bbf0fd9ace0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8faf370e-4304-422e-8fad-d65da0f94386" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_3571fea2-7f93-44ea-b5d6-3bbf0fd9ace0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_b3707cc0-d984-415c-8bea-6661a928b38a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8faf370e-4304-422e-8fad-d65da0f94386" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_b3707cc0-d984-415c-8bea-6661a928b38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_8f85c687-dbc0-4460-8ce3-2b8167d37ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8faf370e-4304-422e-8fad-d65da0f94386" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_8f85c687-dbc0-4460-8ce3-2b8167d37ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_d6ac5a44-df99-4583-84e9-d0b6c3ac2624" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8faf370e-4304-422e-8fad-d65da0f94386" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_d6ac5a44-df99-4583-84e9-d0b6c3ac2624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_90f04a0d-9bc1-425d-8c9e-f1c99000f921" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8faf370e-4304-422e-8fad-d65da0f94386" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_90f04a0d-9bc1-425d-8c9e-f1c99000f921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_c68d3297-2f91-4b82-b6bc-b047da2e2887" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8faf370e-4304-422e-8fad-d65da0f94386" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_c68d3297-2f91-4b82-b6bc-b047da2e2887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_a4084d61-73f0-49f2-99f7-0d44a3b08671" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8faf370e-4304-422e-8fad-d65da0f94386" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_a4084d61-73f0-49f2-99f7-0d44a3b08671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_34e79749-304f-4a49-b705-ffb620bf60b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8faf370e-4304-422e-8fad-d65da0f94386" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_34e79749-304f-4a49-b705-ffb620bf60b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_669b3ba7-d198-4b83-b671-a6a621e4ad47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8faf370e-4304-422e-8fad-d65da0f94386" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_669b3ba7-d198-4b83-b671-a6a621e4ad47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESTables" xlink:type="simple" xlink:href="ovid-20230630.xsd#CASHCASHEQUIVALENTSANDMARKETABLESECURITIESTables"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_e888c43c-5662-4de9-96d2-e1ec5107a11f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_b11196cd-edb8-4438-b07f-24363d8a93e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_e888c43c-5662-4de9-96d2-e1ec5107a11f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_b11196cd-edb8-4438-b07f-24363d8a93e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_4b233ca8-3dfa-4f46-ae1a-fdef8fe4d7ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_e888c43c-5662-4de9-96d2-e1ec5107a11f" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_4b233ca8-3dfa-4f46-ae1a-fdef8fe4d7ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSTables" xlink:type="simple" xlink:href="ovid-20230630.xsd#PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSTables"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_043d799d-144d-42c9-b132-cbe9d9888d16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_e949ff97-ec5f-4e6b-a8d1-d5782a72bc20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_043d799d-144d-42c9-b132-cbe9d9888d16" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_e949ff97-ec5f-4e6b-a8d1-d5782a72bc20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/LEASESTables" xlink:type="simple" xlink:href="ovid-20230630.xsd#LEASESTables"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/LEASESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_09326be1-dcda-42fe-988b-feebbfb7c476" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock_0a1708ac-540d-4b73-a12b-79da7771c577" xlink:href="ovid-20230630.xsd#ovid_RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_09326be1-dcda-42fe-988b-feebbfb7c476" xlink:to="loc_ovid_RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock_0a1708ac-540d-4b73-a12b-79da7771c577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_22d06d9b-0708-4d7c-8bdd-dc7953e90069" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_09326be1-dcda-42fe-988b-feebbfb7c476" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_22d06d9b-0708-4d7c-8bdd-dc7953e90069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_94b36ba9-88e6-4d6c-b9d0-76540579766a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_09326be1-dcda-42fe-988b-feebbfb7c476" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_94b36ba9-88e6-4d6c-b9d0-76540579766a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/ACCRUEDEXPENSESTables" xlink:type="simple" xlink:href="ovid-20230630.xsd#ACCRUEDEXPENSESTables"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/ACCRUEDEXPENSESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_a211666f-b8f3-49e8-a151-537e8a471e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_809289b0-ddc4-452c-9f0c-89f9859de91a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a211666f-b8f3-49e8-a151-537e8a471e4b" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_809289b0-ddc4-452c-9f0c-89f9859de91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="ovid-20230630.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_53ff0110-4768-49a7-b78f-d731ae27c863" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_31da562f-84c7-492a-a474-23297e604f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_53ff0110-4768-49a7-b78f-d731ae27c863" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_31da562f-84c7-492a-a474-23297e604f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_e6d9d216-4ff1-4422-81a0-f1e1a9ea85b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_53ff0110-4768-49a7-b78f-d731ae27c863" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_e6d9d216-4ff1-4422-81a0-f1e1a9ea85b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_fea73e46-c85a-4785-820e-1d5bf1500908" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_53ff0110-4768-49a7-b78f-d731ae27c863" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_fea73e46-c85a-4785-820e-1d5bf1500908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_51d15a47-ff46-4da7-afdd-40be42e481f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_53ff0110-4768-49a7-b78f-d731ae27c863" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_51d15a47-ff46-4da7-afdd-40be42e481f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/NETLOSSPERSHARETables" xlink:type="simple" xlink:href="ovid-20230630.xsd#NETLOSSPERSHARETables"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/NETLOSSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0ea8c252-0f68-427e-9445-54a5eba23135" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_13c68100-b266-4436-b3f5-c92a65180935" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0ea8c252-0f68-427e-9445-54a5eba23135" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_13c68100-b266-4436-b3f5-c92a65180935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_7390baa4-fb29-43bc-86be-aea73752dcec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0ea8c252-0f68-427e-9445-54a5eba23135" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_7390baa4-fb29-43bc-86be-aea73752dcec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/NATUREOFOPERATIONSAdditionalInformationDetail" xlink:type="simple" xlink:href="ovid-20230630.xsd#NATUREOFOPERATIONSAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/NATUREOFOPERATIONSAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3d6876d6-f1fa-48f4-b0cd-c54df5c1ef90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_76eb4452-cbc5-44c4-b674-7db517da6c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3d6876d6-f1fa-48f4-b0cd-c54df5c1ef90" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_76eb4452-cbc5-44c4-b674-7db517da6c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4d825a32-4e61-46bb-bafc-26ecb61c140f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3d6876d6-f1fa-48f4-b0cd-c54df5c1ef90" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4d825a32-4e61-46bb-bafc-26ecb61c140f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6cb9ebb2-7617-403e-b760-5d3258985640" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3d6876d6-f1fa-48f4-b0cd-c54df5c1ef90" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6cb9ebb2-7617-403e-b760-5d3258985640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_WorkingCapital_6100c463-bf32-4ef1-a622-332f905a50d0" xlink:href="ovid-20230630.xsd#ovid_WorkingCapital"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3d6876d6-f1fa-48f4-b0cd-c54df5c1ef90" xlink:to="loc_ovid_WorkingCapital_6100c463-bf32-4ef1-a622-332f905a50d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a9b62435-3e12-4d7b-99df-6e20b4f67443" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3d6876d6-f1fa-48f4-b0cd-c54df5c1ef90" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a9b62435-3e12-4d7b-99df-6e20b4f67443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7d7d281a-e10d-4bc3-9f50-d44c3c37d8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3d6876d6-f1fa-48f4-b0cd-c54df5c1ef90" xlink:to="loc_us-gaap_NetIncomeLoss_7d7d281a-e10d-4bc3-9f50-d44c3c37d8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail" xlink:type="simple" xlink:href="ovid-20230630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_00229f0f-1fba-4d63-8d16-2c46be2ec816" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_SummaryOfSignificantAccountingPolicyTable_f7a1a32e-c764-4a5f-884b-b522f0cc0736" xlink:href="ovid-20230630.xsd#ovid_SummaryOfSignificantAccountingPolicyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_00229f0f-1fba-4d63-8d16-2c46be2ec816" xlink:to="loc_ovid_SummaryOfSignificantAccountingPolicyTable_f7a1a32e-c764-4a5f-884b-b522f0cc0736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_e8e5adc4-8617-4ed9-bd56-16272b308a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyTable_f7a1a32e-c764-4a5f-884b-b522f0cc0736" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_e8e5adc4-8617-4ed9-bd56-16272b308a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_48d6b9f7-b694-4ee9-8239-5bde1ebf945f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_e8e5adc4-8617-4ed9-bd56-16272b308a9c" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_48d6b9f7-b694-4ee9-8239-5bde1ebf945f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MoneyMarketFundsAndShortTermInvestmentsMember_0260e7e4-c29d-49c3-862c-1e8a5a9ff12c" xlink:href="ovid-20230630.xsd#ovid_MoneyMarketFundsAndShortTermInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_48d6b9f7-b694-4ee9-8239-5bde1ebf945f" xlink:to="loc_ovid_MoneyMarketFundsAndShortTermInvestmentsMember_0260e7e4-c29d-49c3-862c-1e8a5a9ff12c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_37e0d5ec-e1c7-4ae0-8258-d84c2ddb30fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyTable_f7a1a32e-c764-4a5f-884b-b522f0cc0736" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_37e0d5ec-e1c7-4ae0-8258-d84c2ddb30fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_779d865d-933d-441e-a894-675a18dc6172" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_37e0d5ec-e1c7-4ae0-8258-d84c2ddb30fc" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_779d865d-933d-441e-a894-675a18dc6172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_fd65d26d-c137-4361-81c9-489bdf310358" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_779d865d-933d-441e-a894-675a18dc6172" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_fd65d26d-c137-4361-81c9-489bdf310358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1618721c-89c3-463f-b32d-c44466386a48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_779d865d-933d-441e-a894-675a18dc6172" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1618721c-89c3-463f-b32d-c44466386a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d1dda017-2af3-481a-a1e8-dde534ab8564" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyTable_f7a1a32e-c764-4a5f-884b-b522f0cc0736" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d1dda017-2af3-481a-a1e8-dde534ab8564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_e78bafd0-68d7-4667-9e33-1024ab8d587f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d1dda017-2af3-481a-a1e8-dde534ab8564" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_e78bafd0-68d7-4667-9e33-1024ab8d587f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_GravitonBioscienceCorporationMember_7d249ac6-9f95-470c-b09c-8c4e9c07cf2b" xlink:href="ovid-20230630.xsd#ovid_GravitonBioscienceCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e78bafd0-68d7-4667-9e33-1024ab8d587f" xlink:to="loc_ovid_GravitonBioscienceCorporationMember_7d249ac6-9f95-470c-b09c-8c4e9c07cf2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MarinusTherapeuticsIncMember_78e1b361-6103-48dc-8a72-2b67c5185752" xlink:href="ovid-20230630.xsd#ovid_MarinusTherapeuticsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e78bafd0-68d7-4667-9e33-1024ab8d587f" xlink:to="loc_ovid_MarinusTherapeuticsIncMember_78e1b361-6103-48dc-8a72-2b67c5185752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_GensaicIncMember_c485e850-7bf0-4416-80e8-70b64b6a6f65" xlink:href="ovid-20230630.xsd#ovid_GensaicIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e78bafd0-68d7-4667-9e33-1024ab8d587f" xlink:to="loc_ovid_GensaicIncMember_c485e850-7bf0-4416-80e8-70b64b6a6f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_SummaryOfSignificantAccountingPolicyLineItems_583153a4-d947-4df0-9894-315b0de2b9a4" xlink:href="ovid-20230630.xsd#ovid_SummaryOfSignificantAccountingPolicyLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyTable_f7a1a32e-c764-4a5f-884b-b522f0cc0736" xlink:to="loc_ovid_SummaryOfSignificantAccountingPolicyLineItems_583153a4-d947-4df0-9894-315b0de2b9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_7efa82ab-5374-4440-930c-4b68ba35c7f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyLineItems_583153a4-d947-4df0-9894-315b0de2b9a4" xlink:to="loc_us-gaap_LongTermInvestments_7efa82ab-5374-4440-930c-4b68ba35c7f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2e247dde-fd79-4c98-94c9-128bfffac787" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyLineItems_583153a4-d947-4df0-9894-315b0de2b9a4" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_2e247dde-fd79-4c98-94c9-128bfffac787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7c190afb-aa73-4933-a226-3177f809c7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ovid_SummaryOfSignificantAccountingPolicyLineItems_583153a4-d947-4df0-9894-315b0de2b9a4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7c190afb-aa73-4933-a226-3177f809c7c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail" xlink:type="simple" xlink:href="ovid-20230630.xsd#CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_be072ea5-1bcb-4dcf-9bbd-4afdba4398d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_6229f8ed-c4ac-479e-a81c-2e7b0ed2dfff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_be072ea5-1bcb-4dcf-9bbd-4afdba4398d0" xlink:to="loc_us-gaap_Cash_6229f8ed-c4ac-479e-a81c-2e7b0ed2dfff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CashEquivalentsAmortizedCost_07b5b5c1-4d99-486e-96a2-ed8ede03f9c8" xlink:href="ovid-20230630.xsd#ovid_CashEquivalentsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_be072ea5-1bcb-4dcf-9bbd-4afdba4398d0" xlink:to="loc_ovid_CashEquivalentsAmortizedCost_07b5b5c1-4d99-486e-96a2-ed8ede03f9c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_756fb6bd-81d1-4767-ab60-470e6f238c55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_be072ea5-1bcb-4dcf-9bbd-4afdba4398d0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_756fb6bd-81d1-4767-ab60-470e6f238c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CashEquivalentsUnrealizedHoldingGains_604fa569-c086-4f6d-9cfe-3d0eab8b5e00" xlink:href="ovid-20230630.xsd#ovid_CashEquivalentsUnrealizedHoldingGains"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_be072ea5-1bcb-4dcf-9bbd-4afdba4398d0" xlink:to="loc_ovid_CashEquivalentsUnrealizedHoldingGains_604fa569-c086-4f6d-9cfe-3d0eab8b5e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CashEquivalentsUnrealizedHoldingLosses_8c2c86bc-7688-4d52-a7a4-8b8792f78857" xlink:href="ovid-20230630.xsd#ovid_CashEquivalentsUnrealizedHoldingLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_be072ea5-1bcb-4dcf-9bbd-4afdba4398d0" xlink:to="loc_ovid_CashEquivalentsUnrealizedHoldingLosses_8c2c86bc-7688-4d52-a7a4-8b8792f78857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e2fc4e8f-453e-4863-beff-1d973390a43f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_be072ea5-1bcb-4dcf-9bbd-4afdba4398d0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e2fc4e8f-453e-4863-beff-1d973390a43f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f3c3aaa8-4615-4e1d-be50-ebadc478d6c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_be072ea5-1bcb-4dcf-9bbd-4afdba4398d0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f3c3aaa8-4615-4e1d-be50-ebadc478d6c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_84fea0fe-f2b0-4709-aa3b-3b00ca2c5df1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_be072ea5-1bcb-4dcf-9bbd-4afdba4398d0" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_84fea0fe-f2b0-4709-aa3b-3b00ca2c5df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f5bbcc56-01bd-4b74-baac-fb7d858727b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_be072ea5-1bcb-4dcf-9bbd-4afdba4398d0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f5bbcc56-01bd-4b74-baac-fb7d858727b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost_f0a11293-52e9-4293-8126-1b4cf435382a" xlink:href="ovid-20230630.xsd#ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_be072ea5-1bcb-4dcf-9bbd-4afdba4398d0" xlink:to="loc_ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost_f0a11293-52e9-4293-8126-1b4cf435382a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingGain_ad2ed696-eaa8-4a61-90e9-7c347fb9c8e7" xlink:href="ovid-20230630.xsd#ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingGain"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_be072ea5-1bcb-4dcf-9bbd-4afdba4398d0" xlink:to="loc_ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingGain_ad2ed696-eaa8-4a61-90e9-7c347fb9c8e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingLoss_f29698a5-c398-4fe7-b144-fa61b8aa62ee" xlink:href="ovid-20230630.xsd#ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_be072ea5-1bcb-4dcf-9bbd-4afdba4398d0" xlink:to="loc_ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingLoss_f29698a5-c398-4fe7-b144-fa61b8aa62ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_503f0f29-f8c2-4cba-8f4d-e4db62dcee12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_be072ea5-1bcb-4dcf-9bbd-4afdba4398d0" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_503f0f29-f8c2-4cba-8f4d-e4db62dcee12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue_2d7084a5-12eb-40ae-9bdf-83c429988be5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_be072ea5-1bcb-4dcf-9bbd-4afdba4398d0" xlink:to="loc_us-gaap_MoneyMarketFundsAtCarryingValue_2d7084a5-12eb-40ae-9bdf-83c429988be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail_1" xlink:type="simple" xlink:href="ovid-20230630.xsd#CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail_1"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail" xlink:type="simple" xlink:href="ovid-20230630.xsd#CASHCASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_d302c041-3f5c-4842-a959-78b4d27f2a62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_1cc4ac48-68c2-4b74-a6dc-1f00e486c9c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_d302c041-3f5c-4842-a959-78b4d27f2a62" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_1cc4ac48-68c2-4b74-a6dc-1f00e486c9c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSSummaryofPropertyandEquipmentDetail" xlink:type="simple" xlink:href="ovid-20230630.xsd#PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSSummaryofPropertyandEquipmentDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSSummaryofPropertyandEquipmentDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_30211dc7-6eeb-42c1-8359-442bba9ce807" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2abc5f9b-ee66-439b-9356-65a9982d53cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_30211dc7-6eeb-42c1-8359-442bba9ce807" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2abc5f9b-ee66-439b-9356-65a9982d53cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a43a0eb5-1918-43bb-8439-2dd5abded7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2abc5f9b-ee66-439b-9356-65a9982d53cb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a43a0eb5-1918-43bb-8439-2dd5abded7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_be465f0f-ccdf-404b-9c02-ded5be91d7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a43a0eb5-1918-43bb-8439-2dd5abded7a9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_be465f0f-ccdf-404b-9c02-ded5be91d7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_61d921b7-c435-4913-a516-d7a589644faa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_be465f0f-ccdf-404b-9c02-ded5be91d7bb" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_61d921b7-c435-4913-a516-d7a589644faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_3f05ebad-5a5e-4c8f-97ce-e51cd412ecb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_be465f0f-ccdf-404b-9c02-ded5be91d7bb" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_3f05ebad-5a5e-4c8f-97ce-e51cd412ecb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c9abad77-a2de-47a3-8a9c-8d6b73436582" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2abc5f9b-ee66-439b-9356-65a9982d53cb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c9abad77-a2de-47a3-8a9c-8d6b73436582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_3cc6a649-978b-43aa-9e45-1ec9462c2bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c9abad77-a2de-47a3-8a9c-8d6b73436582" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_3cc6a649-978b-43aa-9e45-1ec9462c2bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c608ba24-239f-46de-a75e-b696327681bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c9abad77-a2de-47a3-8a9c-8d6b73436582" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c608ba24-239f-46de-a75e-b696327681bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1618780a-e898-4610-8ec0-535638d54f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c9abad77-a2de-47a3-8a9c-8d6b73436582" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1618780a-e898-4610-8ec0-535638d54f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSAdditionalInformationDetail" xlink:type="simple" xlink:href="ovid-20230630.xsd#PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ec0220cd-5694-4e6a-bf96-5dc55c2d29e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_315a9c4e-355b-4213-8130-0c72eaae8cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ec0220cd-5694-4e6a-bf96-5dc55c2d29e9" xlink:to="loc_us-gaap_Depreciation_315a9c4e-355b-4213-8130-0c72eaae8cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_bf298380-198e-48ba-b294-f9b89eebb9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ec0220cd-5694-4e6a-bf96-5dc55c2d29e9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_bf298380-198e-48ba-b294-f9b89eebb9fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1d4a4989-553b-4a95-a992-0ee9713d711a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ec0220cd-5694-4e6a-bf96-5dc55c2d29e9" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1d4a4989-553b-4a95-a992-0ee9713d711a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/LEASESAdditionalInformationDetail" xlink:type="simple" xlink:href="ovid-20230630.xsd#LEASESAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/LEASESAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_7972686c-224b-4c22-8a32-46f559bcccd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_8f9012ea-d3c4-4783-a51b-9e7fe1ad03d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7972686c-224b-4c22-8a32-46f559bcccd1" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_8f9012ea-d3c4-4783-a51b-9e7fe1ad03d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_b72fc0e2-0599-4808-98d0-5554489365f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_8f9012ea-d3c4-4783-a51b-9e7fe1ad03d5" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_b72fc0e2-0599-4808-98d0-5554489365f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_b94f07a8-ff89-4727-8a8d-f4998173efdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_b72fc0e2-0599-4808-98d0-5554489365f3" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_b94f07a8-ff89-4727-8a8d-f4998173efdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_0f26bdec-945f-48de-89e0-d9a9508f6e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_b94f07a8-ff89-4727-8a8d-f4998173efdb" xlink:to="loc_us-gaap_LetterOfCreditMember_0f26bdec-945f-48de-89e0-d9a9508f6e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_8a90234a-c35d-4465-9425-c80ae02e4171" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_8f9012ea-d3c4-4783-a51b-9e7fe1ad03d5" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_8a90234a-c35d-4465-9425-c80ae02e4171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_b73bf226-08ce-4a4e-a16d-bfe027bc2efa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8a90234a-c35d-4465-9425-c80ae02e4171" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_b73bf226-08ce-4a4e-a16d-bfe027bc2efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_5838059e-1a47-41a4-8281-a31db3e6ed9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8a90234a-c35d-4465-9425-c80ae02e4171" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_5838059e-1a47-41a4-8281-a31db3e6ed9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LesseeOperatingLeaseBaseRent_5ea3c333-1ffa-4f73-9b0b-eccd9813e469" xlink:href="ovid-20230630.xsd#ovid_LesseeOperatingLeaseBaseRent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8a90234a-c35d-4465-9425-c80ae02e4171" xlink:to="loc_ovid_LesseeOperatingLeaseBaseRent_5ea3c333-1ffa-4f73-9b0b-eccd9813e469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod_c8b45c8a-2dc4-4d9e-8e1e-1a558fa8b36e" xlink:href="ovid-20230630.xsd#ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8a90234a-c35d-4465-9425-c80ae02e4171" xlink:to="loc_ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod_c8b45c8a-2dc4-4d9e-8e1e-1a558fa8b36e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_8a375785-6d25-4c3e-bb98-e25416f7ca10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8a90234a-c35d-4465-9425-c80ae02e4171" xlink:to="loc_us-gaap_RestrictedCash_8a375785-6d25-4c3e-bb98-e25416f7ca10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_bc25e0c4-2997-444e-a90b-1651804f6cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8a90234a-c35d-4465-9425-c80ae02e4171" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_bc25e0c4-2997-444e-a90b-1651804f6cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_a9ed583e-737c-4528-b9c9-2505fdda02bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8a90234a-c35d-4465-9425-c80ae02e4171" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_a9ed583e-737c-4528-b9c9-2505fdda02bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LeaseIncrementalBorrowingRate_187afe0f-8448-44ac-b523-fee6dedd6ce1" xlink:href="ovid-20230630.xsd#ovid_LeaseIncrementalBorrowingRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8a90234a-c35d-4465-9425-c80ae02e4171" xlink:to="loc_ovid_LeaseIncrementalBorrowingRate_187afe0f-8448-44ac-b523-fee6dedd6ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/LEASESScheduleofROUAssetandLeaseLiabilitiesRelatedtotheCompanyOperatingLeaseDetail" xlink:type="simple" xlink:href="ovid-20230630.xsd#LEASESScheduleofROUAssetandLeaseLiabilitiesRelatedtotheCompanyOperatingLeaseDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/LEASESScheduleofROUAssetandLeaseLiabilitiesRelatedtotheCompanyOperatingLeaseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e437b705-0aaf-411f-8c99-83bd0981901b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_5b162587-428c-42c2-9af5-517bae34be06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e437b705-0aaf-411f-8c99-83bd0981901b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_5b162587-428c-42c2-9af5-517bae34be06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_688f81a3-ea08-4bb5-ac8f-39f84cbf1353" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e437b705-0aaf-411f-8c99-83bd0981901b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_688f81a3-ea08-4bb5-ac8f-39f84cbf1353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5c6ce8b9-1ec1-488a-bb03-74f5ec4d2449" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e437b705-0aaf-411f-8c99-83bd0981901b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5c6ce8b9-1ec1-488a-bb03-74f5ec4d2449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/LEASESScheduleofComponentsofOperatingLeaseCostDetail" xlink:type="simple" xlink:href="ovid-20230630.xsd#LEASESScheduleofComponentsofOperatingLeaseCostDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/LEASESScheduleofComponentsofOperatingLeaseCostDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0b125ce2-fd19-4849-829b-5f452f974df0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_169b2337-7340-405b-abf4-582df0ac1244" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0b125ce2-fd19-4849-829b-5f452f974df0" xlink:to="loc_us-gaap_OperatingLeaseCost_169b2337-7340-405b-abf4-582df0ac1244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_4eb47880-75d6-4697-9dd6-865c11be0394" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0b125ce2-fd19-4849-829b-5f452f974df0" xlink:to="loc_us-gaap_VariableLeaseCost_4eb47880-75d6-4697-9dd6-865c11be0394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_495949f5-0451-422d-94c8-74be317dec1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0b125ce2-fd19-4849-829b-5f452f974df0" xlink:to="loc_us-gaap_ShortTermLeaseCost_495949f5-0451-422d-94c8-74be317dec1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/LEASESScheduleofFutureMinimumCommitmentsUnderUndertheNonCancelableOperatingLeaseDetail" xlink:type="simple" xlink:href="ovid-20230630.xsd#LEASESScheduleofFutureMinimumCommitmentsUnderUndertheNonCancelableOperatingLeaseDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/LEASESScheduleofFutureMinimumCommitmentsUnderUndertheNonCancelableOperatingLeaseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_897719f3-42b5-441b-8054-7d0e7568e359" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_56e1cc30-decf-4bf9-922c-af2b7c5c6731" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_897719f3-42b5-441b-8054-7d0e7568e359" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_56e1cc30-decf-4bf9-922c-af2b7c5c6731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_911dfcfc-68dc-4527-983a-73626c47ef54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_897719f3-42b5-441b-8054-7d0e7568e359" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_911dfcfc-68dc-4527-983a-73626c47ef54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3111ee7b-bb25-4889-84ac-e68d30f28944" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_897719f3-42b5-441b-8054-7d0e7568e359" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3111ee7b-bb25-4889-84ac-e68d30f28944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_fa3cc661-fe41-406a-b72e-243bade983a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_897719f3-42b5-441b-8054-7d0e7568e359" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_fa3cc661-fe41-406a-b72e-243bade983a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_bed135af-f708-468d-ac32-67c84ac41f70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_897719f3-42b5-441b-8054-7d0e7568e359" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_bed135af-f708-468d-ac32-67c84ac41f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_42ed66fa-5fbe-47ce-bf9c-0ac6963f72f0" xlink:href="ovid-20230630.xsd#ovid_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_897719f3-42b5-441b-8054-7d0e7568e359" xlink:to="loc_ovid_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour_42ed66fa-5fbe-47ce-bf9c-0ac6963f72f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_64e83877-84b2-40d2-80c2-21cea1f9ad3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_897719f3-42b5-441b-8054-7d0e7568e359" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_64e83877-84b2-40d2-80c2-21cea1f9ad3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/ACCRUEDEXPENSESScheduleofAccruedExpensesDetail" xlink:type="simple" xlink:href="ovid-20230630.xsd#ACCRUEDEXPENSESScheduleofAccruedExpensesDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/ACCRUEDEXPENSESScheduleofAccruedExpensesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_b74dff6c-40d8-418b-b8ee-2ca73aecc890" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2acdb961-d31a-43dc-b54c-ca7ea017a7e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b74dff6c-40d8-418b-b8ee-2ca73aecc890" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2acdb961-d31a-43dc-b54c-ca7ea017a7e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AccruedResearchAndDevelopment_d64b896c-b99b-49b1-a202-c86e6f60cafc" xlink:href="ovid-20230630.xsd#ovid_AccruedResearchAndDevelopment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b74dff6c-40d8-418b-b8ee-2ca73aecc890" xlink:to="loc_ovid_AccruedResearchAndDevelopment_d64b896c-b99b-49b1-a202-c86e6f60cafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_f28bc341-3a88-4ecb-b8be-5b442cf76750" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b74dff6c-40d8-418b-b8ee-2ca73aecc890" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_f28bc341-3a88-4ecb-b8be-5b442cf76750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1362c9bd-7fd9-4e85-893c-319112205ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b74dff6c-40d8-418b-b8ee-2ca73aecc890" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1362c9bd-7fd9-4e85-893c-319112205ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3a5dfaba-4af4-4135-8124-db22263dd633" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b74dff6c-40d8-418b-b8ee-2ca73aecc890" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_3a5dfaba-4af4-4135-8124-db22263dd633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetail" xlink:type="simple" xlink:href="ovid-20230630.xsd#STOCKHOLDERSEQUITYAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d67ce65e-b1c5-4198-b25c-f927f17e29d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1813e5f0-7047-4147-8ef4-aae54c3814c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d67ce65e-b1c5-4198-b25c-f927f17e29d6" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1813e5f0-7047-4147-8ef4-aae54c3814c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0a7ed296-11d0-41a5-960a-3b19dd7bf221" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1813e5f0-7047-4147-8ef4-aae54c3814c0" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0a7ed296-11d0-41a5-960a-3b19dd7bf221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_168f1f3d-ee2c-4338-8b14-c3f6ed55b051" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0a7ed296-11d0-41a5-960a-3b19dd7bf221" xlink:to="loc_us-gaap_ClassOfStockDomain_168f1f3d-ee2c-4338-8b14-c3f6ed55b051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_SeriesAConvertiblePreferredStockMember_36b34ab0-2813-456f-ba57-943b8eca718a" xlink:href="ovid-20230630.xsd#ovid_SeriesAConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_168f1f3d-ee2c-4338-8b14-c3f6ed55b051" xlink:to="loc_ovid_SeriesAConvertiblePreferredStockMember_36b34ab0-2813-456f-ba57-943b8eca718a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5d229b3a-79ed-4a64-a56b-e40c2625e9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1813e5f0-7047-4147-8ef4-aae54c3814c0" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5d229b3a-79ed-4a64-a56b-e40c2625e9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a880afdc-53bd-4a06-afeb-acc17ae220db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5d229b3a-79ed-4a64-a56b-e40c2625e9a1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a880afdc-53bd-4a06-afeb-acc17ae220db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_ATMAgreementMember_7294afa4-8135-4a0b-ba9c-5b48a868cc3f" xlink:href="ovid-20230630.xsd#ovid_ATMAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a880afdc-53bd-4a06-afeb-acc17ae220db" xlink:to="loc_ovid_ATMAgreementMember_7294afa4-8135-4a0b-ba9c-5b48a868cc3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fc6e899d-924f-4b9d-a0dd-f15414c162ba" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1813e5f0-7047-4147-8ef4-aae54c3814c0" xlink:to="loc_srt_RangeAxis_fc6e899d-924f-4b9d-a0dd-f15414c162ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a65f29fc-9907-4dd2-9e9f-5af3baa05d70" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fc6e899d-924f-4b9d-a0dd-f15414c162ba" xlink:to="loc_srt_RangeMember_a65f29fc-9907-4dd2-9e9f-5af3baa05d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3450f4b3-16cf-4aac-a0c6-7e2951b90d49" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a65f29fc-9907-4dd2-9e9f-5af3baa05d70" xlink:to="loc_srt_MinimumMember_3450f4b3-16cf-4aac-a0c6-7e2951b90d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_574e9b46-4f52-4a1b-ac71-016d7f6040f9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a65f29fc-9907-4dd2-9e9f-5af3baa05d70" xlink:to="loc_srt_MaximumMember_574e9b46-4f52-4a1b-ac71-016d7f6040f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_67ab73b4-07db-43cd-8e4b-73a7cdcee81b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1813e5f0-7047-4147-8ef4-aae54c3814c0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_67ab73b4-07db-43cd-8e4b-73a7cdcee81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_926e029c-de92-43a6-9f7e-0a34cde1c017" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_67ab73b4-07db-43cd-8e4b-73a7cdcee81b" xlink:to="loc_us-gaap_EquityComponentDomain_926e029c-de92-43a6-9f7e-0a34cde1c017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6f66d500-eda6-499c-b798-e68f26bcac84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_926e029c-de92-43a6-9f7e-0a34cde1c017" xlink:to="loc_us-gaap_CommonStockMember_6f66d500-eda6-499c-b798-e68f26bcac84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_bd5060c1-4a68-4993-bd54-ec47ab949f0b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1813e5f0-7047-4147-8ef4-aae54c3814c0" xlink:to="loc_srt_CounterpartyNameAxis_bd5060c1-4a68-4993-bd54-ec47ab949f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_892c776a-3c04-445e-a254-bed167fe94c5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_bd5060c1-4a68-4993-bd54-ec47ab949f0b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_892c776a-3c04-445e-a254-bed167fe94c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CowenAndCompanyLLCMember_2c07a4a3-eb68-48b6-8192-eed66e9dc33c" xlink:href="ovid-20230630.xsd#ovid_CowenAndCompanyLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_892c776a-3c04-445e-a254-bed167fe94c5" xlink:to="loc_ovid_CowenAndCompanyLLCMember_2c07a4a3-eb68-48b6-8192-eed66e9dc33c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_780cf5ec-0770-4ca8-8d76-bafa766742d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1813e5f0-7047-4147-8ef4-aae54c3814c0" xlink:to="loc_us-gaap_ClassOfStockLineItems_780cf5ec-0770-4ca8-8d76-bafa766742d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_8d583848-6c82-46e8-93c8-b0604db1ba75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_780cf5ec-0770-4ca8-8d76-bafa766742d1" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_8d583848-6c82-46e8-93c8-b0604db1ba75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2743b22c-7f51-4462-b343-1862b8e7c332" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_780cf5ec-0770-4ca8-8d76-bafa766742d1" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2743b22c-7f51-4462-b343-1862b8e7c332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CommonStockNumberOfVotesForEachShare_d53002e4-625d-4837-aa1a-3aadd05e2ca9" xlink:href="ovid-20230630.xsd#ovid_CommonStockNumberOfVotesForEachShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_780cf5ec-0770-4ca8-8d76-bafa766742d1" xlink:to="loc_ovid_CommonStockNumberOfVotesForEachShare_d53002e4-625d-4837-aa1a-3aadd05e2ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_3cda2bd7-a2f3-4748-af6d-d67b4c173c25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_780cf5ec-0770-4ca8-8d76-bafa766742d1" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_3cda2bd7-a2f3-4748-af6d-d67b4c173c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_902c8ea3-aea8-4894-ab21-abc5a12d007b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_780cf5ec-0770-4ca8-8d76-bafa766742d1" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_902c8ea3-aea8-4894-ab21-abc5a12d007b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates_dde2b7ed-eb9b-4aee-8dca-ae6e1c48aeef" xlink:href="ovid-20230630.xsd#ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_780cf5ec-0770-4ca8-8d76-bafa766742d1" xlink:to="loc_ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates_dde2b7ed-eb9b-4aee-8dca-ae6e1c48aeef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders_83478555-3a0d-42bc-b2c6-3586905f633c" xlink:href="ovid-20230630.xsd#ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_780cf5ec-0770-4ca8-8d76-bafa766742d1" xlink:to="loc_ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders_83478555-3a0d-42bc-b2c6-3586905f633c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates_e041034f-8095-42bf-98c2-c94e6953bab4" xlink:href="ovid-20230630.xsd#ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_780cf5ec-0770-4ca8-8d76-bafa766742d1" xlink:to="loc_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates_e041034f-8095-42bf-98c2-c94e6953bab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod_45d31ab5-9e79-4f88-8b44-4dc969a3ace2" xlink:href="ovid-20230630.xsd#ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_780cf5ec-0770-4ca8-8d76-bafa766742d1" xlink:to="loc_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod_45d31ab5-9e79-4f88-8b44-4dc969a3ace2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock_de7081f4-6083-4ef1-9222-db0aa1cd3931" xlink:href="ovid-20230630.xsd#ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_780cf5ec-0770-4ca8-8d76-bafa766742d1" xlink:to="loc_ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock_de7081f4-6083-4ef1-9222-db0aa1cd3931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockLiquidationPreference_af3d5b03-973d-45c8-a712-0948ccb8acdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreference"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_780cf5ec-0770-4ca8-8d76-bafa766742d1" xlink:to="loc_us-gaap_PreferredStockLiquidationPreference_af3d5b03-973d-45c8-a712-0948ccb8acdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AggregateOfferingPriceOfCommonStock_67376fe6-7b55-4c93-a474-63a7898d15e2" xlink:href="ovid-20230630.xsd#ovid_AggregateOfferingPriceOfCommonStock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_780cf5ec-0770-4ca8-8d76-bafa766742d1" xlink:to="loc_ovid_AggregateOfferingPriceOfCommonStock_67376fe6-7b55-4c93-a474-63a7898d15e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7ec34851-e8ed-491f-a6e6-02044606c31d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_780cf5ec-0770-4ca8-8d76-bafa766742d1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7ec34851-e8ed-491f-a6e6-02044606c31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_2b775415-56fb-4fc1-b114-fc4267b8408a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Dividends"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_780cf5ec-0770-4ca8-8d76-bafa766742d1" xlink:to="loc_us-gaap_Dividends_2b775415-56fb-4fc1-b114-fc4267b8408a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail" xlink:type="simple" xlink:href="ovid-20230630.xsd#STOCKBASEDCOMPENSATIONAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1acb6da9-f0e2-4d1a-9743-f678e832f760" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e33db-af4b-45c2-a2bd-ea81e214310a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1acb6da9-f0e2-4d1a-9743-f678e832f760" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e33db-af4b-45c2-a2bd-ea81e214310a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9e20ce50-c86c-4b7f-ae34-daae8d9ee5c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e33db-af4b-45c2-a2bd-ea81e214310a" xlink:to="loc_us-gaap_PlanNameAxis_9e20ce50-c86c-4b7f-ae34-daae8d9ee5c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2c1bf2bc-bba3-4fa6-95ec-7964cddbad27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_9e20ce50-c86c-4b7f-ae34-daae8d9ee5c4" xlink:to="loc_us-gaap_PlanNameDomain_2c1bf2bc-bba3-4fa6-95ec-7964cddbad27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_TwoThousandSeventeenEquityIncentivePlanMember_b89484bb-0c48-45a0-872a-e517c340b7e4" xlink:href="ovid-20230630.xsd#ovid_TwoThousandSeventeenEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_2c1bf2bc-bba3-4fa6-95ec-7964cddbad27" xlink:to="loc_ovid_TwoThousandSeventeenEquityIncentivePlanMember_b89484bb-0c48-45a0-872a-e517c340b7e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember_8e6ebc90-607a-43dd-85d0-e87b7e76a618" xlink:href="ovid-20230630.xsd#ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_2c1bf2bc-bba3-4fa6-95ec-7964cddbad27" xlink:to="loc_ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember_8e6ebc90-607a-43dd-85d0-e87b7e76a618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_A2014EmployeeStockPurchasePlanMember_e59797c5-0805-4ae4-8fc9-c2e6163c3ed8" xlink:href="ovid-20230630.xsd#ovid_A2014EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_2c1bf2bc-bba3-4fa6-95ec-7964cddbad27" xlink:to="loc_ovid_A2014EmployeeStockPurchasePlanMember_e59797c5-0805-4ae4-8fc9-c2e6163c3ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_73e84e71-854c-44d2-ad88-8f70cfcfcf5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e33db-af4b-45c2-a2bd-ea81e214310a" xlink:to="loc_us-gaap_AwardTypeAxis_73e84e71-854c-44d2-ad88-8f70cfcfcf5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc951b13-7b4a-49f9-9078-f62f3ae1e7f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_73e84e71-854c-44d2-ad88-8f70cfcfcf5b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc951b13-7b4a-49f9-9078-f62f3ae1e7f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_f8814181-bb36-4f8b-b7c1-52bdc0832c31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc951b13-7b4a-49f9-9078-f62f3ae1e7f3" xlink:to="loc_us-gaap_PerformanceSharesMember_f8814181-bb36-4f8b-b7c1-52bdc0832c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0167d7af-195e-4946-b0aa-138255d4a19b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc951b13-7b4a-49f9-9078-f62f3ae1e7f3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0167d7af-195e-4946-b0aa-138255d4a19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_NonemployeePerformanceBasedOptionAwardsMember_5ac5fecc-6cf9-4086-87ff-255ef4ad21f9" xlink:href="ovid-20230630.xsd#ovid_NonemployeePerformanceBasedOptionAwardsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc951b13-7b4a-49f9-9078-f62f3ae1e7f3" xlink:to="loc_ovid_NonemployeePerformanceBasedOptionAwardsMember_5ac5fecc-6cf9-4086-87ff-255ef4ad21f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_EmployeePerformanceBasedOptionAwardsMember_2ed7b35d-a01b-4af1-aca6-919bbb972048" xlink:href="ovid-20230630.xsd#ovid_EmployeePerformanceBasedOptionAwardsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc951b13-7b4a-49f9-9078-f62f3ae1e7f3" xlink:to="loc_ovid_EmployeePerformanceBasedOptionAwardsMember_2ed7b35d-a01b-4af1-aca6-919bbb972048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_1ae41743-aa57-40b6-8b6a-918799a99301" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e33db-af4b-45c2-a2bd-ea81e214310a" xlink:to="loc_us-gaap_GranteeStatusAxis_1ae41743-aa57-40b6-8b6a-918799a99301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_dcfb23ea-ca34-4d81-ae2a-57602ec62117" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusAxis_1ae41743-aa57-40b6-8b6a-918799a99301" xlink:to="loc_us-gaap_GranteeStatusDomain_dcfb23ea-ca34-4d81-ae2a-57602ec62117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_6622253f-e6e2-4d87-abf7-339b84dc75eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_dcfb23ea-ca34-4d81-ae2a-57602ec62117" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_6622253f-e6e2-4d87-abf7-339b84dc75eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_93bdfd13-ae91-4545-9b33-f85ec29303f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_dcfb23ea-ca34-4d81-ae2a-57602ec62117" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_93bdfd13-ae91-4545-9b33-f85ec29303f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_de984da4-dc44-4ee2-82e2-2fbcddae1057" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e33db-af4b-45c2-a2bd-ea81e214310a" xlink:to="loc_srt_RangeAxis_de984da4-dc44-4ee2-82e2-2fbcddae1057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_36727336-2dd6-4139-9edc-b0b9898df373" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_de984da4-dc44-4ee2-82e2-2fbcddae1057" xlink:to="loc_srt_RangeMember_36727336-2dd6-4139-9edc-b0b9898df373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3cb084bc-a19d-4a32-a509-03a37a2a2d3b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_36727336-2dd6-4139-9edc-b0b9898df373" xlink:to="loc_srt_MaximumMember_3cb084bc-a19d-4a32-a509-03a37a2a2d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56b7c12f-f379-47aa-a75f-49010f98c000" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_019e33db-af4b-45c2-a2bd-ea81e214310a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56b7c12f-f379-47aa-a75f-49010f98c000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_cf1c40d5-613b-488a-80fa-9b804d0c4d69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56b7c12f-f379-47aa-a75f-49010f98c000" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_cf1c40d5-613b-488a-80fa-9b804d0c4d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_d89df948-86d7-4702-b3c0-110ecd8aa403" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56b7c12f-f379-47aa-a75f-49010f98c000" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_d89df948-86d7-4702-b3c0-110ecd8aa403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_7b93ffde-16ca-4d3e-b7ff-3503c5032a56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56b7c12f-f379-47aa-a75f-49010f98c000" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_7b93ffde-16ca-4d3e-b7ff-3503c5032a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_4936ae33-6666-4d5f-b07c-bf0ef37b626c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56b7c12f-f379-47aa-a75f-49010f98c000" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_4936ae33-6666-4d5f-b07c-bf0ef37b626c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_56a99248-3a97-4121-b255-20782bc3495a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56b7c12f-f379-47aa-a75f-49010f98c000" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_56a99248-3a97-4121-b255-20782bc3495a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_f1d2cb08-0e5f-49d0-b587-8674dd14926e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56b7c12f-f379-47aa-a75f-49010f98c000" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_f1d2cb08-0e5f-49d0-b587-8674dd14926e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ae113fd4-31f9-4baf-ac46-2424327c6b46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56b7c12f-f379-47aa-a75f-49010f98c000" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ae113fd4-31f9-4baf-ac46-2424327c6b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease_d6d45436-5bc0-4726-ad2a-ac003cda04ce" xlink:href="ovid-20230630.xsd#ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56b7c12f-f379-47aa-a75f-49010f98c000" xlink:to="loc_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease_d6d45436-5bc0-4726-ad2a-ac003cda04ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum_153fb89e-8cc4-42cb-a491-f8cea8a6e6d6" xlink:href="ovid-20230630.xsd#ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56b7c12f-f379-47aa-a75f-49010f98c000" xlink:to="loc_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum_153fb89e-8cc4-42cb-a491-f8cea8a6e6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3e2c1e3a-5664-4603-863d-1ce3ce5e84a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56b7c12f-f379-47aa-a75f-49010f98c000" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3e2c1e3a-5664-4603-863d-1ce3ce5e84a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_90c1d6ca-0f40-483b-b597-c90ec9846019" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56b7c12f-f379-47aa-a75f-49010f98c000" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_90c1d6ca-0f40-483b-b597-c90ec9846019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5deb5a4e-a6a6-4788-a156-a4e984cfe124" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56b7c12f-f379-47aa-a75f-49010f98c000" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5deb5a4e-a6a6-4788-a156-a4e984cfe124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a43a64ef-3d44-4297-bca2-a69436617b67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56b7c12f-f379-47aa-a75f-49010f98c000" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a43a64ef-3d44-4297-bca2-a69436617b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_856e8b35-48c8-47fc-87d2-f8a48ce18f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56b7c12f-f379-47aa-a75f-49010f98c000" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_856e8b35-48c8-47fc-87d2-f8a48ce18f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f6c74401-dd12-435c-8b8d-7898b3dc738d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56b7c12f-f379-47aa-a75f-49010f98c000" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f6c74401-dd12-435c-8b8d-7898b3dc738d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_9c0d0c1c-9d7c-4171-8698-c788c94e5cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_b55c4a7b-687b-4249-aab0-58ca08c20cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56b7c12f-f379-47aa-a75f-49010f98c000" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_b55c4a7b-687b-4249-aab0-58ca08c20cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3248e339-ac47-468f-bb8e-3fb9d896573e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_56b7c12f-f379-47aa-a75f-49010f98c000" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3248e339-ac47-468f-bb8e-3fb9d896573e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONScheduleofRecognizedStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="ovid-20230630.xsd#STOCKBASEDCOMPENSATIONScheduleofRecognizedStockBasedCompensationExpenseDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONScheduleofRecognizedStockBasedCompensationExpenseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_baecdb54-398b-48b0-a131-3a549a1f8a31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_54390a50-4465-4a98-97d6-975ac14c32f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_baecdb54-398b-48b0-a131-3a549a1f8a31" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_54390a50-4465-4a98-97d6-975ac14c32f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2d2df5ff-17c1-4f7e-af2f-155e76f79d86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_54390a50-4465-4a98-97d6-975ac14c32f3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2d2df5ff-17c1-4f7e-af2f-155e76f79d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8fa52429-3817-4c7e-af0a-ee1e05437fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2d2df5ff-17c1-4f7e-af2f-155e76f79d86" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8fa52429-3817-4c7e-af0a-ee1e05437fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d7d5df5e-eba0-4489-b09b-5f5533efce43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8fa52429-3817-4c7e-af0a-ee1e05437fdf" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d7d5df5e-eba0-4489-b09b-5f5533efce43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b96475ba-b549-4b9a-ae9a-5ca1796a169f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8fa52429-3817-4c7e-af0a-ee1e05437fdf" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b96475ba-b549-4b9a-ae9a-5ca1796a169f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc644d8e-bd28-4973-9d1b-7cc5ec89ac80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_54390a50-4465-4a98-97d6-975ac14c32f3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc644d8e-bd28-4973-9d1b-7cc5ec89ac80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_02f3c014-926a-4968-8a33-ec5f86cc8104" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc644d8e-bd28-4973-9d1b-7cc5ec89ac80" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_02f3c014-926a-4968-8a33-ec5f86cc8104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONScheduleofAllocationofStockBasedCompensationExpensebyPlanDetail" xlink:type="simple" xlink:href="ovid-20230630.xsd#STOCKBASEDCOMPENSATIONScheduleofAllocationofStockBasedCompensationExpensebyPlanDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONScheduleofAllocationofStockBasedCompensationExpensebyPlanDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_96a9c1c3-1949-4331-a94d-4c6721da3148" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_11417bbc-4db2-4060-b468-6c4161983dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_96a9c1c3-1949-4331-a94d-4c6721da3148" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_11417bbc-4db2-4060-b468-6c4161983dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0177de1f-573a-4c89-a474-82fc821d0c79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_11417bbc-4db2-4060-b468-6c4161983dfb" xlink:to="loc_us-gaap_AwardTypeAxis_0177de1f-573a-4c89-a474-82fc821d0c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2d4e2890-e6f5-4585-a533-03d039fb3330" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0177de1f-573a-4c89-a474-82fc821d0c79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2d4e2890-e6f5-4585-a533-03d039fb3330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ff6ee1b7-44f8-4b0c-8abc-69bdeb471c35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2d4e2890-e6f5-4585-a533-03d039fb3330" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ff6ee1b7-44f8-4b0c-8abc-69bdeb471c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_EmployeeStockPurchasePlanMember_f662d5f5-410d-4c9c-b7ed-09adfb1a431b" xlink:href="ovid-20230630.xsd#ovid_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2d4e2890-e6f5-4585-a533-03d039fb3330" xlink:to="loc_ovid_EmployeeStockPurchasePlanMember_f662d5f5-410d-4c9c-b7ed-09adfb1a431b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_978dd9dd-7e21-443d-bb82-482c125ca515" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_11417bbc-4db2-4060-b468-6c4161983dfb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_978dd9dd-7e21-443d-bb82-482c125ca515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5dfe7df4-bb28-4e20-b62e-7426a88ef1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_978dd9dd-7e21-443d-bb82-482c125ca515" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5dfe7df4-bb28-4e20-b62e-7426a88ef1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail" xlink:type="simple" xlink:href="ovid-20230630.xsd#STOCKBASEDCOMPENSATIONSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1fd73caa-178a-462c-8c0d-326b537af95b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ef531cfa-b116-4d55-bc4c-e4207355a1e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1fd73caa-178a-462c-8c0d-326b537af95b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ef531cfa-b116-4d55-bc4c-e4207355a1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_17965999-6907-4511-b1d7-29fe415939f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ef531cfa-b116-4d55-bc4c-e4207355a1e8" xlink:to="loc_us-gaap_AwardTypeAxis_17965999-6907-4511-b1d7-29fe415939f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45f1177d-8ec0-4ecf-b61f-cfa55c3b0a49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_17965999-6907-4511-b1d7-29fe415939f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45f1177d-8ec0-4ecf-b61f-cfa55c3b0a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9b5c16f5-9165-4e89-af0b-f7ab589a9cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45f1177d-8ec0-4ecf-b61f-cfa55c3b0a49" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9b5c16f5-9165-4e89-af0b-f7ab589a9cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_226cde09-ee10-4b2d-86f7-00665063c26b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ef531cfa-b116-4d55-bc4c-e4207355a1e8" xlink:to="loc_us-gaap_GranteeStatusAxis_226cde09-ee10-4b2d-86f7-00665063c26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_7b0bd26c-9c64-4570-92e5-3537bde8787a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusAxis_226cde09-ee10-4b2d-86f7-00665063c26b" xlink:to="loc_us-gaap_GranteeStatusDomain_7b0bd26c-9c64-4570-92e5-3537bde8787a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_b6ff1958-ad6f-498c-a7d6-951beeb23e47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_7b0bd26c-9c64-4570-92e5-3537bde8787a" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_b6ff1958-ad6f-498c-a7d6-951beeb23e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_d7a0ba38-4d6c-4618-a54b-a4f9d28e0b73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_7b0bd26c-9c64-4570-92e5-3537bde8787a" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_d7a0ba38-4d6c-4618-a54b-a4f9d28e0b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7238dc71-e33e-4df2-b501-c6b6ddb6a466" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ef531cfa-b116-4d55-bc4c-e4207355a1e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7238dc71-e33e-4df2-b501-c6b6ddb6a466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_e48ef4c1-4b98-4a67-b527-55bed7faba4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7238dc71-e33e-4df2-b501-c6b6ddb6a466" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_e48ef4c1-4b98-4a67-b527-55bed7faba4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0bbe11e9-a366-421d-b656-3c9c9190cca7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7238dc71-e33e-4df2-b501-c6b6ddb6a466" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0bbe11e9-a366-421d-b656-3c9c9190cca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b067385c-3239-40c2-b7b4-a8c5a7cf1727" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7238dc71-e33e-4df2-b501-c6b6ddb6a466" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b067385c-3239-40c2-b7b4-a8c5a7cf1727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_08c15ba4-e853-462a-85b6-344405d25f81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7238dc71-e33e-4df2-b501-c6b6ddb6a466" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_08c15ba4-e853-462a-85b6-344405d25f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0a2a858e-8a69-4f9a-9723-53e2604140ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7238dc71-e33e-4df2-b501-c6b6ddb6a466" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0a2a858e-8a69-4f9a-9723-53e2604140ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail" xlink:type="simple" xlink:href="ovid-20230630.xsd#STOCKBASEDCOMPENSATIONSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b021e6a8-2c3c-4211-85a1-ad9d1e0bf1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_480f0aa2-3d12-4825-ae2d-52b9acd2d732" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b021e6a8-2c3c-4211-85a1-ad9d1e0bf1a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_480f0aa2-3d12-4825-ae2d-52b9acd2d732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fef68a6d-583a-41ad-9e17-380f7a69fa5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_480f0aa2-3d12-4825-ae2d-52b9acd2d732" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fef68a6d-583a-41ad-9e17-380f7a69fa5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ab3815ce-cc4b-4032-8e7c-ad5f4580a632" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_480f0aa2-3d12-4825-ae2d-52b9acd2d732" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ab3815ce-cc4b-4032-8e7c-ad5f4580a632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_fa5bea34-8f13-4058-b6a6-7b9fab90eb20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_480f0aa2-3d12-4825-ae2d-52b9acd2d732" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_fa5bea34-8f13-4058-b6a6-7b9fab90eb20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c13e9815-70ce-4f77-b70c-4ddd2857cc6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_480f0aa2-3d12-4825-ae2d-52b9acd2d732" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c13e9815-70ce-4f77-b70c-4ddd2857cc6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7d6b879a-e881-4a6b-ad65-1cd117071dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_480f0aa2-3d12-4825-ae2d-52b9acd2d732" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7d6b879a-e881-4a6b-ad65-1cd117071dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_ce34f62e-2969-4b48-a2ec-ced7979750f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b021e6a8-2c3c-4211-85a1-ad9d1e0bf1a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_ce34f62e-2969-4b48-a2ec-ced7979750f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7f585fc1-8ab7-4275-bf11-ce93424dfbd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b021e6a8-2c3c-4211-85a1-ad9d1e0bf1a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7f585fc1-8ab7-4275-bf11-ce93424dfbd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_efc050c8-176d-47ba-8464-e6a252b2dc25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7f585fc1-8ab7-4275-bf11-ce93424dfbd8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_efc050c8-176d-47ba-8464-e6a252b2dc25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_dc9d9265-509f-4731-b20c-08820f9b7d02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7f585fc1-8ab7-4275-bf11-ce93424dfbd8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_dc9d9265-509f-4731-b20c-08820f9b7d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9a6d2fdb-c011-4aa9-80d4-3572bb12e503" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7f585fc1-8ab7-4275-bf11-ce93424dfbd8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9a6d2fdb-c011-4aa9-80d4-3572bb12e503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_ed3aed07-b08b-43a7-afc8-9af60057db72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7f585fc1-8ab7-4275-bf11-ce93424dfbd8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_ed3aed07-b08b-43a7-afc8-9af60057db72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_91a58b6d-b422-482f-be08-a14a7dc320af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7f585fc1-8ab7-4275-bf11-ce93424dfbd8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_91a58b6d-b422-482f-be08-a14a7dc320af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_6fccf25f-cba5-4a82-ba9b-886f787c6901" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b021e6a8-2c3c-4211-85a1-ad9d1e0bf1a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_6fccf25f-cba5-4a82-ba9b-886f787c6901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d227878e-41fb-4ecb-9802-b194c2470cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b021e6a8-2c3c-4211-85a1-ad9d1e0bf1a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d227878e-41fb-4ecb-9802-b194c2470cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_99819662-ab2c-42ac-a9cf-2935204239a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d227878e-41fb-4ecb-9802-b194c2470cd8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_99819662-ab2c-42ac-a9cf-2935204239a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife_05eb9b68-f797-4f00-a1bc-7651e9e25f54" xlink:href="ovid-20230630.xsd#ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d227878e-41fb-4ecb-9802-b194c2470cd8" xlink:to="loc_ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife_05eb9b68-f797-4f00-a1bc-7651e9e25f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_e20e0cba-2ed8-4a7c-952a-5d468589642e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d227878e-41fb-4ecb-9802-b194c2470cd8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_e20e0cba-2ed8-4a7c-952a-5d468589642e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_271606a1-bda7-4c0f-bbe8-cbb19df5df9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d227878e-41fb-4ecb-9802-b194c2470cd8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_271606a1-bda7-4c0f-bbe8-cbb19df5df9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_74c9a59e-5c13-40a2-833a-8ba0a68586ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d227878e-41fb-4ecb-9802-b194c2470cd8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_74c9a59e-5c13-40a2-833a-8ba0a68586ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/INCOMETAXESAdditionalInformationDetail" xlink:type="simple" xlink:href="ovid-20230630.xsd#INCOMETAXESAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/INCOMETAXESAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_929ee591-ed6c-4ea1-bde9-5db3f144a84d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_68478f92-1a16-4f52-844a-64be6a3e69cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_929ee591-ed6c-4ea1-bde9-5db3f144a84d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_68478f92-1a16-4f52-844a-64be6a3e69cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail" xlink:type="simple" xlink:href="ovid-20230630.xsd#COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0da8fa63-fe37-4c65-a078-ee2a479baf69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_10113294-4df5-422b-88d2-bd157027e2f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0da8fa63-fe37-4c65-a078-ee2a479baf69" xlink:to="loc_us-gaap_LossContingenciesTable_10113294-4df5-422b-88d2-bd157027e2f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_29185a2a-c08b-4e68-8c65-7be3887590c1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_10113294-4df5-422b-88d2-bd157027e2f5" xlink:to="loc_srt_CounterpartyNameAxis_29185a2a-c08b-4e68-8c65-7be3887590c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_979e3d0b-0343-4b2c-aa8a-467a0cc71729" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_29185a2a-c08b-4e68-8c65-7be3887590c1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_979e3d0b-0343-4b2c-aa8a-467a0cc71729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_NorthwesternUniversityMember_2fb2f0c5-6552-4a74-b85e-daed789ef622" xlink:href="ovid-20230630.xsd#ovid_NorthwesternUniversityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_979e3d0b-0343-4b2c-aa8a-467a0cc71729" xlink:to="loc_ovid_NorthwesternUniversityMember_2fb2f0c5-6552-4a74-b85e-daed789ef622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AstrazenecaMember_5229bee4-a7db-4a42-87ef-47c8bb2f6a8b" xlink:href="ovid-20230630.xsd#ovid_AstrazenecaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_979e3d0b-0343-4b2c-aa8a-467a0cc71729" xlink:to="loc_ovid_AstrazenecaMember_5229bee4-a7db-4a42-87ef-47c8bb2f6a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_HLundbeckASMember_ed28f8b0-7499-4bd1-84d1-398bd6a65695" xlink:href="ovid-20230630.xsd#ovid_HLundbeckASMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_979e3d0b-0343-4b2c-aa8a-467a0cc71729" xlink:to="loc_ovid_HLundbeckASMember_ed28f8b0-7499-4bd1-84d1-398bd6a65695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_cc0bca8f-1092-44ff-bd41-dfedc5b6414e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_10113294-4df5-422b-88d2-bd157027e2f5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_cc0bca8f-1092-44ff-bd41-dfedc5b6414e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ceb2d60c-075e-47bd-b58b-bc39b5d1a17a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cc0bca8f-1092-44ff-bd41-dfedc5b6414e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ceb2d60c-075e-47bd-b58b-bc39b5d1a17a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LicenseAgreementMember_8de84737-14b8-4854-a232-096467057069" xlink:href="ovid-20230630.xsd#ovid_LicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ceb2d60c-075e-47bd-b58b-bc39b5d1a17a" xlink:to="loc_ovid_LicenseAgreementMember_8de84737-14b8-4854-a232-096467057069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8c0a5046-8680-4e0f-ad37-4639fb9d3c04" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_10113294-4df5-422b-88d2-bd157027e2f5" xlink:to="loc_srt_RangeAxis_8c0a5046-8680-4e0f-ad37-4639fb9d3c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2b42fd29-2540-461f-8130-577aaecb9d37" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8c0a5046-8680-4e0f-ad37-4639fb9d3c04" xlink:to="loc_srt_RangeMember_2b42fd29-2540-461f-8130-577aaecb9d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a829a84f-9189-4eb1-bdb0-2656b8f81867" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2b42fd29-2540-461f-8130-577aaecb9d37" xlink:to="loc_srt_MaximumMember_a829a84f-9189-4eb1-bdb0-2656b8f81867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_ff8556f4-fc3e-4a8f-ba9c-1e82f5dd6cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_10113294-4df5-422b-88d2-bd157027e2f5" xlink:to="loc_us-gaap_LossContingenciesLineItems_ff8556f4-fc3e-4a8f-ba9c-1e82f5dd6cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment_9f974638-2c49-4a9c-b614-341e958d4034" xlink:href="ovid-20230630.xsd#ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_ff8556f4-fc3e-4a8f-ba9c-1e82f5dd6cd5" xlink:to="loc_ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment_9f974638-2c49-4a9c-b614-341e958d4034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AnnualLicenseMaintenanceFeePayable_d6cc4a2c-fc08-4e44-8dff-93078b7e72ec" xlink:href="ovid-20230630.xsd#ovid_AnnualLicenseMaintenanceFeePayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_ff8556f4-fc3e-4a8f-ba9c-1e82f5dd6cd5" xlink:to="loc_ovid_AnnualLicenseMaintenanceFeePayable_d6cc4a2c-fc08-4e44-8dff-93078b7e72ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_ConsiderationPayableForRightsGrant_64cbda7f-7a4b-4935-b0b6-9223059a7f38" xlink:href="ovid-20230630.xsd#ovid_ConsiderationPayableForRightsGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_ff8556f4-fc3e-4a8f-ba9c-1e82f5dd6cd5" xlink:to="loc_ovid_ConsiderationPayableForRightsGrant_64cbda7f-7a4b-4935-b0b6-9223059a7f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_RoyaltyObligationTerm_674375af-6507-4d8b-8036-effdf49004c9" xlink:href="ovid-20230630.xsd#ovid_RoyaltyObligationTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_ff8556f4-fc3e-4a8f-ba9c-1e82f5dd6cd5" xlink:to="loc_ovid_RoyaltyObligationTerm_674375af-6507-4d8b-8036-effdf49004c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement_ee457584-4a6f-4e4c-9a91-78f4ad52d54f" xlink:href="ovid-20230630.xsd#ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_ff8556f4-fc3e-4a8f-ba9c-1e82f5dd6cd5" xlink:to="loc_ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement_ee457584-4a6f-4e4c-9a91-78f4ad52d54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_UpfrontCashPayment_d2f42cbc-5a57-4952-86e5-696e155f8d5c" xlink:href="ovid-20230630.xsd#ovid_UpfrontCashPayment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_ff8556f4-fc3e-4a8f-ba9c-1e82f5dd6cd5" xlink:to="loc_ovid_UpfrontCashPayment_d2f42cbc-5a57-4952-86e5-696e155f8d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LicenseAgreementConsiderationSharesIssued_902f8440-2e3d-4ed9-9c92-bcec8062a154" xlink:href="ovid-20230630.xsd#ovid_LicenseAgreementConsiderationSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_ff8556f4-fc3e-4a8f-ba9c-1e82f5dd6cd5" xlink:to="loc_ovid_LicenseAgreementConsiderationSharesIssued_902f8440-2e3d-4ed9-9c92-bcec8062a154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate_64f4b2a2-3633-4ae2-88ac-76a48c539e9f" xlink:href="ovid-20230630.xsd#ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_ff8556f4-fc3e-4a8f-ba9c-1e82f5dd6cd5" xlink:to="loc_ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate_64f4b2a2-3633-4ae2-88ac-76a48c539e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9e540dd2-f5f9-4576-b41f-f43524503613" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_ff8556f4-fc3e-4a8f-ba9c-1e82f5dd6cd5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9e540dd2-f5f9-4576-b41f-f43524503613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LicenseAgreementMilestonePayments_5b2d0b0c-18da-4641-8ccb-a3b40e30236b" xlink:href="ovid-20230630.xsd#ovid_LicenseAgreementMilestonePayments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_ff8556f4-fc3e-4a8f-ba9c-1e82f5dd6cd5" xlink:to="loc_ovid_LicenseAgreementMilestonePayments_5b2d0b0c-18da-4641-8ccb-a3b40e30236b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_FirstPaymentDueUponCompletionOfFirstPhase_c2c16910-7ce9-4a57-a184-a6f17781e0d9" xlink:href="ovid-20230630.xsd#ovid_FirstPaymentDueUponCompletionOfFirstPhase"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_ff8556f4-fc3e-4a8f-ba9c-1e82f5dd6cd5" xlink:to="loc_ovid_FirstPaymentDueUponCompletionOfFirstPhase_c2c16910-7ce9-4a57-a184-a6f17781e0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_CollaborationAndOptionAgreementResearchPlanAndBudgetExpectedCosts_b72f35c4-8bce-486e-8c18-4a834f8713e2" xlink:href="ovid-20230630.xsd#ovid_CollaborationAndOptionAgreementResearchPlanAndBudgetExpectedCosts"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_ff8556f4-fc3e-4a8f-ba9c-1e82f5dd6cd5" xlink:to="loc_ovid_CollaborationAndOptionAgreementResearchPlanAndBudgetExpectedCosts_b72f35c4-8bce-486e-8c18-4a834f8713e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LicenseAgreementDevelopmentMilestoneApprovalsProductThreshold_30e75d00-c1b6-4e73-8620-d8da303684d8" xlink:href="ovid-20230630.xsd#ovid_LicenseAgreementDevelopmentMilestoneApprovalsProductThreshold"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_ff8556f4-fc3e-4a8f-ba9c-1e82f5dd6cd5" xlink:to="loc_ovid_LicenseAgreementDevelopmentMilestoneApprovalsProductThreshold_30e75d00-c1b6-4e73-8620-d8da303684d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LicenseAgreementTerminationAdvanceNoticePeriod_9598e842-389e-463f-adf7-ac1b73d2ee22" xlink:href="ovid-20230630.xsd#ovid_LicenseAgreementTerminationAdvanceNoticePeriod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_ff8556f4-fc3e-4a8f-ba9c-1e82f5dd6cd5" xlink:to="loc_ovid_LicenseAgreementTerminationAdvanceNoticePeriod_9598e842-389e-463f-adf7-ac1b73d2ee22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail" xlink:type="simple" xlink:href="ovid-20230630.xsd#COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7227d9d5-689f-4017-b73c-1904e79bd376" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d80c429-1b84-43a4-8f81-6566f04e9209" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7227d9d5-689f-4017-b73c-1904e79bd376" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d80c429-1b84-43a4-8f81-6566f04e9209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7d04e5e0-0be7-4536-a263-e5019fbae934" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d80c429-1b84-43a4-8f81-6566f04e9209" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7d04e5e0-0be7-4536-a263-e5019fbae934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_2d58a240-8174-4e46-8198-3fe91140f7b3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7d04e5e0-0be7-4536-a263-e5019fbae934" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_2d58a240-8174-4e46-8198-3fe91140f7b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_TakedaPharmaceuticalCompanyLimitedMember_1005a210-4325-4b9e-8612-148da4ec2f45" xlink:href="ovid-20230630.xsd#ovid_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_2d58a240-8174-4e46-8198-3fe91140f7b3" xlink:to="loc_ovid_TakedaPharmaceuticalCompanyLimitedMember_1005a210-4325-4b9e-8612-148da4ec2f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MarinusPharmaceuticalsIncMember_09625768-1795-421d-b4bc-e550e58dcfd3" xlink:href="ovid-20230630.xsd#ovid_MarinusPharmaceuticalsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_2d58a240-8174-4e46-8198-3fe91140f7b3" xlink:to="loc_ovid_MarinusPharmaceuticalsIncMember_09625768-1795-421d-b4bc-e550e58dcfd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_GravitonBioscienceCorporationMember_65dce5e0-c660-4abf-b2ca-31229f53b59a" xlink:href="ovid-20230630.xsd#ovid_GravitonBioscienceCorporationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_2d58a240-8174-4e46-8198-3fe91140f7b3" xlink:to="loc_ovid_GravitonBioscienceCorporationMember_65dce5e0-c660-4abf-b2ca-31229f53b59a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_19eea97b-5832-4097-bc39-14652c95938e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d80c429-1b84-43a4-8f81-6566f04e9209" xlink:to="loc_us-gaap_TypeOfArrangementAxis_19eea97b-5832-4097-bc39-14652c95938e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_01eb28ef-ac63-42f6-a2c9-c843f8fb22cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_19eea97b-5832-4097-bc39-14652c95938e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_01eb28ef-ac63-42f6-a2c9-c843f8fb22cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_e40e8c8f-0e48-4965-8840-2daf12b6d415" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_01eb28ef-ac63-42f6-a2c9-c843f8fb22cd" xlink:to="loc_us-gaap_CollaborativeArrangementMember_e40e8c8f-0e48-4965-8840-2daf12b6d415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_HealxLicenseAndOptionAgreementMember_5dd42088-a86b-461a-98e6-8f77e00e9280" xlink:href="ovid-20230630.xsd#ovid_HealxLicenseAndOptionAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_01eb28ef-ac63-42f6-a2c9-c843f8fb22cd" xlink:to="loc_ovid_HealxLicenseAndOptionAgreementMember_5dd42088-a86b-461a-98e6-8f77e00e9280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MarinusLicenseAgreementMember_9725ff5c-03f1-45e9-92f8-c21d4c624142" xlink:href="ovid-20230630.xsd#ovid_MarinusLicenseAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_01eb28ef-ac63-42f6-a2c9-c843f8fb22cd" xlink:to="loc_ovid_MarinusLicenseAgreementMember_9725ff5c-03f1-45e9-92f8-c21d4c624142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_PatentLicenseAgreementMember_75e86e84-8005-4c7c-b9c4-5691b50269af" xlink:href="ovid-20230630.xsd#ovid_PatentLicenseAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_01eb28ef-ac63-42f6-a2c9-c843f8fb22cd" xlink:to="loc_ovid_PatentLicenseAgreementMember_75e86e84-8005-4c7c-b9c4-5691b50269af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_38c15dc9-a5de-4404-9cc7-0c868523112b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d80c429-1b84-43a4-8f81-6566f04e9209" xlink:to="loc_dei_LegalEntityAxis_38c15dc9-a5de-4404-9cc7-0c868523112b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b63b851f-b574-4752-b1f1-56af20c40847" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_38c15dc9-a5de-4404-9cc7-0c868523112b" xlink:to="loc_dei_EntityDomain_b63b851f-b574-4752-b1f1-56af20c40847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_TakedaPharmaceuticalCompanyLimitedMember_bf95a4b9-c5c6-4dfb-a00f-8e96b1a9683e" xlink:href="ovid-20230630.xsd#ovid_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b63b851f-b574-4752-b1f1-56af20c40847" xlink:to="loc_ovid_TakedaPharmaceuticalCompanyLimitedMember_bf95a4b9-c5c6-4dfb-a00f-8e96b1a9683e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_MarinusPharmaceuticalsIncMember_5cab7436-fae1-42a3-be22-88424c3c5921" xlink:href="ovid-20230630.xsd#ovid_MarinusPharmaceuticalsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b63b851f-b574-4752-b1f1-56af20c40847" xlink:to="loc_ovid_MarinusPharmaceuticalsIncMember_5cab7436-fae1-42a3-be22-88424c3c5921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_312b85e9-85cf-419f-abe7-165ba6084601" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d80c429-1b84-43a4-8f81-6566f04e9209" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_312b85e9-85cf-419f-abe7-165ba6084601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_cf3750b1-1ba0-42d9-9f89-5f342db48047" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_312b85e9-85cf-419f-abe7-165ba6084601" xlink:to="loc_us-gaap_RelatedPartyDomain_cf3750b1-1ba0-42d9-9f89-5f342db48047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_7c5b6a20-ce28-4413-b466-ba5437d8a210" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_cf3750b1-1ba0-42d9-9f89-5f342db48047" xlink:to="loc_us-gaap_RelatedPartyMember_7c5b6a20-ce28-4413-b466-ba5437d8a210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_71fa09e5-6279-417c-b4af-60016481a445" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d80c429-1b84-43a4-8f81-6566f04e9209" xlink:to="loc_us-gaap_StatementClassOfStockAxis_71fa09e5-6279-417c-b4af-60016481a445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_829240a0-7791-4277-ac7e-de898f37967e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_71fa09e5-6279-417c-b4af-60016481a445" xlink:to="loc_us-gaap_ClassOfStockDomain_829240a0-7791-4277-ac7e-de898f37967e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_39195e8d-1e07-4b29-9faf-1dd554321de4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_829240a0-7791-4277-ac7e-de898f37967e" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_39195e8d-1e07-4b29-9faf-1dd554321de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12cdbfd3-5761-4cae-8849-bc17502a1c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d80c429-1b84-43a4-8f81-6566f04e9209" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12cdbfd3-5761-4cae-8849-bc17502a1c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_17e823c1-947a-42d8-9260-81566e7967ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12cdbfd3-5761-4cae-8849-bc17502a1c7d" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_17e823c1-947a-42d8-9260-81566e7967ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_UpfrontPaymentReceivable_110a8a31-1835-49e1-962c-c3318d66b8be" xlink:href="ovid-20230630.xsd#ovid_UpfrontPaymentReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12cdbfd3-5761-4cae-8849-bc17502a1c7d" xlink:to="loc_ovid_UpfrontPaymentReceivable_110a8a31-1835-49e1-962c-c3318d66b8be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AgreementMilestonePayments_f3a8ace4-62cd-4704-b562-1219a91d544e" xlink:href="ovid-20230630.xsd#ovid_AgreementMilestonePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12cdbfd3-5761-4cae-8849-bc17502a1c7d" xlink:to="loc_ovid_AgreementMilestonePayments_f3a8ace4-62cd-4704-b562-1219a91d544e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_AdditionalPaymentReceivableOnSalesPercentage_b5951430-41a4-4d31-9cb2-0d5d648a56d0" xlink:href="ovid-20230630.xsd#ovid_AdditionalPaymentReceivableOnSalesPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12cdbfd3-5761-4cae-8849-bc17502a1c7d" xlink:to="loc_ovid_AdditionalPaymentReceivableOnSalesPercentage_b5951430-41a4-4d31-9cb2-0d5d648a56d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_UpFrontFeeAmount_ee5c9f1c-67f9-4ae0-b518-eaae8f10dadf" xlink:href="ovid-20230630.xsd#ovid_UpFrontFeeAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12cdbfd3-5761-4cae-8849-bc17502a1c7d" xlink:to="loc_ovid_UpFrontFeeAmount_ee5c9f1c-67f9-4ae0-b518-eaae8f10dadf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LicenseAndCollaborationAgreementExpense_70da4a0e-f50a-4816-b8bc-b2c77a89fc60" xlink:href="ovid-20230630.xsd#ovid_LicenseAndCollaborationAgreementExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12cdbfd3-5761-4cae-8849-bc17502a1c7d" xlink:to="loc_ovid_LicenseAndCollaborationAgreementExpense_70da4a0e-f50a-4816-b8bc-b2c77a89fc60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_UpFrontPayment_021189be-e22f-4d51-b9fd-7b218aead1a0" xlink:href="ovid-20230630.xsd#ovid_UpFrontPayment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12cdbfd3-5761-4cae-8849-bc17502a1c7d" xlink:to="loc_ovid_UpFrontPayment_021189be-e22f-4d51-b9fd-7b218aead1a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LicenseOptionAgreementDevelopmentAndCommercialMilestonePayments_deff84ec-d4bb-48a6-a408-11e941e4ae00" xlink:href="ovid-20230630.xsd#ovid_LicenseOptionAgreementDevelopmentAndCommercialMilestonePayments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12cdbfd3-5761-4cae-8849-bc17502a1c7d" xlink:to="loc_ovid_LicenseOptionAgreementDevelopmentAndCommercialMilestonePayments_deff84ec-d4bb-48a6-a408-11e941e4ae00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_LicenseOptionAgreementExtensionPeriod_17ff2b22-a583-4791-8834-af3b0d7ce44b" xlink:href="ovid-20230630.xsd#ovid_LicenseOptionAgreementExtensionPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12cdbfd3-5761-4cae-8849-bc17502a1c7d" xlink:to="loc_ovid_LicenseOptionAgreementExtensionPeriod_17ff2b22-a583-4791-8834-af3b0d7ce44b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_PercentageOfDevelopmentCosts_9499d029-3570-4587-bdc0-ee1c5cf1ed9a" xlink:href="ovid-20230630.xsd#ovid_PercentageOfDevelopmentCosts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12cdbfd3-5761-4cae-8849-bc17502a1c7d" xlink:to="loc_ovid_PercentageOfDevelopmentCosts_9499d029-3570-4587-bdc0-ee1c5cf1ed9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_567029e2-ca97-4dd5-b2de-e3be0c1ce776" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12cdbfd3-5761-4cae-8849-bc17502a1c7d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_567029e2-ca97-4dd5-b2de-e3be0c1ce776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_15c67a5a-5698-4d9b-b8db-5d2c40683924" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12cdbfd3-5761-4cae-8849-bc17502a1c7d" xlink:to="loc_us-gaap_CommonStockSharesIssued_15c67a5a-5698-4d9b-b8db-5d2c40683924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_6c0b7688-c44c-496d-be2f-ffa052362f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12cdbfd3-5761-4cae-8849-bc17502a1c7d" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_6c0b7688-c44c-496d-be2f-ffa052362f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_cf25ca16-4b59-48b8-bf38-b15c7ec34d41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12cdbfd3-5761-4cae-8849-bc17502a1c7d" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_cf25ca16-4b59-48b8-bf38-b15c7ec34d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock_ebe02bce-93d4-4d20-844d-eeb49f46620f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12cdbfd3-5761-4cae-8849-bc17502a1c7d" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock_ebe02bce-93d4-4d20-844d-eeb49f46620f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/NETLOSSPERSHARESummaryofCalculationofBasicandDilutedEarningsLossperShareDetails" xlink:type="simple" xlink:href="ovid-20230630.xsd#NETLOSSPERSHARESummaryofCalculationofBasicandDilutedEarningsLossperShareDetails"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/NETLOSSPERSHARESummaryofCalculationofBasicandDilutedEarningsLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c9e6387e-9756-4305-9dc4-6dc3cec4c442" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4d516007-7241-404c-b1bc-67cb5ad42241" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c9e6387e-9756-4305-9dc4-6dc3cec4c442" xlink:to="loc_us-gaap_NetIncomeLoss_4d516007-7241-404c-b1bc-67cb5ad42241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_d3bf48a3-c530-4906-b493-f19d9fc0c1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c9e6387e-9756-4305-9dc4-6dc3cec4c442" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_d3bf48a3-c530-4906-b493-f19d9fc0c1a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_bbd75566-c95e-433f-a782-6bf7655c8465" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c9e6387e-9756-4305-9dc4-6dc3cec4c442" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_bbd75566-c95e-433f-a782-6bf7655c8465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_b42e55aa-6cbd-4202-8b13-cb0280441899" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c9e6387e-9756-4305-9dc4-6dc3cec4c442" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_b42e55aa-6cbd-4202-8b13-cb0280441899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_26dc74ff-ab07-4152-89fb-fd43bb7ecc09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c9e6387e-9756-4305-9dc4-6dc3cec4c442" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_26dc74ff-ab07-4152-89fb-fd43bb7ecc09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8288dcaa-d74c-4198-974b-b03e56fee405" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c9e6387e-9756-4305-9dc4-6dc3cec4c442" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8288dcaa-d74c-4198-974b-b03e56fee405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9742c751-11ad-45f7-a748-4fcb1093fb50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c9e6387e-9756-4305-9dc4-6dc3cec4c442" xlink:to="loc_us-gaap_EarningsPerShareBasic_9742c751-11ad-45f7-a748-4fcb1093fb50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_b2bcfa92-6e59-48ec-894d-a91c670a2289" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c9e6387e-9756-4305-9dc4-6dc3cec4c442" xlink:to="loc_us-gaap_EarningsPerShareDiluted_b2bcfa92-6e59-48ec-894d-a91c670a2289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/role/NETLOSSPERSHAREScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageSharesOutstandingDetail" xlink:type="simple" xlink:href="ovid-20230630.xsd#NETLOSSPERSHAREScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageSharesOutstandingDetail"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/NETLOSSPERSHAREScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageSharesOutstandingDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f4ad9ab5-c2a5-4b37-9ef3-c18ca17d68ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e1248751-25be-459b-8afe-6b13ef24a1aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f4ad9ab5-c2a5-4b37-9ef3-c18ca17d68ee" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e1248751-25be-459b-8afe-6b13ef24a1aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_78129ad4-9f5b-40c2-8672-08c9fb5458d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e1248751-25be-459b-8afe-6b13ef24a1aa" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_78129ad4-9f5b-40c2-8672-08c9fb5458d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dd01bc73-ac56-4fa4-be13-3426adb2fd9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_78129ad4-9f5b-40c2-8672-08c9fb5458d4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dd01bc73-ac56-4fa4-be13-3426adb2fd9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_20bd633d-35f6-4119-be30-a5fa06dccecd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dd01bc73-ac56-4fa4-be13-3426adb2fd9e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_20bd633d-35f6-4119-be30-a5fa06dccecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ovid_SeriesAConvertiblePreferredStockMember_4deba7fe-8625-457d-9ec6-bfd683985e80" xlink:href="ovid-20230630.xsd#ovid_SeriesAConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dd01bc73-ac56-4fa4-be13-3426adb2fd9e" xlink:to="loc_ovid_SeriesAConvertiblePreferredStockMember_4deba7fe-8625-457d-9ec6-bfd683985e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cf23fd84-2c76-430b-9c19-4a53ccbb679f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e1248751-25be-459b-8afe-6b13ef24a1aa" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cf23fd84-2c76-430b-9c19-4a53ccbb679f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e2ed304c-a8aa-4e41-9e63-d341ddb64dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cf23fd84-2c76-430b-9c19-4a53ccbb679f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e2ed304c-a8aa-4e41-9e63-d341ddb64dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ovid-20230630_g1.jpg
<TEXT>
begin 644 ovid-20230630_g1.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1":17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0>.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $-A8F\L(%)A
M<75E;     'J'  '   (#   "&H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*BK_P  1" (A!-D# 2(  A$! Q$!_\0 'P   04! 0$! 0$
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M'_#1WB[_ *!VB_\ ?B7_ ..T?\-'>+O^@=HO_?B7_P".T?V?7"Y]+T5\T?\
M#1WB[_H':+_WXE_^.T?\-'>+O^@=HO\ WXE_^.T?V?7"Y]+T5\T?\-'>+O\
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MB7_X[1_9]<+GTO17S1_PT=XN_P"@=HO_ 'XE_P#CM'_#1WB[_H':+_WXE_\
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M!VB_]^)?_CM'_#1WB[_H':+_ -^)?_CM']GUPN?2]%?-'_#1WB[_ *!VB_\
M?B7_ ..T?\-'>+O^@=HO_?B7_P".T?V?7"Y]+T5\T?\ #1WB[_H':+_WXE_^
M.T?\-'>+O^@=HO\ WXE_^.T?V?7"Y]+T5\T?\-'>+O\ H':+_P!^)?\ X[1_
MPT=XN_Z!VB_]^)?_ ([1_9]<+GTO17S1_P -'>+O^@=HO_?B7_X[1_PT=XN_
MZ!VB_P#?B7_X[1_9]<+GTO17S1_PT=XN_P"@=HO_ 'XE_P#CM'_#1WB[_H':
M+_WXE_\ CM']GUPN?2]%?-'_  T=XN_Z!VB_]^)?_CM'_#1WB[_H':+_ -^)
M?_CM']GUPN?2]%?-'_#1WB[_ *!VB_\ ?B7_ ..T?\-'>+O^@=HO_?B7_P".
MT?V?7"Y]+T5\T?\ #1WB[_H':+_WXE_^.T?\-'>+O^@=HO\ WXE_^.T?V?7"
MY]+T5\T?\-'>+O\ H':+_P!^)?\ X[1_PT=XN_Z!VB_]^)?_ ([1_9]<+GTO
M17S1_P -'>+O^@=HO_?B7_X[1_PT=XN_Z!VB_P#?B7_X[1_9]<+GTO17S1_P
MT=XN_P"@=HO_ 'XE_P#CM'_#1WB[_H':+_WXE_\ CM']GUPN?2]%?-'_  T=
MXN_Z!VB_]^)?_CM'_#1WB[_H':+_ -^)?_CM']GUPN?2]%?-'_#1WB[_ *!V
MB_\ ?B7_ ..T?\-'>+O^@=HO_?B7_P".T?V?7"Y]+T5\T?\ #1WB[_H':+_W
MXE_^.T?\-'>+O^@=HO\ WXE_^.T?V?7"Y]+T5\T?\-'>+O\ H':+_P!^)?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBI(();JXC@MT:265PB(HR68G  _&@".BO?\
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M=3D2,'^%?+C;'YL3^->KUY)^SC_R3J__ .PK)_Z*BKUNOE\5_'EZE!1117,
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MR8W#C^ ;,\COV]*:IU7.3DM'?K]P'?B;2K_X_6OA%O"OAZ'3K2YE;,.G(KS
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MY@4P$>2V5"XV]0&Z<;A7&:!\5-0\)^!AH?AFU6QOGNC//J1993(#QM$;(0.
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M?W7WU]1GGGC_ .*4_C[0]+LKS3$M;BQ)>6=)MRS,5 )";1MY&<9-5/%GC_\
MX2B_T&Y_LW[+_8\$<.WS]_G;2#G.T;<X]ZV[WPCH</PL\4:O'98O[#Q ]G;3
M>:_[N$-& N-V#]X\D$\]:T_AEX(TG7OAK?ZO+X5_X2+58=2,$4']HO:9CV1G
M[VX+QN8\C)K7FHTX<R6B=OO^8C-D^--V?'%_K<>C0M8:E:I;7FF3R^8LJJ"
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MK"2DHIO[C.KP_CZ<'-Q6GF<_17N\/P/\-R?>OM5_"6/_ .-U>3X!>%V7)O\
M5_\ O]%_\;KN>,I(\ ^>J*^A_P#A0'A;_G_UC_O]%_\ &Z/^% >%O^?_ %C_
M +_1?_&ZGZ[1 ^>**^A_^% >%O\ G_UC_O\ 1?\ QNC_ (4!X6_Y_P#6/^_T
M7_QNCZ[1 ^>**^A_^% >%O\ G_UC_O\ 1?\ QNC_ (4!X6_Y_P#6/^_T7_QN
MCZ[1 ^>**^A_^% >%O\ G_UC_O\ 1?\ QNC_ (4!X6_Y_P#6/^_T7_QNCZ[1
M ^>**^A_^% >%O\ G_UC_O\ 1?\ QNC_ (4!X6_Y_P#6/^_T7_QNCZ[1 ^>*
M*^A_^% >%O\ G_UC_O\ 1?\ QNC_ (4!X6_Y_P#6/^_T7_QNCZ[1 ^>**^A_
M^% >%O\ G_UC_O\ 1?\ QNC_ (4!X6_Y_P#6/^_T7_QNCZ[1 ^>**^A_^% >
M%O\ G_UC_O\ 1?\ QNC_ (4!X6_Y_P#6/^_T7_QNCZ[1 ^>**^A_^% >%O\
MG_UC_O\ 1?\ QNC_ (4!X6_Y_P#6/^_T7_QNCZ[1 ^>**^A_^% >%O\ G_UC
M_O\ 1?\ QNC_ (4!X6_Y_P#6/^_T7_QNCZ[1 ^>**^A_^% >%O\ G_UC_O\
M1?\ QNC_ (4!X6_Y_P#6/^_T7_QNCZ[1 ^>**^A_^% >%O\ G_UC_O\ 1?\
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M ,;H_P"%$^&?^?[5O^_T7_QNC^T* K'@5%>_?\*)\,_\_P!JW_?Z+_XW2_\
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MJL6HZJAB:XU)T(MHSGA-I.<9XSSGDDXQ7;_\* \+?\_^L?\ ?Z+_ .-T?\*
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M%_\ &ZOV^'YE)MNPCYXHKZ'_ .% >%O^?_6/^_T7_P ;H_X4!X6_Y_\ 6/\
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M1W<FK1_V;J$>G7:*SQ3R77V?!"DX$A("DC(&2!VSS78MJ.G6%U:G5WTZWO\
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YFZ_Y&2Y^J_\
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M _\ 0%K%K:\7?\C3=_\  /\ T!:Q":]JE\$?0@"::3033":U$!--)H)II-
M332:":830 $TTF@FFDTP FFDT$TTF@8$TTF@FFDTP FFDT$TTF@ )II-!-,)
MIB FFDT$TTF@8$TTF@FFDT !--)H)II- P)II-!--)I@!-,)H)II-  332:"
M::33 "::30332:8 33":"::30 $TTF@FFDT !--)H)II-, )II-!--)H ":8
M30332:8 332:"::30 $TTF@FFDT !--)H)II-, )II-!--)H ":830332:8
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M%UCWI:3'S7)(V1X3]ZP*D%4W$8Y I[^*]'CTR&^,\QCFD,,<*6LK3M(,[D$
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M9(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /,?%Y_XJF\_P"
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M@MHVGD^]JG^%1_:,+VY1\NESY\)II-?17_",Z#_T!-._\!(_\*7_ (1C0?\
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M-/\ M"/\H6/E8FFDU]6?\(?X:_Z%W2O_  !C_P#B:7_A#_#/_0NZ3_X Q_\
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MN:>)HPR)VVKYF">?FR."IJIH]M>7 N8+W1M>L+[4(#'<:U//9ETX.T)LE?8
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MW)/S%.X'.>)/^/BR_P"!_P#LM3VO_'NM3:V^F":U^U17+'YMGEL!CIG/Z5-
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M&_\ D?\ ^QH_X6#C_F&?^3'_ -C1]5K=OR"Z.U%**XC_ (6)C_F%_P#DQ_\
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MC=Y487_A'\X[_;?_ +763P6(YF^7\45=6/7J6O(_^%Z?]2[_ .3W_P!KI/\
MA>W_ %+O_D]_]KI_4L1_+^*%='KU**\@_P"%\?\ 4N?^3W_VND_X7UC_ )ES
M_P GO_M=/ZE7_E_%!='L0I17CG_"_,?\RW_Y/_\ VNC_ (7_ (_YEK_R?_\
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MM#<WFA:W97%M$W[_ %#7'O(=Y&&$:F=R0>?F95.,<9X'8T44P"BBB@ HHHH
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MD%**8A12BD%**8"BE%(*44P*^H_\@J[_ .N+_P#H)K$TC_5#Z5MZC_R"KO\
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MYV%C5\RS_P"?O_R&:/,L_P#G[_\ (9K)HHYV%C6\RS_Y^_\ R&:/,L_^?O\
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M]G;CY1WK0%O:?\_O_D(US0_Y#4WU7_T$5M#I2B[@RYY%I_S^_P#D(T>3:?\
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M[_\ (9K(HI>TD%C7\VS_ .?O_P AM1YMG_S]_P#D-JR**/:2"QK^;9_\_?\
MY#:CS;+_ )^__(;5D4E'M)!8V/-LO^?O_P AM1YME_S]_P#D-JQZ*7M)!8U_
M.LO^?O\ \AM1YUE_S]_^0VK'HH]I(?*CI-.DB=I1!)Y@ 7)VD>OK5ZL;P_\
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M=-J,NW&/]K.<]JL:1J]K8Z9J%A?6<US#>^7DPW B9-A)')1@<Y]*[7_A3_\
MU'/_ "4_^SH_X4__ -1S_P E/_LZ;S# M-.6^NS_ ,@LSD%\2MI^FO9^'%NM
M,$D_FRSB[S*X"X5-RJGR@ECC'\0].8;_ %^;4[>P^WB2>\LRP-U)*6:5"VX*
M<\\$M@YZ'IQ7:_\ "G_^HY_Y*?\ V='_  I__J.?^2G_ -G26.P"=^;7T?\
MD%F<6->QK^IZG]F_X_UN5\OS/N><K#KCG&[T&<=JJZ3J;:7=.YACN(9HS#/!
M)G;+&<9&1R#D @CD$"N^_P"%/_\ 4<_\E/\ [.C_ (4__P!1S_R4_P#LZ?\
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M*BG<V[+M6W!_JZQ++M6W!_JZ^3B6R6BBBK)$HHHI#"BBB@!#24II* "BBB@
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M&VCE^;GU<CC'&/K6;'XFU.?4M-BEN=/TN&ZMK:5&N[61EO7D^]'%)YBJCC&
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M5U#_ )_KG_O\W^-6?$?_ "'[G_@/_H(K+KZ.C"/LHZ=$8O<M?VKJ'_/]<_\
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MEAAB6,MWX6LI;:R33Y;C2I]/C\JTN;)E$D49QN3YPRNIVC(=6&0#]X C:HH
MRHM#.W3S?:G>:A-87+7,<TXB5F8QO'AA&BK@+(W0 YQS6:W@>&-;9--UG4M.
MBLYGEM(H! ZVV]=I1!)$^%P6P/X0Q4$+A1T]!. 2>WH* *VGVLUE9K!<W]QJ
M$BDYN+E8P[<]Q&BKQTX%4]+\/6NDFT-M),WV2S%G'YC Y0$')P!SQ]/:KMM?
MV]VL)B=E>:+S4BF1HI=G')C8!AU .0,9I;&]M]2T^WOK*3S;:ZB6:%]I&Y&
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M33R3_9$M"9&!W*K%@QXR6)8Y/Z5H56N=0MK6ZMK>XEV2W3,L*D'YBJECST'
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MC8;5**%QR ,9-=$:2@"EI>E0:3;O' TLLDS^;//.Y>2>3 !=CZX4# P
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M:2@ HHHH *#10:0"4444 %%%% !24M)2&%%%% !1110 4444 )1112 ****
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MLZ[_ ,^FG?\ ?M__ (NNK^R,5V7WA='K]%>0?\+9UW_GTT[_ +]O_P#%T?\
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M^.TG_$M];K_QV@93HJY_Q+?6Z_\ ':/^);ZW7_CM("G15S_B6^MU_P".T?\
M$M];K_QV@"G15S_B6^MU_P".T?\ $M];K_QV@"E15S_B6^MU_P".T?\ $M];
MK_QVD!3HJY_Q+?6Z_P#':/\ B6^MU_X[0!3-)5T_V;ZW7_CM)_Q+/6Z_\=H&
M4Z*N?\2SUNO_ !VC_B6>MU_X[0!SX_Y#4WU7_P!!%;0Z56']B_VI+S?>;D9X
M3;T%:G_$O];G_P =JHBD5**M?\2_UN?_ !VC_B7^MS_X[3$4Z*N?\2[UNO\
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M@"G15S_B6^MU_P".T?\ $M];K_QVD,IFDJ[_ ,2WUNO_ !VD_P");ZW7_CM
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ME( HHHH 2BBBD,V?#_\ R\?\!_K6S6-X?_Y>/^ _UK9K1;$O<****8@HHHH
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M_P !'_PKZ%HH_MNI_(@L?/7_  C6N_\ 0%U'_P !'_PH_P"$:UW_ * NH_\
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M(84444 98_Y#4WU7_P!!%;0Z5R6HZS_9^NSCR/,QM_CQ_"/:G_\ ";?]0_\
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M]E;M!Y1 &8Y(V=RK@GD$@C." :RX?$EXFN7ZZE=6=G;VAF9=/DM7%S-#&O\
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M\LP2M+&RAE()#.3\P(X'%5H?"TEM#<_9]?U6.ZNKA9YKS]PTCD1A-NTQ% N
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M> Z]\@:MG<?:[&"Y,,D!FC63RI0 \>1G:V"1D=#@F@"6BBBD,V?#_P#R\?\
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MG$:+%$\KNQZ*J("S'J< '@$] :IS>)],@LK>YD-WBY+>5"EC.T[;3ACY(0R
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M+2J-SA<;5(/.<9SP3GD#%49/%VBQ:DUB]U)YR3BW=A;2F..4XVH\@78K'<N
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MW=P#U-<Y<>!99M*LK-KO3IDMVE+6UWIQFL_G(*[(#*-FP+A<LP4,V!SQV-%
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MT4459(E%%%(84444 (:2E-)0 4444 %!HH-(!**** "BBB@ I*6DI#"BBB@
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M (6)XI_Z"G_DO%_\31_8N([K\?\ (+GN513VT5S&$G3< P8<X(/J".E>)?\
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M*0!0:*#2&)1110 &DI324@"DI:2D,S-5_P"/BU_X%_2M2V_U K+U7_CXM?\
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MDTKP_-JENDWVNUM$EN!;0FX9OWLA .T!5;&,KDG ^8<UH>*K^74]*T:]N/\
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M[_OK_P!\#_"JE)0,N?VI=_WU_P"^!_A1_:EW_P ]%_[X'^%4Z*5P+G]J7?\
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M_P ]%_[X'^%5*2B[ N?VK=_\]%_[X'^%']JW?_/1?^^!_A5.BE=@6_[5N_\
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M_P! 73O_  $3_"C_ (1K0O\ H"Z=_P" B?X4?VW3_D86/GJBOH7_ (1K0O\
MH"Z=_P" B?X4?\(UH7_0%T[_ ,!$_P */[;I_P C"Q\]45]"_P#"-:%_T!=.
M_P# 1/\ "C_A&M"_Z NG?^ B?X4?VW3_ )&%CYZHKZ%_X1K0O^@+IW_@(G^%
M'_"-:%_T!=._\!$_PH_MNG_(PL?/5%?0O_"-:%_T!=._\!$_PH_X1K0O^@+I
MW_@(G^%']MT_Y&%CYZHKZ%_X1K0O^@+IW_@(G^%176B>&K*UENKW3-*M[>%2
M\DLMO&B(HZDDC 'O1_;=/^1A8^?Z*^A1X;T$@$:-IQ!Z$6L?^%'_  C6A?\
M0%T[_P !$_PH_MNG_(PL?/5%?0O_  C6A?\ 0%T[_P !$_PH_P"$:T+_ * N
MG?\ @(G^%']MT_Y&%CYZHKZ%_P"$:T+_ * NG?\ @(G^%'_"-:%_T!=._P#
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MD%CGL? VEV6G>#]+>TMXXY;BR@>>8*-\S>6/F=NI/UZ=!Q0!T%%%%( HHHH
M#24II*0PHHHH X3Q'_R'[G_@/_H(K*)K4\2'_BH+G_@/_H K))KZ6C_"CZ(P
M>X$U&S4,U1LU;"!FJ)FH9JA=Z !WJ!WH=ZKR24#"22J[O0[U6DDH ]%\%^.
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MI7-GPK8:EIOANUM=:NOM-TB_,W78.RY_BQZUKFEI#7STI.3;9JB&\_X\9_\
MKFW\J@TC_5#Z5/>?\>,__7-OY5!I'^J'TI+<'L:9HH-%:$B4E+24@"DI:2D
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M?O*58%<@AE([XR 1@>(?"NW14BCFU#4+N[U2R>ZO&;]\529/F'EJJH$7)^4
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M5HH ^JO[9T#_ *&?0_\ P81_XT?VSH'_ $,^A_\ @PC_ ,:^5:*5@/JK^V=
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M?VSH'_0SZ'_X,(_\:^5:*5@/JK^V= _Z&?0__!A'_C2?VQH'_0SZ'_X,(_\
M&OE:BBP'U3_;&@?]#/H?_@PC_P :/[8T#_H9]#_\&$?^-?*U%%D!]4_VQH'_
M $,^A_\ @PC_ ,:3^U] _P"AGT/_ ,&$?^-?*]%%D!]4?VOH'_0SZ'_X,(_\
M:/[7T'_H9]#_ /!A'_C7RO11RH9].:C>Z)=P(D7BC005<,=VHQ],'W]Z=:7V
MB08W^*-!/TU&/_&OF&BERH+GU9_;?A__ *&?0_\ P81_XT?VWX?_ .AGT/\
M\&$?^-?*=%4(^J_[:\/_ /0SZ'_X,(_\:/[:\/\ _0SZ'_X,(_\ &OE2B@#Z
MK_MKP_\ ]#/H?_@PC_QI/[9T#_H9]#_\&$?^-?*M% 'U5_;.@?\ 0SZ'_P"#
M"/\ QH_MG0/^AGT/_P &$?\ C7RK10!]5?VSH'_0SZ'_ .#"/_&C^V= _P"A
MGT/_ ,&$?^-?*M%*P'U5_;.@?]#/H?\ X,(_\:/[9T#_ *&?0_\ P81_XU\J
MT46 ^J?[8T#_ *&?0_\ P81_XT?VQH'_ $,^A_\ @PC_ ,:^5J*+(#ZI_MC0
M/^AGT/\ \&$?^-']L:!_T,^A_P#@PC_QKY6HHL@/JG^V- _Z&?0__!A'_C2?
MVOH'_0SZ'_X,(_\ &OE>BBR ^J/[7T#_ *&?0_\ P81_XT?VOH'_ $,^A_\
M@PC_ ,:^5Z*+(#ZH_M?0?^AGT/\ \&$?^-']KZ#_ -#/H?\ X,(_\:^5Z*.5
M#N?8_AN:UN89YK"^M+Z'<$\VTF650PY*DCO@@X]Q6W7E7[/7_)/K[_L*2?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P! "/\ \")?_BZ /E&BOJ[_ (5!X%_Z $?_ ($2_P#Q='_"H/ O_0 C_P#
MB7_XN@#Y1HKZN_X5!X%_Z $?_@1+_P#%T?\ "H/ O_0 C_\  B7_ .+H ^4:
M*^KO^%0>!?\ H 1_^!$O_P 71_PJ#P+_ - "/_P(E_\ BZ /E&BOJ[_A4'@7
M_H 1_P#@1+_\71_PJ#P+_P! "/\ \")?_BZ /E&BOJ[_ (5!X%_Z $?_ ($2
M_P#Q='_"H/ O_0 C_P# B7_XN@#Y1HKZN_X5!X%_Z $?_@1+_P#%T?\ "H/
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M_P! "/\ \")?_BZ /E&BOJ[_ (5!X%_Z $?_ ($2_P#Q='_"H/ O_0 C_P#
MB7_XN@#Y1HKZN_X5!X%_Z $?_@1+_P#%T?\ "H/ O_0 C_\  B7_ .+H ^4:
M*^KO^%0>!?\ H 1_^!$O_P 71_PJ#P+_ - "/_P(E_\ BZ /E&BOJ[_A4'@7
M_H 1_P#@1+_\71_PJ#P+_P! "/\ \")?_BZ /E&BOJ[_ (5!X%_Z $?_ ($2
M_P#Q='_"H/ O_0 C_P# B7_XN@#Y1HKZN_X5!X%_Z $?_@1+_P#%T?\ "H/
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M_P! "/\ \")?_BZ /E&BOJ[_ (5!X%_Z $?_ ($2_P#Q='_"H/ O_0 C_P#
MB7_XN@#Y1HKZN_X5!X%_Z $?_@1+_P#%T?\ "H/ O_0 C_\  B7_ .+H ^4:
M*^KO^%0>!?\ H 1_^!$O_P 71_PJ#P+_ - "/_P(E_\ BZ /E&BOJ[_A4'@7
M_H 1_P#@1+_\71_PJ#P+_P! "/\ \")?_BZ /E&BOJ[_ (5!X%_Z $?_ ($2
M_P#Q='_"H/ O_0 C_P# B7_XN@#Y1HKZN_X5!X%_Z $?_@1+_P#%T?\ "H/
MO_0 C_\  B7_ .+H ^4:*^KO^%0>!?\ H 1_^!$O_P 71_PJ#P+_ - "/_P(
ME_\ BZ /E&BOJ[_A4'@7_H 1_P#@1+_\71_PJ#P+_P! "/\ \")?_BZ /E&B
MOJ[_ (5!X%_Z $?_ ($2_P#Q='_"H/ O_0 C_P# B7_XN@#Y1HKZN_X5!X%_
MZ $?_@1+_P#%T?\ "H/ O_0 C_\  B7_ .+H ^4:*^KO^%0>!?\ H 1_^!$O
M_P 71_PJ#P+_ - "/_P(E_\ BZ /E&BOJ[_A4'@7_H 1_P#@1+_\71_PJ#P+
M_P! "/\ \")?_BZ /E&BOJ[_ (5!X%_Z $?_ ($2_P#Q='_"H/ O_0 C_P#
MB7_XN@#Y1HKZN_X5!X%_Z $?_@1+_P#%T?\ "H/ O_0 C_\  B7_ .+H ^4:
M*^KO^%0>!?\ H 1_^!$O_P 71_PJ#P+_ - "/_P(E_\ BZ /E&BOJ[_A4'@7
M_H 1_P#@1+_\71_PJ#P+_P! "/\ \")?_BZ /E&BOJ[_ (5!X%_Z $?_ ($2
M_P#Q='_"H/ O_0 C_P# B7_XN@#Y1HKZN_X5!X%_Z $?_@1+_P#%T?\ "H/
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M_P! "/\ \")?_BZ /E&BOJ[_ (5!X%_Z $?_ ($2_P#Q='_"H/ O_0 C_P#
MB7_XN@#Y1HKZN_X5!X%_Z $?_@1+_P#%T?\ "H/ O_0 C_\  B7_ .+H ^4:
M*^KO^%0>!?\ H 1_^!$O_P 71_PJ#P+_ - "/_P(E_\ BZ /E&BOJ[_A4'@7
M_H 1_P#@1+_\71_PJ#P+_P! "/\ \")?_BZ /E&BOJ[_ (5!X%_Z $?_ ($2
M_P#Q='_"H/ O_0 C_P# B7_XN@#Y1HKZN_X5!X%_Z $?_@1+_P#%T?\ "H/
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M_P! "/\ \")?_BZ /E&BOJ[_ (5!X%_Z $?_ ($2_P#Q='_"H/ O_0 C_P#
MB7_XN@#Y1HKZN_X5!X%_Z $?_@1+_P#%T?\ "H/ O_0 C_\  B7_ .+H ^4:
M*^KO^%0>!?\ H 1_^!$O_P 71_PJ#P+_ - "/_P(E_\ BZ /E&BOJ[_A4'@7
M_H 1_P#@1+_\71_PJ#P+_P! "/\ \")?_BZ /E&BOJ[_ (5!X%_Z $?_ ($2
M_P#Q='_"H/ O_0 C_P# B7_XN@#Y1HKZN_X5!X%_Z $?_@1+_P#%T?\ "H/
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M>O-*U**WLFN3=C45%NKA@"CR(K[, @D\X!'% '4453_MC3/[3&F_VC:?;B6
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MV5MNY@H(,;\,5^[[C-74-,U=K'Q!HL7AZ28ZY))(FJ":$1Q&1 JF8%Q)NCP
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M;^T5_LXVDD%E/&JVC^9O109"F8@&*Y4%@$'R\X'=44 ><:%INL>%=.TV:_\
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MC41!&5S<+Y@(8,P,9(^8D -U]+HH XR\\,W$NG>+ EA&UQJ>H1W$!)3,H2*
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MIW%M)&T%L#,S(F<@D%7^7"]%.=O KIJ* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
@B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628740675808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Aug. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Ovid Therapeutics Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-5270895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">441 Ninth Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">14th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">661-7661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">OVID<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,602,793<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001636651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628740685088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 71,623,256<span></span>
</td>
<td class="nump">$ 44,867,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">24,894,144<span></span>
</td>
<td class="nump">84,133,565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,653,465<span></span>
</td>
<td class="nump">2,379,280<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">102,170,865<span></span>
</td>
<td class="nump">131,380,691<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term equity investments</a></td>
<td class="nump">16,470,542<span></span>
</td>
<td class="nump">5,622,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">1,930,753<span></span>
</td>
<td class="nump">1,930,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset, net</a></td>
<td class="nump">14,412,068<span></span>
</td>
<td class="nump">14,922,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">955,569<span></span>
</td>
<td class="nump">1,147,963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">289,967<span></span>
</td>
<td class="nump">261,191<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">136,229,764<span></span>
</td>
<td class="nump">155,265,814<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,763,289<span></span>
</td>
<td class="nump">1,952,910<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">5,433,290<span></span>
</td>
<td class="nump">4,504,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion, lease liability</a></td>
<td class="nump">944,943<span></span>
</td>
<td class="nump">533,946<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">10,141,522<span></span>
</td>
<td class="nump">6,991,525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability</a></td>
<td class="nump">15,389,567<span></span>
</td>
<td class="nump">16,001,725<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">25,531,089<span></span>
</td>
<td class="nump">22,993,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares authorized; Series A convertible preferred stock, 10,000 shares designated, 1,250 shares issued and outstanding at June&#160;30, 2023 and December&#160;31, 2022</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 125,000,000 shares authorized; 70,602,793 and 70,466,885 shares issued and outstanding at June&#160;30, 2023 and December&#160;31, 2022, respectively</a></td>
<td class="nump">70,603<span></span>
</td>
<td class="nump">70,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in-capital</a></td>
<td class="nump">361,913,944<span></span>
</td>
<td class="nump">357,770,825<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">5,208<span></span>
</td>
<td class="num">(42,187)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(251,291,081)<span></span>
</td>
<td class="num">(225,526,542)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">110,698,675<span></span>
</td>
<td class="nump">132,272,564<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 136,229,764<span></span>
</td>
<td class="nump">$ 155,265,814<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628743156784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_PreferredStockShareDesignated', window );">Preferred stock, share designated (in shares)</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued (in shares)</a></td>
<td class="nump">70,602,793<span></span>
</td>
<td class="nump">70,466,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">70,602,793<span></span>
</td>
<td class="nump">70,466,885<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_PreferredStockShareDesignated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock shares designated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_PreferredStockShareDesignated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628743175888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 141,160<span></span>
</td>
<td class="nump">$ 1,445,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">5,998,766<span></span>
</td>
<td class="nump">6,046,670<span></span>
</td>
<td class="nump">12,613,482<span></span>
</td>
<td class="nump">13,878,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">8,248,216<span></span>
</td>
<td class="nump">8,257,617<span></span>
</td>
<td class="nump">16,591,964<span></span>
</td>
<td class="nump">18,137,820<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">14,246,982<span></span>
</td>
<td class="nump">14,304,287<span></span>
</td>
<td class="nump">29,205,447<span></span>
</td>
<td class="nump">32,016,759<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(14,171,982)<span></span>
</td>
<td class="num">(14,304,287)<span></span>
</td>
<td class="num">(29,064,286)<span></span>
</td>
<td class="num">(30,571,393)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">1,763,652<span></span>
</td>
<td class="num">(284,127)<span></span>
</td>
<td class="nump">3,299,747<span></span>
</td>
<td class="num">(125,076)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">(12,408,330)<span></span>
</td>
<td class="num">(14,588,414)<span></span>
</td>
<td class="num">(25,764,539)<span></span>
</td>
<td class="num">(30,696,470)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (12,408,330)<span></span>
</td>
<td class="num">$ (14,588,414)<span></span>
</td>
<td class="num">$ (25,764,539)<span></span>
</td>
<td class="num">$ (30,696,470)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="num">$ (0.44)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="num">$ (0.44)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic (in shares)</a></td>
<td class="nump">70,534,181<span></span>
</td>
<td class="nump">70,391,458<span></span>
</td>
<td class="nump">70,512,479<span></span>
</td>
<td class="nump">70,391,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">70,534,181<span></span>
</td>
<td class="nump">70,391,458<span></span>
</td>
<td class="nump">70,512,479<span></span>
</td>
<td class="nump">70,391,236<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628740812544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (12,408,330)<span></span>
</td>
<td class="num">$ (14,588,414)<span></span>
</td>
<td class="num">$ (25,764,539)<span></span>
</td>
<td class="num">$ (30,696,470)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive (loss) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on marketable securities</a></td>
<td class="num">(422)<span></span>
</td>
<td class="num">(90,127)<span></span>
</td>
<td class="nump">47,395<span></span>
</td>
<td class="num">(90,127)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (12,408,752)<span></span>
</td>
<td class="num">$ (14,678,541)<span></span>
</td>
<td class="num">$ (25,717,144)<span></span>
</td>
<td class="num">$ (30,786,597)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628737388128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th">
<div>Preferred Stock </div>
<div>Series A Convertible Preferred Stock</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 179,746,436<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 70,359<span></span>
</td>
<td class="nump">$ 351,033,589<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (171,357,513)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,364,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock from exercise of stock options and purchases from employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock from exercise of stock options and purchases from employee stock purchase plan</a></td>
<td class="nump">33,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">33,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,324,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,324,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(16,108,056)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,108,056)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">164,996,271<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 70,373<span></span>
</td>
<td class="nump">352,391,466<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(187,465,569)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,417,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">179,746,436<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 70,359<span></span>
</td>
<td class="nump">351,033,589<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(171,357,513)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,364,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(30,696,470)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">152,147,496<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 70,414<span></span>
</td>
<td class="nump">354,221,191<span></span>
</td>
<td class="num">(90,127)<span></span>
</td>
<td class="num">(202,053,983)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,419,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">164,996,271<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 70,373<span></span>
</td>
<td class="nump">352,391,466<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(187,465,569)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,417,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock from exercise of stock options and purchases from employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock from exercise of stock options and purchases from employee stock purchase plan</a></td>
<td class="nump">109,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">109,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,720,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,720,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="num">(90,127)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90,127)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(14,588,414)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,588,414)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">$ 152,147,496<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 70,414<span></span>
</td>
<td class="nump">354,221,191<span></span>
</td>
<td class="num">(90,127)<span></span>
</td>
<td class="num">(202,053,983)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,419,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 132,272,564<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 70,467<span></span>
</td>
<td class="nump">357,770,825<span></span>
</td>
<td class="num">(42,187)<span></span>
</td>
<td class="num">(225,526,542)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">70,466,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,466,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock from exercise of stock options and purchases from employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock from exercise of stock options and purchases from employee stock purchase plan</a></td>
<td class="nump">$ 66,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">66,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,916,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,916,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="nump">47,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(13,356,209)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,356,209)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 120,947,682<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 70,492<span></span>
</td>
<td class="nump">359,754,310<span></span>
</td>
<td class="nump">5,630<span></span>
</td>
<td class="num">(238,882,751)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,491,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 132,272,564<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 70,467<span></span>
</td>
<td class="nump">357,770,825<span></span>
</td>
<td class="num">(42,187)<span></span>
</td>
<td class="num">(225,526,542)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">70,466,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,466,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (25,764,539)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="nump">$ 110,698,675<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 70,603<span></span>
</td>
<td class="nump">361,913,944<span></span>
</td>
<td class="nump">5,208<span></span>
</td>
<td class="num">(251,291,081)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="nump">70,602,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,603,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2023</a></td>
<td class="nump">$ 120,947,682<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 70,492<span></span>
</td>
<td class="nump">359,754,310<span></span>
</td>
<td class="nump">5,630<span></span>
</td>
<td class="num">(238,882,751)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,491,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock from exercise of stock options and purchases from employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock from exercise of stock options and purchases from employee stock purchase plan</a></td>
<td class="nump">211,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111<span></span>
</td>
<td class="nump">210,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,948,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,948,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="num">(422)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(422)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (12,408,330)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="nump">$ 110,698,675<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 70,603<span></span>
</td>
<td class="nump">$ 361,913,944<span></span>
</td>
<td class="nump">$ 5,208<span></span>
</td>
<td class="num">$ (251,291,081)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="nump">70,602,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,603,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628738019584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (25,764,539)<span></span>
</td>
<td class="num">$ (30,696,470)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction', window );">Non-cash consideration received in licensing agreement transaction</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(945,366)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized (gain) loss on equity investment</a></td>
<td class="num">(847,995)<span></span>
</td>
<td class="nump">348,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_ChangeInAccruedInterestAndAccretionOfDiscountsShortTermInvestments', window );">Change in accrued interest and accretion of discount on marketable securities</a></td>
<td class="num">(1,139,113)<span></span>
</td>
<td class="num">(223,649)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">3,865,166<span></span>
</td>
<td class="nump">3,045,029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">282,121<span></span>
</td>
<td class="nump">172,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use asset</a></td>
<td class="nump">510,601<span></span>
</td>
<td class="nump">354,185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_AccretionOfLeaseLiability', window );">Accretion of lease liability</a></td>
<td class="nump">573,015<span></span>
</td>
<td class="nump">368,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(4,048,361)<span></span>
</td>
<td class="num">(230,877)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Security deposit</a></td>
<td class="nump">12,491<span></span>
</td>
<td class="nump">15,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="nump">1,810,379<span></span>
</td>
<td class="num">(2,510,503)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">928,621<span></span>
</td>
<td class="num">(3,072,434)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(23,817,614)<span></span>
</td>
<td class="num">(33,375,022)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of marketable securities</a></td>
<td class="num">(24,574,071)<span></span>
</td>
<td class="num">(79,416,203)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Sales/maturities of marketable securities</a></td>
<td class="nump">85,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLongtermInvestments', window );">Purchase of long-term equity investment</a></td>
<td class="num">(10,000,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_PaymentsForProceedsFromIssuanceOfShortTermNoteReceivable', window );">Issuance of convertible short-term note receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(21,357)<span></span>
</td>
<td class="num">(1,085,840)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToDevelopSoftware', window );">Software development and other costs</a></td>
<td class="num">(109,637)<span></span>
</td>
<td class="num">(251,340)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">50,294,935<span></span>
</td>
<td class="num">(81,753,383)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options and purchases from employee stock purchase plan</a></td>
<td class="nump">278,089<span></span>
</td>
<td class="nump">142,628<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">278,089<span></span>
</td>
<td class="nump">142,628<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">26,755,410<span></span>
</td>
<td class="num">(114,985,777)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, at beginning of period</a></td>
<td class="nump">46,798,599<span></span>
</td>
<td class="nump">189,728,285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, at end of period</a></td>
<td class="nump">73,554,009<span></span>
</td>
<td class="nump">74,742,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset in exchange for lease liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 15,791,769<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_AccretionOfLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion of lease liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_AccretionOfLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_ChangeInAccruedInterestAndAccretionOfDiscountsShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued interest and accretion of discounts, short term investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_ChangeInAccruedInterestAndAccretionOfDiscountsShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash consideration received in licensing agreement transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_PaymentsForProceedsFromIssuanceOfShortTermNoteReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for (Proceeds from) Issuance of Short-Term Note Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_PaymentsForProceedsFromIssuanceOfShortTermNoteReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireLongtermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireLongtermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToDevelopSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the development or modification of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToDevelopSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628740665248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">NATURE OF OPERATIONS</a></td>
<td class="text">NATURE OF OPERATIONS<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ovid Therapeutics Inc. (the &#8220;Company&#8221;) was incorporated under the laws of the state of Delaware and commenced operations on April 1, 2014 and maintains its principal executive office in New York, New York. The Company is a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its inception, the Company has devoted substantially all of its efforts to business development, research and development, recruiting management and technical staff, and raising capital, and has financed its operations through the issuance of convertible preferred stock, common stock and other equity instruments. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development and regulatory success, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, and the ability to secure additional capital to fund operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s major sources of cash have been licensing revenue, proceeds from various public and private offerings of its capital stock, option exercises and interest income. As of June&#160;30, 2023, the Company had approximately $96.5 million in cash, cash equivalents and marketable securities. Since inception, the Company has generated $222.6 million in revenue, primarily from the Company&#8217;s royalty, license and termination agreement (&#8220;RLT Agreement&#8221;) with Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;). Historically, the Company has incurred recurring losses, has experienced negative operating cash flows and has required significant cash resources to execute its business plans, which the Company expects will continue for the foreseeable future. The Company has an accumulated deficit of $251.3 million as of June&#160;30, 2023, working capital of $92.0 million and had cash used in operating activities of $23.8 million for the six months ended June&#160;30, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded net losses of $12.4 million and $25.8 million during the three and six months ended June&#160;30, 2023, respectively, and expects to incur losses in subsequent periods for at least the next several years. The Company is highly dependent on its ability to find additional sources of funding through either equity offerings, debt financings, collaborations, strategic alliances, licensing agreements or a combination of any such transactions. Management believes that the Company&#8217;s existing cash, cash equivalents and marketable securities as of June&#160;30, 2023 will be sufficient to fund its current operating plans through at least the next 12 months from the date of filing of the Company&#8217;s Quarterly Report on Form 10-Q. Adequate additional funding may not be available to the Company on acceptable terms or at all. The failure to raise capital as and when needed could have a negative impact on the Company&#8217;s financial condition and ability to pursue its business strategy. The Company may be required to delay, reduce the scope of or eliminate research and development programs, or obtain funds through arrangements with collaborators or others that may require the Company to relinquish rights to certain drug candidates that the Company might otherwise seek to develop or commercialize independently.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to other challenges and risks specific to its business and its ability to execute on its strategy, as well as risks and uncertainties common to companies in the pharmaceutical industry with development and commercial operations, including, without limitation, risks and uncertainties associated with: delays or problems in the supply of the Company's product candidates, loss of single source suppliers or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing additional products or product candidates; pharmaceutical product development and the inherent uncertainty of clinical success; the challenges of protecting and enhancing intellectual property rights; complying with applicable regulatory requirements; and obtaining regulatory approval of any of the Company's product candidates.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628745896672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant accounting policies are described in Note 2, &#8220;Summary of Significant Accounting Policies,&#8221; in the Company&#8217;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March 13, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(A) Unaudited Interim Condensed Consolidated Financial Statements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim condensed consolidated balance sheet at June&#160;30, 2023 and the condensed consolidated statements of operations, comprehensive loss, cash flows, and stockholders&#8217; equity for the three and six months ended June&#160;30, 2023 and 2022 are unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) and following the requirements of the SEC for interim reporting. As permitted under those rules, certain notes or other financial information that are normally required by GAAP are condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of its financial information. The results of operations for the three and six month periods ended June&#160;30, 2023 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2023 or for any other future annual or interim period. The balance sheet as of December&#160;31, 2022 included herein was derived from the audited financial statements as of that date. These interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited financial statements as of and for the year ended December&#160;31, 2022 included in the Company&#8217;s Annual Report on Form 10-K.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(B) Basis of Presentation and Consolidation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in conformity with GAAP and include the accounts of Ovid Therapeutics Inc. and its wholly owned subsidiary, Ovid Therapeutics Hong Kong Limited. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(C) Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ materially from those estimates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(D) Marketable Securities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consist of investments in U.S. treasury instruments which are considered available-for-sale securities. The Company classifies its marketable securities with maturities of less than one year from the balance sheet date as current assets on its condensed consolidated balance sheets. The Company classifies its marketable securities with original maturities of less than three months as cash equivalents on its consolidated balance sheets. Unrealized gains and losses on these securities that are determined to be temporary are reported as a separate component of accumulated other comprehensive income (loss) in stockholder's equity.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(E) Restricted Cash</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies as restricted cash all cash pledged as collateral to secure long-term obligations and all cash whose use is otherwise limited by contractual provisions. Amounts are reported as non-current unless restrictions are expected to be released in the next 12 months.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(F) Long-Term Equity Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Long-term equity investments consist of equity investments in the preferred shares of Gensaic, Inc., formerly M13 Therapeutics, Inc. (&#8220;Gensaic&#8221;), and Graviton Bioscience Corporation (&#8220;Graviton&#8221;), both privately held corporations. The preferred shares are not considered in-substance common stock, and the investments are accounted for at cost, with adjustments for observable changes in prices or impairments, and are classified within long-term equity investments on the consolidated balance sheets with adjustments recognized in other income (expense), net on the condensed consolidated statements of operations. The Company has determined that these equity investments do not have a readily determinable fair value and elected the measurement alternative. Therefore, the carrying amount of the equity investments will be adjusted to fair value at the time of the next observable price change for the identical or similar investment of the same issuer or when an impairment is recognized. Each reporting period, the Company performs a qualitative assessment to evaluate whether the investments are impaired. The assessment includes a review of recent operating results and trends, recent sales/acquisitions of the investees' securities, and other publicly available data. If an investment is determined to be impaired, the Company will then write it down to its estimated fair value. As of June&#160;30, 2023 and December&#160;31, 2022, the equity investment in Gensaic had a carrying value of $5.1&#160;million. As of June&#160;30, 2023, the equity investment in Graviton had a carrying value of $10.0&#160;million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term equity investments also consist of an equity investment in the common shares of Marinus Pharmaceuticals, Inc. (&#8220;Marinus&#8221;) that were received as non-cash consideration via the terms of a licensing agreement executed between the two companies effective March 2022. The equity shares are marked-to-market at each reporting date with changes in the fair value being reflected in the carrying value of the investment on the Company's consolidated balance sheets and other income (expense) on the Company's consolidated statements of operations. As of June&#160;30, 2023 and December&#160;31, 2022, the equity investment in Marinus had a carrying value of approximately $1.3 million and $0.5 million, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(G) Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Accounting Standards Board (&#8220;FASB&#8221;) guidance specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three levels of the fair value hierarchy are as follows:</span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 1&#8212;Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities. The Company&#8217;s Level 1 assets consisted of investments in a U.S. treasury money market fund and equity securities totaling $42.2 million as of June&#160;30, 2023. The Company's Level 1 assets totaled $42.5 million as of December&#160;31, 2022.</span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 2&#8212;Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly (e.g., quoted prices of similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active). Level 2 includes financial instruments that are valued using models or other valuation methodologies. The Company's Level 2 assets consisted of U.S. treasury bills, totaling $54.8 million as of June&#160;30, 2023 and $84.1 million as of December&#160;31, 2022.</span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 3&#8212;Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable. There were no Level 3 assets or liabilities as of June&#160;30, 2023 or December&#160;31, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reported in the balance sheets for cash and cash equivalents, other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(H) Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at inception and recognizes the lease in accordance with ASC 842. Operating leases are included in right-of-use (&#8220;ROU&#8221;) assets, current liabilities, and long-term lease liability in the Company's consolidated balance sheets. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. The Company determines the portion of the lease liability that is current as the difference between the calculated lease liability at the end of the current period and the lease liability that is projected 12 months from the current period.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(I) Property and Equipment</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost and depreciated over their estimated useful lives of three years using the straight-line method. Repair and maintenance costs are expensed. The Company reviews the recoverability of all long-lived assets, including the related useful life, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(J) Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses the cost of research and development as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and preclinical materials as well as contracted services, license fees, and other external costs. Research and development expenses also include the cost of licensing agreements acquired from third-parties. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received in accordance with ASC 730, Research and Development.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(K) Stock-based Compensation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its stock-based compensation in accordance with ASC 718, Compensation&#8212;Stock Compensation, which establishes accounting for stock-based awards granted to employees for services and requires companies to expense the estimated fair value of these awards over the requisite service period. The Company estimates </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the fair value of all awards granted using the Black-Scholes valuation model. Key inputs and assumptions include the expected term of the option, stock price volatility, risk-free interest rate, dividend yield, stock price and exercise price. Many of the assumptions require significant judgment and any changes could have an impact in the determination of stock-based compensation expense. The Company elected an accounting policy to record forfeitures as they occur. The Company recognizes employee stock-based compensation expense based on the fair value of the award on the date of the grant. The compensation expense is recognized over the vesting period under the straight-line method.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for option awards granted to nonemployee consultants and directors in accordance with ASC 718. The fair value of the option issued or committed to be issued is used to measure the transaction, as this is more reliable than the fair value of the services received. The fair value is measured at the value of the Company&#8217;s common stock award at the earlier of the date that the commitment for performance by the counterparty has been reached or the counterparty&#8217;s performance is complete.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(L) Income Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the asset and liability method, which requires deferred tax assets and liabilities to be recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts and respective tax bases of existing assets and liabilities, as well as for net operating loss carryforwards and research and development credits. Valuation allowances are provided if it is more likely than not that some portion or all of the deferred tax assets will not be realized. The impact of a change in the tax laws is recorded in the period in which the law is enacted.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(M) Net Loss per Share</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per common share is determined by dividing net loss attributable to common stockholders by the basic and diluted weighted-average common shares outstanding during the period. The Company applies the two-class method to allocate earnings between common stock and participating securities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When applicable, net income per diluted share attributable to common stockholders adjusts the basic earnings per share attributable to common stockholders and the weighted-average number of shares of common stock outstanding for the potential dilutive impact of stock options using the treasury-stock method and the potential impact of preferred stock using the if-converted method.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(N) Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, Revenue from Contracts with Customers, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. In applying ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the promises and performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) it satisfies the performance obligations. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services the Company transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to recognizing revenue, the Company makes estimates of the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If there are multiple distinct performance obligations, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The standalone selling price is generally determined using expected cost and comparable transactions. Revenue for performance obligations recognized over time is recognized by measuring the progress toward complete satisfaction of the performance obligations using an input measure.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-refundable upfront fees allocated to licenses that are not contingent on any future performance and require no consequential continuing involvement by the Company, are recognized as revenue when the license term commences and the licensed data, technology or product is delivered. The Company defers recognition of upfront license fees if the performance obligations are not satisfied.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(O) Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has reviewed recently issued accounting standards and plans to adopt those that are applicable. The Company does not expect the adoption of those standards to have a material impact on its financial position, results of operations, or cash flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopts new pronouncements relating to generally accepted accounting principles applicable to the Company as they are issued, which may be in advance of their effective date. Management does not believe that any recently issued, but not yet effective accounting standards, if currently adopted, would have a material effect on the accompanying financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628835906560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock', window );">CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES</a></td>
<td class="text">CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the fair value of cash, cash equivalents and marketable securities as well as gross unrealized holding gains and losses as of June&#160;30, 2023 and December&#160;31, 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrealized holding gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrealized holding losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868,598&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868,598&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,754,658&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,759,866&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,888,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,888,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,512,192&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,208&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,517,400&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="24" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents as of June 30, 2023 include money market funds of $40.9 million.</span></div></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrealized holding gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrealized holding losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,853,042&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,853,042&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,014,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,014,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,175,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,187)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,133,565&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,043,598&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,187)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,001,411&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not hold any securities that were in an unrealized loss position for more than 12 months as of June&#160;30, 2023 and December&#160;31, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no material realized gains or losses on available-for-sale securities during the three and six months ended June&#160;30, 2023 and 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash, cash equivalents, investments in debt and equity instruments (including cost and equity investees and related income statement amounts), equity and cost method investments, investments in joint ventures and any other investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628835906560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock', window );">PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS</a></td>
<td class="text">PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS<div style="margin-top:6pt;text-align:justify;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is summarized as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Furniture and equipment</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">1,444,389&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">1,423,032&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">306,312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">306,312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">(795,132)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">(581,381)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">955,569&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">1,147,963&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $105,292 and $54,631 for the three months ended June&#160;30, 2023 and 2022, respectively. Depreciation expense was $213,751 and $85,470 for the six months ended June&#160;30, 2023 and 2022, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net of accumulated amortization, were $263,367 and $222,100 as of June&#160;30, 2023 and December&#160;31, 2022, respectively, and are included in other assets. Amortization expense was $32,180 and $32,153 for the </span></div>three months ended June&#160;30, 2023 and 2022, respectively. Amortization expense was $68,370 and $86,636 for the six months ended June&#160;30, 2023 and 2022, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for intangible assets and long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628745896672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During September 2021, the Company entered into a 10-year lease agreement for its corporate headquarters with a term commencing March 10, 2022, for approximately 19,000 square feet of office space at Hudson Commons in New York, New York. The lease provides for monthly rental payments over the lease term. The base rent under the lease is currently $2.3&#160;million per year. Rent payments commenced 10 months following the commencement date of the lease, or January 10, 2023, and continue for 10 years following the rent commencement date. The Company issued a letter of credit in the amount of $1.9&#160;million in association with the execution of the lease agreement; the letter of credit is characterized as restricted cash on the Company's condensed consolidated balance sheets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Hudson Commons lease has a remaining lease term of approximately 10 years and includes a single renewal option for an additional five years. The Company did not include the renewal option in the lease term when calculating the lease liability as the Company is not reasonably certain that it will exercise the renewal option. The present value of the lease payments is calculated using an incremental borrowing rate of 7.02%. Lease expense is included in general and administrative and research and development expenses in the condensed consolidated statements of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU asset and lease liabilities related to the Company's operating lease are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Right-of-use asset, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">14,412,068&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Current lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">944,943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Long-term lease liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">15,389,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease cost for the six months ended June&#160;30, 2023 were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,083,617&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum commitments under the non-cancelable operating lease are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,316,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,316,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,316,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,316,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,347,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,511,156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628746008288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES</a></td>
<td class="text">ACCRUED EXPENSES<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payroll and bonus accrual</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,996,003&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,233,802&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development accrual</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,972,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">395,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Professional fees accrual</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">401,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">682,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,433,290&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,504,669&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628746888432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s capital structure consists of common stock and convertible preferred stock. Pursuant to the Company&#8217;s amended and restated certificate of incorporation, as amended, the Company is authorized to issue up to 125,000,000 shares of common stock and 10,000,000 shares of preferred stock. The Company has designated 1,250 of the 10,000,000 authorized shares of preferred stock as non-voting Series A Convertible Preferred Stock (&#8220;Series A Preferred Stock&#8221;).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of common stock are entitled to one vote for each share held. The holders of common stock have no preemptive or other subscription rights, and there are no redemption or sinking fund provisions with respect to such shares. Subject to preferences that may apply to any outstanding series of preferred stock, holders of the common stock are entitled to receive ratably any dividends declared on a non-cumulative basis. The common stock is subordinate to all series of preferred stock with respect to rights upon liquidation, winding up and dissolution of the Company. The holders of common stock are entitled to liquidation proceeds after all liquidation preferences for the preferred stock are satisfied.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were 1,250 shares of Series A Preferred Stock outstanding as of June&#160;30, 2023 and December&#160;31, 2022. Each share of Series A Preferred Stock is convertible into 1,000 shares of common stock at any time at the holder&#8217;s option. However, the holder will be prohibited, subject to certain exceptions, from converting shares of Series A Preferred Stock into shares of common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than, at the written election of the holder, either 9.99% or 14.99% of the total number of shares of common stock then issued and outstanding, which percentage may be changed at the holder&#8217;s election to any other number less than or equal to 19.99% upon 61 days&#8217; notice to the Company; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that effective 61 days after delivery of such notice, such beneficial ownership limitations shall not be applicable to any holder that beneficially owns either 10.0% or 15.0%, as applicable based on the holder&#8217;s initial written election noted above, of the total number of shares of common stock issued and outstanding immediately prior to delivery of such notice. In the event of a liquidation, dissolution, or winding up of the Company, holders of Series A Preferred Stock will receive a payment equal to $0.001 per share of Series A Preferred Stock before any proceeds are distributed to the holders of common stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the Company entered into a sales agreement (the &#8220;2020 ATM agreement&#8221;) with Cowen and Company, LLC (&#8220;Cowen&#8221;), under which the Company may offer and sell in &#8220;at the market offerings,&#8221; from time to time at its sole discretion, shares of its common stock having an aggregate offering price of up to $75.0&#160;million through Cowen acting as sales agent. As of June&#160;30, 2023, the Company has not sold any shares of its common stock under the 2020 ATM agreement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through June&#160;30, 2023, the Company has not declared any dividends. No dividends on the common stock shall be declared and paid unless dividends on the preferred stock have been declared and paid.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628746902880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Board of Directors adopted, and the Company's stockholders approved, the 2017 Equity Incentive Plan (&#8220;2017 Plan&#8221;), which became effective on May 4, 2017. The initial reserve of shares of common stock issuable under the 2017 Plan was 3,052,059 shares. The 2017 Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance-based stock awards, and other forms of stock-based awards. Additionally, the 2017 Plan provides for the grant of performance cash awards. The Company's employees, officers, directors, consultants and advisors are eligible to receive awards under the 2017 Plan. Following the adoption of the 2017 Plan, no further awards will be granted under the Company&#8217;s prior plan. Pursuant to the terms of the 2017 Plan, on each January 1st, the plan limit shall be increased by the lesser of (x) 5% of the number of shares of common stock outstanding as of the immediately preceding December 31 and (y) such lesser number as the Board of Directors may determine at its discretion. On January&#160;1, 2023 and January&#160;1, 2022 an additional 3,523,344 and 1,000,000 shares, respectively, were reserved for issuance under the 2017 Plan. As of June&#160;30, 2023, there were 4,131,738 shares of the Company&#8217;s common stock reserved and available for issuance under the 2017 Plan.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Board of Directors adopted, and the Company's stockholders approved, the 2017 Employee Stock Purchase Plan (&#8220;2017 ESPP&#8221;), which became effective on May 4, 2017. The initial reserve of shares of common stock  issuable under the 2017 ESPP was 279,069 shares. The 2017 ESPP allows employees to purchase common stock of the Company at a 15% discount to the market price on designated semi-annual purchase dates. During the three months ended June&#160;30, 2023 and 2022, there were no shares purchased under the 2017 ESPP, and the Company recorded expense of $13,446 and $20,176, respectively. During the six months ended June&#160;30, 2023 and 2022, 29,830 and 38,583 shares, respectively, were purchased under the 2017 ESPP, and the Company recorded expenses of $28,600 and $41,195, respectively. The number of shares of common stock reserved for issuance under the 2017 ESPP automatically increases </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on January 1 of each year, beginning on January 1, 2018 and continuing through and including January 1, 2027, by the lesser of (i) 1% of the total number of shares of the Company&#8217;s common stock outstanding on December 31 of the preceding calendar year, (ii) 550,000 shares or (iii) such lesser number of shares determined by the Board. The Board acted prior to each of January&#160;1, 2023 and January&#160;1, 2022 to provide that there be no increase in the number of shares reserved for issuance under the 2017 ESPP on either such date. As of June&#160;30, 2023, there were 386,777 shares of the Company&#8217;s common stock reserved and available for issuance under the 2017 ESPP.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s Board of Directors adopted and the Company&#8217;s stockholder&#8217;s approved the 2014 Equity Incentive Plan (&#8220;2014 Plan&#8221;), which authorized the Company to grant shares of common stock in the form of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock and restricted stock units. The 2014 Plan was terminated as to future awards in May 2017, although it continues to govern the terms of options that remain outstanding under the 2014 Plan. No additional stock awards will be granted under the 2014 Plan, and all outstanding stock awards granted under the 2014 Plan that are repurchased, forfeited, expire or are cancelled will become available for grant under the 2017 Plan in accordance with its terms. As of June&#160;30, 2023, options to purchase 1,663,597 shares of common stock were outstanding under the 2014 Plan.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless specified otherwise in an individual option agreement, stock options granted under the prior plan and the 2017 Plan generally have a ten-year term and a four-year graded vesting period. The vesting requirement is generally conditioned upon the grantee&#8217;s continued service with the Company during the vesting period. Once vested, all options granted are exercisable from the date of grant until they expire. The option grants are non-transferable. Vested options generally remain exercisable for 90 days subsequent to the termination of the option holder&#8217;s service with the Company. In the event of the option holder&#8217;s death or disability while employed by or providing service to the Company, the exercisable period extends to 12 months.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance-based option awards generally have similar terms, with vesting commencing on the date the performance condition is achieved and expire in accordance with the specific terms of the agreement. At June&#160;30, 2023, there were no performance-based options outstanding.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of options granted during the three and six months ended June&#160;30, 2023 and 2022 was estimated using the Black-Scholes option valuation model. The inputs for the Black-Scholes option valuation model require significant assumptions that are detailed in the table below. The risk-free interest rates were based on the rate for U.S. Treasury securities at the date of grant with maturity dates approximately equal to the expected life at the grant date. The expected life was based on the simplified method in accordance with the SEC Staff Accounting Bulletin No. Topic 14D. Beginning in January 1, 2023, the expected volatility was estimated based on historical volatility information of the Company since the Company's initial public offering.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All assumptions used to calculate the grant date fair value of nonemployee options are generally consistent with the assumptions used for options granted to employees. In the event the Company terminates any of its consulting agreements, the unvested options underlying the agreements would also be canceled.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted 50,000 stock options to nonemployee consultants for services rendered during the three and six months ended June&#160;30, 2023 and no stock options during the three and six months ended June 30, 2022. There were 130,834 unvested nonemployee options outstanding as of June&#160;30, 2023 and 2022. Total expense recognized related to nonemployee stock options for the three months ended June&#160;30, 2023 and 2022 was $163,199 and $160,337, respectively. Total expense recognized related to nonemployee stock options for the six months ended June&#160;30, 2023 and 2022, was $271,784 and $355,107, respectively. Total unrecognized compensation expenses related to the nonemployee stock options was $994,411 as of June&#160;30, 2023. The Company did not recognize any expense for nonemployee performance-based option awards during the six months ended June&#160;30, 2023 or 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted 270,000 and 2,426,750 stock options to employees during the three months ended June&#160;30, 2023 and 2022, respectively. The Company granted 2,950,500 and 4,296,355 stock options to employees during the six months ended June&#160;30, 2023 and 2022, respectively. There were 6,710,485 and 7,354,964 unvested employee options outstanding as of June&#160;30, 2023, and 2022, respectively. Total expense recognized related to the employee stock options for the three months ended June&#160;30, 2023 and 2022 was $1.8&#160;million and $1.5&#160;million, respectively. Total expense recognized related to the employee stock options for the six months ended June&#160;30, 2023 and 2022 was $3.6 million and $2.6 million, respectively. Total unrecognized compensation expense related to employee stock options was $12.8 million as of June&#160;30, 2023. No expense for employee performance-based options was recognized during the six months ended in June&#160;30, 2023 and 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s stock-based compensation expense was recognized in operating expenses as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.606%"><tr><td style="width:1.0%"></td><td style="width:41.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Research and development</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">579,917&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">387,384&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">1,090,177&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">782,876&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">1,368,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">1,332,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">2,774,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">2,262,153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">1,948,648&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">1,720,217&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">3,865,165&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">3,045,029&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.606%"><tr><td style="width:1.0%"></td><td style="width:41.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,935,202&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700,041&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,836,565&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,003,834&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,948,648&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,720,217&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,865,165&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,045,029&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of employee options granted during the three and six months ended June&#160;30, 2023 and 2022 was estimated utilizing the following assumptions:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.757%"><tr><td style="width:1.0%"></td><td style="width:41.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.665%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.591%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.665%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.665%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.671%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">84.11&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">87.20&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">84.56&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">87.20&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">6.08</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">6.08</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">6.07</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">6.08</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">3.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">2.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">3.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">2.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Fair value of option on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">2.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">2.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">1.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">2.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of non-employee options granted during the three and six months ended June&#160;30, 2023 and 2022 was estimated utilizing the following assumptions:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:33.050%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.932%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.936%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">83.00&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">83.00&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Expected term in years</span></td><td colspan="3" style="padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">5.25</span></td><td colspan="3" style="padding:0 7pt 0 1pt"></td><td colspan="3" style="padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">0.00</span></td><td colspan="3" style="padding:0 8.02pt 0 1pt"></td><td colspan="3" style="padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">5.25</span></td><td colspan="3" style="padding:0 7pt 0 1pt"></td><td colspan="3" style="padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">0.00</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Risk-free interest rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">3.89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">3.89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Fair value of option on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">2.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">2.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the number of options outstanding and the weighted average exercise price:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life in Years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,961,238&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.42</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000,500&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.62&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.69</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,078)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(421,825)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,448,835&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.37</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,854,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable at June 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,607,516&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.64&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.17</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,406,178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2023 there was approximately $13.8 million of unrecognized stock&#8211;based compensation expense related to employee and nonemployee grants, which is expected to be recognized over a remaining average vesting period of 2.43 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628746948112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s interim income tax provision consists of U.S. federal and state income taxes based on the estimated annual effective tax rate that the Company expects for the full year together with the tax effect of discrete items. Each quarter the Company updates its estimate of the annual effective tax rate and records cumulative adjustments as necessary. As of June&#160;30, 2023, the Company was in a pre-tax loss position, and is anticipated to remain so throughout the year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June&#160;30, 2023, the Company did not record any tax benefit or expense.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, management evaluates whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in those periods in which temporary differences become deductible and/or net operating losses can be utilized. Management assesses all positive and negative evidence when determining the amount of the net deferred tax assets that are more likely than not to be realized. This evidence includes, but is not limited to, prior earnings history, scheduled reversal of taxable temporary differences, tax planning strategies and projected future taxable income. Significant weight is given to positive and negative evidence that is objectively verifiable. Based on these factors, including cumulative losses in recent years, the Company continues to maintain a full valuation allowance against its net deferred tax assets as of June&#160;30, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628745874000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License Agreements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Northwestern University License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, the Company entered into a license agreement with Northwestern University, (&#8220;Northwestern&#8221;), pursuant to which Northwestern granted the Company an exclusive, worldwide license to patent rights of certain inventions (&#8220;Northwestern Patent Rights&#8221;) which relate to a specific compound and related methods of use for such compound, along with certain Know-How related to the practice of the inventions claimed in the Northwestern Patents. The Company is developing OV329 under this agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Northwestern agreement, the Company was granted exclusive rights to research, develop, manufacture and commercialize products utilizing the Northwestern Patent Rights for all uses. The Company has agreed that it will not use the Northwestern Patent Rights to develop any products for the treatment of cancer, but Northwestern may not grant rights in the technology to others for use in cancer. The Company also has an option, exercisable during the term of the agreement to an exclusive license under certain intellectual property rights covering novel compounds with the same or similar mechanism of action as the primary compound that is the subject of the license agreement. Northwestern has retained the right, on behalf of itself and other non-profit institutions, to use the Northwestern Patent Rights and practice the inventions claimed therein for educational and research purposes and to publish information about the inventions covered by the Northwestern Patent Rights. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon entry into the Northwestern agreement, the Company paid an upfront non-creditable one-time license issuance fee of $75,000, and is required to pay an annual license maintenance fee of $20,000, which will be creditable against any royalties payable to Northwestern following first commercial sale of licensed products under the agreement. The Company is responsible for all ongoing costs of filing, prosecuting and maintaining the Northwestern Patents, but also has the right to control such activities using its own patent counsel. In consideration for the rights granted to the Company under the Northwestern agreement, the Company is required to pay to Northwestern up to an aggregate of $5.3&#160;million upon the achievement of certain development and regulatory milestones for the first product covered by the Northwestern Patents, and upon commercialization of any such products, will be required to pay to Northwestern a tiered royalty on net sales of such products by the Company, its affiliates or sublicensees, at percentages in the low to mid-single-digits, subject to standard reductions and offsets. The Company&#8217;s royalty obligations continue on a product-by-product and country-by-country basis until the later of the expiration of the last-to-expire valid claim in a licensed patent covering the applicable product in such country and 10 years following the first commercial sale of such product in such country. If the Company sublicenses a Northwestern Patent Right, it will be obligated to pay to Northwestern a specified percentage of sublicense revenue received by the Company, ranging from the high single digits to the low-teens. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Northwestern agreement requires that the Company use commercially reasonable efforts to develop and commercialize at least one product that is covered by the Northwestern Patent Rights.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the Northwestern agreement will remain in force until the expiration of the Company&#8217;s payment obligations thereunder. The Company has the right to terminate the agreement for any reason upon prior written notice or for an uncured material breach by Northwestern. Northwestern may terminate the agreement for the Company&#8217;s uncured material breach or insolvency.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AstraZeneca AB License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2021, the Company entered into an exclusive license agreement with AstraZeneca AB (&#8220;AstraZeneca&#8221;), for a library of early-stage small molecules targeting the KCC2 transporter, including lead candidate OV350. Upon execution of the agreement, the Company was obligated to pay an upfront cash payment of $5.0&#160;million and issued shares of the Company's common stock in an amount that equaled $7.3&#160;million based on the volume-weighted average price of shares of the Company's common stock for the 30 business days immediately preceding the execution date of the transaction. Since the intangibles acquired in the AstraZeneca license agreement do not have an alternative future use, all costs incurred were treated as research and development expense. The Company recorded a total of $12.3&#160;million as research and development expense related to this agreement during December 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the AstraZeneca license agreement, the Company agreed to potential milestone payments of up to $203.0&#160;million upon the achievement of certain developmental, regulatory and sales milestones. The first payment of $3.0&#160;million is due upon the successful completion of the first Phase 2 clinical study of a licensed product following a positive biomarker readout in a Phase 1 clinical study.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gensaic Collaboration and Option Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Company entered into a collaboration and option agreement (&#8220;Collaboration Agreement&#8221;) with Gensaic. The Collaboration Agreement involves the research and development of phage-derived particle (&#8220;PDP&#8221;) products on Gensaic's proprietary platform for certain central nervous system rare disorder targets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Collaboration Agreement, Gensaic grants the Company an exclusive option to obtain an exclusive license with respect to certain identified lead PDP products, which are exercisable at any time prior to the expiration of the option period. Once a product is identified by the Company that demonstrates sufficient efficacy, the Company may exercise its option with respect to the specific research program for that PDP product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company shall reimburse Gensaic for Gensaic's research costs related to the specific research plan for PDP products identified, the research plan and budget shall be mutually agreed upon by the parties and shall not exceed $3.0&#160;million in any research year. The Company will record these reimbursement payments as research and development costs in the period the research costs are incurred. In May 2023, the Company identified a lead PDP candidate for further research and provided $3.5&#160;million to Gensaic to support the approved research plan and budget. The amount is included in prepaid expenses and other current assets in the condensed consolidated balance sheets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product is ultimately commercialized under this agreement, the Company shall make tiered royalty payments to Gensaic in the mid-single to low double-digit range based on the net sales of all licensed PDP products during the royalty term. The Company is also responsible for potential tiered milestone payments of up to $452.0&#160;million based upon the achievement of certain sales milestone events and developmental milestone approvals for three or more products. Gensaic also has the option to become a collaborative partner in the development and commercialization of PDP products in exchange for a fee based on a percentage of the costs incurred by the Company through the date Gensaic exercises its option. The Company would no longer be required to pay Gensaic royalty or milestone payments if Gensaic elects to exercise its option.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may terminate this agreement by providing written notice to Gensaic 90 days in advance of the termination date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2023, none of these contingent payments were considered probable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. The Company is not currently involved in any legal matters arising in the normal course of business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of their respective employment agreements, certain of our executive officers are eligible to receive severance payments and benefits upon a termination without &#8220;cause&#8221; or due to &#8220;permanent disability,&#8221; or upon &#8220;resignation for good reason,&#8221; contingent upon the executive officer&#8217;s delivery to the Company of a satisfactory release of claims, and subject to the executive officer&#8217;s compliance with non-competition and non-solicitation restrictive covenants.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628746948112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COLLABORATION AND LICENSE AGREEMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COLLABORATION AND LICENSE AGREEMENTS</a></td>
<td class="text">COLLABORATION AND LICENSE AGREEMENTS<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Takeda Collaboration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 6, 2017, the Company entered into a license and collaboration agreement with Takeda under which the Company licensed from Takeda certain exclusive rights to develop and commercialize soticlestat in certain territories.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Company entered into the RLT Agreement, pursuant to which Takeda secured rights to the Company&#8217;s 50% global share in soticlestat, and the Company granted to Takeda an exclusive worldwide license under the Company&#8217;s relevant intellectual property rights to develop and commercialize the investigational medicine soticlestat for the treatment of developmental and epileptic encephalopathies, including Dravet syndrome and Lennox-Gastaut syndrome.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the RLT Agreement, all rights in soticlestat were owned by Takeda or exclusively licensed to Takeda by the Company. Takeda assumed all responsibility for, and costs of, both development and commercialization of soticlestat, and the Company will no longer have any financial obligation to Takeda under the original collaboration agreement, including milestone payments or any future development and commercialization costs. On March 29, 2021 upon the closing of the RLT Agreement, the Company received an upfront payment of $196.0&#160;million and, if soticlestat is successfully developed, will be eligible to receive up to an additional $660.0&#160;million upon Takeda achieving developmental, regulatory and sales milestones. In addition, the Company will be entitled to receive tiered royalties beginning in the low double-digits, and up to 20% on sales of soticlestat if regulatory approval is achieved. Royalties will be payable on a country-by-country and product-by-product basis for any indications that soticlestat is approved for and sold during the period beginning on the date of the first commercial sale of such product in such country and ending on the </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">later to occur of the expiration of patent rights covering the product in such country and a specified anniversary of such first commercial sale.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified the following material promises under the RLT Agreement: (1) no later than the second business day prior to the closing of the RLT Agreement (the &#8220;Closing Date&#8221;), the Company and Takeda were required to agree on an estimate of the development expenses that accrued, or would accrue, under the original collaboration agreement as of March 31, 2021; (2) on the Closing Date, the Company was required to (i) provide and transfer to Takeda the materials, information and data relating to the soticlestat program, including clinical trial data and results, as further set forth in the RLT Agreement, (ii) assign to Takeda certain agreements applicable to the soticlestat program, and (iii) assign to Takeda all of its right, title and interest in, to and under all intellectual property rights developed or created pursuant to the original collaboration agreement and owned jointly by the Company and Takeda as of the Closing Date; (3) within 45 days after March 31, 2021, the Company and Takeda were required to provide a written report to the finance officer designated by the other party setting forth a final total of the development expenses that accrued as of March 31, 2021 and, within 10 business days after receipt of such report, the finance officers shall agree on whether a net settlement payment is due from Takeda to the Company or from the Company to Takeda; and (4) within 75 days after the Closing Date, to the extent not provided on the Closing Date, Ovid shall provide to Takeda (i) any materials, information and data relating to the soticlestat program, including clinical trial data and results, as further set forth in the RLT Agreement, (ii) other documents (including all expired agreements and related data developed thereunder) to the extent relating to the soticlestat program that are necessary for the exploitation, development, commercialization and manufacture of soticlestat, as further set forth in the RLT Agreement and (iii) any tangible embodiment of the intellectual property rights controlled by Ovid that are reasonably necessary for, used in or held for use in Takeda&#8217;s exploitation of the soticlestat program.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the transaction price is equal to the upfront fee of $196.0&#160;million and is associated with all four performance obligations identified above. It is noted that the incremental effort associated with performance obligations three and four is negligible and not material in the context of the RLT Agreement since all of the information is related to the collaboration period for which the Company already has the information readily available. Therefore, since they are not material in the context of the RLT Agreement, the full upfront fee was allocated to the two performance obligations satisfied at closing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2023, no expense was recognized pursuant to the RLT Agreement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Healx License and Option Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2022, the Company entered an exclusive license option agreement (&#8220;Healx License and Option Agreement&#8221;) with Healx, Ltd. (&#8220;Healx&#8221;). Under the terms of the Healx License and Option Agreement, Healx has secured a one-year option to investigate gaboxadol (&#8220;OV101&#8221;) as part of a potential combination therapy for Fragile X syndrome in a Phase 1B/2A clinical trial, as well as a treatment for other indications, for an upfront payment of $0.5&#160;million, and fees to support prosecution and maintenance of our relevant intellectual property rights. At the end of the one-year option period, Healx has the option to secure rights to an exclusive license under the Company's relevant intellectual property rights, in exchange for an additional payment of $2.0&#160;million, development and commercial milestone payments, and low to mid-tier double digit royalties. On February 1, 2023, the Company granted an extension of the option period for up to four months for Healx to continue to investigate gaboxadol. Royalties are payable on a country-by-country and product-by-product basis during the period beginning on the date of the first commercial sale of such product in such country and ending on the later to occur of the expiration of patent rights covering the product in such country and a specified anniversary of such first commercial sale. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healx will assume all responsibility for, and costs of, both development and commercialization of gaboxadol following the exercise of the option. The Company will retain the option to co-develop and co-commercialize the program with Healx (&#8220;Ovid Opt-In Right&#8221;) at the end of a positive readout of clinical Phase 2B and would share net profits and losses in lieu of the milestones and royalty payments. If the Ovid Opt-In Right were exercised, the Company would be required to pay Healx 50% of development costs. The Company does not plan to conduct further trials of gaboxadol. The term of the Healx License and Option Agreement will continue until the later of (a) the expiration of all relevant royalty terms, or in the event that Healx does not exercise its option during the option period defined in the Healx License and Option Agreement, or the Option Period, the expiration of such period, or (b) in the event that Healx does exercise its option during the Option Period, and the Company does not exercise the Ovid Opt-In Right during the period of time it has to opt-in, or the Opt-In Period, or the opt-in terms are otherwise terminated, upon the expiration of all payment obligations, or (c) in the event that Healx does exercise the Option during the Option Period, and the Company does exercise the Ovid Opt-In Right during the Opt-In Period, such time as neither Healx nor the Company is continuing to exploit gaboxadol. Further, if the Company exercises the Ovid Opt-In Right to co-develop and co-commercialize the program, it will owe a share of the net profit share to a third party with which it previously established a licensing agreement. If the Company does not exercise the Ovid Opt-In Right, it will owe the third party a share of all milestone and royalty payments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 9, 2023, the Company entered into an amendment to the Healx License and Option Agreement whereby revisions were made to terms regarding the timing of the option exercise fee payable by Healx to the Company, the clinical and regulatory milestone payment structure, and the royalty payment structure. Additionally, the parties agreed that following the exercise of the option, Healx would assume direct responsibility for patent maintenance and prosecution and that the Company would transfer to Healx all supply obligations with respect to the active pharmaceutical ingredient and finished gaboxadol products and any related licensed technology and know-how in the Company's possession that is relevant to the manufacture of such licensed products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">No revenue was recognized relating to this agreement during the six months ended June&#160;30, 2023. During the six months ended June&#160;30, 2022, the Company recorded revenue of $0.5&#160;million associated with the Healx License and Option Agreement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marinus Pharmaceuticals Out-License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 1, 2022, the Company entered into an exclusive patent license agreement with Marinus (&#8220;Marinus License Agreement&#8221;). Under the Marinus License Agreement, the Company granted Marinus an exclusive, non-transferable (except as expressly provided therein), royalty-bearing right and license under certain Ovid patents relating to ganaxolone to develop, make, have made, commercialize, promote, distribute, sell, offer for sale and import licensed products in the territory (which consist of the United States, the European Economic Area, United Kingdom and Switzerland) for the treatment of CDKL5 deficiency disorders. Following the date of regulatory approval by the FDA of the first licensed product in the territory which was received on March 18, 2022, Marinus issued, at the Company's option, 123,255 shares of Marinus common stock, par value $0.001 per share, as payment. The Marinus License Agreement also provides for payment of royalties from Marinus to the Company in single digits on net sales of each such licensed product sold.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded revenue and an associated investment in equity securities of approximately $0.9&#160;million related to the patent license agreement on March 18, 2022, based on the price of Marinus common stock on March 1, 2022. The Company had unrealized gains on the Marinus common stock of $0.8&#160;million and unrealized losses of $0.3&#160;million for the six months ended June&#160;30, 2023 and 2022, respectively, which were recorded as unrealized gains (losses) on equity securities and are reflected in other income (expense), net in the condensed consolidated statements of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Graviton License Agreement and Equity Purchase</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 30, 2023, the Company entered into a collaboration and license agreement with Graviton (&#8220;Graviton Agreement&#8221;), whereby it secured from Graviton an exclusive license to develop and commercialize Graviton's library of ROCK2 inhibitors including their lead program GV101 in rare central nervous system (&#8220;CNS&#8221;) disorders (excluding amyotrophic lateral sclerosis) worldwide (excluding China, Hong Kong, Macau and Taiwan). Under the Graviton Agreement, the Company and Graviton plan to investigate GV101 in cerebral cavernous malformations as well as Graviton's library of ROCK2 inhibitors in other rare CNS disorders. The Company will be responsible for all development and commercialization costs of the products. Should the Company receive regulatory approval and commercialize any of Graviton&#8217;s ROCK2 inhibitors, it will pay Graviton tiered royalties on net sales ranging from the mid to high teens. As part of the Graviton Agreement, the Company also purchased shares of Graviton's preferred stock for $10.0&#160;million. The Company recorded the purchase of the preferred stock as a long-term equity investment on its condensed consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628746955472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text">RELATED PARTY TRANSACTIONSIn March 2021, the Company entered into the RLT Agreement with Takeda. For a description of the RLT Agreement, see Note 11.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628745881264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER SHARE</a></td>
<td class="text">NET LOSS PER SHAREBasic net loss per share is calculated based upon the weighted-average number of common shares outstanding during the period, excluding outstanding stock options that have not yet vested. For any period in which the Company records net income, diluted net income per share is calculated based upon the weighted-average number of common shares outstanding during the period plus the dilutive impact of weighted-average common equivalent shares outstanding during the period resulting from the assumed exercise of outstanding stock options determined under the treasury stock method and the assumed conversion of preferred stock into common shares determined using the if-converted method. Diluted net loss per share is equivalent to the basic net loss per share due to the exclusion of outstanding stock options and convertible preferred stock because the inclusion of these securities would result in an anti-dilutive effect on per share amounts.<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The basic and diluted net loss per common share is presented in conformity with the two-class method required for participating securities and multiple classes of shares. The Company considers its preferred stock to be participating securities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For any period in which the Company records net income, undistributed earnings allocated to the participating securities are subtracted from net income in determining net income attributable to common stockholders. The undistributed earnings have been allocated based on the participation rights of preferred stock and common shares as if the earnings for the year have been distributed. For periods in which the Company recognizes a net loss, undistributed losses are allocated only to common shares as the participating securities do not contractually participate in the Company&#8217;s losses. Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Participating securities are excluded from basic weighted-average common shares outstanding.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the calculation of basic and diluted net loss per share:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"><tr><td style="width:1.0%"></td><td style="width:44.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.989%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.989%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.989%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,408,330)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,588,414)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,764,539)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,696,470)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to participating securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,408,330)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,588,414)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,764,539)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,696,470)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,408,330)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,588,414)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,764,539)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,696,470)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding used in</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;computing net loss per share - basic</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,534,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,391,458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,512,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,391,236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding used in</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;computing loss per share - diluted</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,534,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,391,458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,512,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,391,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.18)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.21)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.37)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.44)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.18)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.21)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.37)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.44)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding as they would be anti-dilutive:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.839%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.839%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,448,835&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,451,517&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,448,835&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,103,587&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issuable upon conversion of Series A convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628743238352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_UnauditedInterimFinancialStatementsPolicyPolicyTextBlock', window );">Unaudited Interim Condensed Consolidated Financial Statements</a></td>
<td class="text">Unaudited Interim Condensed Consolidated Financial StatementsThe interim condensed consolidated balance sheet at June&#160;30, 2023 and the condensed consolidated statements of operations, comprehensive loss, cash flows, and stockholders&#8217; equity for the three and six months ended June&#160;30, 2023 and 2022 are unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) and following the requirements of the SEC for interim reporting. As permitted under those rules, certain notes or other financial information that are normally required by GAAP are condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of its financial information. The results of operations for the three and six month periods ended June&#160;30, 2023 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2023 or for any other future annual or interim period. The balance sheet as of December&#160;31, 2022 included herein was derived from the audited financial statements as of that date. These interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited financial statements as of and for the year ended December&#160;31, 2022 included in the Company&#8217;s Annual Report on Form 10-K.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Presentation and Consolidation</a></td>
<td class="text">Basis of Presentation and ConsolidationThe accompanying condensed consolidated financial statements have been prepared in conformity with GAAP and include the accounts of Ovid Therapeutics Inc. and its wholly owned subsidiary, Ovid Therapeutics Hong Kong Limited. All intercompany transactions and balances have been eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ materially from those estimates.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text">Marketable SecuritiesMarketable securities consist of investments in U.S. treasury instruments which are considered available-for-sale securities. The Company classifies its marketable securities with maturities of less than one year from the balance sheet date as current assets on its condensed consolidated balance sheets. The Company classifies its marketable securities with original maturities of less than three months as cash equivalents on its consolidated balance sheets. Unrealized gains and losses on these securities that are determined to be temporary are reported as a separate component of accumulated other comprehensive income (loss) in stockholder's equity.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text">Restricted CashThe Company classifies as restricted cash all cash pledged as collateral to secure long-term obligations and all cash whose use is otherwise limited by contractual provisions. Amounts are reported as non-current unless restrictions are expected to be released in the next 12 months.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Long-Term Equity Investments</a></td>
<td class="text">Long-Term Equity Investments<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Long-term equity investments consist of equity investments in the preferred shares of Gensaic, Inc., formerly M13 Therapeutics, Inc. (&#8220;Gensaic&#8221;), and Graviton Bioscience Corporation (&#8220;Graviton&#8221;), both privately held corporations. The preferred shares are not considered in-substance common stock, and the investments are accounted for at cost, with adjustments for observable changes in prices or impairments, and are classified within long-term equity investments on the consolidated balance sheets with adjustments recognized in other income (expense), net on the condensed consolidated statements of operations. The Company has determined that these equity investments do not have a readily determinable fair value and elected the measurement alternative. Therefore, the carrying amount of the equity investments will be adjusted to fair value at the time of the next observable price change for the identical or similar investment of the same issuer or when an impairment is recognized. Each reporting period, the Company performs a qualitative assessment to evaluate whether the investments are impaired. The assessment includes a review of recent operating results and trends, recent sales/acquisitions of the investees' securities, and other publicly available data. If an investment is determined to be impaired, the Company will then write it down to its estimated fair value. As of June&#160;30, 2023 and December&#160;31, 2022, the equity investment in Gensaic had a carrying value of $5.1&#160;million. As of June&#160;30, 2023, the equity investment in Graviton had a carrying value of $10.0&#160;million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term equity investments also consist of an equity investment in the common shares of Marinus Pharmaceuticals, Inc. (&#8220;Marinus&#8221;) that were received as non-cash consideration via the terms of a licensing agreement executed between the two companies effective March 2022. The equity shares are marked-to-market at each reporting date with changes in the fair value being reflected in the carrying value of the investment on the Company's consolidated balance sheets and other income (expense) on the Company's consolidated statements of operations. As of June&#160;30, 2023 and December&#160;31, 2022, the equity investment in Marinus had a carrying value of approximately $1.3 million and $0.5 million, respectively.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text">Fair Value of Financial Instruments<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Accounting Standards Board (&#8220;FASB&#8221;) guidance specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three levels of the fair value hierarchy are as follows:</span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 1&#8212;Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities. The Company&#8217;s Level 1 assets consisted of investments in a U.S. treasury money market fund and equity securities totaling $42.2 million as of June&#160;30, 2023. The Company's Level 1 assets totaled $42.5 million as of December&#160;31, 2022.</span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 2&#8212;Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly (e.g., quoted prices of similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active). Level 2 includes financial instruments that are valued using models or other valuation methodologies. The Company's Level 2 assets consisted of U.S. treasury bills, totaling $54.8 million as of June&#160;30, 2023 and $84.1 million as of December&#160;31, 2022.</span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 3&#8212;Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable. There were no Level 3 assets or liabilities as of June&#160;30, 2023 or December&#160;31, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reported in the balance sheets for cash and cash equivalents, other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">LeasesThe Company determines if an arrangement is a lease at inception and recognizes the lease in accordance with ASC 842. Operating leases are included in right-of-use (&#8220;ROU&#8221;) assets, current liabilities, and long-term lease liability in the Company's consolidated balance sheets. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. The Company determines the portion of the lease liability that is current as the difference between the calculated lease liability at the end of the current period and the lease liability that is projected 12 months from the current period.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and EquipmentProperty and equipment are stated at cost and depreciated over their estimated useful lives of three years using the straight-line method. Repair and maintenance costs are expensed. The Company reviews the recoverability of all long-lived assets, including the related useful life, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text">Research and Development ExpensesThe Company expenses the cost of research and development as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and preclinical materials as well as contracted services, license fees, and other external costs. Research and development expenses also include the cost of licensing agreements acquired from third-parties. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received in accordance with ASC 730, Research and Development<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-based Compensation</a></td>
<td class="text">Stock-based CompensationThe Company accounts for its stock-based compensation in accordance with ASC 718, Compensation&#8212;Stock Compensation, which establishes accounting for stock-based awards granted to employees for services and requires companies to expense the estimated fair value of these awards over the requisite service period. The Company estimates <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the fair value of all awards granted using the Black-Scholes valuation model. Key inputs and assumptions include the expected term of the option, stock price volatility, risk-free interest rate, dividend yield, stock price and exercise price. Many of the assumptions require significant judgment and any changes could have an impact in the determination of stock-based compensation expense. The Company elected an accounting policy to record forfeitures as they occur. The Company recognizes employee stock-based compensation expense based on the fair value of the award on the date of the grant. The compensation expense is recognized over the vesting period under the straight-line method.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for option awards granted to nonemployee consultants and directors in accordance with ASC 718. The fair value of the option issued or committed to be issued is used to measure the transaction, as this is more reliable than the fair value of the services received. The fair value is measured at the value of the Company&#8217;s common stock award at the earlier of the date that the commitment for performance by the counterparty has been reached or the counterparty&#8217;s performance is complete.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">Income TaxesThe Company accounts for income taxes under the asset and liability method, which requires deferred tax assets and liabilities to be recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts and respective tax bases of existing assets and liabilities, as well as for net operating loss carryforwards and research and development credits. Valuation allowances are provided if it is more likely than not that some portion or all of the deferred tax assets will not be realized. The impact of a change in the tax laws is recorded in the period in which the law is enacted.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss per Share<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per common share is determined by dividing net loss attributable to common stockholders by the basic and diluted weighted-average common shares outstanding during the period. The Company applies the two-class method to allocate earnings between common stock and participating securities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When applicable, net income per diluted share attributable to common stockholders adjusts the basic earnings per share attributable to common stockholders and the weighted-average number of shares of common stock outstanding for the potential dilutive impact of stock options using the treasury-stock method and the potential impact of preferred stock using the if-converted method.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">Revenue Recognition<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, Revenue from Contracts with Customers, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. In applying ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the promises and performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) it satisfies the performance obligations. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services the Company transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to recognizing revenue, the Company makes estimates of the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If there are multiple distinct performance obligations, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The standalone selling price is generally determined using expected cost and comparable transactions. Revenue for performance obligations recognized over time is recognized by measuring the progress toward complete satisfaction of the performance obligations using an input measure.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-refundable upfront fees allocated to licenses that are not contingent on any future performance and require no consequential continuing involvement by the Company, are recognized as revenue when the license term commences and the licensed data, technology or product is delivered. The Company defers recognition of upfront license fees if the performance obligations are not satisfied.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text">Recent Accounting Pronouncements<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has reviewed recently issued accounting standards and plans to adopt those that are applicable. The Company does not expect the adoption of those standards to have a material impact on its financial position, results of operations, or cash flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopts new pronouncements relating to generally accepted accounting principles applicable to the Company as they are issued, which may be in advance of their effective date. Management does not believe that any recently issued, but not yet effective accounting standards, if currently adopted, would have a material effect on the accompanying financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_UnauditedInterimFinancialStatementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unaudited interim financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_UnauditedInterimFinancialStatementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21D<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-21D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628746945456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Debt Securities, Available-for-Sale</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the fair value of cash, cash equivalents and marketable securities as well as gross unrealized holding gains and losses as of June&#160;30, 2023 and December&#160;31, 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrealized holding gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrealized holding losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868,598&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868,598&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,754,658&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,759,866&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,888,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,888,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,512,192&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,208&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,517,400&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="24" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents as of June 30, 2023 include money market funds of $40.9 million.</span></div></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrealized holding gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrealized holding losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,853,042&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,853,042&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,014,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,014,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,175,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,187)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,133,565&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,043,598&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,187)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,001,411&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the fair value of cash, cash equivalents and marketable securities as well as gross unrealized holding gains and losses as of June&#160;30, 2023 and December&#160;31, 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrealized holding gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrealized holding losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868,598&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868,598&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,754,658&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,759,866&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,888,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,888,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,512,192&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,208&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,517,400&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="24" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents as of June 30, 2023 include money market funds of $40.9 million.</span></div></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrealized holding gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrealized holding losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,853,042&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,853,042&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,014,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,014,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,175,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,187)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,133,565&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,043,598&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,187)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,001,411&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628745878784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is summarized as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Furniture and equipment</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">1,444,389&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">1,423,032&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">306,312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">306,312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">(795,132)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">(581,381)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">955,569&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">1,147,963&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628740873936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock', window );">Schedule of ROU Asset and Lease Liabilities Related to the Company Operating Lease</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU asset and lease liabilities related to the Company's operating lease are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Right-of-use asset, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">14,412,068&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Current lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">944,943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Long-term lease liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">15,389,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Components of Operating Lease Cost</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease cost for the six months ended June&#160;30, 2023 were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,083,617&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Commitments Under the non-cancelable Operating Lease</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum commitments under the non-cancelable operating lease are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,316,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,316,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,316,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,316,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,347,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,511,156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-of-use asset and lease liabilities operating lease table text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628746965056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payroll and bonus accrual</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,996,003&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,233,802&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development accrual</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,972,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">395,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Professional fees accrual</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">401,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">682,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,433,290&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,504,669&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628745633296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Recognized Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s stock-based compensation expense was recognized in operating expenses as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.606%"><tr><td style="width:1.0%"></td><td style="width:41.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Research and development</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">579,917&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">387,384&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">1,090,177&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">782,876&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">1,368,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">1,332,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">2,774,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">2,262,153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">1,948,648&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">1,720,217&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">3,865,165&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">3,045,029&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Allocation of Stock-based Compensation Expense by Plan</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.606%"><tr><td style="width:1.0%"></td><td style="width:41.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,935,202&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700,041&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,836,565&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,003,834&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,948,648&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,720,217&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,865,165&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,045,029&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used to Compute Fair Value of Employee Option Granted</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of employee options granted during the three and six months ended June&#160;30, 2023 and 2022 was estimated utilizing the following assumptions:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.757%"><tr><td style="width:1.0%"></td><td style="width:41.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.665%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.591%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.665%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.665%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.671%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">84.11&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">87.20&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">84.56&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">87.20&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">6.08</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">6.08</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">6.07</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">6.08</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">3.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">2.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">3.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">2.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Fair value of option on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">2.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">2.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">1.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">2.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of non-employee options granted during the three and six months ended June&#160;30, 2023 and 2022 was estimated utilizing the following assumptions:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:33.050%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.932%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.936%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">83.00&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">83.00&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Expected term in years</span></td><td colspan="3" style="padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">5.25</span></td><td colspan="3" style="padding:0 7pt 0 1pt"></td><td colspan="3" style="padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">0.00</span></td><td colspan="3" style="padding:0 8.02pt 0 1pt"></td><td colspan="3" style="padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">5.25</span></td><td colspan="3" style="padding:0 7pt 0 1pt"></td><td colspan="3" style="padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">0.00</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Risk-free interest rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">3.89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">3.89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Fair value of option on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">2.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">2.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Options Outstanding and Weighted Average Exercise Price</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the number of options outstanding and the weighted average exercise price:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life in Years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,961,238&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.42</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000,500&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.62&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.69</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,078)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(421,825)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,448,835&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.37</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,854,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable at June 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,607,516&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.64&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.17</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,406,178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628745870592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the calculation of basic and diluted net loss per share:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"><tr><td style="width:1.0%"></td><td style="width:44.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.989%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.989%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.989%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,408,330)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,588,414)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,764,539)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,696,470)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to participating securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,408,330)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,588,414)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,764,539)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,696,470)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,408,330)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,588,414)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,764,539)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,696,470)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding used in</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;computing net loss per share - basic</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,534,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,391,458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,512,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,391,236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding used in</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;computing loss per share - diluted</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,534,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,391,458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,512,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,391,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.18)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.21)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.37)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.44)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.18)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.21)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.37)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.44)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Shares Outstanding</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding as they would be anti-dilutive:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.839%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.839%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,448,835&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,451,517&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,448,835&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,103,587&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issuable upon conversion of Series A convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628738292528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">111 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and marketable securities</a></td>
<td class="nump">$ 96,517,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,517,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,517,400<span></span>
</td>
<td class="nump">$ 129,001,411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,160<span></span>
</td>
<td class="nump">$ 1,445,366<span></span>
</td>
<td class="nump">222,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">251,291,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">251,291,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">251,291,081<span></span>
</td>
<td class="nump">$ 225,526,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_WorkingCapital', window );">Working capital</a></td>
<td class="nump">92,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,817,614<span></span>
</td>
<td class="nump">33,375,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 12,408,330<span></span>
</td>
<td class="nump">$ 13,356,209<span></span>
</td>
<td class="nump">$ 14,588,414<span></span>
</td>
<td class="nump">$ 16,108,056<span></span>
</td>
<td class="nump">$ 25,764,539<span></span>
</td>
<td class="nump">$ 30,696,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628741905920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term equity investments</a></td>
<td class="nump">$ 16,470,542<span></span>
</td>
<td class="nump">$ 5,622,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, fair value</a></td>
<td class="nump">24,888,936<span></span>
</td>
<td class="nump">84,133,565<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ovid_GravitonBioscienceCorporationMember', window );">Graviton Bioscience Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term equity investments</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ovid_MarinusTherapeuticsIncMember', window );">Marinus Therapeutics, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term equity investments</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ovid_GensaicIncMember', window );">Gensaic, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term equity investments</a></td>
<td class="nump">5,100,000<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, fair value</a></td>
<td class="nump">54,800,000<span></span>
</td>
<td class="nump">84,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=ovid_MoneyMarketFundsAndShortTermInvestmentsMember', window );">Money Market Funds and Short-term Investments | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value assets</a></td>
<td class="nump">$ 42,200,000<span></span>
</td>
<td class="nump">$ 42,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_SummaryOfSignificantAccountingPolicyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_SummaryOfSignificantAccountingPolicyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ovid_GravitonBioscienceCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ovid_GravitonBioscienceCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ovid_MarinusTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ovid_MarinusTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ovid_GensaicIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ovid_GensaicIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=ovid_MoneyMarketFundsAndShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=ovid_MoneyMarketFundsAndShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628741078832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Fair Value of Cash and Cash Equivalents and Gross Unrealized Holding Gains and Losses (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash Amortized cost</a></td>
<td class="nump">$ 868,598<span></span>
</td>
<td class="nump">$ 2,853,042<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_CashEquivalentsAmortizedCost', window );">Cash equivalents, amortized cost</a></td>
<td class="nump">70,754,658<span></span>
</td>
<td class="nump">42,014,804<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable securities, Amortized cost</a></td>
<td class="nump">24,888,936<span></span>
</td>
<td class="nump">84,175,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_CashEquivalentsUnrealizedHoldingGains', window );">Cash equivalents, unrealized holding gains</a></td>
<td class="nump">5,208<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_CashEquivalentsUnrealizedHoldingLosses', window );">Cash equivalents, unrealized holding losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Marketable securities, unrealized holding gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable securities, unrealized holding losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(42,187)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents, fair value</a></td>
<td class="nump">70,759,866<span></span>
</td>
<td class="nump">42,014,804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities, fair value</a></td>
<td class="nump">24,888,936<span></span>
</td>
<td class="nump">84,133,565<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost', window );">Total cash, cash equivalents and marketable securities, amortized cost</a></td>
<td class="nump">96,512,192<span></span>
</td>
<td class="nump">129,043,598<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingGain', window );">Total cash, cash equivalents and marketable securities, unrealized holding gains</a></td>
<td class="nump">5,208<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingLoss', window );">Total cash, cash equivalents and marketable securities, unrealized holding losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(42,187)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Total cash, cash equivalents and marketable securities, fair value</a></td>
<td class="nump">96,517,400<span></span>
</td>
<td class="nump">$ 129,001,411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market funds</a></td>
<td class="nump">$ 40,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents And Available-for-sale Debt Securities, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_CashEquivalentsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_CashEquivalentsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_CashEquivalentsUnrealizedHoldingGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents, Unrealized Holding Gains</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_CashEquivalentsUnrealizedHoldingGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_CashEquivalentsUnrealizedHoldingLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents, Unrealized Holding Losses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_CashEquivalentsUnrealizedHoldingLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax, Including Cash Equivalents, Accumulated Unrealized Holding Gain</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax, Including Cash Equivalents, Accumulated Unrealized Holding Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628738019616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Gains or losses on available-for-sale securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628740795296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS - Summary of Property and Equipment (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">$ (795,132)<span></span>
</td>
<td class="num">$ (581,381)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">955,569<span></span>
</td>
<td class="nump">1,147,963<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,444,389<span></span>
</td>
<td class="nump">1,423,032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 306,312<span></span>
</td>
<td class="nump">$ 306,312<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628741090816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 105,292<span></span>
</td>
<td class="nump">$ 54,631<span></span>
</td>
<td class="nump">$ 213,751<span></span>
</td>
<td class="nump">$ 85,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net of accumulated amortization</a></td>
<td class="nump">263,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 222,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 32,180<span></span>
</td>
<td class="nump">$ 32,153<span></span>
</td>
<td class="nump">$ 68,370<span></span>
</td>
<td class="nump">$ 86,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628738291488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Additional Information (Detail)<br> ft&#178; in Thousands</strong></div></th>
<th class="th"><div>Mar. 10, 2022</div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, term of contract</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Land subject to ground leases (sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_LesseeOperatingLeaseBaseRent', window );">Rent lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod', window );">Rent payments commencement following this period</a></td>
<td class="text">10 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,930,753<span></span>
</td>
<td class="nump">$ 1,930,753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal option term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_LeaseIncrementalBorrowingRate', window );">Lease incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.02%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_LeaseIncrementalBorrowingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease incremental borrowing rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_LeaseIncrementalBorrowingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_LesseeOperatingLeaseBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease, Base Rent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_LesseeOperatingLeaseBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Rent Payments Commencement Following This Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandSubjectToGroundLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land subject to a ground lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandSubjectToGroundLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628743444080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Schedule of ROU Asset and Lease Liabilities Related to the Company Operating Lease (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset, net</a></td>
<td class="nump">$ 14,412,068<span></span>
</td>
<td class="nump">$ 14,922,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current lease liability</a></td>
<td class="nump">944,943<span></span>
</td>
<td class="nump">533,946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liability</a></td>
<td class="nump">$ 15,389,567<span></span>
</td>
<td class="nump">$ 16,001,725<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628746062592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Schedule of Components of Operating Lease Cost (Detail)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 1,083,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628741948464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Schedule of Future Minimum Commitments Under Under the Non-Cancelable Operating Lease (Detail)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2023</a></td>
<td class="nump">$ 898,709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">2,316,303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">2,316,303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">2,316,303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">2,316,303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">12,347,235<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease, liability, to be paid</a></td>
<td class="nump">$ 22,511,156<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, to be Paid, Due after Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628740864944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES - Schedule of Accrued Expenses (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and bonus accrual</a></td>
<td class="nump">$ 2,996,003<span></span>
</td>
<td class="nump">$ 3,233,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_AccruedResearchAndDevelopment', window );">Research and development accrual</a></td>
<td class="nump">1,972,801<span></span>
</td>
<td class="nump">395,247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees accrual</a></td>
<td class="nump">401,099<span></span>
</td>
<td class="nump">682,664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">63,387<span></span>
</td>
<td class="nump">192,956<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 5,433,290<span></span>
</td>
<td class="nump">$ 4,504,669<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_AccruedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_AccruedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628734175888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">32 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_CommonStockNumberOfVotesForEachShare', window );">Number of votes per share | vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends declared | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ovid_ATMAgreementMember', window );">ATM Agreement | Cowen And Company, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_AggregateOfferingPriceOfCommonStock', window );">Net proceeds from offering, value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ovid_ATMAgreementMember', window );">ATM Agreement | Common Stock | Cowen And Company, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ovid_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of shares issued for each share of convertible preferred stock that is converted (in shares)</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates', window );">Maximum allowable owning percentage of outstanding common stock by associates or affiliates</a></td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders', window );">Maximum allowable voting right percentage of outstanding common stock holders</a></td>
<td class="nump">14.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates', window );">Allowable voting right percentage of outstanding common stock holders</a></td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod', window );">Allowable voting right percentage of outstanding common stock holders upon notice of days</a></td>
<td class="text">61 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred stock, liquidation preference per share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ovid_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock', window );">Beneficial ownership limitations, percentage of issued and outstanding common stock</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ovid_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock', window );">Beneficial ownership limitations, percentage of issued and outstanding common stock</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_AggregateOfferingPriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate offering price of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_AggregateOfferingPriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allowable Owning Percentage Of Outstanding Common Stock By Associates Or Affiliates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allowable Owning Percentage Of Outstanding Common Stock By Associates Or Affiliates, Notice Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Beneficial Ownership Limitations, Percentage of Issued and Outstanding Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_CommonStockNumberOfVotesForEachShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Number Of Votes For Each Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_CommonStockNumberOfVotesForEachShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum allowable owning percentage of outstanding common stock by associates or affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum allowable voting right percentage of outstanding common stock holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481071/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ovid_ATMAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ovid_ATMAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ovid_CowenAndCompanyLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ovid_CowenAndCompanyLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ovid_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ovid_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628737059296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>May 04, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,948,648<span></span>
</td>
<td class="nump">$ 1,720,217<span></span>
</td>
<td class="nump">$ 3,865,165<span></span>
</td>
<td class="nump">$ 3,045,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,448,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,448,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,961,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation not yet recognized, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 5 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based Option Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested stock options, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,935,202<span></span>
</td>
<td class="nump">1,700,041<span></span>
</td>
<td class="nump">$ 3,836,565<span></span>
</td>
<td class="nump">3,003,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Share-Based Payment Arrangement, Nonemployee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 163,199<span></span>
</td>
<td class="nump">$ 160,337<span></span>
</td>
<td class="nump">$ 271,784,000,000<span></span>
</td>
<td class="nump">$ 355,107,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested stock options, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 994,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 994,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Share-Based Payment Arrangement, Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested stock options, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,710,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,710,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,354,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,000<span></span>
</td>
<td class="nump">2,426,750<span></span>
</td>
<td class="nump">2,950,500<span></span>
</td>
<td class="nump">4,296,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ovid_NonemployeePerformanceBasedOptionAwardsMember', window );">Non-employee Performance Based Option Awards | Share-Based Payment Arrangement, Nonemployee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ovid_EmployeePerformanceBasedOptionAwardsMember', window );">Employee Performance Based Option Awards | Share-Based Payment Arrangement, Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ovid_TwoThousandSeventeenEquityIncentivePlanMember', window );">2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of company's common stock reserved for issuance under the plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,131,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,131,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,052,059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of number of shares of common stock outstanding (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares reserved for issuance under the plan (in shares)</a></td>
<td class="nump">3,523,344<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share based compensation, term of plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share based compensation, graded vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share based compensation, exercisable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ovid_TwoThousandSeventeenEquityIncentivePlanMember', window );">2017 Equity Incentive Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share based compensation, exercisable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember', window );">2017 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of company's common stock reserved for issuance under the plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">386,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">386,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares reserved for issuance under the plan (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">279,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Share based compensation, percentage of discount from market price on purchase date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Share based compensation, number of shares purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">29,830<span></span>
</td>
<td class="nump">38,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,446<span></span>
</td>
<td class="nump">$ 20,176<span></span>
</td>
<td class="nump">$ 28,600<span></span>
</td>
<td class="nump">$ 41,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease', window );">Percentage increase, outstanding stock maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum', window );">Common stock, reserved for future issuance increase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ovid_A2014EmployeeStockPurchasePlanMember', window );">2014 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,663,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,663,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum, Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ovid_NonemployeePerformanceBasedOptionAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ovid_NonemployeePerformanceBasedOptionAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ovid_EmployeePerformanceBasedOptionAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ovid_EmployeePerformanceBasedOptionAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ovid_TwoThousandSeventeenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ovid_TwoThousandSeventeenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ovid_A2014EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ovid_A2014EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628743366160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Schedule of Recognized Stock-Based Compensation Expense (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense, Total</a></td>
<td class="nump">$ 1,948,648<span></span>
</td>
<td class="nump">$ 1,720,217<span></span>
</td>
<td class="nump">$ 3,865,165<span></span>
</td>
<td class="nump">$ 3,045,029<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense, Total</a></td>
<td class="nump">579,917<span></span>
</td>
<td class="nump">387,384<span></span>
</td>
<td class="nump">1,090,177<span></span>
</td>
<td class="nump">782,876<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense, Total</a></td>
<td class="nump">$ 1,368,731<span></span>
</td>
<td class="nump">$ 1,332,833<span></span>
</td>
<td class="nump">$ 2,774,988<span></span>
</td>
<td class="nump">$ 2,262,153<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628740841056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Schedule of Allocation of Stock-Based Compensation Expense by Plan (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="nump">$ 1,948,648<span></span>
</td>
<td class="nump">$ 1,720,217<span></span>
</td>
<td class="nump">$ 3,865,165<span></span>
</td>
<td class="nump">$ 3,045,029<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="nump">1,935,202<span></span>
</td>
<td class="nump">1,700,041<span></span>
</td>
<td class="nump">3,836,565<span></span>
</td>
<td class="nump">3,003,834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ovid_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="nump">$ 13,446<span></span>
</td>
<td class="nump">$ 20,176<span></span>
</td>
<td class="nump">$ 28,600<span></span>
</td>
<td class="nump">$ 41,195<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ovid_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ovid_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628741856288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Summary of Assumptions Used to Compute Fair Value of Options Granted (Detail) - Stock options - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">84.11%<span></span>
</td>
<td class="nump">87.20%<span></span>
</td>
<td class="nump">84.56%<span></span>
</td>
<td class="nump">87.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 25 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.63%<span></span>
</td>
<td class="nump">2.78%<span></span>
</td>
<td class="nump">3.97%<span></span>
</td>
<td class="nump">2.16%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value of option on grant date</a></td>
<td class="nump">$ 2.66<span></span>
</td>
<td class="nump">$ 2.38<span></span>
</td>
<td class="nump">$ 1.92<span></span>
</td>
<td class="nump">$ 2.17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Nonemployee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">83.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">5 years 3 months<span></span>
</td>
<td class="text">0 years<span></span>
</td>
<td class="text">5 years 3 months<span></span>
</td>
<td class="text">0 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.89%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">3.89%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value of option on grant date</a></td>
<td class="nump">$ 2.42<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2.42<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628740834608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Summary of Options Outstanding and Weighted Average Exercise Price (Detail)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning balance (in shares) | shares</a></td>
<td class="nump">12,961,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">3,000,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(91,078)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited or expired (in shares) | shares</a></td>
<td class="num">(421,825)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending balance (in shares) | shares</a></td>
<td class="nump">15,448,835<span></span>
</td>
<td class="nump">12,961,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Vested and exercisable, ending balance (in shares) | shares</a></td>
<td class="nump">8,607,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">2.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">2.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited or expired (in dollars per share) | $ / shares</a></td>
<td class="nump">3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">3.87<span></span>
</td>
<td class="nump">$ 4.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested and exercisable (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Life in Years and Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life in Years, Options outstanding</a></td>
<td class="text">7 years 4 months 13 days<span></span>
</td>
<td class="text">7 years 5 months 1 day<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife', window );">Weighted Average Remaining Contractual Life in Years, Granted</a></td>
<td class="text">9 years 8 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life in Years, Vested and exercisable</a></td>
<td class="text">6 years 2 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, options outstanding | $</a></td>
<td class="nump">$ 5,854,085<span></span>
</td>
<td class="nump">$ 62,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value, vested and exercisable | $</a></td>
<td class="nump">$ 2,406,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation by share based payment award options granted contractual life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628743421552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">(Benefit) provision for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628737004128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Additional Information (Detail)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($) </div>
<div>product</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>product</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,998,766<span></span>
</td>
<td class="nump">$ 6,046,670<span></span>
</td>
<td class="nump">$ 12,613,482<span></span>
</td>
<td class="nump">$ 13,878,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_CollaborationAndOptionAgreementResearchPlanAndBudgetExpectedCosts', window );">Research plan and budget, expected costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ovid_LicenseAgreementMember', window );">License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_LicenseAgreementMilestonePayments', window );">License agreement milestone payments (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 452,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_LicenseAgreementDevelopmentMilestoneApprovalsProductThreshold', window );">Developmental milestone approvals, number of products (at least) | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_LicenseAgreementTerminationAdvanceNoticePeriod', window );">Advance written notice required to terminate agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ovid_NorthwesternUniversityMember', window );">Northwestern University | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment', window );">Upfront non-creditable one-time license issuance fee payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_AnnualLicenseMaintenanceFeePayable', window );">Annual license maintenance fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_ConsiderationPayableForRightsGrant', window );">Consideration payable for rights grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement', window );">Minimum number of product covered under license agreement | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ovid_NorthwesternUniversityMember', window );">Northwestern University | License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_RoyaltyObligationTerm', window );">Royalty obligation period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ovid_AstrazenecaMember', window );">AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_UpfrontCashPayment', window );">Upfront cash payment</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_LicenseAgreementConsiderationSharesIssued', window );">License agreement, consideration (in shares) | shares</a></td>
<td class="nump">7.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate', window );">Days immediately preceding the execution date</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_LicenseAgreementMilestonePayments', window );">License agreement milestone payments (up to)</a></td>
<td class="nump">$ 203,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ovid_HLundbeckASMember', window );">Lundbeck</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_FirstPaymentDueUponCompletionOfFirstPhase', window );">First payment due upon completion of first phase</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_AnnualLicenseMaintenanceFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual license maintenance fee payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_AnnualLicenseMaintenanceFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_CollaborationAndOptionAgreementResearchPlanAndBudgetExpectedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration and Option Agreement, Research Plan And Budget, Expected Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_CollaborationAndOptionAgreementResearchPlanAndBudgetExpectedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Issuance , Period Immediately Preceding Execution Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_ConsiderationPayableForRightsGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consideration payable for rights grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_ConsiderationPayableForRightsGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_FirstPaymentDueUponCompletionOfFirstPhase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>First payment due upon completion of first phase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_FirstPaymentDueUponCompletionOfFirstPhase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_LicenseAgreementConsiderationSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Consideration, Shares Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_LicenseAgreementConsiderationSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_LicenseAgreementDevelopmentMilestoneApprovalsProductThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Development Milestone Approvals, Product Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_LicenseAgreementDevelopmentMilestoneApprovalsProductThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_LicenseAgreementMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Global commercial and regulatory milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_LicenseAgreementMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_LicenseAgreementTerminationAdvanceNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Termination, Advance Notice Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_LicenseAgreementTerminationAdvanceNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum number of product covered under license agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_RoyaltyObligationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Obligation, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_RoyaltyObligationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_UpfrontCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront Cash Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_UpfrontCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront non-creditable one-time license issuance fee payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ovid_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ovid_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ovid_NorthwesternUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ovid_NorthwesternUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ovid_AstrazenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ovid_AstrazenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ovid_HLundbeckASMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ovid_HLundbeckASMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628733856736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COLLABORATION AND LICENSE AGREEMENTS - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2023</div></th>
<th class="th"><div>Feb. 01, 2023</div></th>
<th class="th"><div>Mar. 18, 2022</div></th>
<th class="th"><div>Feb. 01, 2022</div></th>
<th class="th"><div>Mar. 29, 2021</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 01, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,602,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,466,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) on equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 847,995<span></span>
</td>
<td class="num">$ (348,812)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement, Co-promotion | Takeda Pharmaceutical Company Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_UpfrontPaymentReceivable', window );">Upfront payment under royalty and termination agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 196,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_AgreementMilestonePayments', window );">Aggregate milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 660,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_AdditionalPaymentReceivableOnSalesPercentage', window );">Additional payment on sales percentage (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_UpFrontFeeAmount', window );">Up-front fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement, Co-promotion | Takeda Pharmaceutical Company Limited | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_LicenseAndCollaborationAgreementExpense', window );">Related party transaction expenses recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ovid_HealxLicenseAndOptionAgreementMember', window );">Healx License and Option Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_UpFrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_LicenseOptionAgreementDevelopmentAndCommercialMilestonePayments', window );">Development and commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_LicenseOptionAgreementExtensionPeriod', window );">Granted option extension period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ovid_PercentageOfDevelopmentCosts', window );">Percentage of development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ovid_MarinusLicenseAgreementMember', window );">Marinus License Agreement | Marinus Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ovid_TakedaPharmaceuticalCompanyLimitedMember', window );">Takeda Pharmaceutical Company Limited | Collaborative Arrangement, Co-promotion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Agreement ownership share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ovid_MarinusPharmaceuticalsIncMember', window );">Marinus Pharmaceuticals, Inc | Marinus License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) on equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ovid_MarinusPharmaceuticalsIncMember', window );">Marinus Pharmaceuticals, Inc | Patent License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ovid_GravitonBioscienceCorporationMember', window );">Graviton Bioscience Corporation | Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock', window );">Purchase of preferred stock</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_AdditionalPaymentReceivableOnSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional payment receivable on sales percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_AdditionalPaymentReceivableOnSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_AgreementMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_AgreementMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_LicenseAndCollaborationAgreementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License and Collaboration Agreement, Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_LicenseAndCollaborationAgreementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_LicenseOptionAgreementDevelopmentAndCommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Option Agreement, Development and Commercial Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_LicenseOptionAgreementDevelopmentAndCommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_LicenseOptionAgreementExtensionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Option Agreement, Extension Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_LicenseOptionAgreementExtensionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_PercentageOfDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_PercentageOfDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_UpFrontFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Up-front fee amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_UpFrontFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_UpFrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Up front Payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_UpFrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_UpfrontPaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_UpfrontPaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire preferred stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ovid_TakedaPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ovid_TakedaPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ovid_HealxLicenseAndOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ovid_HealxLicenseAndOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ovid_MarinusLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ovid_MarinusLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ovid_MarinusPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ovid_MarinusPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ovid_TakedaPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ovid_TakedaPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ovid_MarinusPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ovid_MarinusPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ovid_PatentLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ovid_PatentLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ovid_GravitonBioscienceCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ovid_GravitonBioscienceCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628741946048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE - Summary of Calculation of Basic and Diluted Earnings (Loss) per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (12,408,330)<span></span>
</td>
<td class="num">$ (13,356,209)<span></span>
</td>
<td class="num">$ (14,588,414)<span></span>
</td>
<td class="num">$ (16,108,056)<span></span>
</td>
<td class="num">$ (25,764,539)<span></span>
</td>
<td class="num">$ (30,696,470)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Net loss attributable to participating securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(12,408,330)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,588,414)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,764,539)<span></span>
</td>
<td class="num">(30,696,470)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (12,408,330)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (14,588,414)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (25,764,539)<span></span>
</td>
<td class="num">$ (30,696,470)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding used in computing net loss per share - basic (in shares)</a></td>
<td class="nump">70,534,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,391,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,512,479<span></span>
</td>
<td class="nump">70,391,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding used in computing net loss per share - diluted (in shares)</a></td>
<td class="nump">70,534,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,391,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,512,479<span></span>
</td>
<td class="nump">70,391,236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="num">$ (0.44)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="num">$ (0.44)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 65<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-65<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 66<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-66<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140628733847888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE - Schedule of Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Shares Outstanding (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Dilutive Securities Included and Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive securities excluded from computations of diluted weighted average shares outstanding (in shares)</a></td>
<td class="nump">15,448,835<span></span>
</td>
<td class="nump">13,451,517<span></span>
</td>
<td class="nump">15,448,835<span></span>
</td>
<td class="nump">13,103,587<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ovid_SeriesAConvertiblePreferredStockMember', window );">Common stock issuable upon conversion of Series A convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Dilutive Securities Included and Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive securities excluded from computations of diluted weighted average shares outstanding (in shares)</a></td>
<td class="nump">1,250,000<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ovid_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ovid_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>ovid-20230630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:ovid="http://www.ovidrx.com/20230630"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ovid-20230630.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
        </entity>
        <period>
            <instant>2023-08-01</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
        </entity>
        <period>
            <startDate>2014-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ovid:GensaicIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ovid:GensaicIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ovid:GravitonBioscienceCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ovid:MarinusTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ovid:MarinusTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ovid:MoneyMarketFundsAndShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ovid:MoneyMarketFundsAndShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
        </entity>
        <period>
            <instant>2022-03-10</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
        </entity>
        <period>
            <startDate>2022-03-10</startDate>
            <endDate>2022-03-10</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:CowenAndCompanyLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ovid:ATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:CowenAndCompanyLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ovid:ATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-04</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-04</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:NonemployeePerformanceBasedOptionAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:NonemployeePerformanceBasedOptionAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:EmployeePerformanceBasedOptionAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:EmployeePerformanceBasedOptionAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:NorthwesternUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:NorthwesternUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:NorthwesternUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:AstrazenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-30</startDate>
            <endDate>2021-12-30</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:AstrazenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-30</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:AstrazenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:HLundbeckASMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-30</startDate>
            <endDate>2021-12-30</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ovid:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-29</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-29</startDate>
            <endDate>2021-03-29</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:HealxLicenseAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-01</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:HealxLicenseAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-01</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:HealxLicenseAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:HealxLicenseAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:MarinusLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:MarinusPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-01</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ovid:MarinusPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:PatentLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-18</startDate>
            <endDate>2022-03-18</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ovid:MarinusPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:MarinusLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ovid:MarinusPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:MarinusLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ovid:GravitonBioscienceCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-30</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="vote">
        <measure>ovid:vote</measure>
    </unit>
    <unit id="product">
        <measure>ovid:product</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-26">0001636651</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-27">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-28">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-29">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-30">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2023-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-38085</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">Ovid Therapeutics Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">46-5270895</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">441 Ninth Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-10">14th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">10001</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">646</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">661-7661</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">OVID</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-19">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-20">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-21">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-22">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-23">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-24">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-25" unitRef="shares">70602793</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="0" id="f-31" unitRef="usd">71623256</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="0" id="f-32" unitRef="usd">44867846</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-3" decimals="0" id="f-33" unitRef="usd">24894144</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-4" decimals="0" id="f-34" unitRef="usd">84133565</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="0" id="f-35" unitRef="usd">5653465</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="0" id="f-36" unitRef="usd">2379280</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="0" id="f-37" unitRef="usd">102170865</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="0" id="f-38" unitRef="usd">131380691</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments contextRef="c-3" decimals="0" id="f-39" unitRef="usd">16470542</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c-4" decimals="0" id="f-40" unitRef="usd">5622547</us-gaap:LongTermInvestments>
    <us-gaap:RestrictedCash contextRef="c-3" decimals="0" id="f-41" unitRef="usd">1930753</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-4" decimals="0" id="f-42" unitRef="usd">1930753</us-gaap:RestrictedCash>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="0" id="f-43" unitRef="usd">14412068</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="0" id="f-44" unitRef="usd">14922669</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="0" id="f-45" unitRef="usd">955569</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="0" id="f-46" unitRef="usd">1147963</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-3" decimals="0" id="f-47" unitRef="usd">289967</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="0" id="f-48" unitRef="usd">261191</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-3" decimals="0" id="f-49" unitRef="usd">136229764</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="0" id="f-50" unitRef="usd">155265814</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="0" id="f-51" unitRef="usd">3763289</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="0" id="f-52" unitRef="usd">1952910</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="0" id="f-53" unitRef="usd">5433290</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="0" id="f-54" unitRef="usd">4504669</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="0" id="f-55" unitRef="usd">944943</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="0" id="f-56" unitRef="usd">533946</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="0" id="f-57" unitRef="usd">10141522</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="0" id="f-58" unitRef="usd">6991525</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="0" id="f-59" unitRef="usd">15389567</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="0" id="f-60" unitRef="usd">16001725</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="0" id="f-61" unitRef="usd">25531089</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="0" id="f-62" unitRef="usd">22993250</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-63"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-64"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-65" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-66" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <ovid:PreferredStockShareDesignated contextRef="c-3" decimals="INF" id="f-67" unitRef="shares">10000</ovid:PreferredStockShareDesignated>
    <ovid:PreferredStockShareDesignated contextRef="c-4" decimals="INF" id="f-68" unitRef="shares">10000</ovid:PreferredStockShareDesignated>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-69" unitRef="shares">1250</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-70" unitRef="shares">1250</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="INF" id="f-71" unitRef="shares">1250</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c-3" decimals="INF" id="f-72" unitRef="shares">1250</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue contextRef="c-3" decimals="0" id="f-73" unitRef="usd">1</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="0" id="f-74" unitRef="usd">1</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-75"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-76"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-77" unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-78" unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="INF" id="f-79" unitRef="shares">70602793</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-80" unitRef="shares">70602793</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-81" unitRef="shares">70466885</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-82" unitRef="shares">70466885</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="0" id="f-83" unitRef="usd">70603</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="0" id="f-84" unitRef="usd">70467</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-3" decimals="0" id="f-85" unitRef="usd">361913944</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="0" id="f-86" unitRef="usd">357770825</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="0" id="f-87" unitRef="usd">5208</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="0" id="f-88" unitRef="usd">-42187</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="0" id="f-89" unitRef="usd">-251291081</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="0" id="f-90" unitRef="usd">-225526542</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="0" id="f-91" unitRef="usd">110698675</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="0" id="f-92" unitRef="usd">132272564</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="0" id="f-93" unitRef="usd">136229764</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="0" id="f-94" unitRef="usd">155265814</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="0" id="f-95" unitRef="usd">75000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="0" id="f-96" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="0" id="f-97" unitRef="usd">141160</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="0" id="f-98" unitRef="usd">1445366</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="0" id="f-99" unitRef="usd">75000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="0" id="f-100" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="0" id="f-101" unitRef="usd">141160</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="0" id="f-102" unitRef="usd">1445366</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-5" decimals="0" id="f-103" unitRef="usd">5998766</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-6" decimals="0" id="f-104" unitRef="usd">6046670</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="0" id="f-105" unitRef="usd">12613482</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-7" decimals="0" id="f-106" unitRef="usd">13878939</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-5" decimals="0" id="f-107" unitRef="usd">8248216</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-6" decimals="0" id="f-108" unitRef="usd">8257617</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="0" id="f-109" unitRef="usd">16591964</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-7" decimals="0" id="f-110" unitRef="usd">18137820</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-5" decimals="0" id="f-111" unitRef="usd">14246982</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-6" decimals="0" id="f-112" unitRef="usd">14304287</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="0" id="f-113" unitRef="usd">29205447</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-7" decimals="0" id="f-114" unitRef="usd">32016759</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="0" id="f-115" unitRef="usd">-14171982</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-6" decimals="0" id="f-116" unitRef="usd">-14304287</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="0" id="f-117" unitRef="usd">-29064286</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-7" decimals="0" id="f-118" unitRef="usd">-30571393</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-5" decimals="0" id="f-119" unitRef="usd">1763652</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-6" decimals="0" id="f-120" unitRef="usd">-284127</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="0" id="f-121" unitRef="usd">3299747</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-7" decimals="0" id="f-122" unitRef="usd">-125076</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-5" decimals="0" id="f-123" unitRef="usd">-12408330</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-6" decimals="0" id="f-124" unitRef="usd">-14588414</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="0" id="f-125" unitRef="usd">-25764539</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-7" decimals="0" id="f-126" unitRef="usd">-30696470</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-5" decimals="0" id="f-127" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-6" decimals="0" id="f-128" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="0" id="f-129" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-7" decimals="0" id="f-130" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="0" id="f-131" unitRef="usd">-12408330</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="0" id="f-132" unitRef="usd">-14588414</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="0" id="f-133" unitRef="usd">-25764539</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="0" id="f-134" unitRef="usd">-30696470</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-135"
      unitRef="usdPerShare">-0.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-136"
      unitRef="usdPerShare">-0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-137"
      unitRef="usdPerShare">-0.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-138"
      unitRef="usdPerShare">-0.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-139"
      unitRef="usdPerShare">-0.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-140"
      unitRef="usdPerShare">-0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-141"
      unitRef="usdPerShare">-0.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-142"
      unitRef="usdPerShare">-0.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="0" id="f-143" unitRef="shares">70534181</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="0" id="f-144" unitRef="shares">70391458</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-145" unitRef="shares">70512479</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="0" id="f-146" unitRef="shares">70391236</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="0" id="f-147" unitRef="shares">70534181</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="0" id="f-148" unitRef="shares">70391458</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-149" unitRef="shares">70512479</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="0" id="f-150" unitRef="shares">70391236</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="0" id="f-151" unitRef="usd">-12408330</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="0" id="f-152" unitRef="usd">-14588414</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="0" id="f-153" unitRef="usd">-25764539</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="0" id="f-154" unitRef="usd">-30696470</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-5" decimals="0" id="f-155" unitRef="usd">-422</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-6" decimals="0" id="f-156" unitRef="usd">-90127</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-1" decimals="0" id="f-157" unitRef="usd">47395</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-7" decimals="0" id="f-158" unitRef="usd">-90127</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-5" decimals="0" id="f-159" unitRef="usd">-12408752</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-6" decimals="0" id="f-160" unitRef="usd">-14678541</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="0" id="f-161" unitRef="usd">-25717144</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-7" decimals="0" id="f-162" unitRef="usd">-30786597</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-8" decimals="INF" id="f-163" unitRef="shares">1250</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="0" id="f-164" unitRef="usd">1</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-9" decimals="INF" id="f-165" unitRef="shares">70466885</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="0" id="f-166" unitRef="usd">70467</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="0" id="f-167" unitRef="usd">357770825</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="0" id="f-168" unitRef="usd">-42187</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-12" decimals="0" id="f-169" unitRef="usd">-225526542</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="0" id="f-170" unitRef="usd">132272564</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-13"
      decimals="INF"
      id="f-171"
      unitRef="shares">24625</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-13" decimals="0" id="f-172" unitRef="usd">25</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-14" decimals="0" id="f-173" unitRef="usd">66968</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-15" decimals="0" id="f-174" unitRef="usd">66993</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-14" decimals="0" id="f-175" unitRef="usd">1916518</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-15" decimals="0" id="f-176" unitRef="usd">1916518</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent contextRef="c-16" decimals="0" id="f-177" unitRef="usd">47817</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent contextRef="c-15" decimals="0" id="f-178" unitRef="usd">47817</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-17" decimals="0" id="f-179" unitRef="usd">-13356209</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="0" id="f-180" unitRef="usd">-13356209</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-18"
      decimals="INF"
      id="f-181"
      unitRef="shares">1250</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="0" id="f-182" unitRef="usd">1</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-19"
      decimals="INF"
      id="f-183"
      unitRef="shares">70491510</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="0" id="f-184" unitRef="usd">70492</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="0" id="f-185" unitRef="usd">359754310</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="0" id="f-186" unitRef="usd">5630</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="0" id="f-187" unitRef="usd">-238882751</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="0" id="f-188" unitRef="usd">120947682</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-24"
      decimals="INF"
      id="f-189"
      unitRef="shares">112283</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-24" decimals="0" id="f-190" unitRef="usd">111</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-25" decimals="0" id="f-191" unitRef="usd">210986</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-5" decimals="0" id="f-192" unitRef="usd">211097</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-25" decimals="0" id="f-193" unitRef="usd">1948648</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-5" decimals="0" id="f-194" unitRef="usd">1948648</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent contextRef="c-26" decimals="0" id="f-195" unitRef="usd">-422</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent contextRef="c-5" decimals="0" id="f-196" unitRef="usd">-422</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="0" id="f-197" unitRef="usd">-12408330</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="0" id="f-198" unitRef="usd">-12408330</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-27"
      decimals="INF"
      id="f-199"
      unitRef="shares">1250</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="0" id="f-200" unitRef="usd">1</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-28"
      decimals="INF"
      id="f-201"
      unitRef="shares">70603793</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="0" id="f-202" unitRef="usd">70603</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="0" id="f-203" unitRef="usd">361913944</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="0" id="f-204" unitRef="usd">5208</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="0" id="f-205" unitRef="usd">-251291081</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="0" id="f-206" unitRef="usd">110698675</us-gaap:StockholdersEquity>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-32"
      decimals="INF"
      id="f-207"
      unitRef="shares">1250</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="0" id="f-208" unitRef="usd">1</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-33"
      decimals="INF"
      id="f-209"
      unitRef="shares">70364912</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="0" id="f-210" unitRef="usd">70359</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="0" id="f-211" unitRef="usd">351033589</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="0" id="f-212" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-36" decimals="0" id="f-213" unitRef="usd">-171357513</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-37" decimals="0" id="f-214" unitRef="usd">179746436</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-38"
      decimals="INF"
      id="f-215"
      unitRef="shares">52333</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-38" decimals="0" id="f-216" unitRef="usd">14</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-39" decimals="0" id="f-217" unitRef="usd">33065</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-40" decimals="0" id="f-218" unitRef="usd">33079</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-39" decimals="0" id="f-219" unitRef="usd">1324812</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-40" decimals="0" id="f-220" unitRef="usd">1324812</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-41" decimals="0" id="f-221" unitRef="usd">-16108056</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-40" decimals="0" id="f-222" unitRef="usd">-16108056</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-42"
      decimals="INF"
      id="f-223"
      unitRef="shares">1250</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-42" decimals="0" id="f-224" unitRef="usd">1</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-43"
      decimals="INF"
      id="f-225"
      unitRef="shares">70417245</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-43" decimals="0" id="f-226" unitRef="usd">70373</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-44" decimals="0" id="f-227" unitRef="usd">352391466</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-45" decimals="0" id="f-228" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-46" decimals="0" id="f-229" unitRef="usd">-187465569</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-47" decimals="0" id="f-230" unitRef="usd">164996271</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-48"
      decimals="INF"
      id="f-231"
      unitRef="shares">2143</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-48" decimals="0" id="f-232" unitRef="usd">41</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-49" decimals="0" id="f-233" unitRef="usd">109507</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-6" decimals="0" id="f-234" unitRef="usd">109548</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-49" decimals="0" id="f-235" unitRef="usd">1720217</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-6" decimals="0" id="f-236" unitRef="usd">1720217</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent contextRef="c-50" decimals="0" id="f-237" unitRef="usd">-90127</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent contextRef="c-6" decimals="0" id="f-238" unitRef="usd">-90127</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-51" decimals="0" id="f-239" unitRef="usd">-14588414</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="0" id="f-240" unitRef="usd">-14588414</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-52"
      decimals="INF"
      id="f-241"
      unitRef="shares">1250</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-52" decimals="0" id="f-242" unitRef="usd">1</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-53"
      decimals="INF"
      id="f-243"
      unitRef="shares">70419388</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-53" decimals="0" id="f-244" unitRef="usd">70414</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-54" decimals="0" id="f-245" unitRef="usd">354221191</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-55" decimals="0" id="f-246" unitRef="usd">-90127</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-56" decimals="0" id="f-247" unitRef="usd">-202053983</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-57" decimals="0" id="f-248" unitRef="usd">152147496</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="0" id="f-249" unitRef="usd">-25764539</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="0" id="f-250" unitRef="usd">-30696470</us-gaap:NetIncomeLoss>
    <ovid:NoncashConsiderationReceivedInLicensingAgreementTransaction contextRef="c-1" decimals="0" id="f-251" unitRef="usd">0</ovid:NoncashConsiderationReceivedInLicensingAgreementTransaction>
    <ovid:NoncashConsiderationReceivedInLicensingAgreementTransaction contextRef="c-7" decimals="0" id="f-252" unitRef="usd">945366</ovid:NoncashConsiderationReceivedInLicensingAgreementTransaction>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-1" decimals="0" id="f-253" unitRef="usd">847995</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-7" decimals="0" id="f-254" unitRef="usd">-348812</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <ovid:ChangeInAccruedInterestAndAccretionOfDiscountsShortTermInvestments contextRef="c-1" decimals="0" id="f-255" unitRef="usd">-1139113</ovid:ChangeInAccruedInterestAndAccretionOfDiscountsShortTermInvestments>
    <ovid:ChangeInAccruedInterestAndAccretionOfDiscountsShortTermInvestments contextRef="c-7" decimals="0" id="f-256" unitRef="usd">-223649</ovid:ChangeInAccruedInterestAndAccretionOfDiscountsShortTermInvestments>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="0" id="f-257" unitRef="usd">3865166</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-7" decimals="0" id="f-258" unitRef="usd">3045029</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="0" id="f-259" unitRef="usd">282121</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-7" decimals="0" id="f-260" unitRef="usd">172105</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="0" id="f-261" unitRef="usd">510601</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-7" decimals="0" id="f-262" unitRef="usd">354185</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <ovid:AccretionOfLeaseLiability contextRef="c-1" decimals="0" id="f-263" unitRef="usd">573015</ovid:AccretionOfLeaseLiability>
    <ovid:AccretionOfLeaseLiability contextRef="c-7" decimals="0" id="f-264" unitRef="usd">368226</ovid:AccretionOfLeaseLiability>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="0" id="f-265" unitRef="usd">4048361</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-7" decimals="0" id="f-266" unitRef="usd">230877</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-1" decimals="0" id="f-267" unitRef="usd">-12491</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-7" decimals="0" id="f-268" unitRef="usd">-15920</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c-1" decimals="0" id="f-269" unitRef="usd">1810379</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c-7" decimals="0" id="f-270" unitRef="usd">-2510503</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="0" id="f-271" unitRef="usd">928621</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-7" decimals="0" id="f-272" unitRef="usd">-3072434</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="0" id="f-273" unitRef="usd">-23817614</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-7" decimals="0" id="f-274" unitRef="usd">-33375022</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="0" id="f-275" unitRef="usd">24574071</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-7" decimals="0" id="f-276" unitRef="usd">79416203</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-1" decimals="0" id="f-277" unitRef="usd">85000000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-7" decimals="0" id="f-278" unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireLongtermInvestments contextRef="c-1" decimals="0" id="f-279" unitRef="usd">10000000</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:PaymentsToAcquireLongtermInvestments contextRef="c-7" decimals="0" id="f-280" unitRef="usd">0</us-gaap:PaymentsToAcquireLongtermInvestments>
    <ovid:PaymentsForProceedsFromIssuanceOfShortTermNoteReceivable contextRef="c-1" decimals="0" id="f-281" unitRef="usd">0</ovid:PaymentsForProceedsFromIssuanceOfShortTermNoteReceivable>
    <ovid:PaymentsForProceedsFromIssuanceOfShortTermNoteReceivable contextRef="c-7" decimals="0" id="f-282" unitRef="usd">1000000</ovid:PaymentsForProceedsFromIssuanceOfShortTermNoteReceivable>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="0" id="f-283" unitRef="usd">21357</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-7" decimals="0" id="f-284" unitRef="usd">1085840</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToDevelopSoftware contextRef="c-1" decimals="0" id="f-285" unitRef="usd">109637</us-gaap:PaymentsToDevelopSoftware>
    <us-gaap:PaymentsToDevelopSoftware contextRef="c-7" decimals="0" id="f-286" unitRef="usd">251340</us-gaap:PaymentsToDevelopSoftware>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="0" id="f-287" unitRef="usd">50294935</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-7" decimals="0" id="f-288" unitRef="usd">-81753383</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="0" id="f-289" unitRef="usd">278089</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-7" decimals="0" id="f-290" unitRef="usd">142628</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="0" id="f-291" unitRef="usd">278089</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-7" decimals="0" id="f-292" unitRef="usd">142628</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c-1" decimals="0" id="f-293" unitRef="usd">26755410</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c-7" decimals="0" id="f-294" unitRef="usd">-114985777</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="0" id="f-295" unitRef="usd">46798599</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-37" decimals="0" id="f-296" unitRef="usd">189728285</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="0" id="f-297" unitRef="usd">73554009</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-57" decimals="0" id="f-298" unitRef="usd">74742508</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="0" id="f-299" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-7" decimals="0" id="f-300" unitRef="usd">15791769</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-301">NATURE OF OPERATIONS&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Ovid Therapeutics Inc. (the &#x201c;Company&#x201d;) was incorporated under the laws of the state of Delaware and commenced operations on April 1, 2014 and maintains its principal executive office in New York, New York. The Company is a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since its inception, the Company has devoted substantially all of its efforts to business development, research and development, recruiting management and technical staff, and raising capital, and has financed its operations through the issuance of convertible preferred stock, common stock and other equity instruments. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development and regulatory success, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, and the ability to secure additional capital to fund operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s major sources of cash have been licensing revenue, proceeds from various public and private offerings of its capital stock, option exercises and interest income. As of June&#160;30, 2023, the Company had approximately $96.5 million in cash, cash equivalents and marketable securities. Since inception, the Company has generated $222.6 million in revenue, primarily from the Company&#x2019;s royalty, license and termination agreement (&#x201c;RLT Agreement&#x201d;) with Takeda Pharmaceutical Company Limited (&#x201c;Takeda&#x201d;). Historically, the Company has incurred recurring losses, has experienced negative operating cash flows and has required significant cash resources to execute its business plans, which the Company expects will continue for the foreseeable future. The Company has an accumulated deficit of $251.3 million as of June&#160;30, 2023, working capital of $92.0 million and had cash used in operating activities of $23.8 million for the six months ended June&#160;30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded net losses of $12.4 million and $25.8 million during the three and six months ended June&#160;30, 2023, respectively, and expects to incur losses in subsequent periods for at least the next several years. The Company is highly dependent on its ability to find additional sources of funding through either equity offerings, debt financings, collaborations, strategic alliances, licensing agreements or a combination of any such transactions. Management believes that the Company&#x2019;s existing cash, cash equivalents and marketable securities as of June&#160;30, 2023 will be sufficient to fund its current operating plans through at least the next 12 months from the date of filing of the Company&#x2019;s Quarterly Report on Form 10-Q. Adequate additional funding may not be available to the Company on acceptable terms or at all. The failure to raise capital as and when needed could have a negative impact on the Company&#x2019;s financial condition and ability to pursue its business strategy. The Company may be required to delay, reduce the scope of or eliminate research and development programs, or obtain funds through arrangements with collaborators or others that may require the Company to relinquish rights to certain drug candidates that the Company might otherwise seek to develop or commercialize independently.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to other challenges and risks specific to its business and its ability to execute on its strategy, as well as risks and uncertainties common to companies in the pharmaceutical industry with development and commercial operations, including, without limitation, risks and uncertainties associated with: delays or problems in the supply of the Company's product candidates, loss of single source suppliers or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing additional products or product candidates; pharmaceutical product development and the inherent uncertainty of clinical success; the challenges of protecting and enhancing intellectual property rights; complying with applicable regulatory requirements; and obtaining regulatory approval of any of the Company's product candidates.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-3" decimals="-5" id="f-302" unitRef="usd">96500000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-58" decimals="-5" id="f-303" unitRef="usd">222600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-5" id="f-304" unitRef="usd">-251300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <ovid:WorkingCapital contextRef="c-3" decimals="-5" id="f-305" unitRef="usd">92000000</ovid:WorkingCapital>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-5" id="f-306" unitRef="usd">-23800000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-5" id="f-307" unitRef="usd">-12400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-308" unitRef="usd">-25800000</us-gaap:NetIncomeLoss>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-309">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s significant accounting policies are described in Note 2, &#x201c;Summary of Significant Accounting Policies,&#x201d; in the Company&#x2019;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March 13, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(A) Unaudited Interim Condensed Consolidated Financial Statements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interim condensed consolidated balance sheet at June&#160;30, 2023 and the condensed consolidated statements of operations, comprehensive loss, cash flows, and stockholders&#x2019; equity for the three and six months ended June&#160;30, 2023 and 2022 are unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) and following the requirements of the SEC for interim reporting. As permitted under those rules, certain notes or other financial information that are normally required by GAAP are condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the Company&#x2019;s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of its financial information. The results of operations for the three and six month periods ended June&#160;30, 2023 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2023 or for any other future annual or interim period. The balance sheet as of December&#160;31, 2022 included herein was derived from the audited financial statements as of that date. These interim condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited financial statements as of and for the year ended December&#160;31, 2022 included in the Company&#x2019;s Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(B) Basis of Presentation and Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements have been prepared in conformity with GAAP and include the accounts of Ovid Therapeutics Inc. and its wholly owned subsidiary, Ovid Therapeutics Hong Kong Limited. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(C) Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(D) Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities consist of investments in U.S. treasury instruments which are considered available-for-sale securities. The Company classifies its marketable securities with maturities of less than one year from the balance sheet date as current assets on its condensed consolidated balance sheets. The Company classifies its marketable securities with original maturities of less than three months as cash equivalents on its consolidated balance sheets. Unrealized gains and losses on these securities that are determined to be temporary are reported as a separate component of accumulated other comprehensive income (loss) in stockholder's equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(E) Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies as restricted cash all cash pledged as collateral to secure long-term obligations and all cash whose use is otherwise limited by contractual provisions. Amounts are reported as non-current unless restrictions are expected to be released in the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(F) Long-Term Equity Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Long-term equity investments consist of equity investments in the preferred shares of Gensaic, Inc., formerly M13 Therapeutics, Inc. (&#x201c;Gensaic&#x201d;), and Graviton Bioscience Corporation (&#x201c;Graviton&#x201d;), both privately held corporations. The preferred shares are not considered in-substance common stock, and the investments are accounted for at cost, with adjustments for observable changes in prices or impairments, and are classified within long-term equity investments on the consolidated balance sheets with adjustments recognized in other income (expense), net on the condensed consolidated statements of operations. The Company has determined that these equity investments do not have a readily determinable fair value and elected the measurement alternative. Therefore, the carrying amount of the equity investments will be adjusted to fair value at the time of the next observable price change for the identical or similar investment of the same issuer or when an impairment is recognized. Each reporting period, the Company performs a qualitative assessment to evaluate whether the investments are impaired. The assessment includes a review of recent operating results and trends, recent sales/acquisitions of the investees' securities, and other publicly available data. If an investment is determined to be impaired, the Company will then write it down to its estimated fair value. As of June&#160;30, 2023 and December&#160;31, 2022, the equity investment in Gensaic had a carrying value of $5.1&#160;million. As of June&#160;30, 2023, the equity investment in Graviton had a carrying value of $10.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term equity investments also consist of an equity investment in the common shares of Marinus Pharmaceuticals, Inc. (&#x201c;Marinus&#x201d;) that were received as non-cash consideration via the terms of a licensing agreement executed between the two companies effective March 2022. The equity shares are marked-to-market at each reporting date with changes in the fair value being reflected in the carrying value of the investment on the Company's consolidated balance sheets and other income (expense) on the Company's consolidated statements of operations. As of June&#160;30, 2023 and December&#160;31, 2022, the equity investment in Marinus had a carrying value of approximately $1.3 million and $0.5 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(G) Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial Accounting Standards Board (&#x201c;FASB&#x201d;) guidance specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The three levels of the fair value hierarchy are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 1&#x2014;Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities. The Company&#x2019;s Level 1 assets consisted of investments in a U.S. treasury money market fund and equity securities totaling $42.2 million as of June&#160;30, 2023. The Company's Level 1 assets totaled $42.5 million as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 2&#x2014;Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly (e.g., quoted prices of similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active). Level 2 includes financial instruments that are valued using models or other valuation methodologies. The Company's Level 2 assets consisted of U.S. treasury bills, totaling $54.8 million as of June&#160;30, 2023 and $84.1 million as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 3&#x2014;Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable. There were no Level 3 assets or liabilities as of June&#160;30, 2023 or December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts reported in the balance sheets for cash and cash equivalents, other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(H) Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is a lease at inception and recognizes the lease in accordance with ASC 842. Operating leases are included in right-of-use (&#x201c;ROU&#x201d;) assets, current liabilities, and long-term lease liability in the Company's consolidated balance sheets. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. The Company determines the portion of the lease liability that is current as the difference between the calculated lease liability at the end of the current period and the lease liability that is projected 12 months from the current period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(I) Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost and depreciated over their estimated useful lives of three years using the straight-line method. Repair and maintenance costs are expensed. The Company reviews the recoverability of all long-lived assets, including the related useful life, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(J) Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses the cost of research and development as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and preclinical materials as well as contracted services, license fees, and other external costs. Research and development expenses also include the cost of licensing agreements acquired from third-parties. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received in accordance with ASC 730, Research and Development.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(K) Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its stock-based compensation in accordance with ASC 718, Compensation&#x2014;Stock Compensation, which establishes accounting for stock-based awards granted to employees for services and requires companies to expense the estimated fair value of these awards over the requisite service period. The Company estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the fair value of all awards granted using the Black-Scholes valuation model. Key inputs and assumptions include the expected term of the option, stock price volatility, risk-free interest rate, dividend yield, stock price and exercise price. Many of the assumptions require significant judgment and any changes could have an impact in the determination of stock-based compensation expense. The Company elected an accounting policy to record forfeitures as they occur. The Company recognizes employee stock-based compensation expense based on the fair value of the award on the date of the grant. The compensation expense is recognized over the vesting period under the straight-line method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for option awards granted to nonemployee consultants and directors in accordance with ASC 718. The fair value of the option issued or committed to be issued is used to measure the transaction, as this is more reliable than the fair value of the services received. The fair value is measured at the value of the Company&#x2019;s common stock award at the earlier of the date that the commitment for performance by the counterparty has been reached or the counterparty&#x2019;s performance is complete.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(L) Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes under the asset and liability method, which requires deferred tax assets and liabilities to be recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts and respective tax bases of existing assets and liabilities, as well as for net operating loss carryforwards and research and development credits. Valuation allowances are provided if it is more likely than not that some portion or all of the deferred tax assets will not be realized. The impact of a change in the tax laws is recorded in the period in which the law is enacted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(M) Net Loss per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss per common share is determined by dividing net loss attributable to common stockholders by the basic and diluted weighted-average common shares outstanding during the period. The Company applies the two-class method to allocate earnings between common stock and participating securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When applicable, net income per diluted share attributable to common stockholders adjusts the basic earnings per share attributable to common stockholders and the weighted-average number of shares of common stock outstanding for the potential dilutive impact of stock options using the treasury-stock method and the potential impact of preferred stock using the if-converted method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(N) Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 606, Revenue from Contracts with Customers, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. In applying ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the promises and performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) it satisfies the performance obligations. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services the Company transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to recognizing revenue, the Company makes estimates of the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If there are multiple distinct performance obligations, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The standalone selling price is generally determined using expected cost and comparable transactions. Revenue for performance obligations recognized over time is recognized by measuring the progress toward complete satisfaction of the performance obligations using an input measure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-refundable upfront fees allocated to licenses that are not contingent on any future performance and require no consequential continuing involvement by the Company, are recognized as revenue when the license term commences and the licensed data, technology or product is delivered. The Company defers recognition of upfront license fees if the performance obligations are not satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(O) Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has reviewed recently issued accounting standards and plans to adopt those that are applicable. The Company does not expect the adoption of those standards to have a material impact on its financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopts new pronouncements relating to generally accepted accounting principles applicable to the Company as they are issued, which may be in advance of their effective date. Management does not believe that any recently issued, but not yet effective accounting standards, if currently adopted, would have a material effect on the accompanying financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <ovid:UnauditedInterimFinancialStatementsPolicyPolicyTextBlock contextRef="c-1" id="f-310">Unaudited Interim Condensed Consolidated Financial StatementsThe interim condensed consolidated balance sheet at June&#160;30, 2023 and the condensed consolidated statements of operations, comprehensive loss, cash flows, and stockholders&#x2019; equity for the three and six months ended June&#160;30, 2023 and 2022 are unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) and following the requirements of the SEC for interim reporting. As permitted under those rules, certain notes or other financial information that are normally required by GAAP are condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the Company&#x2019;s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of its financial information. The results of operations for the three and six month periods ended June&#160;30, 2023 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2023 or for any other future annual or interim period. The balance sheet as of December&#160;31, 2022 included herein was derived from the audited financial statements as of that date. These interim condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited financial statements as of and for the year ended December&#160;31, 2022 included in the Company&#x2019;s Annual Report on Form 10-K.</ovid:UnauditedInterimFinancialStatementsPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-311">Basis of Presentation and ConsolidationThe accompanying condensed consolidated financial statements have been prepared in conformity with GAAP and include the accounts of Ovid Therapeutics Inc. and its wholly owned subsidiary, Ovid Therapeutics Hong Kong Limited. All intercompany transactions and balances have been eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-312">Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ materially from those estimates.</us-gaap:UseOfEstimates>
    <us-gaap:MarketableSecuritiesPolicy contextRef="c-1" id="f-313">Marketable SecuritiesMarketable securities consist of investments in U.S. treasury instruments which are considered available-for-sale securities. The Company classifies its marketable securities with maturities of less than one year from the balance sheet date as current assets on its condensed consolidated balance sheets. The Company classifies its marketable securities with original maturities of less than three months as cash equivalents on its consolidated balance sheets. Unrealized gains and losses on these securities that are determined to be temporary are reported as a separate component of accumulated other comprehensive income (loss) in stockholder's equity.</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c-1" id="f-314">Restricted CashThe Company classifies as restricted cash all cash pledged as collateral to secure long-term obligations and all cash whose use is otherwise limited by contractual provisions. Amounts are reported as non-current unless restrictions are expected to be released in the next 12 months.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:EquityMethodInvestmentsPolicy contextRef="c-1" id="f-315">Long-Term Equity Investments&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Long-term equity investments consist of equity investments in the preferred shares of Gensaic, Inc., formerly M13 Therapeutics, Inc. (&#x201c;Gensaic&#x201d;), and Graviton Bioscience Corporation (&#x201c;Graviton&#x201d;), both privately held corporations. The preferred shares are not considered in-substance common stock, and the investments are accounted for at cost, with adjustments for observable changes in prices or impairments, and are classified within long-term equity investments on the consolidated balance sheets with adjustments recognized in other income (expense), net on the condensed consolidated statements of operations. The Company has determined that these equity investments do not have a readily determinable fair value and elected the measurement alternative. Therefore, the carrying amount of the equity investments will be adjusted to fair value at the time of the next observable price change for the identical or similar investment of the same issuer or when an impairment is recognized. Each reporting period, the Company performs a qualitative assessment to evaluate whether the investments are impaired. The assessment includes a review of recent operating results and trends, recent sales/acquisitions of the investees' securities, and other publicly available data. If an investment is determined to be impaired, the Company will then write it down to its estimated fair value. As of June&#160;30, 2023 and December&#160;31, 2022, the equity investment in Gensaic had a carrying value of $5.1&#160;million. As of June&#160;30, 2023, the equity investment in Graviton had a carrying value of $10.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term equity investments also consist of an equity investment in the common shares of Marinus Pharmaceuticals, Inc. (&#x201c;Marinus&#x201d;) that were received as non-cash consideration via the terms of a licensing agreement executed between the two companies effective March 2022. The equity shares are marked-to-market at each reporting date with changes in the fair value being reflected in the carrying value of the investment on the Company's consolidated balance sheets and other income (expense) on the Company's consolidated statements of operations. As of June&#160;30, 2023 and December&#160;31, 2022, the equity investment in Marinus had a carrying value of approximately $1.3 million and $0.5 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:LongTermInvestments contextRef="c-59" decimals="-5" id="f-316" unitRef="usd">5100000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c-60" decimals="-5" id="f-317" unitRef="usd">5100000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c-61" decimals="-5" id="f-318" unitRef="usd">10000000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c-62" decimals="-5" id="f-319" unitRef="usd">1300000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c-63" decimals="-5" id="f-320" unitRef="usd">500000</us-gaap:LongTermInvestments>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-321">Fair Value of Financial Instruments&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial Accounting Standards Board (&#x201c;FASB&#x201d;) guidance specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The three levels of the fair value hierarchy are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 1&#x2014;Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities. The Company&#x2019;s Level 1 assets consisted of investments in a U.S. treasury money market fund and equity securities totaling $42.2 million as of June&#160;30, 2023. The Company's Level 1 assets totaled $42.5 million as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 2&#x2014;Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly (e.g., quoted prices of similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active). Level 2 includes financial instruments that are valued using models or other valuation methodologies. The Company's Level 2 assets consisted of U.S. treasury bills, totaling $54.8 million as of June&#160;30, 2023 and $84.1 million as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 3&#x2014;Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable. There were no Level 3 assets or liabilities as of June&#160;30, 2023 or December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts reported in the balance sheets for cash and cash equivalents, other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-64" decimals="-5" id="f-322" unitRef="usd">42200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-65" decimals="-5" id="f-323" unitRef="usd">42500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-66" decimals="-5" id="f-324" unitRef="usd">54800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-67" decimals="-5" id="f-325" unitRef="usd">84100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-326">LeasesThe Company determines if an arrangement is a lease at inception and recognizes the lease in accordance with ASC 842. Operating leases are included in right-of-use (&#x201c;ROU&#x201d;) assets, current liabilities, and long-term lease liability in the Company's consolidated balance sheets. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term. The Company determines the portion of the lease liability that is current as the difference between the calculated lease liability at the end of the current period and the lease liability that is projected 12 months from the current period.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-327">Property and EquipmentProperty and equipment are stated at cost and depreciated over their estimated useful lives of three years using the straight-line method. Repair and maintenance costs are expensed. The Company reviews the recoverability of all long-lived assets, including the related useful life, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-328">Research and Development ExpensesThe Company expenses the cost of research and development as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and preclinical materials as well as contracted services, license fees, and other external costs. Research and development expenses also include the cost of licensing agreements acquired from third-parties. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received in accordance with ASC 730, Research and Development</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="c-1" id="f-329">Stock-based CompensationThe Company accounts for its stock-based compensation in accordance with ASC 718, Compensation&#x2014;Stock Compensation, which establishes accounting for stock-based awards granted to employees for services and requires companies to expense the estimated fair value of these awards over the requisite service period. The Company estimates &lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the fair value of all awards granted using the Black-Scholes valuation model. Key inputs and assumptions include the expected term of the option, stock price volatility, risk-free interest rate, dividend yield, stock price and exercise price. Many of the assumptions require significant judgment and any changes could have an impact in the determination of stock-based compensation expense. The Company elected an accounting policy to record forfeitures as they occur. The Company recognizes employee stock-based compensation expense based on the fair value of the award on the date of the grant. The compensation expense is recognized over the vesting period under the straight-line method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for option awards granted to nonemployee consultants and directors in accordance with ASC 718. The fair value of the option issued or committed to be issued is used to measure the transaction, as this is more reliable than the fair value of the services received. The fair value is measured at the value of the Company&#x2019;s common stock award at the earlier of the date that the commitment for performance by the counterparty has been reached or the counterparty&#x2019;s performance is complete.&lt;/span&gt;&lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-330">Income TaxesThe Company accounts for income taxes under the asset and liability method, which requires deferred tax assets and liabilities to be recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts and respective tax bases of existing assets and liabilities, as well as for net operating loss carryforwards and research and development credits. Valuation allowances are provided if it is more likely than not that some portion or all of the deferred tax assets will not be realized. The impact of a change in the tax laws is recorded in the period in which the law is enacted.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-331">Net Loss per Share&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss per common share is determined by dividing net loss attributable to common stockholders by the basic and diluted weighted-average common shares outstanding during the period. The Company applies the two-class method to allocate earnings between common stock and participating securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When applicable, net income per diluted share attributable to common stockholders adjusts the basic earnings per share attributable to common stockholders and the weighted-average number of shares of common stock outstanding for the potential dilutive impact of stock options using the treasury-stock method and the potential impact of preferred stock using the if-converted method.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c-1" id="f-332">Revenue Recognition&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 606, Revenue from Contracts with Customers, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. In applying ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the promises and performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) it satisfies the performance obligations. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services the Company transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to recognizing revenue, the Company makes estimates of the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If there are multiple distinct performance obligations, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The standalone selling price is generally determined using expected cost and comparable transactions. Revenue for performance obligations recognized over time is recognized by measuring the progress toward complete satisfaction of the performance obligations using an input measure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-refundable upfront fees allocated to licenses that are not contingent on any future performance and require no consequential continuing involvement by the Company, are recognized as revenue when the license term commences and the licensed data, technology or product is delivered. The Company defers recognition of upfront license fees if the performance obligations are not satisfied.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-333">Recent Accounting Pronouncements&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has reviewed recently issued accounting standards and plans to adopt those that are applicable. The Company does not expect the adoption of those standards to have a material impact on its financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopts new pronouncements relating to generally accepted accounting principles applicable to the Company as they are issued, which may be in advance of their effective date. Management does not believe that any recently issued, but not yet effective accounting standards, if currently adopted, would have a material effect on the accompanying financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock contextRef="c-1" id="f-334">CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the fair value of cash, cash equivalents and marketable securities as well as gross unrealized holding gains and losses as of June&#160;30, 2023 and December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross unrealized holding gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross unrealized holding losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,754,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,759,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,888,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,888,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,512,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,517,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents as of June 30, 2023 include money market funds of $40.9 million.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross unrealized holding gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross unrealized holding losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,853,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,853,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,014,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,014,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,175,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,133,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,043,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,001,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not hold any securities that were in an unrealized loss position for more than 12 months as of June&#160;30, 2023 and December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no material realized gains or losses on available-for-sale securities during the three and six months ended June&#160;30, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="c-1" id="f-335">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the fair value of cash, cash equivalents and marketable securities as well as gross unrealized holding gains and losses as of June&#160;30, 2023 and December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross unrealized holding gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross unrealized holding losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,754,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,759,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,888,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,888,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,512,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,517,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents as of June 30, 2023 include money market funds of $40.9 million.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross unrealized holding gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross unrealized holding losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,853,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,853,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,014,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,014,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,175,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,133,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,043,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,001,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="c-1" id="f-336">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the fair value of cash, cash equivalents and marketable securities as well as gross unrealized holding gains and losses as of June&#160;30, 2023 and December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross unrealized holding gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross unrealized holding losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,754,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,759,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,888,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,888,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,512,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,517,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents as of June 30, 2023 include money market funds of $40.9 million.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross unrealized holding gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross unrealized holding losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,853,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,853,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,014,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,014,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,175,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,133,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,043,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,001,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:Cash contextRef="c-3" decimals="0" id="f-337" unitRef="usd">868598</us-gaap:Cash>
    <us-gaap:Cash contextRef="c-3" decimals="0" id="f-338" unitRef="usd">868598</us-gaap:Cash>
    <ovid:CashEquivalentsAmortizedCost contextRef="c-3" decimals="0" id="f-339" unitRef="usd">70754658</ovid:CashEquivalentsAmortizedCost>
    <ovid:CashEquivalentsUnrealizedHoldingGains contextRef="c-3" decimals="0" id="f-340" unitRef="usd">5208</ovid:CashEquivalentsUnrealizedHoldingGains>
    <ovid:CashEquivalentsUnrealizedHoldingLosses contextRef="c-3" decimals="0" id="f-341" unitRef="usd">0</ovid:CashEquivalentsUnrealizedHoldingLosses>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-3" decimals="0" id="f-342" unitRef="usd">70759866</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-3" decimals="0" id="f-343" unitRef="usd">24888936</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-3" decimals="0" id="f-344" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-3" decimals="0" id="f-345" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-3" decimals="0" id="f-346" unitRef="usd">24888936</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ovid:CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost contextRef="c-3" decimals="0" id="f-347" unitRef="usd">96512192</ovid:CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost>
    <ovid:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingGain contextRef="c-3" decimals="0" id="f-348" unitRef="usd">5208</ovid:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingGain>
    <ovid:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingLoss contextRef="c-3" decimals="0" id="f-349" unitRef="usd">0</ovid:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingLoss>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-3" decimals="0" id="f-350" unitRef="usd">96517400</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="c-3" decimals="-5" id="f-351" unitRef="usd">40900000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:Cash contextRef="c-4" decimals="0" id="f-352" unitRef="usd">2853042</us-gaap:Cash>
    <us-gaap:Cash contextRef="c-4" decimals="0" id="f-353" unitRef="usd">2853042</us-gaap:Cash>
    <ovid:CashEquivalentsAmortizedCost contextRef="c-4" decimals="0" id="f-354" unitRef="usd">42014804</ovid:CashEquivalentsAmortizedCost>
    <ovid:CashEquivalentsUnrealizedHoldingGains contextRef="c-4" decimals="0" id="f-355" unitRef="usd">0</ovid:CashEquivalentsUnrealizedHoldingGains>
    <ovid:CashEquivalentsUnrealizedHoldingLosses contextRef="c-4" decimals="0" id="f-356" unitRef="usd">0</ovid:CashEquivalentsUnrealizedHoldingLosses>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-4" decimals="0" id="f-357" unitRef="usd">42014804</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-4" decimals="0" id="f-358" unitRef="usd">84175752</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-4" decimals="0" id="f-359" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-4" decimals="0" id="f-360" unitRef="usd">42187</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-4" decimals="0" id="f-361" unitRef="usd">84133565</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ovid:CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost contextRef="c-4" decimals="0" id="f-362" unitRef="usd">129043598</ovid:CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost>
    <ovid:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingGain contextRef="c-4" decimals="0" id="f-363" unitRef="usd">0</ovid:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingGain>
    <ovid:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingLoss contextRef="c-4" decimals="0" id="f-364" unitRef="usd">42187</ovid:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingLoss>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-4" decimals="0" id="f-365" unitRef="usd">129001411</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss contextRef="c-1" decimals="0" id="f-366" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss contextRef="c-5" decimals="0" id="f-367" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss contextRef="c-6" decimals="0" id="f-368" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss contextRef="c-7" decimals="0" id="f-369" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock contextRef="c-1" id="f-370">PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS&lt;div style="margin-top:6pt;text-align:justify;text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;June 30,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;1,444,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;1,423,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;306,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;306,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;(795,132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;(581,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;955,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;1,147,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense was $105,292 and $54,631 for the three months ended June&#160;30, 2023 and 2022, respectively. Depreciation expense was $213,751 and $85,470 for the six months ended June&#160;30, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net of accumulated amortization, were $263,367 and $222,100 as of June&#160;30, 2023 and December&#160;31, 2022, respectively, and are included in other assets. Amortization expense was $32,180 and $32,153 for the &lt;/span&gt;&lt;/div&gt;three months ended June&#160;30, 2023 and 2022, respectively. Amortization expense was $68,370 and $86,636 for the six months ended June&#160;30, 2023 and 2022, respectively.</us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-371">&lt;div style="margin-top:6pt;text-align:justify;text-indent:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;June 30,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;1,444,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;1,423,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;306,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;306,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;(795,132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;(581,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;955,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;1,147,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-68" decimals="0" id="f-372" unitRef="usd">1444389</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-69" decimals="0" id="f-373" unitRef="usd">1423032</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-70" decimals="0" id="f-374" unitRef="usd">306312</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-71" decimals="0" id="f-375" unitRef="usd">306312</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-3" decimals="0" id="f-376" unitRef="usd">795132</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="0" id="f-377" unitRef="usd">581381</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="0" id="f-378" unitRef="usd">955569</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="0" id="f-379" unitRef="usd">1147963</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c-5" decimals="0" id="f-380" unitRef="usd">105292</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-6" decimals="0" id="f-381" unitRef="usd">54631</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-1" decimals="0" id="f-382" unitRef="usd">213751</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-7" decimals="0" id="f-383" unitRef="usd">85470</us-gaap:Depreciation>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-3" decimals="0" id="f-384" unitRef="usd">263367</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-4" decimals="0" id="f-385" unitRef="usd">222100</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-5" decimals="0" id="f-386" unitRef="usd">32180</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-6" decimals="0" id="f-387" unitRef="usd">32153</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="0" id="f-388" unitRef="usd">68370</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-7" decimals="0" id="f-389" unitRef="usd">86636</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-390">LEASES&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During September 2021, the Company entered into a 10-year lease agreement for its corporate headquarters with a term commencing March 10, 2022, for approximately 19,000 square feet of office space at Hudson Commons in New York, New York. The lease provides for monthly rental payments over the lease term. The base rent under the lease is currently $2.3&#160;million per year. Rent payments commenced 10 months following the commencement date of the lease, or January 10, 2023, and continue for 10 years following the rent commencement date. The Company issued a letter of credit in the amount of $1.9&#160;million in association with the execution of the lease agreement; the letter of credit is characterized as restricted cash on the Company's condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Hudson Commons lease has a remaining lease term of approximately 10 years and includes a single renewal option for an additional five years. The Company did not include the renewal option in the lease term when calculating the lease liability as the Company is not reasonably certain that it will exercise the renewal option. The present value of the lease payments is calculated using an incremental borrowing rate of 7.02%. Lease expense is included in general and administrative and research and development expenses in the condensed consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU asset and lease liabilities related to the Company's operating lease are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;June 30,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;Right-of-use asset, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;14,412,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;Current lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;944,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;Long-term lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;15,389,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of operating lease cost for the six months ended June&#160;30, 2023 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,083,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum commitments under the non-cancelable operating lease are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;898,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,316,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,316,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,316,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,316,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,347,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,511,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-72" id="f-391">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LandSubjectToGroundLeases contextRef="c-3" decimals="-3" id="f-392" unitRef="sqft">19000</us-gaap:LandSubjectToGroundLeases>
    <ovid:LesseeOperatingLeaseBaseRent contextRef="c-3" decimals="-5" id="f-393" unitRef="usd">2300000</ovid:LesseeOperatingLeaseBaseRent>
    <ovid:LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod contextRef="c-73" id="f-394">P10M</ovid:LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-72" id="f-395">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:RestrictedCash contextRef="c-74" decimals="-5" id="f-396" unitRef="usd">1900000</us-gaap:RestrictedCash>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c-3" id="f-397">P10Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-3" id="f-398">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <ovid:LeaseIncrementalBorrowingRate contextRef="c-3" decimals="4" id="f-399" unitRef="number">0.0702</ovid:LeaseIncrementalBorrowingRate>
    <ovid:RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock contextRef="c-1" id="f-400">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU asset and lease liabilities related to the Company's operating lease are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;June 30,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;Right-of-use asset, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;14,412,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;Current lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;944,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;Long-term lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;15,389,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ovid:RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="0" id="f-401" unitRef="usd">14412068</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="0" id="f-402" unitRef="usd">944943</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="0" id="f-403" unitRef="usd">15389567</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-404">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of operating lease cost for the six months ended June&#160;30, 2023 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,083,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="0" id="f-405" unitRef="usd">1083617</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-1" decimals="0" id="f-406" unitRef="usd">0</us-gaap:VariableLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-1" decimals="0" id="f-407" unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-408">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum commitments under the non-cancelable operating lease are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;898,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,316,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,316,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,316,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,316,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,347,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,511,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c-3" decimals="0" id="f-409" unitRef="usd">898709</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-3" decimals="0" id="f-410" unitRef="usd">2316303</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-3" decimals="0" id="f-411" unitRef="usd">2316303</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-3" decimals="0" id="f-412" unitRef="usd">2316303</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-3" decimals="0" id="f-413" unitRef="usd">2316303</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <ovid:LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour contextRef="c-3" decimals="0" id="f-414" unitRef="usd">12347235</ovid:LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-3" decimals="0" id="f-415" unitRef="usd">22511156</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c-1" id="f-416">ACCRUED EXPENSES&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payroll and bonus accrual&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,996,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,233,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development accrual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,972,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;395,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Professional fees accrual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;401,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;682,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;192,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,433,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,504,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-417">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payroll and bonus accrual&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,996,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,233,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development accrual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,972,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;395,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Professional fees accrual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;401,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;682,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;192,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,433,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,504,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-3" decimals="0" id="f-418" unitRef="usd">2996003</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="0" id="f-419" unitRef="usd">3233802</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <ovid:AccruedResearchAndDevelopment contextRef="c-3" decimals="0" id="f-420" unitRef="usd">1972801</ovid:AccruedResearchAndDevelopment>
    <ovid:AccruedResearchAndDevelopment contextRef="c-4" decimals="0" id="f-421" unitRef="usd">395247</ovid:AccruedResearchAndDevelopment>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-3" decimals="0" id="f-422" unitRef="usd">401099</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-4" decimals="0" id="f-423" unitRef="usd">682664</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-3" decimals="0" id="f-424" unitRef="usd">63387</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="0" id="f-425" unitRef="usd">192956</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="0" id="f-426" unitRef="usd">5433290</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="0" id="f-427" unitRef="usd">4504669</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-428">STOCKHOLDERS&#x2019; EQUITY&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s capital structure consists of common stock and convertible preferred stock. Pursuant to the Company&#x2019;s amended and restated certificate of incorporation, as amended, the Company is authorized to issue up to 125,000,000 shares of common stock and 10,000,000 shares of preferred stock. The Company has designated 1,250 of the 10,000,000 authorized shares of preferred stock as non-voting Series A Convertible Preferred Stock (&#x201c;Series A Preferred Stock&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The holders of common stock are entitled to one vote for each share held. The holders of common stock have no preemptive or other subscription rights, and there are no redemption or sinking fund provisions with respect to such shares. Subject to preferences that may apply to any outstanding series of preferred stock, holders of the common stock are entitled to receive ratably any dividends declared on a non-cumulative basis. The common stock is subordinate to all series of preferred stock with respect to rights upon liquidation, winding up and dissolution of the Company. The holders of common stock are entitled to liquidation proceeds after all liquidation preferences for the preferred stock are satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were 1,250 shares of Series A Preferred Stock outstanding as of June&#160;30, 2023 and December&#160;31, 2022. Each share of Series A Preferred Stock is convertible into 1,000 shares of common stock at any time at the holder&#x2019;s option. However, the holder will be prohibited, subject to certain exceptions, from converting shares of Series A Preferred Stock into shares of common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than, at the written election of the holder, either 9.99% or 14.99% of the total number of shares of common stock then issued and outstanding, which percentage may be changed at the holder&#x2019;s election to any other number less than or equal to 19.99% upon 61 days&#x2019; notice to the Company; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;provided, however,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; that effective 61 days after delivery of such notice, such beneficial ownership limitations shall not be applicable to any holder that beneficially owns either 10.0% or 15.0%, as applicable based on the holder&#x2019;s initial written election noted above, of the total number of shares of common stock issued and outstanding immediately prior to delivery of such notice. In the event of a liquidation, dissolution, or winding up of the Company, holders of Series A Preferred Stock will receive a payment equal to $0.001 per share of Series A Preferred Stock before any proceeds are distributed to the holders of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020, the Company entered into a sales agreement (the &#x201c;2020 ATM agreement&#x201d;) with Cowen and Company, LLC (&#x201c;Cowen&#x201d;), under which the Company may offer and sell in &#x201c;at the market offerings,&#x201d; from time to time at its sole discretion, shares of its common stock having an aggregate offering price of up to $75.0&#160;million through Cowen acting as sales agent. As of June&#160;30, 2023, the Company has not sold any shares of its common stock under the 2020 ATM agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Dividends&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Through June&#160;30, 2023, the Company has not declared any dividends. No dividends on the common stock shall be declared and paid unless dividends on the preferred stock have been declared and paid.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-429" unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-430" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-75"
      decimals="INF"
      id="f-431"
      unitRef="shares">1250</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-432" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <ovid:CommonStockNumberOfVotesForEachShare contextRef="c-1" decimals="0" id="f-433" unitRef="vote">1</ovid:CommonStockNumberOfVotesForEachShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-75"
      decimals="INF"
      id="f-434"
      unitRef="shares">1250</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-76"
      decimals="INF"
      id="f-435"
      unitRef="shares">1250</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="c-75"
      decimals="INF"
      id="f-436"
      unitRef="shares">1000</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <ovid:MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates contextRef="c-77" decimals="4" id="f-437" unitRef="number">0.0999</ovid:MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates>
    <ovid:MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders contextRef="c-77" decimals="4" id="f-438" unitRef="number">0.1499</ovid:MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders>
    <ovid:AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates contextRef="c-77" decimals="4" id="f-439" unitRef="number">0.1999</ovid:AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates>
    <ovid:AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod contextRef="c-77" id="f-440">P61D</ovid:AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod>
    <ovid:AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod contextRef="c-77" id="f-441">P61D</ovid:AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod>
    <ovid:BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock contextRef="c-78" decimals="3" id="f-442" unitRef="number">0.100</ovid:BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock>
    <ovid:BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock contextRef="c-79" decimals="3" id="f-443" unitRef="number">0.150</ovid:BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="c-75"
      decimals="3"
      id="f-444"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockLiquidationPreference>
    <ovid:AggregateOfferingPriceOfCommonStock contextRef="c-80" decimals="-5" id="f-445" unitRef="usd">75000000</ovid:AggregateOfferingPriceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-81"
      decimals="INF"
      id="f-446"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:Dividends contextRef="c-1" decimals="INF" id="f-447" unitRef="usd">0</us-gaap:Dividends>
    <us-gaap:Dividends contextRef="c-1" decimals="INF" id="f-448" unitRef="usd">0</us-gaap:Dividends>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-449">STOCK-BASED COMPENSATION&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's Board of Directors adopted, and the Company's stockholders approved, the 2017 Equity Incentive Plan (&#x201c;2017 Plan&#x201d;), which became effective on May 4, 2017. The initial reserve of shares of common stock issuable under the 2017 Plan was 3,052,059 shares. The 2017 Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance-based stock awards, and other forms of stock-based awards. Additionally, the 2017 Plan provides for the grant of performance cash awards. The Company's employees, officers, directors, consultants and advisors are eligible to receive awards under the 2017 Plan. Following the adoption of the 2017 Plan, no further awards will be granted under the Company&#x2019;s prior plan. Pursuant to the terms of the 2017 Plan, on each January 1st, the plan limit shall be increased by the lesser of (x) 5% of the number of shares of common stock outstanding as of the immediately preceding December 31 and (y) such lesser number as the Board of Directors may determine at its discretion. On January&#160;1, 2023 and January&#160;1, 2022 an additional 3,523,344 and 1,000,000 shares, respectively, were reserved for issuance under the 2017 Plan. As of June&#160;30, 2023, there were 4,131,738 shares of the Company&#x2019;s common stock reserved and available for issuance under the 2017 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's Board of Directors adopted, and the Company's stockholders approved, the 2017 Employee Stock Purchase Plan (&#x201c;2017 ESPP&#x201d;), which became effective on May 4, 2017. The initial reserve of shares of common stock  issuable under the 2017 ESPP was 279,069 shares. The 2017 ESPP allows employees to purchase common stock of the Company at a 15% discount to the market price on designated semi-annual purchase dates. During the three months ended June&#160;30, 2023 and 2022, there were no shares purchased under the 2017 ESPP, and the Company recorded expense of $13,446 and $20,176, respectively. During the six months ended June&#160;30, 2023 and 2022, 29,830 and 38,583 shares, respectively, were purchased under the 2017 ESPP, and the Company recorded expenses of $28,600 and $41,195, respectively. The number of shares of common stock reserved for issuance under the 2017 ESPP automatically increases &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on January 1 of each year, beginning on January 1, 2018 and continuing through and including January 1, 2027, by the lesser of (i) 1% of the total number of shares of the Company&#x2019;s common stock outstanding on December 31 of the preceding calendar year, (ii) 550,000 shares or (iii) such lesser number of shares determined by the Board. The Board acted prior to each of January&#160;1, 2023 and January&#160;1, 2022 to provide that there be no increase in the number of shares reserved for issuance under the 2017 ESPP on either such date. As of June&#160;30, 2023, there were 386,777 shares of the Company&#x2019;s common stock reserved and available for issuance under the 2017 ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company&#x2019;s Board of Directors adopted and the Company&#x2019;s stockholder&#x2019;s approved the 2014 Equity Incentive Plan (&#x201c;2014 Plan&#x201d;), which authorized the Company to grant shares of common stock in the form of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock and restricted stock units. The 2014 Plan was terminated as to future awards in May 2017, although it continues to govern the terms of options that remain outstanding under the 2014 Plan. No additional stock awards will be granted under the 2014 Plan, and all outstanding stock awards granted under the 2014 Plan that are repurchased, forfeited, expire or are cancelled will become available for grant under the 2017 Plan in accordance with its terms. As of June&#160;30, 2023, options to purchase 1,663,597 shares of common stock were outstanding under the 2014 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless specified otherwise in an individual option agreement, stock options granted under the prior plan and the 2017 Plan generally have a ten-year term and a four-year graded vesting period. The vesting requirement is generally conditioned upon the grantee&#x2019;s continued service with the Company during the vesting period. Once vested, all options granted are exercisable from the date of grant until they expire. The option grants are non-transferable. Vested options generally remain exercisable for 90 days subsequent to the termination of the option holder&#x2019;s service with the Company. In the event of the option holder&#x2019;s death or disability while employed by or providing service to the Company, the exercisable period extends to 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Performance-based option awards generally have similar terms, with vesting commencing on the date the performance condition is achieved and expire in accordance with the specific terms of the agreement. At June&#160;30, 2023, there were no performance-based options outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of options granted during the three and six months ended June&#160;30, 2023 and 2022 was estimated using the Black-Scholes option valuation model. The inputs for the Black-Scholes option valuation model require significant assumptions that are detailed in the table below. The risk-free interest rates were based on the rate for U.S. Treasury securities at the date of grant with maturity dates approximately equal to the expected life at the grant date. The expected life was based on the simplified method in accordance with the SEC Staff Accounting Bulletin No. Topic 14D. Beginning in January 1, 2023, the expected volatility was estimated based on historical volatility information of the Company since the Company's initial public offering.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All assumptions used to calculate the grant date fair value of nonemployee options are generally consistent with the assumptions used for options granted to employees. In the event the Company terminates any of its consulting agreements, the unvested options underlying the agreements would also be canceled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company granted 50,000 stock options to nonemployee consultants for services rendered during the three and six months ended June&#160;30, 2023 and no stock options during the three and six months ended June 30, 2022. There were 130,834 unvested nonemployee options outstanding as of June&#160;30, 2023 and 2022. Total expense recognized related to nonemployee stock options for the three months ended June&#160;30, 2023 and 2022 was $163,199 and $160,337, respectively. Total expense recognized related to nonemployee stock options for the six months ended June&#160;30, 2023 and 2022, was $271,784 and $355,107, respectively. Total unrecognized compensation expenses related to the nonemployee stock options was $994,411 as of June&#160;30, 2023. The Company did not recognize any expense for nonemployee performance-based option awards during the six months ended June&#160;30, 2023 or 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company granted 270,000 and 2,426,750 stock options to employees during the three months ended June&#160;30, 2023 and 2022, respectively. The Company granted 2,950,500 and 4,296,355 stock options to employees during the six months ended June&#160;30, 2023 and 2022, respectively. There were 6,710,485 and 7,354,964 unvested employee options outstanding as of June&#160;30, 2023, and 2022, respectively. Total expense recognized related to the employee stock options for the three months ended June&#160;30, 2023 and 2022 was $1.8&#160;million and $1.5&#160;million, respectively. Total expense recognized related to the employee stock options for the six months ended June&#160;30, 2023 and 2022 was $3.6 million and $2.6 million, respectively. Total unrecognized compensation expense related to employee stock options was $12.8 million as of June&#160;30, 2023. No expense for employee performance-based options was recognized during the six months ended in June&#160;30, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s stock-based compensation expense was recognized in operating expenses as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.606%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.433%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.433%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.433%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.693%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;Six Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;579,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;387,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;1,090,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;782,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;1,368,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;1,332,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;2,774,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;2,262,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;1,948,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;1,720,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;3,865,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;3,045,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.606%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.433%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.433%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.433%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.693%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;Six Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,935,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,700,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,836,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,003,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,948,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,720,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,865,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,045,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of employee options granted during the three and six months ended June&#160;30, 2023 and 2022 was estimated utilizing the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.757%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.779%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.665%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.591%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.665%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.432%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.665%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.432%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;Six Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;84.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;87.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;84.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;87.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;6.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;3.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;2.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;3.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;2.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;Fair value of option on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;2.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;2.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;1.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;2.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of non-employee options granted during the three and six months ended June&#160;30, 2023 and 2022 was estimated utilizing the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.050%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.547%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.076%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.936%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;Six Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;83.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;83.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;5.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 7pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 8.02pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;5.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 7pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;3.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;3.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;Fair value of option on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;2.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;2.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the number of options outstanding and the weighted average exercise price:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life in Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,961,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91,078)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(421,825)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,448,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,854,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and exercisable at June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,607,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,406,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At June&#160;30, 2023 there was approximately $13.8 million of unrecognized stock&#x2013;based compensation expense related to employee and nonemployee grants, which is expected to be recognized over a remaining average vesting period of 2.43 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-82"
      decimals="INF"
      id="f-450"
      unitRef="shares">3052059</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="c-83"
      decimals="INF"
      id="f-451"
      unitRef="number">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-84"
      decimals="INF"
      id="f-452"
      unitRef="shares">3523344</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-85"
      decimals="INF"
      id="f-453"
      unitRef="shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-86"
      decimals="INF"
      id="f-454"
      unitRef="shares">4131738</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-87"
      decimals="INF"
      id="f-455"
      unitRef="shares">279069</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate contextRef="c-88" decimals="2" id="f-456" unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="c-89"
      decimals="INF"
      id="f-457"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="c-90"
      decimals="INF"
      id="f-458"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-89" decimals="0" id="f-459" unitRef="usd">13446</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-90" decimals="0" id="f-460" unitRef="usd">20176</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="c-88"
      decimals="INF"
      id="f-461"
      unitRef="shares">29830</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="c-91"
      decimals="INF"
      id="f-462"
      unitRef="shares">38583</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-88" decimals="0" id="f-463" unitRef="usd">28600</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-91" decimals="0" id="f-464" unitRef="usd">41195</us-gaap:AllocatedShareBasedCompensationExpense>
    <ovid:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease contextRef="c-88" decimals="2" id="f-465" unitRef="number">0.01</ovid:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease>
    <ovid:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum
      contextRef="c-88"
      decimals="INF"
      id="f-466"
      unitRef="shares">550000</ovid:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-92"
      decimals="INF"
      id="f-467"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-93"
      decimals="INF"
      id="f-468"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-94"
      decimals="INF"
      id="f-469"
      unitRef="shares">386777</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-95"
      decimals="INF"
      id="f-470"
      unitRef="shares">1663597</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-83" id="f-471">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-83" id="f-472">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-83" id="f-473">P90D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-96" id="f-474">P12M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="c-97"
      decimals="INF"
      id="f-475"
      unitRef="shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-98"
      decimals="INF"
      id="f-476"
      unitRef="shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-99"
      decimals="INF"
      id="f-477"
      unitRef="shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-100"
      decimals="INF"
      id="f-478"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-101"
      decimals="INF"
      id="f-479"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="c-102"
      decimals="INF"
      id="f-480"
      unitRef="shares">130834</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-98" decimals="0" id="f-481" unitRef="usd">163199</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-100" decimals="0" id="f-482" unitRef="usd">160337</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-99" decimals="0" id="f-483" unitRef="usd">271784000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-101" decimals="0" id="f-484" unitRef="usd">355107000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-102" decimals="0" id="f-485" unitRef="usd">994411</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-103" decimals="INF" id="f-486" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-104" decimals="INF" id="f-487" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-105"
      decimals="INF"
      id="f-488"
      unitRef="shares">270000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-106"
      decimals="INF"
      id="f-489"
      unitRef="shares">2426750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-107"
      decimals="INF"
      id="f-490"
      unitRef="shares">2950500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-108"
      decimals="INF"
      id="f-491"
      unitRef="shares">4296355</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="c-109"
      decimals="INF"
      id="f-492"
      unitRef="shares">6710485</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="c-110"
      decimals="INF"
      id="f-493"
      unitRef="shares">7354964</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-105" decimals="-5" id="f-494" unitRef="usd">1800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-106" decimals="-5" id="f-495" unitRef="usd">1500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-107" decimals="-5" id="f-496" unitRef="usd">3600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-108" decimals="-5" id="f-497" unitRef="usd">2600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-109" decimals="-5" id="f-498" unitRef="usd">12800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-111" decimals="INF" id="f-499" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-112" decimals="INF" id="f-500" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-501">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s stock-based compensation expense was recognized in operating expenses as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.606%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.433%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.433%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.433%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.693%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;Six Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;579,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;387,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;1,090,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;782,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;1,368,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;1,332,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;2,774,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;2,262,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;1,948,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;1,720,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;3,865,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;3,045,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-113" decimals="0" id="f-502" unitRef="usd">579917</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-114" decimals="0" id="f-503" unitRef="usd">387384</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-115" decimals="0" id="f-504" unitRef="usd">1090177</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-116" decimals="0" id="f-505" unitRef="usd">782876</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-117" decimals="0" id="f-506" unitRef="usd">1368731</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-118" decimals="0" id="f-507" unitRef="usd">1332833</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-119" decimals="0" id="f-508" unitRef="usd">2774988</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-120" decimals="0" id="f-509" unitRef="usd">2262153</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-5" decimals="0" id="f-510" unitRef="usd">1948648</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-6" decimals="0" id="f-511" unitRef="usd">1720217</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="0" id="f-512" unitRef="usd">3865165</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-7" decimals="0" id="f-513" unitRef="usd">3045029</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="c-1" id="f-514">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.606%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.433%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.433%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.433%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.693%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;Six Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,935,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,700,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,836,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,003,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,948,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,720,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,865,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,045,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-121" decimals="0" id="f-515" unitRef="usd">1935202</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-122" decimals="0" id="f-516" unitRef="usd">1700041</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-123" decimals="0" id="f-517" unitRef="usd">3836565</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-124" decimals="0" id="f-518" unitRef="usd">3003834</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-125" decimals="0" id="f-519" unitRef="usd">13446</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-126" decimals="0" id="f-520" unitRef="usd">20176</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-127" decimals="0" id="f-521" unitRef="usd">28600</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-128" decimals="0" id="f-522" unitRef="usd">41195</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-5" decimals="0" id="f-523" unitRef="usd">1948648</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-6" decimals="0" id="f-524" unitRef="usd">1720217</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="0" id="f-525" unitRef="usd">3865165</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-7" decimals="0" id="f-526" unitRef="usd">3045029</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-527">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of employee options granted during the three and six months ended June&#160;30, 2023 and 2022 was estimated utilizing the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.757%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.779%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.665%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.591%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.665%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.432%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.665%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.432%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;Six Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;84.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;87.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;84.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;87.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;6.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;3.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;2.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;3.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;2.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;Fair value of option on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;2.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;2.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;1.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;2.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of non-employee options granted during the three and six months ended June&#160;30, 2023 and 2022 was estimated utilizing the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.050%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.547%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.076%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.936%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;Six Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;83.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;83.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;5.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 7pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 8.02pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;5.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 7pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 8.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;3.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;3.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;Fair value of option on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;2.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;2.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-105" decimals="4" id="f-528" unitRef="number">0.8411</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-106" decimals="4" id="f-529" unitRef="number">0.8720</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-107" decimals="4" id="f-530" unitRef="number">0.8456</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-108" decimals="4" id="f-531" unitRef="number">0.8720</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-105" id="f-532">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-106" id="f-533">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-107" id="f-534">P6Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-108" id="f-535">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-105" decimals="4" id="f-536" unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-106" decimals="4" id="f-537" unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-107" decimals="4" id="f-538" unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-108" decimals="4" id="f-539" unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-105" decimals="4" id="f-540" unitRef="number">0.0363</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-106" decimals="4" id="f-541" unitRef="number">0.0278</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-107" decimals="4" id="f-542" unitRef="number">0.0397</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-108" decimals="4" id="f-543" unitRef="number">0.0216</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-105"
      decimals="2"
      id="f-544"
      unitRef="usdPerShare">2.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-106"
      decimals="2"
      id="f-545"
      unitRef="usdPerShare">2.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-107"
      decimals="2"
      id="f-546"
      unitRef="usdPerShare">1.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-108"
      decimals="2"
      id="f-547"
      unitRef="usdPerShare">2.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-98" decimals="4" id="f-548" unitRef="number">0.8300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-100" decimals="4" id="f-549" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-99" decimals="4" id="f-550" unitRef="number">0.8300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-101" decimals="4" id="f-551" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-98" id="f-552">P5Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-100" id="f-553">P0Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-99" id="f-554">P5Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-101" id="f-555">P0Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-98" decimals="4" id="f-556" unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-100" decimals="4" id="f-557" unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-99" decimals="4" id="f-558" unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-101" decimals="4" id="f-559" unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-98" decimals="4" id="f-560" unitRef="number">0.0389</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-100" decimals="4" id="f-561" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-99" decimals="4" id="f-562" unitRef="number">0.0389</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-101" decimals="4" id="f-563" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-98"
      decimals="2"
      id="f-564"
      unitRef="usdPerShare">2.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-100"
      decimals="2"
      id="f-565"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-99"
      decimals="2"
      id="f-566"
      unitRef="usdPerShare">2.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-101"
      decimals="2"
      id="f-567"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-568">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the number of options outstanding and the weighted average exercise price:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life in Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,961,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91,078)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(421,825)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,448,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,854,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and exercisable at June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,607,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,406,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="INF" id="f-569" unitRef="shares">12961238</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-570"
      unitRef="usdPerShare">4.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-129" id="f-571">P7Y5M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-4" decimals="0" id="f-572" unitRef="usd">62158</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-573" unitRef="shares">3000500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-574"
      unitRef="usdPerShare">2.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <ovid:ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife contextRef="c-1" id="f-575">P9Y8M8D</ovid:ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-576" unitRef="shares">91078</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-577"
      unitRef="usdPerShare">2.52</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="c-1" decimals="INF" id="f-578" unitRef="shares">421825</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-579"
      unitRef="usdPerShare">3.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-3" decimals="INF" id="f-580" unitRef="shares">15448835</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-581"
      unitRef="usdPerShare">3.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-582">P7Y4M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-3" decimals="0" id="f-583" unitRef="usd">5854085</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="c-3" decimals="INF" id="f-584" unitRef="shares">8607516</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-585"
      unitRef="usdPerShare">4.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-586">P6Y2M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="c-3" decimals="0" id="f-587" unitRef="usd">2406178</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-3" decimals="-5" id="f-588" unitRef="usd">13800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-1" id="f-589">P2Y5M4D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-590">INCOME TAXES&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s interim income tax provision consists of U.S. federal and state income taxes based on the estimated annual effective tax rate that the Company expects for the full year together with the tax effect of discrete items. Each quarter the Company updates its estimate of the annual effective tax rate and records cumulative adjustments as necessary. As of June&#160;30, 2023, the Company was in a pre-tax loss position, and is anticipated to remain so throughout the year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the six months ended June&#160;30, 2023, the Company did not record any tax benefit or expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In assessing the realizability of deferred tax assets, management evaluates whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in those periods in which temporary differences become deductible and/or net operating losses can be utilized. Management assesses all positive and negative evidence when determining the amount of the net deferred tax assets that are more likely than not to be realized. This evidence includes, but is not limited to, prior earnings history, scheduled reversal of taxable temporary differences, tax planning strategies and projected future taxable income. Significant weight is given to positive and negative evidence that is objectively verifiable. Based on these factors, including cumulative losses in recent years, the Company continues to maintain a full valuation allowance against its net deferred tax assets as of June&#160;30, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-591" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-592">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Northwestern University License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2016, the Company entered into a license agreement with Northwestern University, (&#x201c;Northwestern&#x201d;), pursuant to which Northwestern granted the Company an exclusive, worldwide license to patent rights of certain inventions (&#x201c;Northwestern Patent Rights&#x201d;) which relate to a specific compound and related methods of use for such compound, along with certain Know-How related to the practice of the inventions claimed in the Northwestern Patents. The Company is developing OV329 under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Northwestern agreement, the Company was granted exclusive rights to research, develop, manufacture and commercialize products utilizing the Northwestern Patent Rights for all uses. The Company has agreed that it will not use the Northwestern Patent Rights to develop any products for the treatment of cancer, but Northwestern may not grant rights in the technology to others for use in cancer. The Company also has an option, exercisable during the term of the agreement to an exclusive license under certain intellectual property rights covering novel compounds with the same or similar mechanism of action as the primary compound that is the subject of the license agreement. Northwestern has retained the right, on behalf of itself and other non-profit institutions, to use the Northwestern Patent Rights and practice the inventions claimed therein for educational and research purposes and to publish information about the inventions covered by the Northwestern Patent Rights. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon entry into the Northwestern agreement, the Company paid an upfront non-creditable one-time license issuance fee of $75,000, and is required to pay an annual license maintenance fee of $20,000, which will be creditable against any royalties payable to Northwestern following first commercial sale of licensed products under the agreement. The Company is responsible for all ongoing costs of filing, prosecuting and maintaining the Northwestern Patents, but also has the right to control such activities using its own patent counsel. In consideration for the rights granted to the Company under the Northwestern agreement, the Company is required to pay to Northwestern up to an aggregate of $5.3&#160;million upon the achievement of certain development and regulatory milestones for the first product covered by the Northwestern Patents, and upon commercialization of any such products, will be required to pay to Northwestern a tiered royalty on net sales of such products by the Company, its affiliates or sublicensees, at percentages in the low to mid-single-digits, subject to standard reductions and offsets. The Company&#x2019;s royalty obligations continue on a product-by-product and country-by-country basis until the later of the expiration of the last-to-expire valid claim in a licensed patent covering the applicable product in such country and 10 years following the first commercial sale of such product in such country. If the Company sublicenses a Northwestern Patent Right, it will be obligated to pay to Northwestern a specified percentage of sublicense revenue received by the Company, ranging from the high single digits to the low-teens. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Northwestern agreement requires that the Company use commercially reasonable efforts to develop and commercialize at least one product that is covered by the Northwestern Patent Rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the Northwestern agreement will remain in force until the expiration of the Company&#x2019;s payment obligations thereunder. The Company has the right to terminate the agreement for any reason upon prior written notice or for an uncured material breach by Northwestern. Northwestern may terminate the agreement for the Company&#x2019;s uncured material breach or insolvency.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AstraZeneca AB License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 30, 2021, the Company entered into an exclusive license agreement with AstraZeneca AB (&#x201c;AstraZeneca&#x201d;), for a library of early-stage small molecules targeting the KCC2 transporter, including lead candidate OV350. Upon execution of the agreement, the Company was obligated to pay an upfront cash payment of $5.0&#160;million and issued shares of the Company's common stock in an amount that equaled $7.3&#160;million based on the volume-weighted average price of shares of the Company's common stock for the 30 business days immediately preceding the execution date of the transaction. Since the intangibles acquired in the AstraZeneca license agreement do not have an alternative future use, all costs incurred were treated as research and development expense. The Company recorded a total of $12.3&#160;million as research and development expense related to this agreement during December 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the AstraZeneca license agreement, the Company agreed to potential milestone payments of up to $203.0&#160;million upon the achievement of certain developmental, regulatory and sales milestones. The first payment of $3.0&#160;million is due upon the successful completion of the first Phase 2 clinical study of a licensed product following a positive biomarker readout in a Phase 1 clinical study.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gensaic Collaboration and Option Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, the Company entered into a collaboration and option agreement (&#x201c;Collaboration Agreement&#x201d;) with Gensaic. The Collaboration Agreement involves the research and development of phage-derived particle (&#x201c;PDP&#x201d;) products on Gensaic's proprietary platform for certain central nervous system rare disorder targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Collaboration Agreement, Gensaic grants the Company an exclusive option to obtain an exclusive license with respect to certain identified lead PDP products, which are exercisable at any time prior to the expiration of the option period. Once a product is identified by the Company that demonstrates sufficient efficacy, the Company may exercise its option with respect to the specific research program for that PDP product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company shall reimburse Gensaic for Gensaic's research costs related to the specific research plan for PDP products identified, the research plan and budget shall be mutually agreed upon by the parties and shall not exceed $3.0&#160;million in any research year. The Company will record these reimbursement payments as research and development costs in the period the research costs are incurred. In May 2023, the Company identified a lead PDP candidate for further research and provided $3.5&#160;million to Gensaic to support the approved research plan and budget. The amount is included in prepaid expenses and other current assets in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a product is ultimately commercialized under this agreement, the Company shall make tiered royalty payments to Gensaic in the mid-single to low double-digit range based on the net sales of all licensed PDP products during the royalty term. The Company is also responsible for potential tiered milestone payments of up to $452.0&#160;million based upon the achievement of certain sales milestone events and developmental milestone approvals for three or more products. Gensaic also has the option to become a collaborative partner in the development and commercialization of PDP products in exchange for a fee based on a percentage of the costs incurred by the Company through the date Gensaic exercises its option. The Company would no longer be required to pay Gensaic royalty or milestone payments if Gensaic elects to exercise its option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may terminate this agreement by providing written notice to Gensaic 90 days in advance of the termination date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2023, none of these contingent payments were considered probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. The Company is not currently involved in any legal matters arising in the normal course of business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of their respective employment agreements, certain of our executive officers are eligible to receive severance payments and benefits upon a termination without &#x201c;cause&#x201d; or due to &#x201c;permanent disability,&#x201d; or upon &#x201c;resignation for good reason,&#x201d; contingent upon the executive officer&#x2019;s delivery to the Company of a satisfactory release of claims, and subject to the executive officer&#x2019;s compliance with non-competition and non-solicitation restrictive covenants.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ovid:UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment contextRef="c-130" decimals="-3" id="f-593" unitRef="usd">75000</ovid:UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment>
    <ovid:AnnualLicenseMaintenanceFeePayable contextRef="c-131" decimals="-3" id="f-594" unitRef="usd">20000</ovid:AnnualLicenseMaintenanceFeePayable>
    <ovid:ConsiderationPayableForRightsGrant contextRef="c-131" decimals="-5" id="f-595" unitRef="usd">5300000</ovid:ConsiderationPayableForRightsGrant>
    <ovid:RoyaltyObligationTerm contextRef="c-132" id="f-596">P10Y</ovid:RoyaltyObligationTerm>
    <ovid:MinimumNumberOfProductCoveredUnderLicenseAgreement
      contextRef="c-130"
      decimals="INF"
      id="f-597"
      unitRef="product">1</ovid:MinimumNumberOfProductCoveredUnderLicenseAgreement>
    <ovid:UpfrontCashPayment contextRef="c-133" decimals="-5" id="f-598" unitRef="usd">5000000</ovid:UpfrontCashPayment>
    <ovid:LicenseAgreementConsiderationSharesIssued
      contextRef="c-134"
      decimals="-5"
      id="f-599"
      unitRef="shares">7300000</ovid:LicenseAgreementConsiderationSharesIssued>
    <ovid:CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate contextRef="c-133" id="f-600">P30D</ovid:CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-135" decimals="-5" id="f-601" unitRef="usd">12300000</us-gaap:ResearchAndDevelopmentExpense>
    <ovid:LicenseAgreementMilestonePayments contextRef="c-134" decimals="-5" id="f-602" unitRef="usd">203000000</ovid:LicenseAgreementMilestonePayments>
    <ovid:FirstPaymentDueUponCompletionOfFirstPhase contextRef="c-136" decimals="-5" id="f-603" unitRef="usd">3000000</ovid:FirstPaymentDueUponCompletionOfFirstPhase>
    <ovid:CollaborationAndOptionAgreementResearchPlanAndBudgetExpectedCosts contextRef="c-137" decimals="-5" id="f-604" unitRef="usd">3000000</ovid:CollaborationAndOptionAgreementResearchPlanAndBudgetExpectedCosts>
    <ovid:CollaborationAndOptionAgreementResearchPlanAndBudgetExpectedCosts contextRef="c-138" decimals="-5" id="f-605" unitRef="usd">3500000</ovid:CollaborationAndOptionAgreementResearchPlanAndBudgetExpectedCosts>
    <ovid:LicenseAgreementMilestonePayments contextRef="c-139" decimals="-5" id="f-606" unitRef="usd">452000000</ovid:LicenseAgreementMilestonePayments>
    <ovid:LicenseAgreementDevelopmentMilestoneApprovalsProductThreshold
      contextRef="c-139"
      decimals="0"
      id="f-607"
      unitRef="product">3</ovid:LicenseAgreementDevelopmentMilestoneApprovalsProductThreshold>
    <ovid:LicenseAgreementTerminationAdvanceNoticePeriod contextRef="c-140" id="f-608">P90D</ovid:LicenseAgreementTerminationAdvanceNoticePeriod>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-609">COLLABORATION AND LICENSE AGREEMENTS&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Takeda Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 6, 2017, the Company entered into a license and collaboration agreement with Takeda under which the Company licensed from Takeda certain exclusive rights to develop and commercialize soticlestat in certain territories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, the Company entered into the RLT Agreement, pursuant to which Takeda secured rights to the Company&#x2019;s 50% global share in soticlestat, and the Company granted to Takeda an exclusive worldwide license under the Company&#x2019;s relevant intellectual property rights to develop and commercialize the investigational medicine soticlestat for the treatment of developmental and epileptic encephalopathies, including Dravet syndrome and Lennox-Gastaut syndrome.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the RLT Agreement, all rights in soticlestat were owned by Takeda or exclusively licensed to Takeda by the Company. Takeda assumed all responsibility for, and costs of, both development and commercialization of soticlestat, and the Company will no longer have any financial obligation to Takeda under the original collaboration agreement, including milestone payments or any future development and commercialization costs. On March 29, 2021 upon the closing of the RLT Agreement, the Company received an upfront payment of $196.0&#160;million and, if soticlestat is successfully developed, will be eligible to receive up to an additional $660.0&#160;million upon Takeda achieving developmental, regulatory and sales milestones. In addition, the Company will be entitled to receive tiered royalties beginning in the low double-digits, and up to 20% on sales of soticlestat if regulatory approval is achieved. Royalties will be payable on a country-by-country and product-by-product basis for any indications that soticlestat is approved for and sold during the period beginning on the date of the first commercial sale of such product in such country and ending on the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;later to occur of the expiration of patent rights covering the product in such country and a specified anniversary of such first commercial sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company identified the following material promises under the RLT Agreement: (1) no later than the second business day prior to the closing of the RLT Agreement (the &#x201c;Closing Date&#x201d;), the Company and Takeda were required to agree on an estimate of the development expenses that accrued, or would accrue, under the original collaboration agreement as of March 31, 2021; (2) on the Closing Date, the Company was required to (i) provide and transfer to Takeda the materials, information and data relating to the soticlestat program, including clinical trial data and results, as further set forth in the RLT Agreement, (ii) assign to Takeda certain agreements applicable to the soticlestat program, and (iii) assign to Takeda all of its right, title and interest in, to and under all intellectual property rights developed or created pursuant to the original collaboration agreement and owned jointly by the Company and Takeda as of the Closing Date; (3) within 45 days after March 31, 2021, the Company and Takeda were required to provide a written report to the finance officer designated by the other party setting forth a final total of the development expenses that accrued as of March 31, 2021 and, within 10 business days after receipt of such report, the finance officers shall agree on whether a net settlement payment is due from Takeda to the Company or from the Company to Takeda; and (4) within 75 days after the Closing Date, to the extent not provided on the Closing Date, Ovid shall provide to Takeda (i) any materials, information and data relating to the soticlestat program, including clinical trial data and results, as further set forth in the RLT Agreement, (ii) other documents (including all expired agreements and related data developed thereunder) to the extent relating to the soticlestat program that are necessary for the exploitation, development, commercialization and manufacture of soticlestat, as further set forth in the RLT Agreement and (iii) any tangible embodiment of the intellectual property rights controlled by Ovid that are reasonably necessary for, used in or held for use in Takeda&#x2019;s exploitation of the soticlestat program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined the transaction price is equal to the upfront fee of $196.0&#160;million and is associated with all four performance obligations identified above. It is noted that the incremental effort associated with performance obligations three and four is negligible and not material in the context of the RLT Agreement since all of the information is related to the collaboration period for which the Company already has the information readily available. Therefore, since they are not material in the context of the RLT Agreement, the full upfront fee was allocated to the two performance obligations satisfied at closing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June&#160;30, 2023, no expense was recognized pursuant to the RLT Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Healx License and Option Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 1, 2022, the Company entered an exclusive license option agreement (&#x201c;Healx License and Option Agreement&#x201d;) with Healx, Ltd. (&#x201c;Healx&#x201d;). Under the terms of the Healx License and Option Agreement, Healx has secured a one-year option to investigate gaboxadol (&#x201c;OV101&#x201d;) as part of a potential combination therapy for Fragile X syndrome in a Phase 1B/2A clinical trial, as well as a treatment for other indications, for an upfront payment of $0.5&#160;million, and fees to support prosecution and maintenance of our relevant intellectual property rights. At the end of the one-year option period, Healx has the option to secure rights to an exclusive license under the Company's relevant intellectual property rights, in exchange for an additional payment of $2.0&#160;million, development and commercial milestone payments, and low to mid-tier double digit royalties. On February 1, 2023, the Company granted an extension of the option period for up to four months for Healx to continue to investigate gaboxadol. Royalties are payable on a country-by-country and product-by-product basis during the period beginning on the date of the first commercial sale of such product in such country and ending on the later to occur of the expiration of patent rights covering the product in such country and a specified anniversary of such first commercial sale. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Healx will assume all responsibility for, and costs of, both development and commercialization of gaboxadol following the exercise of the option. The Company will retain the option to co-develop and co-commercialize the program with Healx (&#x201c;Ovid Opt-In Right&#x201d;) at the end of a positive readout of clinical Phase 2B and would share net profits and losses in lieu of the milestones and royalty payments. If the Ovid Opt-In Right were exercised, the Company would be required to pay Healx 50% of development costs. The Company does not plan to conduct further trials of gaboxadol. The term of the Healx License and Option Agreement will continue until the later of (a) the expiration of all relevant royalty terms, or in the event that Healx does not exercise its option during the option period defined in the Healx License and Option Agreement, or the Option Period, the expiration of such period, or (b) in the event that Healx does exercise its option during the Option Period, and the Company does not exercise the Ovid Opt-In Right during the period of time it has to opt-in, or the Opt-In Period, or the opt-in terms are otherwise terminated, upon the expiration of all payment obligations, or (c) in the event that Healx does exercise the Option during the Option Period, and the Company does exercise the Ovid Opt-In Right during the Opt-In Period, such time as neither Healx nor the Company is continuing to exploit gaboxadol. Further, if the Company exercises the Ovid Opt-In Right to co-develop and co-commercialize the program, it will owe a share of the net profit share to a third party with which it previously established a licensing agreement. If the Company does not exercise the Ovid Opt-In Right, it will owe the third party a share of all milestone and royalty payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 9, 2023, the Company entered into an amendment to the Healx License and Option Agreement whereby revisions were made to terms regarding the timing of the option exercise fee payable by Healx to the Company, the clinical and regulatory milestone payment structure, and the royalty payment structure. Additionally, the parties agreed that following the exercise of the option, Healx would assume direct responsibility for patent maintenance and prosecution and that the Company would transfer to Healx all supply obligations with respect to the active pharmaceutical ingredient and finished gaboxadol products and any related licensed technology and know-how in the Company's possession that is relevant to the manufacture of such licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;No revenue was recognized relating to this agreement during the six months ended June&#160;30, 2023. During the six months ended June&#160;30, 2022, the Company recorded revenue of $0.5&#160;million associated with the Healx License and Option Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Marinus Pharmaceuticals Out-License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 1, 2022, the Company entered into an exclusive patent license agreement with Marinus (&#x201c;Marinus License Agreement&#x201d;). Under the Marinus License Agreement, the Company granted Marinus an exclusive, non-transferable (except as expressly provided therein), royalty-bearing right and license under certain Ovid patents relating to ganaxolone to develop, make, have made, commercialize, promote, distribute, sell, offer for sale and import licensed products in the territory (which consist of the United States, the European Economic Area, United Kingdom and Switzerland) for the treatment of CDKL5 deficiency disorders. Following the date of regulatory approval by the FDA of the first licensed product in the territory which was received on March 18, 2022, Marinus issued, at the Company's option, 123,255 shares of Marinus common stock, par value $0.001 per share, as payment. The Marinus License Agreement also provides for payment of royalties from Marinus to the Company in single digits on net sales of each such licensed product sold.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded revenue and an associated investment in equity securities of approximately $0.9&#160;million related to the patent license agreement on March 18, 2022, based on the price of Marinus common stock on March 1, 2022. The Company had unrealized gains on the Marinus common stock of $0.8&#160;million and unrealized losses of $0.3&#160;million for the six months ended June&#160;30, 2023 and 2022, respectively, which were recorded as unrealized gains (losses) on equity securities and are reflected in other income (expense), net in the condensed consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Graviton License Agreement and Equity Purchase&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On April 30, 2023, the Company entered into a collaboration and license agreement with Graviton (&#x201c;Graviton Agreement&#x201d;), whereby it secured from Graviton an exclusive license to develop and commercialize Graviton's library of ROCK2 inhibitors including their lead program GV101 in rare central nervous system (&#x201c;CNS&#x201d;) disorders (excluding amyotrophic lateral sclerosis) worldwide (excluding China, Hong Kong, Macau and Taiwan). Under the Graviton Agreement, the Company and Graviton plan to investigate GV101 in cerebral cavernous malformations as well as Graviton's library of ROCK2 inhibitors in other rare CNS disorders. The Company will be responsible for all development and commercialization costs of the products. Should the Company receive regulatory approval and commercialize any of Graviton&#x2019;s ROCK2 inhibitors, it will pay Graviton tiered royalties on net sales ranging from the mid to high teens. As part of the Graviton Agreement, the Company also purchased shares of Graviton's preferred stock for $10.0&#160;million. The Company recorded the purchase of the preferred stock as a long-term equity investment on its condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-141" decimals="2" id="f-610" unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <ovid:UpfrontPaymentReceivable contextRef="c-142" decimals="-5" id="f-611" unitRef="usd">196000000</ovid:UpfrontPaymentReceivable>
    <ovid:AgreementMilestonePayments contextRef="c-142" decimals="-5" id="f-612" unitRef="usd">660000000</ovid:AgreementMilestonePayments>
    <ovid:AdditionalPaymentReceivableOnSalesPercentage contextRef="c-143" decimals="2" id="f-613" unitRef="number">0.20</ovid:AdditionalPaymentReceivableOnSalesPercentage>
    <ovid:UpFrontFeeAmount contextRef="c-144" decimals="-5" id="f-614" unitRef="usd">196000000</ovid:UpFrontFeeAmount>
    <ovid:LicenseAndCollaborationAgreementExpense contextRef="c-145" decimals="INF" id="f-615" unitRef="usd">0</ovid:LicenseAndCollaborationAgreementExpense>
    <ovid:UpFrontPayment contextRef="c-146" decimals="-5" id="f-616" unitRef="usd">500000</ovid:UpFrontPayment>
    <ovid:LicenseOptionAgreementDevelopmentAndCommercialMilestonePayments contextRef="c-146" decimals="-5" id="f-617" unitRef="usd">2000000</ovid:LicenseOptionAgreementDevelopmentAndCommercialMilestonePayments>
    <ovid:LicenseOptionAgreementExtensionPeriod contextRef="c-147" id="f-618">P4M</ovid:LicenseOptionAgreementExtensionPeriod>
    <ovid:PercentageOfDevelopmentCosts contextRef="c-148" decimals="2" id="f-619" unitRef="number">0.50</ovid:PercentageOfDevelopmentCosts>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-148" decimals="-5" id="f-620" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-149" decimals="-5" id="f-621" unitRef="usd">500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-150"
      decimals="INF"
      id="f-622"
      unitRef="shares">123255</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-150"
      decimals="3"
      id="f-623"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-151" decimals="-5" id="f-624" unitRef="usd">900000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-152" decimals="-5" id="f-625" unitRef="usd">800000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-153" decimals="-5" id="f-626" unitRef="usd">-300000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:PaymentsForRepurchaseOfPreferredStockAndPreferenceStock contextRef="c-154" decimals="-5" id="f-627" unitRef="usd">10000000</us-gaap:PaymentsForRepurchaseOfPreferredStockAndPreferenceStock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-1" id="f-628">RELATED PARTY TRANSACTIONSIn March 2021, the Company entered into the RLT Agreement with Takeda. For a description of the RLT Agreement, see Note 11.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-629">NET LOSS PER SHAREBasic net loss per share is calculated based upon the weighted-average number of common shares outstanding during the period, excluding outstanding stock options that have not yet vested. For any period in which the Company records net income, diluted net income per share is calculated based upon the weighted-average number of common shares outstanding during the period plus the dilutive impact of weighted-average common equivalent shares outstanding during the period resulting from the assumed exercise of outstanding stock options determined under the treasury stock method and the assumed conversion of preferred stock into common shares determined using the if-converted method. Diluted net loss per share is equivalent to the basic net loss per share due to the exclusion of outstanding stock options and convertible preferred stock because the inclusion of these securities would result in an anti-dilutive effect on per share amounts.&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The basic and diluted net loss per common share is presented in conformity with the two-class method required for participating securities and multiple classes of shares. The Company considers its preferred stock to be participating securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For any period in which the Company records net income, undistributed earnings allocated to the participating securities are subtracted from net income in determining net income attributable to common stockholders. The undistributed earnings have been allocated based on the participation rights of preferred stock and common shares as if the earnings for the year have been distributed. For periods in which the Company recognizes a net loss, undistributed losses are allocated only to common shares as the participating securities do not contractually participate in the Company&#x2019;s losses. Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Participating securities are excluded from basic weighted-average common shares outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the calculation of basic and diluted net loss per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.714%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.989%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.989%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.989%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.995%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,408,330)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,588,414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,764,539)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,696,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,408,330)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,588,414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,764,539)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,696,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,408,330)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,588,414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,764,539)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,696,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding used in&lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;computing net loss per share - basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,534,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,391,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,512,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,391,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding used in&lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;computing loss per share - diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,534,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,391,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,512,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,391,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share, basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding as they would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.839%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.839%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.324%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,448,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,451,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,448,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,103,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock issuable upon conversion of Series A convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-630">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the calculation of basic and diluted net loss per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.714%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.989%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.989%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.989%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.995%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,408,330)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,588,414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,764,539)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,696,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,408,330)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,588,414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,764,539)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,696,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,408,330)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,588,414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,764,539)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,696,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding used in&lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;computing net loss per share - basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,534,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,391,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,512,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,391,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding used in&lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;computing loss per share - diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,534,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,391,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,512,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,391,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share, basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="0" id="f-631" unitRef="usd">-12408330</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="0" id="f-632" unitRef="usd">-14588414</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="0" id="f-633" unitRef="usd">-25764539</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="0" id="f-634" unitRef="usd">-30696470</us-gaap:NetIncomeLoss>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="c-5" decimals="0" id="f-635" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="c-6" decimals="0" id="f-636" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="c-1" decimals="0" id="f-637" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="c-7" decimals="0" id="f-638" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-5" decimals="0" id="f-639" unitRef="usd">-12408330</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-6" decimals="0" id="f-640" unitRef="usd">-14588414</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-1" decimals="0" id="f-641" unitRef="usd">-25764539</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-7" decimals="0" id="f-642" unitRef="usd">-30696470</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-5" decimals="0" id="f-643" unitRef="usd">-12408330</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-6" decimals="0" id="f-644" unitRef="usd">-14588414</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-1" decimals="0" id="f-645" unitRef="usd">-25764539</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-7" decimals="0" id="f-646" unitRef="usd">-30696470</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="0" id="f-647" unitRef="shares">70534181</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="0" id="f-648" unitRef="shares">70391458</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-649" unitRef="shares">70512479</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="0" id="f-650" unitRef="shares">70391236</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="0" id="f-651" unitRef="shares">70534181</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="0" id="f-652" unitRef="shares">70391458</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-653" unitRef="shares">70512479</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="0" id="f-654" unitRef="shares">70391236</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-655"
      unitRef="usdPerShare">-0.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-656"
      unitRef="usdPerShare">-0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-657"
      unitRef="usdPerShare">-0.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-658"
      unitRef="usdPerShare">-0.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-659"
      unitRef="usdPerShare">-0.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-660"
      unitRef="usdPerShare">-0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-661"
      unitRef="usdPerShare">-0.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-662"
      unitRef="usdPerShare">-0.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-663">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding as they would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.839%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.839%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.324%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,448,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,451,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,448,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,103,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock issuable upon conversion of Series A convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-155" decimals="0" id="f-664" unitRef="shares">15448835</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-156" decimals="0" id="f-665" unitRef="shares">13451517</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-157" decimals="0" id="f-666" unitRef="shares">15448835</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-158" decimals="0" id="f-667" unitRef="shares">13103587</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-159" decimals="0" id="f-668" unitRef="shares">1250000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-160" decimals="0" id="f-669" unitRef="shares">1250000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-161" decimals="0" id="f-670" unitRef="shares">1250000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-162" decimals="0" id="f-671" unitRef="shares">1250000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>61
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M*Q'%HC  N+^04N]/3(!F:W;R+U!+ P04    " #L2@17Y(\U=D0#  "!"P
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M:)7+SVSS#IIX/,47LUQ43[*I;7W?(/%*2%8T8-Q!D97U.WIH\K #0!X]P&D
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MXP&I3F]9;9K#S^#A:!M>!,O[IJVVQ\:Z!]OU[O%W\>$X$"<-F!QHP(\-N-5
MB8$&XMA V!Z&&LAC VDUX/%  W5LH*P&,AIH$!T;1+:'H5&*CPWB0[ >1_<0
MFD71%C?7=?40U)VU5NM>'.)[:*TCLMYUJ?BZK?6G:]VNO9E7NY5.K'(5Z%=-
MM5FOBE:_>=WJ7SKCVB:H;O6[:OGNKMJLRKKY?9#^<K]N?PTN@W^\7@3?_/;;
MZZM6=Z23NUH>G?[XZ)0/./U[U18;HMG<W^R5SM*RK@_=TQT*7I?UNFR"'[JN
MOR_K=OUF4P:6$>%EX?<RK[9;?8X,M4[]K7]8K=;=.59L@E?%>G7Y<A?,B_V:
M/M[LC-9R>;^]WQP"\K?VKJSU@6[UA'/7S03OR^#E;EEMR^";OU1-0T4A'R^_
M*&_7RW5KBESI7'I**/Z44/R@*@=4?RS?KG>[]>ZMGB$VQ6ZI^[?>!<U=49?-
MMT'1:E?+[P+!_A#PD#,J=[SZW=3\?;,OEN6+"ST435F_+R]N?O<;%H5_I#+J
M44P=Q+II^?T-XRJ\OGI_FA!(CRE2+$.*Y2 Q(RW$4UJ(B6DQ)A4>-:/3Z,6S
M6$921&8(YX2E%637(@Z%FIE6J6LE% N%4(EEF;F65EKEKL4EBYE0L6+BR=08
M3?DTFO(SGV1>_:DG&5)L(9TS5L<IDC/&K5 AO69(L1PD9J2&>DH-=5 7 ZFA
M+PIZ2=KHC- Y<'CU;;#>T9?P?_]<;3:!7M(]%/7J/U2:*&2:(,462+$4*98A
MQ7*0F)%*T5,J1=Y9YF73W!\F%[T$7#ZNBIK#PNNVKK9!^:&LE^OF\.GCGZM]
MM_)I@F*W"O;W]?).)U]S--[N-]6O97FT_/AIL->SU^G<1>6@MY-3<Q IMHB<
MJ4IQ(80U3R%=9DBQ'"1F)%?\E%SQUY!<5$+%3MB$"&/K^C[W=G]JIL3N\D1:
M:4+V*E+6J@/9JQPD9L0_>8I_XHW_X8)TV5&$51?_O=[3% <X47[H7I=4X!)W
M,2^X3.R5P=SK>6KHD&+IR"/(D$YSD)@1YME3F&?>,/^U;(-O-MT&5:]"NNTJ
M%=>9,RJ7+&)A$BI[F>]U-C6R2+$4*98AQ?(QHVO$EH4]/ J]T4UW*\\FY*>B
M?MJ$<)(2>=6G7MJ/:F?V^E"?*50M@ZKE*#4S-T[ (IN2&Z/R@;D1U#N_6<1C
M:S<_/YKZ-OR$B=Y)QO;RC' J]#)NQF1DS3X986KO^0F32Y;$,E(JF@V<;CU:
M8WZV]MS3#4K6H&H+YH*Z.)0LYE+9\8("-JA:CE(S\Z-G;&PJ9)N*A?P.)J>(
M&#4C(WVF4+4,JI:CU,STZ*$AFTH-1Z6$"^2&(.S1U#LINR84AB6<#G%8PM29
ME%V3<R26];R->1D,XJ2#4C:HVN*H-@+'0OUF4+4<I6:F2,_16/0%F2R# C&H
MV@*JED+5,JA:CE(S4ZJG9\R/ST;MJYG+E"Y%&,TB&8?VU W%75"U%*J60=5R
ME)J9!CU$8WZ*YM\1_/E^IZ\\H6='@.1,<T;0+6*Y!P5J4+4,JI:CU,S<Z,D;
M\Z,W=P-^/A]<5L049S*6,V>M-SN_UG--NCV=#;X)IT))SAF;,7NM1["L6<AX
M;"_X"#M]S*$2LV1@P<=[Z,6? [W.CK%??7)]"U)MP5V$UD5L)I+$"AK4;P95
MRU%J9G[TX(O[P=?9#<%94.-W,#E%"*I&U$ A?:90M0RJEJ/4S/0XJ8^;6B W
M*B6(0K8!-'HT]<W,A F%1@FG0VB4,+5WX83).33*>_3%GXF^SH\P%'U!U1;<
M!6D#=!3J-X.JY2@U,T5Z_,7E%]R%<V@%'51M 55+H6H95"U'J9DIU;,_[F=_
M7TF%E+^7DW,1"A"Y"Q#UAL*YTD#A(50M1ZF9.=;#0_Y55.&1>>46N+%PIF1B
MKSB@#/&H=KHXD<S.%[IG86PO2Z#,#Z5F9D+/_+B?^7U*R11W$:!>-H2<Q78,
MH0 0JI:./8@,ZC9'J9GA[MD>][.]QUM^EL8M/\.LE[OPC4(C<[_3R7&&PCRH
M6C9R1'*45S/,/:;C@ HY3A5Q294D#DZ;^]U-#C"T2 ZJED'5\E%#;-[[U"-#
M\5F1H5]]ZOI.C*J3@_I,H6H95"U'J9FYT>-",;5.[GP^$,5O YB>,K4C3=7)
MN9A>4'5R-*8G3,F9E[([@^E%S]G$<XKESH\QM%@.JK80=+$<@>FA?C.H6HY2
M,_/CY(948+$<G2)CRMOFHZP6_LY.GFZA%!"JEJ/4S+#W%% \LPB.#C51V28X
MC[F*[/4796H'FRJ"DU%LG[Q4$5P<QV'"[=N""--+R5GBS+B$'>=*\4A/Y0,S
M;D_#!+ 2CAYFJMI,1E&2*'N4H9!JM-\4ZC>#JN4H-3/\/:@27[+*34"KW*!J
M"ZA:"E7+H&HY2LU,J9YXB:_B)M%S?-W?R\FY""5MPF5C7$;V!2*%.LV@:CE*
MS4RRGK,)/V?['P+V8\].%P)1-)L)^V('97:$4S==7':F.Q8E]K(#6B^'4C/S
MH =QP@_B/@6O"Z)@;L8BQ>Q_D?A]3PXAE,J-/8@,ZC9'J9E/T.F9G/0SN6EX
M7;K03,:)\U\4O\^I88:JI5"U;-R Y"BG9I![N";]<&T47)?4/9M"J(B']D,A
M_.XFQQ=:<P=5RZ!J^:@A-F/<@SZ)NBM6D-&'@CXYZH%S4)\I5"V#JN4H-3,W
M>L@G_9#/?Q,ZG0_$H^1TELHX2NSGC%"F=J2IQ\[)F?,L,Q<2"C6+E13,RIV,
M,%61L(LM":M++I(DX;%B V?<R=/G_ SMN6<<M'0.JK:0+B#KXL64'8<4ZC>#
MJN4H-3,_>A H/S<(E"Z0(]#Z**N%O[.3)ULH (2JY2@U,^P] )3^2K5/0^O2
M+?<:0NN4J1ULUX1"Z]*M'QM"ZX0IB=8INS-H7?8@3/I!&.",<CG1 %KW=V7R
MA#K6;PKUFT'5<I2:&?X>4<GD"Z)U";WK$ZJV@*JE4+4,JI:CU,R4ZFF7!)2=
M2?<.SDNNXD@JX>R,H8 +JI9"U3*H6HY2,Q\6W%,PA:I,(Y?R:DPMV7R4U<+?
MTZDQAZIE4+4<I6;&O(=BZCD59W2<B3(R%D:S)(KMY0-E:D>:JCB+0ONF$$54
MG$5LQL1,6BO#C#!5/+3X=4Y8Z>F,\1D+DX%-L>HQE$+5F]$C3-5T12&/G?\&
M^?LQ=:8=\"L<ORG4;P95RU%J9NQ[S*2 =Y_2X8?>?:I&U9Q!?:90M0RJEJ/4
MS/3H>9GZA)JS\RE!%)(-@$C*U XV67/F@$A%U9S1()(P)4 D874.1*J3[SIX
M)F@Z/\C8;SC ?L4!695&L4BHWPRJEJ/4S!3IH93ZDE5I"EJ5!E5;0-52J%H&
M5<M1:F9*]3!._5]4I?E[.3D7H=1/$7=L,LX39TT)97Y0M1RE9F99S_S45UN6
MIMSJ+ZZW>S.[VL5_!)-SQJU+8\R^\9OL6JCWH?;B!,KJ4&IF*O2L3N$KTQ15
MU"63R+EYW^][<A"AX&[L0610MSE*S?S6I9[)1<C*M,B%:Y>2VSL$O\NI48:J
MI5"U;-1XY"B?9HA[!!<!ZM(B%Y-=,B[#1-B[K+G?W>3P0NO2H&H95"U'J9EI
MT#/#Z+,RPVA,L=E\E-7"W]/),8>R0JA:CE(S8]ZSPFAJ2=KY.!-U9@/TG3*U
M(TV5I+GTG3 ;HN^$*4'?":MS]#WJ$5OTG)*T\R-,E7V1]-W?C\DS+>V7H.]0
MOQE4+4>I/<;^ZN3;S/?%V_*GHGZ[UAN;37FKY</O8CU:]>,WS#^^::O]X0O.
MWU1M6VT/+^_*8E76G8'^_+:JVH]ONN],?ZCJ=P<?-_\%4$L#!!0    ( .Q*
M!%>E6I:D/P<  -H=   8    >&PO=V]R:W-H965T<R]S:&5E=#<N>&ULM5EM
M;]LV$/XK@C<,+5#7(JG7+#&0NANV 1N"!MT^,Q)M:Y5$CZ2=9+]^1TJ1%)%2
M'" KD%HOQ]-S=^0]=^3E/1??Y)XQY3U492VO%GNE#A>KE<SVK*+R(S^P&MYL
MN:BH@ENQ6\F#8#0W@ZIRA7T_6E6TJ!?K2_/L1JPO^5&51<UNA">/547%XR=6
M\ONK!5H\/?A2[/9*/UBM+P]TQVZ9^GJX$7"WZK3D1<5J6?#:$VQ[M;A&%QL2
MZ %&XL^"W<O!M:=-N>/\F[[Y-;]:^!H1*UFFM H*/R>V866I-0&.?UJEB^Z;
M>N#P^DG[S\9X,.:.2K;AY5]%KO97BV3AY6Q+CZ7ZPN]_8:U!H=:7\5*:_[W[
M5M9?>-E1*EZU@P%!5=3-+WUH'3$8 'K< W [ (\'!!,#2#N &$,;9,:LSU31
M]:7@]Y[0TJ!-7QC?F-%@35'K,-XJ 6\+&*?6&U[G$!26>W E>5GD5,'-K8(?
MB):2'M]Z&RKWWL\0<>DMO:^WG[UWW[^_7"GXO%:RRMI/?6H^A2<^%7F_\UKM
MI?<3?#)_/GX%L#OL^ G[)SRK\+=C_=$C_@</^Y@X\&S.'XYGX)#.E<3H(U.N
MU%[:&B]M!:\\6&J"JJ+>-7.U4 63%RZW-6H#MUJ]CB_D@6;L:@$+53)Q8HOU
M#]^AR/_19?,;*7OF@:#S0#"G??T'I)V22^DRLAD9F9$ZMYS62QS&41"2]')U
M&EK@D"1^E$9!['>2S^"%';QP-D#7^=^PH)I9K3@DH8S765$RKVYQZZ>9CN)1
M+XBB/C^$X5N&\(V4/?-1U/DHF@\AKY?&!> ;6>3&?).P,P;IUCBE+#*=QK53
M=H*9+.$I06M)369VN:?Y9C@(J3\*NBVQ3&%N1)$[Y'%G3CQKSM<:N*TL_@7D
M[W9 :N^;.(-%[)]CH1[!GA-KYH0+=VRC2H(X3<,1>EN.!$F"L!M\TH%/9L%O
M]K3>,>URFF7B:+RO&,1<>;3.S4-FH@,I.B]DQH\0";@%/O[&%+V#F2U9=A1F
MVKK,2VSS$"(I_(WL<PAB3*(@=1N8=@:FLP;>*IY]6VH6SF&^55":R&:ZL0=]
MS5R84]O5212BP41I(#OD_"#T\01DY/>$Z<^"_LQ@V65% ]3$H>)"%?^^B+S5
M.X2$$XPP&B%WR*$8(S^<0#Z@>C2+_'H(%.:,T"7.DF^7D.X\*B5SKH%6Z1!.
MB/S(MV#;<B0,4#(%&_>P\3SLX3PO&<P62$'TKBAA_3H!8QMP3'PT7K0..1(E
M&$^D'-37 >B%0J!;MP/^T.Z59KX\@9_B$O2F]<!;:7ONB[XB0/,EP8U@!UKD
M3^NB\0!7>R:@NA5"<T?C&J<G COO!'Z0D,B:? Y)3/PDCB>"V=<,:)9NU[=-
M!GV$WN# 9>%>(J&]8G&06B =8F&*)ZH:U%,VFN=L6" Z]4OO0!]UUG="M D6
M)<@G\;CZ<@A"H0;9QR<3.'LN1O-D?-VRV--<<.*TJ33%260G20<U$S_& 0DF
M8/:LB^9I5U>Q+U:!3NPNFB0)BB,4C.$[1 DA<6A:$2?^GE11^JH^I"EQSBAB
MT2Q;OSKQO)&VYZUA3]-XGJ9OCB+;:ZX TCB[(,(V]2YQ$,:!'X\GH$LT3@,4
MX:F%@GNBQO-$?4M+)E<552W4U]E@\W 2^N;?V 1;<B(7X9ZL\3Q9#]U>\GJW
MA(*U.J_8QC8?+Y'O1FZ+3B'O61O/,N'Z5RF/M,X,<FA^3@QJ)>/M/51-C1DU
M5ZQMA:;R;/N1N5;'(?)DYX0-/=OB%]BV];Z9,0>A$Q>X75.NCL!ATO,N]D0D
MC,?('7+(3\(DF$+>TRQ^@6;Y5MU3P8!F3ZSD!NJP5N#272)@FU,!4AH1"[M#
M$'B-3$+OZ1>_T#(_\04X_ 0M<^[=/7KO6O)X[TR_3DMLXM7M2I"2<>'JD%P"
MRX2$)%.II^=H'+^*/+9%#8OB#/+ L]S_6O)X*VW/O="7 'B^!+@1/&,L;WW
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M[[6<'Y6R8Z?T>F4P5UKP*C_JIIK==)0N"'42W-NM;8U' TFN= TH 1^9(!K
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M,$Z#?J!OM:V0^C'H^MCKWC;3'!*KH@)Q X"%[='<5Z.,D:7 H<+OP""D>[(
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MJ1F<CJ".RERRJMB&ZFIYM:\E\W;2H(YO(^TY)<N(<7A++_AY5U$==4W21WR
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M-.P-:$"H=H2T"R-KU[;7TM 0<.*.IBXJJT#G&RG-T\(ZZ.;XY&]02P,$%
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MAD^ZTX6E#5A?&^/W W+0_V&P_ ]02P,$%     @ [$H$5PG%"$BL @  MP4
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M$=2]&0XL$-V8Z!:*-\::.Z[(Z";,:;*BT ETGG&N3@M]03^K9W\ 4$L#!!0
M   ( .Q*!%>]^CZ2S 8  +L1   9    >&PO=V]R:W-H965T<R]S:&5E=#$T
M+GAM;)U8VW+;-A#]%8R29M(95:)D.S=?9AS'G:1-&C=VVNET^@"12Q$U"3
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MQ%)G&2DSWPMK3L22([%5.JN-NHN\7JYX&<23F@/N,.Z%UDBTUX^%TT7[*J\
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MT/6,STW&/E6\['U;FJIBR5_0TC2DSBKSF6FWVGVD>V6^3=UM-U_XOI7%4L/
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M;< 6%!\;K)WD6 #?*VO#YH4=;!?9Q3]02P,$%     @ [$H$5ZT-$%7T#0
MKR8  !D   !X;"]W;W)K<VAE971S+W-H965T,3<N>&ULI5IK;]M&%OTK W?1
MW05D69;C])'$@..D;=HF,9JT"^QB/XS(D30;DL/.#*UH?_V>>^?!AV0GP0)-
M+9&<^[[G/JBG.V,_N*U27GRLJ\8].]EZWWY_=N:*K:JEFYM6-;BS-K:6'E_M
MYLRU5LF2#]75V7*Q>'Q62]V<7#WE:[?VZJGI?*4;=6N%Z^I:VOUS59G=LY/S
MDW3A-[W9>KIP=O6TE1OU3OG?VUN+;V>92JEKU3AM&F'5^MG)]?GWSQ_1\_S
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M9W&FJB)K -0("!?.R^PR Z-5*]1Z-X%E&^# &@W)K<Y*Z_"9<NML"18)_D;
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MPY$;\M0<S*D2]E24L!(^( ZVUA.^CZIKBOTY3O*QU0 ^.P,V"HP#DX]M18H
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M.V4/BHJ!U?2QV;(_""K5N1#64C*( W_)ICS9-$J1V=-)![KD/G1XYXN)#*"
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M:11(/A=";R?&0?L<&_X%4$L#!!0    ( .Q*!%<X'0Q+R (  .H%   9
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M,$9I \SY2@B]=VR!>KSW_P)02P,$%     @ [$H$5_ X$Y]C P  MP@  !D
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MP".,\SP<YQE<*;D^L:C%?W80S"#,1N-P4 SAB%*#3JG!FY5RT2I)O(RS7@A
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M&I\.Z?KKMDVVAE5;WYJ6RE*C\\,-?5F@=AMH?:64?3+< =VWRNQ?4$L#!!0
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M<E.A&6!]P;EJ!]I ]X@?_0=02P,$%     @ [$H$5TR#E6@2!   =PL  !D
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M5V+[$5I_+,!4<&6?9-OR^@Y):Z5%T0HC@H*5S9O>M7%XC4#8"H06=V/(HOQ
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M=&-J609TTS3M@QL.B)K$J>U ^]_/3D*6M(&N$OT"=G+OY;WS77+=#:%W; 7
MT4,4QJRGK#A/SE25^2N(,#LE"<3BSH+0"'.QI4N5)13P/ -%H6IHFJ-&.(@5
MMYM=\ZC;)2D/@Q@\BE@:19@^GD-(-CU%5[87)L%RQ>4%U>TF> E3X#>)1\5.
M+5GF000Q"TB,*"QZ2E\_N] U"<@B?@2P894UDE9N";F3F]&\IVA2$83@<TF!
MQ=\:+B ,)9/0<5^0*N4S);"ZWK)?9N:%F5O,X(*$/X,Y7_64MH+FL,!IR"=D
M\P4*0[;D\TG(LE^T*6(U!?DIXR0JP$)!%,3Y/WXH$E$!Z-8.@%$ C/\%F 7
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M;+68;6_;-A#'OPJA%4,*I-:3'^+,-I!8+98A18-X75\4>T%+9XNK)*HD'3?
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M@# !>G_%N7J:F(;4W3_9/U!+ P04    " #L2@17090<_6 "  "C!0  &0
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MM\#.+Y7"IXZKG=W-E_X'4$L#!!0    ( .Q*!%=GKX^NT (  *$'   9
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M.Y"X44'<R$C<AW5T1P7B\[2()FBE+E*6T(_T3A-5H\>!U3@RMMGUZ88$\X#
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M6,A'MC#YBA$<9D9);"++\LP$1ZDQ[&?O'MBP3]<BCE+RP !?)PEF+V,2T^W
M@,;NQ6.T6 KUPASV5WA!ID1\73TP^6267L(H(2F/: H8F0^,$;R<(*0,LA%/
M$=GRO7N@H,PH_:X>;L*!8:F,2$P"H5Q@>=F0"8ECY4GF\:-P:I0QE>'^_<[[
M[QEX"6:&.9G0^%L4BN7 \ T0DCE>Q^*1;O\D!2!7^0MHS+-?L"W&6@8(UES0
MI#"6&211FE_Q<T'$GH%SS  5!NA4 [LPL#.@>689K"LL\+#/Z!8P-5IZ4S<9
M-YFU1!.EJHQ3P>2_D;03P^F7^\G?%^/1]/H*3.YO'Z[OIJ,O-_=WX ),\\H"
M.@?W*\4Y!_=KP05.PRA= 'D!WS*62 A&&\)DU<'U,V%!Q EX8%% P.<K(G 4
MG_5-(7-5$<V@R&N<YX6.Y.6!6YJ*)0?7:4C"!ON)WAXBC0-3DE0RA79,C9'6
MXU_KM -LZQP@"]G@Z_0*?/YT!CX!$_ E9H07EZ94]8ZO2" =P\PQ.M7Q*PAV
M66P[BV0?B72W3F:$J8).C^4ZSCTXS1[4IG+)5S@@ T/N&IRP#3&&O_X"/>NW
M)N#OY.P56*<$Z^B\#W=SEE9S]AS,R")*4S5]9SC&J9JB45H0? ;^.U[#<1[,
MS8*IO7$CIUC/@\CV^^9F'[,VJY:8W1*SJ\7\!\.I6HZG@G(/0-F69;F65<.D
MC=H2DU=B\K28=EO*Z:B\ U07/6AUZX72AFT)JEN"ZFI!R18T)Y$J%66 /*\B
M]@9\W4-\#H(^<FL M2FT!.B7 /VWKSZ2=XZW+CW_<.FYCN/[=AUPP\#Z&GT%
MIE>"Z6G!/!&N2J4Z'LEG(Y[%I#6>WD&:OF=U7>C5X&B3:ED_:%7"P-(VBY_T
M]L:6;KUG\W@O;Z_Q[PDC^%[](Z1QC!D'*]E<L[*K^E<-O)&J/+B_-PF<#K1K
M,T"?8EL*4$4!.KF=M,&8>X=P#R3J>*@.4IM$6Y"5)H):%5+K+VU@VDTPW0.8
M'R&&8*6&H%X.'>TX;1 [AXCMSD'_T6?4%G&EA:!>#)W:@MH0X#81X'?K!+CZ
M1?X:6"6(H%X1-;>CUEB\AB0]IP[E(]02K.02[+ZM&3T2=4:A2CF1GWD,!V*-
M8_!/-"= TO O420H@D:+!2,++ BXD<.BE$<!>,+QNKE_O9-B*BC["/T%*P$&
M]0JL#67GH&'1-#*EC]T%+UD%')#D'^'0!B%^:?PX/M&56[I2GG0,5:H.ZF5=
M.X:*IMC(BCY>KX#B[Z#XQTGY".V'*NV'M-JJ)3/-^U(343\)[Q5$(4W-BY.5
MC]"(J-*(2*\1J]TE*G>7C=I=S@$]7$AJ*VYD(P_B[>W KN\ZEE]OJ T#/03=
M(U\WJ-)Y2*_S-# VS;WF&!)TD"!R+ \>?'OK$WIKW<R]\\^$L$5V+,Q!0->I
MR(]"R[?ET?,H.W UJ^'YN?4M9E+A<Q"3N32U.EW9PEE^%)P_"+K*3E-G5 B:
M9+=+@D/"U #Y_YQ2L7M0 <H#^>'_4$L#!!0    ( .Q*!%< ',.OE0(  ,<'
M   9    >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;*U586^;,!#]*Q:;IE;:
M"@&:3AE!2@)3.ZE;U;3;I&D?'+@$J\9FMDFR?S_;$)96-*VV?@'[N/>>[\[<
M11LN[F0!H-"VI$R.G4*I:N2Z,BN@Q/*$5\#TER47)59Z*U:NK 3@W()*ZOJ>
M-W1+3)@31]9V)>*(UXH2!E<"R;HLL?@]!<HW8V?@[ S79%4H8W#CJ,(KF(.Z
MK:Z$WKD=2TY*8))PA@0LQ\YD,$I#XV\=OA+8R+TU,I$L.+\SFXM\['CF0$ A
M4X8!Z]<:9D"I(=+'^-5R.IVD >ZO=^P?;>PZE@66,./T&\E5,7;>.RB'):ZI
MNN:;<VCC.35\&:?2/M&F\3T]<U!62\7+%JQ/4!+6O/&VS<,>0//T _P6X#\$
MA(\ @A80/%<A; 'A<Q5.6X -W6UBMXE+L,)Q)/@&">.MV<S"9M^B=;X(,_=D
MKH3^2C1.Q1>?9U\N4W0S^9[.T3LTR7-B"H@INF#-+33E/$I 84*/M<?M/$%'
MKX\C5VEUP^%FK=*T4?(?40K0)6>JD"AE.>0]^.0P?G@ [^JHN]#]7>A3_R#A
MIYJ=H,![BWS/#WK.,WL^W.\+Y__4TW]6OY>,H+L'@>4+'KL'+.,EH!N\10F1
M&>6R%H!^3!92"?TS_^RK=\,8]C.:!C>2%<Y@[.@.)D&LP8G?O!H,O0]]R7Y)
MLN0ER=(7(KM7EK K2WB(/3Z: H,E4<>H$GQ-;'?6OR4B3;D4WH+L*TW#.K2L
M9E2L8R]RU_OY?M(C>=(C/>31A.ON=:82Q,J.!(DR7C/57,[.VDV=B6VV#^S3
MP6@VZ+$G>DHU0^4O?3/B+K%8$281A:66\D[.=.,4S=AH-HI7MB\NN-)=UBX+
M/6E!& ?]?<FYVFV,0#>[XS]02P,$%     @ [$H$5\I-U RY"   A%H  !D
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MP<??5BOPL'@$JP\WCPMP"59E7@*R 7<P#O,8RK01S5O(< A@&H$YCG..(K"
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M^=>_ MM[6NNR.>2S[G_K]!-02P$"% ,4    " #L2@17!T%-8H$   "Q
M$               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M .Q*!%>(1Q!0[P   "L"   1              "  :\   !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( .Q*!%>97)PC$ 8  )PG   3
M  "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ [$H$5Z:%
M<.SF!0  M1\  !@              ("!#@@  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( .Q*!%?&.7[<'08  "X8   8
M  " @2H.  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " #L
M2@17ZVGBNQH#   L"P  &               @(%]%   >&PO=V]R:W-H965T
M<R]S:&5E=#,N>&UL4$L! A0#%     @ [$H$5ZR4SN@1!0  IA4  !@
M         ("!S1<  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0
M   ( .Q*!%?DCS5V1 ,  ($+   8              " @10=  !X;"]W;W)K
M<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #L2@17()@ 55T,  #S?P
M&               @(&.(   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L!
M A0#%     @ [$H$5Z5:EJ0_!P  VAT  !@              ("!(2T  'AL
M+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( .Q*!%=4*>& !@D
M *05   8              " @98T  !X;"]W;W)K<VAE971S+W-H965T."YX
M;6Q02P$"% ,4    " #L2@17L"Z\^%H7  !_1@  &               @('2
M/0  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ [$H$5\?;
MH7GJ P  (PH  !D              ("!8E4  'AL+W=O<FMS:&5E=',O<VAE
M970Q,"YX;6Q02P$"% ,4    " #L2@17;R7G1&D#  #3!P  &0
M    @(&#60  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    (
M .Q*!%<>M[!!5P4  "0,   9              " @2-=  !X;"]W;W)K<VAE
M971S+W-H965T,3(N>&UL4$L! A0#%     @ [$H$5PG%"$BL @  MP4  !D
M             ("!L6(  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"
M% ,4    " #L2@17O?H^DLP&  "[$0  &0              @(&490  >&PO
M=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( .Q*!%>-T4T&M@T
M ,8L   9              " @9=L  !X;"]W;W)K<VAE971S+W-H965T,34N
M>&UL4$L! A0#%     @ [$H$5T,R((O-!   U H  !D              ("!
MA'H  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " #L2@17
MK0T05?0-  "O)@  &0              @(&(?P  >&PO=V]R:W-H965T<R]S
M:&5E=#$W+GAM;%!+ 0(4 Q0    ( .Q*!%?NVTW>_A   $LT   9
M      " @;.-  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%
M  @ [$H$5]""G6M8 @  / 4  !D              ("!Z)X  'AL+W=O<FMS
M:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " #L2@17  ]B;^T%  "#$@
M&0              @(%WH0  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+
M 0(4 Q0    ( .Q*!%?U0XL"Q1<  .9,   9              " @9NG  !X
M;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ [$H$5Q5C9VBY
M P  F@T  !D              ("!E[\  'AL+W=O<FMS:&5E=',O<VAE970R
M,BYX;6Q02P$"% ,4    " #L2@17.!T,2\@"  #J!0  &0
M@(&'PP  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( .Q*
M!%?P.!.?8P,  +<(   9              " @8;&  !X;"]W;W)K<VAE971S
M+W-H965T,C0N>&UL4$L! A0#%     @ [$H$5PE9"0&Z @  NP4  !D
M         ("!(,H  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
M    " #L2@174R0PJ8P%  #0#P  &0              @($1S0  >&PO=V]R
M:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( .Q*!%=,@Y5H$@0  '<+
M   9              " @=32  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL
M4$L! A0#%     @ [$H$5T]'W)J9!   :1<  !D              ("!'=<
M 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " #L2@17UB/_
M)! $  #?$P  &0              @('MVP  >&PO=V]R:W-H965T<R]S:&5E
M=#(Y+GAM;%!+ 0(4 Q0    ( .Q*!%<9V =- 00  'H/   9
M  " @33@  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @
M[$H$5V;D1GB_ @  ^P<  !D              ("!;.0  'AL+W=O<FMS:&5E
M=',O<VAE970S,2YX;6Q02P$"% ,4    " #L2@17#U'_S20#  !2"P  &0
M            @(%BYP  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4
M Q0    ( .Q*!%?!?C/&7P,  +L+   9              " @;WJ  !X;"]W
M;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ [$H$5Z$Q-7OE P
M'Q(  !D              ("!4^X  'AL+W=O<FMS:&5E=',O<VAE970S-"YX
M;6Q02P$"% ,4    " #L2@17E=O)#*$"  "+!@  &0              @(%O
M\@  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( .Q*!%=!
ME!S]8 (  *,%   9              " @4?U  !X;"]W;W)K<VAE971S+W-H
M965T,S8N>&UL4$L! A0#%     @ [$H$5V4JGNBD @  !0<  !D
M     ("!WO<  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .Q*!%?%JXN\EP,  &P0   9              "
M@6X5 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ [$H$
M5X.*H<M^!   +A8  !D              ("!/!D! 'AL+W=O<FMS:&5E=',O
M<VAE970T,RYX;6Q02P$"% ,4    " #L2@17AZ^N4=@$  "<%P  &0
M        @('Q'0$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0
M   ( .Q*!%< ',.OE0(  ,<'   9              " @0 C 0!X;"]W;W)K
M<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ [$H$5\I-U RY"   A%H
M !D              ("!S"4! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q0
M2P$"% ,4    " #L2@17]2XUBIH*  #!@@  &0              @(&\+@$
M>&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( .Q*!%<'Y:6W
M@ 0  .L5   9              " @8TY 0!X;"]W;W)K<VAE971S+W-H965T
M-#@N>&UL4$L! A0#%     @ [$H$5\WUA$*J P  >@\  !D
M ("!1#X! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " #L
M2@17$[3G(C<#  #,$P  #0              @ $E0@$ >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( .Q*!%>7BKL<P    !,"   +              "  8=%
M 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( .Q*!%<;$%$]000  .$@   /
M          "  7!& 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #L2@17
MCF$X^KT!  !Z'0  &@              @ '>2@$ >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    " #L2@17G"O3#[T!  !W'0  $P
M        @ '33 $ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     .0 Y (8/
(  #!3@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>162</ContextCount>
  <ElementCount>263</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>48</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/CondensedConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - NATURE OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/NATUREOFOPERATIONS</Role>
      <ShortName>NATURE OF OPERATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIES</Role>
      <ShortName>CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETS</Role>
      <ShortName>PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/ACCRUEDEXPENSES</Role>
      <ShortName>ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/STOCKBASEDCOMPENSATION</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - COLLABORATION AND LICENSE AGREEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTS</Role>
      <ShortName>COLLABORATION AND LICENSE AGREEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/RELATEDPARTYTRANSACTIONS</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - NET LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/NETLOSSPERSHARE</Role>
      <ShortName>NET LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9954701 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9954702 - Disclosure - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESTables</Role>
      <ShortName>CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIES</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9954703 - Disclosure - PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETS</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9954704 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/LEASESTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ovidrx.com/role/LEASES</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954705 - Disclosure - ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/ACCRUEDEXPENSESTables</Role>
      <ShortName>ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ovidrx.com/role/ACCRUEDEXPENSES</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954706 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ovidrx.com/role/STOCKBASEDCOMPENSATION</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954707 - Disclosure - NET LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/NETLOSSPERSHARETables</Role>
      <ShortName>NET LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ovidrx.com/role/NETLOSSPERSHARE</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954708 - Disclosure - NATURE OF OPERATIONS - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/NATUREOFOPERATIONSAdditionalInformationDetail</Role>
      <ShortName>NATURE OF OPERATIONS - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954709 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954710 - Disclosure - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Fair Value of Cash and Cash Equivalents and Gross Unrealized Holding Gains and Losses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail</Role>
      <ShortName>CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Fair Value of Cash and Cash Equivalents and Gross Unrealized Holding Gains and Losses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954711 - Disclosure - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail</Role>
      <ShortName>CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954712 - Disclosure - PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS - Summary of Property and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSSummaryofPropertyandEquipmentDetail</Role>
      <ShortName>PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS - Summary of Property and Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954713 - Disclosure - PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSAdditionalInformationDetail</Role>
      <ShortName>PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954714 - Disclosure - LEASES - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/LEASESAdditionalInformationDetail</Role>
      <ShortName>LEASES - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954715 - Disclosure - LEASES - Schedule of ROU Asset and Lease Liabilities Related to the Company Operating Lease (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/LEASESScheduleofROUAssetandLeaseLiabilitiesRelatedtotheCompanyOperatingLeaseDetail</Role>
      <ShortName>LEASES - Schedule of ROU Asset and Lease Liabilities Related to the Company Operating Lease (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954716 - Disclosure - LEASES - Schedule of Components of Operating Lease Cost (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/LEASESScheduleofComponentsofOperatingLeaseCostDetail</Role>
      <ShortName>LEASES - Schedule of Components of Operating Lease Cost (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954717 - Disclosure - LEASES - Schedule of Future Minimum Commitments Under Under the Non-Cancelable Operating Lease (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/LEASESScheduleofFutureMinimumCommitmentsUnderUndertheNonCancelableOperatingLeaseDetail</Role>
      <ShortName>LEASES - Schedule of Future Minimum Commitments Under Under the Non-Cancelable Operating Lease (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954718 - Disclosure - ACCRUED EXPENSES - Schedule of Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/ACCRUEDEXPENSESScheduleofAccruedExpensesDetail</Role>
      <ShortName>ACCRUED EXPENSES - Schedule of Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954719 - Disclosure - STOCKHOLDERS??? EQUITY - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetail</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954720 - Disclosure - STOCK-BASED COMPENSATION - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail</Role>
      <ShortName>STOCK-BASED COMPENSATION - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954721 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Recognized Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONScheduleofRecognizedStockBasedCompensationExpenseDetail</Role>
      <ShortName>STOCK-BASED COMPENSATION - Schedule of Recognized Stock-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954722 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Allocation of Stock-Based Compensation Expense by Plan (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONScheduleofAllocationofStockBasedCompensationExpensebyPlanDetail</Role>
      <ShortName>STOCK-BASED COMPENSATION - Schedule of Allocation of Stock-Based Compensation Expense by Plan (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954723 - Disclosure - STOCK-BASED COMPENSATION - Summary of Assumptions Used to Compute Fair Value of Options Granted (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail</Role>
      <ShortName>STOCK-BASED COMPENSATION - Summary of Assumptions Used to Compute Fair Value of Options Granted (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954724 - Disclosure - STOCK-BASED COMPENSATION - Summary of Options Outstanding and Weighted Average Exercise Price (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail</Role>
      <ShortName>STOCK-BASED COMPENSATION - Summary of Options Outstanding and Weighted Average Exercise Price (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954725 - Disclosure - INCOME TAXES - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/INCOMETAXESAdditionalInformationDetail</Role>
      <ShortName>INCOME TAXES - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954726 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954727 - Disclosure - COLLABORATION AND LICENSE AGREEMENTS - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail</Role>
      <ShortName>COLLABORATION AND LICENSE AGREEMENTS - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954728 - Disclosure - NET LOSS PER SHARE - Summary of Calculation of Basic and Diluted Earnings (Loss) per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/NETLOSSPERSHARESummaryofCalculationofBasicandDilutedEarningsLossperShareDetails</Role>
      <ShortName>NET LOSS PER SHARE - Summary of Calculation of Basic and Diluted Earnings (Loss) per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ovid-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954729 - Disclosure - NET LOSS PER SHARE - Schedule of Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Shares Outstanding (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/NETLOSSPERSHAREScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageSharesOutstandingDetail</Role>
      <ShortName>NET LOSS PER SHARE - Schedule of Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Shares Outstanding (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="ovid-20230630.htm">ovid-20230630.htm</File>
    <File>ovid-20230630.xsd</File>
    <File>ovid-20230630_cal.xml</File>
    <File>ovid-20230630_def.xml</File>
    <File>ovid-20230630_lab.xml</File>
    <File>ovid-20230630_pre.xml</File>
    <File>ovid2023q2exhibit311.htm</File>
    <File>ovid2023q2exhibit312.htm</File>
    <File>ovid2023q2exhibit321.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ovid-20230630_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="574">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>66
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ovid-20230630.htm": {
   "axisCustom": 0,
   "axisStandard": 18,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 574,
    "http://xbrl.sec.gov/dei/2023": 30
   },
   "contextCount": 162,
   "dts": {
    "calculationLink": {
     "local": [
      "ovid-20230630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ovid-20230630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ovid-20230630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ovid-20230630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ovid-20230630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ovid-20230630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "elementCount": 397,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2023": 5,
    "total": 5
   },
   "keyCustom": 51,
   "keyStandard": 212,
   "memberCustom": 22,
   "memberStandard": 22,
   "nsprefix": "ovid",
   "nsuri": "http://www.ovidrx.com/20230630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.ovidrx.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIES",
     "shortName": "CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETS",
     "shortName": "PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - LEASES",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.ovidrx.com/role/LEASES",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - ACCRUED EXPENSES",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.ovidrx.com/role/ACCRUEDEXPENSES",
     "shortName": "ACCRUED EXPENSES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - STOCKHOLDERS\u2019 EQUITY",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.ovidrx.com/role/STOCKHOLDERSEQUITY",
     "shortName": "STOCKHOLDERS\u2019 EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - STOCK-BASED COMPENSATION",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - INCOME TAXES",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.ovidrx.com/role/INCOMETAXES",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.ovidrx.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - COLLABORATION AND LICENSE AGREEMENTS",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTS",
     "shortName": "COLLABORATION AND LICENSE AGREEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - RELATED PARTY TRANSACTIONS",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.ovidrx.com/role/RELATEDPARTYTRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-3",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-3",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - NET LOSS PER SHARE",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.ovidrx.com/role/NETLOSSPERSHARE",
     "shortName": "NET LOSS PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ovid:UnauditedInterimFinancialStatementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954701 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "menuCat": "Policies",
     "order": "21",
     "role": "http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ovid:UnauditedInterimFinancialStatementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954702 - Disclosure - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESTables",
     "shortName": "CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954703 - Disclosure - PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSTables",
     "shortName": "PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ovid:RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954704 - Disclosure - LEASES (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.ovidrx.com/role/LEASESTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ovid:RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954705 - Disclosure - ACCRUED EXPENSES (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.ovidrx.com/role/ACCRUEDEXPENSESTables",
     "shortName": "ACCRUED EXPENSES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954706 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONTables",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954707 - Disclosure - NET LOSS PER SHARE (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.ovidrx.com/role/NETLOSSPERSHARETables",
     "shortName": "NET LOSS PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-3",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954708 - Disclosure - NATURE OF OPERATIONS - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.ovidrx.com/role/NATUREOFOPERATIONSAdditionalInformationDetail",
     "shortName": "NATURE OF OPERATIONS - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-58",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-3",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954709 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-61",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LongTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-3",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-3",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-3",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954710 - Disclosure - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Fair Value of Cash and Cash Equivalents and Gross Unrealized Holding Gains and Losses (Detail)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail",
     "shortName": "CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Fair Value of Cash and Cash Equivalents and Gross Unrealized Holding Gains and Losses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-3",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-5",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954711 - Disclosure - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail",
     "shortName": "CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-5",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-3",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954712 - Disclosure - PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS - Summary of Property and Equipment (Detail)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSSummaryofPropertyandEquipmentDetail",
     "shortName": "PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS - Summary of Property and Equipment (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-3",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-5",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954713 - Disclosure - PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSAdditionalInformationDetail",
     "shortName": "PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-5",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-72",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954714 - Disclosure - LEASES - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.ovidrx.com/role/LEASESAdditionalInformationDetail",
     "shortName": "LEASES - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-72",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-3",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954715 - Disclosure - LEASES - Schedule of ROU Asset and Lease Liabilities Related to the Company Operating Lease (Detail)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.ovidrx.com/role/LEASESScheduleofROUAssetandLeaseLiabilitiesRelatedtotheCompanyOperatingLeaseDetail",
     "shortName": "LEASES - Schedule of ROU Asset and Lease Liabilities Related to the Company Operating Lease (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954716 - Disclosure - LEASES - Schedule of Components of Operating Lease Cost (Detail)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.ovidrx.com/role/LEASESScheduleofComponentsofOperatingLeaseCostDetail",
     "shortName": "LEASES - Schedule of Components of Operating Lease Cost (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-3",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954717 - Disclosure - LEASES - Schedule of Future Minimum Commitments Under Under the Non-Cancelable Operating Lease (Detail)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.ovidrx.com/role/LEASESScheduleofFutureMinimumCommitmentsUnderUndertheNonCancelableOperatingLeaseDetail",
     "shortName": "LEASES - Schedule of Future Minimum Commitments Under Under the Non-Cancelable Operating Lease (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-3",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-3",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954718 - Disclosure - ACCRUED EXPENSES - Schedule of Accrued Expenses (Detail)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.ovidrx.com/role/ACCRUEDEXPENSESScheduleofAccruedExpensesDetail",
     "shortName": "ACCRUED EXPENSES - Schedule of Accrued Expenses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-3",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-3",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954719 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.ovidrx.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetail",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": "0",
      "lang": "en-US",
      "name": "ovid:CommonStockNumberOfVotesForEachShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "vote",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-5",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-5",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-5",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954720 - Disclosure - STOCK-BASED COMPENSATION - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail",
     "shortName": "STOCK-BASED COMPENSATION - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-5",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954721 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Recognized Stock-Based Compensation Expense (Detail)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONScheduleofRecognizedStockBasedCompensationExpenseDetail",
     "shortName": "STOCK-BASED COMPENSATION - Schedule of Recognized Stock-Based Compensation Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-113",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-5",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954722 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Allocation of Stock-Based Compensation Expense by Plan (Detail)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONScheduleofAllocationofStockBasedCompensationExpensebyPlanDetail",
     "shortName": "STOCK-BASED COMPENSATION - Schedule of Allocation of Stock-Based Compensation Expense by Plan (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-125",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-105",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954723 - Disclosure - STOCK-BASED COMPENSATION - Summary of Assumptions Used to Compute Fair Value of Options Granted (Detail)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail",
     "shortName": "STOCK-BASED COMPENSATION - Summary of Assumptions Used to Compute Fair Value of Options Granted (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-105",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-4",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954724 - Disclosure - STOCK-BASED COMPENSATION - Summary of Options Outstanding and Weighted Average Exercise Price (Detail)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail",
     "shortName": "STOCK-BASED COMPENSATION - Summary of Options Outstanding and Weighted Average Exercise Price (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-5",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954725 - Disclosure - INCOME TAXES - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.ovidrx.com/role/INCOMETAXESAdditionalInformationDetail",
     "shortName": "INCOME TAXES - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-5",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954726 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.ovidrx.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-138",
      "decimals": "-5",
      "lang": "en-US",
      "name": "ovid:CollaborationAndOptionAgreementResearchPlanAndBudgetExpectedCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-3",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954727 - Disclosure - COLLABORATION AND LICENSE AGREEMENTS - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail",
     "shortName": "COLLABORATION AND LICENSE AGREEMENTS - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-142",
      "decimals": "-5",
      "lang": "en-US",
      "name": "ovid:UpfrontPaymentReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-5",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954728 - Disclosure - NET LOSS PER SHARE - Summary of Calculation of Basic and Diluted Earnings (Loss) per Share (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.ovidrx.com/role/NETLOSSPERSHARESummaryofCalculationofBasicandDilutedEarningsLossperShareDetails",
     "shortName": "NET LOSS PER SHARE - Summary of Calculation of Basic and Diluted Earnings (Loss) per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-5",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-155",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954729 - Disclosure - NET LOSS PER SHARE - Schedule of Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Shares Outstanding (Detail)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.ovidrx.com/role/NETLOSSPERSHAREScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageSharesOutstandingDetail",
     "shortName": "NET LOSS PER SHARE - Schedule of Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Shares Outstanding (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-155",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-5",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-5",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-32",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-38",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Condensed Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": "0",
      "lang": "en-US",
      "name": "ovid:NoncashConsiderationReceivedInLicensingAgreementTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - NATURE OF OPERATIONS",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.ovidrx.com/role/NATUREOFOPERATIONS",
     "shortName": "NATURE OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 48,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ovid_A2014EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2014 Employee Stock Purchase Plan",
        "label": "2014 Employee Stock Purchase Plan [Member]",
        "terseLabel": "2014 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "A2014EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_ATMAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ATM Agreement.",
        "label": "A T M Agreement [Member]",
        "terseLabel": "ATM Agreement"
       }
      }
     },
     "localname": "ATMAgreementMember",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_AccretionOfLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accretion of lease liability",
        "label": "Accretion of Lease Liability",
        "terseLabel": "Accretion of lease liability"
       }
      }
     },
     "localname": "AccretionOfLeaseLiability",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_AccruedResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.ovidrx.com/role/ACCRUEDEXPENSESScheduleofAccruedExpensesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development.",
        "label": "Accrued Research And Development",
        "terseLabel": "Research and development accrual"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopment",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/ACCRUEDEXPENSESScheduleofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_AdditionalPaymentReceivableOnSalesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional payment receivable on sales percentage.",
        "label": "Additional Payment Receivable On Sales Percentage",
        "terseLabel": "Additional payment on sales percentage (up to)"
       }
      }
     },
     "localname": "AdditionalPaymentReceivableOnSalesPercentage",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ovid_AggregateOfferingPriceOfCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate offering price of common stock.",
        "label": "Aggregate Offering Price Of Common Stock",
        "terseLabel": "Net proceeds from offering, value"
       }
      }
     },
     "localname": "AggregateOfferingPriceOfCommonStock",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_AgreementMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate milestone payments.",
        "label": "Agreement Milestone Payments",
        "terseLabel": "Aggregate milestone payments"
       }
      }
     },
     "localname": "AgreementMilestonePayments",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowable Owning Percentage Of Outstanding Common Stock By Associates Or Affiliates",
        "label": "Allowable Owning Percentage Of Outstanding Common Stock By Associates Or Affiliates",
        "terseLabel": "Allowable voting right percentage of outstanding common stock holders"
       }
      }
     },
     "localname": "AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ovid_AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowable Owning Percentage Of Outstanding Common Stock By Associates Or Affiliates, Notice Period",
        "label": "Allowable Owning Percentage Of Outstanding Common Stock By Associates Or Affiliates, Notice Period",
        "terseLabel": "Allowable voting right percentage of outstanding common stock holders upon notice of days"
       }
      }
     },
     "localname": "AllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliatesNoticePeriod",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "ovid_AnnualLicenseMaintenanceFeePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual license maintenance fee payable.",
        "label": "Annual License Maintenance Fee Payable",
        "terseLabel": "Annual license maintenance fee payable"
       }
      }
     },
     "localname": "AnnualLicenseMaintenanceFeePayable",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_AstrazenecaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AstraZeneca",
        "label": "AstraZeneca [Member]",
        "terseLabel": "AstraZeneca"
       }
      }
     },
     "localname": "AstrazenecaMember",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beneficial Ownership Limitations, Percentage of Issued and Outstanding Common Stock",
        "label": "Beneficial Ownership Limitations, Percentage of Issued and Outstanding Common Stock",
        "terseLabel": "Beneficial ownership limitations, percentage of issued and outstanding common stock"
       }
      }
     },
     "localname": "BeneficialOwnershipLimitationsPercentageOfIssuedAndOutstandingCommonStock",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents And Available-for-sale Debt Securities, Amortized Cost",
        "label": "Cash, Cash Equivalents And Available-for-sale Debt Securities, Amortized Cost",
        "totalLabel": "Total cash, cash equivalents and marketable securities, amortized cost"
       }
      }
     },
     "localname": "CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_CashEquivalentsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail_1": {
       "order": 1.0,
       "parentTag": "ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Equivalents, Amortized Cost",
        "label": "Cash Equivalents, Amortized Cost",
        "totalLabel": "Cash equivalents, amortized cost"
       }
      }
     },
     "localname": "CashEquivalentsAmortizedCost",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_CashEquivalentsUnrealizedHoldingGains": {
     "auth_ref": [],
     "calculation": {
      "http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail": {
       "order": 1.0,
       "parentTag": "ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingGain",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Equivalents, Unrealized Holding Gains",
        "label": "Cash Equivalents, Unrealized Holding Gains",
        "terseLabel": "Cash equivalents, unrealized holding gains"
       }
      }
     },
     "localname": "CashEquivalentsUnrealizedHoldingGains",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_CashEquivalentsUnrealizedHoldingLosses": {
     "auth_ref": [],
     "calculation": {
      "http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail": {
       "order": 2.0,
       "parentTag": "ovid_CashEquivalentsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Equivalents, Unrealized Holding Losses",
        "label": "Cash Equivalents, Unrealized Holding Losses",
        "negatedTerseLabel": "Cash equivalents, unrealized holding losses"
       }
      }
     },
     "localname": "CashEquivalentsUnrealizedHoldingLosses",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_ChangeInAccruedInterestAndAccretionOfDiscountsShortTermInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued interest and accretion of discounts, short term investments.",
        "label": "Change In Accrued Interest And Accretion Of Discounts Short Term Investments",
        "terseLabel": "Change in accrued interest and accretion of discount on marketable securities"
       }
      }
     },
     "localname": "ChangeInAccruedInterestAndAccretionOfDiscountsShortTermInvestments",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_CollaborationAndOptionAgreementResearchPlanAndBudgetExpectedCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and Option Agreement, Research Plan And Budget, Expected Costs",
        "label": "Collaboration and Option Agreement, Research Plan And Budget, Expected Costs",
        "terseLabel": "Research plan and budget, expected costs"
       }
      }
     },
     "localname": "CollaborationAndOptionAgreementResearchPlanAndBudgetExpectedCosts",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Issuance , Period Immediately Preceding Execution Date",
        "label": "Common Stock Issuance , Period Immediately Preceding Execution Date",
        "terseLabel": "Days immediately preceding the execution date"
       }
      }
     },
     "localname": "CommonStockIssuancePeriodImmediatelyPrecedingExecutionDate",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "ovid_CommonStockNumberOfVotesForEachShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Number Of Votes For Each Share",
        "label": "Common Stock, Number Of Votes For Each Share",
        "terseLabel": "Number of votes per share"
       }
      }
     },
     "localname": "CommonStockNumberOfVotesForEachShare",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "ovid_ConsiderationPayableForRightsGrant": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consideration payable for rights grant.",
        "label": "Consideration Payable For Rights Grant",
        "terseLabel": "Consideration payable for rights grant"
       }
      }
     },
     "localname": "ConsiderationPayableForRightsGrant",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_CowenAndCompanyLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cowen and Company, LLC.",
        "label": "Cowen And Company L L C [Member]",
        "terseLabel": "Cowen And Company, LLC"
       }
      }
     },
     "localname": "CowenAndCompanyLLCMember",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingGain": {
     "auth_ref": [],
     "calculation": {
      "http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail": {
       "order": 2.0,
       "parentTag": "ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax, Including Cash Equivalents, Accumulated Unrealized Holding Gain",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax, Including Cash Equivalents, Accumulated Unrealized Holding Gain",
        "totalLabel": "Total cash, cash equivalents and marketable securities, unrealized holding gains"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingGain",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail": {
       "order": 1.0,
       "parentTag": "ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax, Including Cash Equivalents, Accumulated Unrealized Holding Loss",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax, Including Cash Equivalents, Accumulated Unrealized Holding Loss",
        "negatedTotalLabel": "Total cash, cash equivalents and marketable securities, unrealized holding losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingLoss",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_EmployeePerformanceBasedOptionAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee performance based option awards.",
        "label": "Employee Performance Based Option Awards [Member]",
        "terseLabel": "Employee Performance Based Option Awards"
       }
      }
     },
     "localname": "EmployeePerformanceBasedOptionAwardsMember",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONScheduleofAllocationofStockBasedCompensationExpensebyPlanDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_FirstPaymentDueUponCompletionOfFirstPhase": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First payment due upon completion of first phase.",
        "label": "First Payment Due Upon Completion Of First Phase",
        "terseLabel": "First payment due upon completion of first phase"
       }
      }
     },
     "localname": "FirstPaymentDueUponCompletionOfFirstPhase",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_GensaicIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gensaic, Inc",
        "label": "Gensaic, Inc [Member]",
        "terseLabel": "Gensaic, Inc"
       }
      }
     },
     "localname": "GensaicIncMember",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_GravitonBioscienceCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Graviton Bioscience Corporation",
        "label": "Graviton Bioscience Corporation [Member]",
        "terseLabel": "Graviton Bioscience Corporation"
       }
      }
     },
     "localname": "GravitonBioscienceCorporationMember",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail",
      "http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_HLundbeckASMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "H. Lundbeck A/S.",
        "label": "H Lundbeck A S [Member]",
        "terseLabel": "Lundbeck"
       }
      }
     },
     "localname": "HLundbeckASMember",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_HealxLicenseAndOptionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Healx License and Option Agreement",
        "label": "Healx License and Option Agreement [Member].",
        "terseLabel": "Healx License and Option Agreement"
       }
      }
     },
     "localname": "HealxLicenseAndOptionAgreementMember",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_LeaseIncrementalBorrowingRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease incremental borrowing rate",
        "label": "Lease Incremental Borrowing Rate",
        "terseLabel": "Lease incremental borrowing rate"
       }
      }
     },
     "localname": "LeaseIncrementalBorrowingRate",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/LEASESAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ovid_LesseeOperatingLeaseBaseRent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease, Base Rent",
        "label": "Lessee Operating Lease, Base Rent",
        "terseLabel": "Rent lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseBaseRent",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/LEASESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.ovidrx.com/role/LEASESScheduleofFutureMinimumCommitmentsUnderUndertheNonCancelableOperatingLeaseDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, to be Paid, Due after Year Four",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Due after Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/LEASESScheduleofFutureMinimumCommitmentsUnderUndertheNonCancelableOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Rent Payments Commencement Following This Period",
        "label": "Lessee, Operating Lease, Rent Payments Commencement Following This Period",
        "terseLabel": "Rent payments commencement following this period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRentPaymentsCommencementFollowingThisPeriod",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/LEASESAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "ovid_LicenseAgreementConsiderationSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Consideration, Shares Issued",
        "label": "License Agreement, Consideration, Shares Issued",
        "terseLabel": "License agreement, consideration (in shares)"
       }
      }
     },
     "localname": "LicenseAgreementConsiderationSharesIssued",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "ovid_LicenseAgreementDevelopmentMilestoneApprovalsProductThreshold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Development Milestone Approvals, Product Threshold",
        "label": "License Agreement, Development Milestone Approvals, Product Threshold",
        "terseLabel": "Developmental milestone approvals, number of products (at least)"
       }
      }
     },
     "localname": "LicenseAgreementDevelopmentMilestoneApprovalsProductThreshold",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "ovid_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement.",
        "label": "License Agreement [Member]",
        "terseLabel": "License Agreement"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_LicenseAgreementMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global commercial and regulatory milestone payments.",
        "label": "License Agreement Milestone Payments",
        "terseLabel": "License agreement milestone payments (up to)"
       }
      }
     },
     "localname": "LicenseAgreementMilestonePayments",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_LicenseAgreementTerminationAdvanceNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Termination, Advance Notice Period",
        "label": "License Agreement, Termination, Advance Notice Period",
        "terseLabel": "Advance written notice required to terminate agreement"
       }
      }
     },
     "localname": "LicenseAgreementTerminationAdvanceNoticePeriod",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "ovid_LicenseAndCollaborationAgreementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and Collaboration Agreement, Expense",
        "label": "License and Collaboration Agreement, Expense",
        "terseLabel": "Related party transaction expenses recognized"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementExpense",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_LicenseOptionAgreementDevelopmentAndCommercialMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Option Agreement, Development and Commercial Milestone Payments",
        "label": "License Option Agreement, Development and Commercial Milestone Payments",
        "terseLabel": "Development and commercial milestone payments"
       }
      }
     },
     "localname": "LicenseOptionAgreementDevelopmentAndCommercialMilestonePayments",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_LicenseOptionAgreementExtensionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Option Agreement, Extension Period",
        "label": "License Option Agreement, Extension Period",
        "terseLabel": "Granted option extension period"
       }
      }
     },
     "localname": "LicenseOptionAgreementExtensionPeriod",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "ovid_MarinusLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "marinus license agreement member.",
        "label": "Marinus License Agreement [Member]",
        "terseLabel": "Marinus License Agreement"
       }
      }
     },
     "localname": "MarinusLicenseAgreementMember",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_MarinusPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marinus pharmaceuticals, inc [Member]",
        "label": "Marinus Pharmaceuticals, Inc [Member]",
        "terseLabel": "Marinus Pharmaceuticals, Inc"
       }
      }
     },
     "localname": "MarinusPharmaceuticalsIncMember",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_MarinusTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marinus therapeutics inc member.",
        "label": "Marinus Therapeutics Inc [Member]",
        "terseLabel": "Marinus Therapeutics, Inc"
       }
      }
     },
     "localname": "MarinusTherapeuticsIncMember",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum allowable owning percentage of outstanding common stock by associates or affiliates.",
        "label": "Maximum Allowable Owning Percentage Of Outstanding Common Stock By Associates Or Affiliates",
        "terseLabel": "Maximum allowable owning percentage of outstanding common stock by associates or affiliates"
       }
      }
     },
     "localname": "MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum allowable voting right percentage of outstanding common stock holders.",
        "label": "Maximum Allowable Voting Right Percentage Of Outstanding Common Stock Holders",
        "terseLabel": "Maximum allowable voting right percentage of outstanding common stock holders"
       }
      }
     },
     "localname": "MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum number of product covered under license agreement",
        "label": "Minimum Number Of Product Covered Under License Agreement",
        "terseLabel": "Minimum number of product covered under license agreement"
       }
      }
     },
     "localname": "MinimumNumberOfProductCoveredUnderLicenseAgreement",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "ovid_MoneyMarketFundsAndShortTermInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money market funds and short-term investments.",
        "label": "Money Market Funds And Short Term Investments [Member]",
        "terseLabel": "Money Market Funds and Short-term Investments"
       }
      }
     },
     "localname": "MoneyMarketFundsAndShortTermInvestmentsMember",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_NoncashConsiderationReceivedInLicensingAgreementTransaction": {
     "auth_ref": [],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash consideration received in licensing agreement transaction.",
        "label": "Noncash Consideration Received in Licensing Agreement Transaction",
        "negatedLabel": "Non-cash consideration received in licensing agreement transaction"
       }
      }
     },
     "localname": "NoncashConsiderationReceivedInLicensingAgreementTransaction",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_NonemployeePerformanceBasedOptionAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-employee performance based option awards.",
        "label": "Nonemployee Performance Based Option Awards [Member]",
        "terseLabel": "Non-employee Performance Based Option Awards"
       }
      }
     },
     "localname": "NonemployeePerformanceBasedOptionAwardsMember",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_NorthwesternUniversityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Northwestern University.",
        "label": "Northwestern University [Member]",
        "terseLabel": "Northwestern University"
       }
      }
     },
     "localname": "NorthwesternUniversityMember",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_PatentLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent license agreement [Member].",
        "label": "Patent License Agreement [Member]",
        "terseLabel": "Patent License Agreement"
       }
      }
     },
     "localname": "PatentLicenseAgreementMember",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_PaymentsForProceedsFromIssuanceOfShortTermNoteReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for (Proceeds from) Issuance of Short-Term Note Receivable",
        "label": "Payments for (Proceeds from) Issuance of Short-Term Note Receivable",
        "negatedTerseLabel": "Issuance of convertible short-term note receivable"
       }
      }
     },
     "localname": "PaymentsForProceedsFromIssuanceOfShortTermNoteReceivable",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_PercentageOfDevelopmentCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of development costs.",
        "label": "Percentage of Development Costs",
        "terseLabel": "Percentage of development costs"
       }
      }
     },
     "localname": "PercentageOfDevelopmentCosts",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ovid_PreferredStockShareDesignated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock shares designated.",
        "label": "Preferred Stock Share Designated",
        "terseLabel": "Preferred stock, share designated (in shares)"
       }
      }
     },
     "localname": "PreferredStockShareDesignated",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "ovid_RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-of-use asset and lease liabilities operating lease table text block.",
        "label": "Right-Of-Use Asset and Lease Liabilities Operating Lease [Table Text Block]",
        "terseLabel": "Schedule of ROU Asset and Lease Liabilities Related to the Company Operating Lease"
       }
      }
     },
     "localname": "RightOfUseAssetAndLeaseLiabilitiesOperatingLeaseTableTextBlock",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ovid_RoyaltyObligationTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Obligation, Term",
        "label": "Royalty Obligation, Term",
        "terseLabel": "Royalty obligation period"
       }
      }
     },
     "localname": "RoyaltyObligationTerm",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "ovid_SeriesAConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A convertible preferred stock.",
        "label": "Series A Convertible Preferred Stock [Member]",
        "terseLabel": "Series A Convertible Preferred Stock",
        "verboseLabel": "Common stock issuable upon conversion of Series A convertible preferred stock"
       }
      }
     },
     "localname": "SeriesAConvertiblePreferredStockMember",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/NETLOSSPERSHAREScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageSharesOutstandingDetail",
      "http://www.ovidrx.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized, Maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized, Maximum",
        "terseLabel": "Common stock, reserved for future issuance increase (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorizedMaximum",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "ovid_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum, Increase",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum, Increase",
        "terseLabel": "Percentage increase, outstanding stock maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumIncrease",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation by share based payment award options granted contractual life.",
        "label": "Share Based Compensation By Share Based Payment Award Options Granted Contractual Life",
        "terseLabel": "Weighted Average Remaining Contractual Life in Years, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "ovid_SummaryOfSignificantAccountingPolicyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policy.",
        "label": "Summary Of Significant Accounting Policy [Line Items]",
        "terseLabel": "Summary of Significant Accounting Policy [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPolicyLineItems",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ovid_SummaryOfSignificantAccountingPolicyTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policy.",
        "label": "Summary Of Significant Accounting Policy [Table]",
        "terseLabel": "Summary Of Significant Accounting Policy [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPolicyTable",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ovid_TakedaPharmaceuticalCompanyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Takeda Pharmaceutical Company Limited.",
        "label": "Takeda Pharmaceutical Company Limited [Member]",
        "terseLabel": "Takeda Pharmaceutical Company Limited"
       }
      }
     },
     "localname": "TakedaPharmaceuticalCompanyLimitedMember",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 employee stock purchase plan.",
        "label": "Two Thousand Seventeen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2017 ESPP"
       }
      }
     },
     "localname": "TwoThousandSeventeenEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_TwoThousandSeventeenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 equity incentive plan.",
        "label": "Two Thousand Seventeen Equity Incentive Plan [Member]",
        "terseLabel": "2017 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandSeventeenEquityIncentivePlanMember",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ovid_UnauditedInterimFinancialStatementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unaudited interim financial statements.",
        "label": "Unaudited Interim Financial Statements Policy [Policy Text Block]",
        "terseLabel": "Unaudited Interim Condensed Consolidated Financial Statements"
       }
      }
     },
     "localname": "UnauditedInterimFinancialStatementsPolicyPolicyTextBlock",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ovid_UpFrontFeeAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Up-front fee amount.",
        "label": "Up Front Fee Amount",
        "terseLabel": "Up-front fee"
       }
      }
     },
     "localname": "UpFrontFeeAmount",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_UpFrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Up front Payment.",
        "label": "Up Front Payment",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "UpFrontPayment",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_UpfrontCashPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront Cash Payment",
        "label": "Upfront Cash Payment",
        "terseLabel": "Upfront cash payment"
       }
      }
     },
     "localname": "UpfrontCashPayment",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront non-creditable one-time license issuance fee payment.",
        "label": "Upfront Non Creditable One Time License Issuance Fee Payment",
        "terseLabel": "Upfront non-creditable one-time license issuance fee payment"
       }
      }
     },
     "localname": "UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_UpfrontPaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment receivable.",
        "label": "Upfront Payment Receivable",
        "terseLabel": "Upfront payment under royalty and termination agreement"
       }
      }
     },
     "localname": "UpfrontPaymentReceivable",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ovid_WorkingCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Working capital.",
        "label": "Working Capital",
        "terseLabel": "Working capital"
       }
      }
     },
     "localname": "WorkingCapital",
     "nsuri": "http://www.ovidrx.com/20230630",
     "presentation": [
      "http://www.ovidrx.com/role/NATUREOFOPERATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r150",
      "r151",
      "r235",
      "r240",
      "r366",
      "r517",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.ovidrx.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail",
      "http://www.ovidrx.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [
      "r209",
      "r210",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail",
      "http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r221",
      "r222",
      "r223",
      "r224",
      "r265",
      "r372",
      "r409",
      "r442",
      "r443",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r513",
      "r514",
      "r525",
      "r528",
      "r532",
      "r537",
      "r595",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.ovidrx.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail",
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail",
      "http://www.ovidrx.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r221",
      "r222",
      "r223",
      "r224",
      "r265",
      "r372",
      "r409",
      "r442",
      "r443",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r513",
      "r514",
      "r525",
      "r528",
      "r532",
      "r537",
      "r595",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r221",
      "r222",
      "r223",
      "r224",
      "r257",
      "r265",
      "r293",
      "r294",
      "r295",
      "r371",
      "r372",
      "r409",
      "r442",
      "r443",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r513",
      "r514",
      "r525",
      "r528",
      "r532",
      "r537",
      "r540",
      "r589",
      "r595",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.ovidrx.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail",
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail",
      "http://www.ovidrx.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r221",
      "r222",
      "r223",
      "r224",
      "r257",
      "r265",
      "r293",
      "r294",
      "r295",
      "r371",
      "r372",
      "r409",
      "r442",
      "r443",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r513",
      "r514",
      "r525",
      "r528",
      "r532",
      "r537",
      "r540",
      "r589",
      "r595",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.ovidrx.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail",
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail",
      "http://www.ovidrx.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r150",
      "r151",
      "r235",
      "r240",
      "r366",
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.ovidrx.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail",
      "http://www.ovidrx.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r209",
      "r210",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail",
      "http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "ACCRUED EXPENSES"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/ACCRUEDEXPENSES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r18",
      "r536"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/ACCRUEDEXPENSESScheduleofAccruedExpensesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/ACCRUEDEXPENSESScheduleofAccruedExpensesDetail",
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/ACCRUEDEXPENSESScheduleofAccruedExpensesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees accrual"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/ACCRUEDEXPENSESScheduleofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r41",
      "r119",
      "r401"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSSummaryofPropertyandEquipmentDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r26",
      "r27",
      "r69",
      "r125",
      "r397",
      "r414",
      "r415"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r2",
      "r11",
      "r27",
      "r331",
      "r334",
      "r359",
      "r410",
      "r411",
      "r559",
      "r560",
      "r561",
      "r568",
      "r569",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r64",
      "r536",
      "r644"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in-capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r302",
      "r303",
      "r304",
      "r429",
      "r568",
      "r569",
      "r570",
      "r625",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r53",
      "r54",
      "r268"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r297",
      "r305"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Share based compensation expense",
        "verboseLabel": "Stock-based compensation expense, Total"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail",
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONScheduleofAllocationofStockBasedCompensationExpensebyPlanDetail",
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONScheduleofRecognizedStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r8",
      "r38",
      "r39"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Dilutive securities excluded from computations of diluted weighted average shares outstanding (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/NETLOSSPERSHAREScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageSharesOutstandingDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/NETLOSSPERSHAREScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageSharesOutstandingDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Dilutive Securities Included and Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/NETLOSSPERSHAREScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageSharesOutstandingDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/NETLOSSPERSHAREScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageSharesOutstandingDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail",
      "http://www.ovidrx.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r95",
      "r121",
      "r146",
      "r186",
      "r193",
      "r197",
      "r212",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r326",
      "r328",
      "r342",
      "r393",
      "r464",
      "r536",
      "r547",
      "r593",
      "r594",
      "r632"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r114",
      "r126",
      "r146",
      "r212",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r326",
      "r328",
      "r342",
      "r536",
      "r593",
      "r594",
      "r632"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Fair value assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r206"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Marketable securities, unrealized holding gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r207"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail": {
       "order": 2.0,
       "parentTag": "ovid_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxIncludingCashEquivalentsAccumulatedUnrealizedHoldingLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Marketable securities, unrealized holding losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r204",
      "r215",
      "r392"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail_1": {
       "order": 2.0,
       "parentTag": "ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Marketable securities, Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r205",
      "r215",
      "r387",
      "r573"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Marketable securities, fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail",
      "http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r203",
      "r215"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail",
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONScheduleofAllocationofStockBasedCompensationExpensebyPlanDetail",
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r100",
      "r394",
      "r440",
      "r459",
      "r536",
      "r547",
      "r555"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
       "weight": 1.0
      },
      "http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail_1": {
       "order": 3.0,
       "parentTag": "ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash Amortized cost"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r31",
      "r116",
      "r516"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r32",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r558"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail": {
       "order": 3.0,
       "parentTag": "ovid_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents, and marketable securities",
        "totalLabel": "Total cash, cash equivalents and marketable securities, fair value"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail",
      "http://www.ovidrx.com/role/NATUREOFOPERATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r31",
      "r75",
      "r143"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r1",
      "r75"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r555",
      "r642"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail": {
       "order": 3.0,
       "parentTag": "ovid_CashEquivalentsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash equivalents, fair value"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r111",
      "r122",
      "r123",
      "r124",
      "r146",
      "r169",
      "r170",
      "r174",
      "r178",
      "r184",
      "r185",
      "r212",
      "r226",
      "r228",
      "r229",
      "r230",
      "r233",
      "r234",
      "r238",
      "r239",
      "r242",
      "r245",
      "r253",
      "r342",
      "r420",
      "r421",
      "r422",
      "r423",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r441",
      "r451",
      "r473",
      "r493",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r554",
      "r566",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail",
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.ovidrx.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r184",
      "r238",
      "r239",
      "r240",
      "r242",
      "r245",
      "r251",
      "r253",
      "r420",
      "r421",
      "r422",
      "r423",
      "r528",
      "r554",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r101",
      "r103",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "COLLABORATION AND LICENSE AGREEMENTS"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement, Co-promotion"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r84",
      "r218",
      "r219",
      "r512",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock, reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r538",
      "r539",
      "r540",
      "r542",
      "r543",
      "r544",
      "r545",
      "r568",
      "r569",
      "r625",
      "r643",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.ovidrx.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail",
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r63",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.ovidrx.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail",
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r12",
      "r63",
      "r451",
      "r470",
      "r645",
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r63",
      "r396",
      "r536"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 125,000,000 shares authorized; 70,602,793 and 70,466,885 shares issued and outstanding at June\u00a030, 2023 and December\u00a031, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r28",
      "r130",
      "r132",
      "r137",
      "r388",
      "r405"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r55",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r238",
      "r239",
      "r242",
      "r542",
      "r543",
      "r544",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Series A Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r17",
      "r45",
      "r62",
      "r87",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Number of shares issued for each share of convertible preferred stock that is converted (in shares)"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "auth_ref": [
      "r586"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)",
        "terseLabel": "Gains or losses on available-for-sale securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Schedule of Debt Securities, Available-for-Sale"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r8",
      "r40"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r8",
      "r189"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r266",
      "r270",
      "r298",
      "r299",
      "r301",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_Dividends": {
     "auth_ref": [
      "r4",
      "r89"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.",
        "label": "Dividends",
        "terseLabel": "Dividends declared"
       }
      }
     },
     "localname": "Dividends",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r138",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r166",
      "r169",
      "r174",
      "r177",
      "r178",
      "r182",
      "r338",
      "r339",
      "r389",
      "r406",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Net loss per share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.ovidrx.com/role/NETLOSSPERSHARESummaryofCalculationofBasicandDilutedEarningsLossperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r138",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r169",
      "r174",
      "r177",
      "r178",
      "r182",
      "r338",
      "r339",
      "r389",
      "r406",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Net loss per share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.ovidrx.com/role/NETLOSSPERSHARESummaryofCalculationofBasicandDilutedEarningsLossperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r33",
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r165",
      "r179",
      "r180",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "NET LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/NETLOSSPERSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/ACCRUEDEXPENSESScheduleofAccruedExpensesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and bonus accrual"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/ACCRUEDEXPENSESScheduleofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r300"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expenses"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation not yet recognized, period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock options",
        "verboseLabel": "Stock options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/NETLOSSPERSHAREScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageSharesOutstandingDetail",
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail",
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONScheduleofAllocationofStockBasedCompensationExpensebyPlanDetail",
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r12",
      "r112",
      "r134",
      "r135",
      "r136",
      "r152",
      "r153",
      "r154",
      "r156",
      "r162",
      "r164",
      "r183",
      "r213",
      "r214",
      "r254",
      "r302",
      "r303",
      "r304",
      "r318",
      "r319",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r359",
      "r410",
      "r411",
      "r412",
      "r429",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.ovidrx.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Agreement ownership share"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r6",
      "r58",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Long-Term Equity Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r407",
      "r587"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "negatedLabel": "Unrealized (gain) loss on equity investment",
        "terseLabel": "Unrealized gain (loss) on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail",
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r56",
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r236",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r340",
      "r368",
      "r369",
      "r370",
      "r526",
      "r527",
      "r529",
      "r530",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r236",
      "r258",
      "r263",
      "r340",
      "r368",
      "r529",
      "r530",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r236",
      "r258",
      "r263",
      "r340",
      "r369",
      "r526",
      "r527",
      "r529",
      "r530",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r236",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r368",
      "r369",
      "r370",
      "r526",
      "r527",
      "r529",
      "r530",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r81",
      "r374"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Intangible assets, net of accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and equipment"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r72",
      "r475"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r267",
      "r269",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]",
        "terseLabel": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail",
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [
      "r267",
      "r269",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]",
        "terseLabel": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail",
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r70",
      "r97",
      "r186",
      "r192",
      "r196",
      "r198",
      "r390",
      "r403",
      "r524"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r216",
      "r217",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONScheduleofRecognizedStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r217",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONScheduleofRecognizedStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r147",
      "r308",
      "r312",
      "r313",
      "r316",
      "r320",
      "r322",
      "r323",
      "r324",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/INCOMETAXES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r99",
      "r109",
      "r163",
      "r164",
      "r190",
      "r311",
      "r321",
      "r408"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "(Benefit) provision for income taxes",
        "verboseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.ovidrx.com/role/INCOMETAXESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r133",
      "r309",
      "r310",
      "r313",
      "r314",
      "r315",
      "r317",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r7"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r7"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r563"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Security deposit"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r7"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for cash, cash equivalents, investments in debt and equity instruments (including cost and equity investees and related income statement amounts), equity and cost method investments, investments in joint ventures and any other investment.",
        "label": "Investments in Debt and Equity Instruments, Cash and Cash Equivalents, Unrealized and Realized Gains (Losses) [Text Block]",
        "terseLabel": "CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES"
       }
      }
     },
     "localname": "InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LandSubjectToGroundLeases": {
     "auth_ref": [
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land subject to a ground lease.",
        "label": "Land Subject to Ground Leases",
        "terseLabel": "Land subject to ground leases (sqft)"
       }
      }
     },
     "localname": "LandSubjectToGroundLeases",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/LEASESAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Components of Operating Lease Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/LEASESAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Commitments Under the non-cancelable Operating Lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r358"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/LEASESScheduleofFutureMinimumCommitmentsUnderUndertheNonCancelableOperatingLeaseDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total operating lease, liability, to be paid"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/LEASESScheduleofFutureMinimumCommitmentsUnderUndertheNonCancelableOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r358"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/LEASESScheduleofFutureMinimumCommitmentsUnderUndertheNonCancelableOperatingLeaseDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/LEASESScheduleofFutureMinimumCommitmentsUnderUndertheNonCancelableOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r358"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/LEASESScheduleofFutureMinimumCommitmentsUnderUndertheNonCancelableOperatingLeaseDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/LEASESScheduleofFutureMinimumCommitmentsUnderUndertheNonCancelableOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r358"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/LEASESScheduleofFutureMinimumCommitmentsUnderUndertheNonCancelableOperatingLeaseDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/LEASESScheduleofFutureMinimumCommitmentsUnderUndertheNonCancelableOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r358"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/LEASESScheduleofFutureMinimumCommitmentsUnderUndertheNonCancelableOperatingLeaseDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/LEASESScheduleofFutureMinimumCommitmentsUnderUndertheNonCancelableOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r630"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/LEASESScheduleofFutureMinimumCommitmentsUnderUndertheNonCancelableOperatingLeaseDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/LEASESScheduleofFutureMinimumCommitmentsUnderUndertheNonCancelableOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease terms"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/LEASESAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal option term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/LEASESAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease, term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/LEASESAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/LEASES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/LEASESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r21",
      "r146",
      "r212",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r327",
      "r328",
      "r329",
      "r342",
      "r450",
      "r523",
      "r547",
      "r593",
      "r632",
      "r633"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r68",
      "r96",
      "r399",
      "r536",
      "r567",
      "r588",
      "r626"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r23",
      "r115",
      "r146",
      "r212",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r327",
      "r328",
      "r329",
      "r342",
      "r536",
      "r593",
      "r632",
      "r633"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Long-term liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-Term Investments",
        "terseLabel": "Long-term equity investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r225",
      "r591",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r225",
      "r591",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "Money Market Funds, at Carrying Value",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofFairValueofCashandCashEquivalentsandGrossUnrealizedHoldingGainsandLossesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r142"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r142"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r75",
      "r76",
      "r77"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedTerseLabel": "Cash used in operating activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.ovidrx.com/role/NATUREOFOPERATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r71",
      "r77",
      "r98",
      "r113",
      "r129",
      "r131",
      "r136",
      "r146",
      "r155",
      "r157",
      "r158",
      "r159",
      "r160",
      "r163",
      "r164",
      "r171",
      "r186",
      "r192",
      "r196",
      "r198",
      "r212",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r339",
      "r342",
      "r404",
      "r472",
      "r491",
      "r492",
      "r524",
      "r546",
      "r593"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ovidrx.com/role/NETLOSSPERSHARESummaryofCalculationofBasicandDilutedEarningsLossperShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss)",
        "negatedTerseLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net (loss) income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.ovidrx.com/role/NATUREOFOPERATIONSAdditionalInformationDetail",
      "http://www.ovidrx.com/role/NETLOSSPERSHARESummaryofCalculationofBasicandDilutedEarningsLossperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r139",
      "r157",
      "r158",
      "r159",
      "r160",
      "r166",
      "r167",
      "r173",
      "r178",
      "r186",
      "r192",
      "r196",
      "r198",
      "r524"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/NETLOSSPERSHARESummaryofCalculationofBasicandDilutedEarningsLossperShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss attributable to common stockholders",
        "totalLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/NETLOSSPERSHARESummaryofCalculationofBasicandDilutedEarningsLossperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r186",
      "r192",
      "r196",
      "r198",
      "r524"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r354",
      "r535"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/LEASESScheduleofComponentsofOperatingLeaseCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r351"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion, lease liability",
        "verboseLabel": "Current lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.ovidrx.com/role/LEASESScheduleofROUAssetandLeaseLiabilitiesRelatedtotheCompanyOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r351"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liability",
        "verboseLabel": "Long-term lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.ovidrx.com/role/LEASESScheduleofROUAssetandLeaseLiabilitiesRelatedtotheCompanyOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r350"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use asset, net",
        "verboseLabel": "Right-of-use asset, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.ovidrx.com/role/LEASESScheduleofROUAssetandLeaseLiabilitiesRelatedtotheCompanyOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r564"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "terseLabel": "Amortization of right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r61",
      "r92",
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "NATURE OF OPERATIONS"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/NATUREOFOPERATIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/ACCRUEDEXPENSESScheduleofAccruedExpensesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/ACCRUEDEXPENSESScheduleofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent": {
     "auth_ref": [
      "r5",
      "r10",
      "r93"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent",
        "verboseLabel": "Other comprehensive income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive (loss) income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r127",
      "r128",
      "r208"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized (loss) gain on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock": {
     "auth_ref": [
      "r30"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire preferred stock during the period.",
        "label": "Payments for Repurchase of Preferred Stock and Preference Stock",
        "terseLabel": "Purchase of preferred stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfPreferredStockAndPreferenceStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r29",
      "r140",
      "r202"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedTerseLabel": "Purchase of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireLongtermInvestments": {
     "auth_ref": [
      "r562"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.",
        "label": "Payments to Acquire Long-Term Investments",
        "negatedTerseLabel": "Purchase of long-term equity investment"
       }
      }
     },
     "localname": "PaymentsToAcquireLongtermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToDevelopSoftware": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the development or modification of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.",
        "label": "Payments to Develop Software",
        "negatedLabel": "Software development and other costs"
       }
      }
     },
     "localname": "PaymentsToDevelopSoftware",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance-based Option Awards"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockLiquidationPreference": {
     "auth_ref": [
      "r45",
      "r46",
      "r62",
      "r566",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.",
        "label": "Preferred Stock, Liquidation Preference Per Share",
        "terseLabel": "Preferred stock, liquidation preference per share (in usd per share)"
       }
      }
     },
     "localname": "PreferredStockLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [
      "r538",
      "r539",
      "r542",
      "r543",
      "r544",
      "r545",
      "r643",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r62",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r62",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.ovidrx.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r62",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r62",
      "r451",
      "r470",
      "r645",
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.ovidrx.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r62",
      "r395",
      "r536"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 10,000,000 shares authorized; Series A convertible preferred stock, 10,000 shares designated, 1,250 shares issued and outstanding at June\u00a030, 2023 and December\u00a031, 2022"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r558"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r140",
      "r141",
      "r574"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "terseLabel": "Sales/maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r3",
      "r16"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of options and purchases from employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock": {
     "auth_ref": [
      "r80",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for intangible assets and long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.",
        "label": "Property, Plant, and Equipment and Intangible Assets [Text Block]",
        "terseLabel": "PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r83",
      "r118",
      "r402"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSSummaryofPropertyandEquipmentDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r9",
      "r391",
      "r402",
      "r536"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSSummaryofPropertyandEquipmentDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r9",
      "r105",
      "r108",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r264",
      "r363",
      "r364",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r469",
      "r471",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party, Type [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyMember": {
     "auth_ref": [
      "r148",
      "r149",
      "r363",
      "r364",
      "r365",
      "r366",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r469",
      "r471",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family.",
        "label": "Related Party [Member]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r264",
      "r363",
      "r364",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r469",
      "r471",
      "r500",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party, Type [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r360",
      "r361",
      "r362",
      "r364",
      "r367",
      "r426",
      "r427",
      "r428",
      "r476",
      "r477",
      "r478",
      "r497",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/RELATEDPARTYTRANSACTIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r60",
      "r307",
      "r640"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail",
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONScheduleofRecognizedStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r555",
      "r565",
      "r641",
      "r642"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.ovidrx.com/role/LEASESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r65",
      "r89",
      "r398",
      "r413",
      "r415",
      "r424",
      "r452",
      "r536"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedTerseLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.ovidrx.com/role/NATUREOFOPERATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r112",
      "r152",
      "r153",
      "r154",
      "r156",
      "r162",
      "r164",
      "r213",
      "r214",
      "r302",
      "r303",
      "r304",
      "r318",
      "r319",
      "r330",
      "r332",
      "r333",
      "r335",
      "r337",
      "r410",
      "r412",
      "r429",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r187",
      "r188",
      "r191",
      "r194",
      "r195",
      "r199",
      "r200",
      "r201",
      "r255",
      "r256",
      "r373"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.ovidrx.com/role/NATUREOFOPERATIONSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r187",
      "r188",
      "r191",
      "r194",
      "r195",
      "r199",
      "r200",
      "r201",
      "r255",
      "r256",
      "r373"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Total revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r474",
      "r515",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r357",
      "r535"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use asset in exchange for lease liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/ACCRUEDEXPENSESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/NETLOSSPERSHAREScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageSharesOutstandingDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Shares Outstanding"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/NETLOSSPERSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CASHCASHEQUIVALENTSANDMARKETABLESECURITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of Allocation of Stock-based Compensation Expense by Plan"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/NETLOSSPERSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Recognized Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/PROPERTYANDEQUIPMENTANDINTANGIBLEASSETSSummaryofPropertyandEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r267",
      "r269",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail",
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONScheduleofAllocationofStockBasedCompensationExpensebyPlanDetail",
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONScheduleofRecognizedStockBasedCompensationExpenseDetail",
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r14",
      "r15",
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Options Outstanding and Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Assumptions Used to Compute Fair Value of Employee Option Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-Term Debt [Table]",
        "terseLabel": "Schedule of Short-term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/LEASESAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r86",
      "r88",
      "r89",
      "r122",
      "r123",
      "r124",
      "r184",
      "r238",
      "r239",
      "r240",
      "r242",
      "r245",
      "r251",
      "r253",
      "r420",
      "r421",
      "r422",
      "r423",
      "r528",
      "r554",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONScheduleofRecognizedStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r556",
      "r557",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r7"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Share based compensation, graded vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date",
        "terseLabel": "Share based compensation, percentage of discount from market price on purchase date"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [
      "r267",
      "r269",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Stock-Based Compensation [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail",
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONScheduleofAllocationofStockBasedCompensationExpensebyPlanDetail",
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONScheduleofRecognizedStockBasedCompensationExpenseDetail",
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares reserved for issuance under the plan (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of company's common stock reserved for issuance under the plan (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Life in Years and Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Forfeited or expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited or expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail",
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Fair value of option on grant date"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r274",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding, ending balance (in shares)",
        "periodStartLabel": "Options outstanding, beginning balance (in shares)",
        "terseLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail",
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r274",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Options outstanding, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r291"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "periodEndLabel": "Aggregate intrinsic value, vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "periodEndLabel": "Vested and exercisable, ending balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Vested and exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Percentage of number of shares of common stock outstanding (percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": {
     "auth_ref": [
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares purchased for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award",
        "terseLabel": "Share based compensation, number of shares purchased (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail",
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONScheduleofAllocationofStockBasedCompensationExpensebyPlanDetail",
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "auth_ref": [
      "r269",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-Based Payment Arrangement, Employee [Member]",
        "terseLabel": "Share-Based Payment Arrangement, Employee"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail",
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "auth_ref": [
      "r267",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-Based Payment Arrangement, Nonemployee [Member]",
        "terseLabel": "Share-Based Payment Arrangement, Nonemployee"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail",
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Share based compensation, term of plan"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofAssumptionsUsedtoComputeFairValueofOptionsGrantedDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Share based compensation, exercisable period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "terseLabel": "Unvested stock options, outstanding (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Life in Years, Options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Life in Years, Vested and exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-Term Debt, Type [Axis]",
        "terseLabel": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/LEASESAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-Term Debt, Type [Domain]",
        "terseLabel": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/LEASESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r355",
      "r535"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/LEASESScheduleofComponentsofOperatingLeaseCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r78",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r111",
      "r122",
      "r123",
      "r124",
      "r146",
      "r169",
      "r170",
      "r174",
      "r178",
      "r184",
      "r185",
      "r212",
      "r226",
      "r228",
      "r229",
      "r230",
      "r233",
      "r234",
      "r238",
      "r239",
      "r242",
      "r245",
      "r253",
      "r342",
      "r420",
      "r421",
      "r422",
      "r423",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r441",
      "r451",
      "r473",
      "r493",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r554",
      "r566",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail",
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.ovidrx.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r12",
      "r25",
      "r112",
      "r134",
      "r135",
      "r136",
      "r152",
      "r153",
      "r154",
      "r156",
      "r162",
      "r164",
      "r183",
      "r213",
      "r214",
      "r254",
      "r302",
      "r303",
      "r304",
      "r318",
      "r319",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r359",
      "r410",
      "r411",
      "r412",
      "r429",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.ovidrx.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r183",
      "r373",
      "r418",
      "r441",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r451",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r460",
      "r461",
      "r462",
      "r463",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r471",
      "r474",
      "r475",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r493",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r183",
      "r373",
      "r418",
      "r441",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r451",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r460",
      "r461",
      "r462",
      "r463",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r471",
      "r474",
      "r475",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r493",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r12",
      "r62",
      "r63",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock from exercise of stock options and purchases from employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r12",
      "r62",
      "r63",
      "r89",
      "r420",
      "r493",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Number of shares issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r12",
      "r62",
      "r63",
      "r89",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKBASEDCOMPENSATIONSummaryofOptionsOutstandingandWeightedAverageExercisePriceDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r12",
      "r62",
      "r63",
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock from exercise of stock options and purchases from employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r63",
      "r66",
      "r67",
      "r79",
      "r453",
      "r470",
      "r494",
      "r495",
      "r536",
      "r547",
      "r567",
      "r588",
      "r626",
      "r645"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.",
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r85",
      "r145",
      "r237",
      "r239",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r252",
      "r254",
      "r336",
      "r496",
      "r498",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity.",
        "label": "Equity [Text Block]",
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKHOLDERSEQUITY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Non-cash investing and financing activities:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/COLLABORATIONANDLICENSEAGREEMENTSAdditionalInformationDetail",
      "http://www.ovidrx.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": {
     "auth_ref": [
      "r172",
      "r175",
      "r176"
     ],
     "calculation": {
      "http://www.ovidrx.com/role/NETLOSSPERSHARESummaryofCalculationofBasicandDilutedEarningsLossperShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.",
        "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Basic",
        "negatedLabel": "Net loss attributable to participating securities"
       }
      }
     },
     "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/NETLOSSPERSHARESummaryofCalculationofBasicandDilutedEarningsLossperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r35",
      "r36",
      "r37",
      "r102",
      "r104",
      "r106",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r356",
      "r535"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/LEASESScheduleofComponentsofOperatingLeaseCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r168",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding, diluted (in shares)",
        "verboseLabel": "Weighted average common shares outstanding used in computing net loss per share - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.ovidrx.com/role/NETLOSSPERSHARESummaryofCalculationofBasicandDilutedEarningsLossperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r166",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding, basic (in shares)",
        "verboseLabel": "Weighted average common shares outstanding used in computing net loss per share - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.ovidrx.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.ovidrx.com/role/NETLOSSPERSHARESummaryofCalculationofBasicandDilutedEarningsLossperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org//808/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.B)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org//260/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "65",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-65",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "66",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-66",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org//718/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org//740/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "808",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iv)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(i)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//842-20/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org//850/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(f)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(g)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(h)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(f)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(14))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(17))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(19))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r548": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r549": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r551": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r552": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r553": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org//450/tableOfContent",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21D",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org//205/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(18))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org//235/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org//350/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org//360/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org//440/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org//505/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org//810/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>67
<FILENAME>0001628280-23-027430-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-027430-xbrl.zip
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MO_\UN:>]7VM.'>81D $^B7KG5P&\;G0)HXN(?QVX]/6_Z:BF(,)Z=:-1N]
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M>-=[OO@,_S @>);5=)MVM]%UB&ZU7*WKVHX!GPRS;3A63_M?5 R3W\3)R =
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M55*B#/MRK' OBPKW8:QF$5F7H+DCVH?[0(,JK-6L\!/[,#8JOY0:*[.M$Z/
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M(G9AD2,PYVZR3.0)'C!S$REV1WYMY+Y-17J[,NAGQ>G%5(!3'$H!^ZJO3BX
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M(%'[K&6MZ<B6SZ90C?$MZ9S-TK?:F^B7;/:SW"Y!\4WZBVATF 'F'3Q=?EP
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M^WC*'H7#0</N:_3L7S:FJ5.W3%1?\0T\U/8)U]\H=MK/*<D\.7.,WK!"0QJ
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M.7_9>_FN[_"JC(6=6OF%@3GD]8QJ2.S?>QHMEMG-45KP[=X"@!(X#?E]PWM
M=^!!Y!"D/R&H2/7#7T(&1ES,RYC%<JF\VP;6E,[A/T+W 1V+(R4\T*L8%:O-
M(8+,=V035^/?4V[@G@O-\(M FHBE)8F(CJ.*K01L9WLUYCMDE-^O?N=^>;J?
M(OU@,PER[L(U@&U2E"2Q!)(45UAIV;H6O=Z^/ICR](';\\S!\U1\6UW%]\85
MWZ\A4Y_XV&D\/EVD(JK:+L/S>4:$'DAJUY9'A!Y,TM;R$'E)Y2L*RI:>$\=
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MZ_9@G[2-3GE]4:ZZ98S"\O>AI0^?'K'?/P668X:]W^R5AHIOZ*MYV;G"A^B
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M6T8"D)@RSFKWQ^-H$@$CA\T]Q(L)R(*'J78?)SCDU$?3B(/E(8GF<P:'F;!
M9<ER91;1NBWGE'I>\Z#2K_Y/[&5ZCM66Z*ZY>L!YN=]8@HY#_Y9=C15"5=21
M]X_G8I@RD')RGIVO9K:I8WLG9\->3:;7OVOQLQ[F#])D:9#:ZA/]C4NZV@,,
M<)9:PPGX#<TQ2JOQ+1."U*/2',?FRBG;P%(4W@.8<1<!5LVRG9+N I@? (K<
MXA=J:2?#%:G?$(J(G4Q82GH0Z5;L7PO8XS*NTQ[DSXLX:&$W8 YI-LLGKGO/
ML]-+P*J +9E#'_J/V1$<L*7[9MEMI<$CJ?1L36F]DI_EG2:5GF=25VC%M^@N
MBH(U%!A2Q<ES<R=X]#/O;^ENN&K/QF-$_1_L$/# ;,0#H2:'; )'21XS\<+Q
M0N>_C-B4C2/8Q 1%!_"INV@&6O4]7" )/60X("=QOC9P##1XHH#<[X(K"&%*
M<,O7 EL%5DLWE2L#E2_8!2B_S]YQ);?[)=^M"G2NDYQ/PWKHU_$%A[P=O:H&
MLI% &>[J%#2 K.X47-W([Q",1&X^UK#_"$Z'6%%1'0 54&:,XA^ 0^VD5+V
MTJ+[>Q8BZ@/:S #K$T2N!K3M:9_Y=H%73$EE\HMVJ&)XZGAKBEU:M$,+IGBC
M_D9:HK3#?3D'/A=Y?UD6)X>+%*Z49>JVO=RL^9*?[EMFX=;HSPX86-@FHEI?
MA*)_#3MBQ,:H.")5YY8V_"'$R>_1:*',"V^PWH_ H ;LN@3,)D0&*\PH1A0H
MZ U@(*W>UU*X H#1+?JH$"O>X+/"<XE?ULYOON8?2Y\E5]\_@+B;$BED^/CE
MRX?,\4D?RV_H8@P 5^34#:$F%X.X2FBEE &R@LTBUA!Z'<#^3S;GCP$EI+I8
MEILS9#WAM0HK"LT*(""Z]B!AG(YR>L:/RXXZ,G#A++=PTEL>HN&O0FH.".EX
MS&4IL92)9&"H1'+J%H6M?->5>-4W?-/5N, :U[$_^SG]@/7OU;%-;I8#KDU(
M&[Y+XL5M=G_!7)CW$A?@HGO:>8.Y7\0F#&2T--0'Y@I#G8[.A<;'1<+U$- C
MN)D.-$(?I2V&D#A@E@/KK3'*@0<0LUB"'/GTBBHY/(%9["C>_5&Z7@^?S=T(
M+'X2BJZ:AE.#GAD(VV"@UX"!F0.\X!?O[7[#8-9?QC7[S5SW0N4JT I7M$')
M5HX5@L(1A7  LK<KWR][MREH,F+ ERIKE*CM2=WE!H?776ZP899*GH]"L@5[
MBA&\1$,%'.B4$F]]CZJT;&)8S5UQAN7<%<NV0&5SQZ.A/W9&ANF/[+XS](;]
MON^&9C"JS5TY?7]^??%1^W#U%5O-G=]\OKK<('-E]:N+6PT"WS7]H&_:MND$
M@X%O]T/?&5H#WV)]<S@Z_$R7OZ;:^]A/0A1B'R-0]^<Q:+=^&,_(+2QBB\K3
MJ9*]A!95 CJCR#ZQ#-/3>$83V"IHR*'I\&T"!WR3Z8;P"/XE5_"X:C=B :"?
MXH" *_L**IZCT[(\="8M,Q"Z+/G!5MA;9.BI<EB\6GO80/NP5FD?&2FHQ'*>
M).AH1-)X_UBAEO,' +R,0HM\A1]^1%.N/L7);_#=UIG"KH%M2@S7@G^J3KXL
MOGM3 (AP1>7!PUM\M<@W$M?(X1K+@  &73%%:0'X\EC^$+.7@"+G>? 13UKW
M 8(]^U0\"SC%T#>DQKC!CB,XP'9.N>U>7)@,:_*XX&.$#_2 >)@_!MII&%+"
M+_II]!)6- -!>;D6^.E=MER1CIAH.9.B<V ,2GF2HE$N:$JGS+'%!$Q_#%_
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M06+29VTL;7W5%".6D2BO!N1#)]?SQ!N&SQ[2VE*\H8^S3@9]W?.J76^?.=J
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M%02J;CA/SD7M:+&CQ2.AQ5W4_IH>A:WLONYN.VS5T6)'BWMT]':TN(OJ7W-
M427#KAU:M;>T>.R53H@\LG&AQDW>;XLDN(-;US"<](IJG=K3T4Z2+(<X^DUW
MG">7"W:% GN-7+M(ZK-PY@A6A7?(==S(M8N\$LL$Y!KH_9II-AUR'1-R[:)$
MT[).SAQ3-X=/MO/VM+[)M/=<B]Q^@9.JWYL%[?X5&:=/ \WQL)5=Z-J6_<(%
M36M>ZV$XECJB[HAZ#PN7+.>%"Y<ZHNZ(^C41]2XR("SWA0N4.J+NB/HU$?5.
M'$;]%RY$>F:B+A8@E4J/LA%7FU04U0]EIG".&)_[AS_A4[/.TW1QS__64"J$
MSL'BS*Q!/S"&8\,:#"S3<0U[:(X=RW1M?]CO#QG.C#V2^51C/TJT'P J&J56
MF0$LQXU79IECC\#6HU<9'/^>YG8NYM$D^C^Y))]EQ><,9W=U8).M/-?;L-3+
M\X;/4N/3=Y^A(,D=;O;-G6S6L:UNL]YZ&^I*O;I2KZ[4JZN]V0LP=J5>';KM
M#-TZ-E=K._\W_0(B893\>G8.._-OF_N"=^#JP-6!:X?@.O9Z563A?\03'_T(
M\\>-<G:W5!2P7U[.I>V6IHO[$4LJT0NCD&G@5)QN]6/=\W8][Q_KO7&?_"A!
M+QQ3/'#H& T <?.[^^[/6>8*/;5RI]S@Y&S@],S#*"G;Q3W_^SK:7]L 2D<Z
MK4BGOY>D,P32\7K6D]-..]+I2.?92,?;1]*Q#9(Z[F&,INI(YW62SF O2<?L
MI$X;TCGV0DL\L<0>#0SH>RV::H_,3RJ]A38]_:!G6+)8X$!HO"'1 4VP&B(>
MK2;B41LBOH%;, M)*7"<X&VX2/!><DJV3L[Z/6-03=EX^KVMXZEY97??WZN[
MM[N[?\&[]_;J[AVZ>^]Y[MZ#*^LPH$Z7VR,,<->@_M?@6_X8_8A"-@VU!+3=
MI[B77X,YL@/_L;R?1F.D?W)F])Y>>+VD/O6@C(T=V.FO ?-WX/Y=B?E>A_D=
MYA^C]W8EY@\ZS.\P_QB=KRLQ?]AA_FMSK7Z/TC]/QYB\'F%Z$DOGF]LJA]FG
M9]]M%;RA3W!!G\7]-%&O8YR<V;W^GLPIWSWU=AVJ#MU661OSL4%:SWMRIYD.
M\SO,WP];96W,Q_FRO>&3V[%TF-]A_G[8*FMCOHT\W]R3?JN[Q_S7$$WY5.@R
MP)L+:/!_:B^@A35FRY,=#7L'@];]6 ZDK\JJ <_?&)_UN\(4L[;&G$3_C]\0
MM]+/4WA_%(>R8$;4RM"''P'O,DY6TXW%<9!3];>5"GI 79(ZZMJGLVU&7?U]
MIRX7J<O>5I?1CKHZZGI!ZO+VG;IP*%MON*W9B!UU==3U@M0UV'?J\LB&W58S
MW>VWVJ.6:94</OA=M+DCB!6:JHE;<[#?V2Q.(WS@;<*PZ.,'$VW.1!-%Y5NB
M29J1?\4?I?%D,6_^2J6P_N4QTT3,1 ^$N"8.+>7?=TG>8."6G8X2YO]YZH]A
MLV_]R8/_F)[\6NQ(%TU/50 VG5WI7&<.EO7]&X\W.?EPC;9_'*V NN*$D. M
MH"-+\"G8C;\O6]'N$N0%_Q8YCA=Z[J@_"GS3&83&*'0#"WZR[*$5.&/C?X$2
MJ:LC.A;^XU?_4,_P 3D@<"4Z0@U>;J._Y!EUBRBN7F()Q. BQ_!&;#AF_J@_
M=BS?&0S&MC=T;<\?#X?#(#AI^-[*KIG'TB<3N.KID?3*K /R"S?/M'J>M5'S
M3-ON&6[SQQMW3>SW0,(_1XM'U][^9NW><,/.D3O8K-LSO/ZA;!8AN]YFN^:9
M7?/,KGEFU\UP+\#8-<_LT&UGZ-:QN:Z]80>N#EP'#:[7D)+3-<_<2HK=<"];
M,3G8.]/>7D'0L;=BZKJ8[2(YU=@]Z:CCN<;13Q:>_A]+XEJ2&IX \0PLTWK7
M$55'5'M*5,/A[FFJ2CNNT8FCCG+VFW),P]P]Z:POCERS$T=;K;,X)-MMXZZ:
M1]E";;A7'=1<Z^3,[5GN!CWT6K?*.\KK)+M@C^[3+K;6V.@^Q>6\UBM%K72/
M;M3I*/2)%%H=S+S+^W37H-#7X-+M>E;NM=MV51,GMVM9N6LK^/@1?R=>UY68
MW[6L[##_&%VC*Q&_ZUC9(?Y1>C978G[7L?)8O9.;-Z8\?EI\2;MCW89,?6H_
M.1BV(\6#I[@-<^)>$[:^J+%0CZ[K1\3ZFT;$.DP^?DQ^2>5_;;YK=7RWP]:=
M:^Q/YKOV:^6[KR&FT'5N[/KS+#=B]K ]3Y\:-SI=\ZN.N Z.N$HVU^ZI:X4F
MH%"=N^V4Q([P.L)[.:DVW"^ZJ])7OY-J'7'M_FR;235SOZAK?:GF[:-4:^CV
M6.SNN#2'KW(#P1T+%Q-V-:Z_B^MY'/PIH'T.Q_\1S1^I\=X-+/I^ A_F( /[
M@ $@9[#\/%FP0V[[EG5;$SW1%O>P?U@DI69LW'V36\:I%B_FZ=R?AM2@;1K2
M4P\"'36?XZ/&?K(DB%*FS>!BV!.:M[UXKS;03GL&;VO9MEF;X_1LU]E^ERZK
M9PPV;1NVM*68L5FCLFZS.]NLN\UF;?NN9B LZ@50NT/M88..RXRMDBQ*M>TV
M,SDL8-1V*\&?+X04H5^^H23IP%0#IN_LWH^F<!#Z#?OLHOJV\"?T^Y=HC'DJ
MVC]:5M ='?S.;V\3=HO^? 3+9X!2-$VC@'XCG?E5A3X0(E<U*MU'%C#B3;:Y
MHM=>NYIKLU!O>VA)B<8RJS E%EXV"!W5'/Q\^6G;!N%5?FF7(L:JFGR@N)^&
M,37NQCW4V7W#DS/3TH=]4[>V-J1FO1O?<V_,$]!V[VB\M9]FS<,?**TN\> X
MS^J_4<BUY+R16@XI.#5TZADG9T[/?/+P[$.BT"U)W+U%S :7E;6],N*5:)=I
MC8K"B/6HUNIZ5,\\.?,4/WV+^N)7[CG?B",?"=]=RF_K.R)LA]]FJGZ-9WRU
MFN19)V=]2S?=?9KCU]HZJ9\EO-=T\AN?-K*1_2&.J\@Z&R =Q@MT);\2 \1\
M9@.D&)'Z+8G3M#5MV2=GM@Y0T]VG%TJUN_/G5G"V.,;]E6#QLN#JTU3S]"FQ
MU97J.9^A_.2DA<-$WZ?)G+W%SA4AY?A'%#:@W3JHAM_(=&[TSZZA<KLG9\->
M?[@5E?L9+K>PQFOPG4JVL)E^<IBEV7CN-]O60C#KXG.:+ECXD<;*<2;,PV)J
M2D8&\-9*1A](Q]0-KZK _W+ *65'CF=[J"9(#-Q84Z"9NNX1IC<>S1JOP:[^
M%"=C%F&V5IQH[.<L2IYF9!\@<]FZ$'NB*2VN9 &O/I^&%W@GM$+&:5K+O,')
MF6.9^B!O KF!T*M'[KVP.XX3+W<@])Z*F6UEX!!+PFNP<C-K>1]1\]#7> W6
M6UWFRWJ3$[NLEZ62TM[WK)>!<7)FNKKC#/2!_60V=$@Q]2[KI<MZJ:H/]IYF
MO0Q,ZAWCO28*?:59+P>1\S*P,.?%]KJ<ER[G9?.<%_LP<EX&]LF9JP]<1S<&
MV]*1NK27]=#I#Y92)>4TE%645/_HS[=@H!1CS*(LLAQF?B7I!KNQ7_CM<E<*
M'P$2XY\N\IO>T*QQ3LX&>M_P=-?L;S<5X6EHLF.OS.Y(8>\8R_HR>*NP.5#V
ML#.3:36':&M)N5@_T'<ZKM"E+VW7T&J-JDWVUQHSL ;]D[-^S]R._?5$H?$*
M>/^1L/"7M;]6TT-6@_Q$^PPS273'Z.MF35;3[D)I#4U[5'(]Q#XYY]SVXG"5
M!A@VODF8]N"GFC^;)?%/N*LYFSQJ?]D8(4_=,D9>W,\F\2-CURSY =*]'D$O
MX^D/CGF(B^E-//<GZN<?XG1^&<__P>"E07P[A9.OF5#0SS%N<')FVKTJLFD
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MO(-2ZS,J1,/<"^[9%#IXU>,J-L=+EGK:%16(Y-&>5'U_,:#"W10A T.:5]@
M3BS&XRB(R.S!G_S@L4A3Z!$5&V4\ ,Y?7SX\:70RKS%/YDEB@/6],/GAY0HL
MC@#E5#LYO?/)=1[=C\",8AFNX=%SHLT@PVWT4K9F#0 G/D\G4)%(N6&]R&?H
M<60VHT5XBV%DVM2(:?<+S&&;9(8::>$".XCWB(0K_@5T- "^LZ7.K%K[PUN:
M/:"0)1C[7"'-R%.Z ;[!&>#3]W0"V64$NPJT-^2<M>R2J8@M"!A2!6_!!2*"
M(E0NRFO LFLF;IZ9M\N\"M(IPT'..S04[HX_@(Q!>FXHL^0K$&"US%:A<3_G
M,KF3%U%FO$@HLZ^P)2HM#]M?[&"O+M;%BVWJVBDO%HA*$B'F,RQFZ!J7X7X
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M31HN'L.2)$6-I42T5=XFMO^TSUKE0==F#Y7.'7U.B61UJ9W+>WN=#[EGNX&
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M 6<,A\FY^*0)*E]?^< :PNE3A,>1%\RBN"RZQ(/2\K-Y5BP4K,<UZ$"&OK%
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MU ]>! )D#L7Y/[\[MG2#IN7\$3:<]YYWRT>E.WT'#^*JQO2/K.J/6"%T*L#
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M-%WX.B#+2-<S,E8T;^ L6E ;=9DKA1; *(HKNS!Q46<)+ITX";QTI7%# UV
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MCT%YXP!PZ+3P-AK-<D6I;[1!\!#0EO.%ZH)@<JD$2G:<+7<G_6BBIC96O9%
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M>M35UWU]+8(/$;I)JB3[<195'JM>-QF)QQO+@)F.D[QZR!>#.RF^8<>0#?7
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M!R-8Z'%:<;P<I1YIYK$E6:%U2FWQNN=KC>J[;CP;DDCFS:U[.!1O6P,I=_7
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MCNYUJ$T,\E@&[1Z&9&%()ST,J8<A;<L<[@Y#>H):SFXC04*&:':3 ]^L5VX
MG"UC:]/J6AE@;UID$BYJY/'$.=B'+%T710ZGBCN4NQ=LM3?#R&OQT8JYAG+K
M-6.OG0%79Y\OUXG9)#1\:%)RMT"D/FG;RT)NMRI PXET%YOI^&J!=%'8;G9?
M$MB>')N&JE@TUBPW"UX0HNCHU>_O?J6?!J]^P&ZZY4(:J(KI:6+F9()4T9<
M$3]DB])6%..Q5I791O@[B9/4LBZ7KI.$<')Q]T\1KC6L7FO56!>!<4F1W)R,
M?RH#I<-F8Y-+:R=KADN<I8X0QHO*L+=)2X@QJ[J,3 S;^Q!:IJ7)T-)-P08Q
M/3>Z$1B*6,<P>NV58*("A8]1F!2>";N04YQ)WD&UD&_ 6:!XZO$ HW2#<^X#
M-,>37HDUC1%96).4BT!Q63APG(,N'A[)\WEL'IU_<YB.R/,3_.IU+:[0_RU&
M.KB*F?C2_)7^36TVP$O#MXX6]+?710F:[#HM:_A."MKK P;QI%+Q9V-%?S1L
M"?YC7U]]^/DC_Z:Q6+;*F]>*!MY>+[+BNA9*SD-[;5"2QU@$I#+"&S _>8V.
M@<<DBJG&AQG*\"A$_T<$:0\.8B./P7+U4:C7CB^&M-ONW\>&IXTZPN3D(W+5
M\>LBH2,TN+PX(WF*9MA_*PE>?(=_^NZ'4+SQDIW1A'DWBNN4X@JT2\1_"0+,
M60;\[%S,-A[8I* (12#*%_PO\+FFZ5R"L*&HX@#IQ%IZ''\U+]6!A&N7-8\C
MQ?0^UE+9+SAEK5WZ'3\08Q0#W7&GE>AMX*.;YS15NI&=X*JQTBMF928E80L$
MQR$,A')C2+6+7!'4&QA[9$^++%%,AC8IP9F6=?7^PB%X\%QMC/STWTQ2E]ML
M6U>95:8;#R@&>A.%HD^/4&VAAX@TDO,BQ9#-"_@(0>U^L.78J'2+&_3XW8.\
M+]+'HJ LLHSI=$JE#@AA@0B6(K& ! J[.%Q+$K37R9),SW%2)C3B(6%6?L%0
M<6@&5F X!E=MFHXKV\&%E\8]XH66WLP.XU& FL7N"Q[(XP?B@C!/#25#"+/+
MR:AHWOA+S3J,_=&46]]R('G<P&[0R/\ .B0J.X^>W!\<4\IT01?,PCZ"!B,W
MI9\ <E]V9Z65'XU8+<L)1S.2PDVE'2[OML:+F6**M*JDR?E]K+2QIS?%@+BQ
MF+-,Y4@U71H,N63<RH[C,Z K.5;GZO#-T#%9>K,7^OP7N83I*)GL%R_9"D:2
M$KUC_'M>L!UA;DJ$N%4"E#;FE96;$*&YN ^(W$41)>DI&,-)"88O*=):PW)_
M/Q@>G@0V(?AU>A37V*OUG)/!X9FE9B% $YF(R^H<328S#7_T-5PIA&#Z?G#L
ML;Q\[5&_15I'\10^49%.Z'S@V<GA8.TGXF[_3U%^[GX8JB]XX/'AY>8/?,T1
MT8ZGDNZ7 T>V(UK7$_!0] HGI,$=TG%GEFV^#&-?LV+"UWG(B$[(.,5NI4$@
MZX!5$52VZ1#%:5NT8<+6:\C9?:O?YH4U%8;PE-C'2^I)"&3)E)?<=3"&2TW@
MY[83XWZAN5][ER3?"YH[_%AZ<-Y@% (K3#971]>7X62U[.GN)O_J*IO(4>C6
M.^P*0(6N[=##;<*VZ')\C%G\D'0Q"VU94[&TMQ?<$K9,&%>H'3)8Y1'E:7"G
M\@41W!XBP"' 4X^?#07^+6DL\_FW-DOU 2-2]--53)81Z.IA\ *_)2;KVP]7
M-@J2SHP*@ZMG8B!;/-XH&("QB?5,LWI&$Y/>O*.BL(H0D7-R8L%.F2C?#9!F
M9<'@WY "#"]^>8CYAOFLF,/$P@=V.F:?O,Y]ZDO*;$;W7%M*9L'51Q&%%,2W
M%+ W6VL)/F6NH@Q_(C-=/.S&7F RG=0EK3QG]>V#)3,G_HT\SGN8=+44>Z>=
M*4><">R&3D?9PN34*L154#,N/F]DJ!&=:0SS+4/?.':KB0M56K :/&:I&7).
M&'U8 HIJHI(E(#]_'F\5\V$,A&#71;2"&9=BR)D2%C13$31V&*^Z$<\P$0OC
M89J A8DZM*C':>R*T( 9^/;:I#N[=3YGRXU@-NJ&.J?7W?',,,SA:H(,&Q)9
M8W9ZL']\EIGG5EX;F_%#XJ*]:97FO>YJ[H*1M#<8=WYMX\[;./O-T=^N$6E4
M.L+Y+J@TZ;+;N=G@V^]1>P6#KAZB/D3(>T%WVXX&_8FMZ[ZEP[+@-[M0->VA
M"N&@5N;H&1;VQ%0%D,[J&H+W\:X> 9[_W@"!V/:J"6%0=!$V\TT&%(NDRWOA
MUFTL6:11._;)\J%(C,)_P#(ANB!'C%)N\ 7>13+_B1'<'"W[21UA9DHU:O]6
M?,]OR"3XS32_1DK"B:'8S6&9:;HF-?/V]S?6*)% .9L0M :*G0'!EC,Y'UDN
M;C88,=/DWG(U#X5BA H.'HX&A<76P;^]%E$.T-1U6!I%/Z,>\N%!/DY[R$</
M^=B6.>P!Y,-TR*.264:,=ZK7!@99].PJ2#$! U"%4838Z+$H2?!%0:IU;8HR
MR,/RJS*XC)MZ;"Q\B*]IM]X@^\4<!98NQJGIA?Z%VA=KKKVQXUTF >,F'Y6$
M)W@ZNGL^-ZT:3$,7Z=V ?GN )2,&8_XPV+@#A!$:VTXN7!\ [E>,\45FC67?
MRG'8?'.QMSAU6W70)AE].QUPJZ^*J=!IAG.Z6(CI :W*!4S?>#$ZKZ2GN2]>
M50>]; \LLA9:Q"[^BH67.O>N$&B"&%*V-;P4$ J0)/BXZA>+)9; ^5X5!CX7
M'/F<VA2V+?Z5Y"F%I/1MT6CGT?<+2=N'+EP;:>]$SV-AD87C$H7NI3.$YEW4
MSL(WS=B,3?;#K/I41=<IMY&!>;BZE%N6NB@UVI:#\U>AM5Y-,M%U-4=?'V,Y
M!KN-X 2<NPF25T5/]?R(;$L8C\F$*ZGC9# >87V&YZ_+>\]Y]HB[R^IK19W3
M1F2Q#2>Y)XW=MHV^G8BKJ]ZXL:&K"^8PCFP9:>E9[O9!GWY]:MJBQ+N; %(,
MH@[]:QKA#<SBL0S<E?N[%ZA'%*@_:UBN,?6!8GOWZZUQ05*\JJ2HNPOTJO+W
M-<4Q#$8%]73FNJR<3(:/%8>&*9D@ H;AKVS1B\SCTZ)2 35L%6ZLT0N&)8X5
M2(-; 6F=T($2-CSY!UPC_%.IV'%-"?B",H7,.&/%A6'-MI="<;@Q!WJJA:PG
M,CV+S#<G19$LO00SA9CQ-#'5^*^_O3=!U5[@GH(IO4O,.*!B2%V]#>QH9-]J
ME(DR$4<YH[H21=0.1N4QE0T]EE0DYV2E3Q$URBNO23K(U9P3>4)WD;I''8"Z
MS%2=J!F)Z]HBW.@*WHO?DQC7LG=^KH-X:!*N=#*[$[:]I%N[@3/TEM4C:#T5
M54)>3#817+;SZ4*GH$4QCS@'D3;MH)?N7(OBMO[X#$O,(R;HJ^$2[2_*1]5;
M7NMU"1$;*YV[LU.,V/;.,7ZWU1!6B?0^UF-NFR40I\UR58VIJ?H0QG Q1'WG
MA[0]%SSV6_:(6Y:K28&-D,B-L70"5//+W:D73<*>T./EL=1J/D$/;G;1[)Y"
MN6%FA&-Z-9NK =MD(NEUOT\FU\MX#^U%XDEN[;;%6)1SK.&A:UA]B;-:(_'.
MPKJL:X<XUW5F^WU_Q'WW=CHT/3J,%# KN3FWC:YXW1T\N'#<3V-@TH;MKQ)\
M!21I*PW7#C*<'4R+FWZ['[.+Q'616E(<Q*@*18X4=OA6,MW?!%-FB@&\NE/1
MS>"[16G?!.31MX])#@UOYKR49H9IS"BWY>@?0ZI_KO&$PA3@;X:&0VCY:B2\
MV@M^;X=C)4XM1Q\M8'9M^$']0EC+(V8X&-'\"23[-T/\7MD@05&.=> 6J"G=
MC %&[6R&N9T;\N .7>!+QWAJL"_,KV&@Y]F"T*H-'*N!\DK6W*!U5[5#[&B!
MUWAK9UW5GG>D:-'KIR;Q3Q&&W&\^03S^G0&LKFQ1._O4J(98!PQ!.QN:&BGI
M,DNE B+OENK"1V8(;TQ7DC-<\3Q&.+4W?2WFY^(KF H#LVZ7GNP+Y/H6H!3]
M3@YDYWXP(L4BTMN"UUK:[D3SFH"$VWA 43$(%Z@7/@UOTUYKVO[+>O40RV],
MKXRN+B,]UMEBG<]ZK'./==Z6.>P!UKG=$.X>=S.7N3@"#53'I9IBM,P!HR4U
M84I(G 'NZV"X,./4,8TL9_&UT'&L:&I@.$66OMS5[Z-+^7>^V,;[_@#/0]N6
M1&R.SNENQ^)11DPN(VS\WDCK&CM7+=O93PS<E\&Y4<F9?[6>O+.(O+."G-F0
MR^(&V9++@KR-?7"K/A95&F>84Z[8F9P52)G#Y..T!_.B9I1WE"9,DN5#'@A%
M0$Z#0/Q'ULG@<MQ/T6>51(8KV''@D\4P3Z^+RF#G BI1B&:6:;?Q5RTUC,Y6
ML1QC=I I$RX[P\9B^CV'B2:9XI314YQ'BYGM-U 6BXCZ&+D6 1]^_11<34JE
MI&8-K)>"B,6P/HQ8^9TO)84#3 #I^XW=C7^\5BKW45CS=*YP7_= &&U5?G2[
MZ=CK]RW6[[LOAC\O=?!Q#I31"T8.J+-::;KD$)O!BOW=!-Q"O9/,.V<X--*R
M48M:P&/S\GO?($]6@[Z2&A0BN3I33DR4,,*%2-@OS OH7D:U+8NEBN"H7;6]
M3"@VJDO8+F) (Y8[.VKLL$2]1Y ]W6_X('$+TKK=Y>FW 2$ELF5?(\NB5ZW+
MJDB7O$/7V(T@I484M21#2A?;\/YLPAR-?H%+]3,<#VC%W1J%\*V_&7Y=KGV3
M#EHJ]*NGI U2DZ*."M\LU4E:QO6,.5PTE^#XH7X;_Z%UMF7<TMCI*VAY>:L-
M)3,HUE%MV!%++1CU>&A%U=+25JUUE1=R.8\I*6J\>D5I'U/A46D?RY '*'*S
MQ2;!?@,P(3'T$M0M#N35@N?JCN3QB7W_ZECJJA&;-37Q,;>X-F3G-S4I EUX
M)\]4"Y*UG$6+O8BO-=IL+'=06T5)L:X^-78@\Q480\UN_:H:S] 5 70#>&UR
MQ@'^/3EJLF=TP\?E0G&'E?P,!RAG,-L:-!YW\996B>ZZ^J^1GMB#',%/0O\L
M39"-%[BB<2!2;Z1JN8&@B=D;E88%A:;=[S5%AV0WY!5A)S6$V19R91V*QPPK
MM1W O*K$]3H<VIO<]XJZ@M:[KU8^NH),?VTJI1T*@@A4VGN8(+TPM4<$A[.4
M:QJ5+W=Q7OH\:1=W;*RE+S+D\Y-:?+51"+#?$:LCV]::)%#AV8MB*5.,QM):
M.&J)"K@'I>LMW0GU)QG24RRCA[?/N#67)TG=:\#?LG/.%J0.Z.[WC2VMJE$4
M?Z8'H0FZ)&^'P2?O/)'"ZQ34M5TV3V,USY6L&H9F7.K71 >\ 6KB&UX:9B._
M6HRXX5'GT5NBN1'^Y17]T47+)F"!)\KV>2#;;@0?*_*5U:4=YJ1'$]=^#&,W
M) +62A]O'.QZB"C7UFCVMU3OTN@])J+#I'3(S\;NG*Y8Y3-OA#/4VS&'QL&X
MU8:VE@KJ!Z(ZCN:+_?*8.Y+KIJ0^Y4K&COQZ1R$U*:(#/IZ-U5K:#Z\]N=_@
MWE*!N5;W4;/(RB^M8J?%E%VMJ*M"NU^JKTKF)8<C:?Y(_6@%",V8.OF'9U$V
M'ZO3JMG4L!V$P08& MYEZ@Q3D4[:<9E?JQVT\3P-7VD67H:66+F8=0*F/8IT
MVNCFN_OR^*F;N:)1*Y>#D9UU2ID.#+D_MK2AHJB1=.ID>L;T6JKRHL_<9M$T
M91W;<)LEGEG,W7:C93A2%5Y!W #6X)10;.BQ>,G2?<@."JG[#ZV)4"]4(1QV
MH11Z=_=L7+RB -\*Z758\ D(+A2??&L@)V75@7FBC]>YJ$SCG(X+-\^V>G38
M&"TQ,B&%M 4>2LK0>&E6!,W(!N&>!AY/CCOR>R"K5QDR%@J;3]0ZX2)\DY2:
M!:L<FR/0,24](N1RSI2"W_T?';P%*S*M:LDX?%#7*8STIP);I%A&O \_.48\
MS)Q4[:_]E!9B<R)G)[:D$1^:V88*= CQN=R?MD"^O'97>:_#IP=HS$5OHA%2
MR_W;^EXDA$TXGW;W )/1NY;"A"Y;;.4QP!\X="658:B >R"*!:*<]T"4'HBR
M+7/8 R"*"R=AOL@:!^MD *F)5V%ZRGN 3W?;3VL8H&M Q)QT%&LTEV\Q;C"6
M+AO1>^#:_2[]*4T3:[3Z#0S>[\ULEUS')5QRO"R-FX)"K_"+"IYB5Y4<]VA&
MG8WX!=2R:.ZGF;O,[?*KW<K-!=@@*[8)F97 [@??R6TQA-XO+:\D/; O=<V=
MGD8+J4UA Z&Q?2F2PZ/-$MJ=M'\S(:.)04^[JG43.#+B4W;7BA\&OQ6EEU<%
M@?/"]'XK#/0M5LCDC<\S;S_4C4ZBP[RBRRI'DR3X@S3U:;D9,*);8CT:!H\\
M4[OX%3W],/C$EE9-<40.'J*HFPY2U%G@.D5BOFM%=1?& 4)?>5)R&Z&JL'3_
MI1HMF"6),4A3C,+$*LN$64\';WZ_"GG=,O8C#/,?DDD<\"J#J"4M^U!"CYB!
MQLY6V%2FUFT;$E0J99 CTP]]V962W*;058--:V/":>401M2,S538RD(;OL"E
M6*-OU'+[JY0I,>8%WGI$N"WCEC1?>]R.7A#\H4(+0*3;]DW8^Y/&Y,1;E+HR
M>T;;+,Q),#K0-D*P%Q?%4G-ZNPN2H2#PIE##G<Y'[(%ZNEKR/%P,QL2P&RY&
M[:%OA&7%Y3917NJL,NVL3!LB"T_H/*.A>/T8LJ40%<M]M3 =+%P'"G?S.2U%
M'.Y&3V&#1Q?;7KK:0E\.W=WI(FP4-I4\2LOD6#5XUIRP&EDT4AE'2ULF#>/J
M.K33,B$M11DPILY]-"CHUU!?%,393YN'6FZF,Y"4.?Y1XO4*<2\Y8B@:R9:N
MN*&!G:!"JZ4"E&0 ^RM12AHCXABO2:6/H!BBU!T64XU,O<+)JY&B=CU>KS;<
MFR:P+H(3PI?2-:Z":5=#$;D$=%>K_Y:39*N%VJT:4PQ3X/OW0+G\TE[ST!([
MF_N^V:'2;!9UO"*^)7__J9Z7180V:)4<' ;O[_ MN;8+;3->AFO83\T9[)A+
MS?&.>1DGTB$<\5D6F,K<W-RF=*FJTXT*_":4/WZ[5T+I1-9(*P?0)$W&05&:
MS8_FT;>*]=)JF>-GID0TZ&Q.;"3ZKAN?$_NFB,-8F'+)3LXVF7*81%\"Z$LW
M]+MK-'H0@\ BPX@!%AKJ/.MW);U-B/34-+N*$3^64"88KGS% !2RD8A&CF&$
M<+]4:>;/@=2W6\PW,@/D#1NIZD:I_-;WDVYW3V,]T>PYN)3U=%E,>XZ<3XZD
M!9SI26,KRF@R%WC^L6<8;!ZX'DB#4+7:&^[#+?*^(PO?J"ST "W<;,9D/T+2
M40<H!_7,T:!ZV=5$X7*Q$VX8A,0E9X)_O'6D&:,<7Z\KFR69(60<9NR]Z+^S
M059DQ.3;!O[GXRHDI$VI.@.OD =U81*Z5D-4DX9#K#&M)UZ5UX"].[RS![>4
MUP'4P#0>K%.5\073TOH]8X&]@V,TA5%PQA=6I(64X686F<HGU90L892W+X;B
M1-)UJ^ _G8;1;2U[Z)8"*3(RQ*5+9'2FS)3$G>@\Z+37JB%BE)9-AX%<8S?E
MR/4L\OH3V6S-[V]<4T5XST_BNNG@5P:C!E<=7_KI5_>E<5%VY4/]'DP&#N'Z
M"_#Q1*J0L31*RNEH$1S=##P/?N?()KRNS1G4'60P#9>LB>[/V!:1&RO?E5T<
M!G^C>.?7M=-ZVBBTT(21@_TMVE9(F4Z*$H,&DNYB!\RN9,.!@;'F]4S1QWU.
M8"_$>PN%;YNS Q>*A89EBK.GMI\YL>*MB 5V-/7$^+,QSB*L9^*-E@=P]@Y>
M(LW;S49V1B]N<_$<K('#4U*>-<-;W@ ]:-.;C]P#W0@G"=7*S(+ZVVP2 N3@
MVZ(+0-9]8NA$$-  GIDI;&C?Z'IABI:0(R TD07&)'2W6&-/.E_&^YFSYX(8
M:#D[D*EY"_7YUC$8DG6F?-Q(T$!Q&^V-&6R.C,E[&=YC0FK,MV(O>E@!N$)G
MEH\6SV5-DS10.39>5;0$PCP,?N;0C+6F#;3&VP:TVAD$LV)#FKV0D.A*]:TY
M'I.ICD*H740C'AC=N\VQO<V7%$<\6;AXF\'4&C)B/(P&6-5Y GN:LJ?<8[\(
M1TC4%;95P,C> ;B$ZCKR0=?VHNIW[5&9[HW?5:*!;%CMP?X$+U ;'J[NS+8$
MR\406[UMSP]R<]%#;GK(S;;,X>Z0FU[!?AL%:Z@G"+_-F 5'YDPJUT0XT?&U
M-Z0#!7GEC*YYQ^L/[W0#_]GR\ BDWE^N3[+WQ5SE75VM^SUYHCU!8(P))BWX
M=,9EG;H*0I=4HNB&E%68YA2$N\#TO_2X[(Y;]QO[N#T-Q%#D@LI&GW<,XZTP
M8TV@D+[4B28*#89(V\9N6<3][-N!9 RQC9E$'V-UI,(]YII6R,W5YE$]4J^D
MGU9)3Z-KX3_G,^Y8.NU)YV: 6'1E,%2EJFI!EQ%7BFMOPU"N@WK>;^=CAB%B
MSF)Q\G<%.K"3?ZJ#PX72$*FZX;Q.45<T',H).2352.5J#+]ZM;KHI-_G!]]G
M#SBT*G5#@.$:MA.%@?;3]&>/9LKR G'2BRY^S-=9'8V-%0J8(>QK4?8[^W@[
MZQB5,813UG/#A640DH2-F:AB7F1PA1NP*_%"N2X6>*2+?%)0.]:HM&"4#[76
M*>-._O$9R;!4Z!$YX2<%+.Y!UIEOH4"B&;89#(9]-DMSR3K*>T/TXDJP+?0L
M#/(([@8,D*4ZTA5"J0PB+\:NY!GB:N"3>P$CL#"/Y8 NMUT58(@$@+5)G%<P
M0:Z((& <X\Q@GRQ)#U(^$I(LCHL2ESA;&#"(J5HTD68\O[,BB627"/\%5CYF
MD5-&![@QP==F,!!,9AG0B)_I-%!;QR205I2QX]G4)D4W,ZTV5O6.;J'";[!8
M.".&+.<+%J:=74J9[\C52+BB6,HF2Q:/Y)OS>XVO"2"<\K,"Y<BB^+-KZXA_
M1/M$6#1@+XB+JY'C[8(;6RH%3L?S6_#PM"9!/$GPB6;UZCZ(-])SW-H<8@,^
M]S88UF<2!26CF>[/JP+Y&DL_*42?5X7[6K=@#=VU(Y8UM2VIS-4UPR1UD^R
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M 3QV*T"MTG+ZR7<;[<-7JV_E*\F%(4#U.08Z="#F9R?6J$^8^0QY9@'3T8=
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M4GRU^B;:J&Y;Z]ZG7CNH"E/40.8H6A]BPBK<%,@#9<2'U_KO4]9_@V;2MN$
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M;4KL+WA".)I9?(*^7[NI198\G"#><(P!&V_S1TPXJXZ%W2[N#&RN?$NY2\P
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M4*E@T6<M7&;\C8A8@!Q,A\P.B%%7M#M[$<G2-%,Y'("E-,> 9M:>W $W4G!
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M-Z,S/L+3"G@&R3S5018"A:X85!$%R)A"I.Q*,VUG2CH%F&M0.$.HET9OIW2
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MW4J</#Y?D%>2+"F,,B2W ]Q/?5W>HW% 3@,2@))R%H"F*ZBFI!:-<I*+3)3
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MF=(#Q@F5K".7OD,M'&Z^0N?X.K3^(O8?CI9*><<G-PG%5/A5]KCX :3%V),
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MZ!0AP=]02TH:T;8:G#M1N1K&F_N]9S3V\2I.1]K KURF]1#:=MS&&<8PKP4
MY#99(^=IKJV[#P)@<X]RT&Z*HS^**) ?RMTM]=R.8-;19] D_ 8Y[WY!+X>K
M+%TNIAW-1(F?%@GI]Z$C"(T.>>D+&@U'G^)#%8D1=R2B*'T36(Y$78E L(_
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M *L##TPO]N?38_<]G,:9>9'!+Q<R!(L#=;D#=CP>\J.>?WJK13-2$+!A5@+
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ME;\_FR]RT4)Q'$=<S5"L9Z=T!I2J-I.4\4SWP":L,WG2T#]:0=<1>>W P52
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M0AF&[,'3LH4*-G[:CE<D#-\.N9)AGIDEQW-COY!0!_+UC/^GZ&H/%N6YQD6
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M_]Q01W>$I>C.QS-'S)CC<>8F!R#)8.(P\_8(768M<I:_6G3T$32)BF0$+/<
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MK=WH# =:YQ[:Z3^-H7;7;@P:=0!L6!B]$OQ4")Z>I!%$QO^4?TF"/P$!))9
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M>%NC]"/![GPVY%,6=MUH0V)P6*=(G%*2666C<;D+N6L^@?O"^VFU[%6YRZO
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M3G=U.)P^:>&'<_#Z$NN+_)LMSPN@9TKB&>F0,IP/4@J>"9] RYH@EBF"-RX
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M9YQ4*4EQ_1Z#M;FS+N9>%>ULDF\;%?:*AOCL]?I/##/\[:?_ U!+ P04
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M:T5(G?ZP7W:CU_C7Q;,*_F[7!E\F@!^1?GG13W_[I6^UEMHF:T/.4IM@K9<
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MZ3DC0@5.).=  @V20/ N>I-D-+$R(Q[#<]S<J*:)^RP157:+\_%X"NGE=(2
MWL&HWZ0YSC,TB)NO +-?>C<=Q4\HJ7<#/QSWC.,B*IJ),JG UI&$Y#FQ44E
MXE/@M0FT(=3CYM8N]'>?=K(CVOW##Z:P$G5/1-PZ(0OB?,Q$,IH(OCF,*&U-
M,MD9EVM;.AL!?9:4JZB[^X13VQ+N)/V_Z7@R<UX_-"<IS?3A!^]\/YT/3_UU
M?^('LY>FA/?0Z[VZ1O=W%C5\#RB]<7\"ES#ZW(\P7^U[B,W'N59G"^\Q[GB
M2$D$C2\44$NLCYPHRVT"YAT%5YF;7:_IN&E\4(RXSWB]+>,O)I]@5&"/X%,)
M!'Y&:<;F"EXWX_%OD)L1?/!?WC6CF48GDU$_3"<^#.!#\PX7/9ST#+?<&0 T
M72U^B?BR!G2OB<&OUDA3KA8J,WI;S,?-V)UJ]#XCS;:,? N3&\ ]JB!"5H$
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M#="]VW;5-+Z*5)VIJTOKK15H8URR6B7BA$BE%Q$07YQ^;91G-D4T)VJW4#L
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MUP8%RPU1*D RV0<ONZOKZVQ9!WC8U.5XM5D]'5&EJY+#\/02PSI+G,^7HR$
M8X".AM":2'0R2-!*$X&GL&..QN@/9E3ADZMYGMS?/S'V$:G8Y*U^V4<[!HV*
MV3L=J#;"JD@$%Z6]342YFR")MU%Y$S,SU?N1=[ZHY_D"' Q-]M% =9T%ON^/
M__EJ!'".]NT(QI/9 JF-3.$!1L J0:3FGE@5\$674E*5N,JV=D.<SA?U\SW8
M*TTZZ-&S\0(?G,AX9_SN[(<O_2UGL$<]]U99(-9K?.VS\\2A@H@2Z(=2R7 C
MJ#UK;,=+_/F.'!"%*K8>J']]"UD)%K,G@3$T!9-2)$09"4A.C5#*,["UWX5G
MF*^Q%;?WHNS#S-<H.:_*.4>THX9(Q1BN)1G"70;)E!,NUS;LCRQ?8RT./)JO
ML8XN?I3[[C9K^IFOL5:^QEHTV<7%]R8Z_E'X*U5F)=& 6(B42(B9!,TRP1=>
MJ2@"];)V/MN/P]NU\C4.CK;KJ':G^1HNJ,C*M;%CI5872F9+IH%DXX.RSKN8
M:I_)QYZOL9:N6^=KK*.H#FXZ[K<>Y5S'!-25NBE<9N"X8)T-H:6:A6H1N:Y]
M2W>$_9JWL>BVTTD',=&'^DBV@?3\^C6OI:@6?7LWD?*.^C6;0$-">,1%+?$L
M-I0X#HH()4Q(8(TUM2>B'VZ_YMIZ7T>X.^[7?*?1:] Y,Z<L\4F7.>TV$C]K
M"J)8 "BM9F5WMWH_1LO=M92Y><O==32QXS;-]WM*)^-I\,+BT5@F,VN&L)4,
MQ,OL$K= 0[NVGI5H<Z ]OKMBSG;ZV$5*Z.G%FS?G']Z<O?UP>?+VY>G%VP_G
M;W\_>WMZ?G9YDM+LP_W@?#B;AC+K ;!QRN>&3]HZI;/&"N^D;)8+0X@B H,@
MA6;>:2N%\R(&QU(TO0V?N=W&\+H9CT^;X:2/Y!O&/HQO(O Y6Z5TEB3'$H'W
M%ETJ]'@(&L<\JX143+6K"E:CV2KU_8]K?*-G+];I"%"2Q0FX&,('M"E>]V,I
M)SX?CZ=E<,\K@,4+V7/9&:GQI>.Q])$H*T>/4A(A&>!&GB05[2:U;_+TW>]P
ME8CP7:I[YW*O72-Q,AQ._6"![0V*#=_@&W@SWQ%7&Z7G$85!2]VYE,2FG(D3
MU-@R2IQ#;$6+IY]U'"2H+-/:D_IPN>,^?LYL2UT >M6,WI?[[/DE=T_+&)(W
MF1A?^NX[H4KC:+3=..I4.?R):#=3[>EG'8?**\NT]CB]]\U7/YA\O0B#_L<9
MQ)+CV=-&"J-\)N@3FC)[(Q!+A2:0<\K242ICNR&,#W[\<2AV>\E53(::(7J#
M<KR:7KV=%F%<Y'>C)DWCY+3Y#'CB_('FUVBQ\YQ\',',O.X!H*VNK"R9Z[GL
M-FC!>\>(L66.H^))R=Q*T>L_^SA8T+',*V;_W+9"3OWXT]+&2#Q+'D,D:C;!
MRRE.K$;733L-3*ELDVIWB-__[.-0\98RNZ]"M94*[_+INP-FYDN/BR4)J><H
MSU9*2CB(A$1+#MUSQTF($"W5W#/5SFIO_<CC4'@W$K[/ [VEL79UA7#*/=W2
M<YCG'YY?7:&#X2<P^/IN!!'_//QX]@7B=.8HEXQ=+;,,W',BM! HF3*]Q?I(
MC/;21B4<W&W8N-*(VQ3#<3!E1SJX3QW3:2O8G@,E:4J<9%4&/"NC29 LDRR%
MXE*A0<-VV@3VAV=+?;'?YX2M>JR\Z0]@/&F&RUC$N*<"3[2T:6 V>2*U9,3&
M&(@705(0J-"[]^TMCY-[C_KAU=V!1._KVVVE[U?]T7BR0/)R"G]<-\.20#"
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MX=_]1S2T#%@N(B-.&H^&5K+$<4UQSU!:@W':^-JAK=;@=N]Z[(V#]QJA=:+
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M%-Y@9F&C71&HS4&C!N'M-GOG^^B:*,FZ;8X *7MXI33%3?@75+8KH<4AW_5
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M6-))MNV2WJ!\.DSI2ZQ=?8F3TI225CPN_4;0+,D2 ]^"N#0O-CYIL@B2;@L
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MVC*&<T;D];GQB[X_T._9<DPRBN]7PO#-"TED'JSO6B\.($"<")SZ*8?^AAH
MYPY_Q '6*Z ]\@H<\,D3SV:0!<9???SC"F89^[!\]FQ63MBV = RG1W>I14L
M;<N(@L;IN6+8-A.H+;:TZX,)ZC)>5RWLH0,.V",KQTO;XJ6M#C7V7(^)1G#
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MF,WL*FG2(E[H/M@?MS)SFK>?&2UW4]E3B,J:D;)Q$Q[@CO"88BDVJ66@M*>
MPVP"%>S[O%VK\3#1F\8S:I$@O-/)OL]"69#"68@#-._I@63U<2F37,$%Y'F
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M.9@ OP6YON5U%&\5F]+Z"G+IJ7+*7U=V7#6N7UUK$@<(X^\K0! P\3/?C@3
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ME98D"\*;5GZ4="_)##N?KHT3#-*^T]911 _VBR> .(H:*FBI9=[!TRUQY$I
M$'^VL6NK<RE)MS'8C7549G[Y@:]SQC6O\WSXO&UQ-28(6C?O6*4A44@L+,)H
MOO>]Q<'![F&7ATBKP$&<P3NYA1AA-V*VI,.F3'4C.G^6U9&M8NK&!(='-1'6
MX4(ZT0*F:B ;EAH+&KK5#B*9XI];F8C&4FJ!2:;";S9V5%]/5-=)#?5?L,#-
M%2<(UF.XR*):F R,V7C,5"O*Y;E:V8A@=;K/8DPE/F!H/C:Z&!7OQW!DORWD
M3(1WY^.TS=A<[)E/VZ!."K$O;6W=*!MUJ)<>+RJ3%*,MA-8NAIMFY@-8@D<4
M<+ $BH32W*?%L_V'6<>(UUF.88\5XY_<SB7&M&@75 \M;9B//9JX[1BX30.%
MG1ZH5=Q+, _ML_.K(..GD6 ,*RN?1 'EK>QC<&VJ901\GJJ?<9R3_Z0G.MP?
MBLU&+453%1A(_C786X>6 (_2OU(S=#-C<\Y 0(8I:VA[O)5 ,6>#M]IR2(PV
MYN2.=H?MM\X/_9Q&RM%"]F*8(T9$WRY#^8V&LS]5#8/+-63\=:;%;J4RQ\WL
MA_$3M-G/<(TL<>=^6'Y5H8T$Z7B<H:RI:;QTR-;6@PL,K];X<H^\A-CJ1=L/
M/WM$_UVD>^7F@,W(^+#U3P1%OW&-Y$CR_"</:?3,T*<+=RB_8]=>")ZKGO=Z
MN=0L6?ET#NI1O74^;AQAK9:P-=9Q+)-W]TD+5#>X[V[W,9*/T1>O5^QKF_BB
MT,M'([&NU86$O*M".K'2GZ.MPM][X(=C^3X/Y0VSYPILM/Z26XF*%3CK+9'E
M;CNGK&-N]N5+RK. M6#I\'8?IWWV2:T@HU4T$/]:1*&-D9N3>XSG3$Y\B/JL
M)G,N3,<^PX0Z'1>/9/K&.;S5:>AC8=[F,+RF8A\U.*,.V]R&>PX;.T1F>"!*
MJ6XBH+FNY3[K\P]"$,?")&=UHDJHE9D->1VL(=6,Y*T4+%((RN1LJ"6MLJ*9
M/('><.SQ5:"-P9# M29V_<RG15DOF"&WSV5A1O) WA_"@\$AB^,>2+!)+[]"
MZ*;"CRXIZ6E,)+X09".N_5[#NZA]6S--,^#Y<[Q:LYNNP6ERI?RNQ#NRFU0S
MT.$R<AO"7++0;T\&0$E#&DKHKE2WS3Y8:=QY\8+,R@D%6JM['R?-7B1@M?9\
M=O<]W)\6<*U 9OI4>Z&7HJS2JFRLZ-C**<>A4A47";(F5@^V,ZL,^HP$37'I
MOHZUG'I[J?=*,)_!5@="1K8%7MM$@AXD\$U"!\81XCSQ$J*F-(JO<^&7T&4N
MR0O%LW,DJ-.TXD=FO%^(_''JP1$2%-[WUZB>C%@A;-+$GTC0K[(BYP#B#1*T
M3U)4"9$"6AI,4N&72- RE]35L5<P] QG[#FA4UEYX:H6D)C.(<2Y/6*@!R=7
M-$V4S-=>&FGT5@+Y;B/<W_R &2"Z<T6T*R/4]1[/YQ[PV<45EK"_YDB@7PO_
M:?47!4J;WY-I<7_\M'R/!S[U9P3OGQ&!],>1V*2(WQUY,_M^SS8:(4$Y)&:D
M_Z<\XE']B^AD!7WFI#2SU5FU_J]R&&_/-2TR=1%"+PAZR%]EY=7OT"N.+#LR
M8JO"-2<.K!NOX</HDDVN6<<MI!Y2WJ(5HC'JK_@SR]AOJN4_@%D$E"IT+"HV
MN60O\U#+=3N.79=6*#:?Z "*V4$\Y>G#.\.5/]*_1%/_MB[#.M^3(I$+1P!,
MT$A% 3$4N/'LYJ@@8\G#G>C?I6\T5[S,P=]9^A'J^:17#R"@T'W\[+94. *Z
M3*-5I=S;!&3Z0&B6.@!_9^%TI9[4LYMC+[.R>YO;<S;!9W! =/*R=< X,,#M
M\P>9R7XA-L?Z!V=7@&-[*_Y(3MH<D"F-S%Z1<7DRY85AE36VAYP]QSB1N'SE
M\!!XQM)0;'.9O6 \=6\)?.EDMZ)T_?9B+)>=\F3GW#X+> T0P -2X43%,T E
MG9+Y"8P!K!Z\J0> YL)#V/YP,THJP\KU1,KL5VGP-S=%YS("<:2:E;^8,/^+
M'2O>M[* O8(/?W$A&?P=L+8UQ%/+GFM3<M.Z+HI;\@$JN_KNYOX(&&7QJM8O
M#>K_I6.)1Y1#XA6THXO#)3G5G):&!(EEPOXVW]NT?"=[G]V8\Z=LD-4 %P#9
M2ELI'/M</1N(M2!"]6\G!O];QM[I[1?_J:[_79V7(,.*X2W+@02Q_>\9$_[-
M#[?IM7;NJNM=+ZK?NE)NZ/FE,^6L*YW9<?[F1N4O(ZY@ -8!1<3CTGO)+CSE
M4:IW/L[X+'/9]C/VWALSO',/SGZTKZF.D7\553;NLJUKNS;N;5=%U=>*A% ]
M'+X&F-E5]=NZXC/R).88?]?V_*D-R,J8-[>NI-J_5B.9-;"6K_D> "3-SEW^
MV]H&$>]_FYT-1BP7-JG''X;[KJWT<5$=_95/<+DN\6:^CKW^+LJ\]BVS)K&_
M5G'V7TO-6.5J@3U<S3EWFDI+5,+'8S<X8W:T=\_HJUH(8U/" YRAIOKM&B"
MC8".*\-#P/);\NHI7[M#<__M\"H9<#6X:$?FKLQ/_PQGL&$8\:81<"#7@%1_
M]X;\\6(\,18,_X-74_X?W* \X2^+^_< XT$IX?=&.GU_N4'K/VZP\]JOC/]5
M ?OC[WC_JUO[:W%"I/[ABRAM?LNLR)/ARGM!!?]XKS6M/]XKS.+!?F;6<%;
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M+?!%; \B6O79Z,^4U,_4.*L%J]E*F![C\\K<LO#ID"D8/=]G#A=CE@6;"K=
M_ICUZ/745[#FIP&%<H4>DA9=WKN0TT):"U<(X(.<F7:"YFM8F^9]JEN@,X=-
M^>48A!L!RA*QX8W/Y,(9QBVPK% =4)ER@;0 7I2^!4),?Y49P#D@J830<;\%
MKA#O"<5/7L,QW:W;0RB5Q^7A6/!0?$5Y<L!8#2F5!($V#U*N+#@/GM?>K>+_
M3%JRQ*>9W.EGU ;+LOD'X1AXGP'R<"-FRV-TO_,PB4GCCLDYGV]#%WLGZK>
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MP[&^YZ<<,/P4&"*CS9V,@E@#5#H"4TV_>//_BW?Y;][)=_< A^4;$25/M5M
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M).?L+JD)'</3%'=^UA.N[Z)0L>)'G8]2R-9F*DU'8,G[X40A38(^VZ57N!%
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MA?@/@(?<D?DM%ES$EQ2J:L,5)QBMLNK*+/!,[-$;R-[-?DU3F%_+88+#VXS
MXQD.<81W!%ZR?=:.E[,E>.W@WI!:)=!IEZ'N/]-\I!6QQ<W5Q3HK^C(9QF[/
M83&]NK:=04*$%[^WX6@K,5_>U:C0'-^LGF9:4;/2_:5>NBC1MTZ@*4(,C0U<
M&GO%G[&(@G\XNL(7U8__=RPB6\*,D"Q3PK,<#"$H=CPVC#>_A!K^ >C](\*0
M=X3).8_HV^,%G7OD'%K,1^]1+3MN=LIYF X7>P\ >=P#4M<EZM67@.9.S#KJ
M Q5S PV1$T<2E]=.)?%$NYE'\F$'C2_S+&U.M\<Y#].(A.]^>%;M+^6F$W(E
M<59>9+9L*IF,G,5$2E>(1.4L%Z?[;]#8> BO>R#1NV0_[EB0!3XH6G\X!$EK
M2HNRLNM>7E;= [P]I2>J'\Q;6D:5O]9C9*R_/RG@]9V)&17.R(M\]$G]P]?G
MW_ XRO^)9_SA7[ACT> OZSSFF;7\@;*8^#2!J(_N1W]XN/[K^M O7DA??G%;
M5:@A$=6,&!O#GQ@HS)L1RY]IRMK;)8BE3 <<M07HVHIGZF-G&X)R3909PF-(
M"0MAB3PF%/-V4+>=&!WM&S-B%?+J3(SU"M*<J3Y!ST^]3F'T61S2L'98$(%L
M4F?X%7VA<*V@!86$AO4)<^,A=2';^DH:);]M=ZHOBE?JYSN6L26J/PS7/QE
MKRPK]U=ZAKA^TQH&AZ5)@B %0AJ>_7ZKREM8Z)=B,3S/%O9:GV.?&1/!B^LY
M-^;&L:&@T>?!G!U4G4Z>.4^3>K(OZT;SZ=)U(L]/&S[ $MCB<@$%,3S*"8[J
M.;*)%H+)>PVW<3YWWGU3(DS';1O:0U[76W["O/)J/[-:FT1E@BWZ:?T<<]4)
M<%!L:*&?TBHMI(8&;K&M!X#LA0AX-EQWJ$Z[VJ/9/G@WT')M5L?A*SN'ESH
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MDP4."D^']V5:KK[]0=Q/#_Z.5.GPSHWQ]DCP:_0#^ ?^@I@8Q+K;?.?;[_>
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MBJ4^/QC('T,36^TK:J!/ /1]$?I*.1;G[[J+??0)2DVL)/!P@]'N[/>'&4^
M /$U_5L K)3RPWX"G#G"G4?@7KK<,V+"P\HV>-'[YTE/@+"<1UQD/Y\]./)'
M1+DG0,\8YS81T\')M2K9LR= )J+/-1;;$P!?^F__E(D9;UY1TK:NY(K_Z LK
M>=?>M=WKDI\6"L%J,C%8O7A*J?_(ZBNBG-U:_B\H?#HS3]D> +#2LSW$Y[H1
M<",5>MOT)XCQ)\"+S^UM%X"H)P \S1-@8P_A/ZC^@^H_J/Z#ZC^H_H/J/ZC^
M@^H_J/XWH$I_2&_;RM#WF5-1?,#%=2\SW2,CGO!D,[C2QOT*J8O]R$3A;-4
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MGP=N)*QC'MRG^CD!@ZO3OB.]#'O"UZ[JWJG>B<<[9[7(5O-E?D=>=+*,.G=
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M<X_OMU+Y-T6]G'-=P>+(K]7ZK-1CA=3ER7+,PH"&-(2AX)$R:+&^DX $C+P
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ME$(D2 JQ1SQ(:8A%0$6"+.M>M_4V-MJILD)MA+2])]>&K.$)B"N\>N:6/:C
M'UI"IZD4#)!P=D.MK:^!+Z,9J+U_[\SDI6Y\H>RDA4Y^^E:4_[V9*PMIL1*\
MD9MK$E&?)S[E4"#"=?4J ;'T*8Q)H+ZD0$82$1O:,.ET;.Q120C$=WVL89OP
MP AF,PYQ#5[/5%*+"WZN!=:%,4 -YWN#=/'6Y&(#D2..,>IR4*JQ 6&7<:S>
M'3BL^N-*;^S?RO+:;=,]+*K]342<I@$F$D:LJ#B#0TB\((4<>\RG+*8)LXO!
MZTG0L1%<*:[VR72P-9F__%.^?955=2867]6<52XVF-8%R59S7A3%%N!9-7=&
M&H*^O@='L2D#C'+/3.P@4'OSC93J;C8DBX^BT'@$@=N&8_+:0=RGQ!Q7_,B9
M8#L+[C;M;PS5T8L=RDF,DQ3[*5/KD, 0A4A"'%$,HY1ZL8=]$5AZW>YE'-MB
M5(AX5E:;'L:QYY7$S>B,?Q%I*4]>:#N"!>3T4+SVVM$BX8^Q;)R&N-]*X=M=
MV2T67$PGU_/E=/GR^8G,9F]6^70N%$%@AN($*8<C"$,"D2]3B-. 0!$Q/TUQ
ME*1>;$+T1]H?&TF7(H)"1E +:4;3QQ!LIU@'N/2]<6H%B3&AG5#\ !GE@OWZ
MD'W]3;U9\I#ZRX9^CK4W"'6<4*:>]J<>LY^R[Q6^L[O';"Y*&W+BIP&.993"
M* PH1)Z?0IH*"64LI> X%@$Q"O(]U/C8)FLA'R@$K-PX\YFZ!]SI:7H.'#W/
M40LDK";H,94[S<Z]Q@:;FL?4:,[+H\]T+;6X7&J7[FHA^'1918TGB*,DU#G?
M,4H@$F$"U8R,81(@O9$G@XA9E44[U,GH)FDA8U&9JY#2ML#B 1C-G)9SP>E[
MRN[@TD.H?1L"SLHF'NABX&*)QY7<+Y'8\FS'S14Q4[]]^%W,Q8+,+N?\DC]-
MYU.='WXY_2JNJZ.UZLLE& =1["<P\G2N%(D93(DO8<*#E DO81&V2T9ET_O8
MF*&2NHCR(5MR6^Z+6 V!X8Y'7\#VO9=1RGT!FN!NRPYJX7M@G$ZPN=IWL.I[
MV!V%+K#L[15T:J0;J]TN'\5";TDLQ*-J535?UI??BR_5 :HZQO1VW@AO74R5
M7_/0S"?\42QOI:YO@&D0(R:9K@1+($K\2-E"$5=4F)) (AD&:6I#@'T).C:N
M;(2N_ZSOY/P"'I1"()L?OLMC1Z"]C;89UXYA#'NFY=NKFPM@=/7AP!T%K3;X
M62O^R_K>PR7_/ZM\J;<#+P"1VI!T6O2B[R%Q1/F]B3GHZM WV+L+2>_]=5QS
MMBJ7UU$Y+Q\5B*N%KG\U"22C41AZ,.*!#Q'U/4BT#YW($/EQA"415O5V3_8X
MME6@D!/,:D$M6?XDOFD0IR@-) RX#C-*%;ZI]&,829:F/ H8#\GDJUC0[%40
M;O;<YU;:_ &JP7P"LW[1-EP<72+8]RI7RPH*82_6D9 O.I5X+;##5<H4&U?+
MS<G^AETW3-7?6P",7W08@*T3A.5WY*7(8ZN3G4X$)X)Y<0(E2Q2=8RPA%4P9
M0XF/A(C]4#*C(L5VW8Z-TVL9=<E7+:2#(.Q]J,VXQCV /1/.\4#L$M)*[ M0
M"-YS,/91H/H,Q][O]/4#LH\"8122??SM;F3T5B@[5U<FT%?U ^&Q-(P%%#[F
M$,6"P#0)A3(H*?%QF+(8"QO*:38^-F)IRE9?\; CERWHS"BD*R ]$T53+'<T
M<$A91Y-]J^E!I_0AI78G[L%G.J0C^D"4%[G*[Y4_2I[%:CEEN>*$^JQ$T@AQ
MY,' +\Y*"(9I%%+H>SB-!4\PE49;A2=[&MO$K60%36&+)!<6^5%:D6V?RD[Q
MZGE>'X)*(W7Z:,,2,HN,+ZZ@&R@A2PWAL@GA5$'X5$C\JZ/L*":HM"8O:6U@
MN-PB)GILI?XP>J%C9HXR(#2_SR[9?ZVF"Z'W+O36Q<U<UY$H?C=),8\B)G7"
MQTAY66'L*1K5X?HQUF<P).3^NLCLO46*#H.^C;[VG?1H _#KG6KH47L-F02S
M]6Z/*.^'3]?B6R;L,!D+,QO*&;0#)>VHQ 7+#%0"@V(3[5[#VI#98;8."X1<
MY>LPZ7+8C!T6(.SE[+!YM_,F4/8DUO?\=7A=$=NN,TO$(HR)X +Z:< 4,:4<
MILS3D:H8)[Z/"2>>Y<[/L;[&9MR5HH*UK* 6UGK?YRBZQIL]+C#K?X?G,%S.
MLW<8X.%N(^=H3T/OWIQ2^<"6S<E7NO%%,Z'VY9Q_S.9D\Y-[];><L.+.2VV1
M$\*EYPL8!DRYAW$0PU3&"'(/A5X:8B%BJT@2R_['QBM7NKH"S:H0K^;-M2("
MK/'OXOA7F?MD#K9>LB,@V^$R(Z4>!Z%GHCH??_#'V^R)3.<..:TCG(YXSK;W
M0;FO(S2[?-BUF:Z7"O)<B"/'=Q_(4L=HO.Q45)5>F"1>&D.,N80(<01Q)#!,
MB!?B.!"I0$87^,Z086Q<V4S6^&ZE)!;@PW0^?5H]%;6QIZ7]"[ZLTX#,LSED
M.C7(K*RPO7W.;7NCP7X,S<BSYY'IF4!+Z2]VP=T*(E >)A7@CDSY!:@5ZC4M
MY!F0.KM@82_!P/<O.D.T?SVC>U.==]!T<YJZBVQ09)9?4AU1S9:3!*4H27D
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M7(_U]F=1)%V;1+00^J)(-JC%+BC9RE8]>\A,B'O(@>B;W9NZ%&-0:@/6ZER
M]3AIC0I7XTTU3K56!8T-.TXVR\60XS74FC+$N%FN/ZY@;E^DSNYEP)7,%2+;
MRYVS5CMZ%;OKK?)G&@7G=1427:BD4?%AR\XC,HF#0(20^'I3+DP"F/IJ8911
M+!'U)"$BL'(]SA)G;/[)O>X#,*721?%GTU<IIOG!?;<SO9CS!M30U1ELF ;P
MAR[ KDU?[L!ME>/)U6\.E.PYQWDZ;Z L/:S!!FQ -ZS_@;/WV9S@?-*Q.Z^7
M8;T_)XCLN8AN6NV8F^R\RWY*E-5\.<%^A#!62R?UTA"B("8PC>, \E#Z)"5(
M)*%=QC(74HW-JUS?WMXLC\J?;%[F93NWMWEU>_M;?7N;5+>W\_+V=K:YO0U^
MGLZK'_]BF>[,R1?0OM:^VKCVO.0ZNJ-=</C*9?T@IT"[2IKF1*9A4ZFYA'$O
MP9K3QKO7*'@_93I*;.VG57&-DJ<I#T4 PT07*>"40BI$!$/N4\02*L+$_%)F
M:U=C(^HZ;WPE[6;GPC[E_A%L#3P39XCU3(%'P3JC4,$1U.PK%9R/WD NP%.%
MXJQ"D:Q1[*5603LN)L4*CK0P>+6"=DT.E2LX\49',_H;6?![]6Z18L&+O$ 7
ME82(L  B*BC$?B(APJ' :4!BEEK%WV^U/C:V+(0#6CI+NW,+,D/[L2L0?=N!
M:PR<9Z,XJ+(KBVRK[6$MJT-J[5E(!Q_J8.GL^,\[WO4E4QR_FNDB';\OLCS?
M5 O698+?%&6I[\GWF[FVS)0)MNNO;UX_6&=X$E"/<C\-U "DB@1\79J-)P@*
MFB(_EHP(EAIO++^J*O^W;$JO-J7('ZM2Y+KHO,U!X>M^4@8&Y _SH?3,S4:U
MZ1OZ@ */9K5ZK="Z/+T"I:A85L*RMVN[W=21DO<_S&=F87'_,)_;0!;]C_39
MV?D0HQCI5A_E=24<S@<:Q4AL^5CCD*ACQFPU?S^J&5W6JIC$U"=!X D82<K*
M.SJ8*)_.#SA#*$6IC*V<N.WFQ^;%%9$X6CS+!-C;F)EY<=V1Z-E46(/00\&2
MPTJ[RF6]W?BPZ:L/*K:7L?KP4^=?']AC@O>*6$0^0:F:IJ$(89!BI+>O&4P)
M"Z&?A!YFZF]2AA;%(2VZ-OJ@AZ\-N7_!X( 7-"LTZ!XY?VPT#/P5A^"^UOV#
M W;7^YX [7XIP0&PKW8]P1[@LVXJG(#*YL["L:9>[?;""=W:[C&<>M6.U+F8
M3MY6']2_K\A"63NSET_B.5LL)Y'TI*=KI!.=]EF1N <Q\P@,8A1')(J]"!G%
ME;3T,39#K!83K.4$I:!F'-*&9CL).\*H[]T<:WB,&<  @ /F6B[8KP_9U]_4
MVZ6EIOZR,=#:VAQDZALH54]UDT>[>5;OR'3Q5S);B0^"Y*M%65-N_<._3,5"
MQX6_5$Y$Q-($,1\K=RM6DQXE')(@$9!%+,9I&F&/6@636?4^-CK0<H)"4+"6
MM-C9_GCY5SM7S6X0S#RYWJ#MF47:4.W!]^L$DR/7T*[O03W'3K#L.I;=&NFX
M0[3(GL5B^:*=67U;7MM$1:*M8C=KD@:,^"STH1\''*(DTF75E+7"4$"#6# _
M"(G5CE%K=V-CJEK:8AZ)6M0+\*"%M=Q5:L?9<)?)&7I][SI5@EX4U^'*%!S7
M&_Q^;\7/?A_*"!97^U+MG0V[3V6D^-Z^E=E;'8NMZ3A.2G(=R?^D4_65-^<V
M97;?O&P>J7*+%C$1Y<VZO%&]JR[P5=7W^B0TW>DM]&Q>Y+I:D9E.X1%,>. A
MZ9$(4AFF$,4DA90' 0R"@%,_P3+@5K4?7T&'L3'?7G&UM>2@(3IX/Y5%.JN_
M";+(+ZIKL5M!_)8EV%[AZS&CWI%_$SWS>:$:U&4@.&CJOU4JG;Z YG-U[NP"
MA?6W<=&LSW>Q7\3O\'>F\7!8XNWUQM)5#;A7T&#8(G&O-T1[5>1>492.^;1U
M+[?R2RXN\UPL;^E2=:-S8EU_9T6:K'?9XDC=Y@DGW.=24,@HTVD<8PR)#!@D
M),8($\+#,+'*L]U=EK&MB84J,)-PI:/9M39ZZ1.5'D!FB[+N%9C5&EAFYCYC
MV,P6L8$&H^?%:#T.7_3=C&(<:DWT@%PW!V2WDL[[DT-CG^7[?%!=9?\^0Y)A
MLX*?#]E>MG '37:M7E"$[]P1Y5+=JT4AUWFO%>_K9(.S3._?;,HO<9&P,*"Z
M4$V*==WH%)+8CR%B/$D\/\9IB.VJ&!CW/3HVO7Y_>7_]%MQ=?KK_&[C_=/GQ
M\^75_<WMQ\^V]0S,X3=DR7Y [9L52ZE!(39HR@TV@H,_>JF2U0$Q9P4/S'L>
MN/"!-23[!1#LFSACT^;-:1/WS:Z)6Y9<OU/?L"X#PQ7'%C^>8.Q%"K4(1LCG
M$(6<0IP$%'I>'%.<1H1X1GG ^Q)P;&18EC4O/(@B8T*MX068K_15/GW'ODJ0
M\%SKTCT]@O/AMMA">:5!'/_^2*DD6&M9F*_%[QQO?/0P BYW-5R*-_R610_@
M'MR/Z*.?;FN'LKAOY76^G#ZIQ2J?\"#B :&A,FZ1T%E8(T@)HC"*F PQ24(>
M61T8;C<_-M[6'JA.?U++9\?#.]"9L6AW0'KFP%TL+L!=-INR%_!']=]>3,_#
M<#@BI)W&!Z63PXKMDL&1I^S#%:_G2^4*OYO.Q,=5E2L%I5$0(1B$4IEP.":0
M>#&%U*>)CQ"/46J43OE0XV.;QJ5\0 L(2@G-(Q/W@&N?QN?"T?,DMD#"*@CQ
MF,J=H@_W&ALL[/"8&LUXPZ//=+@8\N59]3\OBT"5*_F$8Q%X::KCL_U0W^$B
M,,5A!$D<X( +$DAAM(5TI/VQ3<U*PO(J?%4BUN+JP0$ V^>G UCZ7F<K1,I:
M<"X0L;AX<1XR UVRL$+([C;%<?U;;TX<>&VX6Q+'9=ZZ$='R6#?/0%^AT">;
M4^67S-E4Y$6E^$F28)_S,($>"1*(A%3<I7X D]B/?)PF<>H9)6%K[V9L/*:E
M!%MB@C\*00USB9T U<QW.!^JGKFM TK6'D,["(X\AR.=#.I!M"NZZTF<>+KC
MQC)[%'PU4S[*F9DARZ\\C0A&L9 P"$($42@4=> X@"&)E>5#?!(*NVUEI^*-
MC7)J[72)PI-97=_M9G6]/935M1MG.?X*#'>;7VUL^]YKKH<U,QA6LV2][DFV
M'_1=[3.[%6[87>9>@-W;8^ZGEVZ+R)&PC:O58J&]%^+YL1=&@5H*?*SLR1A#
MG' ?)CB@DOD>CWRKZ._V[L9&\I580%]I+ X,SPI!.P4UCR.4"@H)$0KJ*!20
MI$D*8XII%/@D33F9?!4+F@T/=K/;_N'N$V6S]<T=<CVO5SLA>!>;&+P+4$GK
M;MTQ0\71.G*BLT'7!3/%=WG>\*V.QO\R8W^_R?.5X&_5NC%_4(O"-*N.(:^?
MGF?9BQ#%0_69I+Z1E$\\G],XI@*F/)"*9;P48BE2J#A'^D1Z"49VUWFZR3$V
MIM<:$/4M:!..94]/RIC+M="EC2>^BP6;ED=PY8^SZC*.OGM7!XWDU<.5TM63
M]6_+VI#=PTHZCK>A/=__*/9MN!=@ERJ 4@=0*E%'?UR 6A%0/ERK4ERC='AC
M\DPP7=GA':48UN ^#ZH]R_K,YCKF<B_+*U5&^LU\J;[+J;+,BUCI?$(D)[[
M 4R\Q(-(8@9)R E,2.S[E"2,T, JN7MK=V,CUJ:T137<>6Z;][T=7C."<P=:
MSSRVA9=:;C:BEK<Q'/*4&2:N4L>W=S9L+GDCQ?>2RYN]U3E3!!."Y]KG+S*?
MSOD'LM0; B^W<C<MZF:K8)($'*5(,NAC78.4>1+2*"&042E"S]?<8Y=TM)L<
M8V,=+5W^VU,IN=ZS4S/I8&IWZSP3G4;)C*,&P+YG\JHU* UA+69A(-=:Z%$P
M2'/M-'?%.8BZ2VK128JALUV< ]6!-!AG-=<UQN[SHYC-]*8IF;],&/,EIVD
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M1H00:A3XW]+'V(A*BPA51T]%DC^U(D\WLMJ&Y^T#:DA1Y\'4-PEIA+1XX,8
MF@XQ>4>5=Q:0M]_#P-%X1U7<#\4[_FC';,73^72IF.2KSHBQO2OT42PG%$58
MUT:&*2*1GO(88E_]TV-<Q-)+/&IGN;1W-[;9W]B_+++Z*(]_+I9Z)X T"E"1
MQMZ:99;B=O#-Z,$=I#TS12DH+"3=WQJ^ $I:AUF(C5!QE7:XO;-A\PP;*;Z7
M6-CL+<>9A-]/Y^)F*9[R"172CPCU(<,Z4:=@"%))U1]A$G+.!&:Q<))->-WE
MV+BF-3$N^$/+#0K!+4-L#< WWN%U"&G_F[GGHNDNV? >0'TG'-YT.(ZDPWL
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MX;2+G'".>FO(A;O>AHO5<([05I"'^];MTY5_(-^G3ZNG:MLEE3Y/!?-@A)(
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M[M0L^""*4KJ42B)EK)SBR$LA$C%6ZT$2PCB-?"%D(IC$QH%?'008&^\'GI^
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MRQ6=3A@E-!,)A4E1%9SF"C(<1S!/N4*LT&116#DL)YX]-@9HI .\%L\A8.X
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M;+A<3W". NKZ/J<?[=VO?LA%'<1GVH>N%POM84Q8EA<2*PKCN$@@HIA @IB
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M53C#3$8P-IR&HI1#G!*J';,DRE.51U0_QCH]NF.DL5%8+2MHA 5;:5V2>KN
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MHGFBF3$AQ*QB&61,9%"D51MEA5AAE3G1,<;85JI&1%#+>#F7SAI+.SZZ$J'
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MW25-.%"5'K\Y(+T5HC2WT&E]1GJ[7OV8+PS?33#+<![3'#*9F[;BVOBB65)
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M\KLO[O>]G^F(?M0*_1U=EGR21@R+5%(H*#8UQE@&<:Q=*W-<&R691&D6N?"
MT^ACXX>-\) VV8R;!FIU<?96:[4;P(P"_6,:W68IXBQ*3$D6(7,.49%2R)B6
M,R)()AF5:8*QVP%ZL'D:YK1\FW=Z<:; NG;.JJ/U=67^S+039QIHF;.<^@X
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M=4 Z!'CPH)P1$)1!R,D$S8WDDK>Q!G>6W0H.<OAPV%V6 P'#Z3Q,%^,J^$M
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M:H//#MZ[;D%9WRFJQLAY.EG51#T#\+GN<K5N_7EPOOPZFX__"S.%R:4D18Z
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MA-#_<JW^83&C<,$ JN3HJ&<&@K$"DBPR&L>2Y!T!["5D]HO!_7#Q,,@Z4](
M<'C]'NBR4^N-X *O(WA8!JN]IMV93'UE5+-XTK,8E6>I=3;B46(&<XO3N5UK
MHX\! .LSZ8@(J$W.W](VFLQ6G=$NN1K9A%HSVB7:,=HE3D0(OK;7,^BMRIYQ
MU=K3?Y*@?HU6(Z7?[XK92 ,#@--O."4938B7@WPVGHZK?.J \RMV>#:<!8I2
M3(B&V+$&O(X1HO#,"Y*4R*WS\\^0U*_-Z@92+;4P %#=$])(..FYC0I<4>0M
M1%4K),E;<%D&71S%P;JS;JM71/1["=T-</:3] "*1Z\9N*G*'Z7 T5JNP#-5
M.[35KB"T-.2B9)"%%Z]:WS0_0,9@:A9>SS?:40=#@%%]Y?%Q-IW=9>7*?DJ?
MK;+9@91&UXD(L59A>#J92_&9!19X:[?H:8H&4[_0/;C::68 )]O-#KD*7L?3
M<V+J)DOX!LML?BE BEMQ<?2#A$@:'4_#_.(]R7W5>J*&O;/)9"4/(@\7RQ$*
M&X6S&5+* E1 !5'Z LRHDCGWZ%WKY_(=LC.8,HK.$3X43 S #%^S>+F]WY!?
M6\;+D>>%&VDRT,&A0%E)_DAM!N6B--%9@<JWOLU\A)3!5%V\$BSWT\7.D/J.
M\SAK9',_XO*68Z*3+I:AAYKWJT,HB/P0"Q05I/8FLBA:)VOO$#"8THK. ;2[
MW =@B:Y>8U[5&KT)BW$:!2N,=HZHUL*3MY$MQ%0L2*=3<)Y,JVE]Q#Y(R&!J
M*CH'T?YZ&(0-VF3C[7AR7LN[BPG<"^LA^]4X$T]Q-QE1R,0.S\)XFUJ'JH^0
M,IBBBE>'U"ZZ& 2H_AWK<!S,!_2AX0M^/#^+.#\N]XI&UGM&*%='LTN((6<Z
MM^D$]Z(X2%IYCLX'85O[4"\B<+M4/_OO@,#N%#> $/<1YBYWV?V*)HP9=6T/
MA9$74 HS1,XT[3TLY$UFF7SK=Y O)'$[9/ZW*-_H4GD_:3G:'5&O//@NJM+N
MK_(:Q6G/\-93C1J//F%0%LC+HU A<0N>)P2NN2G>I<Q+Z_DTKURC=C<THOT3
M-9(C6W3MV,F<) //.5@LF?:K4<&UKNAX>4@Z&//V$G0\'9*^1.X#.%BWZ41%
M/NUXENGG\]I&^"VN_WLM._)BG>:EOFNPQ+%$K'VJ"G"5'0]*J8C-:X?VIOKG
M*C+:!YZOK.$!8_J/*;$UJ0]R_CJ;5$_CMS">5C$<3T\PG<_7;6GFXP7]U5OZ
MX_3+6B[7'=ETS,)JBN-0UWNA['EM3J,@9".-R-)FTSK:Z8J7GFN@7AF36VZ)
M5P7( #;* R*X9H4SGY(7$9BM79Y*$D#N=X3,90I!VA1+ZPCJ"7)^KKJ'?<QU
M*YW\1,VQ;@</#W1%ZR(R>JSY6L>AT7/<M8^-GNSCQI(+60!*40?1VEI7X^B/
M):&-@IGD6Z>)MR)L_TZ1EXN<UF%S(RD2HD<+#%4&50>W1JM3'3KGHC<^E^;9
M\+L4#"82:H2%^\TB=Y;W ,[ :^K7$JGF=S:MN_7@QW@QRHHL=@D>>& D%VT-
M1"DE1)>*\T%G9.U;C#Y!T$"PM(.F'P/-WF(? (8V>'@[.R._<<0RN:;D#H+,
MF$ 94;T %.!C=B()%MIW7WB0D(%@9G]%;UZY[2WU 4#G;N>;W[&FQD=6YMIH
M/D.VBOQ'KC0$*73U^)!'*[FUW3;66]/1+W :J/?)+D,[R'H >+GUCO^2 <^L
M,U9D*$4[4,H[<$DE<*I(R;7-UK=N>'J/B'ZS:>V1LI^4!P"31R9;7#)#X:(3
M&BD@58J884G59ZL19#$F,57OWEI7'#U)4+_1?7OXM)/^$*#T_-B*2\909F/I
M. >ME"%3:@L$C1J\R\((8:)-K:_8MB:NW[<-'4"L$ZT, &Z;DRLNN6 Y&EG?
MU[,L:\M29."*#6#0NR0=LEA:3\9^F))^GQ"T!U(#>0\ -==1QN$D+!:7J8Y5
MA!&T8<YR!%2"K"U&A#I8!U0TIC:+R,JWG_?X"#$#N71L&+WO)>X!X.8V_9>;
M29)UC(;V$?.24Q@0.3EY*H"4-B FY:)H#9C[5 PD9M]/O9M.]7ZR'@):9M/O
M.%^.:?L\&$L*9,D$;D!(6Z__HB/I6+*AGC/C4!7R[YJ'8D^2U"^.]M7XO:BL
MG?@'@*;K7?:!SM_5>[L1'=B&^T!GK:XM%3#6^ER4D*4O7J(L%#ET=5A=4S&0
MN]:&I]1N AX 1#:K']Y/[]_A?)Y-)N]F\S_#/(\,3[P4Q4C-J:932^T563((
ME(D;)[@(K2.P%Y(XD(-M1T3<?\W8F7H&@+[GNK+[C#XGY<'DVM58\0S>9P$E
M6B>9B/7NL-,T]8Y%]5VAJU,XO+!C_DMTLS/4OJVJGVA3S9>-3L1[\^!"B$)K
M2U:_U(E)];%*#)8#2TDRBX%'W[YL>Z?!?)W%;:\)JSTU,!@D/=GN6&9G5! <
MI(X"E! (L5;I80P^!5N3*:W;U>[=>;HS?^LUT=5,*X/!V8J7=7/VVP6A:^Z.
MSKY-9A>(ZWD3Y_/TE>3[:1*FBY'U0J9:KJIM;:$A3()89[6ZI!72AF,HVG=,
MWHG4?A/GKV[[.M;E +RZ1]A<#4%YE,N13&3NL4CP(150M3-<J,]:M'$VV^*M
M+ZU]O9T([3<]/P"X-M3C ,!ZD/_W^6*YJIX]G3URK;K:H#&LRF[/:E>9E;H_
M(TE[,5[B"<Z_CQ.NI?,9T^S+=/4I*T&-N/"U832#A*:./F .7$AU,HMP&7GP
M#%M73W3-4[_=A%YS"PP*'0/8+4\]JUFW^ZKO:F;S%1:6R_DXGB]KENUTMA[>
M/++""6\1R<UW6!\N<#K*I =+7YU55KGF)>'[TMQOZZ/71/NK:G<0O4CNOJQE
M&A,6'0&1,5!%!_#)^E4S4$.T<^M;=WU^^8OFSOHCO2;2=I?[(&#S7&Y,^5K/
M8 )([VOCZF(@4I ))M%.*#%(JUKW?6Z1M^RL3]*0\I8OT<V>68"C:>XJ:RFL
MCYBU!Q&0N)"Z0#2QNA&6Z<1C\:7]LY&=LI;=]3[J.6WY$A4,!$A/IL<\*LG4
M*E*S%E1D)!YA-$3+G'6V",M;%\#MG;3LKGW18+*6+U%+4YB]<K^BL/CZ;C+[
MLZ,^1=>?_BK]B1[FI?W;V^N%KI]98D8ODK+UBGF5?1$43P8.)G@9,BJA98=/
M;N_1T\ _KY_Y:5YU@/G-Q1\D]O?3Z];]!VDY_KYNFG ]PS($$@(Q[^M+&Y5]
M!A^X@Y+1<(E<>],ZW_)R*@=2I+ O@AYPZ[M4UP 2('<#%RZL8)8"7(^< A>3
M D3-(CF43J60-0NQ=;N6 ;7 ZEK;3\:,+Q'] '!S)Y%8LX#3-)[@'99.9R^5
M9N I%L$#E/I03"4I2)HA@I8YIQ0%4[IUOJ(+/OHM?GAE%/<.A!XW0V5H5$<^
M$'O5=R+VYI?)\H3C[Y7+#^-4,X_$Y9<YKJLTYV&Z(";IUT;&^1B$C^1:L\HG
MQ]J-/0(7F>GZF#;R])RON"\1_=K<_N$SZT&7+\>L7V-VBE^J<]ZP!\--FZYW
MWS^.;_IY737R&DD3.$:7(2E)\5IVC#C,E<-LN)6LY.9MK;:CK%\S.QC@=JC.
M7F&ZVI"'7\/T"[Z?'J0T/Z_26P_4J1,6Z2=8E5W;(B_2[)P4<?)U-E^>XOSL
M_?0[7BIGE$7BRJ8$&G,M5Z[]Y#%Z8"GG3$X5LLWG;(_8V/UIZ;=N;3"([4.S
M W"9KP9GW+U7'R6?BG<V@BDBT(;$!-ZA!DN2Y9:5D-MG.!ZDI-^ZM<&@LZ&Z
M!@"ZMT@KI_&*=OI^LMI8=9.=U6OO_UKS5+P*QL<,+@H2$Z-((.:2JR<34Y!1
MB]CZB-^&KGXKTP8'R.:J'  \KV7UH=Y)?*Y3#XX+B?%@L<#E;<:N!DWJ9$6]
MC0+)=*3M9XA31M9?%V:XR@J5;#TW[*4T]EM--CC8=JKBOH/_6[[*BKT/XQ#'
MDWJ;6ESP0H<$QF=/&Y&^N%"[VFNI+9K DC);N9V/+M%O'==@<-90#P,PB/>O
M::_E=5F>>2.L;(IACE,D5TV]*!$B\QI0,I<EX\'P[I^N/D9=OZ'.*^= .U+:
M(.'X:8[?PCB_O:3GTFB3&[(JMEP9]<6(H0O.RPC%%MIT,3GP0CA PZ3B,105
M6[_*WXW2H3U_;8.;9^'97(F#2&@^(,[+J>7I?%[U<<E85M9CMAQ,3(QDZ>HT
M9I9K6PVC-#*57@&=#Y(VM&>SKP3'_=6T+_Y..[28Y)NL<EB?PL6JN'P>,HX\
M%ZP64=41'.3D6O)Y(N8,/*&VQ93(0NLX9CO*AO:V]I4@N+>2!GE87R97K[QA
M\G=&(7EN14XU825!:9<@5+<G&1FXE5&(S;BD&^!MT#6T1[.O![M]%#0 T&WO
M:H^R#B4Z%4"(&HI9IL"YH($C*Y;YD*KYZ:N2K5\ OG[I41=*&\# ^$<X6U\;
M/2S(S&,N,@N06.</&FT@VI! !L4B<E4TSZ\#RR>H'$@CS%<JL&REK@'81W(H
MKI[;IO\\'\_QX'L83ZJ/\6XV/PD3O+FQ?XMQ.2K&1",R![YJR><Q0-#%  8=
MHXF>%VQ]%_-"$@=9I-D,,9NOKSI4WW""%I)F0LR+=R3NRM3!-/\>EI6OB^/R
M.,<C&95BQ7G(G-?WL9Y"-"$S!.:2=E8Q-*V?V.Q(ZB!K,CL#[2NH<XBF]<-L
M^F6Y4222$H\HE82<Q*H=)O&D:%>F)"B,\^3 -Y] N@U=@\R/OYH1W5=1_5O.
MU:W3%5^TDVYON=IB)DP3'I?KLJ6/LR6N"TE7/5I1A"0S18T^UJFGLA;A:96A
M]HHNP0N)9N.UZR.7@[M2,,AHIS7\7D]'_>/QT:U&3%-4M[RHO8QJ=5TM$_U6
M?V7$B1,K:F(KD(U7J#E$(Q.Y\48SGA5*;-VV?7OJ^JW]Z=L^ME':("YE;GA[
MB]]Q,OMV,BO+/TD+H^B%SLDS"A15??'D*&YTO&XPS3$4C4HU;X;[&#']UNST
M!K=]5#((=&TON5'.9+9+2J!4$>3<!@XA:@K/ C?6Z6PR:QU8;T]=O[4\KXR_
MCI0VW.SCN_&4?(V'!2ESCB)+!\RGU7L,A*"$!!Z=0)NC0?9*2?$GJ!S(@(-7
MRCZV4M<00N3;F8#:C^/X6]7:XN@'SM.8N!T):Y7+/-11LB0_1WO-"R\A1>+-
MN!13:?W\X%FB!IEA;(:*IY(U>ZMH )C;7GXCK8QTO-3"HDC^!@H.CMD,N0B;
MI><DE];@VYZZ0:8,NT)A1TH;P)E<V:K_KS'4]S"ICN]G\C/FXT1.:/T+BJ_N
M_N#6;ZZ[G&[>VQ_]2)/SVLR(OED]8_M,!]11*5@=(PPZ<*W B4R;5=0$0AVI
M%+3$6MT<#6M]F_BZ'/:;.NK,%Q@P3'[V340'6$RJH(&B:R^Q$@*X@@R8)DZ=
M*5ZJYN,C]B&XW^33,"'^(B4.9MK$?BR[4*QE60$*3]&GEAFB20RD%B(DI -/
MMGYAT3UN.\MB#12W+U'B0-I:GIQ_^S99B3),KD3Y?EIF\[.U,J^$F@P:SC2#
M5"1M2<<3N.P#&.:9-$9DS5NWAMN2M'[S69TAL0O%#"!BVWB4>1S7 Z[?3Z\<
MEW>S^=UGG#?OZYR7,N:,P K+H&PJ$)+S4'BFN#1E[GSK>N(]R.VY3V$7\-F<
M3OY*NFP&VZ9M63\>G/[Q^>CXW?&GH\\'I^^//Y[<I7>[]JL/?$J#-JO/T=:H
MG>KQ_$N87CZIOFGHNFX5\.D6Z<?E,K@/DYM>K]<05,E%LH@,>(P$A4CQ?7!9
M0C&!(1ICHFN]K9L0OG=#@GV(J.UJ)K/%^1Q/29EOZ'/_/K(AT+Z)!4H.]4ES
M*."M,O2%T?>T+;1M/B"D,0_]&LW7Q_.]#@9]8F*8=O;DC]]_/_C\M^-W)^]_
M^_C^W?O#@X^G!X>'QW]\/'W_\;=/QQ_>'[X_VLGV;OG)#>SQ+CPTLM&7K\WJ
M"#("4[J3Q.4R"EXT<(:Z M5 4,%"-O2U^*RPM,X?/D[-WH',^,MT7,:I5K'<
M6^1F/WC'!'/2@C2<>%9&@J?]"$(4DXSD,=C6A\UVE/7<&[,-2NX%,>V5,DPC
M=7AP\M?Z_Z/_]<?[?SOX</3Q].3@XUO:\_]Z='KPYL/1R=$A?<3ICH;J!9_>
MHD?_CKPT,EB769:-W,I--8A+=*3E"%)$PHK!&C@4 R:S+(*R636?.?TT1?L_
MI;TN3'X_K0\[+HOPEA?OI[3"^>IO'B;AIN?F*BUUTWYS47OBW-YA,FF>,P5W
MP>9ZN1LEQ,(8&!>\#X:%8MLW<.F>KWZ-9D.DWG^^.S!0#-/L?OI<(]S3OY%]
MJM;JT^]DK.C[]_7K;^_)5AV<G!R=[F1SM_WH!@9W)RX:6=M'RW]OSO^:'[)<
M@F1*@G(&P3,MP!23G=0UE=G\5<MS1#6H57ID@6EM#QNF7\9QLLYJW=HO(G(E
MO1+@N%6@F*]%#YZ3.#)&H5R0S5_O[D1HOU:Q+:(>*&'J6'/#M'35".SF/%[^
MRP9VZB$:&IFA57;XYNA,+#"9,IV:+'D@U=6& _1=LLEHB3+9W/JQYUT*]C4P
M'Y 0B'>3W[=/7L6"-UF!48R8=+7QAA$"/)W'WEKO4VG=%NIIBOHU&7MH?],^
M-!3\, W!P>'AYS^.WA[]QZ>CCSM:A,V/:& :GJ2JE:NR[I>TN.S;?AXF-Y")
M*CO#!*M/."VYLMZ"5UE X>@,CQ&-[^"!SV/D[#WQZ&Z'J*L5[C3O>2C9J[7-
MR1@'43%1V^@%\)Z^LYB#\9Q.5^PHH?=24GMV41HAZ=Z HE?0VS"MTLGI\>&_
M_O7XP]NCSR<UACG]VTX)^?N?TB+Y_@QMC<S3.CR_QE$1,BN,$:),]3F12> S
M?2>2M39:&02VGC)\EX+VDY/KJ^6'X)N<4#%'#DS6EP,RUN$8=&B+(F*=\VLL
M;QTA;DU<OX9F#TP\/T6YA3H&;$W>4+#Q]O#X]^I1K&H8=K8H]S^IE55YAL9&
MEN5&R<?E]H"0SSBIKUL/9XLZM88 &>L(D:LGM]>H,T46A2+7.]_::H6\7Z^E
M!(8LE.21([9^]K<?Q7L/(MEV]3>W5[_90,$895%0Z)$3K^/5$L3B'%@O9*3-
MHWSSIKU[DMROE7M%?-X;5/**JAZFK7S_D>S/T>G!?^P6"][^YPVLXJ/4-#*%
MZXD/I^''C>*O<>2EQ)Q7$VTU?6&,013:@K,IV< ,EM)ZI.L3Y#3HL+OYT;<"
M!DM'.<H"NKA$ 4-]%Q?K%;V0J)04*L?6_52>HJ?WUO9-,/% "]TV&ABFX:"-
M^OO[T]\OK_</CU>E2$<?=RVF>NKC6A0E;$MMJRJ$V=G9>'T!6Z]89ZO*%9RF
M.Q'\-<P8%QF5U5"0&3I&%(+3.8,LU@3KDHRL=;[Z103N_;9IF\5N;8[$0DB8
M '4LH%2*X"/S$",FGIG3NGDCO)=1V'/=0&?8NO><J3N]#=6H??AP\.9X7?1.
MAN+#^\.:D#[X[?/1T<IX[&;:GOO0)@;N190/JH*?.6-X0@<<>>TC7PJXS *X
M.KZ%7'OE^: *S]N9Q0G]=%:OFK[CP7Q>W[S4!1[:6XQAD-PXT-K62^^ZK9QG
M$&SBL=3ILK;U [H7D/??H>[^)2B\;RB[T>0PK>3GHP\'IT=O/QU\/OW;Z>>#
MCR<'ASL_8'KTLQK8Q.WH;&0*+U,&G\)\>7%* %@0IFISG&M\:1F=T=J#MD:!
MHJ.73L?@0*:@Z51&F63K'?P<37N_QGSD\Q^"?0Y*:4P9@JHM7V0J$ ,74(3Q
MFAE=,F\=<[Z O'X-6%/LW'MFV9&2AFF;/AZ=?C@^.?ET]/GDKP>?CW8Q29L?
MT>)!Y5-4M;I #/,IN>>UP\LJ97ES;40 X:7$>@=-2C7!@_/)0:K%NTY;5-BZ
MI\ECM.QK<#8_]_8=N,P%+4*=H5HK<Q0$+')5K"=8XK[XUCTS'R6FYTO#%CC8
M-")M!#],D['=Z[JK9T<[72.^;(57>S'X,$_=OQRLG5+EZK9&,CK.A$"@'V7(
M1N? BE>R^9/M]B\'5SW;_YB&\SQ>UJX%A-'QV0,!QFJ]B_77VU% TDP5 ]8Y
M :KD##%S3\)(M',L11PI/ >KO2@8[(/!EX#C3O_\5]'% 'J@W EQ-WEQ60:I
MA(6B9*T121P<+PQ(C,DRI:7%]JGDQ^GIMS-E8Y0U5\  P/3' H_+T6(Y/J,]
M4B<I1^<#R<%K1[()-D&,7-/ACM*A%RQOCOO8&SYW*>BW?W-'@-E#R . R.]A
M_G=<UHK4FP%,:]2/?+:!8,WKU6B=\: ".,LBY)1B$-F++%J_"WV<FG[;?78$
MG4;"'P",'GYN>J\]WF:_TC6O6<2H6!;K.2)*%.)5& ,A2$?&MG@?6MNE?>CM
MMRUG5\?>:REP &!=E\C^CLNOM5GN]6/J2V9*,%$F3FYB\0%4U!F<] @^%V,2
M*\KJUKG,)PGJMYMF1W!KIX(!X.E=&,__+4S.\7<,->5:67DX&)':\H)! .T)
M":K.E2/F#,@8"RO9A]2\\']KXOKME=D1SKI1S0 PMW[+N'["N,E*)&G9E!AD
M[TA@7"=PD?@QQO#@A8O2M2YV?(*<K7#E?C)<M1+_ )#TZ*OY>\%O<3H99R%'
M8DXIP\ EE""BX\9F:4/SA]?;TK85QOQ/AK%.%#, P)%3B41 =2<O![]5IHY^
MU )]O/(H34@Z* 69G$=0VDEP"CUD%DV2(0DCVE\H/TO6=FE5]I/AK+4^!@"Q
MQYY[;.X<SPI3@0)L'^L3#U$=S42.9N')>\9(<((WAMF6I&T'M9\EA=^E7@8
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M(0)=1E]/-( /@G-C3('HZBMHCXY.*,VA/OQR05F.JG4SHPY'"=PD*^ZWHM^
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M?#X=+\_G2.R\&_^HWUTUZS4\>\&CA53GUBC/)03-#9"$M/-&J1)"8X0]3LU
M@;6KXC?;[K71P@#P] '# K_.)OG]V;?Y[#O>[OXL"ZOSC#/HH!%4<@6\30BH
M><J*"TRQ>5^'Q\GI]QU6UXAJI8<!0.I147VX?D*>?"!^K(4@,G%D@X3:;1]J
M5W,KE33:M4X2/4]5OP#KU_?:335#!MLJ>3V2*9E@E*<-XR@ZDB& 1T7.!":O
MC$@BIM:MWI^F:*#GXH[ZWQ9>+U?& *!U9[@I$9'&EZGU;Q.\G"-W62ZW^OFC
MS(^282X&H4!(3^>"(;D&2Y8\&F^DL,;QF!N#L!7M SUTV\"U%P4/XB'"HZQ\
MQ.6Z;[1C =#YU=L*!@X3 TVGC'19*SI\7LMF$CW]OH3NRV*^5!'-*D[ZN*%H
M?(G;8-77NY%X[>O;YS/*!#$AZHQ3O9XM9 +$X@WHG+1.(@N/KY89;7>)>V/?
M1Y*3JYP4@M2ZILQY+6N7#%BJ%3X!76K>K_#V^@-U 7?2__T[V!WE/ !_[]UX
M.E[BA_'W.A-Z&:9?QA1NK5OD56L<B_!..@;<N_IR-I)8! F(C+#SB#'Z]E.C
MGJ1HH+Y9$QPUU,4 D'7;BSPNFPR->%9!>>=!:TG[)'@-%,H+8(C><IDMYZT3
MMT]3-%"7JPFR&NIBF%4AU;%H7A?W_(<V\)A>2'DCAVB5>;VI0++>"N-, B$4
M 2 )0=Z\%.1^%ZU]3"GEUH^P[U+0KNCBNHR]5D:MDX>N>,;I\(4L$^T<ZU:W
M$Q$\VH(\9"9SZZKOI^CIUQ7:0_./5U+L*?0!G%9W.;BZAXU6E,20+*%>]81C
M#FK).]E)K93S%.4V=YH?)&0H%1+[ZGD30'L+?8C(N;H8\ZHP&QR40B>KLL+2
MSG(9BO+><2NQY.;E70^3TC-Z]E?R<[#90>(# ,X'7-*''9=#6GJ\O!H^7(2)
M&1/48<9UW H".?<,LB>OC+EB4+=.FS]$Q\ @LXN"[]TU[RGM02"&_'5<G>!O
M<9'FXV^7WN9E4M8%3\I5 9+4=:BBT<28T) <"\@$*F[;NW%/DC24Z^7&!U=+
M10P&5\<4@(;:^W[%5Q46[9;9]/(EH)6QU%[TS"6D$%$A!&XRA:#$CXU)8&D=
MKC]/5=^>=$,0/ BP9AH9 L;"-)^<Q_^-:7DZ^VT^.Y_F=2A21RLX\@(0>*BC
M%7CM-2D<AR!YCA(-DC5N#:W'B.G77G6*J";R[[L#TT/[X@W]_W.]D=889))U
MV%DI 52Q$GQD$9""6/(/)"JS<8?S2"N-IU;I-TW8!4+:"G:("*E,? H7J_+"
MP]G961V#6?_P;C:9S/ZDWSK].EY\POEXED?)1:63"R!R=0LR[0N'O&X.K5T)
M+DJS73^6/0GIMX/UJ^*L*_4,X-3[C(OE?)R6N'K\26*35ENGP602EDH2(4;O
M (56W!2; F\]K^0N!?UVMN[R?-M#T@/ R</;H@:]M[V_$7EU&AD!7WAOZ]0[
M\OD\&6)N-'=,%9-RZ_>2VU'6;P/JU_;$]]3,8/$VQ3_#9,5.\)C)+T2PTB90
M6CB(/GD0FNE2QY:+Y@^WGB&IW[;0KX^PW731O_=%Q+^?IOGJ  ^3-[/Y?'6$
M?PY+''%G T6G!9Q2CJ044ATL*Z$@FHPYFX1\2]_JB67Z;>#<H>?42K1#OL*_
M2MG-RN?C/U;E">$R4/TP#G$\6;6Y^(RK^N7E;/D5R6'\%J87=[?/OG?^3:EH
M5B30G6RZJ2I )6VT3 ,+H8#BG-"9O <G8V84-WK&VQ\B+:L*-FSR^,O7Y7'Y
M8[$NFQGIR(W0CDY[X5)M0B# AZ)!<QL#2A61F<;L/4E0W]G0G76_>2"V$_L@
M^M3?9>=JJUX<GL^K7$?&N>)XD("!D>6.44.HKQVE+TZE6+C4K6L,GJ:H[QQH
M1SC:2_!#!M+'V31=LJ03G?,N^OJZC(-R+E#4RR18530FE852K:O8GR6J[X1I
MUW#:4?P-$=6I&U9]B-FTIN9FY:X$:K?\=H[65NMTX$J]G+]NG"46N= )!93,
M:T&,(E *'T$7BOB*MW7D^$_D+*U&*7#CHY#24N2J&"BF(X18%&@GB)N0.&V(
M3LW1]H,N7LG^O$3+3]N?%PMX %FG?POS<:V]N&% 8536.0969P/*> N>@E5P
M1B?.R963OC5"[A$Q*']G'X#L)]X!X..Z2N<6!UY[Y<F]9TK3D2I$!J^2HR,U
MHN0VTT';NA[N/A6#<F'V0<B> OXY$D?OSFMKHM_'T_'9^5F]3QROF]G_08?V
M?/5E^17):SL,TX2K;JE=)8\:4=*!U].%C+KQBYRWEOLB"9H4H"G%(SBF%=C,
MT&KC4.K6(4U;O^BA]/YU\'!U[;V^4<JU0/7=>)'"Y&\8YB-MD*<D&= NI&@E
M%@]>B 2AB&@311M6=E//N0NU@_*S7H*:;>YC.E#8 ,[;K3A]>XX?:6N?_HF3
M[_C[;+K\NAAYSG-))8%Q>74E17Z%DX'<4"-,4A:+;NVV[4KKH+R[SF&YK[)^
M(E#6#7?ZYVPD.>>(-D*,M=+#.?*'ZO47$KN2%>%\\R#SA20.RGU\#0CNHIJ?
M#7D$)1R54-M[&0X%%3G/K+[)M@)!*!E#QKK-6K\L?3&1?1<2]H.^%ZOG)\/?
MN]GY?!0Q<ZE#@6+K#0;M*@A)"C VU7VF./V\1_A5&OLN..P%?2]63O]E.T\P
M=SI[@Y_".!-S!X46O.90U1F?I@30)=8>8 EK1XH$+*3: ZY8L9FR?D&I]+/+
M]UURN#>R7DGR/Y%A&QF%3CIKR4V(@@QV%B3&)$#PA($7'[)L__IU.]KZKC]\
M=4/V(F4,LQ/?P>'AYS^.WA[]QZ>CCW?27P<IS<\Q'_WXAM/K>6Z[9/Q>N$*#
M3-X^/+7JIA<N:D9P-5B]+AHFMR9&UOQS,:GBA4X][LCY=T@N5PI6!DS)^=8N
MR1/D[&NXC@@#LPO$RZ*Z6V5V5T4D(J0</;F86?( 2N9:=ZD2$+L8&+?TG];I
MR6>)ZKG77B-T;-JMMKKHV^.ZW*V?23=$1)T.]Q:_XV2V[JV;C8K.DYRB]Q&4
MCQP"X0"2,VB*82ELMMU[Q+-Z<IF>>^DUQDECL0[ ;;IDYM-\5NC,7G4'>X<W
M<"_"Q23KV,#@2$B8JI#('=11*9&*-5:W-K5/4]1S![V.[$Y#+0P 4\?+KSB_
M9.D!$\JE$<G'#+9D3]PX#<[+!))[SH5@.C2??O(T1?UFK[K"5$,M# !3CS,B
M@\XEQ% 'ABN2D21&N%"0HQ#"R)R-; VG_9#462:J8^NTI^R'&;Z=G!X?_NM?
MCS^\/?I\4KN)G_ZM<8//ERW0('C;@Z-&L5OM*[N\N!D];&Q"4Z<V\*0))-Y!
M%#I!\<(6;E'XW/H-RUT*&C;^7,[2W]]<'$["8K'N\,1K:PI=&%BV:FQ"7QS2
M7@@!*2R0CJO4VD%Z@IQ^H[(]]/Y$V\^]1#Z D^N$%+!Z3KEBX9*A57]"1L%B
M%MX YYG5IC@:O&$!9.0^9UL[+[4NO7F4F,%T_]Q/W9LP:B+[ 8#H-OV7C0JY
M<847F0%1T+$NI0,7N8(DB\&L=62Z-7KN4]$S;-JH=]94UGUG?4YP3A[:P>%L
M^AWGR]J!_=,5&2N6KF8?FBA5B P$[2]0VA2(05OP2I)C2%XA=^$YW^8%Z_4+
ME'U5.NM6O@,P,"?G<3'.XS"_. G7=GBUE706PL=:R^4QDZ-OR/1J$P$52\((
MC3XT/Z4>(V8PK3[;GE)-9#\$$-V0_S&<T;>G\S!=D"]8XXWUM@O.L5!R BUC
MY8@9" 4CA)2X#2@$:]^Q^EFJ>C[%VJA_$U1M=='WJ79P^OO!ESFN3OM+"VN%
M5Z'43I(U[T#D1[*P/M6LJ O.N$2F?+L+C'N?W3,@&JMNUDZ./<)@,5^./H?I
MEW5O]Y(,.N\S>*%J%3Q]%UC.4+@FXYNX$7&KAJ[TJ;=L"/WIQG[<6;#?>X?6
M)\_NLAP" "YQ&XPNPI<$WC-B/&<!'GT!'8J,(3"=MZM,W 8"?9J%/92UJ>X=
M)->SPB^?CUTYU4JSHJ($;NK;EQ 2,9\,U&22YM&SO%WOB6=4?F?1GI6^B\IF
M+>37M^+#CUN$:ZO01V5 %2V(<%Z/.LN!<9-M,4RQTD3QMQ?M)]AHIOB=Y3>$
M0.(JL;-.*=_TSUB90&-#;4RO@-E<QYVG3">>BF!EL"DG1->\Y]>3!/5[?]QY
M[G1O'0P 4!L\7'K17AAD@ES=C)YVA0P&?+$(+$B5,O+$>.M6MP\2,I LZOZ*
MWBRGVUOJ X!.?;D^F]Y.[9EB3-:, 6:B77EB)=K:]]FX.NLGA>1:OP:\1\00
M;OKV4NQFTGTO*??LJQS.SJ?T222[Y46-V-?3QXAXPVJ/KF!<I5\"_4@!)D5;
MJO;#8%N=4L^X+ ^MW6\92A?!ZMX2[CMNQ6_G\_0U+/ Z^[+)TN4F<EXD:TT
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M"M;[_>WC/,9C"CD)HHQ&GD8/)>YU)$2&[@3W+)K:)2,U]S]LWZ[&3M3!@-&
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M&?=;9\<?U8_%REV\.39=/0SF7?@  "WL:I=/7-\K/_U-P@-W@_&_4$L#!!0
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MOL]@+6N4>&X=!RVV2ILY47 OH#)-I;5"_$[E&"I0$6H/)>QS2@Z <"1J0X4
M?XF<SY:E^*V0,-\MP2(+W.G&X?_W<U^3(/02T#T$2P)_M*NF_7D@!=!2%OGY
MOFHB^"-5;4__7-UVQ-6=Q,X.ISX+@^46R)]I;,A_/$1'(^;I[T6\EG0770 Z
ML-**IPX&O,$4*2"#*#EGRK*S\1AOGAJ_[!!LY\&W@SNN'LI_I)%=*H""<#D1
M8'*'Z27J*KYZRFRLDK&@$IKQ4?F;@"[3J$CS1$T%6B>Q\HF3KV :&/Q3^$7M
M,WZOM&Z35C8/@4FAJXAUPG,CNK,OYTCP><*G79FYB+E.YZ6RH;)6I5VZFS"F
M0@'.44++0<HW+ZXMU.K^ZH+5^!_.1BZ;:Z[IR(;K;<?'M?9)Y\7F>JWQ8MOO
MJ6W6SLY>;OUBK2>U9FL[8X]<('PP$&^3\^SM7FMOUJ$$9+>9/['&ZLHEC#X/
MN8_V\LV0K[B W,1>846XTLAZQ0BYY<U^X[A^WJZXVS//;JB4L?D3W?X6'K^?
MKE*!U^'5F_TVDH[[7+E=L.+FEN"M,U?#MPG-%J)EEG))+$=<Z#B444#.OZ?X
M[E9,OZ?(7<921.P]7=:CPQEB0A_F1?#6;U#H.MS!1W^8A[=K[:[7HKVW. $L
M!0[7Y^3(E;T-577Y>EZNC/M-M.N/],=B[<+> L:N;M877?@06"[L>I=/W/$K
M/_UUPR-WS?&_4$L#!!0    ( .Q*!%=804%-\@0  +D5   8    ;W9I9#(P
M,C-Q,F5X:&EB:70S,C$N:'1MY5AM;^)&$/[>7S$E:HY(F-CFW9!('"%JHFO(
M!:)K/U6+=XVW,6O7NX;07]_9-81 2(,BW>5R10AAS^R\/C.SNYU03:/33L@(
M/?VI\[-EP5GL9U,F%/@I(XI1R"07$_A"F;P#RUIR]>)DD?))J,"UW0I\B=,[
M/B,Y77$5L=.5G,YQ_MPY-DHZXY@N3CN4SX#3DP*O59K-AL_JK=J85%M!;4PK
M/L%OL]&@K$'J?SH%7(KL^1JI%A$[*4RYL$*F]7O56J+:<TY5Z#FV_4O!\)UV
M@E@H5);BXOQO+N.I))).4)B*$Z^.@A2[5Q:)^$1XQKU"+FG%[<=1G'H'MOFT
M-<4*R)1'"^_#B$^9A"LVAYMX2L2'DB1"6I*E/,@9)?^'H8FHQ#S.<_,;*"?B
M@JW<<5SM0_\^Y&.NH.*6G4T'=ION-#=M]S'P+'TCXWO]F]'%^46O.[H87,'U
M[<WPMGLU@M'@64^^%\N=)MR6A^5>&8;]GK'>J=3L$G2'T#T;7(_Z9^_*G943
M+;L.@W,8_=J'8??F8_>J/[0&OW_J_P'=WDA37-MV]X*9NPFSOS*I>+#XZNY5
M=[IWG:4R(ZA7Q:!"!BG[.^,I,\U+,@5!G*H0N(";+&*826(YU>+X".+ L ^9
MGZ5<<32H?^^'1$P8='VER4ZK4BT!D4!0&&6T!$6]XO"@Z;IV^S&W>>6TCX (
MJB4J'@L#&BVF%Y($LP_UBGX:Z38("+&E_EO!=7L=*NRR$ALJ95!< _#PP*DW
MVEK246F5FK? $'P;Y;LS?,DPG0OXK0R?V(R+$D:4LP#3A:E3?,9@$ 3<QPAC
M2 <S3F$4LI0D#(F^A OAES<2UXNG"1&+5<Y*)FF7+ A2MD!S!5DI^*AG'I/2
M,)QS083/2?18FY:Z%%<"1OP04#,;+P#I6!(:5"HDJK3"YIA)@ZR02[@3\3QB
M=,(.#VK-]CYUIR=30BC%06Q%+%!>I;ZS$/-7'"$KE&=IIC<J3:?\=K#9C)3;
M+-=T&$;KA.G\.XVVA,\92;$^(TP^2[!9 -;N>9Q.P;&MS[I]F-0E:$1,P30"
MN,P$TZ5IMRLX%_3>QZ1X'G*$@-+9[>4 \(EI!?B"*(7XP+5$-YKU7-^ YK51
MPOVE)6N(!EF$]OEH>:1!-><JW&YV4@-KW7N*!%M<NGY1*]*'GK?9NFJMMD;X
M#XE ][M$(!>(JFD.#1^E$%Q)]8C2R=G"  2$:VPF*9,ZRR7-1Z((<#UR8C]"
M0H)91HI>'CST*91,N=&A^Q=R95$.DABQ;)3+K1Y6?G_3_TP?3DP'A6XV05/R
MLJSF5;FO/VB\(F.<RTOR.$XI2RUT(B*)9-[J3YMRF41DX7%A3#&+VDMAXUBI
M>.KI@\A,5[]/HF6(3+1R\OJ,4K;S<XK"PXFB*\U+<MF0CA5]2JLBD%KU9\EV
MV7DEK6J_3NJ+QC;W$GML I$' ^,M$9 GA4IAM6!93)Z;W(.SB4!=7]LASZ/]
M[4%I<GIX4,7!8GYA:_/R@,AE./[#4UO[6=B+]?T%9;W;VHC("R!8UJ4IVP0]
MB"/<[6G3V^\I$E\5$C]*B%X'D/?DXS.G&'U;5;Q..0[Q!*?X$_K1_[>%[',L
MVPK?FJZYN[X?9T+IF\R=T33H.C93?<>FX?%58Q)+L[?R4A81G9XGEX_K@C3;
M GN]A(RQ*C/U=,D+]Y7+W_SJ]-A<V?X+4$L! A0#%     @ [$H$5S)H<X?R
MZ@$ AZH2 !$              ( !     &]V:60M,C R,S V,S N:'1M4$L!
M A0#%     @ [$H$5Z@ZO<TY$@  %+0  !$              ( !(>L! &]V
M:60M,C R,S V,S N>'-D4$L! A0#%     @ [$H$5QGTS[=]&0  *_(  !4
M             ( !B?T! &]V:60M,C R,S V,S!?8V%L+GAM;%!+ 0(4 Q0
M   ( .Q*!%=/ 4$""#@   12 @ 5              "  3D7 @!O=FED+3(P
M,C,P-C,P7V1E9BYX;6Q02P$"% ,4    " #L2@17@0/A\=16 0#\N $ %
M            @ %T3P( ;W9I9"TR,#(S,#8S,%]G,2YJ<&=02P$"% ,4
M" #L2@17/M6N(KJ^   /\P< %0              @ %ZI@, ;W9I9"TR,#(S
M,#8S,%]L86(N>&UL4$L! A0#%     @ [$H$5S;)^I(4<0  ?/0$ !4
M         ( !9V4$ &]V:60M,C R,S V,S!?<')E+GAM;%!+ 0(4 Q0    (
M .Q*!%=2.4ZB% @  ,@H   8              "  :[6! !O=FED,C R,W$R
M97AH:6)I=#,Q,2YH=&U02P$"% ,4    " #L2@17?VER.QP(  #M*   &
M            @ 'XW@0 ;W9I9#(P,C-Q,F5X:&EB:70S,3(N:'1M4$L! A0#
M%     @ [$H$5UA!04WR!   N14  !@              ( !2N<$ &]V:60R
I,#(S<3)E>&AI8FET,S(Q+FAT;5!+!08     "@ * )X"  !R[ 0    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
